0000875320-13-000045.txt : 20131107 0000875320-13-000045.hdr.sgml : 20131107 20131107162230 ACCESSION NUMBER: 0000875320-13-000045 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131107 DATE AS OF CHANGE: 20131107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 131200936 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6173416100 MAIL ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 10-Q 1 a2013q310-q.htm 10-Q 2013 Q3 10-Q
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2013
or
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM              TO             
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
04-3039129
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
130 Waverly Street, Cambridge, Massachusetts
02139-4242
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (617) 341-6100
____________________________________________

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
Accelerated filer o
Non-accelerated filer o 
Smaller reporting company o
 
                                       (Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
233,756,871
Class
Outstanding at October 31, 2013

 


VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2013

TABLE OF CONTENTS
 
 
Page
 
 
 
 
 
 
 
 
 
 
“We,” “us,” “Vertex” and the “Company” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex,” “INCIVEK®” and “KALYDECO™” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q, including “INCIVO™” and “TELAVIC™,” are the property of their respective owners.



Part I. Financial Information
Item 1.    Financial Statements
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Revenues:
 
 
 
 
 
 
 
Product revenues, net
$
186,653

 
$
303,501

 
$
708,823

 
$
1,052,149

Royalty revenues
27,012

 
25,586

 
119,705

 
98,047

Collaborative revenues
8,035

 
6,919

 
32,290

 
42,852

Total revenues
221,700

 
336,006

 
860,818

 
1,193,048

Costs and expenses:
 
 
 
 
 
 
 
Cost of product revenues
20,048

 
30,680

 
75,698

 
161,147

Royalty expenses
7,291

 
7,856

 
32,315

 
31,023

Research and development expenses
228,624

 
200,161

 
669,174

 
593,076

Sales, general and administrative expenses
87,754

 
97,684

 
287,154

 
326,344

Restructuring expenses
12,048

 
696

 
12,863

 
1,650

Intangible asset impairment charge
—

 
—

 
412,900

 
—

Total costs and expenses
355,765

 
337,077

 
1,490,104

 
1,113,240

Income (loss) from operations
(134,065
)
 
(1,071
)
 
(629,286
)
 
79,808

Other income (expense), net
4,652

 
(4,041
)
 
(6,578
)
 
(11,417
)
Income (loss) before provision for (benefit from) income taxes
(129,413
)
 
(5,112
)
 
(635,864
)
 
68,391

Provision for (benefit from) income taxes
(751
)
 
21,355

 
(132,863
)
 
41,450

Net income (loss)
(128,662
)
 
(26,467
)
 
(503,001
)
 
26,941

Net loss (income) attributable to noncontrolling interest (Alios)
4,530

 
(31,076
)
 
13,688

 
(57,825
)
Net loss attributable to Vertex
$
(124,132
)
 
$
(57,543
)
 
$
(489,313
)
 
$
(30,884
)
Net loss per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Basic
$
(0.54
)
 
$
(0.27
)
 
$
(2.20
)
 
$
(0.15
)
Diluted
$
(0.54
)
 
$
(0.27
)
 
$
(2.20
)
 
$
(0.15
)
Shares used in per share calculations:
 
 
 
 
 
 
 
Basic
230,505

 
213,767

 
222,764

 
211,053

Diluted
230,505

 
213,767

 
222,764

 
211,053

The accompanying notes are an integral part of these condensed consolidated financial statements.


2

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Income (Loss)
(unaudited)
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Net income (loss)
$
(128,662
)
 
$
(26,467
)
 
$
(503,001
)
 
$
26,941

Changes in other comprehensive income (loss):
 
 
 
 
 
 
 
Unrealized holding gains on marketable securities, net of tax
166

 
69

 
7

 
324

Foreign currency translation adjustment
514

 
188

 
(7
)
 
313

Total changes in other comprehensive income (loss)
680

 
257

 
—

 
637

Comprehensive income (loss)
(127,982
)
 
(26,210
)
 
(503,001
)
 
27,578

Comprehensive loss (income) attributable to noncontrolling interest (Alios)
4,530

 
(31,076
)
 
13,688

 
(57,825
)
Comprehensive loss attributable to Vertex
$
(123,452
)
 
$
(57,286
)
 
$
(489,313
)
 
$
(30,247
)
The accompanying notes are an integral part of these condensed consolidated financial statements.


3

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)
 
September 30,
 
December 31,
 
2013(1)
 
2012(1)
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
583,181

 
$
489,407

Marketable securities, available for sale
839,469

 
831,808

Restricted cash and cash equivalents (Alios)
51,059

 
69,983

Accounts receivable, net
120,281

 
143,250

Inventories
13,537

 
30,464

Prepaid expenses and other current assets
41,104

 
24,673

Total current assets
1,648,631

 
1,589,585

Restricted cash
127

 
31,934

Property and equipment, net
648,924

 
433,609

Intangible assets
250,600

 
663,500

Goodwill
30,992

 
30,992

Other assets
3,474

 
9,668

Total assets
$
2,582,748

 
$
2,759,288

Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
51,533

 
$
101,292

Accrued expenses
280,848

 
264,884

Deferred revenues, current portion
31,007

 
27,566

Accrued restructuring expenses, current portion
9,858

 
4,758

Capital lease obligations, current portion
14,429

 
13,707

Other liabilities, current portion
21,824

 
20,417

Total current liabilities
409,499

 
432,624

Deferred revenues, excluding current portion
77,354

 
96,242

Accrued restructuring expenses, excluding current portion
16,280

 
18,570

Capital lease obligations, excluding current portion
39,381

 
15,170

Convertible senior subordinated notes (due 2015)
—

 
400,000

Deferred tax liability
150,203

 
280,367

Construction financing lease obligation
392,569

 
268,031

Other liabilities, excluding current portion
10,782

 
13,902

Total liabilities
1,096,068

 
1,524,906

Commitments and contingencies


 


Redeemable noncontrolling interest (Alios)
39,624

 
38,530

Shareholders’ equity:
 
 
 
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at September 30, 2013 and December 31, 2012
—

 
—

Common stock, $0.01 par value; 300,000,000 shares authorized at September 30, 2013 and December 31, 2012; 233,592,201 and 217,286,868 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively
2,311

 
2,149

Additional paid-in capital
5,274,307

 
4,519,448

Accumulated other comprehensive loss
(550
)
 
(550
)
Accumulated deficit
(4,011,180
)
 
(3,521,867
)
Total Vertex shareholders’ equity
1,264,888

 
999,180

Noncontrolling interest (Alios)
182,168

 
196,672

Total shareholders’ equity
1,447,056

 
1,195,852

Total liabilities and shareholders’ equity
$
2,582,748

 
$
2,759,288

(1)
Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
The accompanying notes are an integral part of these condensed consolidated financial statements.


4

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity and Noncontrolling Interest
(unaudited)
(in thousands)
 
Common Stock
 
Additional
Paid-in Capital
 
Accumulated
Other
Comprehensive Loss
 
Accumulated Deficit
 
Total Vertex
Shareholders’ Equity
 
Noncontrolling
Interest (Alios)
 
Total
Shareholders’ Equity
 
Redeemable
Noncontrolling Interest (Alios)
 
Shares
 
Amount
 
 
 
 
 
 
 
Balance, December 31, 2011
209,304

 
$
2,072

 
$
4,200,659

 
$
(1,053
)
 
$
(3,414,835
)
 
$
786,843

 
$
141,633

 
$
928,476

 
$
37,036

Unrealized holding gains on marketable securities, net of tax
 
 
 
 
 
 
324

 
 
 
324

 
 
 
324

 
 
Foreign currency translation adjustment
 
 
 
 
 
 
313

 
 
 
313

 
 
 
313

 
 
Net income (loss)
 
 
 
 
 
 
 
 
(30,884
)
 
(30,884
)
 
57,825

 
26,941

 
 
Issuance of common stock under benefit plans
7,038

 
69

 
182,803

 
 
 
 
 
182,872

 
150

 
183,022

 
 
Stock-based compensation expense
 
 
 
 
87,168

 
 
 
 
 
87,168

 
369

 
87,537

 
 
Tax benefit from equity compensation
 
 
 
 
1,097

 
 
 
 
 
1,097

 


 
1,097

 
 
Change in liquidation value of noncontrolling interest
 
 
 
 
 
 
 
 
 
 
 
 
(1,263
)
 
(1,263
)
 
1,263

Balance, September 30, 2012
216,342

 
$
2,141

 
$
4,471,727

 
$
(416
)
 
$
(3,445,719
)
 
$
1,027,733

 
$
198,714

 
$
1,226,447

 
$
38,299

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance, December 31, 2012
217,287

 
$
2,149

 
$
4,519,448

 
$
(550
)
 
$
(3,521,867
)
 
$
999,180

 
$
196,672

 
$
1,195,852

 
$
38,530

Unrealized holding gains on marketable securities, net of tax
 
 
 
 
 
 
7

 
 
 
7

 
 
 
7

 
 
Foreign currency translation adjustment
 
 
 
 
 
 
(7
)
 
 
 
(7
)
 
 
 
(7
)
 
 
Net loss
 
 
 
 
 
 
 
 
(489,313
)
 
(489,313
)
 
(13,688
)
 
(503,001
)
 
 
Issuance of common stock under benefit plans
8,029

 
79

 
248,207

 
 
 
 
 
248,286

 
(70
)
 
248,216

 
 
Convertible senior subordinated notes (due 2015) conversion
8,276

 
83

 
402,182

 
 
 
 
 
402,265

 


 
402,265

 
 
Stock-based compensation expense
 
 
 
 
104,470

 
 
 
 
 
104,470

 
348

 
104,818

 
 
Change in liquidation value of noncontrolling interest
 
 
 
 
 
 
 
 
 
 
 
 
(1,094
)
 
(1,094
)
 
1,094

Balance, September 30, 2013
233,592

 
$
2,311

 
$
5,274,307

 
$
(550
)
 
$
(4,011,180
)
 
$
1,264,888

 
$
182,168

 
$
1,447,056

 
$
39,624

The accompanying notes are an integral part of these condensed consolidated financial statements.


5

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
 
Nine Months Ended September 30,
 
2013
 
2012
Cash flows from operating activities:
 
 
 
Net income (loss)
$
(503,001
)
 
$
26,941

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization expense
30,734

 
25,818

Stock-based compensation expense
103,933

 
86,649

Other non-cash based compensation expense
5,856

 
8,070

Intangible asset impairment charge
412,900

 
—

Deferred income taxes
(130,164
)
 
35,759

Impairment of property and equipment
6,650

 
—

Write-down of inventories to net realizable value
10,358

 
78,000

Other non-cash items, net
(1,393
)
 
(304
)
Changes in operating assets and liabilities:
 
 
 
Accounts receivable, net
20,737

 
43,538

Inventories
5,212

 
(32,419
)
Prepaid expenses and other current assets
(16,477
)
 
(22,698
)
Accounts payable
(46,005
)
 
1,359

Accrued expenses and other liabilities
32,872

 
12,027

Excess tax benefit from share-based payment arrangements
—

 
(1,097
)
Accrued restructuring expense
2,810

 
(2,158
)
Deferred revenues
(15,447
)
 
(32,203
)
Net cash provided by (used in) operating activities
(80,425
)
 
227,282

Cash flows from investing activities:
 
 
 
Purchases of marketable securities
(1,850,015
)
 
(1,309,044
)
Sales and maturities of marketable securities
1,842,361

 
941,314

Expenditures for property and equipment
(36,922
)
 
(43,094
)
Decrease in restricted cash and cash equivalents
31,807

 
1,923

Decrease (increase) in restricted cash and cash equivalents (Alios)
18,924

 
(23,075
)
Decrease (increase) in other assets
1,094

 
(997
)
Net cash provided by (used in) investing activities
7,249

 
(432,973
)
Cash flows from financing activities:
 
 
 
Excess tax benefit from share-based payment arrangements
—

 
1,097

Issuances of common stock from employee benefit plans
242,360

 
174,950

Payments to redeem secured notes (due 2015)
(158
)
 
—

Payments on capital lease obligations
(14,601
)
 
(2,408
)
Payments on construction financing lease obligation
(63,242
)
 
(6,272
)
Net cash provided by financing activities
164,359

 
167,367

Effect of changes in exchange rates on cash
2,591

 
(110
)
Net increase (decrease) in cash and cash equivalents
93,774

 
(38,434
)
Cash and cash equivalents—beginning of period
489,407

 
475,320

Cash and cash equivalents—end of period
$
583,181

 
$
436,886

Supplemental disclosure of cash flow information:
 
 
 
Cash paid for interest
$
6,700

 
$
6,700

Conversion of convertible senior subordinated notes (due 2015) for common stock
399,842

 
—

Interest on converted convertible senior subordinated notes (due 2015) offset to additional paid-in capital
6,700

 
—

Unamortized debt issuance costs of converted convertible subordinated notes (due 2015) offset to additional paid-in capital
4,230

 
—

Capitalization of construction in-process related to construction financing lease obligation
176,484

 
167,996

Assets acquired under capital lease
38,520

 
27,552

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)
A.
Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) Alios BioPharma, Inc. (“Alios”), a collaborator that is a variable interest entity (a “VIE”) for which the Company is deemed under applicable accounting guidance to be the primary beneficiary. All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2013 and 2012.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2012, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 that was filed with the Securities and Exchange Commission (the "SEC") on March 1, 2013 (the "2012 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, noncontrolling interest (Alios) and the income tax provision. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2012 Annual Report on Form 10-K.
Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements please refer to Note A, "Nature of Business and Accounting Policies—Recent Accounting Pronouncements," in the 2012 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2013 that had a material effect on the Company's condensed consolidated financial statements.
B.
Product Revenues, Net
The Company sells its products principally to a limited number of major and selected regional wholesalers and specialty pharmacy providers in North America as well as government-owned and supported customers in Europe (collectively, its “Customers”). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery as long as (i) there is persuasive evidence


7

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.
In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customer's locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated costs of incentives offered to certain indirect customers, including patients. These estimates, and in particular estimates regarding INCIVEK net product revenues while they decline, require the Company to make significant estimates and judgments that materially affect the Company's recognition of net product revenues.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2013:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2012
$
5,416

 
$
63,560

 
$
2,852

 
$
3,565

 
$
75,393

Provision related to current period sales
26,584

 
155,269

 
3,687

 
8,161

 
193,701

Adjustments related to prior period sales
348

 
4,433

 
11,125

 
(228
)
 
15,678

Credits/payments made
(29,960
)
 
(153,035
)
 
(3,649
)
 
(9,641
)
 
(196,285
)
Balance at September 30, 2013
$
2,388

 
$
70,227

 
$
14,015

 
$
1,857

 
$
88,487

C.
Collaborative Arrangements
Janssen Pharmaceutica, N.V.
In 2006, the Company entered into a collaboration agreement with Janssen Pharmaceutica, N.V. ("Janssen") for the development, manufacture and commercialization of telaprevir, which Janssen began marketing under the brand name INCIVO in certain of its territories in September 2011. Under the collaboration agreement, Janssen agreed to be responsible for 50% of the drug development costs incurred under the development program for the parties’ territories (North America for the Company, and the rest of the world, other than specified countries in Asia, for Janssen) and has exclusive rights to commercialize telaprevir in its territories including Europe, South America, the Middle East, Africa and Australia.
Janssen pays the Company a tiered royalty averaging in the mid-20% range as a percentage of net sales of INCIVO in Janssen’s territories. Janssen is required under the agreement to use diligent efforts to maximize net sales of INCIVO in its territories through its commercial marketing, pricing and contracting strategies. Janssen is responsible for certain third-party royalties on net sales of INCIVO in its territories.
Janssen made a $165.0 million up-front license payment to the Company in 2006. The up-front license payment is being amortized over the Company’s estimated period of performance under the collaboration agreement. As of September 30, 2013, there were $34.2 million in deferred revenues related to this up-front license payment that the Company expects to recognize over the remaining estimated period of performance. The Company's estimates regarding the period of performance under the Janssen agreement have changed in the past, and due to the evolving nature of the landscape for treatments for HCV infection, the estimated period of performance may change in the future.
Under the collaboration agreement, Janssen agreed to make contingent milestone payments for successful development, approval and launch of telaprevir as a product in its territories. At the inception of the agreement, the Company determined that all of these contingent milestones were substantive and would result in revenues in the period in which the milestone was


8

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

achieved. The Company has earned $350.0 million of these contingent milestone payments and does not expect to receive any further milestone payments under this agreement.
Under the Janssen collaboration agreement, each party incurs internal and external reimbursable expenses related to the telaprevir development program and is reimbursed by the other party for 50% of these expenses. The Company recognizes the full amount of the reimbursable costs it incurs as research and development expenses on its condensed consolidated statements of operations. The Company recognizes the amounts that Janssen is obligated to pay the Company with respect to reimbursable expenses, net of reimbursable expenses incurred by Janssen, as collaborative revenues. In the three and nine months ended September 30, 2013, the Company incurred more reimbursable costs than Janssen, and the net amounts payable by Janssen to reimburse the Company were recorded as collaborative revenues.
Each of the parties is responsible for drug supply in its territories. During the nine months ended September 30, 2013 and 2012, the Company provided Janssen certain services through the Company’s third-party manufacturing network for telaprevir. Reimbursements from Janssen for these manufacturing services were recorded as collaborative revenues.
Janssen may terminate the collaboration agreement upon the later of (i) one year’s advance notice and (ii) such period as may be required to assign and transfer to the Company specified filings and approvals. The agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the agreement will continue in effect until the expiration of Janssen’s royalty obligations, which expire on a country-by-country basis on the later of (a) the last-to-expire patent covering INCIVO or (b) ten years after the first commercial sale in the country. In the European Union, the Company has a patent covering the composition-of-matter of INCIVO that expires in 2026.
During the three and nine months ended September 30, 2013 and 2012, the Company recognized the following revenues attributable to the Janssen collaboration:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Royalty revenues (INCIVO)
$
20,994

 
$
19,957

 
$
104,108

 
$
80,811

Collaborative revenues:
 
 
 
 
 
 
 
Amortized portion of up-front payment
$
3,107

 
$
3,107

 
$
9,321

 
$
9,321

Net reimbursement (payment) for telaprevir development costs
1,413

 
(503
)
 
1,422

 
(2,569
)
Reimbursement for manufacturing services
—

 
—

 
10,299

 
4,449

        Total collaborative revenues attributable to the Janssen collaboration
$
4,520

 
$
2,604

 
$
21,042

 
$
11,201

Total revenues attributable to the Janssen collaboration
$
25,514

 
$
22,561

 
$
125,150

 
$
92,012

Mitsubishi Tanabe Pharma Corporation
The Company has a collaboration agreement (the “MTPC Agreement”) with Mitsubishi Tanabe Pharma Corporation ("Mitsubishi Tanabe") pursuant to which Mitsubishi Tanabe has a fully-paid license to manufacture and commercialize TELAVIC (the brand name under which Mitsubishi Tanabe is marketing telaprevir) in Japan and other specified countries in Asia.
The parties entered into the MTPC Agreement in 2004 and amended it in 2009. Pursuant to the MTPC Agreement, Mitsubishi Tanabe provided financial and other support for the development and commercialization of telaprevir, made a $105.0 million payment in connection with the 2009 amendment of the collaboration agreement and made a $65.0 million commercial milestone payment recognized as collaborative revenues in 2011. There are no further payments under this collaboration agreement. Mitsubishi Tanabe is responsible for its own development and manufacturing costs in its territory.


9

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

Mitsubishi Tanabe may terminate the MTPC Agreement at any time without cause upon 60 days’ prior written notice to the Company. The MTPC Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the MTPC Agreement will continue in effect until the expiration of the last-to-expire patent covering telaprevir in Mitsubishi Tanabe's territories. In Japan, the Company has a patent covering the composition-of-matter of telaprevir that expires in 2021.
The $105.0 million payment that the Company received in 2009 in connection with the amendment to the MTPC Agreement was a nonrefundable, up-front license fee, and revenues related to the 2009 payment were recognized on a straight-line basis over the period of performance of the Company’s obligations under the amended agreement. The final deferred revenues related to the 2009 up-front license payment were recognized in April 2012. In connection with the amendment to the MTPC Agreement, the Company supplied manufacturing services to Mitsubishi Tanabe, until April 2012, through the Company’s third-party manufacturing network for telaprevir.
The Company recognized no collaborative revenues attributable to the Mitsubishi Tanabe collaboration in 2013 or the three months ended September 30, 2012, and $18.9 million in collaborative revenues attributable to the Mitsubishi Tanabe collaboration in the nine months ended September 30, 2012.
Cystic Fibrosis Foundation Therapeutics Incorporated
In April 2011, the Company entered into an amendment (the “April 2011 Amendment”) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) pursuant to which CFFT agreed to provide financial support for (i) development activities for VX-661, a corrector compound discovered under the collaboration, and (ii) additional research and development activities directed at discovering new corrector compounds.
The Company entered into the original collaboration agreement with CFFT in 2004 and amended it several times prior to 2011 to, among other things, provide partial funding for its cystic fibrosis drug discovery and development efforts. In 2006, the Company received a $1.5 million milestone payment from CFFT. There are no additional milestones payable by CFFT to the Company pursuant to the collaboration agreement, as amended. Under the April 2011 Amendment, CFFT agreed to provide the Company with up to $75.0 million in funding over approximately five years for corrector-compound research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), lumacaftor (VX-809), VX-661 and any other compounds discovered during the course of the research collaboration with CFFT.
During the three and nine months ended September 30, 2013 and 2012, the Company recognized the following revenues attributable to the CFFT collaboration:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Collaborative revenues attributable to the CFFT collaboration
$
3,515

 
$
4,315

 
$
11,318

 
$
12,772

In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs discovered during the research term that ended in 2008, including KALYDECO, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of corrector compounds discovered during the research term that began in 2011. In each of the third quarter of 2012 and first quarter of 2013, CFFT earned a commercial milestone payment of $9.3 million from the Company upon achievement of certain sales levels for KALYDECO. These milestones were reflected in the Company's cost of product revenues. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO. The Company also is obligated to make up to two one-time commercial milestone payments to CFFT upon achievement of certain sales levels for corrector compounds such as lumacaftor or VX-661.


10

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

The Company began marketing KALYDECO in the United States in the first quarter of 2012 and began marketing KALYDECO in certain countries in the European Union in the third quarter of 2012. The Company has royalty obligations to CFFT for each compound commercialized pursuant to this collaboration until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent life extensions. CFFT may terminate its funding obligations under the collaboration, as amended, in certain circumstances, in which case there will be a proportional adjustment to the royalty rates and commercial milestone payments for certain corrector compounds. The collaboration also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.
Alios BioPharma, Inc.
License and Collaboration Agreement
In June 2011, the Company entered into a license and collaboration agreement (the “Alios Agreement”) with Alios, a privately-held biotechnology company. The Company and Alios are collaborating on the research, development and commercialization of an HCV nucleotide analogue discovered by Alios, ALS-2200 (now formulated as VX-135), which is designed to act on the HCV polymerase.
Under the terms of the Alios Agreement, the Company received exclusive worldwide rights to ALS-2200 (VX-135) and ALS-2158, a second HCV nucleotide analogue discovered by Alios that was only developed pursuant to the Alios Agreement through the third quarter of 2012. Upon entering into the Alios Agreement, the Company paid Alios a $60.0 million up-front payment. As of September 30, 2013, Alios had earned an aggregate of $60.0 million in development milestone payments pursuant to the Alios Agreement. The Alios Agreement provides for development milestone payments to Alios of up to an additional $312.5 million if VX-135 is approved and commercialized. In addition, Alios is eligible to receive commercial milestone payments of up to $750.0 million, as well as tiered royalties on net sales of approved drugs.
Alios and the Company began clinical development of ALS-2200 (VX-135) in December 2011. The Company is responsible for all costs related to development, commercialization and manufacturing of compounds licensed to the Company pursuant to the Alios Agreement, provided funding to Alios to conduct the Phase 1 clinical trials associated with the Alios Agreement and provided funding for a research program that was directed to the discovery of additional HCV nucleotide analogues that act on the HCV polymerase.
The Company may terminate the Alios Agreement (i) upon 30 days’ notice to Alios if the Company ceases development after VX-135 has experienced a technical failure and/or (ii) upon 60 days’ notice to Alios at any time after the Company completes specified Phase 2a clinical trials. The Alios Agreement also may be terminated by either party for a material breach by the other, and by Alios for the Company’s inactivity or if the Company challenges certain Alios patents, in each case subject to notice and cure provisions. Unless earlier terminated, the Alios Agreement will continue in effect until the expiration of the Company’s royalty obligations, which expire on a country-by-country basis on the later of (a) the date the last-to-expire patent covering a licensed product expires or (b) ten years after the first commercial sale in the country.
Alios is continuing to operate as a separate entity, is engaged in other programs directed at developing novel drugs that are not covered by the Alios Agreement and maintains ownership of the underlying patent rights that are licensed to the Company pursuant to the Alios Agreement. Under applicable accounting guidance, the Company has determined that Alios is a VIE, that Alios is a business and that the Company is Alios’ primary beneficiary. The Company based these determinations on, among other factors, the significance to Alios of the licensed compounds and on the Company’s power, through the joint steering committee for the licensed compounds established under the Alios Agreement, to direct the activities that most significantly affect the economic performance of Alios.
Accordingly, the Company consolidated Alios’ statements of operations and balance sheet with the Company’s consolidated financial statements beginning on June 13, 2011. However, the Company’s interests in Alios are limited to those accorded to the Company in the Alios Agreement. In particular, the Company did not acquire any equity interest in Alios, any interest in Alios’ cash and cash equivalents or any control over Alios’ activities that do not relate to the Alios Agreement. Alios does not have any rights to the Company’s assets except as provided in the Alios Agreement.


11

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

Noncontrolling Interest (Alios)
The Company records noncontrolling interest (Alios) on two lines on its condensed consolidated balance sheets. The noncontrolling interest (Alios) is reflected on two separate lines because Alios has both common shareholders and preferred shareholders that are entitled to redemption rights in certain circumstances. The Company records net loss (income) attributable to noncontrolling interest (Alios) on its condensed consolidated statements of operations, reflecting Alios' net loss (income) for the reporting period, adjusted for changes in the fair value of contingent milestone and royalty payments, which is evaluated each reporting period. A summary of net loss (income) attributable to noncontrolling interest (Alios) for the three and nine months ended September 30, 2013 and 2012 is as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Loss before provision for (benefit from) income taxes
$
9,056

 
$
5,090

 
$
21,177

 
$
14,581

Decrease (increase) in fair value of contingent milestone and royalty payments
(1,220
)
 
(57,560
)
 
1,600

 
(112,760
)
Provision for (benefit from) income taxes
(3,306
)
 
21,394

 
(9,089
)
 
40,354

Net loss (income) attributable to noncontrolling interest (Alios)
$
4,530

 
$
(31,076
)
 
$
13,688

 
$
(57,825
)
The Company uses present-value models to determine the estimated fair value of the contingent milestone and royalty payments, based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the time to develop drug candidates, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liability. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments.
In the three and nine months ended September 30, 2013, the fair value of the contingent milestone payments and royalties payable by the Company to Alios related to the HCV nucleotide analogue program increased by $1.2 million and decreased by $1.6 million, respectively. An increase in the fair value of the contingent milestone payments and royalties payable by the Company increases net loss attributable to Vertex by a corresponding amount.
In the three and nine months ended September 30, 2012, the fair value of contingent milestone and royalty payments increased by $57.6 million and $112.8 million, respectively, primarily because the Company received positive clinical data from a Phase 1 clinical trial evaluating ALS-2200 (VX-135), which increased the probability that Alios would earn future payments from the Company under the Alios Agreement.
If VX-135 continues to advance in clinical development, the Company expects it will record increases in the fair value of the contingent milestone and royalty payments in future periods. Changes in the fair value of these contingent milestone and royalty payments, and the effects of these changes on net loss attributable to Vertex, may be material in future periods.


12

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

Alios Balance Sheet Information
The following table summarizes items related to Alios included in the Company’s condensed consolidated balance sheets:
 
As of
September 30, 2013
 
As of
December 31, 2012
 
(in thousands)
Restricted cash and cash equivalents (Alios)
$
51,059

 
$
69,983

Prepaid expenses and other current assets
8,821

 
672

Property and equipment, net
1,374

 
1,728

Intangible assets
250,600

 
250,600

Goodwill
4,890

 
4,890

Other assets
153

 
861

Accounts payable
1,251

 
1,054

Accrued expenses
6,689

 
6,099

Deferred tax liability
150,203

 
152,781

Other liabilities, excluding current portion
873

 
1,625

Redeemable noncontrolling interest (Alios)
39,624

 
38,530

Noncontrolling interest (Alios)
182,168

 
196,672

The Company has recorded Alios’ cash and cash equivalents as restricted cash and cash equivalents (Alios) because (i) the Company does not have any interest in or control over Alios’ cash and cash equivalents and (ii) the Alios Agreement does not provide for these assets to be used for the development of the assets that the Company licensed from Alios pursuant to the Alios Agreement. Assets recorded as a result of consolidating Alios’ financial condition into the Company’s condensed consolidated balance sheets do not represent additional assets that could be used to satisfy claims against the Company’s general assets.
D.
Net Loss Per Share Attributable to Vertex Common Shareholders
Basic net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The Company did not include the securities described in the following table in the computation of the diluted net loss attributable to Vertex per common share calculations because the effect would have been anti-dilutive during each such period:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Stock options
16,807

 
20,226

 
16,807

 
20,226

Convertible senior subordinated notes
—

 
8,192

 
—

 
8,192

Unvested restricted stock and restricted stock units
2,838

 
2,222

 
2,838

 
2,222

E.
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets


13

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of September 30, 2013, the Company’s investments were in money market funds, short-term U.S. Treasury securities, short-term government-sponsored enterprise securities, corporate debt securities and commercial paper.
As of September 30, 2013, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, U.S. Treasury securities and government-sponsored enterprise securities. The Company’s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade corporations. During the three and nine months ended September 30, 2013 and 2012, the Company did not record an other-than-temporary impairment charge related to its financial assets. The Company’s noncontrolling interest (Alios) includes the fair value of the contingent milestone and royalty payments, which is valued based on Level 3 inputs. Please refer to Note C, "Collaborative Arrangements," for further information.
The following table sets forth the Company’s financial assets (excluding Alios’ cash equivalents) subject to fair value measurements:
 
Fair Value Measurements
as of September 30, 2013
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
308,981

 
$
308,981

 
$
—

 
$
—

Government-sponsored enterprise securities
2,895

 
2,895

 
—

 
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
555,527

 
555,527

 
—

 
—

Commercial paper
125,264

 
—

 
125,264

 
—

Corporate debt securities
158,678

 
—

 
158,678

 
—

Total
$
1,151,345

 
$
867,403

 
$
283,942

 
$
—

Alios’ cash equivalents of $48.7 million as of September 30, 2013 consisted of money market funds, which were valued based on Level 1 inputs.


14

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

F.
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of September 30, 2013
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
580,286

 
$
—

 
$
—

 
$
580,286

Government-sponsored enterprise securities
2,895

 
—

 
—

 
2,895

Total cash and cash equivalents
$
583,181

 
$
—

 
$
—

 
$
583,181

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
—

 
$
—

 
$
—

 
$
—

Government-sponsored enterprise securities (due within 1 year)
555,502

 
35

 
(10
)
 
555,527

Commercial paper (due within 1 year)
125,073

 
191

 
—

 
125,264

Corporate debt securities (due within 1 year)
148,672

 
21

 
(38
)
 
148,655

Corporate debt securities (due after 1 year through 5 years)
10,019

 
5

 
(1
)
 
10,023

Total marketable securities
$
839,266

 
$
252

 
$
(49
)
 
$
839,469

Total cash, cash equivalents and marketable securities
$
1,422,447

 
$
252

 
$
(49
)
 
$
1,422,650

 
 
 
 
 
 
 
 
As of December 31, 2012
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
489,407

 
$
—

 
$
—

 
$
489,407

    Government-sponsored enterprise securities
—

 
—

 
—

 
—

Total cash and cash equivalents
$
489,407

 
$
—

 
$
—

 
$
489,407

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
111,350

 
$
2

 
$
(2
)
 
$
111,350

Government-sponsored enterprise securities (due within 1 year)
440,181

 
49

 
(5
)
 
440,225

Commercial paper (due within 1 year)
225,294

 
155

 
—

 
225,449

Corporate debt securities (due within 1 year)
15,429

 
1

 
(1
)
 
15,429

Corporate debt securities (due after 1 year through 5 years)
39,358

 
10

 
(13
)
 
39,355

Total marketable securities
$
831,612

 
$
217

 
$
(21
)
 
$
831,808

Total cash, cash equivalents and marketable securities
$
1,321,019

 
$
217

 
$
(21
)
 
$
1,321,215

Alios’ $51.1 million and $70.0 million, respectively, of cash and money market funds as of September 30, 2013 and December 31, 2012, recorded on the Company’s condensed consolidated balance sheets in “Restricted cash and cash equivalents (Alios),” are not included in the above table.


15

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

G.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in accumulated other comprehensive loss by component, net of tax:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities, Net of Tax
 
Total
 
(in thousands)
Balance at December 31, 2012
$
(746
)
 
$
196

 
$
(550
)
Other comprehensive income (loss) before reclassifications
(7
)
 
7

 
—

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
—

Net current period other comprehensive income (loss)
(7
)
 
7

 
—

Balance at September 30, 2013
$
(753
)
 
$
203

 
$
(550
)
For the nine months ended September 30, 2013, there were no amounts reclassified from accumulated other comprehensive income (loss). Amounts reclassified for unrealized gains (losses) on available-for-sale securities are recorded as part of other income (expense), net on the Company's condensed consolidated statements of operations.
H.
Inventories
The following table sets forth the Company’s inventories by type:
 
As of
September 30, 2013
 
As of
December 31, 2012
 
(in thousands)
Raw materials
$
232

 
$
3,754

Work-in-process
7,980

 
11,317

Finished goods
5,325

 
15,393

Total
$
13,537

 
$
30,464

In the three and nine months ended September 30, 2013, the Company recorded within cost of product revenues $5.3 million and $10.4 million, respectively, of write-offs for excess and obsolete inventories. In the three and nine months ended September 30, 2012, the Company recorded within cost of product revenues $0.0 million and $78.0 million, respectively, of write-offs for excess and obsolete inventories.
I.
Intangible Assets and Goodwill
Intangible Assets
As of December 31, 2012, the Company's intangible assets consisted of indefinite-lived in-process research and development assets of (i) $250.6 million related to its HCV nucleotide analogue program, which includes the HCV nucleotide analogue VX-135, and (ii) $412.9 million related to VX-222, which also was being developed for the treatment of HCV infection. The Company acquired VX-222 when it acquired ViroChem Pharma Inc. ("ViroChem") in 2009.
The Company tests intangible assets for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstance suggest that impairment may exist. In connection with each annual impairment assessment and any interim impairment assessment in which indicators of impairment have been identified, the Company compares the fair value of the asset as of the date of the assessment with the carrying value of the asset on the Company's condensed consolidated balance sheet.


16

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

In connection with its preparation of its financial statements for the three months ended March 31, 2013, the Company determined that there were indicators that the value of the VX-222 intangible asset had become impaired.  This determination was based on (a) preliminary safety, tolerability and efficacy data from a Phase 2 clinical trial of VX-222, telaprevir and ribavirin, which was received in March 2013 and analyzed through April 2013 and (b) a review of the existing and emerging data regarding all-oral regimens for HCV infection being developed by the Company's competitors that appear to be generally well tolerated with high sustained viral response ("SVR") rates for treatment-naïve patients with genotype 1 HCV infection. After evaluating the data from this Phase 2 clinical trial, the Company determined that regimens containing VX-222 were unlikely to be competitive with the treatment regimens being developed by the Company's competitors. The Company evaluated the fair value of VX-222 from the perspective of a market participant and based on this analysis determined that the fair value of VX-222 was zero as of March 31, 2013. Accordingly, the Company recorded a $412.9 million impairment charge in the nine months ended September 30, 2013.  In connection with this impairment charge, the Company recorded a credit of $127.6 million in its provision for income taxes. In the nine months ended September 30, 2013, the increase to the Company's net loss attributable to Vertex related to this impairment charge, net of the tax credit, was $285.3 million, and the net increase to the Company's net loss per share attributable to Vertex common shareholders was $1.28 per share.
The field of HCV infection treatment is highly competitive and characterized by rapid technological advances and the development of drug candidates for the treatment of HCV infection is subject to numerous risks. Two of the Company's competitors have filed applications seeking approval for potentially competitive treatment regimens that include pegylated-interferon and ribavirin, and several of the Company's competitors are conducting Phase 3 clinical trials evaluating all-oral combinations of their drug candidates for the treatment of genotype 1 HCV infection.
In July 2013, U.S. Food and Drug Administration ("FDA") placed a partial clinical hold on VX-135, which is being evaluated in a Phase 2 clinical trial in combination with ribavirin. The partial clinical hold prevents the Company from evaluating a 200 mg dose of VX-135 in the United States following observation of reversible elevated liver enzymes in patients who received 400 mg of VX-135 in combination with ribavirin in a Phase 2 clinical trial in Europe. The Company has completed dosing of 100 mg of VX-135 in combination with ribavirin as part of the 12-week Phase 2 clinical trial in the United States. The 100 mg dose was well tolerated, no serious adverse events were reported and no liver or cardiac safety issues were identified. The Company recently completed dosing of 100 mg and 200 mg of VX-135 in combination with ribavirin as part of the 12-week Phase 2 clinical trial in Europe. Both the 100 mg and 200 mg doses were well tolerated, no serious adverse events were reported and no liver or cardiac safety issues were identified. The Company also is evaluating VX-135 in combination with daclatasvir, an NS5A replication complex inhibitor being developed by Bristol-Myers Squibb, in a Phase 2 clinical trial in New Zealand. The Company evaluated this data and the related partial clinical hold and has concluded that it does not represent an indicator of impairment.  The Company will continue to evaluate VX-135 for impairment each reporting period.
If the fair value of the HCV nucleotide analogue program becomes impaired as the result of unfavorable safety or efficacy data from any ongoing or future clinical trial or because of any other information regarding the prospects of successfully developing or commercializing VX-135, the Company would incur significant charges in the period in which the impairment occurs.
Goodwill
As of September 30, 2013 and December 31, 2012, goodwill of $31.0 million was recorded on the Company's condensed consolidated balance sheets. There was no change to goodwill recorded during the three and nine months ended September 30, 2013 or 2012.
J.
Convertible Senior Subordinated Notes
In 2010, the Company completed an offering of $400.0 million in aggregate principal amount of 3.35% convertible senior subordinated notes due 2015 (the "2015 Notes"). This offering resulted in $391.6 million of net proceeds to the Company. The underwriting discount and other expenses of $8.4 million were recorded as debt issuance costs and were included in other assets on the Company’s condensed consolidated balance sheets.


17

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

The 2015 Notes were convertible at any time, at the option of the holder, into common stock at a price equal to approximately $48.83 per share, or 20.4794 shares of common stock per $1,000 principal amount of the 2015 Notes. If the closing price of the Company’s common stock exceeded 130% of the conversion price for at least 20 trading days within a period of 30 consecutive trading days, the Company had the right to redeem the 2015 Notes at its option at a redemption price equal to 100% of the principal amount of the 2015 Notes to be redeemed.
In the second quarter of 2013, the Company's common stock exceeded 130% of the conversion price of the 2015 Notes for at least 20 trading days within a period of 30 consecutive trading days, and the Company notified the holders of the 2015 Notes that it would redeem the 2015 Notes on June 17, 2013. In response to the Company's call of the 2015 Notes for redemption, in accordance with the provisions of the 2015 Notes, the holders of $399.8 million in aggregate principal amount of 2015 Notes elected to convert their 2015 Notes into the Company's common stock at the conversion price of approximately $48.83 per share. As a result of these conversions, the Company issued 8,188,448 shares of common stock. The remaining $0.2 million in aggregate principal amount of 2015 Notes was redeemed on June 17, 2013.
Pursuant to the terms of the 2015 Notes, the Company made an additional payment of $16.75 per $1,000 principal amount, payable in shares of the Company’s common stock, to the holders of the 2015 Notes that converted or redeemed their 2015 Notes after the Company called the 2015 Notes for redemption. These payments resulted in the issuance of an additional 87,109 shares of the Company's common stock. In the second quarter of 2013, the Company recognized an aggregate of $6.7 million in interest expense related to the 2015 Notes. Unamortized debt issuance costs for the 2015 Notes of $4.2 million were recorded as an offset to additional paid-in capital.
K.
Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two leases, pursuant to which the Company agreed to lease approximately 1.1 million square feet of office and laboratory space in two buildings (the "Buildings") that the landlord is building at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company plans to transition its Massachusetts operations from Cambridge, Massachusetts to Fan Pier upon the completion of the Buildings. The Company expects to commence lease payments in December 2013 and to make payments for the period ending 15 years from the commencement date. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company is involved in the construction project, including having responsibility to pay for a portion of the costs of finish work and structural elements of the Buildings, the Company is deemed for accounting purposes to be the owner of the Buildings during the construction period. Accordingly, the Company has recorded project construction costs incurred by the landlord as an asset and a related financing obligation in “Property and equipment, net” and “Construction financing lease obligation,” respectively, on the Company’s condensed consolidated balance sheets. The Company bifurcates its future lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings are being constructed, which is recorded as rental expense. Although the Company will not begin making lease payments pursuant to the Fan Pier Leases until the commencement date, the portion of the lease obligations allocated to the land is treated for accounting purposes as an operating lease that commenced in 2011.
Property and equipment, net, included $467.6 million and $290.7 million as of September 30, 2013 and December 31, 2012, respectively, related to construction costs for the Buildings at Fan Pier in Boston, Massachusetts. The construction financing lease obligation related to the Buildings at Fan Pier was $392.6 million and $268.0 million as of September 30, 2013 and December 31, 2012, respectively. As of September 30, 2013 and December 31, 2012, the primary difference between the amounts recorded in property and equipment, net and the construction financing lease obligation represented the cost of finish work and structural elements of the Buildings that the Company was responsible for paying to date.
Once the landlord completes the construction of the Buildings, the Company will evaluate the Fan Pier Leases in order to determine whether or not the Fan Pier Leases meet the criteria for “sale-leaseback” treatment. If the Fan Pier Leases meet the “sale-leaseback” criteria, the Company will remove the asset and the related liability from its consolidated balance sheet and treat the Fan Pier Leases as either operating or capital leases based on the Company’s assessment of the accounting guidance.


18

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

The Company expects that upon completion of construction of the Buildings the Fan Pier Leases will not meet the “sale-leaseback” criteria. If the Fan Pier Leases do not meet “sale-leaseback” criteria, the Company will treat the Fan Pier Leases as a financing obligation and will depreciate the asset over its estimated useful life.
The Company expects to incur restructuring liabilities related to lease obligations that extend beyond the cease use date for certain Cambridge, Massachusetts facilities for several years after it relocates to Fan Pier. Please refer to "Note O: Restructuring Liabilities" for further information.
Capital Leases
The Company has outstanding capital leases for equipment, leasehold improvements and software licenses with terms through 2019. The capital leases bear interest at rates ranging from 3% to 7% per year. The following table sets forth the Company’s future minimum payments due under capital leases as of September 30, 2013:
Year
 
(in thousands)
2013
 
$
1,883

2014
 
18,077

2015
 
15,608

2016
 
8,924

2017
 
8,481

2018
 
7,877

    2019
 
409

Total payments
 
61,259

Less: amount representing interest
 
(7,449
)
Present value of payments
 
$
53,810

Financing Arrangements
In the second quarter of 2013, the Company began supporting $31.9 million in irrevocable stand-by letters of credit issued in support of property leases and other similar agreements with an unsecured credit facility with a one-year term. The Company previously had cash-collateralized these stand-by letters of credit. As a result of this credit facility, the restricted cash reflected on the Company's condensed consolidated balance sheets decreased by $31.8 million net of other activity recorded during the nine months ended September 30, 2013 and the Company's cash and cash equivalents increased by a corresponding amount during the nine months ended September 30, 2013.
L.
Stock-based Compensation Expense
The Company issues stock options, restricted stock and restricted stock units with service conditions, which are generally the vesting periods of the awards. The Company also has issued, to certain members of senior management, restricted stock and restricted stock units that vest upon the earlier of the satisfaction of (i) a performance condition or (ii) a service condition, and stock options that vest upon the earlier of the satisfaction of (a) performance conditions or (b) a service condition. In addition, the Company issues shares pursuant to an employee stock purchase plan ("ESPP").


19

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

The effect of stock-based compensation expense during the three and nine months ended September 30, 2013 and 2012 was as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
19,010

 
$
18,869

 
$
68,633

 
$
59,774

Restricted stock and restricted stock units
10,998

 
7,104

 
30,108

 
21,643

ESPP share issuances
1,504

 
1,948

 
6,077

 
6,120

Less stock-based compensation expense capitalized to inventories
(204
)
 
(339
)
 
(885
)
 
(888
)
Total stock-based compensation expense included in costs and expenses
$
31,308

 
$
27,582

 
$
103,933

 
$
86,649

 
 
 
 
 
 
 
 
Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
19,223

 
$
17,444

 
$
64,312

 
$
54,425

Sales, general and administrative expenses
12,085

 
10,138

 
39,621

 
32,224

Total stock-based compensation expense included in costs and expenses
$
31,308

 
$
27,582

 
$
103,933

 
$
86,649

The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of September 30, 2013
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
184,969

 
2.74
Restricted stock and restricted stock units
103,454

 
2.61
ESPP share issuances
830

 
0.31


20

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

The following table summarizes information about stock options outstanding and exercisable at September 30, 2013:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
Weighted-average
Remaining
Contractual Life
Weighted-average
Exercise Price
 
Number
Exercisable
Weighted-average
Exercise Price
 
 
(in thousands)
(in years)
(per share)
 
(in thousands)
(per share)
$ 9.07–$20.00
 
462
2.64
$15.27
 
462
$15.27
$20.01–$30.00
 
1,076
5.98
$29.37
 
801
$29.19
$30.01–$40.00
 
7,253
5.59
$36.58
 
4,525
$35.93
$40.01–$50.00
 
4,552
9.10
$46.33
 
570
$46.73
$50.01–$60.00
 
1,840
7.61
$53.72
 
805
$54.49
$60.01–$70.00
 
44
8.64
$63.23
 
11
$63.19
$70.01-$80.00
 
85
9.67
$77.73
 
4
$77.73
$80.01-$88.18
 
1,495
9.81
$83.13
 
166
$81.54
Total
 
16,807
7.09
$44.47
 
7,344
$37.87
M.
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of September 30, 2013, the Company had $71.5 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
N.
Income Taxes
For the three and nine months ended September 30, 2013, the Company recorded a net benefit from income taxes of $0.8 million and $132.9 million, respectively. For the three months ended September 30, 2013, the benefit from income taxes was due to a benefit from income taxes of $3.3 million attributable to noncontrolling interest (Alios) offset by a provision for income taxes of $2.6 million attributable to Vertex. For the nine months ended September 30, 2013, the benefit from income taxes was due to a benefit from income taxes of $9.1 million attributable to noncontrolling interest (Alios) and a benefit from income taxes of $123.8 million attributable to Vertex. In the first quarter of 2013, the Company determined that the fair value of VX-222 was zero, which resulted in an impairment charge of $412.9 million in the nine months ended September 30, 2013. In connection with this impairment charge, the Company wrote-off the associated deferred tax liability of $127.6 million resulting in a benefit from income in its condensed consolidated statements of operations for the nine months ended September 30, 2013. Please refer to Note I, "Intangible Assets and Goodwill," for further information regarding the impairment charge.
For the three and nine months ended September 30, 2012, the Company recorded a benefit from and a provision for income taxes attributable to Vertex of $0.0 million and $1.1 million, respectively. These were due to state income taxes. For the three and nine months ended September 30, 2012, the Company recorded a provision for income taxes attributable to noncontrolling interest (Alios) of $21.4 million and $40.4 million, respectively.
The Company has no liability for taxes payable by Alios. As such, the portion of the income tax provision (benefit) related to Alios has been allocated to noncontrolling interest (Alios). As of September 30, 2013 and December 31, 2012,


21

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

Alios had a deferred tax liability of $150.2 million and $152.8 million reflected on the Company's condensed consolidated balance sheets, respectively.
As of September 30, 2013 and December 31, 2012, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of September 30, 2013 and December 31, 2012.
The Company maintains a valuation allowance on its net operating losses and other deferred tax assets because of its extended history of annual losses. As of December 31, 2012, the Company had U.S. federal net operating loss carryforwards of approximately $2.6 billion and tax credits of $98.0 million, which may be used to offset future federal income tax liability. For state income tax purposes, the Company had net operating loss carryforwards of approximately $1.5 billion and tax credits of $60.3 million at December 31, 2012, which may be used to offset future state income tax liability. On a quarterly basis, the Company reassesses the valuation allowance for deferred income tax assets. In future periods, if management determines that it is more likely than not that the deferred tax asset will be realized, (i) the valuation allowance would be decreased, (ii) a portion or all of the deferred tax asset would be reflected on the Company’s consolidated balance sheet and (iii) the Company would record non-cash benefits in its consolidated statements of operations related to the reflection of the deferred tax asset on its consolidated balance sheet.
The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2007 and any other major taxing jurisdiction for years before 2005, except where the Company has net operating losses or tax credit carryforwards that originated before 2005. The Company is currently under examination by Revenue Quebec for the year ended March 11, 2009 and the year ended December 31, 2007. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year.
The Company currently intends to reinvest the total amount of its unremitted earnings, which have not been significant to date, in the local international jurisdiction or to repatriate the earnings only when tax-effective. As a result, the Company has not provided for U.S. federal income taxes on the unremitted earnings of its international subsidiaries. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to U.S. federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries. At September 30, 2013, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability.
O.
Restructuring Liabilities
Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in 2018, and that the Company has not used since it adopted the plan to restructure its operations in 2003. This laboratory and office space currently is subleased to third parties.
In estimating the expense and liability under its lease obligations, the Company estimated (i) the costs to be incurred to satisfy rental and build-out commitments under the lease (including operating costs), (ii) the lead-time necessary to sublease the space, (iii) the projected sublease rental rates and (iv) the anticipated durations of subleases. The Company uses a credit-adjusted risk-free rate of approximately 10% to discount the estimated cash flows. The Company reviews its estimates and assumptions on at least a quarterly basis, intends to continue such reviews until the termination of the applicable lease, and will make whatever modifications the Company believes necessary, based on the Company’s best judgment, to reflect any changed circumstances.


22

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

The activities related to the restructuring liability for the three and nine months ended September 30, 2013 and 2012 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
Liability, beginning of the period
$
22,051

 
$
24,830

 
$
23,328

 
$
26,313

Cash payments
(3,901
)
 
(3,726
)
 
(11,323
)
 
(11,137
)
Cash received from subleases
2,670

 
2,355

 
8,000

 
7,329

Restructuring expense
524

 
696

 
1,339

 
1,650

Liability, end of the period
$
21,344

 
$
24,155

 
$
21,344

 
$
24,155

Strategic Restructuring
In October 2013, the Company adopted a restructuring plan. The restructuring plan included (i) a workforce reduction primarily related to the support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection near approval, and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in cystic fibrosis and other research and development programs.
The Company estimates that it will incur aggregate restructuring charges of approximately $35.0 million to $45.0 million, including $20.0 million to $25.0 million for employee severance and benefit costs, $6.0 million to $8.0 million in assets associated with this restructuring that have become impaired and $9.0 million to $12.0 million for other costs. The Company recorded $11.4 million of these restructuring charges in the third quarter of 2013. The Company expects the vast majority of this restructuring to be completed during the fourth quarter of 2013.
The restructuring charges recorded during the three months ended September 30, 2013 and the related liability balance as of September 30, 2013 for each major type of cost associated with this restructuring plan are as follows:
 
Restructuring Expense
 
Cash
Payments
 
Non-cash Expense
 
Restructuring Liability at September 30, 2013
 
(in thousands)
Employee severance, benefits and related costs
$
409

 
$
—

 
$
—

 
$
409

Asset impairments
6,650

 
—

 
(6,650
)
 
—

Contract termination and other associated costs
4,385

 
—

 
—

 
4,385

Liability, end of the period
$
11,444

 
$
—

 
$
(6,650
)
 
$
4,794

Fan Pier Move Restructuring
In connection with transitioning its Massachusetts operations to Fan Pier in Boston, Massachusetts, the Company expects to incur restructuring charges related to its remaining lease obligations at its current facilities in Cambridge, Massachusetts starting in the fourth quarter of 2013 and continuing through April 30, 2018. Most of these restructuring charges will relate to cease use charges that will be incurred during the fourth quarter of 2013 and the first half of 2014. In addition, the Company will continue to incur restructuring charges related to several buildings in Cambridge through December 31, 2015 and the Kendall Square building through April 30, 2018. The continuing charges will relate to the difference between the Company’s estimated future cash flows related to its lease obligations and the actual cash flows that it incurs.


23

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

P.
Legal Proceedings
On September 6, 2012, a purported shareholder class action, City of Bristol Pension Fund v. Vertex Pharmaceuticals Incorporated, et al., was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleges that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through June 28, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. By order dated December 12, 2012, the court appointed the City of Bristol lead plaintiff and appointed the City of Bristol's attorneys lead counsel. The plaintiffs filed an amended complaint on February 11, 2013. The Company filed a motion to dismiss the complaint on April 12, 2013. On May 28, 2013, the plaintiffs filed an opposition to the Company's motion to dismiss the complaint. On June 27, 2013, the Company filed a reply in further support of the Company's motion to dismiss the plaintiffs' complaint. The court has scheduled a hearing on the Company's motion to dismiss for November 25, 2013. The plaintiffs seek unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney's fees, as well as disgorgement of the proceeds from certain individual defendants' sales of the Company's common stock. The Company believes that this action is without merit and intends to defend it vigorously. As of September 30, 2013, the Company has not recorded any reserves for this purported class action.
Q.
Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of September 30, 2013 or December 31, 2012.
R.
Guarantees
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits


24

VERTEX PHARMACEUTICALS INCORPORATED

Notes to Condensed Consolidated Financial Statements (Continued)

(unaudited)

or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company entered into an underwriting agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated dated September 23, 2010 (the “Underwriting Agreement”), relating to the public offering and sale of the 2015 Notes. The Underwriting Agreement requires the Company to indemnify the underwriter against any loss it may suffer by reason of the Company’s breach of any representation or warranty relating to the public offering, the Company’s failure to perform certain covenants in the Underwriting Agreement, the inclusion of any untrue statement of material fact in the prospectus used in connection with the offering, the omission of any material fact needed to make those materials not misleading, and any actions taken by the Company or its representatives in connection with the offering. The representations, warranties, covenants and indemnification provisions in the Underwriting Agreement are of a type customary in agreements of this sort. The Company believes the estimated fair value of this indemnification arrangement is minimal.
S. Subsequent Events
On October 29, 2013, the Company adopted a strategic restructuring plan. As a result of the actions to be taken under this restructuring plan, including those taken in the third quarter of 2013, the Company estimates that it will incur aggregate restructuring charges of approximately $35.0 million to $45.0 million, $11.4 million of which was recorded in the third quarter of 2013. Please refer to Note O, "Restructuring Liabilities," for further information.


25

Item 2.     Management's Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. Our two products are: KALYDECO (ivacaftor), which is approved in the United States, Australia, Canada and Europe for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation that is referred to as the G551D mutation; and INCIVEK (telaprevir), which is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. We receive royalties from sales in Europe and other countries for telaprevir, where it is marketed as INCIVO, by our collaborator, Janssen Pharmaceutica, N.V.
Our third quarter 2013 revenues included KALYDECO net product revenues of $101.1 million and INCIVEK net product revenues of $85.6 million. As of September 30, 2013, we had cash, cash equivalents and marketable securities of $1.4 billion. Our net product revenues from sales of INCIVEK have declined rapidly over the course of 2013, including a 45% decline in INCIVEK net product revenues in the third quarter of 2013 as compared to the second quarter of 2013. We expect this trend to continue due to reduced demand for current therapies for HCV infection, the anticipated introduction of new competitive therapies in the fourth quarter of 2013 and the reduction in our promotion and support for INCIVEK as a result of the restructuring plan that we implemented in October 2013. In the future, we expect that our net product revenues will be dependent on continued sales of KALYDECO as a monotherapy, the outcomes of ongoing label-expansion programs for ivacaftor monotherapy and the Phase 3 clinical trials of ivacaftor and VX-809 (lumacaftor), and the potential introduction of one or more of our other drug candidates to the market.
We invest in scientific innovation to create transformative medicines for patients with serious diseases, with a focus on specialty markets. Our strategy is to make focused investments to invent and develop innovative drugs, while seeking to maintain a strong financial position. We are focusing most of our drug development investment on the following key programs:
Cystic Fibrosis - Our goal is to develop treatment regimens that will provide benefits to as many patients with CF as possible and to maximize those benefits. We are conducting Phase 3 label-expansion clinical trials and a proof-of-concept clinical trial of ivacaftor monotherapy in patients with certain mutations in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene that were not studied in prior Phase 3 clinical trials. We have submitted a supplemental New Drug Application, or sNDA, to the U.S. Food and Drug Administration, or FDA, and a Marketing Authorization Application, or MAA, variation in the European Union for the use of ivacaftor monotherapy in patients six years of age and older with gating mutations other than the G551D mutation. We have completed enrollment in an international pivotal Phase 3 development program to evaluate combinations of ivacaftor and our investigational CFTR corrector lumacaftor for patients with two copies of the most prevalent genetic mutation that causes CF.
HCV - We are seeking to develop an all-oral, interferon-free treatment regimen that is 12 weeks or less in duration with a goal of providing high viral cure rates and improved tolerability, in order to be commercially competitive in the HCV market of the future. We are conducting Phase 2 clinical trials to evaluate all-oral combination treatment regimens that include our HCV nucleotide analogue VX-135 together with molecules that have potentially complementary mechanisms, such as an HCV protease inhibitor and an HCV NS5A inhibitor.
Autoimmune Diseases - We are evaluating our JAK3 inhibitor, VX-509, in a fully-enrolled Phase 2 clinical trial. In October 2013, we announced that this clinical trial had met its primary endpoints, which were measured after 12 weeks of treatment. We expect 24-week data from this clinical trial in early 2014.
We may seek collaborators for some of our drug candidates in order to diversify risk, broaden or accelerate or otherwise benefit a development program in an effort to fully realize the value of a drug candidate.
We plan to continue investing in our research programs and supporting scientific innovation in order to identify and develop transformative medicines. We believe that pursuing research in diverse areas allows us to balance the risks inherent in drug development and may provide the drug candidates that will form our pipeline in future years. We have on-going research programs, including in the areas of CF, cancer and multiple sclerosis.


26

CF
KALYDECO (ivacaftor) is approved in the United States, Australia, Canada and the European Union for the treatment of patients with CF six years of age and older who have the G551D mutation on at least one allele of the CFTR gene. KALYDECO is currently available to eligible patients in the United States, England, Scotland, Northern Ireland, Wales, the Republic of Ireland, France, Germany, the Netherlands, Austria, Denmark, Sweden, Norway and Greece. We are in active discussions with relevant agencies in Australia and Canada regarding public reimbursement of KALYDECO in these countries. In October 2013, we presented data from an ongoing rollover clinical trial of patients six years of age and older who have the G551D mutation on at least one allele of the CFTR gene. The data from this clinical trial showed that 144 weeks of continuous treatment with KALYDECO provided durable treatment effects in lung function (FEV1), weight and other measures and a consistent safety profile to what was observed in the 48-week Phase 3 clinical trials that supported approval of KALYDECO.
We are continuing our work in CF to identify and develop treatment regimens that will provide benefits to as many patients with CF as possible and to maximize those benefits. We have multiple ongoing clinical development programs to evaluate our CF treatment regimens, and our research group is working to identify additional corrector compounds that could be included in future dual-corrector regimens in combination with ivacaftor in patients with one or two copies of the F508del mutation.
Ivacaftor (monotherapy)
We are conducting Phase 3 label-expansion clinical trials and a Phase 2 proof-of-concept clinical trial of ivacaftor monotherapy:
•
We are evaluating ivacaftor in patients six years of age and older with CF with gating mutations other than the G551D mutation in a Phase 3 clinical trial. In July 2013, we reported that patients in this clinical trial had statistically significant improvements in their lung function (FEV1) and other measures of disease. The safety and tolerability results from this clinical trial were consistent with those observed in prior Phase 3 clinical trials of ivacaftor monotherapy in patients with CF who have the G551D mutation. We submitted an sNDA to the FDA in September 2013 and an MAA variation in the European Union in October 2013 for the use of ivacaftor monotherapy in patients with CF six years of age and older who have gating mutations other than the G551D mutation. We estimate that in North America, Europe and Australia approximately 400 patients with CF six years of age and older have at least one non-G551D gating mutation.
•
We are conducting a fully-enrolled Phase 3 clinical trial evaluating ivacaftor in patients six years of age and older with CF who have the R117H mutation in the CFTR gene on at least one allele. We expect data from this clinical trial to be available at the end of 2013. If this clinical trial is successful, we plan to submit an sNDA to the FDA in early 2014 and an MAA variation in the European Union in the second quarter of 2014 for the use of ivacaftor monotherapy in patients with CF who are six years of age and older who have the R117H mutation in the CFTR gene on at least one allele. We estimate that in North America, Europe and Australia approximately 1,100 patients with CF six years of age and older have at least one copy of the R177H mutation in their CFTR gene. Patients diagnosed with CF who have the R117H mutation exhibit a range of severity and signs and symptoms of the disease, with an average life expectancy in the 50s.
•
We are conducting a fully-enrolled Phase 3 clinical trial in which we are evaluating a pediatric formulation of ivacaftor as a treatment for children with CF two to five years of age with gating mutations in the CFTR gene, including the G551D mutation. We expect data from this clinical trial in the second quarter of 2014. If this clinical trial is successful, we plan to submit an sNDA in the second half of 2014. We estimate that in North America, Europe and Australia approximately 300 patients with CF two to five years of age have a gating mutation.
•
We are conducting a fully-enrolled proof-of-concept Phase 2 clinical trial in which we are evaluating ivacaftor in patients with CF who have clinical evidence of residual CFTR function. We expect data from this clinical trial in the second quarter of 2014. We estimate that in North America, Europe and Australia more than 3,000 patients with CF six years of age and older have non-R117H CFTR mutations that result in residual function.


27

Lumacaftor in Combination with Ivacaftor
We have completed enrollment of patients in an international pivotal Phase 3 clinical program to evaluate combinations of lumacaftor and ivacaftor in patients with CF who have two copies of the F508del mutation in their CFTR gene (homozygous). We are conducting two 24-week Phase 3 clinical trials, which are referred to as TRAFFIC and TRANSPORT, that are designed to support approval of the combination of lumacaftor and ivacaftor for patients 12 years of age and older. Each Phase 3 clinical trial was designed to enroll approximately 500 patients with CF who are homozygous for the F508del mutation, for a total of approximately 1,000 patients. TRAFFIC and TRANSPORT have the same design and together are being conducted at approximately 200 clinical trial sites in North America, Europe and Australia. We expect data from TRAFFIC and TRANSPORT in mid-2014. If these clinical trials are successful, we plan to submit a New Drug Application, or NDA, to the FDA and an MAA in the European Union in the second half 2014.
We also are enrolling patients in a Phase 2 clinical trial to evaluate lumacaftor in combination with ivacaftor in children with CF six to eleven years of age who have two copies of the F508del mutation. If this Phase 2 clinical trial is successful, we plan to use the data from this clinical trial, along with data from the two Phase 3 clinical trials, for registration in the United States and European Union in patients six to eleven years of age, following registration in patients 12 years of age and older.
We recently began enrollment in an 8-week exploratory Phase 2 clinical trial of lumacaftor in combination with ivacaftor in patients with CF who are 18 years of age and older and who have one copy of the F508del mutation in their CFTR gene and one copy of a mutation in their CFTR gene that is not expected to respond to either ivacaftor or lumacaftor alone. This clinical trial will evaluate a twice-daily administration of lumacaftor (400 mg) and ivacaftor (250 mg) and is designed to provide additional safety and lung function data on the combination of ivacaftor and lumacaftor in heterozygous patients.
We estimate that in North America, Europe and Australia more than 28,000 patients with CF six years of age and older have two copies of the F508del mutation, and more than 17,000 patients with CF six years of age and older have one copy of the F508del mutation and one copy of a non-F508del mutation that is not expected to respond to ivacaftor monotherapy treatment.
VX-661
We recently began enrollment in a Phase 2 clinical trial to evaluate a four-week regimen of VX-661 in combination with ivacaftor in patients with CF who have one copy of the F508del mutation and one copy of the G551D mutation. The evaluation of this regimen is supported by in vitro data presented at the European Cystic Fibrosis Society Conference by our researchers that showed increased chloride transport in human bronchial epithelial cells with one copy of the F508del mutation and one copy of the G551D mutation, with the combination of a corrector compound and ivacaftor as compared to the use of ivacaftor alone. This clinical trial is intended to evaluate whether the addition of a corrector to treatment with KALYDECO can further enhance the clinical benefit received from KALYDECO alone in patients with the G551D and F508del mutation in their CFTR genes. We expect data from this clinical trial in the first quarter of 2014.
We are preparing to conduct a 12-week clinical trial of VX-661 in combination with ivacaftor to evaluate the combination in patients with CF who have two copies of the F508del following recent discussions with regulatory authorities. This clinical trial is designed to provide safety, efficacy and dose-response information to characterize VX-661 for further clinical development. We expect to begin enrollment in this clinical trial in the first quarter of 2014 pending protocol approval from regulatory agencies.
VX-983
Based on the emerging profiles for VX-661 and VX-983, we have prioritized VX-661 and do not intend to further develop VX-983.


28

Dual-Correctors in Combination with Ivacaftor
We have an active research program focused on identifying additional corrector compounds that could be included in future dual-corrector regimens in combination with ivacaftor in patients with one or two copies of the F508del mutation. The potential use of a dual-corrector regimen in combination with ivacaftor is supported by in vitro data presented at the European Cystic Fibrosis Society Conference that showed a combination of two CFTR correctors and ivacaftor increased chloride transport in human bronchial epithelial cells with one or two copies of the F50del mutation, as compared to the use of a single CFTR corrector in combination with ivacaftor. Our goal is to advance a second-generation CFTR corrector compound into clinical development by the end of 2014.
HCV
Janssen and we currently market INCIVEK/INCIVO (telaprevir) in competition with Merck & Co., Inc.'s VICTRELIS™ (boceprevir), another HCV protease inhibitor that was approved for sale in the United States and Europe in 2011. We expect that a number of new therapies for HCV infection will become available to patients over the next several years. The most advanced competitive drug candidates are Gilead Sciences, Inc.'s, or Gilead's, sofosbuvir (GS-7977) and Janssen's simeprevir (TMC435). Gilead and Janssen have filed NDAs for sofosbuvir and simeprevir, respectively, and FDA advisory committees have unanimously recommended approval of both sofosbuvir and simeprevir. It is anticipated that each of these drug candidates will be approved as a treatment for genotype 1 HCV infection in combination with pegylated-interferon, or peg-IFN, and ribavirin, or RBV, in the fourth quarter of 2013. The top-line results reported by Gilead and Janssen from Phase 3 clinical trials suggest that the safety and efficacy profiles of sofosbuvir and simeprevir will position them, if approved, to take a significant portion of the market for HCV therapies.
We plan to compete in the HCV infection market as it shifts away from current treatment regimens (including our INCIVEK triple-combination therapy) to regimens that incorporate new drugs with improved safety, efficacy and/or tolerability, by pursuing development of all-oral, interferon-free regimens or 12 weeks or less in duration incorporating our HCV nucleotide analogue VX-135. A number of pharmaceutical companies are investigating combination regimens that incorporate one or more of an HCV protease inhibitor, an HCV nucleotide analogue, an HCV non-nucleotide polymerase inhibitor or an NS5A inhibitor. Clinical trials of these investigational combination regimens are being conducted in a wide variety of patient populations, including treatment-naïve and treatment-failure patients, and across all HCV genotypes, which respond differently to different combinations of molecules employing different mechanisms. We expect that the market for any specific HCV treatment regimen, including INCIVEK triple-combination therapy, will be affected by the introduction of new competitive drugs or drug combinations, sales from currently approved drugs, adverse information regarding the safety characteristics or efficacy of the regimen, significant new information regarding potential treatment regimens being evaluated in clinical trials and enrollment of patients in clinical trials being conducted by us or our competitors. We expect that treatment regimens that include the administration of peg-IFN by injection will command a relatively small portion of the overall market.
We are evaluating potential all-oral treatment regimens that include our HCV nucleotide analogue VX-135 in planned and ongoing Phase 2 clinical trials in order to determine which regimen or regimens appear likely to provide benefits to patients and to advance into Phase 3 clinical development. In July 2013, the FDA placed a partial clinical hold on VX-135 in the United States, which is being evaluated in a Phase 2 clinical trial in combination with RBV in patients with genotype 1 HCV infection. The partial clinical hold prevents us from evaluating a 200 mg dose of VX-135 in the United States following observation of reversible elevated liver enzymes in patients who received 400 mg of VX-135 in combination with RBV in a Phase 2 clinical trial in Europe. Further evaluation of VX-135 in the United States is subject to the resolution of the partial clinical hold. We intend to provide further data to the FDA, including sustained viral response data from the ongoing clinical trials described below of VX-135 and RBV and VX-135 and daclatasvir, through the first half of 2014.
We, in collaboration with BMS, are evaluating VX-135 in combination with daclatasvir, an NS5A replication complex inhibitor being developed by BMS, in a Phase 2 clinical trial in New Zealand. Safety and efficacy data from the first part of this clinical trial are expected to be available in early 2014 to inform future development plans for this combination regimen.
We have completed dosing of VX-135 in combination with RBV in two clinical trials that were conducted to generate safety data for VX-135 in combination with RBV and were not intended to evaluate the combination of VX-135 and RBV as a therapeutic regimen.
•
We recently completed dosing of 100 mg and 200 mg of VX-135 in combination with RBV as part of a 12-week Phase 2 clinical trial in Europe. This clinical trial enrolled 10 patients with genotype 1 HCV infection in each 100 mg and 200 mg dose group, and all 20 patients completed 12 weeks of treatment. Both the 100 mg and 200 mg doses were well tolerated, no serious adverse events were reported and no liver or cardiac safety issues were identified. 70 percent and 80 percent of patients in the 100 mg and 200 mg dosing arms, respectively, had undetectable HCV RNA


29

levels within four weeks of initiating treatment. Sustained viral response rates 12 weeks after completion of treatment, or SVR12 rates, were 10 percent and 50 percent for the 100 mg and 200 mg groups, respectively. This clinical trial also evaluated a 400 mg dose of VX-135 in combination with RBV in 10 patients, which was discontinued following the observation of elevated liver enzymes in 3 of 10 patients in this dose group.
•
We have completed dosing of 100 mg of VX-135 in combination with RBV as part of a 12-week Phase 2 clinical trial in the United States. The 100 mg dose group enrolled 10 patients with genotype 1 HCV infection. All 10 patients completed 12 weeks of treatment. The 100 mg dose was well tolerated, no serious adverse events were reported and no liver or cardiac safety issues were identified. All patients achieved undetectable HCV RNA levels during the 12-week dosing period, and 60 percent of patients had undetectable HCV RNA levels within four weeks of initiating treatment. The sustained viral response rate four weeks after completion of treatment was 10 percent.
A drug-drug interaction clinical trial of VX-135 in combination with Janssen's HCV protease inhibitor simeprevir in healthy volunteers is complete. We are discussing with Janssen the design of additional clinical trials of VX-135 in combination with simeprevir in patients with genotype 1 HCV infection.
Some of our competitors' potential all-oral treatment regimens are more advanced, including all-oral treatment regimens that are being evaluated in Phase 3 clinical trials by Gilead and Abbvie, Inc. While the development and regulatory timelines for drug candidates for the treatment of HCV infection are subject to risk and uncertainty, we believe that (i) substantial additional clinical data regarding potential all-oral treatment regimens will become available in 2013 and 2014 and (ii) it is possible that one or more all-oral treatment regimens for genotype 1 HCV infection could be commercially available as soon as late 2014. As a result, if we are successful in developing an all-oral treatment regimen or regimens that include VX-135, independently or with a collaborator, it is likely that our all-oral treatment regimen(s) would compete directly with one or more previously approved all-oral treatment regimens.
Autoimmune Diseases
VX-509 is an investigational oral drug candidate intended to inhibit Janus kinase 3, or JAK3, which is involved in the modulation of lymphocyte that are central to autoimmune disease pathology. We are evaluating VX-509 in a double-blind, randomized, placebo-controlled 24-week Phase 2b clinical trial that enrolled and dosed 358 people with rheumatoid arthritis, or RA, who had active disease despite methotrexate treatment. Patients in the clinical trial continued to receive stable doses of methotrexate during the clinical trial. Up to 20 percent of the patients in the clinical trial could have previously been treated with a single tumor necrosis factor (TNF) inhibitor. Patients in the clinical trial were randomized to receive placebo or one of four dose regimens of VX-509 (100 mg once daily (QD), 150 mg once daily, 200 mg once daily or 100 mg given twice daily (BID)) for 24 weeks.
The primary endpoints of the clinical trial were the proportion of patients who achieved a 20 percent improvement in signs and symptoms of RA, as measured by the ACR improvement criteria, or ACR20, response at week 12 and the change from baseline in Disease Activity Score for 28 joints, or DAS28, at week 12. Additional secondary endpoints were used to evaluate the clinical activity of VX-509, including the proportion of patients who achieved 50 percent and 70 percent improvement in signs and symptoms of RA, or ACR50 and ACR70, respectively, at week 12. In all VX-509 treatment arms, the proportion of patients achieving ACR20 and ACR50 and the decrease from baseline in DAS28 were significantly greater than in placebo. The three highest dose groups showed ACR20 responses of between 58 percent and 68 percent, compared to 18 percent for placebo, and statistically significant ACR70 responses versus placebo.

In the clinical trial, adverse events led to discontinuation in 6.6 percent and 8.5 percent of patients in the VX-509 and placebo groups, respectively. Through 12 weeks, adverse event rates were 51.2 percent for the pooled VX-509 treatment group compared to 38.0 percent for those who received placebo, and the majority of adverse events observed in the clinical trial were mild to moderate. The most common adverse events in the pooled VX-509 treatment group were headache (8.0 percent), hypercholesterolemia (3.8 percent) and nasopharyngitis (3.5 percent). The safety profile of VX-509 was comparable across all treatment groups. Serious adverse events occurred in equal proportions of patients across the pooled VX-509 and placebo treatment groups (5.6 percent). Infections occurred in 22.0 percent of patients in the pooled VX-509 treatment group compared to 15.5 percent in the placebo group, and serious infections occurred in 2.8 percent of patients in the VX-509 group compared to 1.4 percent for placebo. One death, deemed unrelated to study drug, occurred in the VX-509 100 mg BID group and was due to cardiac failure. Elevations in transaminase levels and decreases in median neutrophil and lymphocyte counts were observed in the VX-509 groups and were generally mild.
The clinical trial is ongoing, and we expect 24-week data to be available in early 2014.



30

Workforce Reduction
On October 29, 2013, we announced a reduction of our workforce primarily related to the support of INCIVEK following the continued and rapid decline in the number of people being treated with INCIVEK as other new medicines for the treatment of HCV infection near approval. This action resulted from our decision to focus our investment on future opportunities in cystic fibrosis and other research and development programs, including VX-135 as part of an all-oral regimen for HCV infection.
As part of this restructuring, we are eliminating approximately 370 full-time positions globally, representing approximately a 15% reduction in our workforce. The eliminated positions included the portion of our U.S. field-based sales force focused on promoting INCIVEK. Approximately 175 positions are being eliminated in Massachusetts. Following the changes, we expect to have approximately 1,800 employees worldwide, including approximately 1,300 in Massachusetts. We estimate that we will incur aggregate restructuring charges of approximately $35.0 million to $45.0 million, including $20.0 million to $25.0 million for employee severance and benefit costs, $6.0 million to $8.0 million in assets associated with this restructuring that have become impaired and $9.0 million to $12.0 million for other costs.
Regulatory Compliance
Our marketing of pharmaceutical products, which began in 2011, is subject to extensive and complex laws and regulations. We have a corporate compliance program designed to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems and the promotion of a culture of compliance. Among other laws, regulations and standards, we are subject to various U.S. federal and state and comparable foreign laws pertaining to health care fraud and abuse, including anti-kickback and false claims statutes, and laws prohibiting the promotion of drugs for unapproved, or off-label, uses. Anti-kickback laws make it illegal for a prescription drug manufacturer to solicit, offer, receive or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase or prescription of a particular drug. False claims laws prohibit anyone from presenting for payment to third-party payors, including Medicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. We expect to continue to devote substantial resources to maintain, administer and expand these compliance programs globally.


31

RESULTS OF OPERATIONS
 
Three Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
Nine Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
2013
 
2012
 
$
 
%
 
2013
 
2012
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Revenues
$
221,700

 
$
336,006

 
$
(114,306
)
 
(34
)%
 
$
860,818

 
$
1,193,048

 
$
(332,230
)
 
(28
)%
Operating costs and expenses
355,765

 
337,077

 
18,688

 
6
 %
 
1,490,104

 
1,113,240

 
376,864

 
34
 %
Other items, net
5,403

 
(25,396
)
 
n/a

 
n/a

 
126,285

 
(52,867
)
 
n/a

 
n/a

Net loss (income) attributable to noncontrolling interest (Alios)
4,530

 
(31,076
)
 
n/a

 
n/a

 
13,688

 
(57,825
)
 
n/a

 
n/a

Net loss attributable to Vertex
$
(124,132
)
 
$
(57,543
)
 
$
66,589

 
116
 %
 
$
(489,313
)
 
$
(30,884
)
 
$
458,429

 
1,484
 %
Net Loss Attributable to Vertex
Net loss attributable to Vertex was $(124.1) million in the third quarter of 2013 compared to net loss attributable to Vertex of $(57.5) million in the third quarter of 2012. Our revenues decreased in the third quarter of 2013 as compared to the third quarter of 2012 due to decreased INCIVEK net product revenues partially offset by increased KALYDECO net product revenues. Our operating costs and expenses increased in the third quarter of 2013 as compared to the third quarter of 2012 due to increased research and development expenses and restructuring expenses recorded in the third quarter of 2013 related to the strategic restructuring plan adopted in October 2013, partially offset by decreased cost of product revenues and sales, general and administrative expenses.
In the nine months ended September 30, 2013, net loss attributable to Vertex was $(489.3) million as compared to net loss attributable to Vertex of $(30.9) million in the nine months ended September 30, 2012. Our revenues decreased in the nine months ended September 30, 2013 as compared to the nine months ended September 30, 2012 due to decreased INCIVEK net product revenues partially offset by increased KALYDECO net product revenues and increased INCIVO royalties. Our operating costs and expenses increased from $1.1 billion in the nine months ended September 30, 2012 to $1.5 billion in the nine months ended September 30, 2013. The increase in operating costs and expenses in the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012 was primarily due to a $412.9 million intangible asset impairment charge for VX-222 recorded in the first quarter of 2013 partially offset by a $78.0 million write-off in the second quarter of 2012 for excess and obsolete INCIVEK inventories.
Stock-based compensation expense was $31.3 million and $27.6 million in the third quarter of 2013 and 2012, respectively, and $103.9 million and $86.6 million in the nine months ended September 30, 2013 and 2012, respectively.
Net Loss Attributable to Vertex per Diluted Share
Net loss attributable to Vertex was $(0.54) per diluted share in the third quarter of 2013 as compared to net loss attributable to Vertex of $(0.27) per diluted share in the third quarter of 2012. Net loss attributable to Vertex was $(2.20) per diluted share in the nine months ended September 30, 2013 compared to net loss attributable to Vertex of $(0.15) per diluted share in the nine months ended September 30, 2012.
Common Shares Outstanding
Our shares of outstanding common stock increased by 16.3 million shares from 217.3 million shares on December 31, 2012 to 233.6 million shares on September 30, 2013 due to the approximately 8.3 million shares of common stock we issued in the second quarter of 2013 in connection with the conversions of our 3.35% convertible senior subordinated notes due 2015, or 2015 Notes, and the approximately 8.0 million shares of common stock we issued in the nine months ended September 30, 2013 pursuant to our employee equity programs.


32

Revenues
 
Three Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
Nine Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
2013
 
2012
 
$
 
%
 
2013
 
2012
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Product revenues, net
$
186,653

 
$
303,501

 
$
(116,848
)
 
(39
)%
 
$
708,823

 
$
1,052,149

 
$
(343,326
)
 
(33
)%
Royalty revenues
27,012

 
25,586

 
1,426

 
6
 %
 
119,705

 
98,047

 
21,658

 
22
 %
Collaborative revenues
8,035

 
6,919

 
1,116

 
16
 %
 
32,290

 
42,852

 
(10,562
)
 
(25
)%
Total revenues
$
221,700

 
$
336,006

 
$
(114,306
)
 
(34
)%
 
$
860,818

 
$
1,193,048

 
$
(332,230
)
 
(28
)%
Product Revenues, Net
 
Three Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
Nine Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
2013
 
2012
 
$
 
%
 
2013
 
2012
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
INCIVEK
$
85,592

 
$
254,340

 
$
(168,748
)
 
(66
)%
 
$
446,962

 
$
939,006

 
$
(492,044
)
 
(52
)%
KALYDECO
101,061

 
49,161

 
51,900

 
106
 %
 
261,861

 
113,143

 
148,718

 
131
 %
Total product revenues, net
$
186,653

 
$
303,501

 
$
(116,848
)
 
(39
)%
 
$
708,823

 
$
1,052,149

 
$
(343,326
)
 
(33
)%
Our total net product revenues decreased in the third quarter of 2013 as compared to the third quarter of 2012 due to decreased INCIVEK net product revenues in the third quarter of 2013 as compared to the third quarter of 2012, partially offset by increased KALYDECO net product revenues in the third quarter of 2013 as compared to the third quarter of 2012. In the fourth quarter of 2013, we expect that total product revenues will be lower than the fourth quarter of 2012 due to decreased INCIVEK net product revenues.
INCIVEK net product revenues have been declining on a quarterly basis since reaching a peak in the fourth quarter of 2011 and declined by 45% in the third quarter of 2013 as compared to the second quarter of 2013. We expect our INCIVEK net product revenues to continue to decline rapidly due to reduced demand for current therapies for HCV infection, the anticipated introduction of new competitive therapies in the fourth quarter of 2013 and the reduction in our promotion and support for INCIVEK as a result of the strategic restructuring plan that we adopted in October 2013.
We began marketing KALYDECO in the United States in the first quarter of 2012 and in certain international markets in the third quarter of 2012. KALYDECO net product revenues were $101.1 million in the three months ended September 30, 2013, including $44.8 million of net product revenues from international markets. KALYDECO net product revenues increased by 2% in the third quarter of 2013 as compared to the second quarter of 2013. We believe that KALYDECO net product revenues in the fourth quarter of 2013 will be similar to KALYDECO net product revenues in the third quarter of 2013.
Royalty Revenues
Our royalty revenues were $27.0 million and $25.6 million in the three months ended September 30, 2013 and 2012, respectively. Our royalty revenues were $119.7 million and $98.0 million in the nine months ended September 30, 2013 and 2012, respectively. Our royalty revenues from INCIVO were $21.0 million and $20.0 million in the three months ended September 30, 2013 and 2012, respectively, and $104.1 million and $80.8 million in the nine months ended September 30, 2013 and 2012, respectively. Mitsubishi Tanabe's license to market telaprevir in Japan is fully paid.
We recognized royalty revenues related to sales by GlaxoSmithKline of an HIV protease inhibitor that was discovered and developed pursuant to a collaboration with GlaxoSmithKline of $6.0 million and $15.4 million in the three and nine months ended September 30, 2013, respectively, compared to $5.6 million and $17.2 million in the three and nine months ended September 30, 2012, respectively. We sold our rights to these HIV royalties in 2008 for a one-time cash payment of $160.0 million.


33

Collaborative Revenues
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Janssen
$
4,520

 
$
2,604

 
$
21,042

 
$
11,201

Mitsubishi Tanabe
—

 
—

 
—

 
18,879

CFFT and other
3,515

 
4,315

 
11,248

 
12,772

Total collaborative revenues
$
8,035

 
$
6,919

 
$
32,290

 
$
42,852

Our collaborative revenues from Janssen relate to the amortization of an up-front payment we received in 2006, net reimbursements (payments) for telaprevir development costs and reimbursements for manufacturing services. We do not expect to earn any future milestone payments pursuant to this collaboration agreement with Janssen.
In the nine months ended September 30, 2012, we recognized collaborative revenues related to a one-time payment that we received from Mitsubishi Tanabe in 2009 and revenues related to manufacturing services we provided to Mitsubishi Tanabe through our third-party manufacturing network. We did not recognize any collaborative revenues from Mitsubishi Tanabe in the nine months ended September 30, 2013 or the three months ended September 30, 2013 and do not expect to recognize any future collaborative revenues pursuant to our collaboration agreement with Mitsubishi Tanabe.
Operating Costs and Expenses
 
Three Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
Nine Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
2013
 
2012
 
$
 
%
 
2013
 
2012
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Cost of product revenues
$
20,048

 
$
30,680

 
$
(10,632
)
 
(35
)%
 
$
75,698

 
$
161,147

 
$
(85,449
)
 
(53
)%
Royalty expenses
7,291

 
7,856

 
(565
)
 
(7
)%
 
32,315

 
31,023

 
1,292

 
4
 %
Research and development expenses
228,624

 
200,161

 
28,463

 
14
 %
 
669,174

 
593,076

 
76,098

 
13
 %
Sales, general and administrative expenses
87,754

 
97,684

 
(9,930
)
 
(10
)%
 
287,154

 
326,344

 
(39,190
)
 
(12
)%
Restructuring expense
12,048

 
696

 
11,352

 
1,631
 %
 
12,863

 
1,650

 
11,213

 
680
 %
Intangible asset impairment charge
—

 
—

 
—

 
n/a

 
412,900

 
—

 
412,900

 
n/a

Total costs and expenses
$
355,765

 
$
337,077

 
$
18,688

 
6
 %
 
$
1,490,104

 
$
1,113,240

 
$
376,864

 
34
 %
Cost of Product Revenues
Our cost of product revenues includes the cost of producing inventories that corresponded to product revenues for the reporting period, plus the third-party royalties payable on our net sales of INCIVEK and KALYDECO. Cost of product revenues decreased in the third quarter of 2013 as compared to the third quarter of 2012 due to decreased product revenues. Cost of product revenues decreased in the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012 primarily due to a $78.0 million write-off of excess and obsolete INCIVEK inventories we recognized in the second quarter of 2012.
Royalty Expenses
Royalty expenses include third-party royalties payable upon net sales of telaprevir by our collaborators and royalty expenses related to a subroyalty payable to a third party on net sales of an HIV protease inhibitor sold by GlaxoSmithKline. Royalty expenses in the third quarter of 2013 decreased by $0.6 million, or 7%, compared to the third quarter of 2012, and increased by $1.3 million, or 4%, in the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012.


34

Research and Development Expenses
 
Three Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
Nine Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
2013
 
2012
 
$
 
%
 
2013
 
2012
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Research expenses
$
60,246

 
$
56,400

 
$
3,846

 
7
%
 
$
186,329

 
$
175,888

 
$
10,441

 
6
%
Development expenses
168,378

 
143,761

 
24,617

 
17
%
 
482,845

 
417,188

 
65,657

 
16
%
Total research and development expenses
$
228,624

 
$
200,161

 
$
28,463

 
14
%
 
$
669,174

 
$
593,076

 
$
76,098

 
13
%
Our research and development expenses include internal and external costs incurred for research and development of our drugs and drug candidates. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual drugs or drug candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. These internal costs are significantly greater than our external costs, such as the costs of services provided to us by clinical research organizations and other outsourced research, which we do allocate by individual program. All research and development costs for our drugs and drug candidates are expensed as incurred.
To date, we have incurred in excess of $6.1 billion in research and development expenses associated with drug discovery and development. The successful development of our drug candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the drug candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our drug candidates to market are not available.
In recent years, costs related to our CF and HCV programs have represented the largest portion of our development costs. Any estimates regarding development and regulatory timelines for our drug candidates are highly subjective and subject to change. In the first half of 2013, we initiated a pivotal Phase 3 clinical program to evaluate lumacaftor in combination with ivacaftor. If these clinical trials are successful, we plan to submit an NDA to the FDA and an MAA in the European Union in the second half of 2014. We cannot make a meaningful estimate when, if ever, our other clinical development programs will generate revenues and cash flows.
Research Expenses
 
Three Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
Nine Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
2013
 
2012
 
$
 
%
 
2013
 
2012
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Research Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
20,692

 
$
18,714

 
$
1,978

 
11
 %
 
$
65,287

 
$
57,536

 
$
7,751

 
13
 %
Stock-based compensation expense
6,577

 
6,268

 
309

 
5
 %
 
21,252

 
19,218

 
2,034

 
11
 %
Laboratory supplies and other direct expenses
11,174

 
8,730

 
2,444

 
28
 %
 
33,249

 
30,943

 
2,306

 
7
 %
Contractual services
5,500

 
5,304

 
196

 
4
 %
 
16,756

 
15,983

 
773

 
5
 %
Infrastructure costs
16,303

 
17,384

 
(1,081
)
 
(6
)%
 
49,785

 
52,208

 
(2,423
)
 
(5
)%
Total research expenses
$
60,246

 
$
56,400

 
$
3,846

 
7
 %
 
$
186,329

 
$
175,888

 
$
10,441

 
6
 %


35

We have maintained a substantial investment in research activities resulting in a 7% increase in research expenses in the third quarter of 2013 as compared to the third quarter of 2012 and a 6% increase in research expenses in the nine months ended September 30, 2013 as compared to the nine months ended September 30, 2012. We expect to continue to invest in our research programs with a focus on identifying drug candidates for specialty markets.
Development Expenses
 
Three Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
Nine Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
2013
 
2012
 
$
 
%
 
2013
 
2012
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Development Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
41,984

 
$
37,555

 
$
4,429

 
12
 %
 
$
130,379

 
$
106,700

 
$
23,679

 
22
%
Stock-based compensation expense
12,646

 
11,176

 
1,470

 
13
 %
 
43,060

 
35,207

 
7,853

 
22
%
Laboratory supplies and other direct expenses
11,639

 
7,953

 
3,686

 
46
 %
 
33,166

 
27,482

 
5,684

 
21
%
Contractual services
66,386

 
58,500

 
7,886

 
13
 %
 
170,224

 
157,763

 
12,461

 
8
%
Drug supply costs
9,773

 
1,705

 
8,068

 
473
 %
 
25,873

 
10,681

 
15,192

 
142
%
Infrastructure costs
25,950

 
26,872

 
(922
)
 
(3
)%
 
80,143

 
79,355

 
788

 
1
%
Total development expenses
$
168,378

 
$
143,761

 
$
24,617

 
17
 %
 
$
482,845

 
$
417,188

 
$
65,657

 
16
%
Our development expenses increased by $24.6 million, or 17%, in the third quarter of 2013 as compared to the third quarter of 2012, principally due to increased compensation expenses, contractual services expenses and drug supply costs. Our development expenses increased by $65.7 million, or 16%, in the nine months ended September 30, 2013 as compared to the nine months ended September 30, 2012, principally due to increased compensation expenses, contractual services expenses and drug supply costs. We expect our development expenses to increase in 2013 as compared to 2012 due to ongoing and planned clinical trials in the areas of CF, HCV infection and autoimmune diseases.
Sales, General and Administrative Expenses
 
Three Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
Nine Months Ended September 30,
 
Increase/
(Decrease)
 
Increase/
(Decrease)
 
2013
 
2012
 
$
 
%
 
2013
 
2012
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Sales, general and administrative expenses
$
87,754

 
$
97,684

 
$
(9,930
)
 
(10
)%
 
$
287,154

 
$
326,344

 
$
(39,190
)
 
(12
)%
Sales, general and administrative expenses decreased by 10% and 12% in the three and nine months ended September 30, 2013, respectively, as compared to the three and nine months ended September 30, 2012, primarily due to decreased INCIVEK and KALYDECO marketing expenses in the United States, partially offset by increased KALYDECO marketing expenses in international markets.


36

Restructuring Expense
On October 29, 2013, we announced a reduction of our workforce. As part of this restructuring, we are eliminating approximately 370 full-time positions globally, representing approximately a 15% reduction in our workforce. We estimate that we will incur aggregate restructuring charges of approximately $35.0 million to $45.0 million, including $20.0 million to $25.0 million for employee severance and benefit costs, $6.0 million to $8.0 million in assets associated with this restructuring that have become impaired and $9.0 million to $12.0 million for other costs. We recorded $11.4 million of these restructuring charges in the third quarter of 2013. Prior to this workforce reduction, our restructuring expense primarily related to remaining lease obligations for space that we do not occupy following restructuring activities in 2003.
In the three months ended September 30, 2013 and 2012, we recorded restructuring expense of $12.0 million and $0.7 million, respectively. In the nine months ended September 30, 2013 and 2012, we recorded restructuring expense of $12.9 million and $1.7 million, respectively.
Intangible Asset Impairment Charge
In the first quarter of 2013, we evaluated for impairment VX-222, an HCV polymerase inhibitor that we acquired through our acquisition of ViroChem Pharma Inc. in 2009. We evaluated the fair value of VX-222 from the perspective of a market participant and, based on our analysis, determined that the fair value of VX-222 was zero as of March 31, 2013. Accordingly, we recorded a $412.9 million impairment charge in the nine months ended September 30, 2013. In connection with this impairment charge, we recorded a credit of $127.6 million in our provision for income taxes, resulting in a net effect on net loss attributable to Vertex related to this impairment charge of $285.3 million in the nine months ended September 30, 2013.
Other Items, net
Other income (expense), net
Other income (expense), net was $4.7 million and $(6.6) million in the three and nine months ended September 30, 2013, respectively, compared to $(4.0) million and $(11.4) million in the three and nine months ended September 30, 2012, respectively. Other income (expense), net consists of interest income, interest expense and realized foreign exchange gain (loss).
Income Taxes
In the three months ended September 30, 2013, we recorded a net benefit from income taxes of $0.8 million. This benefit from income taxes was due to a benefit from income taxes of $3.3 million attributable to noncontrolling interest (Alios) offset by a provision for income taxes of $2.6 million attributable to Vertex. In the first quarter of 2013, we determined that the fair value of VX-222 was zero, which resulted in an impairment charge of $412.9 million in the nine months ended September 30, 2013. In connection with this impairment charge, we wrote-off the associated deferred tax liability of $127.6 million as a benefit in our condensed consolidated statements of operations in the nine months ended September 30, 2013.
For the three and nine months ended September 30, 2012, we recorded a benefit from and a provision for income taxes attributable to Vertex of $0.0 million and $1.1 million, respectively, and a provision for income taxes attributable to noncontrolling interest (Alios) of $21.4 million and $40.4 million, respectively.
Noncontrolling Interest (Alios)
The net loss (income) attributable to noncontrolling interest (Alios) recorded on our condensed consolidated statements of operations reflects Alios’ net loss for the reporting period, adjusted for any changes during the reporting period in the fair value of the contingent milestone and royalty payments payable by us to Alios BioPharma, Inc., or Alios.


37

A summary of net loss (income) attributable to noncontrolling interest (Alios) in the three and nine months ended September 30, 2013 and 2012 is as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Loss before provision for (benefit from) income taxes
$
9,056

 
$
5,090

 
$
21,177

 
$
14,581

Decrease (increase) in fair value of contingent milestone and royalty payments
(1,220
)
 
(57,560
)
 
1,600

 
(112,760
)
Provision for (benefit from) income taxes
(3,306
)
 
21,394

 
(9,089
)
 
40,354

Net loss (income) attributable to noncontrolling interest (Alios)
$
4,530

 
$
(31,076
)
 
$
13,688

 
$
(57,825
)
In the three and nine months ended September 30, 2013, the fair value of the contingent milestone payments and royalties payable by us to Alios related to the HCV nucleotide analogue program increased by $1.2 million and decreased by $1.6 million, respectively.
In the three and nine months ended September 30, 2012, the fair value of contingent milestone and royalty payments increased by $57.6 million and $112.8 million, respectively, primarily because we received positive clinical data from a Phase 1 clinical trial evaluating ALS-2200, now being developed as VX-135, which increased the probability that Alios would earn future payments from us under the license and collaboration agreement we entered into with Alios in June 2011.
Since June 2011, the fair value of the contingent milestone and royalty payments payable by us to Alios has increased by $183.3 million as a result of the advances in the clinical development program for VX-135. Increases in the fair value of the contingent milestone payments and royalties payable by us to Alios result in an increase in net loss attributable to Vertex (or a decrease in net income attributable to Vertex) on a dollar-for-dollar basis. If VX-135 continues to advance in clinical development, we expect to record additional increases in the fair value of these contingent milestone and royalty payments. Changes in the fair value of these contingent milestone and royalty payments and the effects of these changes on net loss were material in the periods presented and may be material in future periods.
LIQUIDITY AND CAPITAL RESOURCES
As of September 30, 2013, we had cash, cash equivalents and marketable securities, excluding Alios’ cash and cash equivalents, of $1.4 billion, which was an increase of $101.4 million from $1.3 billion as of December 31, 2012. This increase was due to cash receipts from product sales and royalties and $242.4 million in cash we received from issuances of common stock pursuant to employee benefit plans, partially offset by cash expenditures we made during the nine months ended September 30, 2013 related to, among other things, research and development expenses and sales, general and administrative expenses, as well as $114.8 million for capital expenditures for property and equipment. In addition, in the nine months ended September 30, 2013, we began supporting $31.9 million in irrevocable stand-by letters of credit issued in support of property leases and other similar agreements with an unsecured credit facility with a one-year term. We previously had cash-collateralized these stand-by letters of credit. As a result of this credit facility, our restricted cash decreased by $31.8 million net of other activity recorded during the nine months ended September 30, 2013 and our cash and cash equivalents increased by a corresponding amount.
As of December 31, 2012, we had $400.0 million in aggregate principal amount of 2015 Notes. In addition to the $400.0 million in aggregate principal amount, which was scheduled to mature on October 1, 2015, we were scheduled to make interest payments in an aggregate amount of $33.5 million during the period from June 30, 2013 through October 1, 2015. In the second quarter of 2013, we called the 2015 Notes for redemption pursuant to a soft-call provision in the 2015 Notes that permitted us to call the 2015 Notes if the price of our common stock exceeded 130% of the conversion price over a specified period. In response to our call of the 2015 Notes for redemption, the holders of the 2015 Notes converted the 2015 Notes into 8.2 million shares of our common stock and received an additional 0.1 million shares of our common stock to compensate them for the semi-annual interest payment that would have been payable on October 1, 2013. As a result of these conversions, as of September 30, 2013, we had no remaining 2015 Notes and our future cash commitments related to the 2015 Notes had been reduced by $400.0 million in aggregate principal amount of 2015 Notes plus the associated future interest payments.


38

Sources of Liquidity
We intend to rely on cash flows from product sales as our primary source of liquidity and cash flows from royalties as a secondary source of liquidity. Our cash flows from product sales have been decreasing in recent periods, and our future cash flows from product sales will be dependent on continued sales of KALYDECO as a monotherapy, the outcomes of ongoing label-expansion programs for ivacaftor monotherapy and the Phase 3 clinical trials of ivacaftor and VX-809 (lumacaftor), and the potential introduction of one or more of our other drug candidates to the market. In recent periods, we also have received significant proceeds from the issuance of common stock under our employee benefit plans, but the amount and timing of future proceeds from employee benefits plans is uncertain. Other possible sources of liquidity include commercial debt, public and private offerings of our equity and debt securities, strategic collaborative agreements that include research and/or development funding, development milestones and royalties on the sales of products, software and equipment leases, strategic sales of assets or businesses and financial transactions.
Future Capital Requirements
We are incurring substantial expenses on our research and development programs and to commercialize KALYDECO. In addition, we have substantial facility and capital lease obligations, including leases for two buildings at Fan Pier that continue through 2028.
We expect that cash flows from KALYDECO and INCIVEK/INCIVO together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by KALYDECO and INCIVEK/INCIVO, and the number, breadth, cost and prospects of our research and development programs.
Financing Strategy
Although we do not have any plans to do so in the near term, we may raise additional capital through public offerings or private placements of our securities. In addition, we may raise additional capital through securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and to consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
CONTRACTUAL COMMITMENTS AND OBLIGATIONS
Our commitments and obligations were reported in our Annual Report on Form 10-K for the year ended December 31, 2012, which was filed with the Securities and Exchange Commission, or SEC, on March 1, 2013. There have been no material changes from the contractual commitments and obligations previously disclosed in that Annual Report on Form 10-K, except that as of September 30, 2013 none of our 2015 Notes remained outstanding and as a result our total commitments and obligations for 2013-2015 decreased by $400.0 million in aggregate principal amount of 2015 Notes plus the associated future interest payments.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the three months ended September 30, 2013, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2012, which was filed with the SEC on March 1, 2013.


39


RECENT ACCOUNTING PRONOUNCEMENTS
Refer to Note A, "Basis of Presentation and Accounting Policies," in the accompanying notes to the condensed consolidated financial statements for a discussion of recent accounting pronouncements. There were no new accounting pronouncements adopted during the three and nine months ended September 30, 2013 that had a material effect on our financial statements.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes. We do not have derivative financial instruments in our investment portfolio.
Interest Rate Risk
We invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment grade corporate bonds and commercial paper, and money market funds. These investments are denominated in U.S. dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative nature of these instruments, we do not believe that we have a material exposure to interest rate risk.
Foreign Exchange Market Risk
As a result of our foreign operations, we face exposure to movements in foreign currency exchange rates, primarily the Euro, Swiss Franc, British Pound and Canadian Dollar against the U.S. dollar. The current exposures arise primarily from cash, accounts receivable, intercompany receivables, payables and inventories, and calculations of royalties receivable from net sales denominated in foreign currencies. Both positive and negative affects to our net revenues from international product sales from movements in foreign currency exchange rates are partially mitigated by the natural, opposite affect that foreign currency exchange rates have on our international operating costs and expenses.
In the fourth quarter of 2013, we plan to implement a foreign currency management program with the objective of reducing the volatility of exchange rate fluctuations on our operating results and to increase the visibility of the foreign exchange impact on forecasted revenues.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our chief executive officer and chief financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, as of September 30, 2013 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended September 30, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


40


PART II. Other Information
Item 1.     Legal Proceedings
On September 6, 2012, a purported shareholder class action, City of Bristol Pension Fund v. Vertex Pharmaceuticals Incorporated, et al., was filed in the United States District Court for the District of Massachusetts, naming us and certain of our current and former officers and directors as defendants. The lawsuit alleges that we made material misrepresentations and/or omissions of material fact in our public disclosures during the period from May 7, 2012 through June 28, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. By order dated December 12, 2012, the court appointed the City of Bristol lead plaintiff and appointed the City of Bristol's attorneys lead counsel. The plaintiffs filed an amended complaint on February 11, 2013. We filed a motion to dismiss the complaint on April 12, 2013. On May 28, 2013, the plaintiffs filed an opposition to our motion to dismiss the complaint. On June 27, 2013, we filed a reply in further support of our motion to dismiss the plaintiffs' complaint. The court has scheduled a hearing on our motion to dismiss for November 25, 2013.
The plaintiffs seek unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney's fees, as well as disgorgement of the proceeds from certain individual defendants' sales of our common stock. We believe that this action is without merit and intend to defend it vigorously.
Item 1A. Risk Factors
Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012, which was filed with the SEC on March 1, 2013. There have been no material changes from the risk factors previously disclosed in that Annual Report on Form 10-K except as set forth in Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I-Item 2, contain or incorporate a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding:
•
expectations regarding the amount of, timing of and trends with respect to our revenues, costs and expenses and other gains and losses, including those related to net product revenues from sales of INCIVEK and KALYDECO and royalty revenues from net sales of INCIVO and to the intangible assets associated with the Alios collaboration;
•
our expectations regarding clinical trials, development timelines and regulatory authority filings and submissions for ivacaftor, lumacaftor, VX-135, VX-509 and VX-661;
•
our expectations regarding the timing of data from our clinical trials of ivacaftor monotherapy and lumacaftor in combination with ivacaftor, the possibility of using that data to support regulatory submissions and the timing of those potential submissions;
•
our ability to successfully market INCIVEK and/or KALYDECO or any of our other drug candidates for which we obtain regulatory approval;
•
our expectations regarding the timing and structure of clinical trials of our drugs and drug candidates, including, ivacaftor, lumacaftor, VX-135, VX-509 and VX-661, and the expected timing of our receipt of data from our ongoing and planned clinical trials;
•
our intent to provide further data to the FDA, including sustained viral response data from our ongoing clinical trials of VX-135 and RBV and VX-135 and daclatasvir, through the first half of 2014;
•
the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance molecules, continue development or support regulatory filings;

41

•
our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our drug candidates for further investigation, clinical trials or potential use as a treatment;
•
the focus of our drug development efforts and our financial and management resources and our plan to continue investing in our research and development programs and our strategy to develop our drug candidates, alone or with third party-collaborators;
•
the establishment, development and maintenance of collaborative relationships;
•
potential business development activities;
•
our estimates regarding the charges associated with the October 2013 workforce reduction and restructuring activities;
•
our ability to use our research programs to identify and develop new drug candidates to address serious diseases and significant unmet medical needs;
•
our estimates regarding obligations associated with a lease of a facility in Kendall Square, Cambridge, Massachusetts; and
•
our liquidity and our expectations regarding the possibility of raising additional capital.
Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from expected results. We also provide a cautionary discussion of risks and uncertainties under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012, which was filed with the SEC on March 1, 2013 and was supplemented by Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, which was filed with the SEC on August 2, 2013. These are factors and uncertainties that we think could cause our actual results to differ materially from expected results. Other factors and uncertainties besides those listed there could also adversely affect us.
Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “intends,” “expects” and similar expressions are intended to identify forward-looking statements. There are a number of factors and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control. In addition, the forward-looking statements contained herein represent our estimate only as of the date of this filing and should not be relied upon as representing our estimate as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
The table set forth below shows all repurchases of securities by us during the three months ended September 30, 2013:
Period
 
Total Number
of Shares Purchased
Average Price
Paid per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares that May Yet
be Purchased Under
the Plans or Programs
July 1, 2013 to July 31, 2013
19,506

$
0.01

—
—
August 1, 2013 to August 31, 2013
38,061

$
0.01

—
—
September 1, 2013 to September 30, 2013
29,099

$
0.01

—
—
The repurchases were made under the terms of our Amended and Restated 2006 Stock and Option Plan. Under this plan, we award shares of restricted stock to our employees that typically are subject to a lapsing right of repurchase by us. We may exercise this right of repurchase if a restricted stock recipient’s service to us is terminated. If we exercise this right, we are required to repay the purchase price paid by or on behalf of the recipient for the repurchased restricted shares, which typically


42

is the par value per share of $0.01. Repurchased shares are returned to the Amended and Restated 2006 Stock and Option Plan and are available for future awards under the terms of that plan.
Item 6.    Exhibits
Exhibit Number
Exhibit Description
31.1
Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification of the Chief Executive Officer and the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
XBRL Instance
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation
101.LAB
XBRL Taxonomy Extension Labels
101.PRE
XBRL Taxonomy Extension Presentation
101.DEF
XBRL Taxonomy Extension Definition



43

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Vertex Pharmaceuticals Incorporated
 
 
 
November 7, 2013
By:
/s/ Ian F. Smith
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer
(principal financial officer and
duly authorized officer)



44
 EX-31.1 2 a2013q210-q_exhibit3112.htm EX-31.1 2013 Q2 10-Q_Exhibit 31.1 (2)


Exhibit 31.1
CERTIFICATION
I, Jeffrey M. Leiden, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
November 7, 2013
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President




 EX-31.2 3 a2013q210-q_exhibit3122.htm EX-31.2 2013 Q2 10-Q_Exhibit 31.2 (2)


Exhibit 31.2
CERTIFICATION
I, Ian F. Smith, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
November 7, 2013
/s/ Ian F. Smith
 
 
 
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer



 EX-32.1 4 a2013q210-q_exhibit3212.htm EX-32.1 2013 Q2 10-Q_Exhibit 32.1 (2)


Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
November 7, 2013
 
 
 
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President
 
 
 
Date:
November 7, 2013
 
 
 
/s/ Ian F. Smith
 
 
 
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 





 EX-101.INS 5 vrtx-20130930.xml XBRL INSTANCE DOCUMENT 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2006-01-01 2006-12-31 0000875320 vrtx:JanssenCollaborativeAgreementMember 2006-01-01 2006-12-31 0000875320 2008-01-01 2008-12-31 0000875320 vrtx:MitsubishiTanabeCollaborativeAgreementMember 2009-01-01 2009-12-31 0000875320 vrtx:KendallRestructuringMember 2010-01-01 2010-01-31 0000875320 vrtx:ConvertibleSeniorSubordinatedNotes335PercentDue2015Member 2010-09-01 2010-09-30 0000875320 2011-04-01 2011-06-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2011-04-01 2011-04-30 0000875320 vrtx:MitsubishiTanabeCollaborativeAgreementMember 2011-01-01 2011-12-31 0000875320 vrtx:AliosBioPharmaIncMember 2012-04-01 2012-06-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2012-04-01 2012-06-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2012-04-01 2012-06-30 0000875320 2012-07-01 2012-09-30 0000875320 2012-01-01 2012-09-30 0000875320 us-gaap:ConvertibleDebtSecuritiesMember 2012-01-01 2012-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-09-30 0000875320 us-gaap:RestrictedStockMember 2012-01-01 2012-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2012-01-01 2012-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2012-01-01 2012-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2012-01-01 2012-09-30 0000875320 vrtx:KendallRestructuringMember 2012-01-01 2012-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-01-01 2012-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-09-30 0000875320 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2012-01-01 2012-09-30 0000875320 us-gaap:ParentMember 2012-01-01 2012-09-30 0000875320 us-gaap:RetainedEarningsMember 2012-01-01 2012-09-30 0000875320 vrtx:RedeemableNoncontrollingInterestsMember 2012-01-01 2012-09-30 0000875320 vrtx:AliosBioPharmaIncMember 2012-01-01 2012-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2012-01-01 2012-09-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2012-01-01 2012-09-30 0000875320 vrtx:MitsubishiTanabeCollaborativeAgreementMember 2012-01-01 2012-09-30 0000875320 us-gaap:ConvertibleDebtSecuritiesMember 2012-07-01 2012-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2012-07-01 2012-09-30 0000875320 us-gaap:RestrictedStockMember 2012-07-01 2012-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2012-07-01 2012-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2012-07-01 2012-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2012-07-01 2012-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2012-07-01 2012-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2012-07-01 2012-09-30 0000875320 vrtx:KendallRestructuringMember 2012-07-01 2012-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2012-07-01 2012-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2012-07-01 2012-09-30 0000875320 vrtx:AliosBioPharmaIncMember 2013-06-01 2013-06-30 0000875320 vrtx:ConvertibleSeniorSubordinatedNotes335PercentDue2015Member 2013-04-01 2013-06-30 0000875320 2013-07-01 2013-09-30 0000875320 vrtx:AliosBioPharmaIncMember 2011-06-12 2013-09-30 0000875320 2013-01-01 2013-09-30 0000875320 us-gaap:ParentMember 2013-01-01 2013-09-30 0000875320 us-gaap:ConvertibleDebtSecuritiesMember 2013-01-01 2013-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-09-30 0000875320 us-gaap:RestrictedStockMember 2013-01-01 2013-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2013-01-01 2013-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2013-01-01 2013-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2013-01-01 2013-09-30 0000875320 vrtx:Vx222AssetMember 2013-01-01 2013-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2013-01-01 2013-09-30 0000875320 us-gaap:ForeignCurrencyGainLossMember 2013-01-01 2013-09-30 0000875320 us-gaap:MaximumMember us-gaap:EmployeeSeveranceMember vrtx:StrategicRestructuringMember us-gaap:SubsequentEventMember 2013-01-01 2013-09-30 0000875320 us-gaap:MaximumMember us-gaap:OtherRestructuringMember vrtx:StrategicRestructuringMember us-gaap:SubsequentEventMember 2013-01-01 2013-09-30 0000875320 us-gaap:MaximumMember vrtx:AssetImpairmentsMember vrtx:StrategicRestructuringMember us-gaap:SubsequentEventMember 2013-01-01 2013-09-30 0000875320 us-gaap:MaximumMember vrtx:StrategicRestructuringMember us-gaap:SubsequentEventMember 2013-01-01 2013-09-30 0000875320 us-gaap:MinimumMember us-gaap:EmployeeSeveranceMember vrtx:StrategicRestructuringMember us-gaap:SubsequentEventMember 2013-01-01 2013-09-30 0000875320 us-gaap:MinimumMember us-gaap:OtherRestructuringMember vrtx:StrategicRestructuringMember us-gaap:SubsequentEventMember 2013-01-01 2013-09-30 0000875320 us-gaap:MinimumMember vrtx:AssetImpairmentsMember vrtx:StrategicRestructuringMember us-gaap:SubsequentEventMember 2013-01-01 2013-09-30 0000875320 us-gaap:MinimumMember vrtx:StrategicRestructuringMember us-gaap:SubsequentEventMember 2013-01-01 2013-09-30 0000875320 vrtx:KendallRestructuringMember 2013-01-01 2013-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-01-01 2013-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-09-30 0000875320 us-gaap:CommonStockMember 2013-01-01 2013-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2013-01-01 2013-09-30 0000875320 us-gaap:ParentMember 2013-01-01 2013-09-30 0000875320 us-gaap:RetainedEarningsMember 2013-01-01 2013-09-30 0000875320 vrtx:RedeemableNoncontrollingInterestsMember 2013-01-01 2013-09-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2013-01-01 2013-09-30 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2013-01-01 2013-09-30 0000875320 vrtx:CopayMitigationRebatesMember 2013-01-01 2013-09-30 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2013-01-01 2013-09-30 0000875320 vrtx:AliosBioPharmaIncMember 2013-01-01 2013-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2013-01-01 2013-09-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2013-01-01 2013-09-30 0000875320 us-gaap:ConvertibleDebtSecuritiesMember 2013-07-01 2013-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2013-07-01 2013-09-30 0000875320 us-gaap:RestrictedStockMember 2013-07-01 2013-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2013-07-01 2013-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2013-07-01 2013-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2013-07-01 2013-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2013-07-01 2013-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2013-07-01 2013-09-30 0000875320 us-gaap:ContractTerminationMember vrtx:StrategicRestructuringMember 2013-07-01 2013-09-30 0000875320 us-gaap:EmployeeSeveranceMember vrtx:StrategicRestructuringMember 2013-07-01 2013-09-30 0000875320 vrtx:AssetImpairmentsMember vrtx:StrategicRestructuringMember 2013-07-01 2013-09-30 0000875320 vrtx:KendallRestructuringMember 2013-07-01 2013-09-30 0000875320 vrtx:StrategicRestructuringMember 2013-07-01 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars2001ToDollars3000Member 2013-07-01 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars3001ToDollars4000Member 2013-07-01 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars4001ToDollars5000Member 2013-07-01 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars5001ToDollars6000Member 2013-07-01 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars60.01to70.00Member 2013-07-01 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars70.01to80.00MemberDomain 2013-07-01 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars80.01to88.18Domain 2013-07-01 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars907ToDollars2000Member 2013-07-01 2013-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2013-07-01 2013-09-30 0000875320 us-gaap:ParentMember 2013-07-01 2013-09-30 0000875320 vrtx:AliosBioPharmaIncMember 2013-07-01 2013-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2013-07-01 2013-09-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2013-07-01 2013-09-30 0000875320 vrtx:MitsubishiTanabeCollaborativeAgreementMember 2013-07-01 2013-09-30 0000875320 vrtx:KendallRestructuringMember 2003-12-31 0000875320 vrtx:ConvertibleSeniorSubordinatedNotes335PercentDue2015Member 2010-09-30 0000875320 2011-12-31 0000875320 vrtx:KendallRestructuringMember 2011-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000875320 us-gaap:CommonStockMember 2011-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2011-12-31 0000875320 us-gaap:ParentMember 2011-12-31 0000875320 us-gaap:RetainedEarningsMember 2011-12-31 0000875320 vrtx:RedeemableNoncontrollingInterestsMember 2011-12-31 0000875320 vrtx:KendallRestructuringMember 2012-06-30 0000875320 2012-09-30 0000875320 vrtx:KendallRestructuringMember 2012-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2012-09-30 0000875320 us-gaap:CommonStockMember 2012-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2012-09-30 0000875320 us-gaap:ParentMember 2012-09-30 0000875320 us-gaap:RetainedEarningsMember 2012-09-30 0000875320 vrtx:RedeemableNoncontrollingInterestsMember 2012-09-30 0000875320 2012-12-31 0000875320 vrtx:Vx222AssetMember us-gaap:ResearchAndDevelopmentArrangementMember 2012-12-31 0000875320 us-gaap:ResearchAndDevelopmentArrangementMember vrtx:AliosBioPharmaIncMember 2012-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2012-12-31 0000875320 us-gaap:ForeignCurrencyGainLossMember 2012-12-31 0000875320 vrtx:KendallRestructuringMember 2012-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000875320 us-gaap:CommonStockMember 2012-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2012-12-31 0000875320 us-gaap:ParentMember 2012-12-31 0000875320 us-gaap:RetainedEarningsMember 2012-12-31 0000875320 vrtx:RedeemableNoncontrollingInterestsMember 2012-12-31 0000875320 us-gaap:AllowanceForSalesReturnsMember 2012-12-31 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2012-12-31 0000875320 vrtx:CopayMitigationRebatesMember 2012-12-31 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2012-12-31 0000875320 vrtx:AliosBioPharmaIncMember 2012-12-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2012-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2012-12-31 0000875320 us-gaap:CommercialPaperMember 2012-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2012-12-31 0000875320 us-gaap:USTreasurySecuritiesMember 2012-12-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2012-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueAfterOneYearThroughFiveYearsMember 2012-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2012-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2012-12-31 0000875320 vrtx:Vx222AssetMember us-gaap:ResearchAndDevelopmentArrangementMember 2013-03-31 0000875320 2013-06-30 0000875320 vrtx:KendallRestructuringMember 2013-06-30 0000875320 2013-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2013-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2013-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2013-09-30 0000875320 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2013-09-30 0000875320 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2013-09-30 0000875320 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2013-09-30 0000875320 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2013-09-30 0000875320 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2013-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2013-09-30 0000875320 us-gaap:ForeignCurrencyGainLossMember 2013-09-30 0000875320 us-gaap:ContractTerminationMember vrtx:StrategicRestructuringMember 2013-09-30 0000875320 us-gaap:EmployeeSeveranceMember vrtx:StrategicRestructuringMember 2013-09-30 0000875320 vrtx:AssetImpairmentsMember vrtx:StrategicRestructuringMember 2013-09-30 0000875320 vrtx:KendallRestructuringMember 2013-09-30 0000875320 vrtx:StrategicRestructuringMember 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars2001ToDollars3000Member 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars3001ToDollars4000Member 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars4001ToDollars5000Member 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars5001ToDollars6000Member 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars60.01to70.00Member 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars70.01to80.00MemberDomain 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars80.01to88.18Domain 2013-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars907ToDollars2000Member 2013-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2013-09-30 0000875320 us-gaap:CommonStockMember 2013-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2013-09-30 0000875320 us-gaap:ParentMember 2013-09-30 0000875320 us-gaap:RetainedEarningsMember 2013-09-30 0000875320 vrtx:RedeemableNoncontrollingInterestsMember 2013-09-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2013-09-30 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2013-09-30 0000875320 vrtx:CopayMitigationRebatesMember 2013-09-30 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2013-09-30 0000875320 vrtx:AliosBioPharmaIncMember 2013-09-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2013-09-30 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2013-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember 2013-09-30 0000875320 us-gaap:CommercialPaperMember 2013-09-30 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-09-30 0000875320 us-gaap:USTreasurySecuritiesMember 2013-09-30 0000875320 vrtx:CashAndMoneyMarketFundsMember 2013-09-30 0000875320 vrtx:CorporateDebtSecuritiesDueAfterOneYearThroughFiveYearsMember 2013-09-30 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2013-09-30 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2013-09-30 0000875320 2013-10-31 vrtx:leases vrtx:lines vrtx:squarefeet vrtx:building xbrli:pure vrtx:payment vrtx:segment xbrli:shares iso4217:USD iso4217:USD xbrli:shares 101292000 51533000 1054000 1251000 120281000 143250000 264884000 280848000 6689000 6099000 -550000 -550000 203000 -746000 -753000 196000 5274307000 4519448000 1097000 1097000 1097000 4200000 0 6700000 87168000 348000 87537000 87168000 104470000 104818000 104470000 369000 4230000 0 7104000 19010000 10998000 30108000 1504000 18869000 1948000 21643000 6077000 59774000 6120000 68633000 8192000 2222000 2838000 16807000 2222000 20226000 0 8192000 0 16807000 20226000 2838000 6650000 0 2759288000 2582748000 1589585000 1648631000 867403000 283942000 0 1151345000 10023000 225449000 839469000 555527000 0 831808000 15429000 148655000 39355000 125264000 440225000 111350000 555502000 15429000 111350000 440181000 125073000 39358000 225294000 831612000 10019000 839266000 0 148672000 839469000 831808000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i)&#160;the Company, (ii)&#160;its wholly-owned subsidiaries and (iii)&#160;Alios BioPharma,&#160;Inc. (&#8220;Alios&#8221;), a collaborator that is a variable interest entity (a &#8220;VIE&#8221;) for which the Company is deemed under applicable accounting guidance to be the primary beneficiary. All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2012, which are contained in the Company's Annual Report on Form&#160;10-K for the year ended December&#160;31, 2012 that was filed with the Securities and Exchange Commission (the "SEC") on March 1, 2013 (the "2012 Annual Report on Form&#160;10-K")</font></div></div> 13707000 14429000 27552000 38520000 39381000 15170000 61259000 1883000 8481000 8924000 15608000 18077000 409000 -7449000 53810000 583181000 489407000 475320000 436886000 0 308981000 308981000 0 2895000 0 2895000 0 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2013</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">580,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">580,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">583,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">583,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">555,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">555,527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">148,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">148,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due after 1 year through 5 years)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">839,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">839,469</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,422,447</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,422,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2012</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">489,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">489,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">489,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">489,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">440,181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">440,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">225,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">225,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due after 1 year through 5 years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,358</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,355</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">831,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">831,808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,321,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,321,215</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alios&#8217; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$51.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$70.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of cash and money market funds as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, recorded on the Company&#8217;s condensed consolidated balance sheets in &#8220;Restricted cash and cash equivalents (Alios),&#8221; are not included in the above table.</font></div></div> 48700000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Janssen Pharmaceutica,&#160;N.V.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2006, the Company entered into a collaboration agreement with Janssen Pharmaceutica, N.V. ("Janssen") for the development, manufacture and commercialization of telaprevir, which Janssen began marketing under the brand name INCIVO in certain of its territories in September 2011. Under the collaboration agreement, Janssen agreed to be responsible for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the drug development costs incurred under the development program for the parties&#8217; territories (North America for the Company, and the rest of the world, other than specified countries in Asia, for Janssen) and has exclusive rights to commercialize telaprevir in its territories including Europe, South America, the Middle East, Africa and Australia.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen pays the Company a tiered royalty averaging in the mid-20% range as a percentage of net sales of INCIVO in Janssen&#8217;s territories. Janssen is required under the agreement to use diligent efforts to maximize net sales of INCIVO in its territories through its commercial marketing, pricing and contracting strategies. Janssen is responsible for certain third-party royalties on net sales of INCIVO in its territories.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen made a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$165.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front license payment to the Company in 2006. The up-front license payment is being amortized over the Company&#8217;s estimated period of performance under the collaboration agreement. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$34.2 million</font><font style="font-family:inherit;font-size:10pt;"> in deferred revenues related to this up-front license payment that the Company expects to recognize over the remaining estimated period of performance. The Company's estimates regarding the period of performance under the Janssen agreement have changed in the past, and due to the evolving nature of the landscape for treatments for HCV infection, the estimated period of performance may change in the future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the collaboration agreement, Janssen agreed to make contingent milestone payments for successful development, approval and launch of telaprevir as a product in its territories. At the inception of the agreement, the Company determined that all of these contingent milestones were substantive and would result in revenues in the period in which the milestone was achieved. The Company has earned </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$350.0 million</font><font style="font-family:inherit;font-size:10pt;"> of these contingent milestone payments and does not expect to receive any further milestone payments under this agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Janssen collaboration agreement, each party incurs internal and external reimbursable expenses related to the telaprevir development program and is reimbursed by the other party for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of these expenses. The Company recognizes the full amount of the reimbursable costs it incurs as research and development expenses on its condensed consolidated statements of operations. The Company recognizes the amounts that Janssen is obligated to pay the Company with respect to reimbursable expenses, net of reimbursable expenses incurred by Janssen, as collaborative revenues. In the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred more reimbursable costs than Janssen, and the net amounts payable by Janssen to reimburse the Company were recorded as collaborative revenues.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of the parties is responsible for drug supply in its territories. During the nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012, the Company provided Janssen certain services through the Company&#8217;s third-party manufacturing network for telaprevir. Reimbursements from Janssen for these manufacturing services were recorded as collaborative revenues.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen may terminate the collaboration agreement upon the later of (i)&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> year&#8217;s advance notice and (ii)&#160;such period as may be required to assign and transfer to the Company specified filings and approvals. The agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the agreement will continue in effect until the expiration of Janssen&#8217;s royalty obligations, which expire on a country-by-country basis on the later of (a) the last-to-expire patent covering INCIVO or (b) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">ten</font><font style="font-family:inherit;font-size:10pt;"> years after the first commercial sale in the country. In the European Union, the Company has a patent covering the composition-of-matter of INCIVO that expires in 2026.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012, the Company recognized the following revenues attributable to the Janssen collaboration:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.61904761904762%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty revenues (INCIVO)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">104,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Collaborative revenues: </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortized portion of up-front payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net reimbursement (payment) for telaprevir development costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Reimbursement for manufacturing services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,299</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,449</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total collaborative revenues attributable to the Janssen collaboration</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total revenues attributable to the Janssen collaboration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,514</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92,012</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mitsubishi Tanabe Pharma Corporation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a collaboration agreement (the &#8220;MTPC Agreement&#8221;) with Mitsubishi Tanabe Pharma Corporation ("Mitsubishi Tanabe") pursuant to which Mitsubishi Tanabe has a fully-paid license to manufacture and commercialize TELAVIC (the brand name under which Mitsubishi Tanabe is marketing telaprevir) in Japan and other specified countries in Asia. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The parties entered into the MTPC Agreement in 2004 and amended it in 2009. Pursuant to the MTPC Agreement, Mitsubishi Tanabe provided financial and other support for the development and commercialization of telaprevir, made a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$105.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment in connection with the 2009 amendment of the collaboration agreement and made a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$65.0 million</font><font style="font-family:inherit;font-size:10pt;"> commercial milestone payment recognized as collaborative revenues in 2011. There are no further payments under this collaboration agreement. Mitsubishi Tanabe is responsible for its own development and manufacturing costs in its territory.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mitsubishi Tanabe may terminate the MTPC Agreement at any time without cause upon </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60</font><font style="font-family:inherit;font-size:10pt;">&#160;days&#8217; prior written notice to the Company. The MTPC Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the MTPC Agreement will continue in effect until the expiration of the last-to-expire patent covering telaprevir in Mitsubishi Tanabe's territories. In Japan, the Company has a patent covering the composition-of-matter of telaprevir that expires in 2021.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$105.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment that the Company received in 2009 in connection with the amendment to the MTPC Agreement was a nonrefundable, up-front license fee, and revenues related to the 2009 payment were recognized on a straight-line basis over the period of performance of the Company&#8217;s obligations under the amended agreement. The final deferred revenues related to the 2009 up-front license payment were recognized in April 2012. In connection with the amendment to the MTPC Agreement, the Company supplied manufacturing services to Mitsubishi Tanabe, until April 2012, through the Company&#8217;s third-party manufacturing network for telaprevir.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> collaborative revenues attributable to the Mitsubishi Tanabe collaboration in 2013 or the three months ended September 30, 2012, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.9 million</font><font style="font-family:inherit;font-size:10pt;"> in collaborative revenues attributable to the Mitsubishi Tanabe collaboration in the nine months ended September 30, 2012.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cystic Fibrosis Foundation Therapeutics Incorporated</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2011, the Company entered into an amendment (the &#8220;April 2011 Amendment&#8221;) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (&#8220;CFFT&#8221;) pursuant to which CFFT agreed to provide financial support for (i)&#160;development activities for VX-661, a corrector compound discovered under the collaboration, and (ii)&#160;additional research and development activities directed at discovering new corrector compounds.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into the original collaboration agreement with CFFT in 2004 and amended it several times prior to 2011 to, among other things, provide partial funding for its cystic fibrosis drug discovery and development efforts. In 2006, the Company received a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment from CFFT. There are no additional milestones payable by CFFT to the Company pursuant to the collaboration agreement, as amended. Under the April 2011 Amendment, CFFT agreed to provide the Company with up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> in funding over approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> years for corrector-compound research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), lumacaftor (VX-809), VX-661 and any other compounds discovered during the course of the research collaboration with CFFT. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012, the Company recognized the following revenues attributable to the CFFT collaboration:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="360px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="49px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="49px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="49px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="49px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Collaborative revenues attributable to the CFFT collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs discovered during the research term that ended in 2008, including KALYDECO, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of corrector compounds discovered during the research term that began in 2011. In each of the third quarter of 2012 and first quarter of 2013, CFFT earned a commercial milestone payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9.3 million</font><font style="font-family:inherit;font-size:10pt;"> from the Company upon achievement of certain sales levels for KALYDECO. These milestones were reflected in the Company's cost of product revenues. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO. The Company also is obligated to make up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> one-time commercial milestone payments to CFFT upon achievement of certain sales levels for corrector compounds such as lumacaftor or VX-661. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began marketing KALYDECO in the United States in the first quarter of 2012 and began marketing KALYDECO in certain countries in the European Union in the third quarter of 2012. The Company has royalty obligations to CFFT for each compound commercialized pursuant to this collaboration until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent life extensions. CFFT may terminate its funding obligations under the collaboration, as amended, in certain circumstances, in which case there will be a proportional adjustment to the royalty rates and commercial milestone payments for certain corrector compounds. The collaboration also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Alios BioPharma,&#160;Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">License and Collaboration Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2011, the Company entered into a license and collaboration agreement (the &#8220;Alios Agreement&#8221;) with Alios, a privately-held biotechnology company. The Company and Alios are collaborating on the research, development and commercialization of an HCV nucleotide analogue discovered by Alios, ALS-2200 (now formulated as VX-135), which is designed to act on the HCV polymerase. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Alios Agreement, the Company received exclusive worldwide rights to ALS-2200 (VX-135) and ALS-2158, a second HCV nucleotide analogue discovered by Alios that was only developed pursuant to the Alios Agreement through the third quarter of 2012. Upon entering into the Alios Agreement, the Company paid Alios a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front payment. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, Alios had earned an aggregate of $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development milestone payments pursuant to the Alios Agreement. The Alios Agreement provides for development milestone payments to Alios of up to an additional $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">312.5 million</font><font style="font-family:inherit;font-size:10pt;"> if VX-135 is approved and commercialized. In addition, Alios is eligible to receive commercial milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$750.0 million</font><font style="font-family:inherit;font-size:10pt;">, as well as tiered royalties on net sales of approved drugs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alios and the Company began clinical development of ALS-2200 (VX-135) in December 2011. The Company is responsible for all costs related to development, commercialization and manufacturing of compounds licensed to the Company pursuant to the Alios Agreement, provided funding to Alios to conduct the Phase&#160;1 clinical trials associated with the Alios Agreement and provided funding for a research program that was directed to the discovery of additional HCV nucleotide analogues that act on the HCV polymerase.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the Alios Agreement (i)&#160;upon </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;">&#160;days&#8217; notice to Alios if the Company ceases development after VX-135 has experienced a technical failure and/or (ii)&#160;upon </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60</font><font style="font-family:inherit;font-size:10pt;">&#160;days&#8217; notice to Alios at any time after the Company completes specified Phase&#160;2a clinical trials. The Alios Agreement also may be terminated by either party for a material breach by the other, and by Alios for the Company&#8217;s inactivity or if the Company challenges certain Alios patents, in each case subject to notice and cure provisions. Unless earlier terminated, the Alios Agreement will continue in effect until the expiration of the Company&#8217;s royalty obligations, which expire on a country-by-country basis on the later of (a)&#160;the date the last-to-expire patent covering a licensed product expires or (b)&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">ten</font><font style="font-family:inherit;font-size:10pt;"> years after the first commercial sale in the country.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alios is continuing to operate as a separate entity, is engaged in other programs directed at developing novel drugs that are not covered by the Alios Agreement and maintains ownership of the underlying patent rights that are licensed to the Company pursuant to the Alios Agreement. Under applicable accounting guidance, the Company has determined that Alios is a VIE, that Alios is a business and that the Company is Alios&#8217; primary beneficiary. The Company based these determinations on, among other factors, the significance to Alios of the licensed compounds and on the Company&#8217;s power, through the joint steering committee for the licensed compounds established under the Alios Agreement, to direct the activities that most significantly affect the economic performance of Alios.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accordingly, the Company consolidated Alios&#8217; statements of operations and balance sheet with the Company&#8217;s consolidated financial statements beginning on June&#160;13, 2011. However, the Company&#8217;s interests in Alios are limited to those accorded to the Company in the Alios Agreement. In particular, the Company did not acquire any equity interest in Alios, any interest in Alios&#8217; cash and cash equivalents or any control over Alios&#8217; activities that do not relate to the Alios Agreement. Alios does not have any rights to the Company&#8217;s assets except as provided in the Alios Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Noncontrolling Interest (Alios)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records noncontrolling interest (Alios) on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> lines on its condensed consolidated balance sheets. The noncontrolling interest (Alios) is reflected on two separate lines because Alios has both common shareholders and preferred shareholders that are entitled to redemption rights in certain circumstances. The Company records net loss (income) attributable to noncontrolling interest (Alios) on its condensed consolidated statements of operations, reflecting Alios' net loss (income) for the reporting period, adjusted for changes in the fair value of contingent milestone and royalty payments, which is evaluated each reporting period. A summary of net loss (income) attributable to noncontrolling interest (Alios) for the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012 is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.66666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss before provision for (benefit from) income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Decrease (increase) in fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(57,560</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(112,760</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for (benefit from) income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,354</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss (income) attributable to noncontrolling interest (Alios)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,530</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(31,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,688</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(57,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses present-value models to determine the estimated fair value of the contingent milestone and royalty payments, based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the time to develop drug candidates, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liability. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the contingent milestone payments and royalties payable by the Company to Alios related to the HCV nucleotide analogue program increased by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> and decreased by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. An increase in the fair value of the contingent milestone payments and royalties payable by the Company increases net loss attributable to Vertex by a corresponding amount. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the three and nine months ended September 30, 2012, the fair value of contingent milestone and royalty payments increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$57.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$112.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, primarily because the Company received positive clinical data from a Phase 1 clinical trial evaluating ALS-2200 (VX-135), which increased the probability that Alios would earn future payments from the Company under the Alios Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If VX-135 continues to advance in clinical development, the Company expects it will record increases in the fair value of the contingent milestone and royalty payments in future periods. Changes in the fair value of these contingent milestone and royalty payments, and the effects of these changes on net loss attributable to Vertex, may be material in future periods.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Alios Balance Sheet Information</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes items related to Alios included in the Company&#8217;s condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of <br clear="none"/>September 30, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of <br clear="none"/>December 31, 2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (Alios)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,983</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">861</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,689</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">150,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">152,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">873</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Redeemable noncontrolling interest (Alios)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest (Alios)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">182,168</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has recorded Alios&#8217; cash and cash equivalents as restricted cash and cash equivalents (Alios) because (i)&#160;the Company does not have any interest in or control over Alios&#8217; cash and cash equivalents and (ii)&#160;the Alios Agreement does not provide for these assets to be used for the development of the assets that the Company licensed from Alios pursuant to the Alios Agreement. Assets recorded as a result of consolidating Alios&#8217; financial condition into the Company&#8217;s condensed consolidated balance sheets do not represent additional assets that could be used to satisfy claims against the Company&#8217;s general assets.</font></div></div> 0.01 0.01 300000000 300000000 217286868 233592201 233592201 217286868 2149000 2311000 -57286000 -30247000 -489313000 -123452000 -4530000 31076000 -13688000 57825000 27578000 -503001000 -127982000 -26210000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive loss by component, net of tax:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.63492063492063%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains on Marketable Securities, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(550</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, there were no amounts reclassified from accumulated other comprehensive income (loss). Amounts reclassified for unrealized gains (losses) on available-for-sale securities are recorded as part of other income (expense), net on the Company's condensed consolidated statements of operations.</font></div></div> 290700000 467600000 400000000 0 400000000 75698000 161147000 20048000 30680000 337077000 355765000 1113240000 1490104000 21400000 0 40400000 1100000 399800000 87109 0 399842000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Senior Subordinated Notes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2010, the Company completed an offering of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$400.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3.35%</font><font style="font-family:inherit;font-size:10pt;"> convertible senior subordinated notes due 2015 (the "2015 Notes"). This offering resulted in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$391.6 million</font><font style="font-family:inherit;font-size:10pt;"> of net proceeds to the Company. The underwriting discount and other expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded as debt issuance costs and were included in other assets on the Company&#8217;s condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2015 Notes were convertible at any time, at the option of the holder, into common stock at a price equal to approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$48.83</font><font style="font-family:inherit;font-size:10pt;"> per share, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20.4794</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock per </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of the 2015 Notes. If the closing price of the Company&#8217;s common stock exceeded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price for at least </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days within a period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days, the Company had the right to redeem the 2015 Notes at its option at a redemption price equal to 100% of the principal amount of the 2015 Notes to be redeemed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2013, the Company's common stock exceeded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price of the 2015 Notes for at least </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days within a period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days, and the Company notified the holders of the 2015 Notes that it would redeem the 2015 Notes on June 17, 2013. In response to the Company's call of the 2015 Notes for redemption, in accordance with the provisions of the 2015 Notes, the holders of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$399.8 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of 2015 Notes elected to convert their 2015 Notes into the Company's common stock at the conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$48.83</font><font style="font-family:inherit;font-size:10pt;"> per share. As a result of these conversions, the Company issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8,188,448</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. The remaining </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of 2015 Notes was redeemed on June 17, 2013. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the 2015 Notes, the Company made an additional payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$16.75</font><font style="font-family:inherit;font-size:10pt;"> per </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount, payable in shares of the Company&#8217;s common stock, to the holders of the 2015 Notes that converted or redeemed their 2015 Notes after the Company called the 2015 Notes for redemption. These payments resulted in the issuance of an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">87,109</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock. In the second quarter of 2013, the Company recognized an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;"> in interest expense related to the 2015 Notes. Unamortized debt issuance costs for the 2015 Notes of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded as an offset to additional paid-in capital.</font></div></div> 48.83 0.03 0.07 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term Obligations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> leases, pursuant to which the Company agreed to lease approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> buildings (the "Buildings") that the landlord is building at Fan Pier in Boston, Massachusetts (the &#8220;Fan Pier Leases&#8221;). The Company plans to transition its Massachusetts operations from Cambridge, Massachusetts to Fan Pier upon the completion of the Buildings. The Company expects to commence lease payments in December 2013 and to make payments for the period ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15 years</font><font style="font-family:inherit;font-size:10pt;"> from the commencement date. The Company has an option to extend the term of the Fan Pier Leases for an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">ten years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company is involved in the construction project, including having responsibility to pay for a portion of the costs of finish work and structural elements of the Buildings, the Company is deemed for accounting purposes to be the owner of the Buildings during the construction period. Accordingly, the Company has recorded project construction costs incurred by the landlord as an asset and a related financing obligation in &#8220;Property and equipment, net&#8221; and &#8220;Construction financing lease obligation,&#8221; respectively, on the Company&#8217;s condensed consolidated balance sheets. The Company bifurcates its future lease payments pursuant to the Fan Pier Leases into (i)&#160;a portion that is allocated to the Buildings and (ii)&#160;a portion that is allocated to the land on which the Buildings are being constructed, which is recorded as rental expense. Although the Company will not begin making lease payments pursuant to the Fan Pier Leases until the commencement date, the portion of the lease obligations allocated to the land is treated for accounting purposes as an operating lease that commenced in 2011.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net, included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$467.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$290.7 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2012, respectively, related to construction costs for the Buildings at Fan Pier in Boston, Massachusetts. The construction financing lease obligation related to the Buildings at Fan Pier was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$392.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$268.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2012, respectively. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2012, the primary difference between the amounts recorded in property and equipment, net and the construction financing lease obligation represented the cost of finish work and structural elements of the Buildings that the Company was responsible for paying to date. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once the landlord completes the construction of the Buildings, the Company will evaluate the Fan Pier Leases in order to determine whether or not the Fan Pier Leases meet the criteria for &#8220;sale-leaseback&#8221; treatment. If the Fan Pier Leases meet the &#8220;sale-leaseback&#8221; criteria, the Company will remove the asset and the related liability from its consolidated balance sheet and treat the Fan Pier Leases as either operating or capital leases based on the Company&#8217;s assessment of the accounting guidance. The Company expects that upon completion of construction of the Buildings the Fan Pier Leases will not meet the &#8220;sale-leaseback&#8221; criteria. If the Fan Pier Leases do not meet &#8220;sale-leaseback&#8221; criteria, the Company will treat the Fan Pier Leases as a financing obligation and will depreciate the asset over its estimated useful life. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expects to incur restructuring liabilities related to lease obligations that extend beyond the cease use date for certain Cambridge, Massachusetts facilities for several years after it relocates to Fan Pier. Please refer to "Note O: Restructuring Liabilities" for further information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Capital Leases</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has outstanding capital leases for equipment, leasehold improvements and software licenses with terms through 2019. The capital leases bear interest at rates ranging from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">7%</font><font style="font-family:inherit;font-size:10pt;"> per year. The following table sets forth the Company&#8217;s future minimum payments due under capital leases as of September 30, 2013:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:447px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="332px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="95px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,924</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">409</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,259</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: amount representing interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Present value of payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">53,810</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2013, the Company began supporting </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$31.9 million</font><font style="font-family:inherit;font-size:10pt;"> in irrevocable stand-by letters of credit issued in support of property leases and other similar agreements with an unsecured credit facility with a one-year term. The Company previously had cash-collateralized these stand-by letters of credit. As a result of this credit facility, the restricted cash reflected on the Company's condensed consolidated balance sheets decreased by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$31.8 million</font><font style="font-family:inherit;font-size:10pt;"> net of other activity recorded during the nine months ended September 30, 2013 and the Company's cash and cash equivalents increased by a corresponding amount during the nine months ended September 30, 2013.</font></div></div> 127600000 34200000 27566000 31007000 96242000 77354000 2600000000 1500000000 60300000 150203000 280367000 150203000 152781000 25818000 30734000 32315000 7856000 7291000 31023000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company issues stock options, restricted stock and restricted stock units with service conditions, which are generally the vesting periods of the awards. The Company also has issued, to certain members of senior management, restricted stock and restricted stock units that vest upon the earlier of the satisfaction of (i) a performance condition or (ii) a service condition, and stock options that vest upon the earlier of the satisfaction of (a) performance conditions or (b) a service condition. In addition, the Company issues shares pursuant to an employee stock purchase plan ("ESPP").</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effect of stock-based compensation expense during the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012 was as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.65079365079364%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended </font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended </font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">68,633</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,948</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation expense included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,085</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,224</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation expense included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="26%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September&#160;30, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense,<br clear="none"/>Net of <br clear="none"/>Estimated Forfeitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition <br clear="none"/>Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">184,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.74</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.61</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">830</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.31</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="82px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="82px" rowspan="1" colspan="1"></td><td width="82px" rowspan="1" colspan="1"></td><td width="82px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="82px" rowspan="1" colspan="1"></td><td width="84px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$ 9.07&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$15.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$15.27</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$30.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,076</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$29.37</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">801</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$29.19</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$30.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$36.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$35.93</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$50.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,552</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$46.33</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">570</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$46.73</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$50.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$53.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$54.49</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$70.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.64</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$63.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$63.19</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$70.01-$80.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$77.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$77.73</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01-$88.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.81</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$83.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">166</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$81.54</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$44.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$37.87</font></div></td></tr></table></div></div></div> -2.20 -0.15 -0.54 -0.27 -2.20 -0.15 -0.54 -0.27 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share Attributable to Vertex Common Shareholders</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities described in the following table in the computation of the diluted net loss attributable to Vertex per common share calculations because the effect would have been anti-dilutive during each such period:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Convertible senior subordinated notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> -110000 2591000 888000 885000 339000 204000 103454000 830000 184969000 P3M22D P2Y8M27D P2Y7M10D 1097000 0 0 -1097000 1280 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td width="12%" rowspan="1" colspan="1"></td><td width="88%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company&#8217;s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s investments were in money market funds, short-term U.S. Treasury securities, short-term government-sponsored enterprise securities, corporate debt securities and commercial paper.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s financial assets that were subject to fair value measurements were valued using observable inputs. The Company&#8217;s financial assets valued based on Level&#160;1 inputs consisted of money market funds, U.S. Treasury securities and government-sponsored enterprise securities. The Company&#8217;s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade corporations. During the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012, the Company did not record an other-than-temporary impairment charge related to its financial assets. The Company&#8217;s noncontrolling interest (Alios) includes the fair value of the contingent milestone and royalty payments, which is valued based on Level&#160;3 inputs. Please refer to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Note C, "Collaborative Arrangements,"</font><font style="font-family:inherit;font-size:10pt;"> for further information.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets (excluding Alios&#8217; cash equivalents) subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.86507936507937%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements <br clear="none"/>as of September 30, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial assets carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">308,981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">308,981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,895</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,895</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">555,527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">555,527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">158,678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">158,678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,151,345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">867,403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">283,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alios&#8217; cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$48.7 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> consisted of money market funds, which were valued based on Level&#160;1 inputs.</font></div></div> 30992000 30992000 4890000 4890000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2012, the Company's intangible assets consisted of indefinite-lived in-process research and development assets of (i) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$250.6 million</font><font style="font-family:inherit;font-size:10pt;"> related to its HCV nucleotide analogue program, which includes the HCV nucleotide analogue VX-135, and (ii) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$412.9 million</font><font style="font-family:inherit;font-size:10pt;"> related to VX-222, which also was being developed for the treatment of HCV infection. The Company acquired VX-222 when it acquired ViroChem Pharma Inc. ("ViroChem") in 2009. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company tests intangible assets for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstance suggest that impairment may exist. In connection with each annual impairment assessment and any interim impairment assessment in which indicators of impairment have been identified, the Company compares the fair value of the asset as of the date of the assessment with the carrying value of the asset on the Company's condensed consolidated balance sheet. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with its preparation of its financial statements for the three months ended March 31, 2013, the Company determined that there were indicators that the value of the VX-222 intangible asset had become impaired.&#160; This determination was based on (a) preliminary safety, tolerability and efficacy data from a Phase&#160;2 clinical trial of VX-222, telaprevir and ribavirin, which was received in March 2013 and analyzed through April 2013 and (b) a review of the existing and emerging data regarding all-oral regimens for HCV infection being developed by the Company's competitors that appear to be generally well tolerated with high sustained viral response ("SVR") rates for treatment-na&#239;ve patients with genotype 1 HCV infection. After evaluating the data from this Phase 2 clinical trial, the Company determined that regimens containing VX-222 were unlikely to be competitive with the treatment regimens being developed by the Company's competitors. The Company evaluated the fair value of VX-222 from the perspective of a market participant and based on this analysis determined that the fair value of VX-222 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">zero</font><font style="font-family:inherit;font-size:10pt;"> as of March 31, 2013. Accordingly, the Company recorded a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$412.9 million</font><font style="font-family:inherit;font-size:10pt;"> impairment charge in the nine months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">.&#160; In connection with this impairment charge, the Company recorded a credit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$127.6 million</font><font style="font-family:inherit;font-size:10pt;"> in its provision for income taxes. In the nine months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the increase to the Company's net loss attributable to Vertex related to this impairment charge, net of the tax credit, was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$285.3 million</font><font style="font-family:inherit;font-size:10pt;">, and the net increase to the Company's net loss per share attributable to Vertex common shareholders was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.28</font><font style="font-family:inherit;font-size:10pt;"> per share. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The field of HCV infection treatment is highly competitive and characterized by rapid technological advances and the development of drug candidates for the treatment of HCV infection is subject to numerous risks. Two of the Company's competitors have filed applications seeking approval for potentially competitive treatment regimens that include pegylated-interferon and ribavirin, and several of the Company's competitors are conducting Phase&#160;3 clinical trials evaluating all-oral combinations of their drug candidates for the treatment of genotype&#160;1 HCV infection. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2013, U.S. Food and Drug Administration ("FDA") placed a partial clinical hold on VX-135, which is being evaluated in a Phase 2 clinical trial in combination with ribavirin. The partial clinical hold prevents the Company from evaluating a 200 mg dose of VX-135 in the United States following observation of reversible elevated liver enzymes in patients who received 400 mg of VX-135 in combination with ribavirin in a Phase 2 clinical trial in Europe. The Company has completed dosing of 100 mg of VX-135 in combination with ribavirin as part of the 12-week Phase 2 clinical trial in the United States. The 100 mg dose was well tolerated, no serious adverse events were reported and no liver or cardiac safety issues were identified. The Company recently completed dosing of 100 mg and 200 mg of VX-135 in combination with ribavirin as part of the 12-week Phase 2 clinical trial in Europe. Both the 100 mg and 200 mg doses were well tolerated, no serious adverse events were reported and no liver or cardiac safety issues were identified. The Company also is evaluating VX-135 in combination with daclatasvir, an NS5A replication complex inhibitor being developed by Bristol-Myers Squibb, in a Phase 2 clinical trial in New Zealand. The Company evaluated this data and the related partial clinical hold and has concluded that it does not represent an indicator of impairment. &#160;The Company will continue to evaluate VX-135 for impairment each reporting period. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the fair value of the HCV nucleotide analogue program becomes impaired as the result of unfavorable safety or efficacy data from any ongoing or future clinical trial or because of any other information regarding the prospects of successfully developing or commercializing VX-135, the Company would incur significant charges in the period in which the impairment occurs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, goodwill of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$31.0 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded on the Company's condensed consolidated balance sheets. There was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> change to goodwill recorded during the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> or 2012.</font></div></div> 0 0 0 0 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Guarantees</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As permitted under Massachusetts law, the Company&#8217;s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors&#8217; and officers&#8217; liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company&#8217;s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator&#8217;s institution relating to personal injury or property damage, violations of law or certain breaches of the Company&#8217;s contractual obligations arising out of the research or clinical testing of the Company&#8217;s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company&#8217;s contractual obligations. The indemnification provisions appearing in the Company&#8217;s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into an underwriting agreement with Merrill Lynch, Pierce, Fenner&#160;&amp; Smith Incorporated dated September&#160;23, 2010 (the &#8220;Underwriting Agreement&#8221;), relating to the public offering and sale of the 2015 Notes. The Underwriting Agreement requires the Company to indemnify the underwriter against any loss it may suffer by reason of the Company&#8217;s breach of any representation or warranty relating to the public offering, the Company&#8217;s failure to perform certain covenants in the Underwriting Agreement, the inclusion of any untrue statement of material fact in the prospectus used in connection with the offering, the omission of any material fact needed to make those materials not misleading, and any actions taken by the Company or its representatives in connection with the offering. The representations, warranties, covenants and indemnification provisions in the Underwriting Agreement are of a type customary in agreements of this sort. The Company believes the estimated fair value of this indemnification arrangement is minimal.</font></div></div> 0 0 0 412900000 412900000 285300000 68391000 -129413000 -635864000 -5112000 <div style="font-family:Times New Roman;font-size:10pt;"><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a net benefit from income taxes of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$132.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the three months ended September 30, 2013, the benefit from income taxes was due to a benefit from income taxes of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to noncontrolling interest (Alios) offset by a provision for income taxes of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to Vertex. For the nine months ended September 30, 2013, the benefit from income taxes was due to a benefit from income taxes of </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to noncontrolling interest (Alios) and a benefit from income taxes of </font><font style="font-family:inherit;font-size:10pt;">$123.8 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to Vertex. In the first quarter of 2013, the Company determined that the fair value of VX-222 was zero, which resulted in an impairment charge of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$412.9 million</font><font style="font-family:inherit;font-size:10pt;"> in the nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">. In connection with this impairment charge, the Company wrote-off the associated deferred tax liability of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$127.6 million</font><font style="font-family:inherit;font-size:10pt;"> resulting in a benefit from income in its condensed consolidated statements of operations for the nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">. Please refer to Note I, "Intangible Assets and Goodwill," for further information regarding the impairment charge. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a benefit from and a provision for income taxes attributable to Vertex of </font><font style="font-family:inherit;font-size:10pt;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. These were due to state income taxes. For the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a provision for income taxes attributable to noncontrolling interest (Alios) of </font><font style="font-family:inherit;font-size:10pt;">$21.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$40.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> liability for taxes payable by Alios. As such, the portion of the income tax provision (benefit) related to Alios has been allocated to noncontrolling interest (Alios). As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, Alios had a deferred tax liability of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$150.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$152.8 million</font><font style="font-family:inherit;font-size:10pt;"> reflected on the Company's condensed consolidated balance sheets, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains a valuation allowance on its net operating losses and other deferred tax assets because of its extended history of annual losses. As of December 31, 2012, the Company had U.S. federal net operating loss carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.6 billion</font><font style="font-family:inherit;font-size:10pt;"> and tax credits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$98.0 million</font><font style="font-family:inherit;font-size:10pt;">, which may be used to offset future federal income tax liability. For state income tax purposes, the Company had net operating loss carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.5 billion</font><font style="font-family:inherit;font-size:10pt;"> and tax credits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$60.3 million</font><font style="font-family:inherit;font-size:10pt;"> at December 31, 2012, which may be used to offset future state income tax liability. On a quarterly basis, the Company reassesses the valuation allowance for deferred income tax assets. In future periods, if management determines that it is more likely than not that the deferred tax asset will be realized, (i)&#160;the valuation allowance would be decreased, (ii)&#160;a portion or all of the deferred tax asset would be reflected on the Company&#8217;s consolidated balance sheet and (iii)&#160;the Company would record non-cash benefits in its consolidated statements of operations related to the reflection of the deferred tax asset on its consolidated balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2007 and any other major taxing jurisdiction for years before 2005, except where the Company has net operating losses or tax credit carryforwards that originated before 2005. The Company is currently under examination by Revenue Quebec for the year ended March&#160;11, 2009 and the year ended December&#160;31, 2007. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently intends to reinvest the total amount of its unremitted earnings, which have not been significant to date, in the local international jurisdiction or to repatriate the earnings only when tax-effective. As a result, the Company has not provided for U.S. federal income taxes on the unremitted earnings of its international subsidiaries. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to U.S. federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries. At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability.</font></div></div> -751000 -132863000 41450000 21355000 -9089000 -3306000 21394000 40354000 2600000 -3300000 -9100000 -123800000 -1359000 46005000 -43538000 -20737000 12027000 32872000 -32203000 -15447000 5212000 -32419000 -130164000 35759000 -1094000 997000 16477000 22698000 -31807000 -1923000 -18924000 23075000 250600000 250600000 6700000 6700000 6700000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s inventories by type:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of <br clear="none"/>September 30, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of <br clear="none"/>December 31, 2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,464</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded within cost of product revenues </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of write-offs for excess and obsolete inventories. In the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded within cost of product revenues </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$78.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of write-offs for excess and obsolete inventories.</font></div></div> 5325000 15393000 30464000 13537000 232000 3754000 7980000 11317000 10358000 78000000 5300000 0 <div style="font-family:Times New Roman;font-size:10pt;"><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 6, 2012, a purported shareholder class action, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">City of Bristol Pension Fund v. Vertex Pharmaceuticals Incorporated, et al.</font><font style="font-family:inherit;font-size:10pt;">, was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleges that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through June 28, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. By order dated December 12, 2012, the court appointed the City of Bristol lead plaintiff and appointed the City of Bristol's attorneys lead counsel. The plaintiffs filed an amended complaint on February 11, 2013. The Company filed a motion to dismiss the complaint on April 12, 2013. On May 28, 2013, the plaintiffs filed an opposition to the Company's motion to dismiss the complaint. On June 27, 2013, the Company filed a reply in further support of the Company's motion to dismiss the plaintiffs' complaint. The court has scheduled a hearing on the Company's motion to dismiss for November 25, 2013. The plaintiffs seek unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney's fees, as well as disgorgement of the proceeds from certain individual defendants' sales of the Company's common stock. The Company believes that this action is without merit and intends to defend it vigorously. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company has not recorded any reserves for this purported class action.</font></div></div> 1096068000 1524906000 2759288000 2582748000 409499000 432624000 31900000 0 0 555527000 0 0 125264000 0 0 125264000 0 555527000 0 158678000 158678000 196672000 182168000 182168000 196672000 -1263000 1094000 1094000 -1094000 1263000 1263000 -38434000 93774000 164359000 167367000 -432973000 7249000 -80425000 227282000 -124132000 -489313000 -57543000 -30884000 -30884000 -489313000 31076000 -4530000 -13688000 57825000 13688000 -31076000 4530000 -57825000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of recent accounting pronouncements please refer to Note&#160;A, "Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements," in the 2012 Annual Report on Form&#160;10-K. The Company did not adopt any new accounting pronouncements during the nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> that had a material effect on the Company's condensed consolidated financial statements.</font></div></div> 167996000 176484000 1 -1071000 79808000 -134065000 -629286000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i)&#160;the Company, (ii)&#160;its wholly-owned subsidiaries and (iii)&#160;Alios BioPharma,&#160;Inc. (&#8220;Alios&#8221;), a collaborator that is a variable interest entity (a &#8220;VIE&#8221;) for which the Company is deemed under applicable accounting guidance to be the primary beneficiary. All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2012, which are contained in the Company's Annual Report on Form&#160;10-K for the year ended December&#160;31, 2012 that was filed with the Securities and Exchange Commission (the "SEC") on March 1, 2013 (the "2012 Annual Report on Form&#160;10-K").</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, noncontrolling interest (Alios) and the income tax provision. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's significant accounting policies are described in Note&#160;A, "Nature of Business and Accounting Policies," in the 2012 Annual Report on Form&#160;10-K.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of recent accounting pronouncements please refer to Note&#160;A, "Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements," in the 2012 Annual Report on Form&#160;10-K. The Company did not adopt any new accounting pronouncements during the nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> that had a material effect on the Company's condensed consolidated financial statements.</font></div></div> 3474000 9668000 861000 153000 -7000 514000 313000 188000 -7000 313000 -7000 313000 257000 680000 0 637000 7000 -7000 324000 166000 69000 7000 324000 7000 324000 7000 250600000 663500000 250600000 412900000 0 20417000 21824000 13902000 10782000 1625000 873000 8070000 5856000 0 -6650000 0 -6650000 1393000 304000 -6578000 -11417000 -4041000 4652000 0 0 0 0 -3726000 -3901000 -11137000 -11323000 8400000 1309044000 1850015000 60000000 36922000 43094000 0.01 0.01 1000000 1000000 0 0 0 0 0 0 24673000 41104000 8821000 672000 391600000 242360000 174950000 -63242000 -6272000 31800000 1842361000 941314000 26941000 -503001000 -26467000 -128662000 -13688000 -489313000 57825000 -30884000 648924000 433609000 1728000 1374000 39624000 38530000 39624000 38530000 16.75 0 158000 2408000 14601000 200161000 228624000 669174000 593076000 51059000 69983000 51059000 69983000 127000 31934000 <div style="font-family:Times New Roman;font-size:10pt;"><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Liabilities</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Kendall Restructuring</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease that terminates in 2018, and that the Company has not used since it adopted the plan to restructure its operations in 2003. This laboratory and office space currently is subleased to third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In estimating the expense and liability under its lease obligations, the Company estimated (i)&#160;the costs to be incurred to satisfy rental and build-out commitments under the lease (including operating costs), (ii)&#160;the lead-time necessary to sublease the space, (iii)&#160;the projected sublease rental rates and (iv)&#160;the anticipated durations of subleases. The Company uses a credit-adjusted risk-free rate of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10%</font><font style="font-family:inherit;font-size:10pt;"> to discount the estimated cash flows. The Company reviews its estimates and assumptions on at least a quarterly basis, intends to continue such reviews until the termination of the applicable lease, and will make whatever modifications the Company believes necessary, based on the Company&#8217;s best judgment, to reflect any changed circumstances. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012 were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,051</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,726</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,323</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,137</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">524</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">696</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,344</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,344</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Strategic Restructuring</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2013, the Company adopted a restructuring plan. The restructuring plan included (i) a workforce reduction primarily related to the support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection near approval, and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in cystic fibrosis and other research and development programs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates that it will incur aggregate restructuring charges of approximately </font><font style="font-family:inherit;font-size:10pt;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$45.0 million</font><font style="font-family:inherit;font-size:10pt;">, including </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> for employee severance and benefit costs, </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> in assets associated with this restructuring that have become impaired and </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$12.0 million</font><font style="font-family:inherit;font-size:10pt;"> for other costs. The Company recorded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11.4 million</font><font style="font-family:inherit;font-size:10pt;"> of these restructuring charges in the third quarter of 2013. The Company expects the vast majority of this restructuring to be completed during the fourth quarter of 2013. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The restructuring charges recorded during the three months ended September 30, 2013 and the related liability balance as of September 30, 2013 for each major type of cost associated with this restructuring plan are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.65873015873017%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="42%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Restructuring Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash<br clear="none"/>Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-cash Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Restructuring Liability at September 30, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Employee severance, benefits and related costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Asset impairments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,650</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contract termination and other associated costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,444</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Move Restructuring</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with transitioning its Massachusetts operations to Fan Pier in Boston, Massachusetts, the Company expects to incur restructuring charges related to its remaining lease obligations at its current facilities in Cambridge, Massachusetts starting in the fourth quarter of 2013 and continuing through April 30, 2018. Most of these restructuring charges will relate to cease use charges that will be incurred during the fourth quarter of 2013 and the first half of 2014. In addition, the Company will continue to incur restructuring charges related to several buildings in Cambridge through December 31, 2015 and the Kendall Square building through April 30, 2018. The continuing charges will relate to the difference between the Company&#8217;s estimated future cash flows related to its lease obligations and the actual cash flows that it incurs.</font></div></div> 12000000 8000000 25000000 6000000 9000000 20000000 45000000 35000000 12048000 696000 12863000 1650000 4385000 6650000 409000 1339000 1650000 696000 524000 4794000 0 409000 4385000 24830000 24155000 21344000 23328000 26313000 22051000 9858000 4758000 16280000 18570000 -2158000 2810000 -4011180000 -3521867000 336006000 1193048000 221700000 860818000 25514000 125150000 92012000 22561000 98047000 119705000 25586000 27012000 19957000 104108000 20994000 80811000 1052149000 303501000 708823000 186653000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive loss by component, net of tax:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.63492063492063%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains on Marketable Securities, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(550</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share Attributable to Vertex Common Shareholders</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities described in the following table in the computation of the diluted net loss attributable to Vertex per common share calculations because the effect would have been anti-dilutive during each such period:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Convertible senior subordinated notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2013</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">580,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">580,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">583,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">583,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">555,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">555,527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">148,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">148,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due after 1 year through 5 years)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">839,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">839,469</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,422,447</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,422,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2012</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">489,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">489,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">489,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">489,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Treasury securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">440,181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">440,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">225,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">225,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due after 1 year through 5 years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,358</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,355</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">831,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">831,808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,321,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,321,215</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effect of stock-based compensation expense during the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012 was as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.65079365079364%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended </font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended </font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">68,633</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,948</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation expense included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,085</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,224</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation expense included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets (excluding Alios&#8217; cash equivalents) subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.86507936507937%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements <br clear="none"/>as of September 30, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial assets carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">308,981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">308,981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,895</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,895</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">555,527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">555,527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">158,678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">158,678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,151,345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">867,403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">283,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:447px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="332px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="95px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,924</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">409</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,259</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: amount representing interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Present value of payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">53,810</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s inventories by type:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of <br clear="none"/>September 30, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of <br clear="none"/>December 31, 2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,464</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The restructuring charges recorded during the three months ended September 30, 2013 and the related liability balance as of September 30, 2013 for each major type of cost associated with this restructuring plan are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.65873015873017%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="42%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Restructuring Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash<br clear="none"/>Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-cash Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Restructuring Liability at September 30, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Employee severance, benefits and related costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Asset impairments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,650</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contract termination and other associated costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,444</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012 were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,051</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,726</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,323</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,137</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">524</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">696</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,344</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,344</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="82px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="82px" rowspan="1" colspan="1"></td><td width="82px" rowspan="1" colspan="1"></td><td width="82px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="82px" rowspan="1" colspan="1"></td><td width="84px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$ 9.07&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$15.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$15.27</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$30.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,076</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$29.37</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">801</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$29.19</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$30.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$36.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$35.93</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$50.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,552</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$46.33</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">570</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$46.73</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$50.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$53.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$54.49</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$70.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.64</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$63.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$63.19</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$70.01-$80.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$77.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$77.73</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01-$88.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.81</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$83.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">166</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$81.54</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$44.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$37.87</font></div></td></tr></table></div></div></div> 87754000 326344000 97684000 287154000 86649000 103933000 32224000 27582000 39621000 12085000 31308000 17444000 54425000 19223000 64312000 10138000 70.01 40.01 50.01 30.01 9.07 20.01 60.01 80.01 462000 805000 166000 570000 7344000 11000 4525000 801000 4000 7253000 4552000 1840000 85000 16807000 462000 1076000 44000 1495000 50.00 20.00 80.00 60.00 30.00 40.00 70.00 88.18 81.54 15.27 54.49 37.87 77.73 29.19 35.93 63.19 46.73 53.72 29.37 83.13 63.23 44.47 15.27 36.58 46.33 77.73 P7Y1M2D P9Y1M6D P2Y7M21D P9Y9M22D P8Y7M21D P5Y11M23D P7Y7M10D P5Y7M2D P9Y8M1D 217287000 233592000 209304000 216342000 8276000 8188448 7038000 8029000 402265000 402182000 83000 402265000 248216000 248286000 79000 183022000 182872000 248207000 182803000 69000 -70000 150000 200000 999180000 1264888000 1195852000 1447056000 -1053000 -3521867000 38530000 38299000 198714000 -3445719000 5274307000 4200659000 1226447000 2149000 -550000 -550000 182168000 999180000 37036000 4519448000 2141000 786843000 1264888000 4471727000 -416000 39624000 -4011180000 1027733000 141633000 -3414835000 2311000 196672000 2072000 928476000 0.0335 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 29, 2013, the Company adopted a strategic restructuring plan. As a result of the actions to be taken under this restructuring plan, including those taken in the third quarter of 2013, the Company estimates that it will incur aggregate restructuring charges of approximately </font><font style="font-family:inherit;font-size:10pt;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$45.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$11.4 million</font><font style="font-family:inherit;font-size:10pt;"> of which was recorded in the third quarter of 2013. Please refer to Note O, "Restructuring Liabilities," for further information.</font></div></div> 98000000 0 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, noncontrolling interest (Alios) and the income tax provision. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's significant accounting policies are described in Note&#160;A, "Nature of Business and Accounting Policies," in the 2012 Annual Report on Form&#160;10-K.</font></div></div> -228000 15678000 4433000 11125000 348000 2388000 14015000 88487000 75393000 2852000 63560000 1857000 70227000 5416000 3565000 222764000 211053000 213767000 230505000 211053000 222764000 230505000 213767000 3107000 9321000 3107000 9321000 0 0 0 -57560000 -1220000 1600000 -112760000 7877000 2895000 1321215000 489407000 489407000 1422650000 583181000 0 580286000 1321019000 0 583181000 489407000 2895000 580286000 489407000 1422447000 1000 252000 21000 191000 10000 0 2000 217000 217000 49000 0 0 35000 0 0 0 155000 0 252000 5000 21000 38000 2000 0 0 0 5000 49000 1000 13000 0 0 49000 1000 21000 0 0 10000 0 0 750000000 350000000 0.5 0.5 312500000 P10Y 105000000 9300000 1500000 65000000 9300000 P60D P30D P10Y P1Y P60D 75000000 -503000 1413000 1422000 -2569000 0 0 4449000 10299000 165000000 6919000 8035000 32290000 42852000 21042000 2604000 11201000 4520000 18900000 0 12772000 11318000 3515000 4315000 P30D 1.30 P20D 268031000 392569000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> material contingent liabilities accrued as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> 1000 1000 20.4794 71500000 P15Y 2 2 0.10 P15Y 14581000 5090000 21177000 9056000 60000000 2 2 P5Y P10Y 7000 -7000 0 160000000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenues, Net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products principally to a limited number of major and selected regional wholesalers and specialty pharmacy providers in North America as well as government-owned and supported customers in Europe (collectively, its &#8220;Customers&#8221;). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery as long as (i)&#160;there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii)&#160;collectibility is reasonably assured and (iii)&#160;the price is fixed or determinable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to conclude that the price is fixed or determinable, the Company must be able to (i)&#160;calculate its gross product revenues from sales to Customers and (ii)&#160;reasonably estimate its net product revenues upon delivery to its Customer's locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a)&#160;trade allowances, such as invoice discounts for prompt payment and customer fees, (b)&#160;estimated government and private payor rebates, chargebacks and discounts, (c)&#160;estimated reserves for expected product returns and (d)&#160;estimated costs of incentives offered to certain indirect customers, including patients. These estimates, and in particular estimates regarding INCIVEK net product revenues while they decline, require the Company to make significant estimates and judgments that materially affect the Company's recognition of net product revenues. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:174%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at December 31, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">155,269</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,687</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">193,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(29,960</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(153,035</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,649</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(196,285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at September 30, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> 7329000 2355000 2670000 8000000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sale of HIV Protease Inhibitor Royalty Stream</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline&#160;plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of </font><font style="font-family:inherit;font-size:10pt;">$160.0 million</font><font style="font-family:inherit;font-size:10pt;">. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline&#160;plc. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$71.5 million</font><font style="font-family:inherit;font-size:10pt;"> in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline&#160;plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of net loss (income) attributable to noncontrolling interest (Alios) for the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012 is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.66666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss before provision for (benefit from) income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Decrease (increase) in fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(57,560</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(112,760</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for (benefit from) income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,354</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss (income) attributable to noncontrolling interest (Alios)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,530</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(31,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,688</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(57,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes items related to Alios included in the Company&#8217;s condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of <br clear="none"/>September 30, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of <br clear="none"/>December 31, 2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (Alios)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,983</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">861</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,689</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">150,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">152,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">873</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Redeemable noncontrolling interest (Alios)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest (Alios)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">182,168</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012, the Company recognized the following revenues attributable to the CFFT collaboration:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="360px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="49px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="49px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="49px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="6px" rowspan="1" colspan="1"></td><td width="49px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Collaborative revenues attributable to the CFFT collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012, the Company recognized the following revenues attributable to the Janssen collaboration:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.61904761904762%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty revenues (INCIVO)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">104,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Collaborative revenues: </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortized portion of up-front payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net reimbursement (payment) for telaprevir development costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Reimbursement for manufacturing services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,299</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,449</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total collaborative revenues attributable to the Janssen collaboration</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total revenues attributable to the Janssen collaboration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,514</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92,012</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="26%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September&#160;30, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense,<br clear="none"/>Net of <br clear="none"/>Estimated Forfeitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition <br clear="none"/>Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">184,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.74</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.61</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">830</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.31</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:174%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at December 31, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">155,269</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,687</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">193,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(29,960</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(153,035</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,649</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(196,285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at September 30, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> 1100000 11444000 -155269000 -8161000 -3687000 -26584000 -193701000 -29960000 -153035000 -196285000 -9641000 -3649000 false --12-31 Q3 2013 2013-09-30 10-Q 0000875320 233756871 Large Accelerated Filer VERTEX PHARMACEUTICALS INC / MA Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts. EX-101.SCH 6 vrtx-20130930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2408402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Notes) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Collaborative Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - Contingencies Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Convertible Senior Subordinated Notes link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Convertible Senior Subordinated Notes (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Guarantees link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Inventories Inventories- Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Long-term Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Long-term Obligations link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Long-term Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Long-term Obligations Schedule of Capital Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Marketable Securities (Details 2) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Net Income (Loss) Per Share Attributable to Vertex Common Shareholders link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Net Income (Loss) Per Share Attributable to Vertex Common Shareholders (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Net Income (Loss) Per Share Attributable to Vertex Common Shareholders (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Product Revenues, Net link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Product Revenues, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Product Revenues, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Restructuring Liability link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Restructuring Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Restructuring Liability (Details 2) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Restructuring Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Sale of HIV Protease Inhibitor Royalty Stream link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Sale of HIV Protease Inhibitor Royalty Stream (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Stock-based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Stock-based Compensation Expense (Details 2) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Stock-based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2423401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Subsequent Events (Notes) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vrtx-20130930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vrtx-20130930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vrtx-20130930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Captital Lease Obligations [Abstract] Captital Lease Obligations [Abstract] Schedule of Future Minimum Lease Payments for Capital Lease Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Income Statement [Abstract] Revenues: Revenues [Abstract] Product revenues, net Sales Revenue, Goods, Net Royalty revenues Royalty Revenue Collaborative revenues Collaborative Revenues The aggregate revenue from collaborative revenues. It includes the revenues earned by the entity from nonrefundable, up-front license fees; net reimbursements of research and/or development efforts, including manufacturing services; and milestone payments. Total revenues Revenues Costs and expenses: Costs and Expenses [Abstract] Cost of product revenues Cost of Goods Sold Royalty expenses Direct Operating Cost, Royalty Expense Research and development expenses Research and Development Expense Sales, general and administrative expenses Selling, General and Administrative Expense Restructuring expense Restructuring Charges Intangible asset impairment charge Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Total costs and expenses Costs and Expenses Income (loss) from operations Operating Income (Loss) Other income (expense), net Other Nonoperating Income (Expense) Income (loss) before provision for (benefit from) income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Provision for (benefit from) income taxes Income Tax Expense (Benefit) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss (income) attributable to noncontrolling Interest (Alios) Net Income (Loss) Attributable to Noncontrolling Interest Net income (loss) attributable to Vertex Net Income (Loss) Attributable to Parent Net income (loss) per share attributable to Vertex common shareholders: Earnings Per Share [Abstract] Basic (usd per share) Earnings Per Share, Basic Diluted (usd per share) Earnings Per Share, Diluted Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Sale of HIV Protease Inhibitor Royalty Stream Sale of HIV Protease Inhibitor Royalty Stream Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline Proceeds from Sale of Royalty Rights The cash inflow from the sale of the entity's right to receive future royalty payments. Deferred Revenue Royalty Purchase Agreement Deferred Revenue Royalty Purchase Agreement This element represents the carrying value of deferred revenue recorded with regard to agreement to sell rights to receive royalty payments, as on the balance sheet date. Cash and Cash Equivalents [Abstract] Summary of cash, cash equivalents and marketable securities Cash, Cash Equivalents and Investments [Table Text Block] Collaborative Arrangements Collaborative Arrangements Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Product Revenues [Abstract] Product Revenues [Abstract] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Trade Allowances [Member] Allowance for Trade Receivables [Member] Rebates Chargebacks and Discounts [Member] Rebates Chargebacks and Discounts [Member] A valuation allowance for amounts due to the entity for rebates, chargebacks and discounts in the normal course of business that are expected to be uncollectible. Product Returns [Member] Allowance for Sales Returns [Member] Other Incentives [Member] Copay Mitigation Rebates [Member] A valuation allowance for amounts due to the entity for copay mitigation rebates in the normal course of business that are expected to be uncollectible. Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Product Revenue Allowance and Reserve [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Product revenue allowance and reserve, beginning balance Valuation Allowances and Reserves, Balance Provision related to current period sales Valuation Allowances and Reserves Provision Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to product revenues. Adjustments related to prior period sales Valuation Allowances and Reserves, Adjustments Credits/payments made Valuation Allowances and Reserves, Sales Credits or Payments, Current Represents the credits or payments to allowances and reserves. Product revenue allowance and reserve, ending balance Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Exercise Price Range from Dollars 9.07 to Dollars 20.00 [Member] Exercise Price Range from Dollars 9.07 to Dollars 20.00 [Member] Represents the range of exercise prices from $9.07 to $20.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Exercise Price Range from Dollars 20.01 to Dollars 30.00 [Member] Exercise Price Range from Dollars 20.01 to Dollars 30.00 [Member] Represents the range of exercise prices from $20.01 to $30.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Exercise Price Range from Dollars 30.01 to Dollars 40.00 [Member] Exercise Price Range from Dollars 30.01 to Dollars 40.00 [Member] Represents the range of exercise prices from $30.01 to $40.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Exercise Price Range from Dollars 40.01 to Dollars 50.00 [Member] Exercise Price Range from Dollars 40.01 to Dollars 50.00 [Member] Represents the range of exercise prices from $40.01 to $50.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Exercise Price Range from Dollars 50.01 to Dollars 60.00 [Member] Exercise Price Range from Dollars 50.01 to Dollars 60.00 [Member] Represents the range of exercise prices from $50.01 to $60.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Exercise Price Range From Dollars 60.01 to 64.30 [Member] Exercise Price Range From Dollars 60.01 to 70.00 [Member] Represents the range of exercise prices from $60.01 to $70.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Exercise Price Range From Dollars 70.01 to 80.00 [Member] [Domain] Exercise Price Range From Dollars 70.01 to 80.00 [Member] [Domain] Exercise Price Range From Dollars 70.01 to 80.00 [Member] [Domain] Exercise Price Range From Dollars 80.01 to 88.18 [Domain] Exercise Price Range From Dollars 80.01 to 88.18 [Domain] Exercise Price Range From Dollars 80.01 to 88.18 [Domain] Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Exercise price, low end of range (usd per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise price, high end of range (usd per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Exercise price range, options outstanding (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Exercise price range, options outstanding, weighted-average remaining contractual life (in years) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Exercise price range, options exercisable (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Income Statement Location [Domain] Research and development expenses Research and Development Expense [Member] Sales, general and administrative expenses Selling General and Administrative Expense [Member] The allocation (or location) of expense to (in) selling, general and administrative expense. Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock options Employee Stock Option [Member] Restricted stock and restricted stock units Employee Restricted Stock Option [Member] An arrangement whereby certain members of senior management are entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. ESPP share issuances Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Stock-based compensation expense by type of award Allocated Share-based Compensation Expense Less stock-based compensation expense capitalized to inventories Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Total stock-based compensation expense included in costs and expenses Share-based Compensation Type of award: Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Unrecognized Expense, Net of Estimated Forfeitures Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted-average Recognition Period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Commitments and Contingencies Disclosure [Abstract] Material contingent liabilities accrued Loss Contingency Accrual Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Kendall Restructuring [Member] Kendall Restructuring [Member] Kendall Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring activities Restructuring Reserve [Roll Forward] Liability, beginning of the period Restructuring Reserve Cash payments Payments for Restructuring Cash received from subleases Restructuring Reserve Settled with Cash Receipt from Sublease Amount of cash received in the period to fully or partially offset a specified, previously accrued type of restructuring cost. Liability, end of the period Accumulated Other Comprehensive Income (Loss) [Abstract] Accumulated Other Comprehensive Income (Loss) [Abstract] Comprehensive Income (Loss) Note Comprehensive Income (Loss) Note [Text Block] Long-term Debt and Capital Lease Obligations [Abstract] Long-term Obligations Debt, Policy [Policy Text Block] Accounting Policies [Abstract] Number of operating segments Number of Operating Segments Contingencies Contingencies [Text Block] Contingencies [Text Block] Restructuring Liability Restructuring and Related Activities Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Strategic Restructuring [Member] Strategic Restructuring [Member] Strategic Restructuring [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Restructuring Cost and Reserve [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance [Member] Employee Severance [Member] Other Restructuring [Member] Other Restructuring [Member] Contract Termination [Member] Contract Termination [Member] Asset Impairments [Member] Asset Impairments [Member] Asset Impairments [Member] Lease term (in years) Lease Term Total length of time of a real estate lease, stated in years. Discount rate, lease restructuring liability (as a percent) Lease Restructuring Liability Accrual Discount Rate The credit-adjusted risk-free discount rate applied to the undiscounted amount of projected cash inflows and/or outflows to arrive at the present value of the lease restructuring liability recorded as of the balance sheet date. Expected restructuring charges Restructuring and Related Cost, Expected Cost Strategic Restructuring Strategic Restructuring Strategic Restructuring Non-cash Expense Other Noncash Expense Restructuring Reserve Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Legal Proceedings [Abstract] Legal Proceedings [Abstract] Legal Proceedings Legal Matters and Contingencies [Text Block] Schedule of Collaborative Arrangement Agreements [Table] Schedule of Collaborative Arrangement Agreements [Table] A schedule reflecting significant collaboration agreements in which the entity is a participant. Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Collaborative Arrangement Agreement [Domain] Collaborative Arrangement Agreement [Domain] Listing of significant collaboration agreements. Janssen Pharmaceutica, N.V. Janssen Collaborative Agreement [Member] Collaboration agreement entered into with Janssen Pharmaceutical, N.V. for the development, manufacture and commercialization of a product of the entity. Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Collaborative Agreement [Member] Collaboration agreement entered into with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of a product of the entity. Cystic Fibrosis Foundation Therapeutics Incorporated Cystic Fibrosis Foundation Therapeutics Incorporated Agreement [Member] Collaboration agreement entered into with Cystic Fibrosis Foundation Therapeutics Inc., for the development, manufacture and commercialization of a product of the entity. Alios Bio Pharma Inc Alios Bio Pharma Inc [Member] Collaboration agreement entered into with Alios BioPharma, Inc. Schedule of Collaborative Arrangements Schedule of Collaborative Arrangement Agreements [Line Items] -- None. No documentation exists for this element. -- Drug development costs to be paid by collaborator (as a percent) Collaborative Arrangement Development Cost Contribution, Percent Percent of total development cost for the parties' territories, as specified in the collaboration agreement, that is to be funded by the other party to the agreement. Up-front license payment Collaborative Arrangement Up-front License Fee The amount of the up-front license fee received by the entity pursuant to a collaborative arrangement. Deferred revenue related to up-front license payment Deferred Revenue Total contingent milestone payments earned Collaborative Arrangement Contingent Consideration Earned, Gross The total amount of contingent milestone payments earned to date pursuant to the collaboration agreement. Notice period required to terminate without cause (in years) Collaborative Arrangement, Notice Period Required for Termination after Marketing Approval, Years The minimum number of years notice required to terminate a collaboration agreement. Notice period required for termination after first commercial sale ( in years) Collaborative Arrangement, Notice Period Required for Termination after First Commercial Sale Collaborative Arrangement, Notice Period Required for Termination after First Commercial Sale Collaborative revenues recognized Recognized Collaborative Revenue [Abstract] -- None. No documentation exists for this element. -- Royalty revenues Amortized portion of up-front payment Amortized Portion of Up-front Payment This element represents the amortized portion of the up-front payment. Net reimbursement (payment) for telaprevir development costs Collaborative Arrangement Revenues, Net Reimbursement Development Program Expense This element represents the net amount of reimbursable costs incurred by the entity that the collaborator is obligated to pay the entity, after offsetting any reimbursable expenses incurred by the collaborator, which are recognized as collaborative revenues. Reimbursement for manufacturing services Collaborative Arrangement Revenues Through Third Party Manufacturing Network This element represents revenues from collaborator for manufacturing services provided through the entity's third-party manufacturing network. Total revenues License fee paid upon amendment of agreement Collaborative Arrangement License Fee Paid on Amendment The amount of the license fee received by the entity upon amendment of a collaborative agreement. Milestone payment received Collaborative Arrangement, Milestone Payment Received Represents the milestone payment received. Notice period required to terminate without cause (in days) Collaborative Arrangement Notice Period Required for Termination, Days The number of days notice required to terminate a collaboration agreement. Collaborative funding Collaborative Arrangement Research Development Funding This element represents the funding under collaborative agreement 2011 amendment for research and development. Number of years over which funding will be made (in years) Number of Years over which Research Development Funding will be Made This element represents the number of years over which research and development funding will be made as per the collaboration agreement 2011 amendment. Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661 (in payments) Number of Commercial Milestone Payments for Achievement of Certain Sales Levels for Corrector Compound Represents the milestone payments to be made upon achievement of certain sales levels for a corrector compound. Up-front payment Payments to Acquire Businesses, Gross Milestone payments Milestone Revenues This element represents the revenues recorded for milestone payments received. Development milestone payments, maximum Collaborative Arrangement Development Potential Milestone Payments, Maximum Represents the potential additional development milestone amount to be paid by the entity as of period end under the collaboration agreement if the compound is approved and commercialized. Commercial milestone payments, maximum Collaborative Arrangement Commercial Milestone Payments, Maximum Represents the maximum amount of commercial milestone to be paid by the entity. Notice period for termination of contract due to technical failure (in days) Collaborative Arrangement Notice Period for Termination of Agreement Due to Technical Failure Represents the notice period for the termination of contract due to technical failure. Notice period for termination of contract after completion of clinical trials (in days) Collaborative Arrangement Notice Period for Termination of Agreement after Completion of Clinical Trials Represents the notice period for the termination of contract after completion of clinical trials. Latest expiration period for royalty obligation after first commercial sale in country unless contract is terminated earlier (in years) Collaborative Arrangement Latest Expiration Period Unless Terminated Earlier Represents the latest expiration period for royalty obligation after first commercial sale in country unless the contract is terminated earlier. Noncontrolling Interest (Alios) Net Income (Loss) Attributable to Noncontrolling Interest [Abstract] Number of lines on balance sheet where noncontrolling interest is reported Noncontrolling Interest, Number of Lines on Balance Sheet Represents the number of lines in the condensed consolidated balance sheet used by the entity to record the noncontrolling interest. Loss (income) before provision for (benefit from) income taxes Loss (Income) Attributable to Noncontrolling Interest before Income Tax Provision and Change in Fair Value of Contingent Milestone and Royalty Payments Represents the loss (income) of noncontrolling interest before provision for (benefit from) income taxes and change in fair value of contingent milestone and royalty payments during the period. Decrease (increase) in fair value of contingent milestone and royalty payments Business Acquisition Change in Fair Value of Contingent Consideration This element represents change in fair value, recognized during the reporting period, of potential milestone and royalty payments payable by the Company to the noncontrolling interest. Net loss (income) attributable to noncontrolling interest (Alios) Restricted cash and cash equivalents (Alios) Restricted Cash and Cash Equivalents, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Property and equipment, net Property, Plant and Equipment, Net Intangible assets Intangible Assets, Net (Excluding Goodwill) Goodwill Goodwill Other assets Other Assets, Noncurrent Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Deferred tax liability Deferred Tax Liabilities, Net, Noncurrent Other liabilities, excluding current portion Other Liabilities, Noncurrent Redeemable noncontrolling interest (Alios) Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value Noncontrolling interest (Alios) Stockholders' Equity Attributable to Noncontrolling Interest Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events [Text Block] Debt Disclosure [Abstract] 2013 Capital Leases, Future Minimum Payments Due, Next Twelve Months 2014 Capital Leases, Future Minimum Payments Due in Two Years 2015 Capital Leases, Future Minimum Payments Due in Three Years 2016 Capital Leases, Future Minimum Payments Due in Four Years 2017 Capital Leases, Future Minimum Payments Due in Five Years Capital Leases, Future Minimum payments due in Six years Capital Leases, Future Minimum payments due in Six years Capital Leases, Future Minimum payments due in Six years 2018 Capital Leases, Future Minimum Payments Due Thereafter Total payments Capital Leases, Future Minimum Payments Due Less: amount representing interest Capital Leases, Future Minimum Payments, Interest Included in Payments Present value of payments Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments Cash equivalents (Alios) Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Inventory, Net Write-down of inventories to net realizable value Inventory Write-down Collaborator revenues Schedule of Recognized Collaborative Revenue [Table Text Block] This element represents the revenues related to the collaboration recognized by the entity during the period. Summary of activity related to net loss (income) attributable to noncontrolling interest (Alios) Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest [Table Text Block] Represents the summary of activity related to the Alios Collaboration. Summary of Alios' items included in the Company's consolidated balance sheets Schedule of Collaborative Arrangement Summary of Items Related to Alios Collaboration [Table Text Block] Represents details pertaining to Alios' assets and liabilities included in the company's consolidated balance sheets. Activity related to the restructuring liability Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Restructuring charges and related liability Restructuring and Related Costs [Table Text Block] Income Tax Disclosure [Abstract] Operating Loss and Tax Credit, Carryforwards [Table] Operating Loss and Tax Credit, Carryforwards [Table] Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization and tax credit carryforwards. Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Total Vertex Shareholders' Equity Parent [Member] Noncontrolling Interest (Alios) Noncontrolling Interest [Member] Tax Carryforwards Tax Carryforwards [Line Items] -- None. No documentation exists for this element. -- Current State and Local Tax Expense (Benefit) Current State and Local Tax Expense (Benefit) Intangible asset impairment charge Deferred federal income tax expense (benefit) Deferred Federal Income Tax Expense (Benefit) Federal income tax net operating loss carryfowards Deferred Tax Assets, Operating Loss Carryforwards, Domestic Income taxes payable Taxes Payable, Current Federal income tax credit carryforwards Tax Credit Carryforward, Amount State income tax net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, State and Local State income tax credit credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Convertible senior subordinated notes Convertible Debt Securities [Member] Unvested restricted stock and restricted stock units Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Indefinite-Lived Intangible Assets by Major Class [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Vertex Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Research and Development Arrangement Research and Development Arrangement [Member] VX-222Asset [Member] VX222asset [Member] VX-222 Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Indefinite-Lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Intangible assets Other Indefinite-lived Intangible Assets Extraordinary Item, Earnings Per Share Impact, Net Extraordinary Item, Earnings Per Share Impact, Net Goodwill, period increase (decrease) Goodwill, Period Increase (Decrease) Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities, available for sale Available-for-sale Securities, Current Accounts receivable, net Accounts Receivable, Net, Current Inventories Total current assets Assets, Current Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Total assets Assets Liabilities and Shareholders' Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Deferred revenues, current portion Deferred Revenue, Current Accrued restructuring expense, current portion Restructuring Reserve, Current Capital lease obligations, current portion Capital Lease Obligations, Current Other liabilities, current portion Other Liabilities, Current Total current liabilities Liabilities, Current Deferred revenues, excluding current portion Deferred Revenue, Noncurrent Accrued restructuring expense, excluding current portion Restructuring Reserve, Noncurrent Capital lease obligations, excluding current portion Capital Lease Obligations, Noncurrent Convertible senior subordinated notes (due 2015) Convertible Subordinated Debt, Noncurrent Construction financing lease obligation Construction Financing Obligation, Noncurrent Represents the noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Redeemable noncontrolling interest (Alios) Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at September 30, 2013 and December 31, 2012 Preferred Stock, Value, Issued Common stock, $0.01 par value; 300,000,000 shares authorized at September 30, 2013 and December 31, 2012; 233,592,201 and 217,286,868 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total Vertex shareholders’ equity Stockholders' Equity Attributable to Parent Total shareholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and shareholders’ equity Liabilities and Equity Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Debt Instrument, Interest Rate, Low of Range Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, High of Range Debt Instrument, Interest Rate, Stated Percentage Number of leases (leases) Lease Agreement, Number of Leases Represents the number of leases entered by the reporting entity. Area of leased property (in square feet) Square Footage of Leased Property The amount of area of square footage of office and laboratory space related to the leased property. Number of buildings under lease agreement (buildings) Lease Agreements Number of Buildings Represents number of buildings under lease agreements. Initial term of lease agreement (in years) Initial Term of Lease Agreement Represents initial period term of lease agreement. Optional term of lease agreement (in years) Optional Term of Lease Agreement Represents additional period to extend term of lease agreement. Construction in progress Construction in Progress, Gross Change in Restricted Cash Balance as Result of Transactions Proceeds from (Repayments of) Restricted Cash, Financing Activities Stock-based Compensation Expense Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Financial assets subject to fair value measurements (excluding restricted cash and cash equivalents (Alios)) Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Stock-based compensation expense by line item Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Unrecognized stock-based compensation expense, net of estimated forfeitures Schedule of Unrecognized Share-based Compensation Expense [Text Block] Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported. Stock options outstanding and exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Sale of HIV Protease Inhibitor Royalty Stream Sale of HIV Protease Inhibitor Royalty Stream Disclosure [Text Block] Disclosure related to the sale of the HIV protease inhibitor royalty stream. Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Potential gross common equivalent shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement [Table] Statement [Table] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Foreign Currency Translation Adjustment Foreign Currency Gain (Loss) [Member] Unrealized Holding Gains on Marketable Securities, Net of Tax Accumulated Net Unrealized Investment Gain (Loss) [Member] Statement [Line Items] Statement [Line Items] Accumulated Other Comprehensive Income (Loss) [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Roll Forward] Balance at balance sheet date Other comprehensive income (loss) before reclassifications Other comprehensive income (loss) before reclassifications Amount of other comprehensive income (loss) during the period before reclassification adjustments. Amounts reclassified from accumulated other comprehensive loss Amounts reclassified from accumulated other comprehensive income (loss) Amounts reclassified from accumulated other comprehensive income (loss) into the statement of operations during the period. Net current period other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Balance at balance sheet date Convertible Senior Subordinated Notes Debt Disclosure [Text Block] Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Net income (loss) Changes in other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized holding gains (losses) on marketable securities, net of tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total changes in other comprehensive income (loss) Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss (income) attributable to noncontrolling interest (Alios) Comprehensive (Income) Loss, Net of Tax, Attributable to Noncontrolling Interest Comprehensive income (loss) attributable to Vertex Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of product revenues and allowances and reserve categories Schedule of Valuation and Qualifying Accounts [Table Text Block] Tabular disclosure of product revenues allowances and reserve accounts (their beginning and ending balances, as well as reconciliation by type of activity during the period). Guarantees [Abstract] Guarantees Guarantees [Text Block] Product Revenues, Net Product Revenues Disclosure [Text Block] Product Revenues Disclosure [Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Entity Common Stock, Shares Outstanding Basis of Presentation Basis of Presentation and Significant Accounting Policies [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Net Loss Per Share Attributable to Vertex Common Stockholders Earnings Per Share [Text Block] Statement of Stockholders' Equity [Abstract] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income (Loss) [Member] Accumulated Deficit Retained Earnings [Member] Redeemable Noncontrolling Interest (Alios) Redeemable Noncontrolling Interests [Member] This element represents that portion of redeemable noncontrolling interests (temporary equity). Statement Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance (shares) Shares, Outstanding Balance Foreign currency translation adjustment Net income (loss) attributable to Vertex common shareholders Issuances of common stock: Issuances of Common Stock [Abstract] -- None. No documentation exists for this element. -- Benefit plans (shares) Stock Issued During Period, Shares, Employee Benefit Plan Benefit plans Stock Issued During Period, Value, Employee Benefit Plan Convertible senior subordinated notes (due 2015) conversion Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Value, Conversion of Convertible Securities Stock Issued During Period, Value, Conversion of Convertible Securities Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Tax benefit from equity compensation Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Change in liquidation value of noncontrolling interest Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Balance (shares) Balance Statement of Cash Flows [Abstract] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization expense Depreciation, Depletion and Amortization Stock-based compensation expense Other non-cash based compensation expense Deferred income taxes Increase (Decrease) in Other Deferred Liability Asset impairment charges Asset Impairment Charges Other non-cash items, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Excess tax benefit from share-based payment arrangements Excess Tax Benefit from Share-based Compensation, Operating Activities Accrued restructuring expense Restructuring Reserve, Period Increase (Decrease) Deferred revenues Increase (Decrease) in Deferred Revenue Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of marketable securities Payments to Acquire Available-for-sale Securities Sales and maturities of marketable securities Proceeds from Sale and Maturity of Available-for-sale Securities Expenditures for property and equipment Payments to Acquire Property, Plant, and Equipment Decrease in restricted cash and cash equivalents Increase (Decrease) in Restricted Cash Decrease (increase) in restricted cash and cash equivalents (Alios) Increase (Decrease) in Restricted Cash and Investments Decrease (increase) in other assets Increase (Decrease) in Other Noncurrent Assets Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Excess tax benefit from share-based payment arrangements Excess Tax Benefit from Share-based Compensation, Financing Activities Issuances of common stock from employee benefit plans Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payments to redeem secured notes (due 2015) Repayments of Convertible Debt Payments on capital lease obligations Repayments of Long-term Capital Lease Obligations Payments on construction financing lease obligation Proceeds from (Payments for) Other Financing Activities Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations Net increase (decrease) in cash and cash equivalents Net Cash Provided by (Used in) Continuing Operations Cash and cash equivalents—beginning of period Cash and cash equivalents—end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Conversion of convertible senior subordinated notes (due 2015) for common stock Debt Conversion, Original Debt, Amount Interest on converted convertible senior subordinated notes (due 2015) offset to additional paid-in capital Adjustments to Additional Paid in Capital, Other Unamortized debt issuance costs of converted convertible subordinated notes (due 2015) offset to additional paid-in capital Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Capitalization of construction in-process related to construction financing lease obligation Noncash or Part Noncash Acquisition, Fixed Assets Acquired Assets acquired under capital lease Capital Lease Obligations Incurred Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring basis Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Total Estimate of Fair Value Measurement [Member] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Investment Type [Axis] Investment Type [Axis] Investment Type Categorization [Domain] Investments [Domain] Money market funds Money Market Funds [Member] U.S. Treasury securities US Treasury Securities [Member] Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Commercial paper Commercial Paper [Member] Corporate debt securities Corporate Debt Securities [Member] Fair value of financial assets and liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets carried at fair value: Assets, Fair Value Disclosure [Abstract] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Marketable securities: Marketable Securities Total Assets, Fair Value Disclosure Cash equivalents (Alios) Cash Equivalents, at Carrying Value Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] This element represents a number of concepts which capture the categories of financial instruments classified as cash and cash equivalents and available-for-sale investments. Types of Financial Instruments [Domain] Types of Financial Instruments [Domain] Provides general categories of financial instruments included as cash, cash equivalents and available-for-sale investments. Total cash and cash equivalents Cash and Cash Equivalents [Member] Cash and money market funds Cash and Money Market Funds [Member] Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time. Available-for-sale Securities [Member] Available-for-sale Securities [Member] Government-sponsored enterprise securities (due within 1 year) U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] Corporate debt securities (due within 1 year) Corporate Debt Securities, Due Within One Year [Member] Corporate Debt Securities, Due Within One Year [Member] Corporate debt securities (due after 1 year through 5 years) Corporate Debt Securities, Due After One Year Through Five Years [Member] Corporate Debt Securities, Due After One Year Through Five Years [Member] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Amortized Cost Cash, Cash Equivalents, Available-for-sale Securities, Amortized Cost This item represents the cost of cash and cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any. Gross Unrealized Gains Cash, Cash Equivalents, Available-for-sale Securities, Gross Unrealized Gain This item represents the gross unrealized gains for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized gains are the excess of the fair value over the carrying value as of the reporting date. Gross Unrealized Losses Cash, Cash Equivalents, Available-for-sale Securities, Unrealized Loss, Gross This item represents the gross unrealized losses for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized losses are the excess of the carrying value over the fair value as of the reporting date. Fair Value Cash, Cash Equivalents and Available-for-sale Securities, Fair Value This item represents the fair value of cash, cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading. Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Fair Value Disclosure Available-for-sale Securities Debt Exchange and Debt Conversion [Table] Debt Exchange and Debt Conversion [Table] A schedule of debt conversions and exchanges by the entity. Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible Senior Subordinated Notes 3.35 Percent Due 2015 Convertible Senior Subordinated Notes 3.35 Percent Due 2015 [Member] A contractual arrangement to borrow and repay an amount, by issuance of long-term convertible senior subordinated notes, bearing interest at the rate of 3.35% per annum, maturing in 2015. Convertible Senior Subordinated Notes Convertible Senior Subordinated Notes and Collaborator Loan [Line Items] -- None. No documentation exists for this element. -- Convertible senior subordinated notes Net proceeds from convertible debt offering Proceeds from Issuance of Long-term Debt Underwriting discount Payments of Debt Issuance Costs Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Convertible senior subordinated notes (due 2015) conversion Stock Redeemed or Called During Period, Value Stock Redeemed or Called During Period, Value Redemption Premium Redemption Premium Original conversion rate, number of shares to be issued per $1000 of principal (in shares) Debt Instrument, Convertible, Conversion Ration, Shares Debt Instrument, Convertible, Conversion Ration, Shares Convertible debt principal amount, basis for exchange Debt Exchange Rate, Principal Amount Used in Calculation The unit of measurement in dollars which establishes the exchange rate of the debt instrument into common shares. Interest rate (as a percent) Subordinated Borrowing, Interest Rate Percent closing price needs to exceed the conversion price for at least 20 trading days within 30 consecutive trading days for provisional redemption (as a percent) Condition for Provisional Redemption if Percentage in Excess of Conversion Price for Common Stock Traded for Atleast 20 Days within 30 Consecutive Trading Days This element represents the condition for provisional redemption, if percentage is in excess of conversion price for common stock that is traded for at least 20 days within 30 consecutive trading days. Minimum number of days within 30 consecutive trading days the closing price needs to exceed the conversion price for provisional redemption (in days) Condition for Provisional Redemption, Minimum Number of Days within 30 Consecutive Trading Days, Closing Price Needs to Exceed Conversion Price The number of trading days within a period of 30 consecutive trading days the closing price of the Company's common stock must exceed the applicable conversion price by 130% in order for the Company to, at its option, redeem all or part of the convertible notes. Total consecutive trading days during which the closing price must exceed the conversion price for at least 20 trading days for provisional redemption (in days) Condition for Provisional Redemption, Consecutive Trading Days with the Closing Price in Excess of the Conversion Price for Provisional Redemption The number of consecutive trading days during which the closing price of the Company's common stock must exceed the applicable conversion price by 130% for at least 20 days in order for the Company to, at its option, redeem all or part of the convertible notes. Debt Conversion, Converted Instrument, Amount Debt Conversion, Converted Instrument, Amount Debt Conversion, Converted Instrument, Shares Issued Debt Conversion, Converted Instrument, Shares Issued Interest Expense, Debt Interest Expense, Debt Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature EX-101.PRE 10 vrtx-20130930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Convertible Senior Subordinated Notes
 3 Months Ended
Sep. 30, 2013
Debt Disclosure [Abstract]  
Convertible Senior Subordinated Notes
Convertible Senior Subordinated Notes
In 2010, the Company completed an offering of $400.0 million in aggregate principal amount of 3.35% convertible senior subordinated notes due 2015 (the "2015 Notes"). This offering resulted in $391.6 million of net proceeds to the Company. The underwriting discount and other expenses of $8.4 million were recorded as debt issuance costs and were included in other assets on the Company’s condensed consolidated balance sheets.
The 2015 Notes were convertible at any time, at the option of the holder, into common stock at a price equal to approximately $48.83 per share, or 20.4794 shares of common stock per $1,000 principal amount of the 2015 Notes. If the closing price of the Company’s common stock exceeded 130% of the conversion price for at least 20 trading days within a period of 30 consecutive trading days, the Company had the right to redeem the 2015 Notes at its option at a redemption price equal to 100% of the principal amount of the 2015 Notes to be redeemed.
In the second quarter of 2013, the Company's common stock exceeded 130% of the conversion price of the 2015 Notes for at least 20 trading days within a period of 30 consecutive trading days, and the Company notified the holders of the 2015 Notes that it would redeem the 2015 Notes on June 17, 2013. In response to the Company's call of the 2015 Notes for redemption, in accordance with the provisions of the 2015 Notes, the holders of $399.8 million in aggregate principal amount of 2015 Notes elected to convert their 2015 Notes into the Company's common stock at the conversion price of approximately $48.83 per share. As a result of these conversions, the Company issued 8,188,448 shares of common stock. The remaining $0.2 million in aggregate principal amount of 2015 Notes was redeemed on June 17, 2013.
Pursuant to the terms of the 2015 Notes, the Company made an additional payment of $16.75 per $1,000 principal amount, payable in shares of the Company’s common stock, to the holders of the 2015 Notes that converted or redeemed their 2015 Notes after the Company called the 2015 Notes for redemption. These payments resulted in the issuance of an additional 87,109 shares of the Company's common stock. In the second quarter of 2013, the Company recognized an aggregate of $6.7 million in interest expense related to the 2015 Notes. Unamortized debt issuance costs for the 2015 Notes of $4.2 million were recorded as an offset to additional paid-in capital.
XML 12 R53.htm IDEA: XBRL DOCUMENT v2.4.0.8
Sale of HIV Protease Inhibitor Royalty Stream (Details) (USD $)
In Millions, unless otherwise specified
 12 Months Ended
Dec. 31, 2008
Sep. 30, 2013
Sale of HIV Protease Inhibitor Royalty Stream    
Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline $ 160.0  
Deferred Revenue Royalty Purchase Agreement   $ 71.5
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"=$[JX*@(```DC```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,VLMNVS`0!=!]@?Z#P&UA MT7PH30++6?2Q;`,T_0!6&EN")5(@F=3^^U)R$@2!Z\"H@=Z-!%GDS#479Z-9 MW&S[+GL@'UIG2R;R.F_9H/IMJ8-7$YGU_PRME(-L[B M6(,M%Y]I9>Z[F'W9II_W23QU@66?]@O'7B4SP]"UE8DI*7^P]:LNL\<.>=HY MK0E-.X0/*0;C!SN,;_[>X''?]W0TOJTINS4^?C-]BL&W'?_M_.:7)$# M*=UJU594N^J^3R>0A\&3J4-#%/LNG^YY;UK[E/M(_VEQX---G#G(^/^FPB?F MD"`Y%$@.#9*C`,EQ`9+C(TB.2Y`<5R`YQ!PE"(JH`H54@6*J0$%5H*@J4%@5 M**X*%%@%BJP215:)(JM$D56BR"I19)4HLDH4626*K!)%5HDBJT*15:'(JE!D M52BR*A19%8JL"D56A2*K0I%5HS:D0N1C2\_3&8>F')X[IK&/TQN^&K.@<;"DIOI`;SX-LBS_````__\#`%!+ M`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@ M``(````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4 M'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIX MK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QR MI9$P4P>J/OH\^;*W-$UO>"_F?6*7 M3HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;',@H@0!**```0`````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````````"\ MFD^+VS`0Q>^%?@>C^T;1C)3=+>OL92GLM=U^`!,K<=C$#I;Z)]^^(@2G@?;U M$MXE8)G(C]',;YYD/SW_VN^J'W%,VZ&OC9O-317[U=!N^TUMOKU]OGLP5SS7YYA?P[C>^IBS&729MS$7)MI*-G3':>SHMG8?\@I\>#*>4!R M9$&6(PLD1Q_)R?%"EN,%RKEGR[E'PS1V;"([2&1A$UD@D1V;R`X26=A$%DAD96>RPE16=I4K M+'//)K*'1/9L(GM(Y,#VR0'ZY,#VR0'Z9/9:P:5:W!2"J6O&V'[-8]FRI6(2 MSMN:JV'4RAV[0SC<(=A(=A#)PD:R0"0+&\D"D:QL)"M$LK++7&&=>S:2/42R M9R/98R2SC7*`1ID='!R;FW:(Z83KTAVFH?.A5X`VF9W',(T=F\@.$MFQB>P@ MD86-0($(5'KJP-Q1=I4K+'//1J"'"`PW=8*YO`.(%^*<+NWI%[)&V)9"H*7P M;!)[&)W`=LP@AX7-88$<%C:'!7)8V:FC,'?\33D\ M6;T+BZ>AL_OS<$<>V`XG0(?CV`W"P0:A;`8JA*!G-P@/&T1@F_4`S?KBIKF3 M\G%7/H>X'+F=KM%9&WUQD!@V92;(V*MO1Y:_`0``__\#`%!+`P04``8`"``` M`"$`'66YJM8$``"%$0``#P```'AL+W=O"-0J?8&UDG5"8*K>#,>P;K M?3[_^Z_3K3:/2ZT?1RB@[)F7.[]`86?K+0IA<.E68_MQH#( M;`[@RF(<3";3<2FD\O8*)^8C&GJUDBE\*;U0(ZVXRZ2`[\V)A-SYOD[PS MHPQ6HBKJ2>^U(@EV*KE13KKG9*[V MU9<:6UA7?8Z9^=[(G$B\,//,KP.G*E=:9:`L9`E>65W(3&"QDH7#EQ*(2D!4 M@O^G@@&TP81$IJGW!X*Y%(50*0TFGA&9Z(/1O,C0:+#Z;6GB#\J\E`;KT28U MQ3ZW.@T;'\CJ10<+TNH<$9FC?CB7PDJ;Z%5R9\#B)#0#T#3_(DUIOZ>TX<=] MF3NCLRIUR2]X`E6!37Z`(R%,:9]G_9NO=%&(I3;X["=(+HP1:HV8*&>I!.VQ M/^EKX/.0TU27D-QJ:Y,[,,DB%P;UG#-4)R+E\!FY7X0TR8,H*DB^@["5X8'0 M]OH,VN_"/((3RP*2!:25D4ZBT[UU8SJESV>P8M6KLD(?PG'YZ7+,XDJ7Z' M39'T&9,+I]/'I=B[4(G;B-W#?;.KKZD.I=-G>"X$U@,GY-O\`:=$.\0"D+5< M+B46F.I01-&E>Z;X@N>]V'6`.*)`!@S(7[BU&!PM)$FMDULIEK)`4Z:/I4`& M#,A;6(NB#CP%J'?C3N84QH#!B.;M\`[UTK@"#OHIDG1"QAZ MR(>%_RID-KFIR44'P4IW8J7,[?=*ZH?#1D;M^9A"%S#H#EE9M[1:BC3OF+(7,/:&;:V3%84O9/"]XVL'$J,XA@S'@_9V0(4R&3(FAUVN MDQ8E-&2$$IL[$`3%-&28'G*79)'FD%4X\+1'%%T\;_7F>MAG.LE0A$-FF^^, M.D]L1@D.&<'#HX#`M3X^HQ2'C.*#HW"-NYLLZ"R$G;08PP.S@%HT&CH+$4-X M>!9H6A%-"Q>]AKTW"_O,2$!1)R!&\>%9X/69T=&,&,.#,I3#&1W-B/$\/%2= M^M#IC!C0=*CH]7XV:'WH<$:,Y^'C!!V,62<@!C3N0P/GB8Y0)R(&],&1/]`P M:AP1`[I5N8:EHV>3I)8B]9E1XX@9T,/&01L64Z!QT0-Z6`CI:P<^ID3CHB\T M>-2AA8XIT[CH"=&S3E.5KF/,J&/$C.3WC)`-:$RYP44OBF&=3CJ4FYB1W#D( MU;]IWXY%F!VM+R4G9B#S4PZ'#W^_DT-ZW#`\;AJ(/]534:3X'T+]4O\(;Y`: MO_Z#&PO M=V]R:W-H965T&ULE%I=;^.Z$7TOT/]@^'UCD=1GD.1BI7#; M"[1`4?3CV7&4Q%C;,BQGL_??=Z@9*9R136[OP_6&/#SD(8><(XEWO_W<[Q8_ MVE._[0[W2W63+!?M8=,];P^O]\M__^O;EW*YZ,_KP_-ZUQW:^^4?;;_\[>'/ M?[K[Z$[?^[>V/2^`X=#?+]_.Y^/M:M5OWMK]NK_ICNT!:EZZTWY]AC]/KZO^ M>&K7ST.C_6ZEDR1?[=?;PQ(9;D^_PM&]O&PW[6.W>=^WAS.2G-K=^@SC[]^V MQWYDVV]^A6Z_/GU_/W[9=/LC4#QM=]OS'P/INA.ZZ<=Z/ZITO5F MY![^F-'OMYM3UW[YRTH<-.^.+4O]\NOZM:F^7+U M<#=,T'^V[4?O_7O1OW4??SEMG_^V/;0PV[!.;@6>NNZ[@_[^[(J@\6K6^MNP M`O\X+9[;E_7[[OS/[N.O[?;U[0S+G;DFFVX'/<'_%_NMBP&0OOXY_'YLG\]O M]TN3WV1%8I3.EHNGMC]_V[JVR\7FO3]W^_\B2!$5DF@B@=\+)(&&AAK"+S54 MZJ90264*Z#W0,*6&\/O_]0BT@U[X_:4>5SA?PSP_KL_KA[M3][&`X(49Z8]K MMQ74+9"Y"38)+/3&57YUM0,&BGLH_?&0IW>K'[!B&X+4""F6BPFB.:(9$6[5 M'.OC6/#9),]X&SM"7'#`2*?APM($ANMJ^7`S05PCI!C6W0VFD06/LL!Z!6PL ML-K>6,8IC&&^6PP*JX M@5TQ#M@![I<@(AYT#"$DBJFJ$H"2E$ST+ M.P2$-3&2U.A,3)P-DS!1SE:(PY*+<@`A2IR&-4)(E,F,V`4-UH69 M;,,<3%(UE^3M)%E*E$I$?&JP/Z_$Y=)H7H@\;YF!Z7$?A-1H0 M0I08=$T86J4\+7,C@K,AB/NY?N9QGJRLLE(<]3;"P\6YM!@,0(6)TS_-"]%C M39AT./R4E@%(U1%AV`].D%&5$3-H(RQ6XR M26,C-%R:R]=A:9C1F321(FN%&`JDI*K$>=D0(*(LPF(C+%R82]MA89C8F3`1 M)34\IKBSDX2EQ2P8P^:`G+)/4N6YF#U+G5R;'"[+9>^P+,SOOJQ2!%JM?(^@ MLU(7J1A40Y!K@R)EC*?(*ET*'AOAX>)<%O\4-WI;AF,B.29D.`R#+X M5D(E2LO]9R,T?!5&A,H8BRXR^8!I(RQ^P,,SO3)B(LEK['B!-JK2:+1DB(LH8C=&YG"!+'5VCX=)<`A?2 M_$C$_,YTB5'7[@7F9"2*PF3B4&D(<&T\=&;X+!6($OG$1EBXJ@M6PE;BK^'T9C[F2II,P@SSG*B$X%H"'%M3"2-V8PR,?+M MJ8W0,&FP,A%I`X(GKTJ<"#5AQC#4V>SU)B'"TAB-SD&;B'<;H>'2PD;#S(U& M)7QX31A:LJ20IK@A0$26[S24J1(1[S;"PE5!C(5CT3B$6##I-@@S"JOR1#[J M-02)2,.^QIC6:96(KFR$AXN+.@XS=QR5L`(U82"O3JZD$LF[(4Q$'786(K(1 M(B[/I7IQCD!$CP^/!IT`.T1D23632R$T0^"YL+3B+WEF#N).`A M50X:09?3T]`!?!,,OJ8ET$4&&V'@*DNFT)A!&>08OCHQ\'&H($I'&S$2F MJE2^(+`1'J[N@IOP3X&YE9A]Y*@-@C"`OF3R&U-#]1%=81(;(6&BTJB/&!`\ M+4&DBJU%(%RR+VFB%'SEY)B&,&%MG,AD\.`Y\TD1(J[O@IG@(9G._822R;`F M$.I3VKTDDIF)(!%YOJ6HJFHV2S9"P\6Y+![<;RGF>;[?9-XE$(DKM9IY"D)$ MM&%?1`,OH0OIER(T7%O44J1S2Z'DE_6:0#2H-"V23!B=AB`1<=@9\2CW?6ZF M#B'7>+BZL*-(YXX"+@GQ_503"&];7'[#3I!K0\('$\YS\0U[A(=+NVPK4G0, M\+EO]`/UO*B9%SW.BRPKXIU?M@ETM6JZ&3;E6;B3)CVW#/Z:,.YKWJI[_&PX%KD[<*X_1.'(\4X;WK7:MZ?7MFEWNWZQZ=X/T)W+%%,IWJ6K MU6TS]"+*'^&.W:7RKVD&E^^&RW"B!4@;K^6MIBJX+7=MX=^L6M? M8!C)C;N@=L*+=?C'N3L.5ZB>NC/&PO=V]R M:W-H965TT`5*@ M*+J<:8FRB$BB0-)Q\O<=DI:B)372BVD.WSS.O.&,EKF515QA7_]O+^98:0T+1.:BY*M\"M3^';]^=/R+.23RAC3"!A*M<*9UM7" M]U6*5JMB+^"%U!Y=.INHE%40'%@>="R%$JGV@,YW@0YSGOMS'YC6RX1#!D9V)%FZPG=DL8^P MOUY:?7YS=E:M_TAEXOQ%\N21EPS$AC*9`AR$>#+0A\28P-D?>-_;`GR7*&$I M/>7ZASA_9?R8::AV:%QBD<--\(L*;IX`9$Y?['KFB!QYX308DU&(T8$I M?<^-+T;Q26E1_'$@T$15U/0"60";D7@<0*5C'-)0J[/OL:8MX'A-K$ M"]6Y$J\Y[<8;]H@W#C*UI3?!;/N&7=^P;QDZL4#!6['4FADKB-C28SR:=K/; M.`R4O=&L%^:V1C2:U89_NNQK1%\RN*85IBTQF7K0&77$!K#"D&4331207L0. M,[-O("1!..^>;]TY@1Y_(YEU,;LV1S2?S\;=\_UUCH[T\%1;.=6)&"N4W_6U M*>YF8-D.++N!9=^V=*Z-.M=:*2-(V;5X,Z(:80V\)VQ/DXV#D+;XA/1:;-N` MFM/FJNOV@LDCV[(\5R@6IQ)J-($H&ZL;YQNR@&Z`.WKV M'8SY]^QWX0*D&N(WT>6SX#=$,*TK>F3?J#SR4J&D&N]MH4=G^ M/0@-<]K^S>#[RZ"6@0?@5`A=;\P[;[[HZ[\```#__P,`4$L#!!0`!@`(```` M(0#"\#)1&PO=V]R:W-H965T288VVB,L8!,9OY^JZFNAKZD MR4L<5YTZ7:>K+V5X^ORCOCK?R[:KFMO>]1=+UREO17.L;N>]^\_?Z:<'U^GZ M_';,K\VMW+L_R\[]_/SK+T]O3?NMNY1E[P##K=N[E[Z_[SRO*RYEG7>+YE[> MP'-JVCKOX6M[]KI[6^;'(:B^>L%RN?'JO+JYR+!K/\+1G$Y54<9-\5J7MQY) MVO*:]Y!_=ZGN';'5Q4?HZKS]]GK_5#3U'2A>JFO5_QQ(7:_R@OB'KYH]'55M$W7G/H%T'F8J*[YT7OT@.GYZ5B!`C;M3EN>]NX7?Y<% M*]=[?AHFZ-^J?.LF_SO=I7G+VNKX>W4K8;:A3JP"+TWSC4&_'ID)@CTM.ATJ M\&?K',M3_GKM_VK>?BNK\Z6'!3TX2/(PDEL"0!\(G#_3# MQ2I8;Q^&X2V1*QX)GX:\+8&@:A`,GQ2X7/BKY8;IM<1M>!Q\4JH@UQ*PY0'P M20--9E8/]+`R0T7CO,^?G]KFS8%M`G/?W7.VZ?P=D/%2\J%%<6&-%0S]A<&' M("A;!];OSYO0?_*^PVHI."9"#)`)C((X$(*M&$8;JX:$#"-'L)&'20E")-G$ MX($Z(1%F4I48+H4BYI45K=?R2!%"IH("&7$@!.42ZZS!5HY)*&8B44:DA"#6 MS,HJ:88U;]',O+`7)Q7:A(JD"#&P`T05E6DY$(+2B\GP;D@RBT@)0:09&4RD MDF1(597L;Q>P\6CM,L#>A3D4BC9A*$]YA!B;:D)0@C$91EIEHA)$/`S;Y=-Z MO93'3-'MPS$\)O8@8S+;(-(LP#FCSL)DL3.O/`7A1LDV0@P,*+)1$`="B"D@ MP[LA"2'8B:'J)Q_1960PT4EBX;BTB&5>5:RR"2/$V,02@K*+R6#*;CC-$D*8 MQ)*/Z#(RF.@DL7#^6,0RKRI664018E9X;#\H93B0ES*+R,F MH*O+Q][&?G=QD%4R\@R_#08]\7Q0(B##UM*,>H?^053=!J"3Q?%`B(*A;/O]2X27*3%CF5;.FQJ(:>QY9]7AH#H6+ M?%MC-$`.`D(IQL)B2I$O<.)EJM6#7<038R8L)D9Y:4.!;**96SW*U!O,1Y"U MU`2A%./YH$1`S*56*3.!GU?-FIFQU&)#8X\S+;%^E\%O:C8E_#+;KI5F]2#\ MHU2*,.7%ZTL0E*J2IAII)BPF4KG$K)D9Q6J[&7N=J>APH_[N\&T-$5_7!!EU MD\64(M<]"TG%T,2;"8N)5Y;.6AR+=.R`8&^)KEK_R>53FS2"U-9;0"C%6%C> M#4KF(:F`$&\F+"9>63KK94;I8HECBS.MMF&)V_H@7FV"4&JQ3Q93:KS:!&&K MW'_4KBQR$V=FY93ELCYFE*LMF,))S%FPF)B ME$7+S9A:Z4!ORL*->F-QD%6TVC_%\T&)@)@J+9RC:!IC7C2LW,GRIMT<,+-< M87TW89E^O+6IUQ)PNIV`%! M$TN<4:"9#KHIUDV);DIU4R:9Y!19ZS&F."S!%=S@^(17?SX+C_VU,FE+$C&L M7167D>\K&^?`F0!%LQ#KID0WI;J)O8Q@62$7ZL.7"_@HNB[;&L2&CQ1 ML*+W*9X8'%YSW/-S^4?>GJM;YUS+$Z2]7&RA-BV^$<$O?7,?GBZ_-#V\X!C^ MO<";JQ*>>B\7`#XU34]?("E/O`M[_A\``/__`P!02P,$%``&``@````A`,`, MQL:8!```*!```!D```!X;"]W;W)K&ULC%?;CJ,X M$'U?:?\!\3[A%G)!249#`@%I5EJM]O),$R=!#3@"NM/S]UNV*6+L3CHO3>?X MU+'K5!GLU?>/JC3>2=,6M%Z;SL0V#5+G]%#4I[7YS]_QMX5IM%U6'[*2UF1M M_B*M^7WS^V^K*VU>VS,AG0$*=;LVSUUW"2RKS<^DRMH)O9`:1HZTJ;(.?C8G MJ[TT)#OPH*JT7-N>6556U*90")IG-.CQ6.1D1_.WBM2=$&E(F76P_O9<7%I4 MJ_)GY*JL>7V[?,MI=0&)EZ(LNE]F]YLXL]MSW%]TW@A;1<7+-8T\K>V MH]5_@N3T4D+$[47@B2+>9.'[T]EB#BH/(KT^$IY]I`,B#P*F?0`\<2IIO0\" M81T\47ABX..ES?H`>.+2[.>2FO>1\,2IGELC[#Z^1GABX),^+OM(>.)B/_71 M$N7G;;/+NFRS:NC5@+T(!6XO&=O93@`B?;_TE1@Z"!HY9^P?C,Z#H#=:0-\W M,V^ZLMZA)?.>$PH.F#!PG#%CBPS6EDQVIP(1`C<-=S86B9&"(GL52%0@E0`+ M\A],`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``#__P,` M4$L#!!0`!@`(````(0"^),@`R`8``+(?```9````>&PO=V]R:W-H965T+^U%!Q4.I4Z.?J\0%I)$"#-S,73_^?(G9*V$=#+]^GF[MGX$<1)&]YFBMKM**[C[T3&\ MGV?*/W];7T9**TF]^]&[1O=@IOP,$N7K_,\_IA]1_#VY!$':`H=[,E,N:?J8 M=#J)?PEN7M*.'L$=2DY1?/-2^#4^=Y)'''C'K-+MVM&Z7;US\\*[0ATF<1./ MZ'0*_<"(_/=;<$^I21QV]7>.]/M>_YZ)W](MC?0C^.DNB4ML&N0SLJOO.X,^Z`TWQZ M#.$-R+"WXN`T4[ZI$U?M*9WY-!N@?\/@(RG]W$HNT8<=A\=M>`]@M"%.)`)O M4?2=H*LCD:!R1ZAM91%PX]8Q.'GOU_2OZ,,)PO,EA7`/2!4_ND)+\'_K%I(< M@%?W/K/G1WA,+S.EI[<'PVY/U09*ZRU(4BLD=966_YZDT>T_"JFY%37119.U+8%=]J+P+"HT MZZ.>UX3GK_5QF%>$9]%D;1]A]F5]A&=1H5D?QWE->/Y:'U5(+9H`$.*\ZF]D M@(HI0'[`'@S::K\KRP"8!7D'GJ'4U&9)`!F=UWU&]77AD@50GQ"V?=_D4*&8B+`@^P;\1?J9`@L`< M2T#],==[@VGG!TQM/V<6(J.RQ!(),KV)K<$+)@K/=C2=-;$001.;%QQ>6/'" MF@IT<2`=V?#"%H7JCNP0P8[LJ3#,EASB>N`%%ZN\=.U`;(H`07J6`X1Q(#*) M`[:Y0*'DR([7$@FL8J!0JC)DZY@O$):PD$!7&X5J5T=$="Z'5HB@[9H*,&ZE MQ.,R8O."X7RW(J*Q+[23$GN1X+M_D".NB#Q[PF0`K#?E#,BF:*];S$A2S&0" M+RQYP>`%DQ&%%2^LJ0%BQ=L7G!X8<4+:RJPH>.&?-.`V2*# MLWC'"WM>.*!0GN=<)%UDP)89;OBHU@TW*8;M8GD)Z7>+P&4?H@5EH(%BF>%6 MD"42^$X&"I553"EA(8&F-@J5IHZ46"&!IFL4*DTW4F(K)7928B\E#E+"K2.8 MI(!-C9`4L%F"?3Y^2PDQ4V`]+F(^Y#)N09%1MN'1!EV]2_ZQJ;.D#-F?%CXZ M-VD,RM2DE]F@):M!2[:T):?*]+-$X@9KB64X7PT4 MR#:;@TU:IF=&%2-K87TTM%%X8>A@V3-[N95OA03:K5&HK+*1$EM*U+['3NJR MEQ('*>&6>P)G`3TV5YGXDU,G_J^FTI:,%+-YH/>Y/X$6E*G)^B42.-P&"I7# M;5*"#J:J#5\M4Q:ZH*V-0J6M(R562*#I&H5*TXV4V$J)G9382XF#E'#K""8M MX#"C+BU(,9\6SST_71\H4Y<62.!0&RA4#K5)"?KU4K41MY18:(".-@J5CHZ4 M6"&!IFL4*DTW4F(K)7928B\E#E+"K2.8C""[`2$EV-U'AK!I,>2V#8NO^10S7Y939HRVK2EBUORVG0UJI)6VMY6QLYLI4CNQS) MOU>C;$/#[@/W=AWN%/@SF?GM2($42TRA5%;:R)&M'-G)D;T<.<@1MQ9A MLX"<)[W*@ORDY8?O=_A$P?#.)\6,EY3:G!/J9'$YDI@\/$&DRN!J\UOV;+$Z0MU M`O<2HI.I3N"J0=0==0(7#**^5R=P`2#J"VT"YWNB;F@3..83=5.;P.&>J-O: M!,[X1-W1)G"R!WJG>#&X2'UXYV#GQ>?PGK2NP0G&L=LF5YP%U&MPWP*8I2_(4T4-RVS_\'``#__P,`4$L#!!0`!@`( M````(0#4*ZZE:P8``$D9```9````>&PO=V]R:W-H965TGAE$)4?$`'/FG'^_U5U4 M0S<7QP<=/[XJZJNJ;LJ>YR\_BJOQ/:OJO+SM3;98FD9V2\MC?COOS7_^CIX\ MTZB;Y'9,KN4MVYL_L]K\\O+K+\\?9?6MOF198X"'6[TW+TUSWUE6G5ZR(JD7 MY3V[P953615)`U^KLU7?JRPY"J/B:MG+I6L527XST<.N^HR/\G3*TRPHT_XL#'2H>6MM+?#T\GS,00%/NU%EI[WY MRG:Q;9O6R[-(T+]Y]E'W_C;J2_D15_GQ]_R60;:A3KP";V7YC5._'CD$QM;` M.A(5^+,RCMDI>;\V?Y4?OV7Y^=)`N=?<)"VO<"=X-XJ<]P!(3WZ(SX_\V%SV MYLI=K#?+%;/7IO&6U4V4:[*#P/:'7)8WQ.^>-@.'+23G[E=/W)A`A_36@WU]< MQWFVOD/5TY;C#SFVRC@0@U>>NPT(Z+E=JS8A4<@F0@#>>Z%H1O&0LW9=Z=B" M',A$0)OHB5@MI6Y^E>NFN_LZ<-"!0`="'8@04!5TT8G,Q/,<10%T3T\!58RC ML'YZ:5IY&YD"<1,?.=#!,I5:(@_$(/T!`9,F(3'()")@TB2>8RA2(=2>5.S: MS0)6-JGFA+T)R9.*[*VGJ4:.)[IXJ5X[X#4&6YQTX&KV0=_>6;8OU4_X"3_1 M)_S$R(%W&4Y7(24SL)GHF>FU,;^JIL5U]&9`SOBM1+L$:D*8K[#]LI,2U?`NE8F76!]6]*<6$FAT`.)3,8>2@H9 M11*9-(HEA<]$S%ULNFY4!?.11.MKIWMN,9Q8^@\N=ZV-3WY+FA6.?APYL`2/ MC4))Z823&Z[*7BZD MV2R@GWX6"!D+$5>X]-ME`8VPFUF_EUO=D]=5T7R\Z43+7L>I!WS(9[N['LS4 MB=*D@9"851"&CJ+T3I8(MM!:,9T-1A?-9 MIJO]0#B..FH/:#\%?/BIS+,S*YPHI"%X;!1*"AE%$NFRY:ZU.3$>(76E4L7S MZ69&/`X_JGAM;_'9W(34+@"BD([@L5$H*6042:03O]X.6I[NU2/)QY,JGD\\ MFOC^5H<#D2I>']U@+3ZL/%%(1_#8*)04,HHD,J:KW>WP3K@;PM/`$SO#A'@^ M^\R(Q]%($>]VDX*XG\\>3E@'22$=@40F=8220D:11":-XI:"XKT-6W:E4JO. M!Z!.N-S@<"Y2!0_FFH?CU8$1A6(/)#(9>R@I9!1)9-(H;BDHV-W,U-I61SFQ MQ?4F&W%9V]M=;5GY+6ENBY,44A%(9%)%*"ED%$EDTBAN*7A`X,Q-L;8ZU%&U M!0P':W@NR0^Z_"%T&$+!$`J'4#2$8@52&A+.=?L-*:KC0L7PO'%XT"?X6KGT M/;GE\(%)CBZ,:>OWT+$H^<$0"H=0-(3XZ33?".&.X`OUX6DSGFD6677.#MGU M6AMI^7Z#H/AL(5%YROTJ[#7<9SLXQ`._&AZP'1S=#?%7FQ^7B]IJ%KYMTT&Z M)2_!^?8].6=_)-4YO]7&-3M!>$OXG6`:%1Z%XY>FO(M3V;>R@9-M\><%_F61 M0?&PO=V]R:W-H965TR510&U;5L]O7UN`O_^?OSPR8,NKZX[HMSJ"S^\_/S3\WO3?NE.5=4'TL.UVX6GOK\]K===>:HN1;=J;M556@Y->REZ M^;$]KKM;6Q5[?='EO.91E*XO17T-P<-3^R,^FL.A+JM/3?EVJ:X].&FK<]%+ M_MVIOG6#MTOY(^XN1?OE[?90-I>;=/%:G^O^NW8:!I?RZ;?CM6F+U[.\[V\L M+LK!M_Y@N;_49=MTS:%?27=K(&K?\W:]74M/+\_[6MZ!2GO05H==^)$]Y2D+ MUR_/.D'_UM5[-_M_T)V:]U_:>O][?:UDMF6=5`5>F^:+@OZV5TORXK5U]6== M@3_;8%\=BK=S_U?S_FM5'T^]+'>B+BF;LXPD_PXNM>H!>>O%-_WO>[WO3[M0 MI*OD,1*,)V'P6G7]YUI=&P;E6])'M:IMDE4G5[^^I)P_K[_*9)0& MDP'F,0Q&#$'D-B)-1B=K26!D(>]MQB)0B131R$99,9MD\J,)9P!YU+E7=Y#/ M%E`DF3U/)&65H6?WE/#M2!E"`2:>8S`B]R$0&>ED1F9(OEK=A?(&QL0*BP1@ M-KHT+.8\CA\)"800G$5LNA%$0G:@@X1:Q212+G"(##"Q)L$36GUD91,]%#QU M!E>K-'A,@@,&@C_$T[WI(N7(RMEX+0HN>]=QYVH5!Q>"!@=,.J8_3:(Q!!!` M")E^SJ:612349F`/H%JE)#8X1`886>>Q3Z800,*'0"2VB`2=/V6]-Q6`\9'Q M(1`9)H78D1*]3')BS84!0662C6";J?:0$X2(-]LX6FA-MB"-H&KS\;0G0U^[ M"Z$[:6LL&'$.E'[9;<%`UG!PVIP&M!`W)X,!B!?`>8( M;P&4A#EH@+)A&E,-=94S!B!?/WHA.!]8(NEXR"W__GP8D)?0H)BN@<:$W++) M;-VT=PX#&@H4\4V*=25'"&^!W`+*;`5U3`B`:!^:&74;<0[;B,.C@5SV+D9:!QN32LX@'P%F"-\!>!8*6EC:C-53**'F0'Y&M,+ M07GA6#,M0J"=4@"F+<,1#K4"\&$E-S9&L+5,LT,.4-D!@2%XILM MW5V-G;8PCJ_$SA$?-'#>*/:(<`!1_S`B"T8<7.;0%5PMXYNW1X0#:"&XVXB# M8]$<1D0]JI#@]B9B0,N9'Y02SR^.[]9(;FND?'S"_949D+S+J4\Q)/=",!&L MDM9,@-;=F8E!$#V$?!!,R*V`W(**C$M=XA9480NJK>8&M!!\KJ8/2]&Q MG%JU<,DJ&8A,`&B!!1BA@1EC8O9(C8O@UU,!.HBW5FM:!K'$&PALK<;##S#! M0FKEQ"6H9"HS`2!O?_H@.#586"U"H)UW!F80V.6M1O@@B%",A78X!.CE>P-C M0-`M@FS1.;+.OO[!X;&PCN'A&(I;A![38P!!^`=&GQ*P>6*'XV,EI?6(78I* MA\:`H!L3^2>:)A3Z%2'B.)I_YX'I**&;Y,NB`SJ(TT(G)P;01(<31(X0D@Z? M':\P';>:QK::"NNK1P/RC8T7@HE@9;7R`OKH'YMX$-'EL?%","$LMF/?ND26 M[C/Q7&39ECSNY=@\^QX=$\`:.Q)P::LU.#YMC=U&'-POJ[%+5JVI`9#1<)Y$ MCR1/N7$#"-FC?#O="*;C%]48Q/#.U`!HI,/3*9@9XCE"THF7-"W!DDJ;59NQ MM(J8W'MF0+[I\4)0?A(LLA8AT%'_]&@?_F=^+P03PJH[-&_B4ELK,P`"U9\] M/D"1C`NP3I.%HRN!G$1VC`ZZB=N$-$&6`,CL.8(C&:_^P*5!!`;$4RC3DFX]=5^6*#_=!)1\>`S._$443/4>KU".4%`(K,5#<@ M`R\_P"L#EZH]5GEU/G=!V;Q=Y7=C7/X".J["2Q<9>\JX^AV>K.?R90R]OAX- M\A6)6W&L_BC:8WWM@G-UD"ZCU:.IH`/?7/3/_^_-KU\.4+_]R3?>JGD M[_S12H(/3=,/']3[&N-[-"__`P``__\#`%!+`P04``8`"````"$`B>C=[.D% M```&'@``&0```'AL+W=ONNS1>A[19TW^[(^;OU__G[YM/*]KL_J?79NZF+K M_RPZ__/NUU\VUZ9]ZTY%T7N0H>ZV_JGO+T]!T.6GHLJZ17,I:KAR:-HJZ^%C M>PRZ2UMD>WE3=0ZB,.1!E96UKS(\M90%0YL77)G^OBKI72=KBG/7P_-VI MO'1#MBJGI*NR]NW]\BEOJ@ND>"W/9?]3)O6]*G_Z=JR;-GL]0]T_6)+E0V[Y MP4E?E7G;=,VA7T"Z0#VH6_,Z6`>0:;?9EU"!D-UKB\/6_\*>GOG2#W8;*="_ M97'M[O[WNE-S_:TM]W^4=0%JPSB)$7AMFC_9!_K^6^/VW]F"_291BS*/6] MUZ+K7TIQK^_E[UW?5/\I$-.I5))()X&_.@F+%DL6KN/E;))`/9`LY&O69[M- MVUP]F!U`V5TR,=?8$R06%<0A*)F+BU_$58F!<`?1CQT/PTWP`9KD&O/L8J(1 M$0#+2`7I[Z@&"A$%3M\;*6*V&A/(QWA6F.0.DXX(@P+2(!0BNO4AR4C!0S8F M4!0*LY(U)JME*'Y&B,$!CX%PB*C-<=-!<2@,H0P83H1"1.>44A@"!4)O(PNT1T3C.% M(5"L40H1-:N(V=K23&&49G&X6J_80\D8N-!=(;9F\K))Q\/$HM,@0DG,[/]! M-AF>TTV#*"QXZS/5U_>-Z4JG04J[:+5^/-D8WOTR;"H61W9K:I!B2>$G$A8P MRFH8`(.*IT9(7#;Y>'CS*]5$,L?6IVB'FP$L,_,S6X,H++@?,-<0$.T,1XC2 MB">/M9MV!(99`A^'06M']@2&FX(,S\YNLBTPW!=DV)P'B';WSL#2%5^N'FH7 MFT4B,*".X+825J^X[JI!I%6HLCT!$<[ MUQMX:"]\,@?)YR+3&4;M5+/#$(R;-V1_2':$"'<$&39["-%..0)A)8IP1Y!A MB\59B32(M!+!3OU^OMDC)"^;?)S=%C7EIAI$F'[-8C"@CM#[#J# MZZ8:E,B]Z:U08_6.IQU!7K8UC!$'8/;.2H,H(X\[0$QQ``VBL.`.$*OFAEDV^HR[\FC0X`#Q M.H$O7![-,],#G-Y4"_\]'V?VRT^L0(2J$M,)AA&2X;EYID$4%MP!$A&VYIGS M"J1!D_,L,7O?UDQ>-GDXL]]]-(A2C>D$HV:JN>'W.!/<%2T!*\0`-HK``!O&`5(3-6MPU1X,F M>S0U/<#N47G9Y.'.=ZP:1*G&=(1Q9%233_MF2G:"%'<"&39K<7U3@Z8U,SW` MT'3;?NFOIQ6(,"8<[WT9GO-+#:*P``;I?2["9BWN6J-!TYI- M]SYW]P$\LM]G-(A2#=[[G-+[&D1AP7L?CO((FBF0.LFY30[U#JA.\M0!V"4[ M%G]F[;&L.^]<'&"S%R[$05JKSO'4A[ZYR/.OUZ:'8SGY[PG.6PLX'`L7`#XT M33]\$">%XPGN[G\```#__P,`4$L#!!0`!@`(````(0"^T4_.;0,``"<,```9 M````>&PO=V]R:W-H965T(S6N("+`EE.1+PR,X6+QE&<>649Y9KVTLK1Z0P M580-^T@,FB0DP@&-+CDNA`K"<(8$Y,]34O(F6AY])%R.V-.EO(MH7D*($\F( M>*V"FD8>;;Z="\K0*0/=+\X"14WLZF$0/B<1HYPF8@;A+)7H4+-O^19$VF]C M`@IDV0V&DYWYX&Q"QS&M_;8JT%^"K[SSV>`IO7YA)/Y."@S5AC[)#IPH?9+H MMU@>@;,U\'ZL.O"3&3%.T"43O^CU*R;G5$"[/>D2T0R^"?X:.9$S`-+12_7_ M2F*1[LSYJ9QPEP\$NEK&M&%"YK_4U"5>AO$K8.`1QW$<6?NVG.\ MY7042V54*0F00/LMHU<#Q@.^DY=(#INS@8KK;U\/3WP88BX.G&\0?0T!S<0/4AX@W@+HBF::XJ:RLO3G0E1VJJZ@\HK M9M%A>F*/DT0P281CA"8$$AEIC;3"1>@FZZ_UHAT4,R9HD@@FB7",T`3!!>D+ M6GCMK$FKWB'/]WN"%+.L;HZS7-MO(U!=A&/7[MIN_Q8$7?L-_[!KU_TU(4M- M2#-B\E07X`XZHIBQCDP2P201CA&:$'C+]#O2N?W2.C5BBAD3-$D$DT0X1FB" MY&[0>Q]W1DQ:]0X-1TPQBVK$;'W\CLJFQF_M^+T773#B&K[KJJ7O#]/O]$-: M]?3=P0U1S%@_)HE@D@C'"$V0`UM!OR$=195Y:L1J:$S3-!),(^$HHLN2/Z?O MSQEL3?U.#0>MAM0TN>MY[^5]U.VNVY\VW3[PEZN;3**.W_574M1>IK:9'+,S M/N(LXT9$+P7\1KIP`=I3M0\>G`VL'K!`],X#N2=6FUYK@.VM1&?\`[$S*;B1 MX01"VK,5O%^96O34@Z!EM5Z&ULE)W90:'[4RJR6!O#]@D7]]IKXLS, MM5HNVXJV5`Y)O9RW/S\()+'\D%K=%RWYRT0"S,1.$/KPSS\??ES]?GYZOK\\ M?KQ.1N/KJ_/CW>7+_>.WC]?_^Z_Z'XOKJ^>7V\/U_\^/U__\]-_ M_]>'/RY/OSY_/Y]?KF#A\?GC]?>7EY_YS;YY]/Y]DN?Z.''33H>SVX>;N\?K[6%_.D]-BY?O][?G3I_./V!>5__G[_\UFL/=R]Q]S#[=.OO_W\Q]WEX2=,_'+_X_[EW[W1ZZN' MN[S[]GAYNOWE!Y[[SR2[O1/;_3_(_,/]W=/E^?+U901S-[J@_,S+F^4-+'WZ M\.4>3Z#KY^^7/YJG^R_;^\U4'\.BW?WZ\3I'#_9>7[Q^O)[/1=#Z>).GT^NJ7\_-+?:_2 M7E_=_?;\C9!0'6N-K(+&]@W8I)(--4O4M[W%5?"F3CQ?.>32D!12273]S[I3)X4 MOYCRSD=9.ITO^CK\UJ.B^F@G.?7HK4>]T:VG;W7E[@"4$;@BX$ZQ!L0K`-P2X$^Q`<0G`,PZ6O?"]>6PFPP4@#1XN&)"E#4(6@#D$3@C8$70C6(=B$8!N"70CV(3B$ MX!B"DP,\1Z,_($=GTZ%.*S&&#Z=.9TG@R)764=V9K?B!KP>5P=E$*B(UD89( M2Z0CLB:R(;(ELB.R)W(@G2HY'K55>K.C?L7I8^^")&T?IXL?$^O MC-);P1A4AF`0J8C41!HB+9&.R)K(ALB6R([(GLB!R)'(R25>,.!W-QC2IRO< M^UQ\M=(DPUQCB$*69'X4BD%)DI5$*B(UD89(2Z0CLB:R(;(ELB.R)W(@7>%['VLOUNIEEC]1:\>7[_=VOJPM#DA1Q M1V1/Y$#D2.3D$B\::CW[=\+1Z_OQ$.1TWP9-51A__Y2.DTD0#*L@CUHQJMER M8[6,Y6!RVEH%L=PQ6K/EC=6*EWEK%<3RCM&>+1^L5KS,1ZL@ED\>\B.FEE"1 M;DO-QX.6(LB-C-9*W9XK3<*>RR2$EA2H8E0S:ABUC#I&:X/,]I9:!V^LEFTS M5-2MU9*B[ACM&1T8'1F=/.3'0:VPG#CT'5F:#1V7FK>'\=`H0VMT.JI@1E^8 MA)-L<'[)J&)4&Y2F0\*&M5I&':,UV]JPUI;1CM&>;1U8Z\CHY"'?^6J1Y3A? MQFZUW14Z7:.)&E]DGR9=!@-A81).L5ZP6DF@51JMR:SOUY+E.!G['5ME-)RN MOV;4O"NW-LAML9@M_=PZ-KUFM'E7;EL_M]EB-@DZ[1V;WC,ZO"NWHY_;=#F? M!TNJDV?:#[Y:U,6";Q9[MOZOU"8FZ@."+[U#81`B+:@4+3M[J@SRXJAM.:AA M6RW;ZMC6FM&&;6W9UHX3[AD=V-:1;9V\A+Z'U9HNYF&]UD.[%-^MU`8&/+SP M)U]!12V,UF2B&\YXN0QZO=)JB.E*D(U4S:@1I$WCO4-0D5JK()8[0=;RFM%& MD+8\06,/"KVU&F)Z)\B:WC,Z"-*FTV26!8WM:#7$]$E0;]J/EUHSQN*EUY)> MO#1"O,1ND6B$X`@J&56"[(/5C!I!UE;+J!-D;:T9;0196UM&.T'6UI[109"U M=61T$A3QL%I%QCQL5I=NB]#(&W"R-!@H"O6"0?5,9BB9AM6VM`H2EJ M&34VH9IN)LLLJ+6M51#+'9M9,]K8A,KR;#P/QL>M51#+.S:S9W2P"7O+2>BN MHU40RR?/C-\`&&0'0W*A%!ED!<+K>6@AA.VC#JVM6:T MX81;1CM.N&=TX(1'1B]AM:!T/*PGO].1FF1%%O&)7G]ZCM=HCD%UF'!E M*;TB95MO8VVY.0:]%=V1[&ELUO,9EDPKSN)1I^;'WW4$>HADNFK^WRJI08K-X-0*Z0"%@;-[&!? M"G(:OR#;@]<&>0'6.3JV6DEH;76"K*TUV]J(EBW75I"UM1-D;>W9UD&TK*VC M(&OK)*BWY7L^MC'A>OY?EY_N#BOV"\CS&CD["8716MA2E8PJ1K5!^"%1;%BK M9=0Q6AN$'V)KPUI;1CM&>X/P0VP=6.O(Z.0AW_/!KD2X)93R[H1!4V_YE`;S MJL)H.;6W9%0QJ@W"RD$>LF&MEE'':,VV-JRU9;1CM&=;!]8Z,CIYR'>^6IX[ M4Y)AN-'+=G?N@5TZ6K-.:+312A,TA;=&&Z-E%K;+-`VF"I7)S-G.JQDU@M[, MK14MD]L\RX)I0B<:MIFN&6T$O9G;5K1T;EBBAB=!=J)A<]LS.@AZ,[>C:.G< MIAD.?_F[72?1Z'/S8Z\V(6*QUYL37NPU_ZGRC6HK9GJ`49(>>2I!]UII1 M(\C::@596YT@:VO-:"/(VMH*LK9V@JRM/:.#(&OK*,C:.@F*>/B5'09T231X MF.T$>'5H..&YN,*DD^5O.EX$T2ZMAG1=E4'X(:AFU-B$_?H7+Y_"!;#5$#L= MVUDSVMB$RO1D.0M7%%NK(:9W;&?/Z&`3]J;3-`V:]M%JB.F39\=O$<%^Q5^] M9E4OA,+IU["/(?D51FNF3P[WIQ4950:E2R=,VA;**[8:3M@RZMC66I"UM>&$ M6T8[26C+M1=D;1TXX9'121+VMGS/JUV`6%^D=P>\ODBCJ=LQ9BD-1%HK\Q9= MO.PQ6KK[C"Y[C(:="]2I1L[8U!CT=FZM:.GRFW-N6W$SIO/MA4MG5M\ MV4/9[3F[@QAZ,[NC:.GLHLL>-S<_^K&-$7?R'1QO0".A=F?V/&Q771BMS*)2 MD.WV*T&V,M<&>0'6YAU;K22TMCI!UM::;6U$RY9K*\C:V@FRMO9LZR!:UM91 MD+5U$M3;\CROCG^X[8YZO T^OWVQ!VF)I.@@7N2K3<&A.,5(75D)#/(/ M8Z;!\%Y8+1L/;0L)!56L53-J&+6,.D9K1AM&6T8[1GM&!T9'1B1E--Y=]<6V!U8*1B6C MBE'-J/&07T:U_G-&>^IU@OX>/3'YUR#7OV95Z>\*!'U3:6RAT4E@*D8UH\9# M_N.HI9#S.(/+]1+)G;RH]UNH*J[MQ8JFW\5$(]5C.T\8;%Z75LL^X9!04&VT M'`!*>YDW,/`P_G`"$.W]&"RU6BETRJAC5!CG;FXV'O&)G MP=Q)BMUS?P@V2+7%H=A\G,IH_<5Q*K%EWH$OLF5XPJDR*D[5JADU8FC9O_-) M1\YA(O\Y@UG(\)P\U5`+('1O>$YQ?&&0>W)(M&S;K@SR2JQM.:B1A+Q^Q,0\ MVAAZ'L1"C\Q_<@/CQKM8U5( MSP+,*D8UHX91RZACM&:T8;1EM&.T9W1@=&1T\I#O M=#57B3G=3'[LG'BEO*UFX>XP1:ADK8I1S:AAU#+J/.0_B3L?4OV@_G)>G8`/ M5IF"[%RZ8%0RJAC5C!I&+:/.0]Z#J!>T0TA0>GTWP*NG&7IU?[`6Y$2*46E0 M,"T/5GZ5U9)&5#-JV'QKM6RWF(6=9V>U8-YW@YK)2,VT\<2'/F$\#5+[Y$,' MG&5VH-)=L&C9^5,IME"+G83!PJ2*:H6'8>IW:35T-)Y!JF-D:NIN]T4*@YPI26D0CK1)&ZI$RUNT9L&T MH>:$C22TX6E9J_.0_\SNU-.I&SSS5"LJU7.ZO0BA4K3S8"U5BX*Z4P/'KZ>C\#1/P[FVDNB57#N1QXSZ M'G*GTXZ'ADFS5/;55*,E?E@/38-Y=&&TG/I62L*Y?L#QW#9DT^<8RWI1.!V% MWWK48D&5#Y^'+D?A\8"&LVTED;:Z&`=#22?RP6ABH^V[R)W2.B[B&>U4([\2 M38.,"Z/E52)C:ZQ/3L[3*?7+QK0..-Z#V,*:9F<4=,35?5[!:XZ&\VT-2DR^ MV30\0]/)(QFS"(XMF>\E--O82*]P,+'1**A(0;LIIB:A[2!*@Y:Z(F73:9"F M$@4=\N4H\'PMBPWGVDHB4SOG08WO1#X8G;_FH?C<=LIS6X." M>F3-]F4MC)97CXPM$\]D$4[5*C&MZ]%\Y&S`F'JD32QUP*>3T3SP^[7(H*`6!9UK(0F=6B0)=3S#J4WEBQ?< M7XN"CO=L,@I/\#6<:2N)=*9)4#$[$0\V7^N+<)(FZA^>3_>:X8`V#0)3&"VW M#DE"74/"8U:5+UZ.9L'DK18%'>OY?.2T!]W(.--6$IGQS#_(UXDT9M*O/OZ< M^:]677A9%'9.@L;PJ#/,!4-6(6INO3+&QJD>Y[)EX.Q*$HWUSNIRM`CJ03UH M&.=/1N%-"(VHV)Q;0<9N,@M*VPT*QFPRP@:8\Y_5][WISZQE,8XK+,EK&BTQ MLQRX))FK MF`]ZRO)3O_D<\FE^ZL,;\,^3+O]!0EN6K M:%@*2-0>.!<6&_>YV@IG"?;O\SHJP39^KC;&.0UV]7*UJ<82O.E"FNCC9RE* M'7O0`A+UOH2MX24/2AV3X%T/2AV3X)4/2A"3%)-EKMY$I8&KP:1*ECDM5DFJ_P3IKSP:$%E#H6A6(R@R36;/#R')*8 M-1Q;R-7K\%@^"Z2)Q10'%7-U(([3X+QBKL[%L01G%'-U/(XE)TC4*3F6K":( M'$[;L*28H";JEV1!6\!!SUP=#^0T'23JE"!+<,XS5X<%68+CGKDZ,\@2'/', MU=%!ENP@42<(6;*"9!65%)"H,Y. M1"4X/`X?Q.H!SI#C26,2'!3'D\8D."^.&A*3X-@XZD%,@K/AJ`7&JAO,0F^SD`^,0F^RD`^,AV3X!L:1#LFP;*4&&]A,K6XDTZN,8 M;@OXS@FECDGPN1,B%Y/@JR>TGY@$WZRBCL9ZJT_268*/ MRW/UZ3A+5BC!*EX"2-2GO9RFA$1]X-27"U1:ZN6^`TN.$B5[&Y'54@HM#$.U8&EP/DJM+*M@:KLV!WV)S)-R>`[_% M)+@B!WZ+27!3#OP6D^#"'/@M)L&M./!;3(++J6`MMB##'56YNB.)GP?W4B&? MF`3W42&?F`17("$^L1+@VB/$)R;!W4:(3TR"*XX0GY@$-QTA/C$)[C-"?&(2 MW"&&-+%2X^XPI(E)<(488AJ3X":Q7-U3Q7[#[6&(=DR"6\,0[9@$%]W!!['> M$M?6H6PQ"2ZA@[68!%?*(3XQR0HE4!>!<:EQZUNN[@-C"6YZ0^1B$MSPAE+' M)+CH#9&+27#?6Z[N"N-\B@2]&.YZ9`ENNH0/8A+<5`D?Q"2X:1(^B$F*)(&U M6)^(:Q:1)B9980(9JU,K3+MC_7N!!4&LCRB6.:Y(Y2=<8YD0XQLL8&)V-LO\ MU.O?#(L4_!&4G[??SKO;IV_WC\]7/\Y?L3>#/U:!EW]/^N^EZ'^\Z!L/KGZY MO.#/GV#[!@&PO=V]R:W-H965T-Z:W;U6'"51C6VY M+&4R\_;[0V03AQ]6G)O8^;K1#70#(`""?O?;7X\/%W]N7PZ[_=/[R^!J='FQ M?;K??]X]?7U_^9_?XW_=7EX7?V\/E;Q_^^8]W/_8O?QR^ M;;?'"UAX.KR__'8\/D?7UX?[;]O'S>%J_[Q]@N3+_N5Q<\1_7[Y>'YY?MIO/ MIT*/#]?CT6AV_;C9/5UV%J*7M]C8?_FRN]\N]_??'[=/Q\[(R_9AQ]GC_%G./FY<_OC__ZW[_^`P3GW8/N^/?)Z.7%X_W4?;U:?^R^?2`=O\5 MA)M[L7WZ#YE_W-V_[`_[+\B_N^V/@_'[Q>';_D?RLOM<[)ZVB#;RI#+P:;__0ZEFGQ5" MX6LJ'9\RT+QGGQ:7LXQCM5]O+B_OOAN'_\7Z<4*.^#D4EO M!#][(U-MXTRYL"^'GWVY(+@:WTZ#Z4QY/U,2TE.U\;,O.;ZZ"49WDYOSY69] M.?P4C[.K(!S]S-]-7PX_?ZF%&$^G>N*G^'MC"^_ZDOCY2RT,T%=.+M4OXO-- M;0RD+ZA??JF5`7I/YU-WH[=F,I#.HW[IO897M]-I.+O]23(#Z3_JEU]KJO0? MC(FAY.B-7J4/!;H3C='N,[TUD.ZC?ADB>ZZC7W?#]#2\EYOCYL.[E_V/"\R9 M2,WA>:-FX"!2UOJ!W7L?ACIFG'NE_E'IO[^$(@;Q`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`6QW%IF[(E+[7"-3/5O M+E[=R*J7&\B$E<$.(8/B;]%KA:>WH?V;B4[+0*M>:WPW%(P%Z:PE;"MEE$E! M;6LM2-O*>S3KWI.J+6W!J)2"VE8E2-NJN6##J)6")UMVY-5NUHC\L#SO=KE6 MA#OD/#*,BZ+1"K+^'D>19GO=:_?0?3$)G,*W$CMZ!Q3V:Z%DC$:VSWE+1 MZKV%@?NTR41#>UNSMURTSGHK1.O5MI6BH;U5[*T6K;/>&M%ZM6VM:)R\V M]$\3GAY5T]`Y#9J+EMECG'750NO(/+EDM&(4,TH8I8PR1FM&.:."4>!(,\TZWSS=G_'&/C'\@]:H6'E1Y6L;G:H]9X6&LS.S&O[.\1 M%TI`C_2*>]%K_>1]CM:2>*T8Q8P21BFCC-&:4VLK2=%CT98Q.M)Z\[=,:H,J!G04N,MHZCA59,Z<@A'3M]>]0K&]B%F ME(B9\]Y245,OMH:ZCT-G.LS8P9I1+L;.^RQ$[;S/DAU4C&HQ=MYG(VJO1;6U M3-L]0>WA?3VAV]M;/:%'J(P,H\68V5(8:B-ZJYY9:>V*&BB1DH:'5)AA+6-K M:T:YE#2L%<(,:R47K1C54M*PU@@SK+5643O4:AOL"W6W/;9"W2/U4F[HN.&= MLU5^+V=E(0 M$BN&%P/3YQ!+#UOUS$A2S"@92NHSU-3#,BZZ9I1[2A8>5@Y,MZMB<_6@IBO7 M>%AK%;5CK;;5GD$TZ;;;YB`2A!%K=C#W+$74\)+G]$B:W#H:2T-#DK;JF3%[ MQ8R2H>39!U!JJ(F#C*VM&>5&2=U&&J6%H28.2K96,:J'DJ]%IS$TQ'9K&;+S MYYP"_&P=KFZ(.#LK0<9,O!"&]TA2B:6'K7HV->:^'AF93(:26BWUL(RMK=E: M[BE9>%C)UBJV5@\E=4L;#VLM:W8*U-[?-X3Z,P$]#Z,/3BM=^O=:L6_H%04BO"T1#UR#ND3'I)6_REHHMK$MUG6CI)UK:XYH] MYF_R6(@MTV-XYSS/2J\M]X9%Q96HO07=*U.-5*)?7]^X_EM1.+78[A?.X<9/ MAR8?>F`027^18;CHV4P?J2\%Z2Z\$J1'7-PC*_6=?<-6*@7U#CP3I&VMV58N M6KI>A2!MJQ2DM2JV5;-6(TBWL15TJI<=^I^=3O1O$A#4[H/0[HNQQ^W+U^UB M^_!PN+C??W]"/P_"*9YB`^\^19U/H_94#8=_'(^BCZ@4K#H2O(2(U-&Z3X+O M6G'(RQ+TV4C%AB7HNI$*$4O072,5*9:@G^+[69\$']9^/'5>M\ZHF*]>\S$J M[/$P5PX\_&,8?<0['Z[2/(Q:7X4PU42J&W*)#!+5&UF"6292G9(EF&PBU3=9 M@@DF4EV4)9A4(M5368(9/)I[)0M(U-CD,DM(U!!ER0H2-5)9@GDZ4@.6)9BN MH\0KP7H&,?"E!LL:M-0GP:H%+?5)L'A!]_-)L(9!)_-)L$Y!'_!)YI#,O9(% M)&IIP2W%FA#1\4FP-$1T?!*L$-%W?!(L`-%W?!)LIA`WW^#$G@IQ\TFP94+< M?!+LDA`WGP2;)<3-)\%>"''S27"($:G=,T<'9QF1VD2S!,<7D=I*LP3G%AB[ M/LD<-9A[:X!-,?+CJ]L*$K6)8C_8_R(_/@FVP9.QFC!G-O#1:0J&,CKML2$G5XQ!*<"D;J"(DE.!R, M8J\$9X21.E#B,KB3$:EW_RS!/8Q(70%@">Y?X.GBD\S'ZOGB&Z=SQ&W^2MQ" MM,<74;S407M\$KS;0=_QSK#C*22^,GB!@U[ED^"N3*1N7'!+<64F4A"5+2-1U%ZX;;C1%ZM8+2W"Q*5*77UB"^TU1XI7@3E.D MKL)P&5PY17M\F9NCI7-O2W&U$;7VQ0`W&%%KGP07&5%KGP3W&5$WGP37%M%W M?!+<7D3?\4EPB1$]Q"?!547T$)\$5X7AQQ<#W!B&'Y\$%X?AQR?!]6#X\4EP M2QC]S2?!96'T-Y\$GTL@/[Y1OPBP>L*%;\XI[L@CHCX)[K*CUCX)[IRC!C[) M''53=XK9#RY\HP8^":YUHQ_X)+C=C7[@D^"2-VKMD^!#%\P'OAC@XQ:TQR?! M1RW(@D^";UN0!9\$G[A@OO9)\%D+HN.3+`)L8+IC>6<.P0=*B)N_3(#YP"=9 MHHSZ:H5CC0^0$%&?!-\A(:(^"3Y'PGS@D^`3),3:)\D@R;P2?(&$L>`K,\>4 MZ'LV+S#U^YZ+.1YQ/K[`LLDW1R58`/EXCJ6FC]=8-)[X]9`2_)VBY\W7;;EY M^;I[.EP\;+]@#SLZW1A^Z?ZD4?>?8W>1[N+3_HB_4(1M+OXL"O[TU!:W;D?J M0M>7_?XH_T&2KH<_9O7A_P(```#__P,`4$L#!!0`!@`(````(0#T2A0(1@(` M`!$%```9````>&PO=V]R:W-H965T.,6`%V\AV#OOV'>.$IIM4R@W@8>;[YP3Y MTU&V:,^-%5H5.(EBC+ABNA2J+O#/'^N'1XRLHZJDK5:\P&_!E,E]EF"SROC^_!#_8BV=D&WWX;$3Y52@.S88Q^0%LM-YZUY?2FR"87$6O M^P%\,ZCD%=VU[KL^?.&B;AQ,N]=CN@4EN"(I_`I`Y?38WP^B=$V!QY,HF\;C M9)1AM.'6K86/Q8CMK-/R=W!*O/H`&9T@<#]!DBQ*1]GT\0X*"1GUE3Q31Q>Y MT0<$VP&:MJ-^UY+Y"#K(O''IK06>8@196;#N%UF:YF0/S6`GGU7P@>O@DPP> M!.B#!"1\0\);O80OT6NN@N&2-[K-&]_D>>L_O&"XY&5I=IN8WB1Z*TSJLL!9 M/`!"TL$'KD,3_B,!<[[1!&\M,%3^-SR=O),(/FD_A?<=#JL9!BJYJ?DGWK86 M,;U30$P@9K`.7\1RW"_U\`(6M:,U?Z6F%LJBEE<0&D=3T#5AI\/!Z:Y?EXUV ML*+]8P._'@ZSBR-PKK1VYX/_:H:?V>(/````__\#`%!+`P04``8`"````"$` MEMRE(8<$``#Y$0``&0```'AL+W=O(DJ`..@.[T_/LMNQR(<:"Y M),'UJ$>5'\]V-E\^RK/W+NJFD-76)\O0]T25RWU1';?^/W\_+Q+?:]JLVF=G M68FM_U,T_I?=K[]LKK)^;4Y"M!YDJ)JM?VK;RSH(FOPDRJQ9RHNH('*0=9FU M<%D?@^92BVRO;RK/`0W#."BSHO(QP[J>DT,>#D4NOLG\K115BTEJ</[F M5%R:6[8RGY.NS.K7M\LBE^4%4KP4YZ+]J9/Z7IFOOQ\K66O:AOZ_%OCUM?18O^2IDA'+?>Q%- M^URH>WTO?VM:6?Z'(&)281)JDL"W24+X,J)\E8#F%1`62B*!7= M^O#<=U1IEPBI$)/H]JXX2UD7MXA`*1-$*FH343*L"3&Q)B(I6X7D,5,\R:2B M0Z9A28@Q3#Q>]4]BE;2RB&ZB4Z,#`MK/,_8,,4BP(&E,DUXK%H7RVG%]JZA- MQ7G8-06I$(-421(EO?XMHM0BNM6B1H<$?=>1`#$SI$;`H2:*T>'/=&U`<]@^ ML09\[Z>E31"$S>,1&3$&HE[L\5G28;N+KK@-"*EHS).HFT=KGLBT-^CPD&LH M;P.*])O$HA%U$_5B]U7=)*&'!PR.O@W(")RF:=S+TBYGVA9@.7(%V*="`1J0 M:1U+QNJ9]@7B&@/GP_?6@.;(SS8'9V5"!Y@V<8*@.6S3/D$>&$7DJ.+>*6+& M1Z?,M@JG,MX8.#\1(^E2H#P-"LBAB(PL4M0WC MIG<]/*!P]&Y`1N^$LY"-&#J=]@H=MME<2S<@9%N%E(YX.K6]HJL(-P>6]?&^ M*:9I")JA/6K[Q%`/.OR9K1O0'+9IPU`;TN&*Y2C=@+!_L/3V;[FMO6G#H*YA MN$(W(*1B\=CJ2Z?=0H=M55!7YN@62$4([*H?KR#4]HI.%:Y'4%?G]QZQ8/%= M:^W637L$=3WB@;A%.8:Q:NRAF"D"HA<;]%M%3!IIU" MA^VJ7)4;$.Y=%I2.+/;,MHF;R/7P@,(1N0%A-8LTCL;*F?8'.+H[D^3LS@T( M3T\DX4,GQ\,['GDOV5'\F=7'HFJ\LSC`D2Q-'*BSZ%OL@63N+Z MYPG^8A%P'`Z7`#Y(V=XNU)\#W9\VN_\!``#__P,`4$L#!!0`!@`(````(0`B ME==Z;!T``*#A```9````>&PO=V]R:W-H965T M8N_=\/;F]>WAQ^>'[]/M MM[>WG_=W=Z^/WR[/#Z_OKS\O/^B5+]>7YX'IQRU3N']IHG']\N7I\3*]/O[U?/GQQD1>+M\?WFC\K]^>?KX*M>?' M)G+/#R]__O7SW>/U^2=)_/'T_>GMO[GH[7M/;E\^7CK.O>N MUW-N[SY]R-^AY.GRZ[7T[YO7;]=?_LO3Y^#IQX7>;CI0V2'XXWK],T,7G[,0 M;7QG;.WEAV#[]>MLGC]3MEHK]OGI^R24#[ M_O!/_O/7T^>W;Q]O._WWO4&KX[1[MS=_7%[?O*=LV]N;Q[]>WZ[/*8/RH4N1 M-A>AGUS$:?^V2(>+T$\N\OL:7:Y!/XN!M(<]I]?_C=VA'<_?$_I9J/SN>]+G M(O3S7^_.@&O0SV(@`Z+P MM/OO?W=_:!ISF6*/:,[^]E%VQ#YE,X/OU+^9^^)`=TJS?_3>Z;8:3+D[5HUY M%4\?WAX^?7BY_KHA;Z1Z>_WYD#FMGBT M1)%@Q.CVIFZO-U#?[%AL5.R!-KJ#((1LH@=2$2@T]/$?!2)$3BQ`?U>_KNC6I0%2358 M+DA1=UDXJSLQMK$(E(:FII@(0FPR%8'2)MK;-+,@JJHG"*'JBT"UZMQ$^IIG M+`0B9)7FX)HN^7R>E,8]3BYO.#*2*EX%.N@!6W9 M.O+?Y9V6_-6=O:Q8B!Z8Z(&I'ICI`4\/^'I@K@<6>F#)`N4][/5&ZMNP:L`$ M#9BP`;-NP&Q,IMW3/&';@-DU8*(&S-[&:+,M;L`<&C!)`R9MP!P;,*<&S-ED M>GUMWUVW"31N`O$J4::KD8Y73CW$JZD>XA56!2D&0*<[90,0:XF.D!3P_X>F"N!Q9Z8,D"[!0_.PU8Z8%`#X1Z8*T'-GI@JP=V>B#2`WL] M$(M`L!RFO[ON;[8\;0[A3K?_4W MPT008E>G(E"YR0P2GB"$J"\"E:)S2"P$(427(E`INH)$`(D0$FM(;""QA<0. M$A$D]I"((7&`1`*)%!)'2)P@<8:$ZV($EY`K:ZAR(KJXJEQ<5G0I.B]Y>SDK MO\KH8E>==60O?[REQ7QA"P/MW&_,&'NNW+$G@A`%.16!DJSJ-C-(>((0HKX( M5(K.(;$0A!!=LH#C#/)K<*WWVOGT2FQ0F32`1`B)-1C%!BIL(;`2)/21B M2!P@D4`BA<01$B=(G"'ANAC!Y>/*^JF<9"ZN*!>7E"MKRI9(L0VZ\EFV#;$" MSL*Z76AG:V/&U-F%($013D7`-JS<86:0\`0A1'T1J!2=0V(A""&Z%(%*T14D M`DB$D%@S8IB;EM/OM?(_JL5NH,H6$CM(1)#80R*&Q`$2"2122!PA<8+$&1*N MBQ%<1.X$J^"Z,8VL&4&_!U:Z;I:]K)N'=K%OS)@Z\Q"$*,FI M"-B&Q\P#$IX@A*@O`I6BH*PLRD`=.@XJAS".XS$&#E@ M),%(BI$C1DX8.6.$W`5.<7(7S!3U59J=ZL2C+D2L,VO`%#5GRZ6Z2]9*5;IL M(JZU.JS%2KFM.]#N-(\Y5.LJ3**,91CR)B.KW9<2VSWEASS&RD(C0 M7X*(P%&0HRL,;+!R!8C.XQ$&-EC),;(`2,)1E*,'#%RPL@9(^0IHBHJ MYQ1Y"F8F#9@&]48K%IRKJ#C;F%5/R1JP;)["&K,HE[S?V]$N(HP=QK`K#>U! MR\DN5*HV.>%,V5.4K7J]8=_8:J8H.\YHT,JN8ZC2GB'M*YN-AJWNP-AJ+K,)!A),7+$R`DC9XR0N;")5?-;F,IZLZ62S47TK&:2Q973X/:7?T:K<.@FJ%,)"(*=2HCMK'QTR"H MZTD5H>O+2*7N'",+B0C=)8_PB[5.R_2,%48"!1EUVJ9AA!A92,$?(4.,')4S!35%?EG"=/P3JS!DQ1<;9< MJJ=D#6VE!8O>XII]AM3P%N,";EU77&X3$ZY37KC`C69R(]MNY+J>1(0'^#)2 MN=$<(PN)"-TECS!O<;I.QUA&K!3D7:]E(H&".-VVN<8+%>1=N]V^DTD(HIU*B.5[\<,(YY$A*XO M(Y6ZY+;7:(],M0H7I=KLFLI8Y*G=L@Y$M M1G88B3"RQTB,D0-&$HRD&#EBY(21,T;(4&"UD*%@IBBIROE`AH)U&E09&4J= MCFHH6>]=R5#D)5O6DU'DN=YME*AA7*L-4Q+X%,.%)>I)0WZH\$D3U& M8F4P'7I4CG&@#U@E452Z'8M*JB".TW',RUI'E6D/!N8$.N'1G#%"GL*F5,UB MDSP%,T5Y51XH\A2L(RJN;CQ%Q=ERJ9Z2-=/9/(4UV2F>HG?-.HQAGM)N.]GU M!KWX)QPJNTIYLTZ'KMC:+MJ6(;JJ.[3,`L_0]I4AT;7>3JMKSIZYW,[V]N1G M5@N)%-92'E&[UZ,G]^@[NU+2M^GDQ32%0&'HZ5EY"6A5'2K0B,S%G-]K.<3* MO=A@9(N1'48BC.PQ$F/D@)$$(RE&CA@Y8>2,$3(8-K'J"GK<@"DJK7(^D,'@ M7+,&3%%YMERJP60-=R6#,2ZQL(:\LM'T!OK'B+-G<-'JI>8MFDA$%.Q41FQC MY)=OH:XG582N+R.5NG.,+"0B=)2,$7(7.,5I^8*9HKXJ9R>Y"]:9-6"*FK/E M4MREK77@BE.B/*[>%.H-M5^R8P[5N8I$1)5.9<0V-N8J&/$D(G1]&:G4G6-D M(1&ANY212MT51@*,A!A98V2#D2U&=AQAEF'_G&*$9?88B95,M-PT5\`'C"0X M48J1(T9.REC8RE.KBC-6H<=PX4;7!M5%C^'".@T*CI[#A76*DK,5@FHJ63-> MS9*ES9KUE"7+4+_@PJ%:,)!A),7+$R`DC9XR0 MNXBZJ)Q5])0_S$P:,`TJCMP%YRIJSC9FU5W(-\KN(I1""-[&S+4^IUC&Z3.AP-& M$HRD&#EBY(21,T;(76#ID+M@IJBORMGI-J@X!4Y!,)!A),7+$R`DC9X[PR][YM6B]18%,!58.F0IF)@V8!@5'2Q6< MJR@Y6R&HII)UT]E,A779J::B?ZRY7=>*EZ\*)A(113J5$=O8\HUF&/$D(G1] M&:G4G6-D(1&ANY212MT51@*,A!A98V2#D2U&=AB),++'2(R1`T82C*08.6+D MA)$S1LA38.&0IV"FJ*[*N4FG/UA'%%RM$18E9TNFFDK6EEX<(PN)"-VEC%3JKC`2 M8"3$R!HC&XQL,;+#2(21/49BC!PPDF`DQ<@1(R>,G#%"YH*;8L<-F**Z*N6F_YT'E2GI+I+UI-7YRZL9T]QEY%VUW[X<(PN)"-VEC%3JKC`28"3$R!HC&XQL,;+#2(21/49B MC!PPDF`DQ<@1(R>,G#%"[L(*1[UCIE47+5Y@>5$S"V8:5!R=$&&=HN9LE:"Z M2]:3I[M+MR>_5J[->O94=S&:66!CWX3KE*_=PHUFC^C.[91NKLT8!I4G-N@ MY-RBYFR5H+I+UGBGKUU*]YT[K#%/7;OH72T`GJG6*-YIAQ).(T/5E MQ+;O[+XS1A82$;I+&:G476$DP$B(D35&-AC98F2'D0@C>XS$&#E@),%(BI$C M1DX8.6.$W$5416E.Z4]5)G>Q4(:[8*9!Q9&[8)VBYDJCEN-1W85\H^PNXOYS M)XNK7VSJM/6KN1RJ=16F4SHCPAO-,.))1%2_+R.V?>:N(@93B2RDBM!=RDCE M1BN,!!@),;+&R`8C6XSL,!)A9(^1&",'C"0823%RQ,@)(V>,D*O`B4B>@IE) M`V;:@&E0<+1BJ1N/ZBE9WYV^8BE=;>FPOCS2*VX"C;06RC&':KU%]/>)6IWB MC688\20B='T9*8U8^BGW%C&82F0A583N4D8J-UIA),!(B)$U1C88V6)DAY$( M(WN,Q!@Y8"3!2(J1(T9.&#ECA+Q%3$1+?R"YBGBU^Y[3"HUDD$(BISBC>:8<23B-#U9<2V M[]Q)Q&`JD854$;I+&:G<:(61`",A1M88V6!DBY$=1B*,[#$28^2`D00C*4:. M&#EAY(P1?D9^4F39]W[?Y3&97%!Q+YG1[ M0_.I0>0KL#1HG5+'J.Z2-=W5K5-84UYYG=(>&%=68.?>I",04:U3&:FLUAE& M/(D(75]&*G7G&%E(1.@N9:12=X61`",A1M88V6!DBY$=1B*,[#$28^2`D00C M*4:.&#EAY(P1GI#E->O[`VOK+#=`V#80P?^*!G^N*D([H! M1<%.>81MU'8Z/?-!A3.%>>=TVL.^^;1JS]#VE>VZ9-7FVSV76U6^C0N)B$$O M9:1RHQ5&`HR$&%EC9(.1+49V&(DPLL=(C)$#1A*,I!@Y8N2$D3-&R&64ZNET M+(]9I$5,&:)JL7P9#:UBRM"[42M_$JEF'VK==>D)L^;S$7/\%%W;L*9\J7<\E8=^JX-8)@W&*H#FLNM*M_'A40*DV%CID5BI8U27R?KQZER&]>N576:@K=/&'<8PDZ%U M3,]\E/:$,]F7R,KZ[&L?49IRJ&;79@UR>4UR^3C77,G5'XV&YC)JT237$N=: M823`2(B1-48V&-EB9(>1""-[C,08.6`DP4B*D2-&3A@Y8X2\"1<=F1.#:@J* MK*F!4(/*)&-J("1JDWF%45.J-66->G76Q!KY%&LRNN\8P])UZ?L!S77;I,,8 M8$T,JGDG9URG+I?7))?/H9I<R)FPSK2!CEJ8 M]O&(PN2^I'[C@N)*75M3L#-X3Y_T%G>OS70;UYQAN?K#D=MBS-QJ-Z9 M.%3C%K,FR;PFR7R<;*XDZV9?@6`N!Q=-DBUQLA5&`HR$&%EC9(.1+49V&(DP MLL=(C)$#1A*,I!@Y8N2$D3-&7)*L3FOXF6'$ MDXC0]66D4G>.D85$A.Y21BIU5Q@),!)B9(V1#4:V&-EA),+('B,Q1@X823"2 M8N2(D1-&SA@A2V&%P\J3KF=:[U.-&RB)^JI7:E!SKBBZ>B51=U64:BUD'F5K MR1\3H:U[,D1;]VB7>,9=QK"4'?I^>/.[?R:<`)E2[[,&YO":Y?`[5Y)HW MV*]%DUQ+G&N%D0`C(4;6&-E@9(N1'48BC.PQ$F/D@)$$(RE&CA@Y8>2,$7*H M7%&8K'CM.M,&.K,&XQ&%:<^E.E/6E%A:]-B]-JW=LR95@,9$K09EI`YD9EA%%R2QBJ'[_H6I)5)+(DC)$72SIGVX==QG# M\M%W*5*;0^G,+Z_>"6>`)S$A^EOZG^%).)?7))?/H9I<XS$&#E@),%(BI$C1DX8.6.$;*E<"=EW MF!I%1[[$F)I)3KZ$=:8-=&8-=$1E,J>@._#*92W5FK(F1[!:8GV0Y=724+^Q M1A_[RNR+):0K4D/+5]%..`2\J:[K,O>X69-D7I-D/H=JCMM<3=;O#H?*F\G7 M3&S0M7NVQ,E6&`DP$F)DC9$-1K88V6$DPL@>(S%&#AA),))BY(B1$T;.&"%S M*M<=+>?->RMD3K"BR)RPSK2!CEJ:]O&(RF1>0;>#E#&KYI1U1P)S8@V497,R MGKG390QWPUZKW;(MG!A46\)3KE3C%[,FR3P.U2;S<;*YDHQLM],W/W.S:))L MB9.M,!)@),3(&B,;C&PQLL-(A)$]1F*,'#"28"3%R!$C)XR<,4+FU*#NR)X8 M55-39$]-E!I4)UT);Z(DZE,X1GN@?DQ--:FLN5(WJ=*'/[JL^5)Q*.UL:\P9 MGJ]%?=#&(G/"F5K/F'*HYLV<-TM,R1-]4U M3N=+?_(F*-.@*LF8H(RH2NX2??6S$JHG9;V7=9[$>C,53]*?^M,M]V]V1GUK M1Q)C@",)!A),7+$R`DC9XR0)^%"(%>"!46NU$!HVD!HUD1(U"9S MIHY>4ZHU95VP+C+H"&U6?[]R:&N4LN]K`F':CUC MRJ$:SY@U2>8U2>;C9',U&=VD4]M/^14GMONU>[;$R588"3`28F2-D0U&MAC9 M823"R!XC,48.&$DPDF+DB)$31LX8(8=J4'=D48RJJ2FRJ"9*#:J3UDY-E$1] M&?+-T-P,+^R3A:Z4OOXU^O;]7E^>?KZC6[@.O*3!CVSKU?_ M4.68,X[RV]71/L,Y*2@QSZ=F:&:&/#/DFZ&Y&5J8H:496IFAP`R%9FAMAC9F M:&N&=F8H,D-[,Q2;H8,92LQ0:H:.9NADALYFB&8PFQ)TN,6!=$M30,8L!YQF ML+FMY9#3#"YS;`;?O7Z[7-ZF#V\/GSX\7UZ^7B:7[]]?;QZO?_W(9FSFP3)\ M\W+Y\O&6:NT^+P8:D_82#3A[*?=<[:6=\\6]]OWOBT^;]\O;/%LJ+;XV+FWCG/F MW/NV\<^=^X4MOG3N5[9XX-R'>?Q.[O#KIP\_'[Y>PH>7KT\_7F^^7[[0T6V] M'Y!'O3!S8O]YN_[,?.KFC^L;&5?^SV^7A\^7EXPF^,OU^B;^0\?_[M?UY<]\ M!GWZGP````#__P,`4$L#!!0`!@`(````(0#J;Y"GK04```<6```9````>&PO M=V]R:W-H965T)8>E:6B3E*2LN>_V?O\.7M:[535R4\+&#F751XW\+.ZF/6]2N-3ZY3?3-NR'#./ MLT)G#-OJ9SC*\SE+TJ!,/O*T:!A)E=[B!N*OK]F]YFQY\C-T>5R]?]Q?DC*_ M`\5;=LN:'RVIKN7)]ONE**OX[0:ZO\@R3CAW^T.AS[.D*NORW!A`9[)`5>]_DJV$=GHYF'7)NC?+'W4@_]K];5\1%5V^CTK4L@V MK!-=@;>R?*?0[R=J`F=3\0[;%?BSTD[I.?ZX-7^5C]_2[')M8+E7U"4I;S`3 M_-7RC-8`2(^_VN/D3,O.`9Z=@VNL5ZNELW8AW(F98+35"4\^T])PB;59 MS#@ZG2,\N:-MV.L563DT0Q-3NITG/$6L2WOEKMO4JHXF6YIV28.XB0^[JGQH ML$\@^?4]IKN.;(&L6\MN:K&Z4&0)1;]2^%X'(*Q;#=;/@^,L=N8GE$O283R& M@;\"0V2$K[+8C@P).(16%9WYR%FY(<2(:&`P09V0")4SD,B54"M5POD\9@`2 M$;;C+.6H?.[48VP9$7`$ISUR0^^RY2.PE$[*.3% M!A6RQS"0!E'LN!IF$0%'B%+GAJ>DX2PBX@A4$\ MAIF2/(L(.$)(9H9U>Q(NR,:B_^1Y0^[3QX92'7$$UDP;)G0V#Y:9CF+-&WEN MCV&F-#,$(6XKP3(L=)H'G$)(YH:G>L)91,016/%F4C$=18I=E&V/8:84,P17 M[!KMFO5_W.,+/M,YIT@!-SQ/P2PBX@B<`@+]V^>NJ-6/QZ+WJ=:!ENY9( MA2\>8="(A0*BQ/G<)Y2"0@BE@X0P=B\4E&Z#`6C71Y'.-!?M3:\#/5EOQC`1?R#\ M>]&S3J%PFA#-6131M#^8$,W:!UDT?G41!AKJ#I1<\RAQ*SO;'< M$>9HR"QU:H3V,[UL]GWE&O!U)S+`.IYA!I1NK66920"C80E8;.R50YL1.4M! MQT./X[Y10GW2<7ZRL(.PR6QG#5_TRF31S&1RFF@+A-(T:'6@.U&W!HK;ZT"3 M5<)X>+NV'EG*0-#T1<+[LSYIRK$P"XF&O+)VV@SUVD5=L!X)WA\\$(\H)E\U M!:KIJ)I"U11))CE$VJST(;95O(2MP^X91FX)6',SK&FE'8<;*KJF]&TB:A'> MWG+%^CV*9R%034?5%*HF>B?6S0A<3!^[XV(7(GE:75(_O=UJ+2D_"@B*UHFP M\KNU-5RNK>F:H!&/;/BU&QJ!^[C7]GH,V7VRA6L.E2FD]WPD>DBC_: M6_B65.VAO84O2+";8F*XG;O'E_2/N+ID1:W=TC/(M`QZ356QBSSVHRGO[=70 M6]G`O5S[WRM[A?P```/__`P!02P,$%``&``@` M```A`*M*0.T4`P``+@@``!D```!X;"]W;W)K&UL MC)7);MLP$$#O!?H/@NZQ1.TV;`=)@[0!6J`HNIQIB;*(2*)`TG'R]QUR9"V. MT^9BF3/#-QLY7%\_-[7SQ*3BHMVX9.&[#FMS4?!VOW%__;R_REQ':=H6M!8M MV[@O3+G7VX\?UDX'O)UY#>>LB827?PQ!ER7-V)_)#PUJ-$,EJJB%^5?%.G6A-_AY< M0^7CH;O*1=,!8L=KKE\LU'6:?/6P;X6DNQKR?B81S4]LNWB%;W@NA1*E7@#. MPT!?Y[STEAZ0MNN"0P:F[(YDY<:](:M;$KK>=FT+])NSHYK\=U0ECI\E+[[R MED&UH4^F`SLA'HWI0V%$L-E[M?O>=N"[=`I6TD.M?XCC%\;WE89VQV9++FKP M!+].P\T9@-3IL_T>>:&KC1LFBSCU0Q+$KK-C2M]SL]=U\H/2HOF#1J1'(23H M(?#M(218!%E,XN3_%`\CLIG<44VW:RF.#AP/\*DZ:@X;60'9I!#Z4,K<*&^, MUMJ`6('T:9NDR[7W!$7)>YM;M$E=9[`)!@L/O`RN`/\/5T8[=Q7'`\=&W)%!S.P*?8C122F<059MD9$6VBBH>$$7$`;Z00=G:%1G?1H/TT'_8R=7&0;Z80]IHQE1G7/CA-_+-J, M#1V_$+>13MC)$!>R48WL;!F,:4$8WJ'AUE9/`\0R]G MZ//S;K3&Q7B6D\P?0.@';=!/FKU5>0+3Y$(.5CQ)8JPMPGM]9!L;^>-=FR5! MYK?V5"`KGH?=[8TP_@0&T%L^YM=U\(&7<%JBR#_O,D$C]'&51M%;/B[? M7)C9YVV()J>PKQ0:X>V*PXR,?<):X=C&8=?6%TK)Q>'UL[:[7J0XG-Q M"\]%8(?+H(`AWM$]^T;EGK?*J5D)6_U%"M=/XKS'A1:=G5T[H6%\V[\5O,L, M9JB_`.-2"'U:F!=E>.FW?P$``/__`P!02P,$%``&``@````A`.C9I$(1!@`` M&1L``!D```!X;"]W;W)K&ULE)EMCYLX$,??GW3? M`?&^"38/@=5FJP+N7:6>=#K=PVN6D`UJ"!&PW?;;WQ@3\`PYN_=FLV%^3/SW MC&>,>7S_K3D[7ZNNK]O+WF4;SW6J2]D>ZLO+WOWKSX_O8M?IA^)R*,[MI=J[ MWZO>??_T\T^/;VWWI3]5U>"`ATN_=T_#<'W8;OOR5#5%OVFOU04LQ[9KB@&^ M=B_;_MI5Q6&\J3EON>=%VZ:H+Z[R\-#]B(_V>*S+*F_+UZ:Z#,I)5YV+`<;? MG^IK?_/6E#_BKBFZ+Z_7=V7;7,'%V*Y[/H/L;"XKR MYGO\LG+?U&77]NUQV("[K1KH6G.R3;;@Z>GQ4(,".>U.5QWW[@?V('CB;I\> MQPGZNZ[>>NU_IS^U;[]T]>%S?:E@MB%.,@+/;?M%HI\.\A+MY^*-]^[6J7TX#A#N4MY3M&7X)_CI-+7,`I!??QL^W^C"<]JX?;<*= MYS,>NLYSU0\?:WFOZY2O_=`V_RB(3:Z4$SXY@<_)"?X'!RR,+*/9:MTC?.1%T/Q]-BU;PXD&8R\OQ8R9=D#>)XF8E(S3PU$J)3T M!XF/-X'H'JY^?8IB]KC]"G-=3DRJF)WKS`PALALAYUNZS6\7EEMXA+V*&R+# M"F.?!<"D4@&^-X]76O%XPQ`[3M<(QT1VA]AA)+^#8$+<(18G2!$$6E-TFWEY M%;)/F]4H)@--%1-H#!&;68G<2@@3@83`0#0A8VYIH9'6O0O3,J=)P$FBI(J) MQT1[Q[T`SVF&S+Z?8'..S'%,YD(0*4;G%$H]Y.#4R9(_C:$D-57AU>Q1'J]32[6&RVRTK$`E) MD)!;1.15')'`IZFE&%-$K$1N)82)0$(8;"4,(1G--";+G*C5,D%34.(@H;.> M381!=6YU(HQ.L"C9._\[SYAJK7HECFBQ3"=('S+D"\FV.Q`I%+D=$48$"Y-- MU2!,]5Q=6,#("DB9@G1A9,R9'%3P%W8+C!R$A,F;J[5/*V9P(HQ,L2G9@@RC5H+$HLNA3MN[B44RZ5W8' M(GYR.R*,"!8F^_$B;*X,JDWK@@).M@(I4Y`Q^:Q(;OMK MZ4ZA,_7T,:4R9D5R.R*,")+#S9N'T6PK=!,TK:60UK$,VY.`E+$:E.]-2,"/RW&3E0QZP'-G!#7*DFV(,")8S?VM@CRM M`S7Z(EJ7MPDRRK%O%>Q>A!'!=GU*P'/,F@:\W":N'UXDQ!FF]C5C&HW8^ M=B_"B&!5]W<(7'5V2\Y9VW\V^3$HSNV(,")8#MXAC(5;SSG5X2TYIR!UB@@= MCS[;9O"F02[("?"83\I@C@`_B>@YI7Q7L7CP.>=+UBHYZDV$.GEOJNZERJKS MN7?*]O4"#W,<>LI\5;T!2=D#')/#83>YGL.;D?'Z=C;`^XIK\5+]5G0O]:5W MSM417'J;'92'3KW:4%^&]CH>A3^W`[RI&/\]P2NH"@[@O0W`Q[8=;E_D*?O\ M4NOI7P```/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T M:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z' M'FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7 M,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPX MVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:" M8LT`;Q)__/QY.1`R M:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX M15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DW MQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2( MGIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q M7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9 M>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y" MG$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY M&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8G MB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<) M:G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*]) M`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^ M@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI M9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"V MENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%] M6QE*-V@>WV<)NB!7I%H6)9(R M97K1"VYC*^;PF6>&#X>4+-U\]Q+XVAU'H;O07]U$_^[VU[^Z2=)7W_WT[+JI!B;"9*$_I^GFVC`2Y]D- M[.0\VK@A_&4=Q8&=PMOXR4@VL6NO$M(H\(W):'1A!+87ZKF%Z\#A,1+8\>?M MYLR)@HV=>H^>[Z6OF2U="YSK]T]A%-N//D!]&9NV4]K.WC3,!YX31TFT3L_! MG!&MUY[C-E'.C;D!EFYOPFU@!6FB.=$V3!?ZI#JDY7]YOUKH%[J6N[R,5@#B M=__>1NFWO\E_O?G#FS>C?WWS[3]^<%?__/'WS;_]^(UNE-T@FQ"#;IOGHTZS M\.?D`-9#A2?"SR("#EHY#T7 M[XY&I_S.VKPK9/A8(X`,.+DL>C!T.\;WI45^CI$G1Y[0I$8,:K7TK>\]A?ET MFVPW4+PYL;=)"7/[Z!W4V\PW:NK)!*!6Z`0J2Z,$LM3S_:K4GYJD0H8CMS>PZDC=.+3@C5:\?GC= M0'TQJ-IY/3/@_4Z3A$*X\J0J`HJ@C!L:-:+JN6]_=6MAG5K,S:Z^-L)0=K MQ\^.EG".#D['+?3TV7,^0V?4]D".-^]BJ!XJ)3))A6]>FJ-+57WOS16@D7#+=AQQ&%:=%.E0[TT:)`I%^#A;9*'.(LW9 M`'*B3`G.%C)\K/?I>7U$+?A\1`TX?40M>'V$H;-O<)5,KJ(MG![>#;!E78U& M^68D;S_=!A'P/1FS'P1JT^23V60/H\PVHKZ"OC3&QMV$_&05ZQY/&2V:?C(: M[/&2T8+71SIORNA2QJOM!"+/>Y#L\$U]O!\,Z"AO6.+9$<%"G\A.0E[!O7;S,ZXK\#<2RK=&DM9%F;S;^Z\=M\.C&5G:=3]9% M=I3LC]?O[K*"J'Z?G<$*W&Q34,_-?!]'J>NDV75(V;F%-CS3%CSCPA`/GD/Z M-UOZ!YZX^3BD?]ATVAM$X$5I_Y!&0B@*V%$@$$ M004"4S/&$6E` M$%0I),J&B2J)Q!A4:60=BHDJB4005"DDCH0JB<085&DD"H4JB400@!$E"HDC MH4HB,095&EF'8JI*(A$$50J)(C$=6"(-O&V:;Z*B_=,QS-?M>Z$0H7+]OQNL MES5S)W7?` M`3?6R9D,AZDBHI>:,7,5=4Y>T`)2(K)SY?+\D!YJ(L;D0`M0T;LEE+ M`RIWP)@C1Z3[21L?S?[I<,EUW9*EA:HT'"`-T+GM`0.>DIKR72W3+/$V@N_>T36D3G M$*'%>M.LM7I6$$,#/9#'[FC3(^08<:7P##*3'$@8'4_63$)K7J]YI9F)<)VQ MP5O`[L`%<>1?E`P)MT5\=N`VYFD>^9'`.6^.\'G1(/W$O(`QMR[V9?%F#"L6 MM#CT9%UH.FV=VLE%4P/DM1`XPB+7;BK-&Y>H]M``Q!6EJ?"FBZFAX!Q]ZN;9 M"V"?RL,E\$`T2@+:NE,&&M45\%XBWV?QC*FDI861DK2R""2H)&91ZIYV"@P/ M5$@0$1PZWJRRC@YXKP3EG<`AH!Q3GU""7TQ[U)X)+D\2:+"> M\RI/RZ"A`07@.S M(VEQHQ2H2#U&SWF-P4'K"[V"D+QD%+N"X'1PY[>PXMTXIN220;=D@L6`T@2S M5A)T9O0J-@Z2&V774'G0$^\7TU& M]"&S[;)ZUM9CKY3M53\?76'[QGN@0@##.?ZE%;WB+%.:&O/HUZA,#2>.+TQH M&%&)RJH#>R5`KX&.-L)H71=BCZN4*O%UK`U/:PVDH_$VU$G>@U\3?PR&LOJU*UG2H2\J.!9V@*J=>\I*K"M@? MB=:1N&^IDMV9">[%A.YL3]_7OKISDT8>,`Q?B![]5CO3WCID2JPNVR!?.G[< M>CX\&XM(&[FKEK--X!$P=_G!XC9(7;:J$UL3&%;8%DRCHK;`0BZM$W*G-80+ M:D116]!];FL*WB);<--_85N0DX4M>(5MP>4(HKB@26&+YG[&R;VY+X[9'2,1 M7^`R#RYLJXXC,(=\G(++HK;J.$+@L"UP6=16'4=`B&R9T(FHK3J.$`5L"])- MU%851Q,"AVS-.+F_V!M'.E?)[=UX<&%;=1SI7)URYBJV5<>1SE7BLBBN.HY@ M%?%EPA]$;=5QI'7"Y-0)[&,=1YK[&2?WNXI*9_R$,^-S*W7LX!7BB%0F/!SE M5NJHT5D^Y"DF<8H@SD//"<.$JB=7KNP,,]H_7:ZX>&+E.?/A47#A;@/]4'UOHZ$T./WOT'L"&K]:73A@)>2S8 M)]+)[?\```#__P,`4$L#!!0`!@`(````(0`((RSQU78``";D`0`4````>&PO MMD&X8O@IE!,KN2F>R,3$FLJX8Q;S!S,\`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`S3/_S81^KY)_[WOH; M^+L.IQW`T&-CZL?3\J33XW$YK3O3#>L[/SN;SXH7R_GHA\WBQ6FYJ.KB^]72 MY!3!S1L[G,,(LQH*\U<]GT[&1NX72_Y+(ZB+^7'Q_;E6`6FJBXU7+[XI/KN= M-_-D5KP\G:]JA+#>+*IWH^I\63!K-X*"1LM-9'A:U32X/*T6;R=U5=3GU6AR M/.G*X8.UI70O'\GSZDTU6U7UK_('SQ;S\6JT+!;^AS<^J8F,ZK^O;Q?%B?E9@:SS7YB]_+PXL)M@R?>)G=+N7(9[XEUR[1Q6& MI=*RO)G(*A;\L]@X@EK'DZ7U>CLTNRS?51UE`0^^WX=/1:MT*/F4](+&6&RX MUVX7Y7*YF!RMEJ6HO9P7LSG?H_SA8*T02U&A&Y;%QL%T,J\[$MWIL=/@ZVJQ MK-[U#:0UTH)E*&HIHH$6,/2FL^R=T_ETC,?1D=ZORWHR*C96];AIKS/F;R;3 ME8S%%:]YK;B2UIO,FO8*K-IH-76:;F@$-LHNN6+7`\_7TK.'\[/S176*3I!V M":SWK;'T6HIW?0U[25>;A=8>[?.R?+>I44Q7#7#7YQ.?F3QQ"P:V4DYD6D2_U=(/V,\*Q<_ M5([UZVJ$3EI.I-=F;F+(9LZVCY'KRTUS>EEF[R4C*QKJ5-<_[']*LN+4*8VHND[V=SR)K!A:'1\)/-@(+=Y%`,S:)O[ MSCQ^,Y^/WTZFT[P/9Z`OFT+_L\`JTTEY-)F:T'?T1R3_>7DAVN=]\WRQ8EV' M')UOJN,*'3%F^9RGN>F5QK(X=QIRJ$69VXZ+=.77A^7Y1.[DM"IQF>='T\F) MLU!7?NFHF-#BRB_:[)%\F4^IAP@X_=Y0.!WZON18NYU+"+-^&_,9`,?2/-*Z MFDTD[BO\>\R*Q4&S^1([M3%>58($[G0]CL`,F)0BT.LBIY9"*UMYC:2 MVMY^?.??_KYIWQXSZMQ M!:@C-9GYEE=9&W/`O*?W[__VIW_YWW_Z;_]FFGMYT1%75)V7M]K%M)_M;._L M%N=@#^CY5?77Q>XFB(7^SWF93&>U/$5MXB'\M496%9.ZED1+8X:$&U,?>PA[Y7QW_O[FW<>[&W"?C:T MO=U[FWOW[V[>OWL_S/?#I[>),E,PK@AOVF'?@_$853J?H81D=;9PVT9.*>4L M@>Y'+4\._DLEWTS)HX:30:\+!=ON$GW,T_>=.:97L663F;,@5^O M_8Z0V0I=HX&#,^<)X/:A.PG33GU@[&0R$5_YXXX`06!J^'^!G4/\XL3P%X1_ M;M@[__>_OW[RR/[Z^5\);BW,*[Z>S)\1BYV5F__^+S__A'._'=^V%\+[VYW> M0B=N:(D=*MY.EJ>!@11I:A:A:R2;#Q3K=Z>DD'`Z00O!+?;9'`-7XATMQNX7 MO^+PVT2?GRS0-TS1=6C#W4:"J^(I6KHXW"QNM>&9@P4^_(F#L39O^9'1!:K. M8U[\U6!>QTXQP^6`90']D@-8NE7:SMD+M=Z'G>4N[S/F">1<+2?$E[>'$+2( MN&FE'\>A/)O7)GN7`,@=#1EUXU6!<.=+8UTH'15H/N6A+YP*6O?M1`GGG\@L M$;]Y7;_V3-J?73F-WM?[Y]#[ZJ43Z&6*N+P&J+X0'.)US.?%(YQH[T]G&NM) M#-NN`;M:X]>&7$V7Y:OA%)P7P[Y!YQ]X:AG\G#]+S,@S;T:\"]=Y,S$CS@FB MW?,&&1$B*=]9F20N*9*.KY=XM]<\\N@`7`PTLBVDPP)[VTXAA5F=_D' MZ&O`#U38!NW:7\(;'=J?L5-.GW7QO#XT+F_K"?Z4HGKCY5$BL1WO[6L/C9Z# M`N!'^WGF[;7>RA\:+VT=,6M";-@`=,SBGQ"@Y>^#6A5'"2+K':S6< M,F#G`RS8F^N$/S*=?"#H.Y^\+5,ASF"=OG%9`!)`)-DVB]=RU#>58?(?BZAI MWR\B1IBS0TK`E2SO(-3K"Q?/H-6BG2W-IS-'%\K3@(GX:P]\=+)1BX66K1:^<)E8/%N1JD3/FUGI1?#S;BQ=::2FG,2C_.*2M3Y^ MI.PKD>T*JAG0BWSU()MYG\'RREH8O:^`@0>_5Z:NL>'K-#6$*,M5SZ1?(U]_'3Y&@^Z#BYG6YV=3^<7A'1!',QQR'M^YD3"*T^A4(5E M>5"-LRL`N_@I]MV#&!T1NVW'TO.D#BC_]Z1,'2;"899X@( M$J;_VFT@D,-?OUB=GT\MG"=&'U.$!)R$\!I%E/N1&6::A.QH`UR4CI*V*5CB M1&']D!O7=E,PS==SD=1TZA/G-(@QG=;*-6Z>[36[F1\?JX`"_Z!<&YY[-?-F MGP['U1$\X1UY!J(""[%6_X@NP\3Y[/I#\9%?\$!]YY1+XIK>K?#PO!0S2,^4RLPOU#2G6QK"$LZUF)5E\(6T2X=.2 M^H*CJJ+X09E$$06?\K45=!0.'QQ5*P.L:JM#6)#:,E1WXY9[ZU8!FPOH`W.S M0=VR2%1C7(PMXVNHH/[MJ75.8=!H@@#7H;QH2@Z1$C\0>*O#4&NO9C9&\\*- M_I3"+<#-BHU;OSDX>';K=@;"+2@!5:GIK^KSPZ1"+- M,)5ZU2B:RB&)Q,;D]L\_Z6<_TTU^T4_")-\2=4\OMG!.F0.9HWHRGH#*,D>1 MF??T8HZ\!MSU3W_\7_;H3W\4/ELRW%!<9K0EY($'RTM@WK*@"9!6-6`>S-O3 M"<5>R5C5@NPCHW-<7Z)"H:=0XV1M3A3S*DV/D!TY&)KEPHNZ\(:8T&%QL0V& M/,6WHG!H@@8V_>E9LCAR>7XW;ZN=4/R#O":\5@GLM;S:-M6"D9Z>W-`,C\HQ M/LNJ_SSC_]4_*@ZG_'CGUA/"9[Y=Y[,J.V M:[+4RU]8`\N'I(#6:A:ZG<%#N_KVTA;[.0X?Y$2>^F9Q;@A[E"#/LTPF%B+S M]P#?'B*$E+.D=LQXZ7@^7\Z$&K\;;P=3!@+QM"80H1YY5/]=ZS%8LEM>6 M_%4WX':C!AI)@;QS('EDTA8)K,G6>7+6V\2FUDS\-C^G2!"+AKRY* M*SFI8I!^L/RD_+"%`DD8/"/C5M=B.$/GAM M:;KP>@22R8#;P![R;KZ88)]7:EL;=<.KO5S/3+2X/I/4-MJUACH3+PP#4J5]Y`B;+[[)( M/L&[B2J7[M3$Z4(BV%BE1IH.G#0]KU3J(6_[,1+X\T^4FO_.&%>#N;0?V!&] M_K8DX@3P&3=3:"`P$W>0`>?7T_<9;IID:T.MWWKQZ!!;RS\I7F+`?C^"?R@6 M*"X99,>`+A^^0L19ST>$YU+M3H._6)V9]N?!"\KB*-(>:2/"06/.AYR?EXP1 MN<6I<#X3+33*A;^NR+>A3F274A]"AI_E-^>M3K2+C-59^0/KY56F$(9F"L2] MJ[-S9X.,Z*6+GT1$QL?Z07Z?VA,!7)QLQ$\0&_MWHW+UHM@#]86F'_S&N1'` MR$9:]7@-&N`*(,SZ*!E=P&KL62A-*L8K4Z2M*7D=1V8T6;B&-$Y?L^;7&%%B MP\]*TM2TP=?H!H/)S=&S.3;ELZ)3&+)L1`3MK-+@\IKT39?]NP3RMT;Z2JDT M"K,<$;I'\[;WCO1,QCB[L;AHRNF$NC2#1IS6K"G]N($]QF_#"J0]X*I309/+K M58V&!WO5LO2H->H%_'"O4JF=T3['N&2Z]?NF?E M]+_)E+6=3KO5=D%\I?R@%4U)0;[/W/_TQ_]QU1RN09Z6JS^F:%5^13F>LT&( M6!8/XVT:B<#<":E2!0>R5!74!FCSWB_/?S,Y/L7%*9L`J_*`G_.P&P&XAN;N M=0>?^5U%SV,!*_C@5]E&R?RE2Q",1#R)@:93IQ)92>VWJM%7%OA;G`)'EK'F M9[:RRCO8^JS\O9@=4>1[YS8N0!.MY$PA=J4:[(435MLT9INT?)AUX=2SMHU( M9I]BV4^+@!O@:+UE2%CJXF0.D#>3"/IXW?H#4W2N`%*V1-^[1AZME`LH-A22 M2]>J+`X=S6R(N`_#FXJ[6Q:!>"L^[(Y%^`!N#`/`FT8I:ES2QY%24.<QUL3K'-HVQ M#Y`!Y*5FOY"P>E*;'N"@%^`"_`>R^[8#I5*/!@O(:2UQS9H<%*8-,U>CN)=O M!21I(IY%;>SV;T^H@)@$:EIM-D&K2N!+9Y\T((&Y"`!`J;C"L`"`$)6+5<^?9'YD^(2ZDI(Q8T##'4VC&GJWN0B6UF=L:,%(V81:4U M(QV&WK8-,4P(R(>G`5I;5$>*CRBBM^D? ME:,?G)C&3FEOU&I/0@X:Z=*+,2)N%A-O!(3,6&#<^C#B\:A.U`$B*S04CPP1 M$!-'D&@,H@UJ&:;%Z!I',N@28X'4@W,1!KJ2*`V0EX)=`N/HR*%Y2Q7`LT?P MZ>&3UX]^9YJE&;3;]2#G#:\2MM`RCMA32(6'C]):(L-P+4I+W;:F,\W]]ZNQ M`6=(AO1,`!@%#S8 M!;^F4WT1AP"VHBKA-3IT@M':3-SPI"VF7W84M^UO%QP<0(A?B!?ST.?64DP3 MG$GRF3L2!U%<\R?/O4#EOQ->H%Y,OO)'8I=O@HSG#Y\YCR/_^7EE8I;_;&4A M^8]/HKCE3TBML_)^BWNG5C`I4PK84C@JHE-T]5G>-./VNX+37)??H^7">6?" M\P\/$@`U^12U)>4'#,X)!V9R\@\W]O;NY[]UYG2(LD$C?^'5IZ"7[NIN[#W8 M?'!W)V]L8_?._N;._IW.[_N;=[]\T/GU`;]VJB,W=A_<9:M#IXV$UA%MC=LW M\J8/8TX%'5JD%>'YFW]+A2)HQK`VP='0`29MGP'];7H; M*$+>KYP@?X0`5C8K:N\?1*$QD`+S3X'_@CI)]O1OLCZSU3$:"S?*U-`(Z+!: MD+IAMVP$XY:D4\]Q(R:+`'F&/LG?X^*YTADIPP8P.**.GKB-4TB<2?A>ZC#8 M(#2B[#9S).UBNQ7UM%D9XN?=;1)[YG^A;0?FOUF$<1A)S,SA:*%*<5MKVZ"E M2;M58P7TGX^4'[JS\U=K-8OB_Z#\D+<=X\7J!)/9',;@C#UV6R(?$G6R,NE+ MV-^314D6!B*8!9+IKNH__?%_MDB_T0Y_PMO>>C;0(G0%OW;&[.U\,:5*TY4+ M88(IOP\'<[!:*\X,D`5C40_J2;EI(_!K==OXC)HMH@&\:@L:%I.34_.V& M__`4(N.IJ2[+!/C+A5Z<74*1?8SCG$1]-QF/\3D>E35)MH-C2PR+,P]6E`7` MY65ON!OX"CTF#Z-QYLL""HKB"W_J!UGQ14D1RXE&J#?/V.VTM_-7A>TCD9]9 M2JW*(R/#)?+)^7!./?\P=\EDPW?)XK0$8SORN(4^K7($==%LD@R)8GDX6XRVYE$2W1E&Q#3IN@$C90-=6LF$]#8HN;T0C M?+9[]\[V#LO/61FAU/D*GUZ$P,6J!%5*FA3-E8EQ8 M-_@1_'54V9JZ.E]%SC!WVI(Q9W#$Q\%=@(WA<)@-8T(\U=B``;4-?&QU&FLI MT/\=2//Z:(MQE:1%?XT!`' M*BI+>=!%LJ:-(O[4\->"3<$4`Z!0KN"N%C0!9A%>%RP40E!UZSW90=8,"J%1 MGU;80)A.EBZ61)R;U9".TVYN+U75F_GTC89*68K<)OI0C^Q6&7/&&0B@&5"0 M&;]36O_\[>%K[(-J,=$-SC"%D0^)T5EYX8LV@V5QN9P>>S7L7+Z7"^42I$W& M$I7&8+4I.KKUFA,XBA+]Y.A3IP-WX1R_@V2:V89I20[#A<"-+7=&T2/*7<.. M?G"\(R##LK&!QG&UVMYR0/?$F(8Z`I*Z54$GRCJQ6MA?B8^;B`!>5D[@*GDR M*T_0(K^U-!9N#F4A(GID>_Y.F(I_Q2Q4TZ8EZ`GWE4IS=3`1VS1GIURH.N`F M=-YG^W?8W_Y)E<.EU&W8Q"1GCD6?D;]Q&D!2A`+@$!,%')3NK(#>L3)Q;9JO M@R%!S\2%?T_N#^(^8)$X?DY`C?-#S*F6[TIXHOWKFD3USO^#$W_.CE:+VL#< MF%-OJ<66V]KGCJM!<^9<4W`%L*;XRWG3;A22L)M@ED\;N"!_@4@MS2T6"#D( MS=P*?5SI0I#U%J5]N".I).*!'Z3OKSBG3FZD_,6!U%=2[0,W-P5@EXXS5%>8 MF@E,Q5KZK>U20,K'N.7T`51GKWMK9H$\MKM(<^]]ZN8M4PRK^'[1M)I<1`80 MJ*"PMBG`-8["D6=CA!CNEP(BMC5_#(!Q637]1#@=RUAHVA`,0HC=%%V$I62U M3)@;PCH5Y873WH\K*:LAUK73!H;)'P5WC>+-1RE$[`)TIQW:$9,A`+5V,QBP MG`="8?NDS>X7G?46,ZN^HLT(KI8.PE! M&S3,_#O2E//%#\Z?B][+=O'AA MZ$?>(2;)U48;CR::H(416M9/DY;G3J&N+TZ/+/H10;%/532M:DE;NW+\QD). MW`ME\L0:KL[>R*PTYHOC'L2<'&$8$"KD?J`2A%>:1R M+0THF1J6#Q<\`/_T_\H=C@LU*.!B^($?`.:TX,W0=%Z:=X2)8_!??9D(.-UD M:N]BAB9-]:7G,J-Q`+J2TUL""FP?X;9`1EH7Z'>Q=72QY?^DOM\VQ#A+U'!? M>=MZG!);;2WG6[X1$H]RT4>"'"0P'AC#"R+?>B.>$/VM)020\H-0&G$KK',L MZ=.R'$\6X*BC"'0:&*A%T4-/NVC`';()O,HNEQ`Y!OY46`&XF!'.M7(6*MVW MYL=;9$>]Z'NJFOOB"&\@[=[.WMUK>=;?-$6DOS@7H[\>Q#1%U^Y$/]8Y%DU: M.+AB17ZFKM8G:/&6SNY/CYH#EYX_GZ1)V"W@.#CDK)V.NGR6&O\_DK+ZW-H`XBH*BZ*?A85BA"1QY4Z,S$2I.\%V:[V3?\FSZ5 M%2UR"C\@0%08Y6UMW-G9[_RVMWGG;B>MV++M9OG;/D&PXWEKU#_F/^G\N_1_ MW<$XR9(G#OOZ7)+WXEJ-Z[1+X+: M<5W[F>(E_-W64,F46YZ)[4V@-NZ[E\\.BX-P4I=M3+/Z\'6&1(:S\QJYSG." M1(Z;,0OJL)K.6Q2H2WTJ\KP@`T&1:4#1L;K-HCNOHM'6RJ*\?/3MP>LGAV[_ M1)+H=(#%4'^$B4VBM,ELW9;J_]OR'!TO9\1A`(WKX0Q"DDR[7IV*?`Y]C&TE M=A&PR>RD@MI$UQA($7QI0R!G:WN=.)[<_?Q@N^";19>\T2-O-M@D M\W,EE,ZU9C0I3**W4GKWIJ%O-)&S\ZD3.5ZQB=R@%9U-$JS,`^)55L7T(,I3 M2S`D5J+?39+GDZ>Y&F;HHH06C5LQ*U6@0W"(8V.5%*"<\*'=3K4(/7KJD\WP M!0=(Z@!QMWL8W:"\=K"NZ%R'S^1LW:@5N;@AA]]*;%]V/9&N(C`A94[1F3+'%BDZNW!%XO*:2;E0ZW-%JS#U>H[VPY]_&I.8)SQ1 M'IH0X2UE)+CS(5CR*LY;(0?HY53XCQ:L9>.[;L0FA7!%1-68',E#AW-(IF$B M0CV.!2!FE=HXRWO$'$F_/7''[K7X'?F]D5CPL]T_F\XWFFCY/+M*HRD[(ELM MF_Q@R"HT!J'?I&O#:(E(0)6VJ:`9(Q&=&%S)(9-H1@H")Z MY56NA?ZJ^5`!SY8*>D/4'RH'^A.QWH3Y*1O.D.`+41&CJKTO$K$,)\WR*91V MO#0_K?.W(5]GRD.3@=X'Z).IP8LF`'W&^`JRM\7%`%LN*TH!G5^QK(M(0M84J7K[F9%.9L'@=V&1Z)F*QG(?I#D]2J7Q5\ M=98E_1BV-^'"39H"9 M?^(C?01JBHK=)%67B#WV8OGP\(*M""/.0#YB)PT.V6/02'\B)UR\H"I#)].T MSZ5QZQ"CV8=/$O%GA[S&$[B_%3TI4(N^>(AAH[#N:AN9<]0MDD7"Y0W:SB?G M],6$72L8MHCW?:91;&A[V>/'+ZV[;N"K1PX*!J(B.>D2):"0=J4`6E0Z"EC& M8C';F]3R6JE8<2=2VO/7_[!U]R[$$=Y+9="(XEW^`FR$W&XC#7H?=<<_/=J9 M,(GP2PF`@^B3(Z@&4[E^*X4"6+=IA:;Q7VWSC,>)M1>T.Y;:0E\ M;56FEE:C2IEL!AGNFYCC,4[U6NU"]P_R,ES"1](:%1,Y,:\DU]!USL4-MF?! MG62ZJDS<8'7RX@$OWR;K-!VW;%3%[PZ^_<=O'AU^CY9]4X[(.LT7'!0V79WY M?Q0;Z/#[.P_XT2ES:T.(@%-"8:#2N$ZCH'/'3;H'/'(!5N`=^#B;MAPX8V8B M%RF^AL/Y_[-*[ER\%-32LJ^953(UTEJ(WI3286_6IC<#T6W1+>?59A5G2B./ M!C3&;ZEF].B-5[']NE&M!%&P1IP70YK=J>=T-X;\A+A;V?#`=.\%6TUUK(L, MJ:[ZY"R/$S:&C+'PV%3&0/IC:\FV="PPW.W/0&OM0Y"4N/2_9((M.4-"$L4" M1.4,0N"SX!/RD?,2[J<[;H/`MH14-MR)IU,&?;0)?H+;*-K9F$)7HEV-%?)[ M4?`W6].)V@D]Y;33->;C=G[9?`2LLM[I7E?;UU'\847V`<<&)U0Z@'V_N?U%,Q+DS9V_!77T&,ZV![ MK<)&&;=I9RJWSJUW8!OC#Y4;9;7-K6-UDEZ`^80[:TWP,UNW&P_[1Y>M1\ME M2CJ22)F()GC2Y;-HY%S@+%%BHPI#\V4%DOA(MAF34CSLC&CE?3L M9(4<3*XM2K/SCD""R"2`-0-D/SXL:;*KSK6C/HS M$^]VPDFV-/KUS;V3EP`",4Z248QEFZU3S.R)2ZMS]+C`-F7Q+$5"G0(VGH-W M7&$)@VTNWM5":W4"#VAG(KU!T&:=&[VIR$]:UZG7AAMSF(-YOZ31EI_UZ6O_ MVG[8\F'_><'Y6]_Z?8*B0>(&XAC$\HOLDWX@]0D5"RNP?L$8ER%EL:3"$;T? M^8H0FNX4;P;2U('8W/`;Y2[J;!7J-4XKG?`Y@4-'IS/.]SUAKY1366WQ4K^. M-.Z0SC@"@2Y.A05?;3,$569ZVUR2[(4'_=-FKMEJ-*VH.M79,@!$\Q/J*I.` MZ>C"=N2L.OAS`?^O7P'R*L)P;S779J-V M,R\_"Q,L^W7W#@YN201Z>55ZA;L1Z7D3,OC9O9O;&XKXH:K#48FM M]:3RO:[$:\ML.6T&(C@NS\W%3/H5V74.$L,0#E>2AM%T" MU@B3CS5H#HC12?.N&"N)59-N.+XM`A+!%1!'M,NY&(M\$*7".$O/>5IFR-.Y M7"&F,?DSCEYTE#O^D$%=:5\(U'E&>,,1M;M%)`QGKK`'13M;YKJV#;MI.*Q> MS@5?H\=K=ENF@K^N>*@4<5"EV@WK3X^QZ$5&.:;@&(D:#?X.T#%X6:,)!OPC M0=@J/AMT:]JN)^IZC91=._KHFZJE-&^LM&U_9RVI96`?@AHT]6XSM],I,@7J M2I,.HC+22;YR(YN3@MS&$Z_3%!(3K.($Z8Q.06WF09M<<0CV=*7JR-GX"SC! M96EOC'`W6!.8TRBM>&RVX422(;-3C@>MDQ.,O&SM@40&K>.$J]^,?L2=7Q+, M$#Q8PC=972N3(AWM4O)('>G@;/E/4665W?,5`E@G^1YBL$#:01Z*HS_.-K-< MM[Q/Z:)?C)O:CNE(4[AAKY3D0L=_KB7TUP2@ M_T/O1XL33H!"M_#84\P21VRLE%I!,;FM].@13!%!(#L0Y(H+2EKJ/&3M13CA M*"Q+AO@3#YRE22R,BCR<#E.C,X`TJOTLX>)L"&H**:=C$#9:0F*TKCDG.AM- MK&<)5%VXM&!_RWD(@S'4U6)J5V-YA"N$MV:GZ"/R@;=X06=<8<5#QA^/AQ9L M=WER^GJX.*D=:THSY^>81`*7!3G!@VBEYO(!J22/4&F9ALZD,&SER%V7Q?TV%5OC MHFN7DK'5:E+AM:0;AVV"P(<+%QV&AP=)^LVYR;]E%1"HUDB]T0$W@;CN1#\# M7X2GZ6XNC=^D0_<]B,OM:(1,7O#(-?EL(2R$L@U*=IQPJUL6R)_Z[V[@@P(7 MX59N^,)&([S8FH0_>=KY610=O*I2UE-?27'K\Z_OTQX MC3"45=$A/-Q.8K/5;O:&7ALV;KL?**KYCPB6?*K,FJK/+>JT&KG^NPY;,N21 M_*O(8@&C74D&JTMWO:56()@UU^E1Y7;0.`:0*C_"LL%;9^A-!!9AX48"K(U+ M/YS;51LR7*U'T;29K=1-3S`:;W'!K6V:]6P$9P3GKI4E:8>Y<='1%=QYJA/[ M[6Z:VT6^1?2J^3.#2R@ZI+*46#*BB=6,+I];]4%[+`HYI1GT70*+M MG&)HH%?\31?0K0DF2,[$_(^(;&3X.R5+OLQW6O><-X]J"C. M<;S.2E43[7%?EX9AGJY,7(/KECK?A.S=.`3;GQ\R>V4E'P@/TN`*F.K>P5=\(%SJK4D+;9)$GE&_?Q?#@/;H*@=LW>,O^LFVU[\DH;26[ M?+BQNTD*I_/KG7OL(._^O,O9-/=Z?M_?W-^YVVGDP>;._MW>F<'^OQ8C,ZB;& M>)^61/8:0AIOD]#M'N$V-@'Z[H(!M8:5/"K]C2#"GNS4/6D//<1((]ZI-L!7 MQ7GQ][RU6[)2#)N)(2869.`T4'`MUZSU(1TUMVE95.C*623-ZM?P35*4\A`, M&ELQ!LLYMS6SYH5#G$SW8_\8&^4@1C;R=O4!3L`VAC`.>BJ#:!RF$Z.R%FRW\&7EM`JQM MB2,A/PZSO.3`@;IXRG:MYW,29[HP^[C$4EVX.[CM!NUP^_9G=^YM?U(V,EWR MP5)^K2GB)F[?OQE1(3&+K4ZJ^O!*,,RB=8A44Q5)J.@VG+M"0O9RQJR' M;UKY2M9N7S"96P'GSUCA#R-4&]XGPMV+P6Z_/M.5,7;$ M872.(%_PB_VH\^C#&>"O/7[YPO#+)S-\5=KH'BOU\"5$:[:\=.[7`G*DE"TQ MYZYY-/)TY?=8)*QB,!LD&NN"!%5^)KAK&PWRT6G`U@!O1:!\+AI<\"T$]#@^ MH&4;Q>60H[V.LSZQ2\Z'HAAXBDDZF(>0+;$N%Z MOS+%F!BN!NVZR*P>7\DR4,;R M4$EPU)1!^/C+9NO"BD`BNJOA_/H8^'E:3N#F\D0IJF6JXXQQ0;5L^[!K*XL> M..T/G.")@T4VA*/<+IZ!8K\0WL@9^C#:T%29I[WA,,F?Q1ZA@ MB%8GC?W3`2?EZXZ7?\Y?UA`,PEF[Y^5\],-`S]=O+(%6LY'U(U-?@C)R-M*1YY4XRUW`1#YR'@S;?HE*F2U!"-UCE^RCS+@ MG%9E:UZA$BQ>-7#;PLC%TYT?5S,%\\94%J4>Z2+5"8$OHL=J^[.MEL4%Z\(- MD(QPF]OOIBOE::Y0[9]NVEPYO8+I&UGI4-/34`?V@D0(VZVUU%>0DT)J?ZVL MC]A9-^Y#XNR'-YVJZ?9&EY!N\E;$!)$"YA7G(2FXI"Z[N1MC5WPCOI,/NBY#YQT_ M%H#X&HR>@PH=V&3IRTM>^X;=RH1AP%+U)==.)^UB(Q[',S">H'P7J]X^7FJU M.WCF(0M-:L^4=&-3O,J7-0WXEKC'9T(DMM%YL"\AD*&2,E@N*/2B+2^S0:*P MYP;*5# M,1KAWF8/\KG4[00ZH)'`V]2]AP9M#X405,OQYB-P+P4XKTU<:;=^,K;]\;JJ MN$H7NQ;O-E/W>"`BQ)Q+LQ=O#`Z:S!!(LE]^S!;0S(]4$0*'NHW`[&C7`?$@ MJ=5Y):N_=`^2U2)K)M>9WH@3[":UI+?5K*>_Y&-;:N84P6RN(-SHH(2'WSRQ4ODD^W".HC!HO@^/.<3?Z*>MM&RNL47-L&IP*`\+812X>RJW$8(=SOHX/A M'>^['D6>GH_G(PR%J\BH5\?'W(SG>,@N;A]!=>CW9LX.3"L="$ZTYB89X%ZH M$`D)T)?LS4XH?CEQ1ZEUG#Y/L[T.S;[O<+TKK\)9F!6!TG0G@=@N'KTK5?AH M06!HTC_DO]Q]YW]88Q6R=$-"5:D^3;W=RAHK1_]QH801?8[ M%'G5(YDQO=0CH5QG99JKT:519FT&N'Q*.Y MSU11I#'[=`[;\Z=4ZZD>B6.T5#N"PE*I0TP/#8R.36J3$2F=E[HCX@29;X::Y<*%'8JL39\DO MO1E0C*T.)^D:XI9`][N>OH&HY#*U;[#(Q+QS)M#'94.L99I\?99ZWZ$6>TBZ M>6PXC9SD)R>`D5Z//P/L[)MPZB-H4-.`IP3O;",6QTNEA6=;7)<,O!5Z4TA$ M]$P0R&I(;/]"TK&VUBK?:;O<(49VD!LON2.CMF#S&7J)K4]XGA@F(J/)PHP5 ML/*"2X\3K%;N?2XG75ZYJB3-^R?.GB0"Y862=;]V1=B`X.Q[=N0$_*D5&%GI MGBS539B?ISB]Q>%F<2O9G$\Z)KV"?O/66AW#K1^RX<@\Y7`U8^*@]FA^AZ,T ML8C'Z[V33A5D;N_RY2\V&@RL#:(WZ`_(9K)9)5GQ5(5VW#\@83@BVO20%NU< M!?*X01M^&\(G1^4F&1`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`DDY(:!NJ<%A5TRX.Z(-\*ELYFH(Z?\1B@4U?['JXXNF]&^N6ETCA3EY0_L&UE`B?R M(;_BGASG3Q6_9:^>()_?R)$2P_0ZF9L4LUJITS;;W.FX!FYA MV[.%4;3/:4.SOHV_2,)$$(K/X9'OZDW5;]S+QX!/N5)FMOD4[K>,YSKTSEO3 M7,ER0=&EWZ.7'!C>L$9K\'D;&_?N9&9QV`:RBH8<_$+VR:&!),.J&[)<5DSW M7W]U6B0F&=*[S%!OU3"T5950/@$3 MVEO!_2!8.R><80`JB:6HDO,+55C4UJMVS'"O5AW:,-JK!)\`S5*=!ZK8U'=< M4M[1JW:&D2@!OVI=B4K4BU)-'6WRO%26WNT#Z@15?\_U\%N3V18I7=+4G<>/ M*1:PLPA.YA3SMJ5AF/.?_`5N_9%]L9WRME4=IO-!V]!1U3?BA7QVYQ.?`'Y3 M[A2WV6U_^2E=_!['6%)#K_VY%+^/[CZ6Z]D/B[43*U'5_EFX_A,'4;:X3A=>0>/+SD^ZUE:;>_>W M=VY&'#H[;3"2U^3\2(H$U'S"D45<58%YIM;!3@B11/P&*Z*])VU#L@3!N)@7GVUQ-_]K_ MS(WTA+FZC;1OT^<:QUP2VQ/)=85($TGR[7+L]9\9]5O^(E9FS]R^Y\BN(R`$ M7=V'%)%M(#Y?6'VBSK?B&$$D4*$E!WN9]T^TKQ,?5(&5!.KI>3,D9$].&!8F MF]1E,@CM#[/K#GMK?ZT@W8\P^4BR[(OO-$#Y@LR6_61G:=/)6]#3GYK>#)R) M)DTVE?&N4/28+&M++:FNBN;TF1]O/(E+F5P[ M3<[R6.F;ZT='K2UI@5D"KC*LA8D9`+%:A>&JM&`5F6#6;&#Y^2=74!CZ8L#3S*6;%1WM9L568X4Q%*71Y7.FYPB:NY M"$>%B+/8/`&?@PI9);B#0\)9NGO-/E`V+B!",$+0*,DMUFJ&K57EFPF%04'7 M:#3X<;%.W]&-(II]DSA=$G"A.T5"Z.2>_>&>HC9L4 MDEU>9>-N#C&A%FV+NILIG9^PPQJ\2HO9TF4=]:=8%W[V09>%ZF?G%>=NS4K__W_`&1R]J+JI:F`(U&GSN96\[G;G@1`QS'Z(-UN[&62 M4T_<]F!RK'9P*S5D<3^OK>/E7!L)I[(A)B%3X;G3P)K5;#KY09<2.FI(:8A6 MPF"CZ#>&)+:6VYS+B-ZJ@`I3-&;)]Y[X@?D90SS.%/,;O<4VL89=B`WEY>_1WMYA]Q M#\>B^%A.^X_5XO^Q=Z:[<257GG^5A,`>L0!2YJ*%RHA9O%Z5R=*0R(?0%='-P32_#2A2 M4L)B4UDDAEKDK!%4`U0ER\F0)F380ZL+):>E]8U%M]0`65P'H69<`Z-,,`7? ML35Q2TZ??TQ\"1KIXA;3GBG/-]T[&AKL%CEB&IW7AX@`C"FZ),&%RLUS4H/0KGP M)'NSLJ+")%5$LH1"+LXL?1BUZ)+:)13C.,K+*_J.:>&'R]B4%UUC[OAA634# MS_KTS6#16PK>Y#"685"NCX8Q06FG=1U9_@=T=>6[6JI=+S9S\H0IFUBGWM?; MXK#4R@P^266TKG18?K:5-#L/M3%7&"OX)#W1S>=0<'=!91>1:MH*F/5[PA9E MSQ?VAOX9Q\I/W;&06:D-3`S1!DTW1F36E&,,/=FK*.$Z1+0FV/2ABKQ5`A'@ M0D7V3%"/&KQFDQ38$5$LFK,=?@]D[!\GP$VVTXJ7.KW"PVE@>*%KWSY6%:X5 MPDFL+-][]6(;$^/BM'^DR[%HI:RW9`2(7&4DHLLR;RU:;&"HZ^A5,UA$5NQS M5+@*O"G=C84Q2Q5F=-]""]DC(5]5K`L/U0)&?D-SN6'FP(>+1-09-8[NC6DXJT])\YO M:!=@E*TM<(73?$>`F6,7^LT(J**7!M8>]\F=N>J/<4U(+>B]W7^T#:E<:#:# M48Z#_2O(\G%X*"](F\?D.8("U\?JFVNU\=XGA_SPT.:I3*,#M;O[WZ05`<'R MRBN>8[J;.74$9A%[5.S:V8F>S]H168-8=^R*8BH[Y4'O MUU\.*F$'/SN%8UKAE$KX1Q&V@\B):J[FCN:J9=CHZAFMUW2DTJ>@OT@RM`W1 M))6"(KPS;H!;$<.R:C+1F3-0W+6AP]/D_*3_&=>7HF3N[I.WNLV_9S7%7E+/ M$Z%969(.P=6G2_F MYKYO_:VZTI[U(:@/H4"AZQ"TV[;S.YNA+?KK=[+0746`F9XIUB&?]3P.I\+( MF;[+[=Q%-U_I*6W(Z!*,G&G%:<`).U"?O^^3`A8W/.=BA\4G35F@2X MDW6AVO:C39_U+/1Y/?`@D<]0[)[UGD)Q3/=O*LCH`.`F^D$MV;13]<7G($" M,LMO:#FM@V.TKL(QZ6JL]=]5HI.P_YC6:THU-_'K*<(A-7AN"L;2UF(3'#UM M.S%H1(_U25&7&KFIP"OE9T@U-^,0LDF]:!T@,5>I$'G6PD,>FAL;C;;PQ6[& MA7P4YPHXZSO*$9\XG_1;6L\-L(>N3`A[`T`1N$2R^S=EW7#YTE\1U:$G)>^" M&NI-1O8(G($'S//UU1K9H?S.A0HHQ-Y:C"!*#M$5Z>[S.,P&R;E/GCZ&[#843 M%]:@.!(02QK072L(&]B[.+\]&";*.4XD1HZ[[U^B"."GANY7^S:+DAWDZ\JE MF6">`DC=,@KE6E_CH(@_.@3BT84G<7'0[V9Q4D]/JB30WS=]!KJMN)B%D_Y) ML3-D%[4X.+X[Q4:7;I`V:F*):P_A(N2/4>3FG4>/KKL%VRD;E>R/$SHEKC^Q M1@>;EDV!.7(A]E%3VD5#6=.Z&G;I^\X0W)]MJ4^FUJ;\-NM9*C%BND3)!YQ: ML\,D/B`9\%ORQ%INMK6ROK6U M\O#A8I(NVK5RMZPO!VB/I;<2F+]!3[.`PFWGJRLKX6F3'-&PM9+ MJLG!E!4Z@VT`4(]&1$N52"9`)<_UO.@5TT'?N^T_>[P=/C!T^"<]JH(4_60Q9JDZN_X-VFVKXS> M[-TI/2M>L='W=!WUEVIQ+.BQ(WB_:]$I0MPY]R&+B`HL!2,X\SQXQ=67Q41' MK=8C65/\#S0*,$+PW[_S5Y$6W3AO+,T+ZC/KS0ZD@M$T%`=5H MWJ*&[6J-,KX@\7%>`:A%W?CA9&A-EQC5(HR^]SS^F\Q.$\GZJ_*H*#("P&T(N#`:?:.IT^"CMN]*31J*,A/N_89A*Q"FR2#%R MI26H:U08$,<'RL^-4*=""YN#K M%3`PWBG30+2E:TA7Y=CAOK>Y*V!L91XP>]8JVIZ')#<=-X(':J(5TNCTLXD. M@P0*L&:$^-PGO#]*FY=W2'%-H0[9\/J?X&\B:]+FA0!9$-/!QO@/-!',N`!; M#Y'R#_5YH!WO%WHG&;+Z.A.5C>)&T0TF2RV112GFV&^P$BV<@;^*Z+-%>":, ML5""*AO!-:TSTG/7''(^F/Y9'-0*94O]7S/P,@"D_X0<%5.J69@4. M6B6Q+D?%4%L.#LH!X@H=@,'KIG.,DM8AM@[;>G\ICL-$%E$W_OKAA>!DC;>L MQR!_Y:F=_-*JKSG'J+YI;0EU<]PIR>&GE$ES3=ID0(A;Q*4+,CLG%JE M;7*)(=&RQK!RD:XUZS1GNHM-/"6>$U#(_:'0\.GI2-\W#J>7JPL58'R"Z0RO MZ3)TYDJER#Z$O/6Z@(08ZAL0F@U8D;B0"FT--K)RD5M"10A^&BC3!4%B=4X;$52!VNIWW@([`P*D9#4I@+2+ MEB+O-(D'['T%PR1]C(9MC2G074;+JV8!,6]`$G%WK*_S3IQY`$S6A*5ANYO>ETF9!UL1$5M8P?S:#> MNK:3^)6D;C?[3_*&'=1X:+;4-REMO!7Y;3[=6'"FVW<@O\=S:T76X4'Z)_GE MY&6X=)GF4@DD= M?K9WLKFUQZ3`'X4:1C2G^I&#\I68=VFV6"E'+/RREYNZ+_&&8^P5[9,6F9<4 MNM)EYN.`E>O0N,FT.DT"=?5=-8SOL'WV2K9!*D%-^ M7.?'6M]G#K:MT'(V8I?6TYP-5O:-MAME7C5OU2QW&0E"&89&ZE;4I08H`V^: MYN+P$GNVW;;""L8VH&&0X.+.&-E-*K\TMZYKJ7B)8H,H;2,W;[3!VK3/RH[\ M,&%#;*3T(B1OC!#.G#D!%8*56V!_'15:SV`8<8YID.YO*L@[;^QX9)AA7YGZ MA99+FPIA\*C-*-7-V-Z9F$P(9LCEV?G\UC5GR@Q`HA:6%:R!A@-*XRB2/0&F M3GO11BCGL"<8C^1LF"AL%OT#HM^(0#Y5V\UF:*5I[1A3"%Z>P\&UDLR$`4?F MF&2?](W@TMJ>=CZ;UYN7H>`:05("ANIJGY'B)% M-:?&W7NK$6_O?M_;*\[U>N@]RECDGJW2/7NM@EL1;9@Y<'!0$8+5D3+9U<:\ M"KPUXM%Q,V>#05F!4]4<7G++[JL1,HQ')U=?Y*FFIE;)[)Z324\'A=UCRS.T M8?H?:OW:.H?J-9;B7!"7=PO#`6L=SXQ7)(8ME^(W2BK:7$PN+@@ZC]T_6[,Z3"'$0B+J,Z%?3R*@U6)!>-[ MI>Z`F/RL7A(4R"AS6Q-C5FF8)PF&X]L"]BR/7#)>W'J2EG0YO'>UK;B`-Z$Y MM(Q$FTW#T-*0H%@Z>BWU8H;R(Y11[U)E[NQY8=#60E,K0F^L4)XE3[@FGJ<2 MKZP&M]F>K,FCD@D4=$S+N`U#!QOC@=!LK.>70;./"@PFRURQR(K;7GF`8I;U M6V,]^U>CHT^KK@)K7TAF;WCQTAW6);NY>I:5RT(CQ1M[(4:QHT*WE=Z^.F6% M+[_OTUE&UF+W^*!4$?U,T:4^&LOQN*13ZRRB&(^S#S,)"OFF^5LC]O.D::&"=1H'E.%N\\P8.$C8+H MJ"-+DN=?F"7WD<=7^W@U8/:IQE!.CA@_AJ%&#H)*IO^,U2"'_TGOITGNECB!O+4FL_M>7Z<"O1I?QP/6'_EP[9?WW/5]= MTJC^TWL3JO6_+H,MYB'YH?[+`5.VQ(O;:'(Z'V]@1C50,._21&+6XS3NO:O<.O4; MB(^\_)J`4']DSYK3<$OAF4'OO6K^&^3^=J)62_6WIZR]%\M;ZN_L(#_4%E0] M!5[C)JS_7FZDXU?=9_VG93DP+/&\@8I+O:D5T]M=U M_;S9^K/^:C\_;/U9?[6?F2'3\G']U7Y^W/JS_FH_:\CM6OU02_KK^NK25NN/ M^JM^W'JPWN#Z^P0$1'Y_V/V9.\49*=V*@KO0^&YO=-T_Q0[:EUOXK%RVFSKQ M1]";<*O4\G#K6YY.'XUS2,ZFVMDQU0,%WFJ6S5$*5]/$A-YE6#:Z2[P_YH^G M_:^C_3.,ZS])9OSZR\7I46+D\948JT)1A]FB1I\KD."94G(U\?=B!ROF7W5C M'5$@9R1V6EA8D%E:%^RC+6KF`2"*RZ4=>DQ#GY^"PW48X9J, M$Q]O0<)?-8RFT'\1L3@%++57487DA>!L5_2Y+-*T3$:UP>B;13E;"C'GS]9* M+!+`EIZL/W@4+T1Z",.B!I9<9ZU5)T`^1IBX#EE3\L0T+C<:B'CKD=)1H,HP MM(B%WE.`0CB@_^ZZ"7/VM(&]##:9KJ2]C>]QX/N.D\\5L)\7;KIR0!H8*-KNX; MJSD"UV7UC>S.6)E$M6#7HD/ M-(>H!A8E!I7B!P[-;K`I7R!)BN['Y@5=NI]%WC;3[4&FLRF([;A%O016[^'$ MXS<27R-P".4+P9,'/.(0\\`U3*1*LG4,EP,KS$9SFM6TN5MJ*` M.Z:5O=:G;#8-1:/_[89FZ$%U&O(3I3)F.(U]W<^`K,K:VN+_N\3P_A;T=X#" M-V9N^Y?>W@@WJF8NG/0)^%R'04;%$(;O,'''P=Q$L9D8PRW9>F*4=;?#?&6; M*4`PG&)8G37!;EQY*0:_2*O61&'#*5)-1I9XHDK7H`UJQDG,$+E>/+XL?L2. MTXQS;:R<-DI'6PYI5FU=!K,9@)!77M46%*Z_E M=V^WFE>[W9S`N]*9I(/>GO<(;Z!TS'Z"QI)?O=NN+M4%F/@!FFPR[,UZ7LH*>NLZYH'%XZVN/&B'1BW8GY7* M7:D%WS]<](VOB-'6';=Q"]#?K%OVEC;6JUZN?BEXSM+X^MJM)$$X`_5P@0F9 M%-)-[TK`?:,4L@5U"Z^DFAGJ,K7ELC+_-;ZN[=/A:&Q>'^80?/2+LWP?7$B@ MO>ZQPMI,B5\.$H/YG%53"?N8I08>RN%4U-S=<)__I1U/7>827'<>F!.KMM&^ MZ.*@".Q,JW"7=['^5AQ7+`FI_Y]'<\(9OA'-G$6`P?C,3`O=4JE>6G^T4=E3 M,ZUPQQN%=.^6W%7CL!6RS\!B/8`YTS&G`?(V9MEW,EOFAC'?BP](*$152TYV M9E@I+FYSKXO0NJRJ("<\49(G^\=_G8RO/.T+M3F*)^7(8SAD=D1HRT/%.GF3 M9:I5&E?D\7*D%.X"V2K=JUO-0=PE1CM"S8=GRB>/I:,SG9/UWR-60C<#YMS+ M,5A;EEF#YY1<5`YV*9OQHWP2&)`DH'.0'T0PK%9K,"'7PRL&!!C:#7CV69@3 M_T]26)]Q&'1+;.G[D,+M3+*#C&S4J5&U(Y"%N;<\N5(*TQ=+T4/[$CY;IBE1 M:'XFUD0SR()OC.'=UO('I:Y_?JY8N7\N M*EX1@C;\2#I%J<2+SG]ZL/^`AD+'RCMNV1KAT,O+:[1,2XZ4]CC_KDI+\O'2 M0@0M-J27S-<%9<`7]7KRM,5M[TRX+?B\]'3!U;[1EWI&$Q:"X=0Y600^]$$+ M_3CBW6<60>3?UV[/UNUJ/J4\/).&>TU-O6'$W(I;%% MVW7]V+&'G)O.4EI6C1N->E_L+Z[XLN*`JY8+DY2]RG=$;8M?^9\G_O@ MRD1YNNB^*TA3^J3;XZ`;.9'GO;].F/MY3)8P)ZEIDF"/!K_2*U(99M5H:1NN M$_`EE!A;"2/(E6UB\)7`DT]8YL^&]C]1W@#'WM=>I`-H#TJL>F([TF==8SCK M_Q64`26E3^0;M-0F+TRMWF;@L68F7%RID)P/ZG8B`L@MUF3A+.[?C]5%I4Y@ MU#$BB4O;9[_94J6J#8"L"9;-MO62O_S4.*[V-%*7)*W_.1F@\MCVM3TKHJ)! M&Q]_TR?_GU'2YB-9>^JBNWPD*CW1D[+VY`&._,)&L>'=YLZ*8/=GOU<_RMX"/#X_PXY/XH#1P;1+"X&JG%5)7F$RTD MTN($?"6\@09P.T]&MI/J+';:?)8H=IJJ[*W'OS[LN&[VCJ,AR^0G-!Q0(M)% M7R-20XEW7(\4*S@F&`7J]K^N>HT%J7RFB<:F[B63-V1C9^8_UMV*I1?J:$4> M0D$G"EF#M;.*HP@,Y=ZAP/&0TJMI[8D.:KAV/D"#!/JP%X#$U M8$3)N`0V9J3V93@&8()6I)C$SS."[S[##Q/N`E(*!=]AH,FF^#-)N*= M<%E:E5]>VBJR3:U`=/<5*]"_HM@MG"9)U%;[3#Z:ZU:9N@>[4;M'I!TX]SJT M([C^[[^[>E8%*J^>E8]IZWLA<+#-AJF@%&"[ZP#+U^,JO%-?YT]0H52BXH7R MH6[^NFO9R)LEW?:/Z?X)BJ!UJ9`,J%ZF(ZL:!9IW$QTQKU^/1L`.;N"UO_LPN0`SD'LV%*/%:_?CZ^G*B7`H6)8KA2-R^M*V`:.1V2?X5U MOA9M]*A'D$)I/@073M4&]=&D3XQ)4JU[,#L^(EL!+49_"Z@^#@KLJ8A!C:?>XM6 M78CS*H;!I]632TI5M8C>G[^K;'U!\P,!>1KKJFNI,,1,Q!-\L)LG/E_*^60-`V;\$VOA^'ET>0,`U-%HK=W-DL3"((URGH6TIUT MR0D+"19WMB\5S#+O$57FU+"_"PJ'30]MGZ\,IY$N@*8.XY*->/J MV4Y6']105)8W5YZNK==?X:]/-AXW_HH1N[D18!+-Q*MGR_QY??-)_6E;EB"5 MZJ,PE2Y'9Q5[JC^;'0K%:?IQJ.R""CX,CZ8I5U?/D#'OCJY&5/=)F'8J4R4. M2G*VZ2XF49W_WL?[*%%@A3WQ\^88 M^4+1#KX?/N+F@E&5GC;-C2_]8>=G/J_V`MK^.8:+RP` MY;4808R^2],B1.AFLX8\:+MRO1K4-$J>.='0AKG"`4Y&1Q/GMI4)(S4T.$%' MUO!'14A2R0'!T?48J4<*-U5!TE@%)W^#:K=)8DC]=6^K,6+3);))/24">:JWR>)2EBYM/LI2]SC^TL/L#[%EM&[3 MJC9C+HEX\M)&]J19?56+"4D#"]7IZ,'OB19C/4Z6'M=6S((Y`JA?GOXG)B(; M`EDJ\;&\K)$E6EUCO0].@^M_?QB!$Q[?V"LQ(>%:7TM0%'J\\?K16?VU'M57P M=FL*%AW^%?/-V$?KJK&59.^-6JL6QZ^OM*L&';6ZBC3$1O@L2[`<3U/Z/-): M4%KK&)V:U6A]+LP/X5R]"_=/3;Q"9-I`->"R893J%O5(L)E[6>=-=M39H!/5 MFDDC.I\+^G:2-4H*:H(3MSMEME$Z3B/1;#T`SI#'#9S())DCB_EO4E?12._& M\>VIW'S.B'_*'D7M7FCUL7^JF4]2P!Y.J1NV=:("I/W,>!NQDZG9[X#$U(0$ M99BG`RB&5V).R:/$DZ*7;M^G5,7OI#?KH#W@9-D-1H*GS=_2E#IJ013NC MC8EN[(TF*\,T,+TM,V2IOH*%T_O\X-> MJ*]XSY[.F$3&Y'J"J&/JW%%.+C2D3/-38)W]T\K+%7=WIYVUJQ%$PF0#$AA6 M0,"NN0RLTN;.^CZA6"/;34P*%]*?H;B"2Q(-4*C6/6T!!9V;A$1`YQ:9GAX9 MF-@\"AS.7G@X^H+L; M1FJ#<6F+0J2$Q;/A.#4L#0X-EOB=U$9^2C.[T_-J*A?A$KXHRV(X/B*5;`(+ MS[4?MXC=^GQ#4I'/&M](%&X3R#=PM9#O@1H,+*.A3J"V-Z$MB7K:X>KCQ27 M.9N<,I21^P4LEP/0<'#YH/<<[U*3I7=1W]\6W_J"\"/FJ,1G4>NS=6*SX?^^>/!J6NEZ4L1*_L8#WXX M'D0GT4(RW5X-#B\G*\,MC`W;DUW;#A>?,DY;S@YGX&C MZ/K"305KOFU?,AO#U#N^GV$=9[QA75O%$2*,I"_5A;A]L!4#'S2)/:XSXWZ6 M!:MMWZ_`YY#RRY6'?WST$:^"6$"_]Q'K5N0+A&_ZOJRMM^IL;7X/,B?D^VC< MXG@P^*1NL`J^G`Q9`R5^@!+"/(7^&3W"S,UY.(CB6XM>4&^/'P_\/+'N4D;D8L[8!(D/W%`$IQ/C7L,QQ]&E$='CX0MYN*)I^4U MBLX&@J.*;TO>52SG?M6YIH0-Z,2IO(U6B8:'T44:&)-\">ZZX+]D`BL2`,L3 M"^.8F4O7EU6XY?.035L[W)BYZG)48N';%6%<[/2@R/H:5D[E M*R`=0N'0'/^VE:`1&BW1'=:D6M3&PY1W M18H4AY?)&A\A9"L_@)(11^=\[3HYL;QT`5O84A'F@:L+*B1,:D`'2!W^,"=S M*LSCH',GRG:M4"D]T9*)B6(XVM(),Z+[$1F,.@:G]5\K=T?U2Z=6?_5L&VQ4 M;,K2LTPW*=7)'@I>P3?,G-G&A#T*/<3>7=*S/:0"&`]]?KTJK5!8K@PEI[>, M7\-V3?,Z'IR=#T\@NDHQ%=5UZ)YB2/%).-&040U8$KPJJ?D!I01#F$7.1-.@ M2ZUAPX">'CQL_8;!%D@G+"-('P<%UXG[C$Q%&P%`=3W\#`%4Y;#$G-W81+JA M[<)`8NZK5Q')PK7IM@Y;=FALQ\\>@GH.*5=^X0Z3\U/:NG.N![T_C+[(^5-< M`*E$P#8T&L;[%[5S+L;`'^&G?T>V)PT&==FMA7YQ'$D.!R2PG6'HG&4QNVSJ\V&1_R!E(;E2FD^XZGC?< M7S`\X%QRW"&(%7:4G>I:=(XRF1C/P[LG1:^6=N!2(2*-72H'/@,.J!$/R;JK MR.4@DR($*ZYHN8*OA;VIM[YY&[2AFT0%X*F?UN@@W"Y:5*U5?TJS4=JB#!+E M4FJ*NQE<"$H47%]>MV/).FU1CQ4&:RLQ67YZ"7$/D=36ZA_UN0CB*A+`YZ.K M58AJE>VI09<(".$C91V=+:;L24^'O^CNLXVS2>;O2DM5\S;A$CR$;YG=&<@L MJA#)$O1+U2$0620C<=GD(9BW8UP3JZ=C4IJ:5P!L(P>8#N,*4AB*0E7BISG0 M='RIC$4:$W]I;6;(YOZ,GBBHJE.N""##3&.'Y1V*O7!MTZ[#"'HZ(Z`;M#P3 M0D`2!2RMQ.+T8GVMG*]`';$U[3)')]MJ=LVQ]E$CA("DUOX;\_68=6'D92I;\^+E-5/UTJ*J.C&"XER;,RX?LHBNZ^`VWX+0W!0;@7[!) M@[I=%^Q4EZP]N2"-'Y;<0!A&16Q7C0O4(BH2<5T(PHN,ROI-] M*G.0W]SOFNC!.\(^P&=(9BQJ>4!+_+*@?]B_$U^YO0KULY$/B.7/F-KN%FE+ M$XH\W(!GQT\%EI`GM4,PUK9)SH7(S):N4%J*A/9YIB`"&,NT/R489HY_Z=TI M'&1L32!F=,-'9EV+9["\'5^M:76G`QLQMC!%*A>MXPRHF0IU4!%437-J48E, M6`@1:NQPIF99D^F"E328/:A6*!96"PAHPU_5%<728>;N>KDEMTQTD,>"[-&YKTRC!Y?7VNKC3OF6]R!"-Z-<"6N/SUE__6/[OX MUY[U=X;PJV"!E:E0!D7)DCGB?OUE8],\<6N]91V2"8<_Y:MN1WIFO"6YI`96 M[<;ABF)_B'H.39U`7-JD5(G0!5N?P\7WR!I_!9VI_=M\ULP/I^\(?):('-,% M30*',6.WH80@*M.6KJ_*W/%$6Y%HKH%[U=.OB%M3@.9:.& M1*GNTQ:X8E\&,4YQB`0-!2JJ/(2BU7,%(B*';P=%%/&D\UH<*&QR`F.CE,N4 MT.B-3.Z&/.H`BS&];X)A)OD$A;:8E^G"?+D8S(@@*;]\3C3.*6%C MA:3LOE#L5SAL!+-0,>)/M.1R!ARC5QF))60W=4"@]\2.J-R;9SW18=`=L=&P M8ZY\;Q%W9V01#R"I$>\ M/K'J+=)SPB[++G(<,_X@A:F>@J2OY#Y_1V%_*>A;K8E/Y6XC_Q>7FG_279$A MIE.'$<'TD M8"(:HCD)4]B5V.;[Z+M9CO_50,\#A`1?H#NMD5.6,R,=1")$2BT3M8/Z!B;` M7\_A.3&)7$X/B,A(')NK2J?UV$Y=1U' MZRJ^GXZ0!91UP2FHS-HA"NZZP[W]ESOW"$,K'JJ45V^]MAE^5)AXVB;O-7#C M)ZZ`ZWP9]*Z&Q_C]Y4C)S;U0Z`SW?TLFQ/*!_#\MC#!$+?5)Y("]2>6#2J3= M!8+WPGO+^#^%UXJ14,DP(*`&>=3YVT[E@>&Y[=QQU[6)ZA5N)*Y>_^Z^S=[! MJ8$``IL(Y015Q*6P:LI-Y5'5#_;E#PJ0WZ;K>+D>,<&.\>S;:%-G-LJ>G=QY MU82$_W"E$\@CN/:TPHGLQJU#Y'W4V0$A`R[X="+E*W#ZBMIA!./V?A0--!51 MR`3`YEU^C:K\`TE&ESYELK==PYR?%:'X*JZB`/5^E0F%?M%!5^]3X.$#NJ>\ M&?:N-'KRHJ2@6$)58UNO9$3]W#]%K7U#4!"UV7W>7>N\2@Q4@13$Q;CJ"I$9 M9&?%MVC.```EBR!G2TP"F):1)DYF_U%ME#,:]']H<"+XV2>2$.17SIAAUTZS MV]0***7\?QOV[0!Q_@)AQ6^.4\9.29K$NXZ.)B3DF-7Y#GY_:0R?]#2EB<%T MRGOMVM"MOE+?PFXU-:\3!_8SWIH_C]:OD63U3[ZFK<"!O/B] M_"/%^/7BJ:XS\@8!`<3K:TL8S3\\1>'-]OW*HT%OPDAM_TQ,I3;F56RJ?J;] M;#B?R)0+LG/%B7+=L,M>A':J%RU\C@@$B%YJ`TNHK_I3/KN.(%`:2=OVI33> M*6JRED#7-;;.#A2'R.;A+M/R!E\5C;`A;_4][;6JE]>=`-AND7%!AHME=@7L(#A:5.S&`^L2+&^,9_?)BE>U>2&1QO,L$.5 MB2OVEG_:?]%;:O"EVFOTGXWM\<3>N`C38/ZRAZ*BL2[*B&J8CMWW8?_HD]\YB:9F?G2_&?>Y%_H7=:W@[!8&BP@SYT37@Y5.)XYT7N,#KR@Y\;UAR9A0]B MFGYHE5R9>E@D_.@]@AIUE]F/ZXU2S>S'M:?ULY%&F=9LO$FC#VD#]7?R?6[6 M?S39W7L^'(432SC6GQ$C;1!?(7@Z=?KZIUXH>I>':3W/T$U,Y1*(<1^ESZ'O M+Z,%DH0@1^WY58.6?[J@WAU<@-GS.WR_`P8OXD2.2+"9JWLRXS=\/*V,250C MJ6B,:8%KDVD95Z4OIDW[JY_Z+?FQ1SSEL93@MW4WN_)RU+0JY2EZFTVLE(YI MI??7[8<9ES`;-JRA]&<+W81B#NF<'AUW[_.R%&89NTUF?7]]S7^I+UN2<;3- M8(!Q-FS]A=?AGD@;]6"%=:6QY./HHDV^POJ[;^KPUCI6C5Q_\NUO`OAQ_[KE MZ(_7HOD(/RA+_/*!&0L\1^`"P)*?(++'(NZRI_/__U^/$ZI=,428=4J6[J[*#*QH4VH/Q"NQI=V):;IUH!:I;(58?[3H7: MMWBKQ)HZZ:"2B/8M5!K&;UP-CCYZ]D*,80@<[6BTV8Y&LZ_II*L;H20TE#)4 MV1-*+,(4ZUK^M>2^S80>4OZBMP,STBGCZ,4L@#R-3["&:0N7UTIC4^YL@@M& MNRP4XVC6"8Y(("R<-]KY2H6])F/D!8M%I../`TQP;Q#8->3!?-;RW#65`-GL M6AAXX>L)#0$O4@,M'3O.FK"D]!_D-I"U;]W-ZOCTK;P!4;.I?W\;F7),%$PZ M4VXLXS5T5X;ES8/5GK4/F,#&EZ'17N69F/K9REY6]\7LLT(I*P;PSTJ$PM4L+WZF;]\&-4#_#GLQ\"Y-:E];>O_5,#L_X&(^C M*@X4#Y?C@.Q%THAF?_=')9:=B_NL5KE>_&MP28TFVD8%T]F_R2U&L7O1APIO M\V:H7D.#.L1#U.D`:<+LM?AHKZ$Q=C[X&^$6EN'M;PFYZJNWAUW^[AVAU]#Q MNZ"W<2?HZ>UO#SU]];="S]^](_0V;\9SOZO-.T%/;W][Z.FKOQ5Z_NZ,T.OP MF=[$3'\T)[+\6NK8A[?V1^)=#3[7>$I"LFG9;7_&82.WK:4.6V+*?F(UG;Z% MJ6\QY(>VUE>VM1UEHID3J8X1-WPB$S5R6!#-P?U=_X9U/CU0&HLR7+M9Y.PX MTEN6MJ>X'FJ,&U\-*3C]VGH;/W1)P5LYF7O+-^'![3XWW<7UW)U-:H%0ZF2J M9JV#/?=?9_^]6OBGLQ]N/LHN,=OS#T-%#[8]="'/VH^CT;&5EMP("JXD.F#6 M6WA/S)[GF[F-D3FBZD?T*;&VETXB\$A0_ MXV/I[2I^U?#:)=]%RYR$Z.Z.NFP#,U]^Q6))!0U:8*5%<>SMDFU]=&6QX/KN M(\C)CW3_!8JRZ(O`V''H(-]8=6=$_`-Z]]C/^1!MF\07WX;B^F^5=7,S#I!P ME[Q=;6U,9EB#6=:/I"#+>]1[`2$KN:Y^1*GWV`;JH(`%;"6JV0%,V8K)>O57 M?\KS_I3AK#2.^D,.#DM-0V_$$V1VFKQ<%-P#55>S&U#T8,(>B638[.3@$L?" MS\Q_O9B80LRQ+#78XH'U-?6:]SA4MLG9<-((@[SSANDTF[##VO;4&X&(1W); MN-:OU#Q<%!1V3UA=&UY:7UM;\Z0`T('.E:?3C(0<'0R:0"&\U3\3P/"46VJ, MS#*,$RN_KQ\(HB'/4UG,04!S3H:Z<.2;[0=*"'=W#U?S>V>3.;:F/#A^&\>,?7H:>Y-0Q-.Q`Q&1JORJ?S0\):^'PZK[+PS].9[* MT1=1.'#@UZOK^B<,%/F5)C:R9ZSN]8@*IY/>GLH';_ON'X8?K#"D]>7,M670 MZ"T[5!I$@4X^%9NBC6B""3V6EQS!G^U*6^KZ<'F@L MOJMVC*"3O'9I$_FK;*+==7>?''7[I0ZU=Z04&(K>_IM@J^>QRD')RL""3/IQ MPY#9\?XL/+&'0$"BBF[-H924UK%^(D%2ASH@,7T<"?OC[ M^K%O>L%2STE"$?BL)TC]`T4.1>)A4J1XXV5(/CQ6_+PK5>+/#$+XR,6M,C7A MDAXE7)@%C"-)ZV2Z7Y\\$E\D%A6FPB[OQD? MV-AH?2"'V=1KFF+OF4QHN^K,\!#L\^?>>WBEMZU,A/H]O/24$H)IIEB"Z1]0 MX&@=#PF1'%S56T_3SV;^"%FU]5NKNN>A$J$)>1W=Z?#$M=R.VWL2;F_=8=YK MA_A=]A5R;2)@9M.XIR\8/FD9;<:=3<`W>.K,'VF!YMUV_=YPP,21FS$O@HU! M0]C-T,&`L"-P"`N2B2D[?Y M0)-F-]9;23+MM//D.NEZ?O3-J4>_'X0:#:\2-]C\C4MKI6)IILA/@7I:.C&J M&XBB\\Q:IUB88=;3%GY:(\;'O_'`6J98EV&!T]:-3"`=N(,SM][R*YGI$9^U MD*W\^.$#C+.NI*/[6^&D:<7;X%6QXI.XXE9QQMY?7M!38GC><.+[VG"XW9TV@^%AW_8_1E'`7X9>788F#(\'"H# M8&]T3>4Q`ND*-?7L9I?-+G4,/C<5A2B$AZT27(.K:)@0&I35SYTG/6W5?W2_ M-4N[C#+%9MD59[DT9-'F!R M'S=:53/+VQ?6VYZRYN]MI(U:PL:2/MFE9,[32O&:+< MWKF4U92@DC)];W"JE;OB7\J3;5Z6W'.-80Z=+!F^,O5Y`F^I2?8^1(H"@O^T M"R0S?`T;T[34WD&6%G>'[WE`0/[S(6U555-ZAX_5JT/3MQ03#3GV79\7ES!# MN+Q=V)ARNV][3RQXF\U\\VNZY>*>=UQB:!>@9D"26ZZ^.!P(?=U/>ZNQ?-PJS-[!8 MZSPF$]V^4G;+[%N/RX9OH4X%1<3N)BI:Z;577]S$QNJ+)A98A\B;VHW5?V]^ MJ%7R_FX\OGKV_P4```#__P,`4$L#!!0`!@`(````(0!'FV?#T@,``/X+```8 M````>&PO=V]R:W-H965T&ULC%9=CZLV$'VOU/^`>$_`!AP2 M);FZ?&Q[I5:JJGX\$^(D:`$C3#9[_WW'=@#;V6[N2P*>,^-S9L9FME_>F]IY MHSVO6+MST=)W'=J6[%BUYYW[]U\OB]AU^%"TQZ)F+=VYWREWO^Q__FE[8_TK MOU`Z.!"AY3OW,@S=QO-X>:%-P9>LHRU83JQOB@%>^[/'NYX61^G4U![V?>(U M1=6Z*L*F_Y$8['2J2IJQ\MK0=E!!>EH7`_#GEZKC8[2F_)%P3=&_7KM%R9H. M0ARJNAJ^RZ"NTY2;;^>6]<6A!MWO*"S*,;9\>0C?5&7/.#L-2PCG*:*/FM?> MVH-(^^VQ`@4B[4Y/3SOW*]KD"+G>?BL3]$]%;UQ[=OB%W7[IJ^-O54LAVU`G M48$#8Z\"^NTHEL#9>_!^D17XHW>.]%181@$Y%^@%B9D.P#B(G(/T#,00Q%P:.B,)H4"2NT MCY;=R$I5HB"A#C')I$\1V5-$_AG"T`-$M`J-C216=RYD9>J2T*Z,@L2RRQ8( MQX38E3$0F(1D3JEJ+`,0^8'O6[V8ZPA,UN%L-T3`T=!$R&.BM9FP6D6QF"0* M`KM->BVYZ5-$]A21?X8P])!/]0BK69PH-ELH49!0%@<1JP53W4K6IFNF&ZTT MY;HMP//58I"'N^638@BK1=YBD"B((A^A>1?9-*EN1;$E/-.M"YN^;@Q0,`DW MZ(O/OW7E:KTDK"9]XD]Q),%$011]$EO65+?BR&*8Z5;+,]=M))@]#?9K@_UX MG,6JQ7H^28JU@I#Q.*_6L7V<#00F&%D$,P/PX7'6$7@5K>;J&2(0?.OM&FB7 MK#1;H*0_G(%]V:OYC?U,K!.C@T'-L`X)A\O,&=3&%;\)8!/C`WC MBYA(ILE]_Q\```#__P,`4$L#!!0`!@`(````(0!%$*WLJ`8``'@9```8```` M>&PO=V]R:W-H965T&ULC%G;;N,V$'TOT'\0]&Z;%XF2@B2+ MU67;`BU0%+T\*[8<"VM;AJ1L=O^^0Y&6.".MO7E(;/)P-&A] MJ=JN;LY//E\SWZO.VV97GU^?_'_^_K2*?:_KR_.N/#;GZLG_5G7^A^>??WI\ M;]K/W:&J>@\LG+LG_]#WEX?-IML>JE/9K9M+=8:9?=.>RAZ^MJ^;[M)6Y6Y8 M=#IN!&-JI+=[5VVOZ( MN5/9?GZ[K+;-Z0(F7NICW7\;C/K>:?OPV^NY:[4]?)F9/]7; MMNF:?;\&NWCOG ML]<=FO=?VGKW>WVN(-J0)YV!EZ;YK*&_[?00+-[,5G\:,O!GZ^VJ??EV[/]J MWG^MZM=##^D.]9)M[WK#T^^5.LP8I*+T/=>JJ[_ M5.NUOK=]Z_KF])\!<6O*&!'6"*RP1KA8BSCDH;IO96,\&ICD95\^/[;-NP?E M`<_L+J4N-OX`EBT%Z\=("F*[U>B/&CXL`G<[&/WR+(+'S1<(TM9"4@.)?&^$ M<(S(K@@=*&TUOPY,2X3":XHK1.<#7!_]AZA0_R4;W=6SQ-T0&TX7(!B1+2`B M#,D7(!A1+"`F(XB11(RN@=>C4#9.5$6,'Y$:2.!`"-?L+B*_BRAN(1`/<,3) MS)6''GWR(1IC=8B$\#"0>*@N'BL52@S(7(!D,F2DP'(7$+$X%L1"X0(X"P4/ M)B<0"6B)!1)Z%).0#/N8&H@R+1(Q+O!\AN;#,";UGKOSG"<1([DL7$`2L^`[ MU:06">A10H#$,#400R"&(!/_W6F5\"E\IJ/=:2E$0L)3N/,!;&)3>%#X81=9 M"+\>)=Y/ZX?GIP9BPR]XQ(@#F0N04H%P8H*Y"X@5BSEIM\(%0(8D"R8$(J'E M?MIBKXV@1W%#2U*EJ8%`K8Z]0K-P%Y'?112W$(A'LLA#CY)D4$4P$)L,YL9I M2%;FSDNF8I*KW)V/0I5,<1[6%^X\5YQ_KQF6 M#,_'(:TF-"^%Y.0!!09PYFQ9*`E<"^&\FH9APH'XD%K,M2EB1:4[PPC&()BD M*Q!"0>-')-D%0H30%M'D!V:B)7%B,AP]'.GF1C%=I9#3'F>ZW&(,HSB*0N), MA@!)I&("R!%`Q!&G)@J$D$+)8+*!^6AEG/A<^YP;P40\2`&G%F-X<#'O$`L( M!CE1R131(0XY61\KLI,4&*#"J<,P!:V+"Q2,7"(*9,-/N<$8#R?SIL%O3>9V MTI`/.&@%65Y\9SEV7>OA@NM&)EW7`V(^A2.[WL*,`S(,(T6:,\,(&;&(5&*. M$'":8)Q-96)V*0SA7`K'$\Q%J^,"%R.:B`OISY2[PKKB,F!S,AC"(F(CQS:4 M2`0]G10($L'Q8ZIHS$2+Y`(3HYV("55P[NIKH)P3@JTI=WX5L&!&`P%4&$T^ MVH0@`,@&G[**66B)G%C,=BJCH(@-:<"4&XRIL144><`)),.0D-,C8XX!2L*A M<59C[F-4+!V=PHRT9-Y@9!05,2*/2KG!F(9?12$)?V;G#6/!H:^HE+BR#:4* M549"4B`;`0^^MV^)96$?AK$H!L2+U&+&Q,#[!JG$#$.$"M14)T,EY1@1,@G2 MB=D6""(4Y'\$H,P(K.^TUH9I0HFH06HQAE(0TE>3#,VO)'<5VO(Q;]O&`I0Q)RST0XJ"<+IS,((/O\=CN_-F,`0X%09SZVA_'Y+?AQ0W M(9C5LO:+N?8[[\J6C<$DP^EDQ=;T#)59(R-`D!SG&`#76@S]D'P7&,[6SFD: M&PO=V]R:W-H965TW&T(:[%Q M6(J/>/"R9#G->+YO:*N,B:`U4<`O*];)DUN3?\2N(>)IW]WDO.G`8LMJIEY[ M4XR:?/FX:[D@VQKR?O%#DI^\^X<+^X;E@DM>*@?L7`-ZF?.M>^N"TWI5,,A` MEQT)6B;XWE]F,7;7J[X^?Q@]R+/O2%;\\$6PXAMK*10;VJ0;L.7\24L?"QV" MQ>[%ZH>^`3\$*FA)]K7ZR0]?*=M5"KH=Z24YKV$G>$<-TT<`,B>!%:I* M\&SN1+$W\X,(HRV5ZH'IM1CE>ZEX\]>(_*.5,0F.)O!Y-/$C)PRB>/$_+K.C M2SBX!+'CA][\?1+79-57(R.*K%>"'Q"<,."6'='GU5^"[[$,QUR&PD![!XUO*])+EV!N2[*31/<04`=>J.`9 M[PE+1S66;I_FW)P";PR!O4%J%.>4(T5V36$Q05\FF'348AH'4A,X1XBCT,;, MIC1OM;(PH'T3&#IJ88P#J0G8&-$(X[K&PH!;,8&AHW!US@Y%',7V)ANC@:V& M@S/"2-]59-<4%N9\$E-'$PR='Q#B<'1Z-T9S#=,H%OW]F$5>_[)SSJ-IA>$T,]9,E8:*'4UI M74N4\WT+59Q!%8;H,-KO0WU71_$41GX_-T?Q3;#<]'IW^`$F=$=V]#L1.]9* M5-,2MO*<&-HOS#`W#XIW_8S;<@6SN?]:P7\NA1GA.2`N.5>G!SUJAG_Q]3\` M``#__P,`4$L#!!0`!@`(````(0!VHF>*(@(``*4$```9````>&PO=V]R:W-H M965T,U6) MOBGPKY^KFSE&QM*^HIWJ>8%?N<'WY>=/^:CTQK2<6P0,O2EP:^VP(,2PEDMJ M(C7P'CRUTI):,'5#S*`YK7R0[$@:QU,BJ>AQ8%CHCW"HNA:,/RFVE;RW@43S MCEK0;UHQF".;9!^ADU1OML,-4W(`BK7HA'WUI!A)MGAN>J7INH.Z]\DM94=N M;US12\&T,JJV$="1(/2ZYCMR1X"IS"L!%;BV(\WK`C\DB^4$DS+W_?DM^&C. MSLBT:ORB1?5-]!R:#6-R`U@KM7'0Y\I=03"YBE[Y`7S7J.(UW7;VAQJ_B"9@,R#/XW2>99DT_^SD*#(5_)$+2USK48$VP$YS4#=KB4+8'8E M3&+H)'/.!^?U&+@V<+LK9UF2DQTTA1TPC]>8]"UB>8V89B<(`2$G-5#C.VJ< M%^1A=%*3Q1>Y'@/F]AQS2N5K6KZ'>",&$IV).;;$W1882$XB9MFEB("9^X;% M%^G_[0N)PZ:%^0RTX2]4-Z(WJ.,U9(NC&6R+#GL6#*L&/YZULK`V_MC"<\!A M=G$$X%HI>S3<)I\>F/(O````__\#`%!+`P04``8`"````"$`4%?S6:P#``#8 M"P``&0```'AL+W=OV2)W38U&?-_;W_YZ?8MMB/*N/64EKLK%_$69_W'[X M:WVC[0N[$,(M8*C9QKYPWJP'=:T)#O*0U7I M>*X;.E56U+9B6+5_PD%/IR(G"6#P_T59&WE-$37P"=HP)] MU+QTE@XP;=?'`A2(M%LM.6WL3VB5(F0[V[5,T(^"W-CHM\4N]/9W6QR_%#6! M;$.=1`4.E+X(Z.>C,,%AY^'TLZS`M]8ZDE-V+?F_]/8/*@!D)Z]R?^WXL@O&QN'BR!R,?("VSH0QI\+<=:V\BOCM/JI0#+T@<3K M2.!$1X*\A1<'*`CG61P5D5229#S;KEMZLZ`]X)VLR42SH14P=Q*Z.`91D-M< MH#\)N#P$X3*POFXC?[EV7B%+>8?9*4QD6P,&Z8A]CQ"9$K1);[@?\4+]3-I# M1$$@]D$`I,44@-TA7N'5XPT"G7CW"/%TQ'X"$>F09`*B(]()Q)U$4X0U17WF MA17Z9I35*'#U=^P4QA]A#+'[640RBTC?0VA"()!1:7HAPKJQ(1U#>^#8T*$@ ML>POY+F^X=^/_>'2Z)1D[$5>'&*=/=7\X2B)6O#P,4P$+ZQZ\!$VVF6G,/"6 M0:!9A5E$,HM(WT-H0L))(<(ZUTX*\YZ0640RBTC?0VA"8*),5$18]8KXD9'O MG<*$LI\\SPW,>:3Y_1@;WU6B^3'VC'Y,-7^(T;WC-`'BWK_/VOY[$%93@-'2 M.X51`I[PTC4%Z/[(')Z)YD<(>_<(Y0!.#0#"OYE-RTD)PFI(B(T0=PK3U2", MC!3O-3N:YQ.QV[X(.\WDI9_!#?\1`&D60__82)U&%^V4.#Y^DC9 M:^['B=2YE7B$\3T^E7W=_]N1!+O,9/SJ:AQ/5#\VAY(\N['53/40]A\D*)8. MX*.'$LPQB%5+M,$4@RJ#6J34^E&1]DSVI"R9E=-K#:/2@]P.5K7`[=`*=@6X M\0U[(A8[N9H-#EBWFNQ,OF;MN:B959(34+J+",9DJS8S]!`^6P:,F? M%]B@"6PA[@+`)TIY_R!6C6$GW_X/``#__P,`4$L#!!0`!@`(````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`<3M1C]]J#? M_?Y4K=:/R^^Z*%O$?)QBTAMBJ5EN5#I]@,I$7:JLO.6Q1_-1@-P0#E,^92K* MFR@3U2JC!8E:)[=$0`68@F'H8!PJ#0F(,M%-I(^;45%U@`HPE:UN6JT2=3L4 MAT@/BD_$-)FH3Y3=$@$18+BF:IW?,`Y9%20S49^LN"4",L"LK:I"S^F,*C4E M8N-GHCX1]0&(``/E4WE!Q^$(,I;KC3FKGHGZ/)4G"#`@*%?QJEJSGQEUZRDK M4V>B/BLE`G6`X3TC_8[`5+M70*$-OS7T"+J'[0W;`$]PYW[E%30%$%1T'<_- M?6JVWFL=*Z(-^U6<6!0XQ\I.8T:[[E90<`U.!);@:O)W.;WZAK'*HJ(-=)G, MRGN2V#2F)NQ+HE0P&`CBO5+)G+*P=^A3UI2/]@CY``3=2LLXHTEUM0G6P:LH M>0>--'(!J`#SF*VBX!V\BI)Y^$N=`NAM58)_<%53`U')9#8`Q#M&PMT:"K[! ME8$IZ%%C9Q5J/=;P;N?(!.=@VFS8GT9_EQ$$=@5,@'(.R7 MOLVDAKI<@G.PV<@EYZ"A1BX`01F+DMVPN52"N6`>7!OX0GB=;8Y-!'4L`NL< MMHY4+VT_S@C"?E5Q/F-5A6`=;#9LV-=&0XW:P#K@Y*R_GI*-OC!+ M/W_)8<,^$Q4(F<`X;JK4G"K!.;BJJ7,H=A^)7`#B'2/A;K\$[^#S`;80WN;B M;N\H!._@VL`6PMML4@G&P;MFPK\G?9@3QV5#)S`FS#+N'#?M\_C8C".:^S&-%!^1,8BDX M!YL-&_:Y:*AA[A%TO=2FL,LD^`:O(EB".X7^-I<`0E7ZRSX:'9=+<`ZN"DR! M4@G=P;6`+7%NUID%#;0"".E;SVUR& MG<.&_>F8U!'L!;9YSNK+L&W8L$_D;S."\,L<6@AW,@3;X+V2;(-6!ZL'(#X9 M*IVQJ2KL'3;L"Z-#!SX$8;?R.)LYAU6";[#)L&&?BT8:N>!^!8J84HF=(E:" M:;`BVK!/Y*\R@FZBYNZ:*\$VN*BI;2AVV"@*0+QAI-M59I9^_I*C,N&WOMQ& MT#UL@G%P;>`)X56N``1U5&:5V?=A[(;#E1GVD$KR$'^O$01[O9H;_["!5-*E M!PT==@]`>'J9:YQ@('PDI3L6?Z\K`/'&J91`;@7#/E))/C+9:P!AZU0\=VVJ M!`]A8V+#_KI1F:"("$)SE*^WE>`?K(8V[//X:XV@MS4)%L(UF;#+I5*R/=0$ M(-XODNUT2PDFPI6!/^C?@>^Y;8Y-=`^;QO@FPK69L*MM>H96`((ZKNY<:Q7V M$QOVB?VU1A`2K^*4KAWPE2O(22H5\`,(RYC$;7I=+\!$^*Y*/4)F0"T!XSJYH)1TF_7S* M9"I9%6W8'PY*!4P(0E5I7!;\9$-H((;'6>`AD$O]TOQ>]R_M>5@LR0V MH];#PRSP8NPN]L&,YV[4SZ;8?P_ZH:-&/R"2Q!J\[[KQ^L(\+G-[C.GI?P`` M`/__`P!02P,$%``&``@````A`,#N)[!L`@``_`4``!D```!X;"]W;W)K&ULE%39CML@%'VOU']`O(^WQ-D49S3)*.U(K51579X) MQC&*,1:09?Z^%XC=Q!FETQ?;<`_GG+O@^>-)5.C`E.:RSG`<1!BQFLJR M835$"JD$,;!4VU`WBI'<'1)5F$31*!2$U]@SS-1[.&11<,J>)=T+5AM/HEA% M#/C7)6]TRR;H>^@$4;M]\T"E:(!BPRMN7ATI1H+.7K:U5&130=ZG>$AHR^T6 M-_2"4R6U+$P`=*$W>IOS-)R&P+28YQPRL&5'BA49?HIGJQ2'B[FKSR_.COKB M&^E2'C\IGG_A-8-B0YML`S92[BST);=;<#B\.;UV#?BF4,X*LJ_,=WG\S/BV M--!MIT=E!4KP1(+;$8#,R*W M!\56O2-)SB3P/I/$HV"8I./)_[`,SBSP;EF2()FD<3KZMY?0Y^7J\4P,69M*6<5[KAEF9Y'*^@[\1?8#VQ#MNPK45M> M:U2Q`MQ'P1C.*W]]_<+(QDW.1AJXC>ZSA+\L@V&.`@`74IIV88>Q^V\O_@`` M`/__`P!02P,$%``&``@````A`%H;9\K$"```>RX``!D```!X;"]W;W)K&ULE)I=VT, M2:Q1L81,9O[]GJ8Y+=T-'"<7,7EYSDM#O[0-]..W7Z=CY6=PC0[A^:EJU!K5 M2G#>AZ^'\_M3]9^M]="K5J)X=W[='<-S\%3]'435;\]___7X%5Y_1!]!$%?` MX1P]53_B^#*HUZ/]1W#:1;7P$IQARUMX/>UB^/?Z7H\NUV#WFA2=CG6ST>C4 M3[O#N M'O;AZ0(6+X?C(?Z=F%8KI_U@^GX.K[N7(QSW+Z.UVZ-W\H]F?SKLKV$4OL4U ML*OSANK'W*_WZ^#T_/AZ@"-@I[UR#=Z>JM^-P=;H5.O/C\D)^O<0?$69ORO1 M1_AE7P^O[N$U:BOI`>]:>0W>=I_'V`^_G.#P M_A%#=[=9R3X\PI[@=^5T8!F`0]_]2CZ_#J_QQU.UV:FUNXVF8;:KE9<@BJT# MJZU6]I]1')[^XY"16G$3,S6!S]3$,&HML]WM)2XEE[CZ]@S_SOBG M*G0(!#H"]>=SUVP\UG_"=;1/F:'.&#(Q0H)=2\QVK`H3%&[[,3NRB84(FMBJ MX*C"5!5F7(#?XG"4ILYU0FV(BZZ%)@LDL*E+%&XEJNL*$:SQ4+C5*&U=(X$E M/@JW$G4W&T2P9LN%9'"J0TA$4B"OV:1@()C,`H'U0Q0R^Y0[;H0$EHQ1R)1T MY9I)#B(3%A+H:J-0[.KH2*+!,)N]',B5H"8['-5G@;LN;-Q2,NFSDZV:K$@33S*!EK!CDL?T=1:! M+NJW-,3/(@_]1J^O(9LLTFHTV[K+EB.05Y&P6W](284;D+*DLLUR4KNF,B,8 M;Y2QV6NH!K=&CROQ-&2 M$7)"^TWYVV7(D31+[8;9T&>$(\ZP1Z1B.M'IR3YCSI0$?7+'GJP[]F23>W*R M>S)[C6:GJPW)PH[>+?X;(A7;:RBPEO M1K+](V668,3K;+$>^::L93J"2<(X'@T#86RBWTMSET,A&=T(@E$/2U MA5+HZZ0([ZSTWBA[AI*]3X416L^$4F@]IQ&71A8TLJ21%8UX-+*F$9]&-C2R M+47DT+)'[YF)`P['!G\DG[WQ[ZK/#X+)C1B"00390NE,%$. MC4P%@KXSH13ZSFG$I9$%C2QI9$4CGD!R)OYKL;'P<'V!Y-1OQ,;"^FTI(J>3 M/9_/I%-].L5>:"JSAJZI#'W#%"I-*??)IA25PL.8T+Z60#!-ME`*?9T4X4-J MGS])4FX.I\(&C6="*32>TXA+(PL:6=+(BD8\&EG3B$\C&QK9EB)R9-D+@;+( M\A<&$"\Q0>VJ+TB'!H=*(XL()F!,%TUHQ!((^MI"N;58N<2<%!%3-I@!L!]Y MWCT51F@]$TJA]9Q&7!I9T,B21E8TXM'(FD9\&MG0R+84D4,+22L-+=NN3EV5 MMVY#@T.EH44$$S"FBR8T8@D$?6VA%";+21'^XJ*3W$SJD54;/*.-YS3BTLB" M1I8TLJ(1CT;6-.+3R(9&MJ6('%GVWB`SSHJ)*W^?`',,S,*0K7:"]&:DD2Z- M=6FB2Y8NV;KDZ-)4EV:Z--;JTUB5?ES:ZM)4DN6O8D_-, MU]`+O/BC]NQWHOK09@BK+I-.S$+P`D7^BAG=*.S]L2Y-=,G2)5N7'%V:ZM), ME^:ZY.K20I>6NK32)4^7UKKDZ])&E]CRUO1$PRGD_&PO=V]R M:W-H965T ME5:K_;BF">F@"2$">GKFWT^5J^RXRN:\F;Y(.N;A`'[MHNI`PN=??C^\3'[; MG<[[X^O#-+N93R>[U^WQ7W/N\.F_/-\6WW:B]Y.IX.FXO] M\?1]=GX[[3:/S94.+[-\/E_.#IO]Z]17N#]]I,;QZ6F_W=7'[8_#[O7BBYQV M+YN+O?_GY_W;N:UVV'ZDW&%S^O7'VZ?M\?!F2WS;O^PO?S1%IY/#]EY]?SV> M-M]>[./^/2LWV[9V\\.@_&&_/1W/QZ?+C2TW\W=T^)CO9G]?01N MMT].NZ>'Z=?LWBSGT]F7S\T.^M]^]_/<^__D_'S\*4[[QW_L7W=V;]N<7`+? MCL=?'56/;I.]\FQP;=XD\*_3Y''WM/GQ5[?'%WI+] M.CGLW3%@'_KF]^;[S_WCY?EA6BQO%JMYD>6+Z>3;[GSA>W?=Z63[XWPY'O[O M419*^2)Y*&*_AR+9XJ;,%ZO;OU*E"%66[U7RF_QVD2V6?^&^K$(5^[V]+_9N M??"!V,._V1OV>W?EOWX7[D(5^[VK\N&[D-FL?2)VGW=7__"=F/E\F^.BWEPV M7SZ?CC\G]F2SU9_2$<$2'6[ABQA^K6\:_./TSM7K3IG^W6W[ZL M\MO/L]_L0;<-9NV-_=J9Q6(5FVI8)XM%W0IW<+J;9NV&][+Y,KX.;TE['>$W M^,/2%9'I!I5NT.D&T]LPLWNMVW7V^.GONG8/NTWV"K=[ECE=_$= MKX8FCT4](I)]RD9(7(2/B*2(&)+%,MG-BH1"0:&A,)2( M4K%3G;%4W.8XE561C)=K;ZA4H*BA8%!P*`04$@H%A8;"4")*Q4YZ^JFDSR_N M8O3\X@V5#A0U%`P*#H6`0D*AH-!0&$I$Z;@E:F\BVSZ_N,WI.5/$\Y"U-_U4 MEJMDW*Z&)A$U%`P*#H6`0D*AH-!0&$I$N=C53C^7]*QQ%Z?YE$D^WO3S2?9] M!44-!8."0R&@D%`H*#04QHLL6S7/F_.;]WENE(U;5/;#:4^:9GN3W;798.?6B5GEPQD8BTV6%?G(Y#E%6>&F:O&9 M+@(B[K3$1&&B,3$DB7-RB]2QG/SBM;^X617)T+7./"(>Q'N7?:`.C\UH'1&;?+X8'C__8A&YG74"CF M%Q!Q'%>8U)@P3#@F`A.)B<)$8V)($B=UI>N0#[L.@Z90,&1`ODP8].;#?DZ- MBS!,."8"$XF)PD1C8D@2YV-'L_Z8US;MV+6 MG?N5OQVKNK>&K`9OM0J(/*-@!Z'&51@F'!.!B<1$8:(Q,22)D[K29,B'38;A MJ81[#*%,&*V*V^%K#G4@1,P,$XZ)P$1BHC#1F!B2Q`&YQ7OO5.HFDM%LV@NO[GC67?\JX9@(3"0F"A.-B2%)E(U]7^_H>=-L1Y.Y@(@Q MJ0J$&MEP%8:K<%Q%8"(Q49AH3`Q)XH22-D(ZG2N&[815D;PM?AT0F92O0Y`: M5V&8<$P$)A(3A8G&Q)`D3BII*`R2\@T!>CI7M%V#JX-1A4F-"<.$8R(PD9@H M3#0FAB1Q4F[Y/S);*'Q;H#];&$SG@B'.DRH0/^B-OV*$JS!,."8"$XF)PD1C M8D@2!V1W[VA`;GO\M#2D0FU9&S*@*_/,.&8"$PD)@H3C8DA29Q-TE]H MIW/%L*\PG,X%1&;CZ_BSY].5TP?V'AB^)8Z)P$1BHC#1F!B2Q!$EC84N(M\( MZ(]OPQ9=`;L%54=&3Q]X?49=GW<77GT&%)A(3!0F&A-#DCB5I(G0S`_*A7U] MH'D9^VLQ;":LRN3=(.N`R!,(-AQJ7(5APC$1F$A,%"8:$T.2."FWH._-#P8S M.;_@!S,YV!6H"DAJ3!@F'!.!B<1$8:(Q,22)DW++^UY2W;GDE_W12%>^OWN_ M.>'6!>P-5)C4F+!`_%-:T?S"8_H&78[+"$PD)@H3C8DA2111F;08FI/)_G&& M-JKF\GA.MRK37\<+B!KV,*DQ89AP3`0F$A.%B<;$D"1."K0:2M\BH(>]@,BD M<*L!5V&8<$P$)A(3A8G&Q)`D3LIU"4:&O=)M3\^E=-@+B$S(UR%(C:NP0/RP M9_]"3?,O?B,$QV4$)A(3A8G&Q)`DCBCI,0R&O6&O856F;^\N/2)RJ#"I,6&8 M<$P$)A(3A8G&Q)`D3LKNWO[)E,[V2GDM=0&12O@Y!:ER%8<(Q$9A(3!0F M&A-#DCBI*ZT'NXCZP+`'>P95J$,F!*NP4,4/>^Y]>?9?.NK!*@+?%XF)PD1C M8D@2)Y1T'@:CWD@'HDQ_3[F$'80*DQH3A@G'1&`B,5&8:$P,2>*DQKH1]F6I M;EKNNPA@L@=;#54)28T)PX1C(C"1F"A,-":&)'%223>B2\AW#^@U;@E;#!4F M-28L$#_JN5]N'AGUX'T1^(8D)@H3C8DA29Q0TH5H1CT[:'9)C74CDK>(K$O< MC<"DQH1APC$1F$A,%"8:$T.2**G%6#.B-^HUEZ.Y7D#$-*'"I,:$8<(Q$9A( M3!0F&A-#DCBII!G1GDL+WSR@1[V`R(1P$P)788'X4:\<[^SA,@(3B8G"1&-B M2!)'Y+H$O2Y$.ME;^"Y"'%7ZUP`"(J/R=0A2XRH,$XZ)P$1BHC#1F!B2Q$F- M-2/ZPY[O,]"3O85'1`P5)C4F#!..BZ8<]M1YV] MA4=D0I#4N`H+)'3VK@Q[\)8$OB6)B<)$8V)($D?D%N_4L.<7]_&PE_ZR[`)V M`"I,:DP8)AP3@8G$1&&B,3$DB9,:ZT;TASW?:`##'NY&+""I,6&8<$P$)A(3 MA8G&Q)`D3BKI1G3#GN\>Q.=2^H+&`K88*DQJ3%@@?MBS?R!W;)&+RPA,)"8* M$XV)(4D<4=*&&,SVQMH1Z=\@7L`60(5)C0G#A&,B,)&8*$PT)H8D<5)C[8C^ ML.<[#6#8P^V(!20U)@P3CHG`1&*B,-&8&))$2=FW0413B7;8:[:CV5Y`U&P/ MDQH3%HC_N^#N[\_9?\D+&KB*P$1BHC#1F+C/!G&SZ?%=YQ/RG_WA/^/AL#M] MWU6[EY?S9'O\\6I_&[.PO;UN:_>9(U]S]VD%R?8JNZ^;#TY(MK/LWG[.@O6S M[@+[R2%OF^^[?VY.W_>OY\G+[LG>U/QF9>>*)_\A(_Z'R_&M^<2);\>+_8W%C\=CY?V!W<#W&PO=V]R:W-H965T&ULC%9= M;YLP%'V?M/^`_-Z`(1]-%%(5JFZ5-FG:Y[,#)E@%S&RGZ?[]KC$A8$C5EP0N MQ^<>7Q_N97OW6A;."Q62\2I$>.8AAU8)3UEU"-&OGX\WM\B1BE0I*7A%0_2/ M2G2W^_AA>^+B6>:4*@<8*AFB7*EZX[HRR6E)Y(S7M((G&1\V>]]`E"'B21#4`GD7_/:>Y]G<7MTO2OSRD? MFV/[)IR49N18J._\])FR0ZX@TT(O3W@!6/AU2J:-`_4BKT8&2U4>HF`Y6ZR\ M`/L+Y.RI5(],KT5.#_U)+,9ROLK8/5^TF"E@3^6Q(, M?&\K<,UNFHH\$$5V6\%/#O@1],J::'?C30#E3'3P7D=#M((3")&$Z,O.V[HO M4,:D140&`;\=`@\1\1FA3P*2=1E!ZT1&'=49=>&UA,@$^@E\*\$8$72(048H M5"^CHX\XT-8Q>]5/(=#;R;RC,5(,8MY#+(:(^"W$0`J0]*2<)>AHB&`_73&7 MPP210?0EK(:(>(RXB!Q(`*--2-#1H83;88+((/H2UD-$/$90*R+T[!F_?CIJB;`] M:2`#$9<41L08%*&CE@C;E0:R:!K$'"_FMB?-\[[(*PHP-/N).C1A M2X.5(VHQ_238LFX\@;DF1'>M\8%@T\SZ;RBVW!^UF+X0W_)O/(&Y)D1WMPDA MINGUA?C6&Q#I:0`G-Q!B>3B>P%P3HGO;18C=/6&@VS;QK;-&;N:@6[&5TG%@<:T**23\&,%C1/#VB[:?7&TGP+=`QCI M-3G0KT0<6"6=@F:PU)OI\2O,]#&ZC\7=?P```/__`P!02P,$%``&``@````A`.&G7HL,!P``\QD``!D```!X M;"]W;W)K&ULE%G;;MM&$'TOT'\@^!Z)I"B)$FP' MYF7;`"U0%&G[3%.41402!9*.D[_OV1OW"B=^":,SEST[,SNSI.\^?KN<@Z_M M,';]]3Z,%U$8M->F/W37Y_OPG\_D0Q8&XU1?#_6YO[;WX?=V##\^_/K+W6L_ M?!E/;3L%\'`=[\/3--WVR^78G-I+/2[Z6WN%Y-@/EWK"S^%Y.=Z&MCXPH\MY MF4319GFINVO(/>R'G_'1'X]=TY9]\W)IKQ-W,K3G>@+_\=3=1NGMTOR,NTL] M?'FY?6CZRPTNGKIS-WUG3L/@TNP_/5_[H7XZ8]_?XK1NI&_VPW%_Z9JA'_OC MM("[)2?J[GFWW"WAZ>'NT&$'-.S!T![OP\=X3Y)MN'RX8P'ZMVM?1^W_P7CJ M7W\;NL,?W;5%M)$GFH&GOO]"53\=*`3CI6--6`;^&H)#>ZQ?SM/?_>OO;?=\ MFI#N-35I^C-6PK_!I:,U@*W7W]CSM3M,I_MPM5FLM]$J3M9A\-2.$^FH;1@T M+^/47_[C2K%PQ9TDP@F>PDFR6\1IM'F'CU3XP%/Z6*3)>ILQ(F\L#IIL!W@* MP^TB6Z_33;8%](;A1ACB*0SC-PV7/'0LY&4]U0]W0_\:H(X1G/%6TU,1[^%, MQ%HL/4J?A]NPP!Q'8%^?5BOTKOE5Z2S$3JYJQ.;&H74H"FE;DL; MJ&R`:,`2U&?^2-M[^%-URE^NG$M`;2BQR$H-:5+:0&4#1`,,LJOWD:7JJ&DC MV&N370<.4CD(T1%C$RCR]T29"Z:U= MS"KS+ARD()'"04H'J1R$Z(A!!(?.0X2B M)A&!J-(M'*1TD,I!B(X81'"H-2*L$R0('V]"JA,$TZEKON0]:ZPR;M36I,N1 M!,U_3GL:K:$Z(BQ*7HG4.U-TJ6H295/4Y,V153+S M*@2B,>5(MIMU*H[LV!AF#9@(A(U&@TB,5'@BR&"3BH#6J8RA-1<*H9!L9B*E M@%8;$:!H:T=0:M7%`M+I"6@U[[*26@HB$O+PH;W;PT>T=)T/AU3E6>.E MB+F"D5H.B7NX\IYNQ$ZT>46_B`6DLQ.06KR26@HB$O+4'6W*'CZ\5QM\.*3JSCI_ M18VO%E!U@PQW)BQHWW;PY6WDL_QDY";Z\0<&.+U M9T%?OGS7'*9N[4.,"*TFA99^61#06MUT*A M)D)+3[V`-A&+ZP9OKDYD^6K04)$5$-N]R9AV?[U10Z_,Z.^(I@Q2*2`D7S>T M^FREM*0AD;[T%9-$-5MS@W2*J`W*JR[]BF'=?01DE8C=NX26D0/N:XT.-4?` MO?,*0U%(ZU461^81)5+#4S5T2JA-_#!+?*@86>*044T<,G;"H8WJ*Q7$-%`; M=42)A#SGDSV/0]"]7Q##=XK3-\/QY M[9%%QL)S?'9C+FT\P>DY="0X*;/P,UF#`TF!Q+I(U&/@D)22E5U)!0M/M,D!E M@IM/DL?9/L?<%5U)"4GDEF.C(I<];GD38J2_-F(78J4]20D+'B1EU)'F^P#OMHX:RSP3H^20D; M>F5SO1%(Z,W-E>0QXH87,5>"UTZLXY/@[1/K^"0$$OI:YWK#BQK6\54OWM"P MCD^"%S6LXY/@;0SK^"0Y"M$7SW*[Q\<.#R^4IZ^>"A2G#R^S?>G#*Y2L#RVVOIH#2=[ M$Y*G6RWI54MJF]S__O-T'/VH+LVA/C^,O9OI>%2=]_7SX?SZ,/[/'_%OR_&H M:7?GY]VQ/E7F=-.^7:O?<-3H=)_YTNIB<=H?SN(^PNGPE1OWR&XIVVG\EW&EW^?[Q_MN^/KTCQ-/A>&C_[(*. M1Z?]*GL]UY?=TQ'S_NG-=GN*W?W!PI\.^TO=U"_M#<)-^H'R.=]-[B:(]'C_ M?,`,A.RC2_7R,/[FK4I_.IX\WG<"_?=0?3;:[Z/FK?Y,+H?GXG"NH#;62:S` M4UU_%Z[9LT!H/&&MXVX%_G49/5_.%"'*EX4PVQ*=LZ-W=S/SY[;+K_DI+Q.W&C4_94AOV ME78+V0Z?U./TQIM-?S726]D.GT-_7QHH=E0W4'Q2A\'7Q+F3+?$I6P93M317 MYN@A7;H^Q2_4Z9=FZ5$ZB%]D2_\K\GC(G[Y+E4C7E]ZCI!&_T"!O;KWI77#K M;#GI,[?+^,VNW3W>7^K/$8X1#+5YWXE#R5N)8#+79=X-V8]-N!?NWX3_PQ@+ MB;QN0'\\SH/I_>0'MM->^H3NDBTN$E<*<5S3'LR0SWRZ!>L+#.L_7@ M1,TVC$2,Q(PDC*2,9(QL&6G@!<"/*B/;ML/\>UM@9WG!D"W=3'TFT/.G)$M)KF\HZDC:# M$Z57Q$C,0B>#CQ[:NC?3P8E"9XQL6>A\\%&A/3\P#])B<*+0I4X,85%YZL+2 M&22P*:`DFH`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`O29B7FQ"U(E968&K>4L(@9<@N^ M!?S6"6/U'^+;P6Y*-O?QK:$C3ABL\#;6$7^V^N;L.)RM\.:1-\#!CDET%X_5 M-4YNC,EE"3&]T-G+&I:UT[*!1>0G'P$.CY5(4VZ)81'9RBT)+")IN26%1>0N MM^"46(D4YA:48EA\5UJ@(H,Z+@M*+JCCLJ`R@#HNW5`-0`.7!=<]-'!98EC$ MU<1'G<`BKB-NP96.F;HLN-DQ4YCU&[-@(>1C%JEP5/FQBURX(G3(S:9<&#)D;M MLN")$J-V6?!@":U=%CQ?(JM<%CQ`8J8N"U[4(.-=&N#E#,;FLN"U#,;FLN#M M#,;FLN`E#8X[EP4O9C!JER7$0='="=8)LL;&[JXBBR?8B"Z>X]1T\?7="J_E M>"Z%&%'H'-$:%O'>AK?9P")>WW`+WJ$A+UP6O#=#7G26R3`5_$O%^^ZU*G>7 MU\.Y&1VK%UPYT^ZYZM+_]T7_1]O?5J.GNL4_4XB+:_2&_Y*I\/TQOML?CU[J MNJ4_,*C)\'\WCW\!``#__P,`4$L#!!0`!@`(````(0#MI#IMOAP``!V(```9 M````>&PO=V]R:W-H965T6-V]YJF*(EA4520]'CF[>='%[*S@#_9E'WAIKY,)%"),PH% M?/C[O^Z_G?WS]O'I[N'[+^>+-Q?G9[??;QX^W7W_\LOY__XC^]O5^=G3\_7W M3]??'K[?_G+^[]NG\[]__.__^O#GP^/O3U]O;Y_/8.'[TR_G7Y^??R1OWS[= M?+V]OWYZ\_#C]CLDGQ\>[Z^?\<_'+V^??CS>7G\Z!+K_]G9Y<7'Y]O[Z[OOY M9"%Y_!D;#Y\_W]W<[A]N_KB__?X\&7F\_7;]C/0_?;W[\236[F]^QMS]]>/O M?_SXV\W#_0^8^.WNV]WSOP]&S\_N;Y+RR_>'Q^O?ON&Y_[587]^([<,_R/S] MWY3<_?]%MY&/KD<^.WAX7>G6GYR"('?4NCL MD`/#X]FGV\_7?WQ[_I^'/XO;NR]?GY'=&Q?DYN$;8L+_S^[O7!G`HU__Z_#[ MY]VGYZ^_G*_6;Q;KB\OEYOSLM]NGY^S.!3T_N_GCZ?GA_O\GG86W--E8>AOX M%1N7;S;O+E:+OV!DY8W@5XR\N=ILUI=7[Y"2$[&O?4#\^H"+=V^65YO%YO`, M)T+"[N'9+^2M>X/2?#)W%A(/KH_)++3(20#%T$._E0^H$C[XHL_)+:?<^@"N3Z5 M_"#[?ZK@+"3_W1\^6A2Z4TE^.]6[0WW=7S]??_SP^/#G&1I!Y,G3CVO7I"X2 M9\[75%_BCW473ABT,=@B,$X`V_A]J/O4:C_DN^= MOO.]>&TK0#-C&3E:-"3(/@9I#+(8Y#$H8E#&H(I!'8,F!FT,NACT,1AB,,Y` MX&BT!7_)T4X?/5%0R-^%GMU..JYQ.]:$3:BR.ZHQ?R@NGC\8)67OT,[F)#$3&.0DR`]W6/#.DD7?XX'/QU78BZY/M_NZH),'V M1%(B&9&<2$&D)%(1J8DT1%HB'9&>R$!DG)/`Q>C>+1<['+IX(FL,S68%_2IJ M4HY*1Q<328ED1'(B!9&22$6D)M(0:8ET1'HB`Y%Q3@(7HU1:+G8X=/%$,"L0 M[^V([(FD1#(B.9&"2$FD(E(3:8BT1#HB/9&!R#@G@3_=+'PV)I16P>'0GY[H MB&1'9$\D)9(1R8D41$HB%9&:2$.D)=(1Z8D,1,8Y"?R)R9/E3X=#?TYD>:GE MTQ-DU:Q1>!\V"ONCDA3KE$A&IO.CSLSTZB(T71R5Q'1)I"+3]5'GA.GFJ"2F M6R(=F>Z/.G/3ZS#5PU%)3(]S$N2-F]!:F7/@8>YX-,\>05H#]HQ21ID@S>I< M4)#7JVCF5*B6/%O)J!*DYFM!)\TWJB7F6T:=(#7?"U)/#(S&`(7YX"9)LT;' M3T3?N-67YZ]W-[]O'U`#%CH/G295&!=*0K=N+(X*%>3/A%:'U2H_TR24^H`S MK8QMY:HU+WK1A*M0+4E7R:AB\[5JS+>>%;[F(YDM[U9*'2QEEC')&!:.24<6H9M0P:AEU MC'I&`Z,Q0*'3W2S*H:'3GF(5>7CG5L606ZOUL=;L&:6,,H^6 M&F/.6@6CDE'%MFK6:ABUC#JVU;/6P&@,4.AT-UNRG.YG4>J"K5LRA#LWZ$-F M3H^6PW9>:]8N[1FEC#*/_,*Y6R?+6:M@5#*JV%;-6@VCEE''MGK6&AB-`0J= M[N9/EM.G>16JB#0)6[?H"J=?A4Z/EF=V7FLU7S=8+B*MO6BM#BN9FZN+Y564 M>ZFH:)7)&.6"3D97B!9&BL?RLEQ'<[Q2M#3&BE$MZ&2,C6B=C+$5+8VQ8]0+ M.AGC(%HONW04E4-T83%PT.JHE0K2 MA\T8Y8+45B'HZFBK%*2V*D:U(+75"%);K2"UU3'J!:FM09`^XRC(\#"Z8-/# MCD?CW0FMW`A,%_NC`>G.O31P3K\\5*'EU?NHS]FK@F14ZM&L1HEX`O^650!;$\!F;"BN$FE[.*\>KP MV$]&M9AL%Q-"=DI\.X\NI_>ITXN826N&4J^U?'\,F`G2"4#NT5KK8\&HE(!J MJQ*DMFH.V#!J):#:Z@2IK=ZCV0,-C$8)>+`5>MY-'6>>/PY\IREET"1-:#-O M(%>KJ'G?+2:M->8AQVIE]$Q>2YK1U>(JJGFI&-(,S3R:C>]RT3H97>&UWJ$R M:Z*X9_*)TA@KCK'^J1B;GXJQ%5L:8\],/VU",4CV,%]&BM:"](NX%4D);JS*-Y1HN6VBH\>J>]3"E::JMB6[5H MJ:V&;;6BI;8ZMM6+EMH:!.DSCH(.MD+/NPG[K`*2Y__Q\&.^,K!T^I'G)Q2. MTY?1U'WG`U[-6D-&*:-,8M1"FK-6P:AD5+&MFK4:1BVCCFWUK#4P&@,49@;: MMGEF2&N(B2$Y?4+1.#U:N]SY@*^,TT4+G=/+S5,J6EJL,D:YH'DK3>UO(5HG M8RQ%2V.L&-6"3L;8B-;)&%O1TA@[1KV@DS$.HG4RQE&T#C&&A>&%Y8DE+T]X M-!^M>S0?K0O2]BH5I,^;,ZSEN/R?=2FI1[/'R!CE$G#> M?WA;BDH.6#&JV5;#J/4HZ#^F&&=)[26@/N/`:/3(\##>_9H>/O"PHG@4SFO6 M4?[NO);T'Q<7BVCFLU<-*0&I(&T4,D:YH*G[B"(N5"IF2T%JMF)4"T)Q/HZ6 M5NOH=4BC6F*^%11,-N+JVXF6)J(7Y/N3BXMEU-P,JB&QC8*XL5N]ME`0;2$X MZ$=Y.RT4S+L9K[71C0U[1JD@+7^91_,E&M'2A8*"42E(;55LJQ8MM=4P:CVZ MU`ZD8UN]!-1G'!B-@@[I"MHG-WNWVJ<#CSSL5/'*%%/$62F+1M<['W`S+XLT M1]][+7S(Y+Y#N%J]7UY&Q345%9V`91[-6H_\IZ(KQ-:[Z4W')NKX2I%K7!7' M5?]47(W8PAAGYJ9H*;DU;7'-FUP^>^#>#!B_'1TD$4?_KB^C1FP4E<,SAV4B M6AR@9;NX-O*B`1I/7U:D]N\\NM169"](*T(J2&M0YM',";EHJ:U"D([=2D%J MJV);M6BIK4:0VFH%J5;'MGK6&@3I,XZ"C-H8+1J0YZ,%4[10\6#0H_!-QCK* M_)W7N@H:_K@4[47+M_+KY7*]CNI[*CKJF,PC_$CFYZ)U,KY"M#8O5=/I<:_4 M<,5QU6+E9%R-:&&B?:J:^A@#6UQ-)RV8E`?NQ7P0,';P(%KJX,M-M.XSBL[! M>%A/W2+!;&Q)I26NI].BPGS,Z>8,KDW7AF_GT?S%AB!]OE20UJW,HYD7\9I8PRC[`-29U. MM@H.6#*JV%;-6@VCEE''MGK6&AB-`0J=[J;*EM.G*73@]`F%\]I5U%/O5I.6 M&_<=>SQC9.ZUIBYI??5^?1$92L60-I49HUS0R>@*T4(F:J)H]X)H:8P5HUK0 MR1@;T3H98RM:&F/'J!=T,L9!M%YVZ2@JA^B"8H!=.68Q./!P@N;1?`KL$?)< MZLM>D,XK4T'ZL!FC7)#:*@3I0+D4I+8J1K4@M=4(4ENM(+75,>H%J:U!D#[C M*,CP<+3X(%V*V^83K;1Z%$Z!-]%+@)W7JY9D3>K1K%G,&.4:\(3Y M0K7$?,FV*D:U!CQAOE$M,=^RK8Y1KP%/F!]42\R/@:VPBJ#ZS5M*&HU%XV`, M;2EC)X2,E?AV7@OE1M">4>H1EB=%*Q.DP]F<`Q:,2@FHMBI!:JOF@`VC5@*J MK4Z0VNHYX,!HE(`'6Z'GHY6"8]7A%8&U7Q&8-Y6\P\YKN;S6JA-/F_:B]7*# MFHJ*#A0RCV8CO5RT3D97>*U7=MB)+8VQXAAKT3H98_-3,;9B2V/L.,9>M$[& M.(C6RRX=1>4075@,W/QW-E1YM0).\^7Y$&8]H?E$U".4/JE:>T':(:2"M%1G M'@49/9F?V2J\UGPBRK8JME6+EJ:K85NM:&FZ.K;5BY;:&@3I,XZ"#K9"S[^V M!!!-1->\!.!1.&*G'79>:SXW990RRCR:C]A9JV!4,JK85LU:#:.64<>V>M8: M&(T!"C,C6A4XMH8\^U]/*!JQQZMT7NN5$;MH355WL5BLXDEN*BI:IC)&N:!Y M$TT3A$*TIG=8\4JZ2#6FBE$MZ&1,C6C-1^JK>.V^%:W`%BW1B9:FJQ<4!(S[ MFD&T7O;N*"H'VV&)>&&UPIW&$0\M)Q0,WB<4#-X]TG%*ZFW-6KN,42Y(&YI" MD`ZX2T'JI8I1+4AM-8+45BM(M3I!:KX7I%J#('W&49#A83?[GW4]QSKG>#0] MFI!;U3N.+5:TSF84H^"D?MD:(9R"3AMDX@7 MY0L5B]V2[5:,:@TX>[)-]$:V42TQWWKTRC8)CK$76T`.G`N&)4O1?)L$V^HEH#[CP&@,`@8>=OV[Y>$##RN*1V'G1-OLO!9>9KF*@OQ?OH\V MYNQ518I`*DB;@(Q1+LAOLXNWX!0J%\.E(#5<,:H%H6X>VP#^C3)O0O/\XA$93I@WIGE$J2)\L8Y0+ MT@:^8%0*4EL5HUJ0VFH8M8+45L>H%Z3/.#`:!1D>1N]O>MCQR,,3BOJ/J)7= MN1>OVG\L-NME-*K;JX:4@-2C>=/$*)>`4_<1K3H5*A6S)=NH&-4:4.L$[QY2 M+3'?>O1*[\$Q]F++;[)C'PVJ(;&-@9VP:7MA%<(MT\5Y."'DH=C=>2UT^(+V MC%*/@AR:;,U0+@%GG0>CDFU5C&H.V#!J/9IW'FRKEX#ZC`.C,0@8>CB:X,LH MRV5][.$)N9=)QQ9V17OL?$#?>:S>KS;1!IF]:DBVI(*T1<@8Y8)\WQ&]3B]4 M+'9+06JW8E0+FG<=JTW4Y36J)>9;06@8CAY9T@1%M#01O:"I-W%.BL=8JB&Q MC8*,INZUM8)HF73#:P4>(7,EOIU'\TUVC%)!6@`SL:4/G(N6ULZ"42E(;55L MJQ8MM=4P:CV:;[)C6[T$U,<>&(V"#ND*J\\+"P,;7ACPR%7%8V%9Q9MN=J(U M+XLT4]][K>,FN\7E(IJNIZ*BTZ_,HZ!9F])Y>D]?(;;\)KMX)EV*7..J.*[: MH]-Q-6(K:&7BZM&:MKCF34\W>^#>#!@_T"")D$UVBZN+J!4;1>7PS&&9<#/Y MV8SGM3535#!J:B>$LJ*U<4+S378^X*56A%20UJ#,HYD3K85L]:@R!]QE&041O=Q/R4YZ,U4U<4XTYN0FY(,JNE MT4!OYP.^LLE.M/P"TVJYH`WGJ>BH8S*/9LL^N6C-4T6M0B%:?I-=7*I+D6M< M%<=5B];)N!K1"I9AJM M3+Q:3WG%8C,AE!:MIQ.:O8_8>RVL]8M6*DCK5N;1S`NY:*GYPJ/YNPW14EL5 MVZI%2VTU;*MEK8YM]:PU"-)G'`5Q/46_Q?5TN7F#PC1=S:!'W$_G#$;U]A`^ MG,)YY-:AM-YNXMU)JB4YL6>4,LH8Y8P*1B6CBE'-J&'4,NH8]8P&1NZB$=?T MP5_PQ%0MIHM#IHL([F\?O]SN;K]]>SJ[>?CC.URZPI<&'S\<^71ER7:3C(>6 M.>:7N,K$629^(7><1))NO',Z8B/DR&4W]53(>>N=(_]=U\BM\RTG:KI/Q4#FB`&BU$U>K.03: MZZ0T)6BV$U?'.0Q:[\15=9:@Q4Y28/2+_+$D&`0C?RP)!K[('TN"P2[RQY)L(=F:$LPC MX#BC\9H7!PB?\9DGP3@!^LYIPO!J`WRP)UO[A-TN" M5P#PFR7!FP#XS9)@M1]^LR1;2+:F9`>)6[KG^H/W*?";)<%K%?C-DN#M"OQF M2?`2!7ZS)'CKF+@W7)P"O'Q,W%LMEN#M8N)>;K&D@Z0S)7BQF+CW6AP&+P_1 M-5J2;HW^!V^(.0Q>\2?N#3-+\%H?\5@2O,U'/)9DBQ1LS13L('%O'#D>O!A. MW(M'EF20N/>/+,%KXL2]0N/?Z'`8;,Y"GE@3[ M,Q+WEI_#8$\&M>+!EA9XU))@ M9TOB=D#P\V##',J.->+"OCF4'4N"O7(H.Y8$6^10=BS);KU!JJV6/(?$[77B MM&%O$SQJ2;!3"?%8$NQ51#FP4E!"4IH2;%-$.;#"8+?B"!/+0F^%$&YMB3X.@2Y;4GP10ARVY)L(=F:$GQR M@W)MA=E#XK[$X%3CZQIXU)+@(QMXU)+@6QN4:TN"S]L2]_$:QX./U1+W*1I+ M\.E9XCXL8PD^),-\UI+@BR[$2="N, M\*>WMU$\^.(V<=]UR!-_6(AY+@F\Q\3S6X@2^K,3S6!)\)XGG ML23XZA'Q6!)\\IRX3V(Y;24DI2G!-\^)^T"6P^#3Y\1])\L2?.Z6!.<-P`>69(L4;,T4X#/UQ'V/S&G# MI^G)WI3@@W3DG!4&WZ4G[B-EMH;/TQ/WK3)+<'($\L=*-"P&CRI)<%I-'A22X(3:%`2+0D.HD%YLR0X;0;E MS9)L(=F:$AS]`^]887"^#[QC27#,#[QC27#:#\J.)<&Q/B@[E@2'8"7NP"4N MB3@+*W&'++$$AUTE[JPEEG20=*8$YUPE[I@E#H.SK+"6:4FVD&Q-"`WJV?"R7KPFR7! MT7GPFR7!"7KPFR7!07KPFR7!87GPFR790K(U)3BJ$'ZSPN`X0OC-DN!40OC- MDN!P0OC-DN`,0OC-DN#03OC-:OEP=B?\9DEP."?\9DEP("?\9DEP+B?\9DEP M]B;\9DEP.BZL6:T+#LE-W`&M7`YP,"[BL20X#!?Q6)(M4K`U4X`S5Y$_5MIP MKBKRQY)DD&2F!*>L(G^L,#A-%?EC27"8,<)8J<8!Q@AC27".,?+4DN`XX\0= MDLM^PQ'&R&U+@F.+D=N69`O)UI3@:.AD9TKVD.Q-"8Z`AD>M>'`2-#QJ27`@ M=.(.$.;GP5'S*#O6B!@GSJ/L6!*<,H^R8TEPN#S*CB7!R>-(M=62XQQQY(\E MP:G@\*@EP1G?B,>2X)1_E`,K!24D[FAX]@$.^$$).Z&"I;@LI#$753!$MP9DKC+*5B"FT'PSM"2X*(> M6+-F!;BO)W'7Q;`UW-&#>"P)KN9!/)9DBQ2X*T38&FZ`2?:F!/>\).[V$`Z# MZUX2=XD(2W#K2^(N#F$)KG5)W/TA+,&]2@ACI;J$Q%W2PV%PI1+RU)+@9J7$ M7=G#87";$G+;DN`&)>2V)<'M7_"!M5J$N[R0-DN"F[E@S9+@GBWDCR7!M5C( M'SL%F\1=C<3/@^NOD'.6!+=>(=66!)=?(>[`2MRU21P/[C;$\U@M4H<& MUA3T:"M-P6Z!'GCZDB>:3^)R.Z39:L=Q51T\;4EP\1Q29DEPC1SBL21;5$5K M%+1%`V8G&6V1*F\\/#\_R#Q24MW\^//[^]/7V]OGC?P0` M``#__P,`4$L#!!0`!@`(````(0"XPI_2'@D```0F```9````>&PO=V]R:W-H M965T7^LSE_ M;=_J^C)"A%/[,'Z[7-Z#R:3=O=7';7O3O-CXR[(7D_->?MTP+B_>_/MCF)W?[#P MQ_WNW+3-R^4&X29]1_F8[R9W$T1ZO'_>8P1"]M&Y?GD8?_&"RO?&D\?[3J#_ M[NO/5OO_J'UK/I/S_KG]%V/-I]M)?F^+_>J>OZ$&0F@^!3!EG=^*N%MUB*(%<:SF5# M?,J&WMW-W%_F'TY-S_95X^F5?SGW_760R9TW17_ MH?Y"K2N:>C3_XC^RR>*JJ),^"[OL#;>7[>/]N?D<84M`=]OWK=A@O$!$DWDK MGSYD,A;43KA_$?X/8TP)3[YA:>RDSYK[^$O394,N8GV(N*$- M(AO$-DALD-H@LT%N@\(&I0TJ#4R@V2`<)NM?"2?\A7`TXC4!I:1OB40>U"2T M062#V`:)#5(;9#;(;5#8H+1!I0%#)"04$VDV'9))F+'_&WO:[K^L&*\,;WF;" MW=1'$BU/>K)""FJ+RC,753@X47I%C,0L=#+XZ*&MDB(=G"ATQDC.0A>#CPKM M^3.SU^7@1*$KG1C"B@);5Y8RK..FA(0T#27RD;^#B+YG%06A\J+^1!S%'"4< MI1QE'.4<%1R5'%4&,H42U:=C*8IRR,HUB5:F*JSN[AO.]'+!]ZP77BACS;`R M!H5G2VO"(_(R8OE6,L?D-1\VRX20T=#N1$I>J^Z4X=U90\G(K@+G'!6$KCZK M)"]SP',SPROR,F)I`S:G#E[.J1/8>HH53>BGH,7YHE02&@UH(B0\HH) M*5420LHK):1B9814PYRC@I"*51)2L2I"G9>IBJA[70DMZV$5=RU.HY!@95'XRHAEBBWJ8Y?8LF[6Q>X1Q*:X&Z]'4)90R%$D M$60DKU@B0S,6*^6Q,MXPYZC@#4N.*J.AJ8HHC5VJ]"4S>J+Z]LR%RHO"1X1T[>03%4K(ZVKX5'E1^(R0BI5S5!"Z&KY47A2^ M(M2%-Q46%;:F\(\*)Z^OR`WE>P3EZ7D;Z;50E4#(441(+=A8HIG2(2$O%2OE M*".D8N4\5D%>*E;)446HBV6J)>IP3:VA&!+<>E'TR-H2K3UBX_5>2WP,.]ML MR;;$P8L4CF3#A9$*?$OL&QK+>XCEW!('*STIHRZJM99+I(4MR`OMAX&PA54J M+PI?$>K"FV)C;+K8/TQ-X6]-0H^,K;)'\^XK`GF?R5#D]6BA-M18(FW0B41: MK)2CC!JJ6#DAE:T%;UAR5%'#+I:IEJC@7:G95_;&@I7%OC%7/DO-WFNN7T0Y MRL_>ZU:/-5M:=UJ1YXK%L[7W,A:_JR$O/X=.B)SVIU;UF]'CU;+/)=*>59#7 MU0&7TLL:,"L_7?W6!FQ,G6\=L7Z4Z)V_F>@2Z66I1'.U;D.);E7E$'&O6")- MFH1[I3Q61EXJJW,>JR`OU:^2QZH,+U,M<2S2$KU3RU_\0:SCZ^_VQ2E\0$IGW9[?V_9GRHLTKY"CB*.8HX2CE*.,HYZC@J.1(?*$J M=D>,$;WO!>V_(.V_8CK6Y]=Z4Q\.[6C7?)RPAR\7D&S`_3>SZT6`VTH$L/DR MP%6=@_O#5[E6"RS`0&0';X-U&(@DX1:LO4#D"K=4L(B4X19\E_RERS3K^6MT MK/N>UN8^`CGBK&VCF\ M#2P;IR6$12QX_ASLQH%8]]P2PR*6/[NVRX!2"7KLL,2RB>.8]P)D$O799<.A` MKUT6W)Y`:^O71:< MU*&URX(#.[+*9<&)'"-U67#S%8CK&*XH;KO0-Y<%]USHF\N"ZR[TS67!K5<@ MKFKXW[=G]K1H7[! M:VK:W?&?^U_Q]']<^A?^Z*FYX$L.OK6K\=F$JRH27IKG0'^CN9/C] MUN,_````__\#`%!+`P04``8`"````"$`'EZB#`X'```:&P``&0```'AL+W=O M%-2NO^_I075]VUC]?DT\;:]9VQ?50G.MKN;-^EJWU^>GWWQ[?ZN9; M>RK+;@8/UW9GG;KNYL_G[?Y47HKVH;Z55[0.^ZD*<]%A_C;4W5KI;?+_CWN+D7S M[?7V:5]?;G#Q7)VK[F?OU)I=]G[^GI\=#!05LV&=->=Q97VP_=Q;6_.FQ'Z!_J_*MG?P_:T_U M6]I4AS^J:XG1QCRQ&7BNZV_,-#\PA,YSTCOI9^"O9G8HC\7KN?N[?LO*ZN74 M8;H]UF5?G_$D_)U=*I8#D%[\Z#_?JD-WVEG.YF'C>R[9**=;9F M^]>VJR__<2M;^.)>'.$%G\*+NWKPU@O7=N#D3D=7=,2GZ+A^6-N+K?J?? M4O3#IPS[?@>T]CI70P?7>U>$:]$1GQ^*$"NI?R`^WQ?A5G3`I^AP/\(YG\D^ M`Z*B*YX>F_IMAF6%J6IO!5NDM@]G8NK%:`[)@)S<,^LOS'QG01YFN07]_K1V M'N??D5Q[81)0$V>EFH32A&48Q#A(=I#K(=)!/@*(/R^,C^ICYSL+?84K=M:U.6,!M M;(SH8.2I)N%@,H@F)"8D(20E)",DGQ)%.E;X1Z0S#S1W7 MV6`D7>=3HHBT4?Q-5(KS_($52-VIVG\+:DBPQ^.P\H[";Z!5IM^P-_ M:7O+M29^M)`AQA0EU'4Z6K%:8FD[ZZ7J.ALMI.M<0:I\=N;3'&4'ERY3H,DB M$U:.,L^V=LY%HY6,)Z8HH2BE**,H5Y"JC9WW!FV\#,`A)N,)V($&N=[T7'/7 MKCJPH;!RIU:.36:6^W(W_=P[KE;JQ-++5!(;!$97"='`XPN#(\0IMCC`2$D42;0842S15*CJ.*)56HZ],(G?P ME4MD$,(.>(,0<>Z/;@.;(P\Q#-N2JR^?4%BYJWY,U]O-0DV#:#20XF.!)EM` M0E$Z=F1+U[9=/7>RT4*ZSA4_Z@RR0L`@G-<'F'GI(\"K:9_>XWB&`D&EM(HH MB@52='%?$Y32CAE%N>)+%<+.?X,07A8H0CC2UJFVX80VMW+YJO!<1S.(1@,I M/I9H3,R$HE0B[MGVW*VV1V2CA72=2V1(758YC,)_>?;P0D,9$(Z4M2G06$U$ M-D&Q1./\)P*YXQ"DTFKTE5&42]3[4F>6U1:C0%D!V:+DF*8H1RZR:UB;MJ.- M;B@Z>C`>K`P[,/>U6O0KV'8]5]NC8^%G-0:0"*3D-?=S_VF9],6?YBZ6*[() MBWCZIZGCP\J2<7Q^F0"\BE$2@".,F\RWT.9H-41D"XBN3 M'4=?N40T`7`)1P0ZN!F2MT_C?0FOMK[6MVFUU7=7JRV!M+<7_;YDM)+#$E$4 M4Y10E%*44<2N&]D>B[CP1#[)_/J07QY=RN:E#,OSN9WMZ]SK66'"UL!F@+;D&_]#FG]0AP.]I?,.K#[>7@U\Y>,=T,`A+3!*PT[@LT2G?2*TL'RG+5CU M/DM[VH+%[R?&EA0MJ;$EL%>(K=\8-?4X?Q"!J06G#"(PM>"P002F%IPYF'A3 M"PX6S*.I!94.8C.--*H;Q&9J00V#V$PM*&40FZD%%0UB,[6@;$%LII;09MEG M3#_;0=2F1$/EC=DVM41H8:4GG5/4V=!C:D&Y#3VF%E3=F&U3"RIM*#6UH,2& M'E-+L/9Q-4`C"[:0:5HVX=;'*S#M$-H+2#'U2+908FI(MSY>>:DKO#XBVK[' M?$A;_&!Q*U[*/XOFI;JVLW-YQ/:TZ%^!&_[;!O_2\&ULC%5=;YLP%'V? MM/]@^;T!0A)"%%*EJ[I5VJ1IVL>S`R98!8QLIVG__>[%A."$2'V)PO'U.??; MZ_NWJB2O7&DAZX0&$Y\27JTXWB+&LO5:4W]?V% M5S%14\NP4A_AD'DN4OXHTT/%:V-)%"^9`?]U(1I]8JO2C]!53+T4*WP>HAF%%OLVX3]%?PHQ[\)[J0QZ]*9-]%S2';4">LP$[* M%S1]SA""R][5[:>V`C\5R7C.#J7Y)8_?N-@7!LH]QRNI+$$)?DDEL`<@=/:6 MT"DHB,P4"0T7DWGDA\%T3LF.:_,D\"XEZ4$;6?VS1D&K;KE:'QZ989NUDD<" MA05KW3!LDV`UA>!3!+>()C2B!/@TH*^;,(K6WBN$D78V#]8&?GN;H+?P@+V7 M`']')!!%"8P3-1\L,.2;CO.%#A_!?(5^[SJ>`C!P*XR6/9&5LC:S@C7Z;%&']"`VHUH(-IJ]/GI$#>RCG(BZG!TR]#*, MXO%<0#<,_&S3'BR@`?O,HX%+WR&@(2W^C*0.8^RO_X\%$X;E+WUX!R.4/Q],3X+A= MY,?UO[6X4.AFU%68W5!PY]168+H<5@!;_C*(#G(E;HQ3@(-W#N)4V!:^\-R. M*.S=<^L,QMAI=C0:L+:.Q^>%T!Y?L..-J\PO+O)B-[;=EA57>_Z%EZ4FJ3S4 MT,Y8VA[M7XKM%!?:)3Y;;>T+XO4GL-@;MN<_F-J+6I.2Y\#I3R*8`MYK#QO1A]D@NI3E]@++7O_Z;_P```/__`P!02P,$%``& M``@````A`*9;@W&8`@``&ULC)5;;YLP%,??)^T[6'XOYM);-4;&TB:G MM6IXAE^YP7>[CQ^V)Z6?3,6Y14!H3(8K:]L-(8957%(3J)8W\*506E(+2UT2 MTVI.\VZ3K$DQBJ*`3C#XH=)6^LAVA>4POQFTJTYDR3[#TX M2?73L;UA2K:`.(A:V-<.BI%DFZ]EHS0]U)#W2W1+V9G=+:[P4C"MC"IL`#CB M`[W..24I`=)NFPO(P)4=:5YD>!]M[E-,=MNN/G\$/YG1.S*5.GW6(O\F&@[% MAC:Y!AR4>G+2K[DSP69RM?NQ:\`/C7)>T&-M?ZK3%R[*RD*W%VX+4S5X@B>2 MPAT!R)R^9#@&#R*W58:39;!8A4D4+S`Z<&,?A=N+$3L:J^1?+XHZ[Y[5Q?!` M+=UMM3HAZ"NH34O=*8DV,>3.G''OK!E>800\`];G7;)>;>\.8%\_SDEF>LT)%1N$DZ_4`\"Z\YG:D60R* M2<@@F0G96:%.$.B0\G59O.@=/J!G(Q_(M3U>!M#*UZ`8S+\7>S^`0``__\#`%!+`P04``8` M"````"$`EZ>$06`.```*10``&0```'AL+W=O>*9%;L[O7BBW'JK$MEZ1,9MY^ M?Y!H@L`/*TDN(OOK1@/LQJ$!4/[PVU\OSZ,_-_O#=O?Z\2PXOSP;;5[O=P_; MUZ\?S_[S>_ROV[/1X;A^?5@_[UXW'\_^WAS.?OOTSW]\^+[;_W%XVFR.(UAX M/7P\>SH>WZ*+B\/]T^9E?3C?O6U>(7G<[5_61_RZ_WIQ>-MOU@]MH9?GB_#R M\OKB9;U]/>LL1/N?L;%[?-S>;^:[^V\OF]=C9V2_>5X?T?[#T_;M(-9>[G_& MW,MZ_\>WMW_=[U[>8.++]GE[_+LU>C9ZN8^RKZ^[_?K+,Y[[KV"ROA?;[2]D M_F5[O]\==H_'/9YR!JQC=G%Y\^ MM`[Z[W;S_3#X>71XVGU/]MN'U`(A2^H=-Q&H-Z/ M'C:/ZV_/QW_OOJ>;[=>G(\)]I8K<[YY1$_X?O6Q5'\"CK_]J/[]O'XY/'\_& MX7EX>Q5<78=79Z,OF\,QWJK"9Z/[;X?C[N5_G5:@;7560FUEC'9J*]?G5S>7 MX^`7C$RT$7QJ(V%@C)RH'>ULG^':%!P^PXF2-[HD/G65D_/;JZO)]>T-C)XH MB''25HE/73"X/0\FEZW33I2[T^4"%='.4^%/MC7H0X4??JVU@<1'_?!+[0T0 MT:Y_#*+RLPV6N*#C2:T_Z=X`H>RJ-3$==*@3#@XDI.J'G_/P13-HT9`B4+JAS^/+YUN M/M5*IX+1J_3!(+(@$A-)B*1$,B(YD8)(2:0BLB2R(E(3:8;$"@86K6$P9))7 MN/6Y^&K:D7_6*TFQ.9$%D9A(0B0EDA')B11$2B(5D261%9&:2#,DEHNQ MN`]=W"ZPX]MSE3-V2SROL:J([?Z.3)")#0;!V)EN>J7>_4061&(B"9&42$8D M)U(0*8E41)9$5D1J(LV06.Y'CQVZ7WJXPK:+.X*PB/=F0V+95!O(0Q6:.0TX]IIAFC9[;CIM>QVJ(QIX.'6&U>!:46746%1D&!- MU4(,]SBMN.WMMVGF3+3L5MSU6G8K5#KAMB*\@C?>';EJF7*"I)$]=@,G99X9 M+7FB.:,%HYA1PBAEE#'*&16,2D85HR6C%:.:46,A.QXJIW#C\8.I5.WMW(!T MR`F(D][-=$%HF8#T!04M6"MFE#!*&66,-T0C$73!BEC#)&.:."4-AP2AF ME#!*&66,_S'=P9V#)(OS MV:!#X3`8'1HC/.N2X(+6G0@E',*&&4,LH8Y8P* M1B6CBM&2T8I1S:BQD.UT9X_<.YTWPF&')IBV!BN%NT/76N-)[^$YHP6C6"-\ M2&@2UDH998QRC?`AM@K6*AE5C)8:X4-LK5BK9M18R':ZLQ'NGM8:=EY5J$%JP5:S3(:1+62AEEC'*V5;!6R:ABM&1; M*]:J&346LIVN=MD^I^O=MYGEIF&'?C0;=5IZ-KK"OY#6_%Y%NOE"V[9Z?J,)\;;3$?&/9LD*G M=MZ^T+7\Q;;HV".,M2VP[O MX%#<&1P=&N:Q;6F\(6<2S3FCA2#S<#&C1)!)#E-&F2!C*V=4"#+M*AE5@HRM M):.5(-.NFE$CR./A=W;I++IM=$2\XUE MRY[7G+W^CZY*D$%12#MDK2@=NNZ^5M"^]JP+#M!"(RQKTM!8D$E[$XTFYD(E M991)06,K%V1L%1H-&E$RJJ2@L;449&RM-!JTJV;42,'6ENWY=[;78]Y>:V2M M*'2^/M-:$ZQ(9M:G4Q;1TI-W7SE*8B8JI+N?J"M$Z65TI6EUUX>WX;N+L!2I1,=4MN;J5:)VLKM9:-\,+ M6DH5&['5UFAW`K4?'^3?[WW=OPCAA?[Z*)KT/VFSZA,YAFNN#P31]&"T8QHX11RBACE#,J&)6, M*D9+1BM&-2/U#3GEPLX373"Z;[QU7]-YV>R_;F:;Y^?#Z'[W[15S6(#W*CY] MZ'GW7;OI5=2T`\GEUU'3AMGE01BI5^TP;Y%D#$F;0)%D`DG;)UW)^$:^ZN=( M,(E$JJ-R/9A+(M5?68+Y(U+=EB68,U"/3X+O&G[V/PV:[+$TQ>-[]?'POF?_ M/(D^(U+"Y3*:>25S2-1\R=:P,$9JVF0)UL=(S9XLP3(9)5X)LD?X MP.=1))%X4I\$B2*>U"=!OHCNYY,@;40G\TF0%Z(/^"132*9>"7)S>,=7!ODW MO..3Q)"HU,[GG3'ZCD^"=!M]QR?!EA1^\W5I[$SA-Y\$NT_XS2?!)A1^\TFP M%X7??!)L-N$WGV0*R=0KP88??O.5P:8>?O-)L+>'WWP2;/'A-Y\$>WCXS2?! M41?\UJ;1SM2%$R_XS2?!D1;\YI/@9`M^\TEPP`6_^20XP8+??))9>!NIXU=/ M#X%$'::R!(>GD3H:90F.0C'G^20XN41\_"VX0WQ\$IQ((CX^20R).@3C%N!\ M$O'Q27`&B?CX)+@JBA.O! M#1;ZCD^"BZQ(79MP&=QG1>JJA"6XM4)_\TEP8XPROE;CHAAE?!+<%R.F/@FN MC2-U&I76)\$L^DX9S(AXR9#+X%U* ME.D.._I%!G^@XFW]=5.M]U^WKX?1\^81N?UE^P+HOOM;%MTOQV['-?JR.^(O M4ZC-U^@)?W-D@V_-7ZJO(CWN=D?Y!55?]'_%Y-/_`0``__\#`%!+`P04``8` M"````"$`OT5UBJ4'``#V'P``&0```'AL+W=O4WX[']]]@>X.;[S]-Q]".OZJ(\WXZMJ^EXE)_WY6-Q?KX=__V7 M]VTU'M5-=G[,CN4YOQW_RNOQ][O??[MY*ZN7^I#GS0@1SO7M^-`T%V' M_)355^4E/\/R5%:GK,&_U?.DOE1Y]M@V.ATG]G2ZG)RRXCSF$9SJ,S'*IZ=B MG^_*_>LI/S<\2)4?LP;CKP_%I1;13OO/A#MEUQ&[_8>$/Q7[JJS+I^8*X29\H'3.Z\EZ@DAW-X\% M9L!D'U7YT^WXWG)2:S6>W-VT`OU3Y&_UX.]1?2C?_*IX3(IS#K6Q3FP%'LKR MA;F&CPRA\82T]MH5^*,:/>9/V>NQ^;-\"_+B^=!@N1>LR;X\HB?\')T*E@.8 M>O;S=FRCA^*Q.=R.9\NKQ?5T9MF+\>@AKQNO8&W'H_UKW92G?[F3U87B069= M$/SN@EB+J]5B,5^NKA'E@Y;SKB6\NI:V+;O_H.&R:XC?7^SRNFN)5/]:E^NN M(7Y_L4L+Z]>J;$''KW5J86%X4[E"GQ77$NO"_OA4MQ.>'6U6[;(FN[NIRK<1 MMBK&75\RMO$MAT5C^33#K/@*]1F&1-\S]WOF?SN&U/"K07_N#CP=^#H(=!#J(-)!K(-$!^D`3"!9KQL6C>B&??BN M;LR?Z29FO!%@(*0JXU9XB"8[';@Z\'3@ZR#00:B#2`>Q#A(=I`.@B(1\^I)( MS!_IIR27K:JRX3YLO_49N%!=MKU+KQPA+B$>(3XA`2$A(1$A,2$)(>F0*!KB M(/V2ALP?FQE+TNMCKV>J0IO.Z2,1>Y=>1$)<0CQ"?$("0D)"(D)B0A)"TB%1 M1,3&'(HH#C.&6ZW$'#>`/;B"O[O70&LA:H:)W-(3TA`2$A( M1$A,2$)(.B2*:DB0H6HBH1A6I>%$DV:I)53OU$M#B$N(1XA/2$!(2$A$2$Q( M0D@Z)(HT[$EC4%$(:1A6I>$$U:B8]9:0'2$N(1XA/B$!(2$A$2$Q(0DAZ9`H M.J":-.G`L*I#1V1ML"5D1XA+B$>(3TA`2$A(1$A,2$)(.B2*#JQ&'@K1GC"H M=-D#1',H]B^;$J>&)2M,YJ\JU(8`&J1*AUBI*L^5HP=8"=?W4TLJ&7=<&#B*,2\-XTJL+HY5POG0080(:)I1>YM%$TD&$B6F8 M1'J91Y-*!X11569U[4!E<92QXDK/T`X-U>3(QD$I,]32;L5=%PM>8A(N11Y% M/D5!AP9+&DJO#P8122\QB)BBA*)40:IVK*`U:=<5NL-,Y&@!O:10ZVMU%VW9 MPRE$G\W:Y+26JZGFL1,>\X&472.)/.'%X]A3V]9N8U]XR$8!1:%`[XXG$AXR M3DQ1(M"[XTF%1QM'%9D5O":1NT)X*#)'$%DL\=;B"(H*M!-(#MFER!-(-O0% MD@T#BD*!9,-((-DPIB@12#9,!3*HPFI=DRJ\!D;.BOENL%584BV0)H/46^FI MQ[UFN.*DUUSSVG6Q[&4?WJ7(Z]!LV:;QREJ3PY%W-@@3T#"A"//AD"+:,*8H M$;'>&U*JM%$3D!7()JEYX:Q(S1&D%NIO+8Z@JT"[#@UF[U+DB892:I]Z!12% MHJ'L,:)>,46):"A[3!4O5156&YM4X36SH@I'VMFGE3%;BWMU9Y^]FI':5#BT852!6=%M M$I@7XXK`'"GG'D?*N=L9Y]5BCJ.FQ_U7BOOV&-3XAGV] M8+M1Y[:#EWP&/G/PYHKR^[ESCX%2PV;NX"V-@2\3!;<, M=#-9<-E`-Y,%MPQT,UE02*$?4]:@GD(_)@O**O1CLJ"<0C\F"ZH!K(]I!%M8 MV&U%=<.MC_4Q67#Y8WU,%M0`6!^3Q8>%W62TGZUEPV+:@BCQ,1^398.9;HPS M13&-^9@T0!&-^9@L+BRL&*1C0TF-^9@L**4Q:I,%%37RS61!88U\,UDV*P=O M6VC_6VN*7MK/IMJ.PP,ZM#%9MI:%>9J..CR^(IK)@B=2Y*')@H=,]--:)OT0 M\#'VDCWG:58]%^=Z=,R?%?]NR_]IR@M[_3%Z*!M\AFW_/.#[>H[/ M8E/V&O:I+!OQ#R8_Z;_8W_T'``#__P,`4$L#!!0`!@`(````(0!#J))Q[",` M`%V_```9````>&PO=V]R:W-H965TX%`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`+4_?;?I]]_[C\]?W[_=K7]9;W:7-\L5YNW;WZ_>WHN[DWBMV\^ M_OWT_/#U_UNKI?-EO:R<%_PZ+U?;7S;7BZN?<7+EG.#7.=E=S'3M[/$K1;^< M`/4YU16_+L'UQ0RVSAZ_2JTNA`-N3QGA]U4UP;`[V>-7,EKZ\%W("/4])<3O MJVJ$+F<3F#\DJZ"E+F2U//<4_/&J6BVE5Y@_)+.KH'-=RDTZP]+WALN-M93N M8/Z0W%Y9->D8&"&2]')/6DK7,'](9J]KLJ5T#O.'2ZK6[)T=J:<1?KQ]OOWP MZ^/#/V]PW$3\G[[?FJ/PA3,*1@ M3,&4@CD`[Q#V<^S1DW\J]L;>Q%ZB=A`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`JA MK7;<(&9)%C2(S##-?#X-ND5)T+?I*#A;282/SE<4=+(JV*ID5#&J&36,6D8= MHY[1P&AD-#&:(Q0'W2R^@J"_8D)D=L;2]K`H:8_KM#W.5KX]".7.?=!$!:.2 M4<6H9M0P:AEUC'I&`Z.1T<1HCE#<'F;]%;3'>1"X==GJ?+0XF/U&M$,2])LT MZ&H9#8Q&1A.C.4)QA,V"3(NP M7:A%$7;([UUF9K/;''$\.C+*&16,2D85HYI1PZAEU#'J&0V,1D83HSE"<83- MHBN(L-N=_^4:'?;Y\_W'OPX/6*TN_>:\7:1%D7DR5VY0W$ M<\VH8<^MM]++W'D#\=PS&MCSZ*WT,D_>0#S/$8I;S"SE@A8[GXKM$B]J&8?" MEK%HA:'A=XF6R;K@N#Q;28%R1@6CDE'%J&;4.!0T=>NM+A2U\U92U)[1P&AD M-#&:(Q2UPRI9.$L[G'B\.G9H@RF]#_HZW9IS5E>1U3*9K1[%ZLH-K=TN667G M8K$^'X0*1J6@B[E58F5S6^YVFZ0\M5CXW!I&K:"+N75BY7);K)>+9-[8BXG/ M;F`T"KJ8W216-KN;Q610=SQSR8SU?.>2K6C`J!?GC1B7( M^ZH%>5\-HU:0]]4)\KYZ0=[7P&@4Y'U-@KRO69`2X1=6\V9C-SV>6;3!J`CF M"\EY/G,)K[:GFW0R,1DD8UR79DYV\E;B?'7JQ+O%Q\X6-!`2: M&M4S"R!S.X`EJJ^KZZ3^>;1 M6TF@U(.^^8=0*LH?ZY6*U2W8_.F\AKGM!WO7`:!1D M7:_7Z\3SY`W$\RSHY#EN-[,5$+3;CS:`5G;K(&I/BZ(3CD-^2G9T"3<>Y8)\ M_RT5\3HUG0R5<<>;.( M#R)_7J+8Q7T488NNS*;<^:;8M-VSE;7:(/;>BA>HUFJ[.)V6UIM5LM>5.S=; M?R(M',+HEQY5OBJS2GS9S%;;17*2K,7`9]9P9NVK,NO$E\MLN4B7&+U8^-P& MSFU\56Z3^+*Y+9?818NOH=E7Q;YJ2>A]-8*\KY9]=>RKEX3>UR#(^QK9 MU\2^9DEX\A5'_H5]@2O>%W`H/DUMDM&2.:LUTE\8=&)EC]FKS6:9#(1<+'Q[ M%@Z%QT*QNIA;)58NM]5FFW3-6BQ\;@WGUHK5Q=PZL7*GNM5FF0:I%Q.?W<#9 MC6)U,;M)K&QV.PR[9"XZB\4IM[CUS49$<,C]X;@S]LFXLR@\V9G%,ZS6_JAR M%.1/8[D@WYD+AZ(&)E^5)/2^:D'>5\.^6K'RY>H$>5^](.]K8%^C6'E?DR#O M:Q9T\A5'/MFXH,C_U\-W!!KG)/L0"+8:*/(6Q;>O;I*>G;F$L)+#VY%1SJA@ M5#*J&-6,&D8MHXY1SVA@-#*:&,T1BAO#+/2#87`.NMT`"&<>Z)NGOAW-*3;) MB,N\E0_Z.:&@G*T*1B6CBE'-J&'4,NH8]8P&1B.CB=$H9#8Q&1A.C.4)Q M>R1;`J]I#]XMP)Z`,CZ2DWOFK60P'!GEC`I&):.*45L53`J&56,:D8-HY91QZAG M-#`:&4V,Y@C%[6&6\-I)PB[MHY.$14G0DSV\S.SDF&F2OW/UR"AG5#`J&56, M:D8-HY91QZAG-#`:&4V,Y@C%03>+!=VB9#J4[J)=G:VD6Q\9Y8P* M1B6CBE'-J&'4,NH8]8P&1B.CB=$:MS M>S#*&16,2D85HYI1PZAEU#'J&0V,1D83HSE"<7M@`1@.@M.9X`>WV)OU=S)5 MH9S0P&AE- MC.8(Q1%^81F\YF6P(+_7GS$Z,LH9%8Q*1A6CFE'#J&74,>H9#8Q&1A.C.4)Q MA+4U[W+SXMW%:U[P"@K[MK4RF[S^&'.5'-B/+B&L9%#DC`I&):.*4VCK8$OM0\O@-<.A>UCT:4<.>6V_UPMW%WD`\]XP&]CQZ*[W,DS<0SW.$XA9+ M5LGGLP(OA+9.E4R\6/K>!T2CH8FZ36+G<5M?7R9;V+!:GW.*F?V&-ON8UND/A MQ2*'T,[28X^"_!U'N2!?UX)1*$7.5@6C MDE'%J&;4,&H9=8QZ1@.CD='$:(Y0W"`XO(4C1*8!YB23;(,X%.\3;M,K%-[* M!]WZ"JZDYFQ5,"H958QJ1@VCEE''J&N(31 M`>N/^-69M-$ M27NDM_QY*PG^D5'.J&!4,JH8U8P:1BVCCE'/:&`T,IH8S1&*V@.W^T<'+%DP MG'B\;'8HFKLNTS=P9][J''1&.:."4RK<'KYK9JF!4,JH8U8P:1BVCCE'/:&`T,IH8 MS1&*V^.%53,>=:&@6Q1>4G56`3HRRAD5C$I&%:.:4<.H9=0QZAD-C$9&$Z,Y M0G&$7U@B;WF)+,A?9<@8'1GEC`I&):.*4OAT8KUPR6[+ZV1!P84AAWYP2=5;R3$F9U0P*AE5C&I&C4/AA2%O%6RMT"55 M;R5%[1D-C$9&$Z,Y0G'[:$OG2^W#R^:M0V'[6(0-0?WRY-&E@8'4-V=4L.?2 M6^F7)RMO()YK1@U[;KV57N;.&XCGGM'`GD=OI9=Y\@;B>8Y0W&+)VOH\->(% M]-:AL&4L^L$E59V0 MK*G/[<#KYJU%9JO6;Z]>IQ<2G-4/+JF*E;T4N%MLD@W#7`S\-:^"42DH*E+Z M\&TE5C:SS6*7K"UK,?"9-8Q:01+'QN`Z-1T,7<)K%R MEU37FYMDG3:+!5_PVYJU5^=(.^K%^1]#8Q&0=[7),C[F@4I$4[6X^<( M\Z)[:Y'9D@\&5WK!R%F9NZH#J^0*Q]%;26OEXA[S$I\P?0=)X:S")\Z]KR#A M=3):*V\E.=:ORK'A'%OQY=YZLETDH[7S!I)9SVX&1J,DC*.7#,_)6XG[V2&S M=:]&+SJBFFM^VK`Z\7C1[Q`:7;+*'$(+"SHRRB6A[[Z%0V';<<**4$`Z-1$OHZ3HQFAQ!T1"*.<++"EV%E-D^2O46'HG/6.AU5SL@\ M(.*;]SK9H3]Z*VF97%!TC*91)5:^L4I!W.6XG[7M#%R@QBY0LQ"K*562^N-DF`)V\ANK8]0[ M%)1K8%^C)/3EFAC-@OAQ\>L7]A%./(FPW5J(3UDBYE5X@MS65^D=-)4.ZNXX.G`;K@0K9HP MK7$GA7!O,;G:WB0'FUXL?)4'SFU\56Z3^(JKG&QESJJOH,KQ$?@G]T.N>3_$ MH>C<9ZVPS)>A=G166$<*R@7Y<54X%/4&\E5)0G\/0BW(Y]BPKY:M.D&^7+T@ M7ZZ!?8UBY7.KI%9G(>S(Z2%7)V?;;R02>4LU7!J&14 M,:H9-8Q:1AVCGM'`:&0T,9HC%`7]YH5=@!./>[I#24]/9H29MSH'G5'.J&!4 M,JH8U8P:1BVCCE'/:&`T,IH8S1&*@QYN#.S.K[6ZX7T!AX++RAFC(Z.<4<&H M9%0QJB,45R1<`P<5X:7NC4-^S9BL9&#FC0I"?G9>"+KJOO)6XKR,45S=<%^&0^!GE MOG`9\H:710Y%87!+&1,^K(^7FW5R0#ZZ1-BFE#+FC`IV77HKZWIUG7)&16,2D85HSI"<=W"J7U0-YZ^ MWU@4[3G2[8S.Z`>7R<3*;JUMEHM-TOMSL?#KR8)1*0@'"S^2TFV)2JQL;MO= M+ET#UF+!Z](;,]652480'CL#C@:Z1>'FW"DQWCKMUT!'07XG+A<45M7Z"C?G MQ,K[J@1Y7[4@I2+A%#6H",]0;RR*]L#H/@&%`XJP"5DM"4\5\?MNFSE)77Q7$=>8E[MYF_*RBE$=)8PJL@OG7;[Y3CB>=CD4#]-T?>&,\%9'$^3E M57I\/'H#J7LN*.BGC$I!SO/U*IGP5=Y`/->"N-?N])G/"2?5MI.A.;C4#S\DC-CYHS<\%MM%G0Y\>A- MI/:Y0V%7953ZA*9O:+XK;R*^Z\A1W'7UN=*.YTH.A6/0H7`,,LH=BBI&\ZZ2 M$U:,ZLA77)%X%B3KS1W/=AR*QV`R$#)GY,;@^B:]?>/H#23*N:"PL]KLH\[J MD!V#[+D2-[XWUX*4KJO/?G8\^W$H&H/6*AJ#A'*7,*A#P:@4Y$M=,:H%*171 MISH[GNHX%(_!9(J2.2-)%>&,F:T%*MPWG,&&]>1*S M%^F'5ZK`0KS7PI31N%R$$YHH`G;.$4Y)K3%N3_/Q1GW=W"28E"H,-;1V<0V) MH8;D#W4BACJ%::-QB>_1!)/LJ$X\N['&R0ML=NDU.;&2L;E9K!:)#=K5>@]Z M-FKMF.^T:%=BJ/4YK3UVKZ[3:^6(PMDF:-G05Q*%<)H318$G.LN%9>&94EA0 M']31V@4,=70LJB,QU)'2HD[$T+)AVJ1.X8PGJA//>?"%%'2#4V_UB_%=>C5) MK-Q9\R9=6*+*;O+B5TJHLF5Q9R:&*KNT`3A;!(T:>DH"$,Y]H@#P M[`>[&!(`\8WAZB8[OC:H(3'4T+*XAL100Y?6#W_4B1@:-4R;U"FSX#0L&YRXP84MGFVR3(&U3[;2.A1 M;[PELQ#_"$/I*PF#F+;+E$W5O.Z&)F]:R^`SK)CY^ MB*&.Q%!'R^(Z$D,=*2V:EACJ%*:-Z[1,YDVON/]B>4J33*DO.3)+" M3")^5%BNL$)AI<(JA=4*:Q36*JQ36*^P06&CPB:%S3&S+?3NZ?/=W?/Q]OGV MPZ]?[Q[_O,ONOGQY>O/QX>]O&%=X[QP67&?^YO'NC_=O#]?7>W,O`6)+R@V4 M4]1)V4$YG412Y6:Q-Y<.%6\H[_Y4:$7;("?]0;E/5T-(V4(YC;%46:_VYE7&2CX;E``O%M,4E,`^KY9ZV\";G6>1 M<@7E-+G4PMK6,G<[/&/YM.<2?>GTPJG,V?+_>GTPAJ* MN#7EU.IFIG6FG)J&(FY-.34-1=R:[.AQ6D**(6J8,MN;_:R M.`TVYO9F2XN5PPY#!]N5K&!K&&73E!R*V2[E-`640E6P'XRR:6FP[8NR:G6<&%]KVY1LT*[KB!HIUI,L1-4W"+ M&4J@><-S2'OS0`I[P[-'>_-<"BMXWFAO'D]A!8\=[5B%%3QB MM#?/K+!R@')0%3S0M<]4!0]Q[5$DJI*GCB M$3'0YKQX\!$UU10\V8B::@J>9D1/U!0\U(C^IBEX/'W/-<5+$/;F(7Q6\.*#O7D6GQ6\\`!+ M$TTYH`0'M009%/.8-7O#@_-H'TW!P_)H'TTIH9@'K=D;'HI'^V@*WE&Q-^\\ MT-)<[\VK#UC!.RKVY@T(K.!5%7OS(@16\'J*O7D?`BMX+<7>O!:!E0.4@ZID M4,R+(#C-$L8.X M:0K>D8.::@K><8.^HRG9%F]7804?2MB;%_6S@N\E[,W[^EG! M-Q+VYK7]K.#;"%BB:\IABVT`O!V,TV1;S#;LXY3)[D0+Q;Q/B=,<-F;)K\7@ ML$%-\796+0W&'%X3R@H^9[$WGT=@!=^QV)NO)+""SUGLS<<26,%7+?;FFPFL MX$L6>_/I!%;P!8N]^8("*PF@=*K20^E5Y0#EH"H9E$Q5CE".JI)#R56E@%*H2@FE5)5FA3G% M2CO3ME`Z5>FA]*HR0!E4980RJ508H@ZJ,4"95F:',JC*LL-Y>:>?Z$4`Y:`J&91,58Y0CJJ20\E5I8!2J$H)I525:;5`/]#V M4&8HLZID*^Q!KK0S4PFE5I462J\J(Y1951J4H%%+T$)I5:6#TJE*#Z57E0'* MH"HCE%%5LB7.,DMM9M="F57E`&\'W1N43%6.4(ZJDD/)5:6`4JA*":54E0I* MI2HUE%I5#DLRK,)-Y2+;$<12WG/#_KPZ_?;/^_ZV\<_[[\]O?ER]P=N35B/^G>9;3_N?YX3ON M%WG[YO>'Y^>'KZ<_/]_=?KI[-`:XG^R/AX=G^0^J^.Z?A\>_3K<_?/@?`0`` M`/__`P!02P,$%``&``@````A`-Z"$)K0`@``40@``!@```!X;"]W;W)KW.%:0K6$F[ M389^_WJZFR)/2-R5N&$=R=`;$>A^^?G38L_X5M2$2`\8.I&A6LI^'@2BJ$F+ MA<]ZTD&F8KS%$A[Y)A`])[C4B]HFB,,P#5I,.V08YOPC'*RJ:$$>6;%K22<- M"2<-EN!?U+071[:V^`A=B_EVU]\5K.V!8DT;*M\T*?+:8OZ\Z1C'ZP;J?HU& MN#ARZX<+^I86G`E621_H`F/TLN99,`N`:;DH*52@VNYQ4F7H(9JOHA`%RX5N MT!]*]N+LNR=JMO_":?F-=@2Z#7-2$U@SME70YU*%8'%PL?I)3^`']TI2X5TC M?[+]5T(WM81QC]62@C6@!'^]EJH]`*7C5_VYIZ6L,Y2D_G@2)E$\1MZ:"/E$ MU5KD%3LA6?O7@*(#E2&)#R0)V#SD8S^>CJ-Q^G^6P#C2E3QBB9<+SO8>;`_0 M%#U6FRV:`[,J(0FAE85*/JBLQD!80/1E&471(GB!IA0'3'Z)B6W$ZA*1CD^0 M`(R)K"[XG',@(G^E!+=-BQ$COUY@?0;2\VZ(H90"@Z$T)_`WN;F2C`/DO7Z)%TS"2>\_EK#U4W@F`U]`%>,R>.# MNG1._PPL_P$``/__`P!02P,$%``&``@````A``?R0]N["@``5S8``!@```!X M;"]W;W)K[D>N_/#DMUYRT5[/G3/Q_/KP_*/WXM5O%Q<;_OS\_Z].['Y=OM]K%;KZ^'M_:TO]YU'^T96EZZRVE_@S\O MK^OKQZ7=/_=.I_>U[WF;]6E_/"]%A-WE5V)T+R_'0_O4';Z?VO--!+FT[_L; MC/_Z=ORXJFBGPZ^$.^TOW[Y_K`[=Z0-"?#V^'V]_]D&7B]-A5[^>N\O^ZSM< M]T\6[@\J=O^'$_YT/%RZ:_=RNX-P:S%0]YJ3=;*&2(_WST>X`B[[XM*^/"R_ ML%T31,OUXWTOT/^.[>?5^/_B^M9]EI?C\[^.YQ;4AGGB,_"UZ[YQM'[F)G!> M.]Y%/P/_N2R>VY?]]_?;?[O/JCV^OMU@NOO^#MT[]`3_+DY'G@-PZ?N?_>?G M\?GV]K`,-G?1U@N8'RT77]OKK3ARW^7B\/UZZT[_%Q#CO>L@O@P"GS((\X8@ M,XZ!=(1/Z>C_DE\H_>!3C9K=^7'$H@T?]DR/T-I?+WRJH8:_YKF1GO"IQ@K= MSW2UE0[PJ0;Y]Z6%&[(?+WRJ\29W+/2HZTRD'WRJT<:_)"V#7!,9P9/N[Z;$ M6J17GY9/^]O^\?[2?2[@7H<$NG[L^F<_NUS\@YP^2204#\AI,8#.98GBZ\L!/RF`ZA;93/L9$-E.,,1N;*<>8 MK8B\+3TO!E+[^M(O8JI8+;]*L!E MS;#A"1MR;"BPH<2&"AMJ;&@,@W6)L*"8EZBRBIL?EN`T9$R`LTHP<9]SB1^' M6S2KF0!"?>U/ILA"R, M`Y2OM8FPD&T"%*,Q@0`V@.&R+65AS1M3EINQLN@Z4\'`OUI]-,A,$?IN589) MEUP0FWZZ?"\)O-#SAKSOL[4@HY0D49%$31+-'&&)#+N3*7*_6AIW*&^&C=H0 MDN'I3`4#/4Z*K0@MMC),NN0D49!$21(52=0DT*Y:)Z^]((E2$:,]5*IULH>:))HYPE*7 M5VOX4&4L$[S95I<%*#U3P8CE8DT1!$B5)5(*8'GE- MAFCF"$MH.$6;0JOC!#?;`H=H1TL%(K>G31*BTT8FV@UY38>Q"3DPIFYOQ]L#L M&;MG.#I*22,5C=0TTLPBMMJ\0!E36Q0NMMJH-$R9@(0J+`X\'YVH,TF88ML^ M?HRKC5S[\`UL@[;;`O7IQQ[:CFL8':&O/"94QC;KXDCL6@W)9[WR&5$H*9JFX+H MM*1#5#12CR`)2H=FA!GV,%ME7K,8*N.J#Y[?.FJ'Z,9))2347C%_@V[?3`*F MW'.U4I^PN7::49R,4M)1*AJI)3)YA8T%6`K8#9^L.$F2L!CIG%L$ MI/R02'*S-$<21BP)0[3&EC*$3/D(GR8JJXM5$/DLWJ#;IK88EFPV^.#46$00 M1U./UQFO?(PIT+J+BLC6'=U7:>_\L)S9VS*-#"D_5VO)%5P@*N6W<#`<27DR M3JD['^9\V,[ZKBH:J6FDF46LE/=1_8CWS;X=UY$XWR4TI[M&M.[:,BE&3B,% MC90T4M%(32/-+&*KCNI(1W6WGG2>G/JJ5N0'5'1#9KIQD'L&SS4^.1<%C90: M&1E1I1LGNZAII)E%;(EAJ3`7$D=BWFX?O_$W1ZDO&+DT.AJKUD%C9>$"K!"? MZVB3"A0T4FIDK(]*MT[V4=-(,XO8*J,"TE%YK)#$R[9O5H6K,$X"_.PYDXAQ M\-:6R2O-::2@D9)&*HF(_6'T`FHZ2C.+V*KS&F]DD_2YW@D9)&*AJI::2916RU>94W MEMFB^H/UU5`;%6>IKXK&`4+"91H9U":=I M:*36")_Q`#]^:73SV$AMF8FB,7"+1GC7U5Z34PD)N>%MN`0=QC,)F&JKRG%L MA&(ET4Z32$$C)8U4-%)+9/(*&PNP%+#EYL4<7D28]3`P$/6>O8Z@'2F5D'@G MDL%C9R]"2TTFD?F'@78<>&@>XU-M;B%^P-#!OK#:(W\;!L[^:2$K]VF@W1YZ MC#D/)6N+@27,^8JNL8@@V1@O?MES@,I+O;*,E)7XSDH#`9UGY+S6F]OAM6;QRP7^SG(:.*;, M-3VYIMPU%:ZI=$V5:ZI=4V.9[(M#E9PZ%4R^1@^_,<'E-'Y$GTJ&?^4^5"8, MK;K90`V))H*#HS+E+E6XIM(U5:ZI=DW\)S/])/8]"F7$3V#$;PU.[>6US=KW M]^OBT'T_P]7`>O1XK\WBMSS]?%>_L"NGAW6Y#R(GX8)/ZX=1_]6_]?NQO\SJ?_[QO\@*N% M.P5^S+-')\W M^^'8WR__ZL?ESP__^.GN8,_,>WW?L8LAVV?R?=87/Z]O&^V@Z'=TCQM-OOSG^YI,O%87O[ MR^MQ.&V>]G#?/U2^V8;<[I=)^L-N>QK&X>5\`^G62'1ZS\VZ64.FA[OG'=R! ME7UQZE_NEU_4[6.AENN'.R?0G[O^`_I\5S_[+YV)]_&S[_U>]>W\Y0[L*&;(<]7`G^71QV M=@W`K6]^N)^?N^?SV_W2E#=%E1FEB^7BJ1_/7W!G2))?#3`^`'[Z@/JF4EEC*KCHE0M!5L<6?H8+$;;3P#7>K5/I<7/>/-R= MAL\%+#VXG_%]8Q>RNH5D7AY_Z2@8U&UKT5\LW`6!%".,?G]0>7.W_@X5V'I, MBYAJN8@877)(%R"V##;O(QE8`[-(#X24]$P6V=A9SJ8H^)5:A#`R'-$%1.0R MS:JK&,/80=4(NZ"1'8750^Y?%5E,X.ZW10P('C42Q+N`B+3"P%P(8P599UC9 MT?LEW%N\8BXNV2*D=F5=%9G),L5I=XC(W?9Q=:,ANFSR%,`HP6(FE-PJRXM8 M1CLK!4N)4##$P.4B?<&^"X@H6!B8"V'LRBD[LLCL+!=.%9KKTB*F=,J9K#(Y MG^]PGNA&`W11JSH&,&:P;HEN88'94<'(I`2H%V*0D02H[ROD8 M:5<(03JYTDV6+H!*(8`0"@/6_A*8L5'0J(A,@8X;YGQ4(19+ZT'(:*5,IDH! MZ3R$<&)!IJB*=)N*E"$!(K2VEJG9^GK#`B=QOCDE36 M;Q,C9PYD12FT8\Y,K)G6@Y`9+/=";(?.`R@US(LA59V1LG/!K.\F>E$PM&-. M*[4)W(0*0;&2C=@*G0=06L'F[>):F2Q5GK.RQIM8341#7X96=8H2$S5M+D%37M5:&5`'0>0%G1$*-S=6E76O--K";E1&]F[,12:A7U M[Q581C41#1&4'HO1T,#3ON&J60]._&(MT9HIKUJ(TBIJWZN\S+*T7M!?/8+R MHC'*7/0R:\0SK-"?*2M%4OBMB2!<8D;7E>#=J>#R:>G3$*6S2Z="S;U?%M-- MBQY0)F]$>AXDC1,%BY.1FA_!NX''AU1Z5D8];_YN6#*2>]*#_)ZLE6#<^7E2 M11:QTM2`."NHU$P9M1V6K$256@]"5BOHI7FZ=2\6IJ&\<,3'&*VSM)O% M:7U-"HE6#=F2R98IE2\D@OS%ZBS7FA$B833SJ#*U%S\WJ`V;Q2<[<4SBD8` MY4=#5*/3=N.KSUKU%?G0R;E\J35[=LSNZT8G);RS(("RHR$K#4^":=DR?G"^ MI?S"QG7#PO+(\P[R\J"P.VB%D)<'$%YQQ!XJFTO=P?#N($OJIB4YL>1;#T)R ME28/D9Y;>""(EL(B5KG1376AJ,;Z=BIJ%,T.BS\?R&[>NMC[Y;QQ>6J8A\H6 M1I+!7ZJG=>Q$;2(=&CJD(YU"--#6A#[`'RL]N3"9=,,15/IRRS?6L:\P0T-G MS(C^[N*MRQ&L3ENG$]P[CZ#:86)/K\H;\K3(MP)O%!/I9AI&)79B:Q"$IR4X M!0BCZ>)\4H]&I+OAS'B7B.MMICN0?>XEHT:_4G#L%3NE,XB@DK$8G6?I-CBO MZ[W!S/2&2G8O#_(F4L*CB>P-'D'YL=Y0PKDDVC7G9SWZRI)#"^=+3CA_:YC/ ME_!`)^RY\PC*C\=4IDQ9.4%KTU<(HHMS@JD6OL#4ZG713,J+\Y1>&'%/]HH< MH!FYG+<&N1_)<@-TSG`80="UF9.B=_P^3\KG>)'`V>B5>G M#8;B>1#RR^LFGW1^C[!_U8J6*<\/CSQ-51B=+L0Y`YTK!<_MM-"T%@5M/0@Y M%S4<5P2B\XC_PQFOY6_=E'6=MB;G;/W]\B+-T?[AWZB/(H\)7F<$7>MZ/@]= M"=>".$7>6X)!YC,]I4X]W5.C_:&LR%_?W'SGDU!>%R,XJ9E^0MXUP'^GM9;] MQ(.P2*9IX'0?K<[3"_TC=A0?(Y_8.3?K\**FE!LV`+YWTHG#"T>[Q)QP.$^% M"R/\8,&9S?24,KUHRV=Z"EFXGAGM#W!*2)O1:X;SE%D8N<9LIIM0S6:Z29U\ MWS-CG:$J\UI4O,L10;FQF+)JFDL;U?IZ*FK1P(M-PSO3/&]M7V'UTZ'NNG0(QOB5YKI".GU]?0= M,KSNEUM06GOK,?;/]LG?2,M$=1(JRL.&D"9^&X!OO0_]Z;7O^OU^7&R'CR/D MMALVCN(W"2U\D^#TD>/Z%MX6PZ7$^)L(Y3\-7!^^:U M__?F]+H[CHM]_P(TLALKV0D_4,!?SL.[>[G]-)SA>P/WWS?XD*2'FF4W`'X9 MAG/X!4BMXZ['0,``,8(```8 M````>&PO=V]R:W-H965T&ULC%9;;YLP&'V?M/]@^;T!DRM1 M2)6NZE9IDZ9IEV<'3+`*&-E.T_[[?;:!8))(?8G"E\,YY[O9V=R_525Z95)Q M42>83$*,6)V*C->'!/_Y_72WPDAI6F>T%#5+\#M3^'[[^=/F).2+*AC3"!AJ ME>!"ZV8=!"HM6$751#2LAE]R(2NJX5$>`M5(1C/[4E4&41@N@HKR&CN&M?P( MA\ASGK)'D1XK5FM'(EE)-?A7!6]4QU:E'Z&KJ'PY-G>IJ!J@V/.2ZW=+BE&5 MKI\/M9!T7T+>;V1&TX[;/ES05SR50HE<3X`N<$8O?>3 M^3*I7/1*%40SMQV!,X"8>9#3#S'N%9!L@5RR8*!02C MYY0ORN)`']"`9@XT;$NBQ01ZW%7(`*Q<7Z(VXB4Y,."EL/#H.TX3]3G;R-`P MB>T@4,?U\2`_#IVXA//[UN M/[Y"/R,]N?G9)V\C4**!]]EU<@(GPH7Y93QLJ(7X"EW(E[@QE<2LW*@^_LA8 MQ$BAW5._P8L;2?B[:H=RNIIZ2;1[&ITWUVR$J9R?Q/*&A%G"41)S,IPAXM84 M6/O![T)^FU6!UPJ5+`?.T/A&TMU#[D&+!KS#%2,T7"OV:P'_%QA<""'L(,J%T-V# MN>GZ?R#;_P```/__`P!02P,$%``&``@````A``RIZKPU#0``8#T``!@```!X M;"]W;W)KM_OUZ>[PL7V'Y/EPW*_/^/?X M4CA]'+?KI[C1_JU0*A9KA?UZ]YY/+(3'6VPX^3F)MO[G%W'Y]_/'SXX_-8?\!$]]W;[OS/['1?&Z_"7LO[X?C^OL; M^OUW4%EOQ';\#YG?[S;'P^GP?+Z#N4)RH=SGA\)#`9:^?GG:H0?FMN>.V^?' M_+<@7)4J^<+7+_$-^M]N^^N4^9X[O1Y^=8Z[I^'N?8N[C3B9"'P_''X8U=Z3 M06AT?5[_?#O/#[^ZV]W+ZQGAKIHFF\,;/.%O;K\S.8"NK_^. M/W_MGLZOC_E2[>X^*#Z4[ZOYW/?MZ1SM3-M\;O/S=#[L_Y\H!:FIQ$@I-8+/ MU$BY=E>]+Y:#$HQ<:5A.&^(S;5B_JU>KE5K=>+_2L)(VQ*=<=N6N5*\&U=IO M7,)NW&%\IBWOKWJJI?KX_%S?8#9VA,_/]0UC,&Z(3^G;C7?E(6V)SYOZ%B"O MDNB;!$LB>V/D@DOBX,OG^A=(NI@OG^QA(!ECOMS61TF50'/EUCY*KF#DB+,; M(Q%(VI@OTL<;,S20S#%?;NNCI$R@.7-K'R5G`DV:&_M8DNPQ7Z2/M[:5]"EI M^J"W/.(+R7P5SW.M]7G]]C5'_ M9O0?\_"!V>P$^M?74C'X4O@+D^@FU6FPCJ/1%`TSD1JS+1>T71"YH.."K@MZ M+NB[8.""H0M&+AB[8.*"J0MF+IB[8.&"I0M6&5!`Z"[QP]C_5/R,OHF?W/F& M@$Q`[7`V14.:M%S0=D'D@HX+NB[HN:#O@H$+ABX8N6#L@HD+IBZ8N6#N@H4+ MEBY898`5+$RVGPJ6T7_,XV]FL)7LZ#02'?,4202)M(A&1#I$N MD1Z1/I$!D2&1$9$QD0F1*9$9D3F1!9$ED5666#'%X_!3,37ZF&R1(I=X\0R: M*ET+ZD7E$E0B;2(1D0Z1+I$>D3Z1`9$AD1&1,9$)D2F1&9$YD061)9%5EEA! MQ4(E&U1Y^!D2,AE:O/P^9%29JUB+2)1$0Z1+I$>D3Z1`9$AD1&1,9$ M)D2F1&9$YD061)9$5EEBA0H+PVRHX@5,J7H'_605Q$L8T\*.8D(J6/5EQF39 MF44O2ID3Z1`9$AD1&1,9$ M)D2F1&9$YD061)9$5EEBA1$C*!M&F3<-MD.5$"=4[KKEHG0)%9$VD8A(ATB7 M2(](G\B`R)#(B,B8R(3(E,B,R)S(@LB2R"I+K%!AG^H+E<%VJ!*"D2A1:!)I M$6D3B8ATB'2)](CTB0R(#(F,B(R)3(A,B5#"G*7E"I>&]'JR4-=,YH+4_$*0WM4EHY6%[,B;\D`F\FD9]*!5U+2< MD,V(!%D9D:+Z)6]:IEYO\D91FU$DZ.'2L).B,IXN.M4$13?\B7EHR0WL:4-! M?38_$*37-60T8C06I):V5$ON<)M1Q*C#J,NHQZC/:,!HR&C$:,QH MPFC*:,9HSFC!:,EH92$[@*9PX`M@4E#`D):;WC#'4R9:F(9:4/*P\2Q#R3%*O:8XWD]03U!)4OFBU!6E?(T8= M06J^*TAM]02IK3ZC@2"U-12DMD:"U-:8T420VIH*4ELS06IKSF@A2&TM!:FM ME:#8EATMK".\T3+G$&KD) M0BZ(W:9Y52`)O*`6HW:*K$@G#3.HPPV[C'ILJ\]HP`V'C$;<<,QHP@VGC&;< M<,YHP0V7C%960SM:IG#BBU924+&BE:`R!D=FY#ICIVE>V#`!K,(+7<9S00E%@.`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`_A"9W6()I(C0IQ!+,%J')))9@J@W-H&$)IMC0C!V68*8- MS1!B"2;!>QT<13OIATX`4]TFP,T!F^B18`N*J?\3')T$5 M/S257_:#RCTBYY/@Y`/WP"?!`0CN@4^"B3X)@*F>B3X+0J-*"^^69+O%$`B6^1@<-F2'QW M!Z^1X%[[)'B;!/GF\X-7"R#Q^<%!-"0^:PT\9.)#9N>YU("7AK=%$Q+SU@[? MFR;\FU-D',?!)\,X/\MWG!R^`0.+S@W<#(/%9PUL_&".QI'#I M*G[V^K%^V8[6QY?=^RGWMGW&RK48O^IP3'XAF_QS3A:]N>^',W[P:M:_N5?\ MDGF+GWL5S>O9SX?#6?Y!YPN7WT9__1<``/__`P!02P,$%``&``@````A`+E, M":6/!@``QQ@``!D```!X;"]W;W)K&ULE)G;;J-( M$(;O5]IW0-Q/;(SQ`249A3/2KK1:S>Y>$XQC-+:Q@$QFWG[_IKN![FIE,C?# M^*OJZOJ[^@2Y__S]P6\_$J,Y'NNRBIKR]5)=>QZD MKZ_S$$M:U+Z>[P\U%+!AM]KJ^&`_.7[N M[.W%X_TP0/_6U5LW^[_5G9JWM*T/?]37"J.-.K$*/#?-5^::'QA"XP5IG0P5 M^*NU#M6Q>#WW?S=O656_G'J4VV--RN:,GO"O=:G9'(#TXOOP?*L/_>G!=M'9 M<]7U2W7KE;7?.ROMP%%=$P5-$0;QW M>ET+?SR%_V;6Z3L-MZ(AGA_J"(MA&!L\/]31@H_M4).HZ(O'^[9YLS#1,8K= MK6#+QO'WMB6*(32.Y<$L*9GW$W-_L)$E"M"!?GOTW-7]XAOJ70J?@/HXJD=$D8YU]RO2F3LF/@9RDN6ZJK!`.+VG?709M1,2$Y(0DA*2$9+/B:(= MN]I,NURPC`X296H!)VOL'*-H=ZO/X-%)-HL(B0E)"$D)R0C)YT11M#$J8E15 MQ`FV=9EL2$A$2$Q(0DA*2$9(/B=*^M@E#05A5$U?D&F'"0F)"(D)20A)"=$29_=MZ:30UXZVW MFO#10687$Y*0L.GHP\[@@P^9SHHAV<(V:J9:E';`J3Z+9TA)H MI537\=1LHLE+IA-3E%"44I11E"M(U<9.?3IMV=&EE4X@;[[[NUMM]P^%ESOW M6CEZ3:77;JCZ2K\2Q=*^'A=)0E$JT;M]9=++'?IRMYXV$W+I,'2F#@XBFP:' M8:WP'&%P9/U"=DS""R,A4231;D2Q1'.EHN&$4NDUQP&8*BR MN!A,80.'(P^/<3-R]<43"B]W,XSI=K];ZO.9AX&#%!^+-K.UGU"4JI$=Q]7G M3C9YR-"Y$D>M(#O^#<+%K6`NG",(EV%#AZ.9B(BB6"!%%V\X0REMF%&4*[%4 M(>S4-PCAEP%47F8=X-V0S3MMG6H;3BB\7+XJ\%*B.423@XP<2S1-S(2B5"(> MV?'/PZX4R(!PI:U.@Z0X1B8;>A&*)IDF< M".1.0Y!*KZEA1E$NT1!+K2R[44P"Q]-%7#3FE>7(9:>M?)UT5MKHA@[W\G"& MCUZ&'9A[;9;#"G9/# M+B/3^/QT`O"[BS(!.,*XR?D6.AQMICI&$DU>L43S"<`;*D-`8F6RX10KE\@P M`=C%XQV!7YH;NU0A=_Z-B'^/N%3M2Q56YW-GELQ4W8OYQ"B/OLVS0 M6+/DL+"DJ`4?M)Z&,F@M`O:AR^`?K'R\6],X@>OCS9/RI[7_9.PX6/MX7:,- M`L_'2X^!0T)@C(1%X+,:TS81+*S4U(()[[.*4POFO9\8+2DLJ=&";1BY#<76 MAA%;+S(P6;#!(@.3!?LL,C!9L-VBP"8+]E34RV3!(8_<3".-@QVYF2PXOI&; MR8)3'+F9+#C,D9O)@A,;N9DLH;.$9?@BJHU;X#C(VC31<.E$M4V6"!9VZZ(U MQ143>DP6W#2AQV3!A1/5-EEPR812DP6W2^@Q68*-CW=AFEFP\X/A<[*F/]SY M>.6C_N'>QQL1YG.Q_N=@>]]O`*!+\:.\77Y5KQ4?Q;M2WWMK'-U MQ#:S'%[W6OXAFO_H^0YE/3<]OB^SS M_P<``/__`P!02P,$%``&``@````A`-/T&TVH"```S2(``!D```!X;"]W;W)K M&ULE%K9;BLW$GT/,/\@Z#U2;UIA.W`O3`)D@,$@ M,_,LRVU+N)+:4+?MF[_/87,M%B-G7JZN3RT\K*JN8E.Z^^G[^33Y:*_]L;O< M3]-9,IVTEWWW?+R\WD__\[OX<3V=],/N\KP[=9?V?OI'VT]_>OC'#W>?W?5; M?VC;80(/E_Y^>AB&M^U\WN\/[7G7S[JW]@+)2W<][P;\>7V=]V_7=O<\&IU/ M\RQ)EO/S[GB9*@_;Z]_QT;V\'/=MW>W?S^UE4$ZN[6DW@']_.+[UQMMY_W?< MG7?7;^]O/^Z[\QMETV'\11VDXG^_=^Z,[_4TJI=J6<9-H)/B-.;ACFVA"?VC!;SK+U(ETLY?(W M+`MMB4]MN9BMTF23KV[;03KN%Y_:+EW/BFRQ6H\;OK'B4EOB4UL6-PWG*M)C MANK=L'NXNW:?$Y0]8MF_[>1#E&[A3*=&;]8F"S6SE]J/4OU^NII.D(8>Z,=# MOLGOYA_(_E[KE%PGI1J5T9`5(-W6(="$@/"`.:A;_LCR_\-?JDO^9N72`&Y# M64#6:!B3.@2:$!`>0,BBLD*R>6)C*Z6H>!+;@I(IE4Z*:-@$+*A*954L888T M#!$^0CBCID/.>';_LD"D.FH)$;`$>85HI5N[L"IV%PQI&")\A.P"C+U=F&J6 MZ$C6+%(JI+A9X)55,F8U0QJ&"!\AW/#81;A)E')3R`KMUPMMF'VK9+DQI&&( M\!'"#8'PN(WM8;V9N7;(.X2TH+P54F":>[R70=5:)S>)4RJ.90PR%!(,I'3I(('S5@D`.S>"D'M:P` M=]ZI.%1SJ.&0(!#E(Z>'XZ//D#-Y]AT.Q_VWLD/?3^TQ)U7#AO!44.:/MB() MSI65,731K36$0Y2;+5D:S,3&:9G("`+1WT_4Z\"R,PA@*2E].E@A]-7`(?07E MKEZJ5$,^806M-W8/C=;:N%X@##2^B5$^^'D)4%&"$[PG14:0ADC=M*0SX]#7F+-QP2Q)#R MD8.!!R]3\\(/GH:03%V+P3-0&05'N#:0KK+%,@G."(W3,+L4!AK]4++Q*93Q M*:0AO_(,Y--3AGEN0]P8+0<)`T7XT)%C'N2,3Q8-N4&F97%NB[6P0&D,39^GK5-),]T_-@\\S&#C4KZI.XTY+/3 MD%N\,88.$@:*\)$M/O+0JLY/'EH%N;H+GK\J4PHJ0>JF1$.Z[E9KUO"<@GMF M?3VY@@?U;$)']W7T23L("V2 MX"&L,JWEIU=#Z['XBB1XO6B,B3N?"P/Q7,N#A\?WJZ//J$X'B8;\FC201UI# M"W?T:3@D##0V`A+7/#Y(1CC@HV8+\NS'-9PFVM!/O8:6\C[KXV&)"\PPLD[# M5J:!QC,(91R?)HA3V($TY%>FA@@]/4UL@AA2/G2:?)EI/F70[B1U M.4"]B@U'C=%RI[):0TB^;QCTV<9IN>A&5LPRUVSI!N,C"(=7%G`%!242]BYM M2'*@#?'XVPCPPZ\VU(6TR-=I\`HMC$:D:N24+WE5Q!I)H41':B MH*5[1!MMN'2/J#!0Y'F4,^8&S]^[-_^5"27*DJ"@X$T^>.0J;>B]MM<<:C@D M"$3K1`Z3@/H7-U3X;HG15Q!]F0\376E#_ZZ$0PV'Y+=9)EMYS123X#LV MW.#$)!DD8RDS;SDDXYDCE.1+,!O+*I#@J[S'N"^XBJV.Q:/Z6#JV\F.Q?41P M(]LHMKA]C^"++6Z^(SAV$-M`B9A'_:^WN#2-^,G3;8FVS245)%544D,BNS^W M$9#((<`EZ,*PB86DS`LPB.VQ@J2*2FI(ZJBD@43V$LX`;0_<8I(R6VU+'*JX M#4Z0VRHJJ2%IHA(!B3RB<6]EML%.8^6-@Q9V&I/4D,BS"O>&8Q7V$Y.468[] MQ*JI@J2*2FI(Y#M.;!W4-7'.C%) MF:(2<3_)U\&%'"2QZ)0I:A371-RF@D3>/'$);LNV=52"&[*MO(?B-K@:`X-1 M,K>]$;\Q>-N]MO_<75^/EWYR:E_0\I/QAO*J?HZ@_AC4V)T\=0-^72`G\.2` MGXVT^(HZF6'DOW3=8/[`TG/[0Y2'/P$``/__`P!02P,$%``&``@````A`&.4 MCB5@`@``=04``!D```!X;"]W;W)K&ULC%3+CILP M%-U7ZC]8W@\&\II$D%'24=J1.E)5];%VC`$KV$:VD\S\?:]Q@L@DE;(!?'WN M.?=)]O0F&W3@Q@JM7X]Z_-PR-&UE%5T$8KGN-W;O'3\O.G M[*C-SM:<.P0,RN:X=JY=$&)9S26UD6ZY@IM2&TD='$U%;&LX+3HGV9`TCJ=$ M4J%P8%B8>SAT60K&GS7;2ZY<(#&\H0[BM[5H[9E-LGOH)#6[??O`M&R!8BL: MX=X[4HPD6[Q42ANZ;2#OMV1,V9F[.US12\&,MKIT$="1$.AUSG,R)\"TS`H! M&?BR(\/+'*^2Q7J*R3+KZO-'\*,=?"-;Z^-7(XKO0G$H-K3)-V"K]"(I_`A`YO0MQRDHB,+5 M.1Y-H\DL'B7I!*,MMVXCO"]&;&^=EG\#*.G4`U<7PS-U=)D9?4305T#;EOHI M219`?!(_,?3A0%&81Z\\/,,.,!9G);"B`W M0O=6*"0$W*=^K1%`=VA`4P<:73KI-()>GROE`9U<7ZJ3Y7])7E1_>H-^/N[) M_?4E^--8Q/1>@5<*]+VUWZY5ZIO]T3Y>K+JM M(_T%+$-+*_Y*326410TO@3*.9I"U"7L3#DZW$#FLA':P!MUG#;\W#L,41P`N MM7;G`PB3_H>Y_`<``/__`P!02P,$%``&``@````A`,O=2Y5N#```HS<``!D` M``!X;"]W;W)K&ULE)O9;JC*K5`O^\O?O_7ON MY_9TWAT/CWGOKIC/;0^;X_/N\/J87RW;?]7RN?-E?7A>OQ\/V\?\/]MS_N^G M__[GRZ_CZ?OY;;N]Y.#A<'[,OUTN'T&A<-Z\;??K\]WQ8WN`Y.5XVJ\O^._I MM7#^.&W7SZ'1_KW@%XO5PGZ].^0C#\'I%A_'EY?=9ML\;G[LMX=+Y.2T?5]? M\/SGM]W'6;WM-[>XVZ]/WW]\_+4Y[C_@XMON?7?Y)W2:S^TW0>_U<#RMO[VC MW;^]\GJCOL/_D/O];G,ZGH\OESNX*T0/RFU^*#P4X.GIR_,.+9!NSYVV+X_Y MKUZP\KU\X>E+V$'_VVU_G5/?<^>WXZ_.:?<\W!VVZ&WD23+P[7C\+JJ]9T$P M+I!U.\S`])1[WKZL?[Q?YL=?W>WN]>V"=%?$9'-\1R3\F]OOI`;0]/7O\//7 M[OGR]I@O5>\J]\62YU?RN6_;\Z6]$]M\;O/C?#GN_Q\IA8^>./%C)_AT.+EB M6(H-\1D;^G=^K>)5JA+]BF$Y-L1G;%B]\\K%/YG!:=A:?,9FWMV]5WPHW5\/ M5XWM\!G;/=QD=Q_;X3-I7]FOW-?"WKW2/HS#\$'Q&1OBVQ7]AU@?GY]JF(?* MBO(O)1;E]K:F>4GEX$O2N!MRX&FUR)?8L'I7JU3*U=H?TN!IO%HU\B4-6;JH:3\M&OGRNF5HWGBF<&].I%>29 M$KJIF;Y6D'R)'_;&=&("C(I/OMS2SD(T>8637G-]63]].1U_Y?`F@?WY8RWO M)2\09_%T%X^89`+$/+P1]:^B_YA'[V)J.X/^?*IX]U\*/S&C;F*=.NMX68V& M:LBL*FZ;-FC9H&V#C@VZ-NC9H&^#@0V&-AC98&R#B0VF-IC98&Z#A0V6-EBE M0`&I2_*'F>!3^1-]R9_V?%V!2:AO)4LUU*1I@Y8-VC;HV*!K@YX-^C88V&!H M@Y$-QC:8V&!J@YD-YC98V&!I@U4*9)*%N?=3R1)]+"M2@\TO6MFI1SKR3C$C MTDI@HI)DD$B+2)M(ATB72(](G\B`R)#(B,B8R(3(E,B,R)S(@LB2R"I-,CG% M6_%3.15]3+8H$9,OKY;-6#U6NI;41"5)*I$6D3:1#I$ND1Z1/I$!D2&1$9$Q MD0F1*9$9D3F1!9$ED56:9)**!4LZJ?KR$QSF3ON\'I$RU@Q)-OUB)9O-1J*D M9DTB+2)M(ATB72(](GTB`R)#(B,B8R(3(E,B,R)S(@LB2R*K-,FD"DM$5ZH$ M9U,5$>R.-`L-(DTB+2)M(ATB72(](GTB`R)#(B,B8R(3(E,B,R)S(@LB2R*K M-,GD!4M$5UX$9_,2$[,D:1!I$FD1:1/I$.D2Z1'I$QD0&1(9$1D3F1"9$ID1 MF1-9$%D26:5))B^8JEQY$9S-2T3\JADO,8'KU&17S4YVS41)AUF+2)M<=Q*= MM&OKK=A-E-1UCTB?7`\2G91KS]J0#!,E=3TB,B;7DT0G[;J4[9!IHJ2N9T3F MY'J1Z!C7GF^Y7B9*ZGJ5)IFT8V_J2KO@;-HCDDY[3+)IM_9\S41)'Z5%I$VN M.XF.::5??,AV8#=14M<](GUR/4AT4JX]:_$\3)34]8C(F%Q/$IVTZW+VJ:>) MDKJ>$9F3ZP7I+(FLTB238SF22B@A,>S$J(3`9D+QBMF.[!HM[HSZ['R@R MCSID-&(T5F0>=:+(^)HRFC&:*S*^%C%"L[5!2T:K#,JF6M,#BU<=18?9J3K+$*H,RV]AMP41*6GJ*FHE&BU%)FVMAEU%!GW747&5T^1 M\=5G-%!D?`T5&5\C1<;7F-%$D?$U561\S1097W-&"T7&UU*1\;52%/K*9DM. M(US9BD\IC-^Z7,5(:K`I3KTXK>5R0[6JX7CWJY6:M49I&@U-<2M&J5=^FU'' M&,H-@%>I^%5[U694U'>/'?49#8RA^"[A:BN[(!@:!?4\8C=C1A-C*)YK7M7: M!4R-@GJ>L9LYHX4Q#/L#MZ)%R_?2J*CO5<91MA;DN,-5"]$Q"(:\.JG+Y5I4 M"XH:BLS6K%()EL1*F4V4YXU=AIR[RDYK84CMU2V1G;3R#7G+45F MCFHSZBB*WB;E^XP&BB+/GH=K>GO8QHTRD^%(C8SK,:.) M(NQMS6SG6\N)J='2)Y\IRKQA?6M@SE7+/,1"4=R82O7>RL#2:&BTE:+03[8^ MY##&51_"K1U7A%`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`EPK,\<8#R2]+,%0#R3+ M+,'P#B39+,&X#B3G+,'P#B3U+,$H#Z0"6((I,I!B9PFFQD!JGB68(0,I?99@ MH@QD!+`$DV,@`X$EF!0#&0\LJ4-2=TKPK@D:3@G>+X%,!.P-+Y9`Y@.6X/T2 MR+3`$KQF`ID=6()5?B"+199@L1_(`I$E6-&C,ET2+-T"69BQ#998@2R@6(*E M4#!T2K!D"61!PC986N#97!)LP0)9E+,-=F*(XY)@NQ7(>IQML.L*9%G.$FR^ M\&PN"797@:S(V:8.2=TIP<86_>:RP?XUD#T,>\,V-I"M#$NPFT5?NR38LP:R MBV$;'`NAI:Y1C],AM-0EP1D06NJ2X"@(5>62X$0(F7-)<.J#JG)+,./A?)"? M&@=^Z%&7#0[YT*,N"4[RT*,N"0[TT*,N"<[UT*,N"<[NT*,N"8[P4(DN"4[R M4(DN"<[K4(DN"8[@`SF5Y3[`L3ORXY+@O!WY<4EP[([\N"0X?0_DQ);CX,0= MF7-)<&.!/G!)<'&!/G!)<'\1R(DUQ\&=!7K')<%E!7K')<&=!:K7)9G7T%#7 MQ+>HH:9<@H8G[UWGBQ=1ZLXHN&@*Y%Z`6].$1*X'6();)=2A2X++)=2A2X([ MID#N#-@;[I50H2[)H!;@-QML,<#K*KQ\M987N!Y&+[MZ9EQ#)[L$DUHPD*W4!HN85GBW8- MG>X2=&H!?D_#!AVL*UPA<'V/X>#RU*]A-(2"0M(^_.74Q_IU.UJ?7G>'<^Y] M^X*U93$\5#E%?V05_><2+4MSWXX7_,V4K%!S;_ACN"W^2*!XAQ.8E^/QHO_! MLQ:2/Z][^A<``/__`P!02P,$%``&``@````A`#V:0KR0'```$(D``!D```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`RF+FL3R2#]%!F_#UF]X9DLY`,?T.RX>C=U70ZF5U=GL[P M,J3$WV.&1Q^=*"A&TZ&@^'NLWYLRO`X)\?>8X1MJ.$0_.63H_O&+=1Q*3W#_ M.&;ZEEH.T7=\KMJ)AH,W=8"A]!SWCV.F;ZFI=)VA]IVWMB;&02AOW('>5%/I M0D/M0]=OZT)#Z4/N'V^HZ84?IX?Q7=V\W'SX[>GQ[S-,FFB=YQ\W;@H>%LY6 M&-EAO!S'.J:<6Z?^T>F_/X/)%77RT2COY%['S6XZ$C+G'U6.WB=2$VF(M$0Z(CV1!9$ED161 M-9$-D2V1'9%]3)*VP`3[2VWA]#$YH6G5SZ-!ZNEY4#K5&$>58V,0J8DT1%HB M'9&>R(+(DLB*R)K(ALB6R([(/B9)8^")%3>&3/(.'WPNOII[,L'*X]@*HUG6 M"N5129)51&HB#9&62$>D)[(@LB2R(K(FLB&R);(CLH])XF(\VBT7.YRZV!.L M5<5[)9&*2$VD(=(2Z8CT1!9$ED161-9$-D2V1'9$]C%)_(FEA^5/AU-_!J*/ MRY)(1:0FTA!IB71$>B(+(DLB*R)K(ALB6R([(ON8)/YT(3HO`-^Y$.;EZ_WM M'_-'C/CA0HQE%I%YKG&@-+_.F"5KCPV`:3_.VJT-FX\DQ_X91*^AD9IUH M^5E M-G_L1>.06]KT,&TVO>/9$/0(32^]H72!!+30SH(J0>,CJ@5I71M&K2"UU0E2 M6[T@M;5@M!2DME:"U-9:D-K:,-H*4EL[06IK+\CPL`O>K,$5@CJU.W<;;7!G M&AB,LZY3JI8Z_9A04,U:#:.64<>H9[1@M&2T8K1FM&&T9;1CM$]0VJU=D&8Y M/01OL=,]BD,%MV^)=HA0Q:AFU#!J&76,>D8+1DM&*T9K1AM&6T8[1OL$I1YV M,9KE81^[83Q(5YR[/5TWET3!`Z.*4RBMLC#83?YU6#"[7L[-\>>#RA>-7GTDW@BV(*6M&+-J&'4,NH8]8P6 M`<$=DN-2M:)5$\45JB4)UXPVC+:,=HSV"4K;QT6!O](^(6J,VR<@K73IC@W0 MBJ]'&*H@]:T9-0%%[FQ5RUZY=ZH@EGM&"[:\5*U7(@U5$,MK1ANVO%4MN\P[ M51#+^P2E+>8BQ:C%CNM<'T$F(R>@N&4\^EF\<=22`M5#0@VCEE''J&>T""AJ MZJ5J12,G7_&N5$N*NF:T8;1EM&.T3U#:#BXBM-K!1XI).X3@$0M-#?(F%&]X MK9_%&T'+KY-'@^OK2;HJKX=!0U>$#:-64%*F/+KI1"NLRJ^OIUG\TXN&YK9@ MM!1T,K>5:(7]'@!?'HE:C_ MP-/G5T!QR!%0''((TN5X+4CKVC!J!>F,W`E26[T@M;5@M!2DME:"U-9:D-K: M,-H*4EL[06IK+\CPL`NLC?$U\@%W/+X"FB;;BY,L?BR#UFAV?#A7C&I&34#1 MW-2R5L>H9[1@6TO66C%:,]JPK2UK[1CM$Y1,:B.,&-/ICF?=VJ-T$V62;266 M!X.'X#J:^O)IIA(M/Q+'PT$VR]2BH%VN8=0*.CGL.]%Z+;->%#2S!:.EH).9 MK43+9W8]'F53S%H4-+,-HZV@DYGM1.NUS/:B8(RV5P+\$0?X`27SF==*YK.` M=*S7(6&\$\:H%:3S1B=(;?6"U&T+1DM!:FLE2&VM!:FM#:.M(+6U$Z2V]H(, M#[\2S8\XF@]H"A=&ZX7L.5\&K?'LL/,XG-`VOBK(TJ@.*)H#&T:M),1"(LH_ MVY3N5$O,]P%-425-F'?Y!>>X%%M2EU$V>:]403);LYD-HZTD3.LR2]=,.]42 M\_N`7JU+.F^^LI&`W1>:-SU"XTI69=!"2PJJ&-4!)6WG;46HE8371UL=HSX@ M5$YR7+#YI23494^F[)%2 MAH1CQ#7:5R?9>K-2+7%4+4A]US!J!9TTWZF6F.\%J?D%HZ4@/]4/!Z/K[#1U MI1IB>BU(36\8;05YTY/))+.\4P6QO!=TL)RVVR]N,+C(-%]IA-T$G7G+H#75 MR+9B5`O2_ML$%#V#6M%26QVC7I#:6K"MI6CI+N&*T5J0VMJPK:UHJ:T=H[V@ M@ZW4\RYBMQ;0/I)/%M`>C3&=1&,A:_=RY+6F^*-:O);S6K/!X;$TF>9O9M7! MS$R;LPD(O4AZ5/NFS#JQY3/#^T?90[(7!V?&[#(<[ITX?67C0.N:5-[[8`HJ;_V:[KR&\9)%W"(W0):9(R M:$UU"J\"FOFW]=U[%'5`^",)&T%Q\WKSD:V.;?624&TM!*FM94"1K17;6DM" MM;41I+:V;&O'MO:2\&`K\;S;DHX]+X^I`T\#J(#2Q]0T>^.D#%H31+TG!IUH M^3E[-)T.LX%0BX:V9Q-0/!>*ULG<.M$*N8VF^=EY+QJ:VX)S6XK6R=Q6HA4> M=2,O_;-R-G7[6 M*SR*HZN@-=%9I1*D3_):D';F)J"D@;WYR%8G"=56+TAM+=C64K2T7"M!:FLM M2&UMV-96M-363I#:V@LZV$H][W8C3LUX_WS\`4?CF>1_M.!V6;WG=5A-\TAE M+EIPVG'P96%0J3HRWU6,:D8-HY91QZAGM&"T9+1BM&:T8;1EM&.T3U#:.FXS M(&J=8ROX38+XN3/V*'E]8)J'@Z5JJ=./"075K-4P:AEUC'I&"T9+1BM&:T8; M1EM&.T;[!*5.?V7#`=,!33H>(?H2WY5!*T(5HYI1PZAEU#'J&2T8+1FM&*T9 M;1AM&>T8[1.4>MB%WU:W]F%YTJT#TL5\Z5;;;@I25#&J&36,6D8=HY[1@M&2 MT8K1FM&&T9;1CM$^0:F'LZC_IP]4W@W`KLK!S7'?]L@]QX_3^HA>1PX)H26# MHF;4,&H9=8QZ1HN`HH.&I6I%1:77!U1+BKIFM&&T9;1CM$]0VCZ_&-V/.;H7 M%+=/"/A??4$YI,'[!5+?FE'#EEO5LH_B.U40RSVC!5M>JM8KKP^H@EA>,]JP MY:UJV67>J8)8WBS$JT0W0RFV4YX+0JZZFX8M8).9M:)EL]L.KC.XK9> M%#2S!:.EH).9K43+9S8:#B^SNJ]%0W/;,-H*.IG;3K1\;L/)]"K?G1&-0VY) MTT]>V2,X\#0:#"B.!@-".\O@J@3ID4(M2.O:,&H%J:U.D-KJ!:FM!:.E(+6U M$J2VUH+4UH;15I#:V@E26WM!AH==E&M,J M()FMVS8>51?`9W2(T7%71[L&)4 M!Q2=FS4!)6WGS4>V.K;5LZT%VUI*0MT^63%:<\(-HZTDU#KN&.T#,L[@)J^$ M\0>>>=A'X\GFYH1&E5=R#\EH5.5'<,$ZM*1?U(+@9TV8[]XTHJ5S32M('A+C M_.VY3C4DMUZ0VEDP6@I**Y.=H:Q42\RO!9VLS$:TM!!;0;XRD\%XFCEXIQJ2 MVUZ0,6EF^P4_B[4FO(\04/*X\EKQ29UHZ;JR#FBFLWL3$*)O*7LK"75=V3'J M!>F(6;"MI6AI(5:,U@%%Y=JPK:TDU'+M&.T%\>;EY)5]A`//QI7?-$@?5U?9 M3%V&A#\YJ0M:QY.Z<6:F%@5]##=V$JKG)\FF+:B*J=+QU_< M#YGP?DA`R;//:\UTJ%5!:Z;#HQ:DXZH)*.D-9*N3A#J!]X(TQP7;6K+62I"6 M:RU(R[5A6UO1TAQW@K1<>T$'K=3S;D\B6E+2[)@=,$R<_F'LZB-J.LJ"MKEH MG3I@4!V9""M&-:.&42`HH.$TI&%:.:4<.H9=0QZA.45,2].&Y4Y(#3 MQZ\@?=*7C"I&-:.&4,9)-!0(D;O-;,N>^O#Y/A M=)(%JE5(!`TI8\VH8=.M:GG3HWR?H5,-,=TG**U^'(Y%K>VCJGC\N>6BJ[D^ M- MMTX]"C%YKKWSP!B(]8#S"["0%+H,6*BFH8E0+BJOE;275"DAM=9)0 M42^(*X+8WYI'#CB=1P)*AU_V9"R#4AA^H^F`-I$K59':UP'%7951JPE=W[!L M=ZHBMOO$4-)U\*QTT\811CY8!Q6.041U04C%O/D(M)^P8]8FMM")N MP:*K('D6X/WJO#,&E#XJLX%0!J4P!B=7^:%=I0KBY5I0U%D9M8+\&&3+G2J( MY5Z0T77MU0^VZJC:'L5C,&C%8Y!1+2BNEK<5CT'1TN[1,>H%&16QESK8C:&* MA*4.RJ"/P&R)4H9T.'PXS*'3[!%9J5R<7`<4=P%S(P7,`$E MH^\JVPTL@Y(\`?&R<_K2?Z4*XN5:4-Q-??9)-PTH/`$'^6%!)V;4T;T@H]/: M*Y@9KV`"2D:?UTI&'Z$Z)(SJT#!J!6FI.T:](*,B;F%@S)Y^O1`'43./DB=@ MOF0O@U)X`LYF5]GPK%1!V\\;CGIE$[0BU&I"-_QFN/@A[1F=*HCE/C&3=ENW M<#"J[=<32;4]2IY^8=41K4`1#+N!&ST0ZX"B.C2,6D[8,>J3A$E%+NT5S`&G M*YB`DO%WGD%$1>P5SR2N8@)(Q M>)V]AE$&I?`$O,K?E*I4+DZN`XK[*J-6$LH;$J,LYTX5Q'*?F$E[KEM*\!"\ M]"N,>`@&%`_!@.)'(*,ZH*1:WGR$6DFHP[ECU">VTHK8"YA+7L`$E`[!;!XK M@U(8@N/KV2@[UJY40]Q<"XH[JL\_Z:@!^1$XOIKF1YZ=V-&NW`LR^JV]B'$7 M);O=-HWYY@$E`]!K)0.04!T21I5H&+6"M-0=HUZ041%[$7/)BYB`D@%(UW64 M02L\!8?8AIEE84:E*MJ&/KNH:S9!*T*M)CRL;Z]GO!>C*F*[3PREO==>R>#; M2=2('B7#,"Q;=.A4(6'\)`PHJD7#J.6$':,^2>@KXK_1Y+_A\G#W].6NO/OV M[?GL]O'/[P@31E>7B`2./'P=:CPJ/N*P$_[))/C-4^%^R6-)QI`<\SWB(''!]IV'INK[!D?CE!V:SZ8.9%V2P)IE>4S9(TD+@9B?-I(7&S$$LPHZ)L MEF1^.4+9+(_BH8ZR61(\NU$V2])`TI@2/,E1-BL-GM"R66FP^8:R69+Y#&,!.Y)6V3`6 M3`FV>5$V*TT#26-*L.F+LEEIL+&+LEF2^11C`3O>1MD@<5OM+,$A0N%VW%G2 M0-*8DA82M]G.:7!P4+@]=Y;,IQ@+.$UA"4ZN4#9+4D/B3G,X#8ZI4#9+@M,J ME,V2X%`*9;,D.)V&Q'J0XJP8$K,?3#%^<+C'9<.):^$.&EE205*9$IRNHJ96 M&ARRHJ:6!&>M16M*<+X*'UAI<*Z*^E@2O.M7N)?'N-1XY:]P[Y"Q!*_Y%>Y5 M,I;L(7%OE+%D/KDNW/LHAF0ZA$?M5AC".U:/+]%R[@T$MH;W,.`W2X+7,>`# MRQK>U"S<*WML#6]GHM26!&]D%NX%/DZ#%S,+]QX?2_`R9N%>YV,)7L(LW%M] M+)E#,C.6U*$U)!8E[G9&MX?W6PKW5R!*\YEJXEQM9TD+2FA*\$PX?6.M' MO!J.FEH2O/N-FEH2O.^-GFA)\-HW^ILEP;O=Z&^69`[)W)24D%2F!"_9PSN6 M-;Q8#^]8$KQ?C[YC2?`2/?J.)<%/4>`WJX_B%RGPFR7![T[@-TN"GY_`;Y8$ MOT*!WRP)?F8"OUD2_#X,U@X_`,[6_OB9&.8#2X*?AB$?2[*'Q/UHB7O5'"68 MFR7`+X_0/E;9\-,BM(\EP<^)T#Z6I(7$_12%2X"?#:%]+`E^Q86MN2S"&9FY(2DM*4X">0\*AE#;]] MA$7D+A?H+(UW(Y3N%M86()+<@IW&0M+<#%.X>YD80DNQ$$^ MEF0^GD!BC?IRC'6(WR.A4L^0QII[<>]0X6ZKX1+@OB%8LR2X=JAP=]=P&MP^ M5+@K;%B"&X<*=Y,-2W#1$-K'DN">K\+=)\5I<-U7X:Z58@FN^"K<[5(LP=5> MV-.P)'.48&Z6`#=%%:4IJ2!Q-P9Q/K@5"GW4DN!RJ,+='\1I6DA:4X+;V`IW MBQ>GP35LA;O,BR6XC:UP=WJQ!)>R%>YJ+Y;@(K;"W?#%$ES`5KB+OE@RAV1N M2G"M7>&N-N,T%23NAC.6X`Z[PEUTQA)<95>X^\Y8@AOMBM:4X'Y'^,`:V[CF M$36U)+C+$36U)+C2$3W1DN!F1_0W2X+[&]'?+,D-QGRS\9DEP:RS\9DEP>2S\9DEP MARS\9DEP22S\9DEPB3.L63$3[G+&?&!)<'\S\K$DN+@9^5B2.4HP-TN`^X'1 M/E;9<`LPVL>2X#)@M(\EP9W`:!]+@DM_T3Z6!#=M(XU5:ERQC326!#=MHTTM M"2[4PZ.6!/>3PZ.6!->4 MPZ.6!+>58SZP)/@P`?J!M:;`!PG0#RP);K='"UCE0#?>$#[6!)\UP'M8TGP.0>4P)+@JPX8/Y8$'W?`^+$DY1!/ M&7RPPZ@I).Y3'BR9P]K\%6M809J2"FDJ4X)O;Z`5K++A$QSH!Y8$7^)`/[`D M^/H&QH\EP5?&!)YD/,8OA(%JI\'W#0OW M]3R6X)N&A?N('DOP+4.4P)+@DX:%^Z0>I\&7#0OW93V6E$.L1_&I2I8L(7$? ML60)ODI9S%^Q-BS<5PHY384T[F.%+,%G)]$*E@1?GRS(OC6`?OWPE[`S?>?I^/H1U[517F^'5M7T_$H/^_+ MQ^+\?#O^^R_OVVH\JIOL_)@=RW-^._Z5U^/O=[__=O-65B_U(<^;$3*RO*%N8:/#"%X0J*]=@7^J$:/^5/V>FS^+-^"O'@^-%CN!0O9ET=< M"3]'IX+5`*:>_;P=V[A"\=@<;L>SY=7B>CJS[,5X])#7C5>PV/%H_UHWY>E? M[F1UJ7B269<$O[LDUN)JM5C,EZMK9/D@WXS^8&2W7<^&^ICJ1Y;X<'*EJ7=Z<#5@:<#7P>!#D(=1#J(=9#H(!V`"23K M=<.B$=UP'[ZK&_-GNHD9;P200MJ:2,)#A.QTX.K`TX&O@T`'H0XB'<0Z2'20 M#H`B$NKI2R(Q?Y3?H+CLM:;*AONP^TU6H"9<[](K1XA+B$>(3TA`2$A(1$A, M2$)(.B2*AMA(OZ0A\\?-C"61^M@+5:%-Y_21B+U++R(A+B$>(3XA`2$A(1$A M,2$)(>F0*"+BQAR**#8SAENMQ!PWG,R'^YN]UO:W;>\DPG:$N(1XA/B$!(2$ MA$2$Q(0DA*1#HDB#(2XA'B$Q(0 M$A(2$1(3DA"2#HFB`[I)DPX,JSIT1/8&6T)VA+B$>(3XA`2$A(1$A,2$)(2D M0Z+HP'KDH1#M#H-.ESU`-(=B_[(IL6M8LL-D_JI";0J@0:ETB+6J]1(VY%'D4^10%'1H,(I1>@T',I^H@(NDE!A%3E%"4*DC5E+6E@YOL?S7E M;2RZ`C&$#>N@F,Q#33E:L+7X<6=/K9DZDUT7`P>1QJ5I/.G5I=%:.%\ZB#0! M31-*+_-H(ND@TL0T32*]S*-)I0/2J"JSOG:@LMC*6'.E5VB'AFIR9&.CE!5J M::?BKLL%+S$)ER*/(I^BH$.#)0VEUP>#B*27&$1,44)1JB!5.];0FK3K&MUA M)7*T@%Y2J/6U6GM;]G`*T6>SMCBMY6JJ>>R$QWP@91\>!Y[:MO::>P+ M#QD44!0*].YX(N$A\\04)0*].YY4>+1Y5)%9PVL2N6N$AR)S!)'%$F\MCJ"H M0#N!Y)!=BCR!9*`OD`P,*`H%DH&10#(PIB@12`:F`AE48;VN217>`Z-FQ7PW MN%5842U0)H/26^FEQ[UF..*DUUSSVG6Y[&6?WJ7(Z]!LV9;QRM*?;WT:$U`4 MBC0?#BFB@3%%B06JB_M3B"K@+M.J2(R+T& MR!.!4FJ?!@84A2)07C&B7C%%B0B45TP5+U45UAN;5.$]LZ(*1]K>I[4Q6XM[ M=7N?O9J1VNLK2D-%$PD'&Q!0E`KTW MFE0XM&E4@5G3;1*8-^.*P!PI^QY'RK[7(3EB%R_QV_-&(D\@6<*^0-(KH"@4 M2`9&`LG`F*)$(!G(/B[(<7%5^,<"_EKWE%?/^38_'NO1OGP]8[]:S+'5]+C_ M2G'?;H,:W["O%^QNU+GMX"6?@<\3!:<,=#-9T$CA.J:J03^%ZY@L:*MP'9,%[12N M8[*@&\#ZF$:PA86=5E0WG/I8'Y,%AS_6QV1!#X#U,5EP^&-]3):M9<-BN@71 MXF,^)LL&,]T89XIF&O,Q:8`F&O,Q65Q86#-(-4!+C?F8+&BE,6J3!1TUZLUD M06.->C-9-BL';UOH];?6%%=I/YMJ=QP>T*&-R;*U+,S3M-7A\1793!8\D:(. M318\9.(ZK672#P$?8R_9R MP6?8]L\#OJ_G^"PV9:]AG\JR$?]@\I/^B_W=?P```/__`P!02P,$%``&``@` M```A`#,6,EB4#```6SD``!D```!X;"]W;W)K&UL ME)M=<^*X$H;O3]7Y#Q3W&V(#"7$EV1H^;`P8VZ?VG'/-$))0$T(*F)G=?[^O M;#6R]&J9F;W829YNM>3NEJR6G/O?_]R]M;YM#L?M_OVA'5Q=MUN;]_7^:?O^ M\M#^[Q_Q;X-VZWA:O3^MWO;OFX?V7YMC^_?'?__K_OO^\.7XNMF<6K#P?GQH MOYY.'U&GQ6 MV_=V;2$Z_(R-_?/S=KT9[]=?=YOW4VWDL'E;G3#^X^OVXRC6=NN?,;=;';Y\ M_?AMO=]]P,3G[=OV]%=EM-W:K:/TY7U_6'U^PW/_&?16:[%=_4+F=]OU87_< M/Y^N8*Y3#Y2?^:YSUX&EQ_NG+9Y`N;UUV#P_M#\%41D.VIW'^\I!_]MNOA\; M/[>.K_OOR6'[M-B^;^!MQ$E%X/-^_T6IID\*H7&'6L=5!(I#ZVGSO/KZ=OK/ M_OMTLWUY/2'*O:MEOKK\?3?O?_6BG0IFHC76T$_VHC,'=!OZ?U\:_6'UP-^OW> MS>`6G5YH>*L;XM^?Z@CI7#T=_M7ZMU>]L'\[J)[N0D>!^$7]\%-=!7CDJB_U MPR]VAH>NF^*'G^OL1EK@!VEQ=1MO#848((1.HX6#6DR=L'$!;$+$A=,79"Z8.:"N0L6+LA84KGXNOAC7IX3UZ MC@)V"'841F1$ M"B)EDU@NOK-=K/?85VJG?GK=KK\,]_!?<-YB*W7;]35INKXF7=2%QO5!UW'] M6>GL>B(QD83(E$A*9$9D3F1!)".R))(3*8B436*Y/H"'FNG](]]7^K;S!346 M9HUNPO-<&#.:,(K95J)1O[EWZ08].Y13HR6Q3!G-&,T9+1AEC):,F&TQ%;&:,GF9+"]E1 M5%56(XKRQE!;=#=:&C6C5:.P^=((`\>=8VT+6C*@":.84<)HRBAE-&,T9[1@ ME#%:,LH9%8Q*"]E.5_64S^FZSC(KT3"H40]K8N/=,+`3=J2UNKVSA\>,)HQB MC4+38\):4T8IHQG;FK/6@E'&:,FV[U MX&[@G/A,1,5,F9A1(NAB=U/1^N?N4E$QWRQ%*VJ1SL-5`'H2X.Z,+32H$9(`\F,45`CQ%S06%#WC":" MS//&C!)!QM94D+&5"C*V9HSF@HRMA:#J,J@Z#,\$&5M+1KD@8ZL09&R5@CP> M5B6AS\.Z5#1VA^IB0$TT>/6/(?&&TQ'QIV;(G MABHS?6&KRT]K8M0(81.[HZ!&C1",&4TTLJ)2-VR@A!M.&:5L:\9H+@WOSD-= M,,JXX9)1S@T+1J75T/:PJB9]'JZK3,O#-;K%N[@Q,=QST:#6LO9:A":L%6MD M[;6HX90;IHQF;&O.6@M&&:,EV\I9JV!46LAR>N@4ZE)55-RN`37ZP6JDM?1J MU,=_[JW!V*C(_)AHU$CSF%%B&E87H![;4Z,BME,V-&,TEX:(\SFE:,E8&"TQ MG[&M):/<-+Q@OC!:8KZT;-FA4[6O9[Z$=4W5MR9'#5R]L3.:<@( M*XIJV*VWG_@8(KQQ3IS&1D528"+([$MB1HD@O##^.8&G1DO,IX*,^1FCN:!_ M'OK"J(CM3)"QO624"[HX],)HB?E2$.^R5$7H#1T7[I5J5B%T1+SI67+7M><6O]'!\+JDS1WO=-G M`(T]KM:Z,6>Q8T83C4*SOL>"C*U$HYXY-IXR2J6AL3439&S--6J,:\$HDX;& MUE*0L95KU!A7P:B4AI4MV_.J0/9-FKIPMB9-C:PW"IVOCY#W*C0]O)3-JD^G M+**E%^^@'W1[3I4X$1U3SL<:-3;0B6A=[&\J6G5_F,B]:^=5F(J*Z6[&W4PMDHF*Z6W)WN6A=[*[06K*U%%M5CW82J'J\ MD00_G'YU_6XE1XV:9R_J:%]E@CD_&`LR+X*)()/3L496E,G65!H:6ZD@8VO& MMN:B9<:U$&1L98*,K27;RD7+V"HTNC6OL5*T*ENVYU4U?WHZM]?[K.X(>X+;M\?[,ZX^+A_VHK*+M<&1:I)X&5AT) M$BY2#\42)%FDGHTE2"Q\P^R3X./F3Y5GG%Z&^.BY>B:7AS#DZ6'8C"-34:>25C2-2D8FM8/2,UMUB"13124XPE6$NCQ"O!%@,^ M\*42=AIX4I\$NPD\J4^"3072SR?!W@))YI-@\X#<\$F&D`R]$FS@X!U?&VS2 MX!V?!'LU>,.38$^&W/%)4+?`;[[41?D"O_DD*%'@-Y\$E0K\YI.@ M8('??!)4)/";3S*$9.B5H"J$WWQM4/G!;SX)"D#XS2=!'0B_^20H].`WGP3G M(?";;XG`L0C\YI/@W`-^\TEP_`&_^20X!8'??!(<<\!O/LDHN(O4&9UG_D"B M3MQ8@A.V2)V?L03G95@+?9(A1C#TCP"2L5>"8RO$QS=JG%XA/CX)#K$0'Y\$ M!U6(CT^"$_1(G=[R\^`@/5(GMBS!23E\X)/@P#Q2Y[?": M`[GCD^"V(XJ]$EQZ1.H\G:WA:@/YYI/@6A%M?*/&;2+:^"2X5$1,?1+<+4;J MQHI'@/M$1-LGP1TBHNV3C`*LO;CV96L)).JBFB6XF(8UGP37S(B/3X);8<3' M/X)^I&X&N1_<_B)R/@DN?3%JGP1WOXB<3X(KX$C=&G(_HR"`-=_,PF=&\(%/ M@B^$X`.?!!_WP`<^R2C`ZE]OTYVY@.\^,`+?VHNO.#`"GP3?9&`$/@F^L$`_ M/LD0>T.?!X:#:.A;]4:#J/1E]`C+I%<_P(J'O2_[&!_484SU7\>='QY_\?:Q M>MEDJ\/+]OW8>ML\8^]\77V!>:C_.*[^Y51ONUN?]R?\K9O:@;=>\4>,&WP( M=GV%DX;G_?XDOZ#KSOG/(A__!@``__\#`%!+`P04``8`"````"$`73\Q9>$; M``"W@P``&0```'AL+W=OKW]\OO[^\./VX_F_;I_.__;I/__CPU\/CW\\?;N]?3Z#AQ]/'\^_ M/3__3-Z^?;KY=GM__?3FX>?M#RA?'A[OKY_QGX]?WS[]?+R]_GQ(=/_][?+B MXO+M_?7=C_/)0_+X*SX>OGRYN[G=/]S\>7_[XWER\GC[_?H9U__T[>[GDWB[ MO_D5=_?7CW_\^?._;A[N?\+%[W??[Y[_=7!Z?G9_DY1??SP\7O_^'??]S\7Z M^D9\'_Z#W-_?W3P^/#U\>7X#=V^G"^5[?O_V_5MX^O3A\QWNP(7][/'VR\?S MWQ;)N'E__O;3AT.`_O?N]J^GV;_/GKX]_)4_WGUN[G[<(MHH)U<"OS\\_.%, MR\\.(?%;2IT=2F!X//M\^^7ZS^_/__WP5W%[]_7;,XI[XY+LSN7]OSLYL^GYX?[ M_YN,%M[5Y&3EG>"O=P)W)^S7WAY_O?W5FZO-9GUY]0Z9GDCXSB?$WU_*"-7Y M<'?XZ^V1Y0G_"PF'^X?DH.$XE1)W?,AJH9%N6>%A(]]P_)\_15 M(DA37OC'KZ6XE!3XAT]Q.N1OIWIRJ%_[Z^?K3Q\>'_XZ0Z-%8)Y^7KLN8)$L M4`Z^9OFH'NL:JOR-,__-V7\\AR%JT1/H/SYMEE0R*&)0QJ&)0QZ")01N#+@9]#(88C#,0 M!!HM\=\*M+-'SSFKY*OENS"RV\G&=2S:$D*3W='D&'TB*9&,2$ZD(%(2J8C4 M1!HB+9&.2$]D(#+.25`6Z+'_K;)P]NB<4+0:Y^7[,-);;W2J,(XFQ\(@DA+) MB.1$"B(ED8I(3:0ATA+IB/1$!B+CG`2%@0?.O#"DDW?X$'.)U78B:SQXCZ6P MBOO]W=%(DNV)I$0R(CF1@DA)I")2$VF(M$0Z(CV1@<@X)T&(\82V0NQP&.*) M8)@FT=L1V1-)B61$B(#D7%.@GABZ&'%T^$PGI[H MXW)'9$\D)9(1R8D41$HB%9&:2$.D)=(1Z8D,1,8Y">+IIHBS`:!T`0Z'\9S( M\E+KIR=P/>L4HJYY?S22:IT2RCD;B>IR3H&S>VV7C<%@V$YF7C2=:^_=$4B(9^-_0NUDMB5C"IV7ZO5W/TJK,>-6HG[EE''[GNV&AB-`0K+Q\VGC"[+C<7C M;14G/,V:I@ M5#*JV%?-5@VCEE''OGJV&AB-`0J#[F915M#][$I#L'6K30CZ!EW*+.B78;7> M>:M9O[1GE#+*//)KCF[))F>K@E')J&)?-5LUC%I&'?OJV6I@-`8H#+J;+5E! M][.H>=`G=!4&/5HIV"TFJ]5\"KM<1%9[L5I-BVI7%\NKJ/12,=$FDS'*!9W, MKA`KC#V.]66YCE;R2K'2'"M&M:"3.39B=3+'5JPTQXY1+^ADCH-8O1S244P. MV875P,WHK&HPS?30:+7#FQ"J@:`=&HIKCBAS07M!JR-*!>G-9HQR0>JK$'1U M]%4*4E\5HUJ0^FH$J:]6D/KJ&/6"U-<@2.]Q%&1$V,WQK`A/<[\@PA-:(:K' MVKI:1L/0W<);71Z:T/+J??3,V:N!E$KJT:Q'S!CEDG#^2*/64JB5N"_95\6H MUH1Z>^2^42MQW[*OCE$O"5^*RZ`&XGD,W(0-PTTE9\7VZO#83SVUFFS=BP;7 M.N;#L@E=3F^BIG<"A%*?<'EXU7881&>"=*B=>[36]E@P*B6A^JH$J:^:$S:, M6DFHOCI!ZJOW:':/`Z-1$AY\A9%W$\59Y&6NOI@FD$&#F=!FWD&N5E'WOO,) MU_-U4^/)-/E:2S>Z6EQ%+2\51UJ@F4>S\5TN5B>S*[S5.Y3^L:U38RC%E^98 M<8ZU6)W,L?FE'%OQI3EVG&,O5B=S',3JY9".8G+(+JP&;N8ZJP:O-L!IIAM4 MCPFA>DB#WRTFM%:T%Z2/@520UNK,HZ"@R5?AK=[I4Z9D7Q7[JL5*KZMA7ZU8 MZ75U[*L7*_4U"-)['`4=?`617[H)^ZG(__WAYWQEX&`?K@QX%([3E]'4?>>M MKF:](:.44>81'KI2L#E;%8Q*1A7[JMFJ8=0RZMA7SU8#HS%`86&@B-1T"<4C=.CE584+ST3K6 M$N+1NB#MKU)!>K\9HUR0]C&%(/55"E)?%:-:D/IJ!*FO5I#ZZACU@M37($A] MC8*,"+^P%K'DM0B/PM'Z.EJ]WXG5-"K=X'\743>X5Q/IS5*/YN-U1KDD?'^8 M"<1K3X7*XK=D)Q6C6A-JXU^MH]%0HU;BOO5H@Z4`[37B"4S'.?;B2Z,4[T08 MU$2R&P-'84-QBQ&S1]BQUYP6*>:#A*5?M]!GR4Z0/F;WC%*/@C*:?,U0+@EU MS%PP*ME7Q:CFA`VCUB,4@@2J8U^])-1['!B-0<(PPF[J;T5X6A(((CRA\+FT MCEK!SNW<<[.E:;"(C7P7[Z*U^+V:R)VE@O1F,T:YH*M#0UF\CZIRH;HX+@6I MXXI1+>ADA]ZHE;AO!:G[CE$OZ!B3Y67\GDU-Q/GY,:'@ M^>$7'G398^\3HM`D]U20WEG&*!>DG7+!J!2DOBI&M2#UU3!J!:FOCE$O2&]H M8#0*,B+L9O-6LYAF^4&SF%#T_(CJ_,Z]P7'-8NH9%^NKRW=1R]FKB1;"E`K7 M*2CS5C.42\+I^1'WTX7*XJ1D)Q6C6A/J8V"UCFINHU;BOO7HM><'W5POOC1* MFVA5;%`3R6[T:`I)V%#0H,UB=#P::$UHOLJS]$BCOV>4>C0KD(Q1+@GGSP_O M7E')"2M&-?MJ&+4>!<^/*AS1J)>Y;01C/'Q,NX^;;B95>1"_(/T\N+I91=S.HA>0V"N+.#J_T@S)\ M;8GF8!^V'H_FCQF/-K--'8Q205K_,H_F2S1BI8.[@E$I2'U5[*L6*_75,&H] MNM0'2,>^>DFH]S@P&@4=KBOHGU8OK`H<>!3A:55@@PG,L;*LUM%[N9U/N)G7 M19JC[[W5Y<5A''6U>K^\C*IK*B8Z`^2]E5XBO=].;CDWTX"M%U[PJ MSJO^I;P:\85GRRQ,T5)R:_JBEL<7T9L)X[>C@US$,;[KRZ@3&\7D<,]AG7#3 M^UF/^FIKG)8#YCVM6Q3"XPUU15K_SJ-+[47V@K0AI(*T!64>!:4^N9_Y*B2A MCMU*0>JK8E^U6.EU-8+45RM(K3KVU;/5($CO<11DM,9HT8`B'RV88K@(K\U+ MS=1[T;PJSJL6+R?S:L0*D\5C!%;Q"_U6K`)?W$RGZYK=<&\FY&9*`;[<1.L^ MHW@ZW'383J.U":HMT<8[7!_5E@G-7VQXJ_F+#4$:]U20MJW,(_R1-I^+E?:K MA4?S%QMBI;XJC_!'?-5BI;X:CV:^6K;J/,(?\=6SU2!(K49!1CMU2PRG>LBX MG4Y+$D$/Z9'V"SLW@4.G.7^+P2AEE'DT?XO!5@6CDE'%OFJV:ABUC#KVU;/5 MP&@,4%CG7UAXP+26ZO:$PGUU/*ONL@BZFN;/0;6>4/B^;A6-[78^X>R1OF>4 M,LHD1VTU.5L5C$I&%?NJV:IAU#+JV%?/5@.C,4!AT-U4V0KZ-(4.@CZA<%Z[ MHI'Y9.5&'\JK8]0+ M4E^#(+W'41!'&/N>S(9VX.$4V*-P"KR)7@+LO)7+\>4ZO5>K8SEX-.L6,T:Y M)CSAOE`K<5^RKXI1K0E/N&_42MRW[*MCU&O"$^X'M1+W8^`K:")N/]:\IWQM M''RPCPKVN+8A^>V\%;(5M&>4>H2E+;'*!.EP-N>$!:-2$JJO2I#ZJCEAPZB5 MA.JK$Z2^>DXX,!HEX<%7&'ET?//(R\``DX=X-.91."^E'7;>RN6H32>>-NW% MZN4.-143'2AD'LU&>KE8GH1LI6GM!>D# M(16DM3KS*"CHR?W,5^&M9I/'DGU5[*L6*[VNAGVU8J77U;&O7JS4UR!([W$4 M=/`51OZU)8!H(KKF)0"/PA$[[;#S5O.Y*:.44>;1?&[*5@6CDE'%OFJV:ABU MC#KVU;/5P&@,4%@8T:K`L3?DV?_:3_7#7\+$JW3>ZI41NUA-37>Q6*SB26XJ M)EJG,D:YH).CV4*LIG=8\4JZJ)I3Q:@6=#*G1JSF(_55O';?BE7@BY;HQ$JO MJQ<4)(R?-8-8O1S=44P.OL,:\<)JQ9I7*SR:#]X]0O%K!S@EG`_>Q4KO+&.4 M"U)?A2`=<)>"U%?%J!:DOAI!ZJL5I%:=('7?"U*K0=!L\"[(B/`+2Q-K7IKP MR*TM'<<6*]IF)U;3!H#U^H)V[^_51,HE]2@8N4]7,$.Y))RV2<2+\H7*XK=D MOQ6C6A/.[FP3O9%MU$KNT_%HJ#XA%*/XW;ES5F"%!2Q!>T:I1[,"R1CEDE`'S@6CDA-6C&I.V#!J M/9IODV!?O234>QP8C4'",,(OK".L>1W!HW`YB;;9>2MT1>Y4,Y3_\GVT,6>O M)E(NJ2#M`C)&N2"_S2[>@E.H+HY+0>JX8E0+0H4Y]@'T8YE&K<1]*TC==XQZ M0<>8K.-&/JB)^!X%<>_F!F56LSCPL%EX-']^>#1[6.P9I8+TSC)&N2#MX`M& MI2#U53&J!:FOAE$K2'UUC'I!^K`8&(V"C`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`>J!&K$*EERX MF5K7S#1_MR%6ZJMB7[58J:^&?;5L MU;&OGJT&07J/HR"CG48K%B^U4X1K^A#`=%#[_>WCU]O=[??O3VWLIP]'/GV"8+O!)PA;=XE[FY8075+W$VQ@BJ6N'MC!14+V5@*/H'P MVR'*4?Y;?!KA<(Q!S)?):-JODO'P`(CL?ULGOYD9;]?)>(A_E``=0^(J#M\$ MNH2D-!7T#(FK1IP&'43B:A,KZ!025ZE8::&XNL5*M]F@4`Y5)+IJ/*I1*):" MQS,*Q5+P5$:A6,H65[`UKV`'96RBN\?)5H]M.7!MF!;UWXIHR*SD4UZ)9 MP?@*Y6-=-496*!]+P0`+Y6,I&&>A?"P%8RN4CZ5@/(7RL90ME*VI[*#L3&4/ MQ0U.^$XQ*D7<+`6#4\3-4G(HN:E@+H<86#4>4SKE,!:M!B)N5!DL^B)NE;*%L307K;XB;E0:+;(B; MI610,E/!DAOB9J7!VAKB9BE8=D;<#KN&HKX*J\^(FZ5@>1EQLQ2L,B-NEH+% M9L3-4K"@C+A9RA;*UE1V4-SJL-$:H;A%8E:P)F*7BQ ME;B7*)P/WF\E[L4)*WB!E;CW)ZQT4#I3P;NKQ+TZX31X/X5'HZ5T:SQ_\!*2 MT^`M8K*"-\?(QU+PPACY6,H65[`UKV`'Q;W4XGSP[C%Q[[98R:"X5URL MX$UDXEYKL8(WCHE[N\4*7OPCC775)13WZIC3X-T_RM12L`4@<2^2.0U>^Z.T M+06O^E':EK*%LC65'92=J>RA[$T%VR4042L?[)I`1"T%FR<2]Y*=[P=[LE!W MK"$:MF:A[E@*MF.A[E@*=F&A[EC*;KW&55L]>0[%;:?A:\/V&4344K`9!OE8 M"K;#H1Y85U!"<7NH.!_LA$,]L!1LB$,]L!1L@D,]L!1L?,-56\H6RM94=E!V MIH+=A*@'EC=L(D1$+05["5$/+`5;"E$/+`5[;1$#:VB/+;>X4TO!GEKQ ME"VN8&M>`39-HQ2L:TNAN&VVG`\V1Z,4+`5[I%%'+06;H%%'+04_14C=U:V4+:FLH.R M,Y4]%+?9G[WA!QR)V_//"G['D;BM_ZS@YQR)^P4`*_@%%;Q9/1]^#X6X60I^ MW80[M13\5@EUQU+PHR'D[L=2\,,Z MY&,I^%4MZK5U!264TE3PLUK4:RL-?EV+>FTI^$4MZK6EX%>TN&I+Z5:8%4S[ MVRC6"\3:&E_CM^V(M:7@)^V(@:5L<05;\PKP2VBT'^O:]E#VIH+?/*/DK#3X MZ3/:CZ7D4-S/8;E,<3@!RL>Z:AQ+@/*Q%)Q.@/*Q%!Q2@/*Q%!Q,@/*Q%!Q& M@/*QE"V4K:G@G`?$S4J#LQT0-TO!D0Z(FZ7@9`?$S5)PP`/B9BDX"`4QL&82 M.`\%=VHI./`$=VHI..0$-=%2<-8)ZINEX$`3U#=+V4+9F@I.ET%TK#0X0@;1 ML12<)(/H6`H.E$'=L12<'(.Z8RDX9REQ9_IP3<1Q2XD[QX<5G*>4N.-\6.F@ M=*:"HY02=Y(/I\%Q25C+M)0ME*VIX/BJQ)U]Q-Y2*.X()%9P4E7B3D)B!0=6 M)86IX&"JQ!V"Q&EP:AOB9CV9<'@;XF8I.)T-<;,4'-*&N%D*SFI#W"P%Y[$A M;I:RA;(U%9R&A[A9:7#B'>)F*3CX#G&S%)Q_A[A9"HZY0]PL!>="(FY6SX?C M(1$W2\'YCXB;I>#,1\3-4G#T(^)F*3C>$7&S%!S`"F]6[X)S6!-W!BC7`YR] MBGPL!>>M(A]+V>(*MN85X%A/E(]U;3BZ$^5C*1F4S%1PD"?*QTJ#`SM1/I:" M\W*1QKIJG)&+-):"HW)1II:"$W,3=PXKQPVGY**T+04GXZ*T+64+96LJ.'TX MV9G*'LK>5'#*,")JY8/#AA%12\&9PXD[HY;O!Z>9)^[0;%9PJ'GBSLYF!0>9 M)^X(;59P?CG>^U@*#K?&55L].8ZJ1OE8"@Z>1D0M!<=(HXY:"@Z23]RQXWQM M.#P^<:>/LX(SY!-W"#DK.$H^<6>1LX+CXQ-W)#DK.#(^<2>3L[*%LC45G,F? MN+/8.BCN2G1464'*6@@\KX:HM!=]70LE9"CZS MA/9C*?A\'N['ZI$ZU\%:0N_Z2DO8+=S;LNN++"%S79$EY.B-K0%JCA&_W77A,6%ZJESO M;651HR.VLJ@Q?3ID\?8X77_Z].'G]=?;]OKQZ]V/I[/OMU^PX^+B\/''Q[NO MWX[_\3Q]ZN'L]X?GYX=[;)`Y/_MV>_WY%I]&NWB#_4%?'AZ>Y3_0_;[]Z^'Q MCZ=OM[?/G_Y?`````/__`P!02P,$%``&``@````A`$#F*1YG%@``[&8``!D` M``!X;"]W;W)K&ULE)W90:'[4RJR M6!O#]HDN[K77Q)F9:[5CEO?WX02&+Y(5G=%RWYRT0"3"16@M"' M?_[U\/WJC_/3\_WE\>-U,AI?7YT?[RZ?[Q^_?KS^WW_5_UA<7SV_W#Y^OOU^ M>3Q_O/[W^?GZGY_^^[\^_'EY^NWYV_G\<@4+C\\?K[^]O/S(;VZ>[[Z='VZ? M1Y'FY?\,^GKS?//Y[.MY_[1`_?;]+Q>';S<'O_>*TMY$_OL7'Y M\N7^[EQ>[GY_.#^^:"-/Y^^W+RC_\[?['\]B[>'N/>8>;I]^^_W'/^XN#S]@ MXM?[[_WBQO8.G3A\_W>`+E]JNG\Y>/U[\D^6DVN;[Y]*%WT/_=G_]\=GZ_ M>OYV^;-YNO^\O7\\P]NH)U4#OUXNORG5[K-"2'Q#J>N^!HY/5Y_/7VY___[R M/Y<_V_/]UV\OJ.ZI2G)W^8Z<\/^KAWL5`WCTV[\^7J?(X?[SR[>/UY/9:#H? M3Y)T>GWUZ_GYI;Y7::^O[GY_?KD\_+]62HPI;61BC."G,8*T;^AG1A\_)=-D ME*73^:+/]8V4L-L7=VY3.L5](R$"NT^(GW\SRZ5)B9^2\GU9)JBU/D_UBTF: MIJ/%=)K-%O.W/91(O:A?3-J?I$`-ZMQL528+6Y5O^":1^E._R#.^LYQ2E8FM MRW<_HU0F`E.R_X*-?'\XU9U?DF>P)II4R;WH96AL=\I]5^4_L=K**+]/(/^\2E+D@\W M?Z#9WAF=%>L$&H5HJ*:KS)8AJ$)0AZ`)01N"+@3K$&Q"L`W!+@3[$!Q"<`S! MR0$W\3TW_*]TE>^%Z^M!-C*2/VJ*$1#DI0AJ$)0AZ`)01N"+@3K$&Q" ML`W!+@3[$!Q"<`S!R0&>H]$#D*.SZ1#32HPAPHOIP)$KK:,ZKB'PIX&O!Y7! MV40J(C61ADA+I".R)K(ALB6R([(G=Z]*#D>M4UZMZ-^Q>EC[X( M-3GXF3L8H_1690PJ0V40J8C41!HB+9&.R)K(ALB6R([(GLB!R)'(R25>9<#O M;F5(GZYP[W/QU4J3[,UNOAB4)%E)I")2$VF(M$0Z(FLB&R);(CLB>R('(DR('(D8*97 M6BV)[8I1S:AAU#+J&*T%V:)N!/E%G?M]V-9J25%WC/:,#HR.C$X>\NM!K7J< MCL*L+$=JC^#EV_W=;ZL+/)P,DW`UM0XBWB"O?K36!)7LU,_,?^C2)(26/'3% MJ&;4,&H9=8S6!CE%W5BM-XJZM5I2U!VC/:,#HR.CDX?\^E&+I;]3/WIQA9FY M%'2E9NFJRIPNWJ"IJM<_/J7C))BVE%9!S%2,:K;<6"UC.5BAM59!+'>,UFQY M8[7B9=Y:!;&\8[1GRP>K%2_ST2J(Y9.'_!I3BRRGQF3H51M<8HZ?V9[,K+_&M5I&':,UV]JPUI;1CM&>;1U8Z\CHY"'?^6KEY3A_:`1Z18;6(]&P4ML, MRIUJP)'-RG09#)"%T9K"]U8K";1*L37K^[5D.4[&?N551L,9`6I&S;MR:X/< M%HO9TL^M8]-K1IMWY;;U;#L.GFF_L%H5?Y&J'R)1X*M:F.>$!-"RH-FMAI56605X\ZH8,:MM6RK8YMK1EM MV-:6;>TXX9[1@6T=V=;)2^A[6*W[8AY6/)@]:[3PIV)!H!;JG8)JA!/=<,;+ M9=#KE59#JJ429&NJ9M0(TJ;GR3@(I-8JB.5.D+6\9K01I"U/T-B#0F^MAIC> M";*F]XP.@K3I-)EE06,[6@TQ?1+4F_;K2ZTK8_6EUYM>B]`(]25VBT0C5(Z@ MDE$ER#Y8S:@19&VUC#I!UM::T4:0M;5EM!-D;>T9'0196T=&)T$1#ZN59LS# M9@7J#C@:>0-.E@8#19$8+3.43,.P+:V"U$IED-,#U8P:FU!--Y-E%D1M:Q7$ M[+('>`$&1'@Y)199!;%XP:3M@RZCCAFM&&$VX9[3CAGM&!$QX9G;R$OH=C MR_HT>W59G_*RWJ"Y.^/*TO`5L=&:NK.W+`T6?:75DNBH#%(_[(0N-%^+EFV^ MC;5E$V9IT#VW5DMR[,36FSFN1]:-D<#]:6 MFV.P"CQ:+R]$/DF!O02;I6*"$LPB#IEAW#K65I<&&3B%:&*\&K90F MZ49K-N[G&I-D$@[;E6A8C]0&.5=NK=C2N:7SZ2((SDXT;&YKSFWSKMRV M8DOGEHPG2YJEBXK-;L_9'=Z5W5%LZ>P6LUD63.Q.HM'GYM>^VD-P1LR?[?RE M>L_!G:L8A*B0`"P,FMG1OA1DY_B5(-N%UP9Y%:QS=&RUDM#:Z@196VNVM1$M M6ZZM(&MK)\C:VK.M@VA96T=!UM9)4&_+][S:0'C+\_^Z_'#W7%.]X>!Y7B/4 MKO6\1@M;JM(D=%#%J#;(L=6P5LNH8[1F6QO6VC+:,=JSK0-K'1F=/.1[7NTU MA)Z'^M#SZ;T(S],:3;WU4QI,K`IU8!'K)R=Z2T85H]H@+*:E(AO6:AEUC-9L M:\-:6T8[1GNV=6"M(Z.3AWSGJ_6YX_S!Z7K=[CE=(V_1.J'11BM-,%J]-=H8 M+;.R7:;A5*%"I?5K7]MP:D:-H#=S:T7+Y#;/LF":T(F&S6W-:"/HS=RVHJ5S MPQHU"<:VG6C8W/:,#H+>S.TH6CJW:89#L_YVUTDT^MS\NG]EPT+MT=+=9VS9(QIV+E`;Y+QK:D3KS=Q:T=*YQ98] MHF%S6W-N&]%Z,[>M:.G4;'9[3F[@VB]F=U1M'1VL66/:/2Y^;4/TV[M M_ZS=391^$!4:(2JD^11&*[.H%&2[_4J0#>;:(*^"M7G'5BL)K:U.D+6U9EL; MT;+EV@JRMG:"K*T]VSJ(EK5U%&1MG03UMGS/HQ6]Z?E@V:,F=J'G-?(/!*;! MZ%&8A-"2^BD958QJ1@VCEE'':,UHPVC+:,=HS^C`Z,CHY"&_,H+5OTS&\9*! MG*X1)O;BSL)H.:AD5#&J&34>\LL8K).',O)Z&.VG+[8]_5`P*AE5C&I&C8?\ M,JJ%GS/M^FEWHA>*[G1,O8A0<>[Z5R/5BPTSM"P-]G9*DQ!:4C$5HYI1XR'_ M<=1:R'F

5ZC>056R-GKE?@!:UZ$M4%V&)/@C2T$9=Q:@69'O7QJ#@2>Q\ MTG\2-<]VZN2G(:;GY5Y=:>0]H49^B$V"]6,Y&;2D8BI&M4&.^4:0%\$3NX3P MGS"8"P]1QW/>B4%N8S'38#?JZ!Q2:1(B-NV3#`D%U6R^,6CIS0&=S0CO2;)7 MYI8]]V<1!OF'C6@99K30`4D92T85H]H@=U?/0WZQU93#"3&I`#6E#89@@U07 M,K0,/JYCM'YR7$=LF37F(EN&)V@JH^*$5LVH$4/+_I5".G(.J_C/&4Q!AN?D MJ0:F7WU?Y@2:0>[)%-&R;;LRR"NQMN6@1A+R\B1[963N>1!">F3VMLFR)!@F M"I,0XZQ>;D^RJ>UI]'>=5D6BK!)D`Z]FU`A:&,?/;!?I._Z5H3SCH=P@=__' M(#R!%*]D5`ER2ZS-.ZVG$:U^#1YS>MJ6(T]D1YNW1$B,R.P&^X&V=5X*5H6 M509Y)=8)'=1X"7VOOS).JZ_:PJY'(W_V'^X=%2:A._MG5#&J&36,6D8=HS6C M#:,MHQVC/:,#HR.CDX=\IZMA/188>KCW`D,C9ZI?J`I`U3BH9%0QJADUC%I& MG8?\)U%CN#R):FCZ^WK^Z/!H*<)LRH-"B8]P5C1F6UI&NJ&35LOK5:3L^8!4N`SFK!O.\&=R9B MZQ-?*H3U:9`_1<]L3]@'0B%:=H`NQ1:B>)C!X&6&_RZCBFJ%+_/K=VDU7(@V MFC`L1!?5<@KAN\Z=W#BNX[F-VL]4#=C&?2'(]9-)Z/O)+K=Z!UPX5HXPF#EQ5=7,N:]_WD3K#0*>B[-%X]&J7.O`1=B4'.PKLPR!GS M2DGH#):BY:V*,KLJZEU:<\)&$MKJ:5FK\Y#_S.[\RXD-GGZI*;MZ7+<7(52* MEAL;M.:J8EJ9LW0RCVO,N[:R\%!D([9LN5I!;D(J1!?3`JH M3KS!3TM$A].+!/UH8;2<55@I"=6I`US+,J..QQC6\G0T"R;KM1A0-V/@_.AT M%)Y&:#C75A*]DFLG\IA1WT-J%B]%@NJ!O%]VW(4KJL;SK:51-KJ8AP,)9W(!Z/. M2LMWD3NE=8*(9[13C?P@F@89%T;+"R)C:ZQ/?LW3*?7+QK2N<%QM$(1F+7GK M&E79;.2,O7TH-IQK*XE,=,Z#B.]$/AB= MO^:A^-QVRG-;@X(XLF;[LA9&RXLC8\O49[((IVJ5F-9Q-!\Y*WS3?6L32QU' MT\EH'GBYX7Q;W^IB'`R!G-09YH(AJQ`U-ZZ,L7&JQ[EL&3B[DD1C MO76W'"W"#FK0,,Z?C,)/N1M1L3FW@HS=9!:4MAL4C-ED-,W&SG]6W_>F/[.6 MQ3@NFR2O:;3$U&]P6A*VB\(D](+-V)(.:[88!_%4F52PK0;_^6@\*GQ$-&]2=X^)C]+/\%=;8RS!*Q&DB3YF-D&I8V&$-P4H=4R" MMP$H=4R"EP(H=4R"=P,H04Q29&-8BP8&2KV*EKJ`I(A*2DC*J`0OCY!/S`=X MAX12QR2KR2Q?X>4E>Q1OM_,*KZ!CDCDDL<913!:0Q*SA_7:NWIO&K"V1IM\T M"`(7!Z9R=3"'T^#<5*[.Y[`$9Z5R=4R')2=(U&D=EJPFJ#G]LB4H03%!).+5 M'Z?!@;-<'5-B20>).JW$$IPWR]6A)9;@V%FNSBZQ!$?-X6%)!HDYRL02G]5"G,0D.[<%O,0D.L>;JP"1;PUG6 M7!V29`D.K.;JK"1+<&XU5TJ4$*>(M5K82:=27AEPV?$V*FHM)\%$IXBTFP;>EB+>8!)_=P]>QN0N^ MOL>3QB3XQAX>C4GPJ3VB-R;!%_?P3DR"[^H1.S')"I)55(+;#."=6!K<60#O MQ"2XN@#>B4EP@P%J.R;!/06(T9@$]W?DZ@X)KA]R-8@KLZN;I%@"6[NR-7-$2S!]1Q8#\0DN"4'UF(S.UR6DZO+6M@:+LA!/C$)+L9! M/C')"B5814N`^U=R=:<'YX-+5G)UM0=+<-=*KF[X8`FN7,G5K1XLP<4JN;K< M@R6XS`AI8J7&)49($Y/@+B/4:4R"*XUR=6$.YX-KC%#;,0FN+T)MQR2X<0L^ MB/66N#\+98M)&ULC%9=;]HP%'V?M/]@^;TD!@(-(E1T5;=*FS1-^W@VB0-6 MDSBR36G__:[CQ+$I2'U!Y.3ZG/OIF_7=:UVA%R85%TV&R23&B#6Y*'BSS_"? MWX\WMQ@I39N"5J)A&7YC"M]M/G]:GX1\5@?&-`*&1F7XH'6[BB*5'UA-U42T MK($WI9`UU?`H]Y%J):-%=ZBNHFD<+Z*:\@9;AI7\"(Y*)N@6+'*Z[?.E*,ZGSUM&^$I+L*XGXEH)T$76T?$M6]V2!H\VZ2]!? MSD[*^X_409R^2EY\YPV#;$.=3`5V0CP;TZ?"0'`X>G?ZL:O`3XD*5M)CI7^) MTS?&]P<-Y4[,D5Q4H`2_J.:F!R!T^IKA*2CP0A\R/%M,DF4\(],$HQU3^I&; MLQCE1Z5%_<\:D4[=_&>P;D#6(+^]M[JT-_#H;XBPBD'7:H.=I#Q(&-1(F`4;SW@(^ MW_0RW^PBGT$A5;X[:>P(K(2UF7LVB;,(7`:3"RX;%!((CHXAIV/05L,:?4`# MBGE!PZ"=ALM+C_B,Q%,-_%X$G+;,\72R3%QEC47(WR,@XT5U)?70$9[/EG\! MW>GHC4%(WR,A_>QRVLU==]ZE<^+(S>N0O$<@!,_WL5&#W*07R)?I!(9J:$EC M$?+WB,^?D"L]0^!*\+P?2#NX8QU]3,C")D&X:ACXK!HD31U'7PUKY6?K6C7,=([5<#(&#EL)[OH. M\DE]Y3`_9BA'VOZ^G@4),B9G$CWDEP"VO`O.2M@-9;=#S>2>?6%5I5`NC@T, MT1RFP:%N,VZ[,ISC\]4V->4YQTF\VD*Q+KV!(W;)1NX0[+Z6[MD/*O>\4:AB M);@1FU"1M&O2/FC10KBP`86&K=?]/<#G#(/=$<,-A$HA]/``TI'[0-K\!P`` M__\#`%!+`P04``8`"````"$`2':O?)<"``!0!@``&0```'AL+W=O;,VY0T!0-L>U<^V6$,MJ+JF- M=,L5?"FUD=3!T%3$MH;3HILD&Y+&\8I(*A0.A*UY#T.7I6#\3K.3Y,H%B.$- M=9"_K45K+S3)WH.3U#R^Z@&$FV_5HI;>BQ@74_)4O*+NQN M\`8O!3/:ZM)%@",AT;=KWI`-`=)^5PA8@2\[,KS,\2'9WEYCLM]U]?DC^-F. M?B-;Z_-G(XIO0G$H-FR3WX"CU@_>^K7P$DPF;V;?=QOPPZ""E_34N)_Z_(6+ MJG:PVYF?PG0#D>")I/`M`"NG3]W[+`I7YSB-HW42;Q;K#*,CM^Y>^+D8L9-U M6OX-IJ1'!4C:0^#=0Q:K*%O'BR3]+X2$A+J%W%%']SNCSPB:`T+:EOI62[8I M%)!Y\>#5'*\Q@J0LJ(_[+%[NR"/4@O6>V^"!Y^!)!@0SI9G`V`$")XEF//X)BD#):9E+T*=8)$1S%>ER68 MWA$#]FPFAE>[&$-=>F6ZLI>HD[Q7$R;R_9AF601-=ME9[YCR>P5>HU6MYNL" M'3'*N>,OXTVT&O#>,,7WRA2_GL?[:_&E&3O\(EN/T_>.*;]7IOSK5_QP@D/C M2VXJ_HDWC45,GY0O$:0_J,/%<4A];[[6E]M#=Z&0X0.<\Y96_#LUE5`6-;P$ M))QNV#<3KH0P<+J%S.&T:P&ULE%;;CMHP$'VOU'^(\K[D0@@0`2O(:MM*K515O3R;8,#: M)(YLL^S^?6?L7(C#KI870B9G9LYA9<9WK#PL MW3^_'^]FKB,5*7KSY\69RZ>Y)%2Y8"%4B[=HU)5XGDR.]*" MR!&O:`E?]EP41,&K.'BR$I3LM%*1>Z'OQUY!6.D:"XGXB`V^W[.,/O#L5-!2 M&2."YD0!?WEDE6RL%=E'S!5$/)VJNXP7%9C8LIRI5VW4=8HL^78HN2#;'.)^ M"2*2-;;UR\!\P3+!)=^K$9CS#-%AS'-O[H&EU6+'(`),NR/H?NFN@R0-QJZW M6N@$_67T+"_^._+(SU\$VWUG)85L0YVP`EO.GQ#Z;8`Z>X-]//,=NJX=,?^*`HGTUD03EQG M2Z5Z9*CL.ME)*E[\,ZB@MF6LA+45>-96@OEH-IE$\6P*5M[1'->:\.S\!Y$? MH_>AGF?HZ[`?B"*KA>!G!WH)^,F*8&<&"=BJXZTMM!F`0F2(7B-\Z4Y=!T*3 M('U>19/YPGN&E&8U9C/$!'U$VB"P$L"C)0-IN(4,PI$,5@?9;1I!QRZT/#<( MVS.$?HMGA$/%+],0^WU7&X,)(-8V5Y,^)&TA-IWH-CH(AP)"<*VK85EJT'M\ M6HC-!WKJ(CU-,Z!4NVT+4$NZDJ27DEZMXZLF4=HW64M\'M^ MH%B10TXX-RQ.(1!_'XJZED5=M,6[F%D9M&8VC1:5$O#W+[F&BJH M.-"4YKET,GXJX7R!V=6B%9MK?Q/@O:_OSL&7$+YH5H,OXV97L+[`$K&^K@$* M&)^%WX"+JWAPH'<1"[^.DK594JP/FRA)HVL.IDFJ9Z:-GR7I[!I^GJ3S:_+` MAPC,AM.:@JVE(@?Z@X@#*Z63TSTDV=?%%F;!,2^*5Y!\6%VX@G5%_SW"(DIA MXNIQN>=<-2]8RG:U7?T'``#__P,`4$L#!!0`!@`(````(0!Q0EM/`Q(``/]6 M```9````>&PO=V]R:W-H965T&#YH11U*:H^=[@CW!'8 M`LAW__S[Z?'LK_W+\>'P_/Y\?C$[/]L_WQ\^/SQ_?7_^O_]*_G%S?G9\O7O^ M?/=X>-Z_/__W_GC^SP___5_O?AQ>_CA^V^]?SV#A^?C^_-OKZ_?H\O)X_VW_ M='>\.'S?/T/RY?#R=/>*_WWY>GG\_K*_^SP4>GJ\7,QF5Y=/=P_/YZ.%Z.4M M-@Y?OCS<[W>'^S^?]L^OHY&7_>/=*^I__/;P_2C6GN[?8N[I[N6//[__X_[P M]!TF/CT\/KS^>S!Z?O9T'^5?GP\O=Y\>\=Q_SU=W]V)[^!\R__1P_W(X'KZ\ M7L#QE_^7]^<=YU*^6YY^SX[?#C_3EX7/U\+Q'M)$GE8%/A\,?2C7_K!`*7U+I9,A`]W+V>?_E[L_' MU_\Y_,CV#U^_O2+=:U7D_O`(3_COV=.#:@-X]+N_WY\OX.'A\^NW]^?+JXOU M]6PY7ZS/SS[MCZ_)@RI[?G;_Y_'U\/3_H])EN=0'\_;VGFZ.!#*[4/W[S^>;2!-0_?O,)Y\C6Z->T MGU]D<"Z-1?U#N[N]N)[/;I?7IU,XE]:B_O&[#RD-!R^!E'UK&N?2=M0_M-]? M/:0TFKEI-:<;ZN7X7@[O\^[N]>[#NY?#CS-TDDC*\?N=ZG+GD;*FWV3=UJ=W M&UW,O5+_J/3?GT,1;^T1]*\/JZN;=Y=_H;.XUSH;UEEV#Q@>M#SH?]!:X1-RGX*-5_U;PE;X*OD1M(\!D M8^$%6C2DR,X'L0\2'Z0^R'R0^Z#P0>F#R@>U#QH?M#[H?-!;P`DT^@(*]'(V M-6HEQLCD-.I;-Y";44=U8E/+7[LJVTEE"C:1F$A")"62$EMXH0>G2F%7O62XY#('8S21V>$3$YQYAY&*YU*QJ0R)8-(3"0ADA+) MB.1$"B(ED8I(3:0ATA+IB/0V<9*!N-O)D$Y=X2'F$JN-)J:KV=K$L8E1*V13 M8=>F)K-QGJAZ_:T@_#79OIY-[Y7C"(-.R)'"KJ.17&.N8AF=3T:'`6<[*;/!A;K"^3^9Z^K*N%& M?R0K_+&B[P]+D](4?2(QD81(2B0CDA,IB)1$*B(UD89(2Z0CTMO$B3[FY13] MY)$WZUN+'C+[WCP-T@:^1%>>5%V6A-8684,TH8I8PR1CFC@E')J&)4,VH8 MM8PZ1KV#W*"KN;'5Y4Q!'^?,F`=([#9J[H7&CM=!T);1CE',*&&4,LH8Y8P* M1B6CBE'-J&'4,NH8]0YR(ZPFQ:$(CY-E)\(:6<.^FHBI'L:@':.84<(H990Q MRAD5C$I&%:.:4<.H9=0QZAWD1EA-?JT(ZT7TA=IP>/WV=Z84:*1%<[4:&G+WNPI,PIB.6=4L.72:(7K7!D%L5PS:MAR M:[3"=>Z,@ECN'>1F3*TVK(Q-HX)>A=B9T+&26,4D89HYQ1P:AD5#&J&36,6D8=H]Y!;M#5:BP4=+U*LX,^HC4&ARG" MJVLOPENUH8D(+VVMQ?S:G27M1&LYOD>+V=I;JL6BL9I>I(11*NBDMTRTM+?5 MS=+KIG+1,-X*1J6@D]XJT=+>ELN%MU=:BX;QUC!J!9WTUHF6]G:U]+ND7C0& M;V[RU9HPE/QQK8C!3U[;C=HF5OV:05N-D&G1V@D:OD(-`T`LR#QKPB@59&QE M@HRM7)"Q53`J!1E;E2!CJQ9D;#6,6D'&5B?(V.H%!2*LUGVA"(_K02?"(UK; M0__JFO;01ZTE%C362TBOUZ0EJ8GG(UI@?)H*+A;>6Y=H+?074C#5R//H->G, M:$G!_$T>"_98&ENFJJMK;Q)4&2WQ6+_)8\,>6V/+\GCC=1*=T1*/_:\\NJ^; M6H6&&L.X.G4:PXC M-Y\9!;&<"S*6"T:EH-'RS6SF1;DR"F*Y%F0L-XQ:0:/EZ^7":S&=41#+O2!^ M< MQ!HMKJ8T)8Q24U`9OKKU^N3,R,5PSE8*1J44O!IJ/%_Z"[W**(CEFLTTC%I3 M4%5Y?K7VWK+.*(CEWC'C=%SJR[3=^^(,H'Y@VDL6ZVU,JO8':-8 MH\6ME:+1EI6UE`MFC'*V50@R+:#4Z,HLX2I&M10T]6H$&5LM%^P8]5)PL.5& MWMMED#71@G<3-/*&#&\5N=5:*[QCTYO$TW/1TMW_?+GR7J98-,Q$(=%H:7J- M5+1.>LM$2WM;S?W1)A<-XZU@;Z5HG?16B=9/GZT6#>.M86^M:)WTUHG63Y^M M%XW!FYM\M9=@S1=^^=J->P_V/$)-][QINT8K,Z7="3*9BP69MIQHY.1W-&_9 MRJ2@L94+,K8*ME6*EJE7)G/C=6M;71!:)A]304$Q:R6,4D89 MHYQ1P:AD5#&J&36,6D8=H]Y!;CZ\78.WY(,W%-1&'5X9+Q_>,F-KM"3X.T8Q MHX11RBACE#,J&)6,*D8UHX91RZACU#O(S8=:V5N=U31'&%?\3J3EYGJ8F'WF5NYGYS0:Z^QO@9I47T5K1F MUNPGP.(`2S1STJ>=PISUZ#?>KEP6L)8'6,$>RH!:%6!U@#5LK@VH=0'6N\Q- MS$_6Z]@(I`1H9`T+6DL-]=,;Q=\PC98TE9A1PBAEE#'*&16,2D85HYI1PZAE MU#'J'>0&W5LGRP0(*U4*ND8S#,!3B%>W_BZ)E'34>)M$U'#226VSK69>VXZU M`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`(LUFQM5F6)1D[:M`><`Y)'RB9K MAN5LK6!K9:!D%6`U6VO86CN5-+/@+L!ZQYJ3`GP^=%(@X]#`W46L('<-J+PO#$;KM0VQ._\6JJ M+Z+>JRG('MXTNS)3OYT@TX1C0>;M2C1R4C^ZM&QE4M"LP'-!QE;!MDK1,O6J M!!E;M2"CU;"MEK4Z0>89>T%#O=S0_VIWPOMZAL^'%/H1N5_/_(,76UW0_GK& M*&:4,$H998QR1@6CDE'%J&;4,&H9=8QZ![G)4-L,_GOPBPMF^!412LB(W"\' MM]YFWU87M#^?,8H9)8Q21AFCG%'!J&14,:H9-8Q:1ATC]4,L*H1C),:$C#^L M,OX0P]/^Y>M^NW]\/)[='_Y\QC@S'^X43'S\29?-XCI27WXP;I/D!I+AU?8E MJP5^!V;H$$FRE%^(\25P$_0")T$?MU$_K)M]._-9I.Y]A>J[1GV'[L,OL[B" M9.A%/`G&C4CU3VP-PT>DNBF68,B(5&_%$HP5>/J0!#^<\S$8+_R@3DA_@P`' M]1'>82G@/(?R$)!O48!.LP182M87!?K#YA/R$)-B#0GY"$FQ%(3\A"7::D)^0!%N_ M*!.J-79[428DP:8O*V^4G M4$3Q817/$Y+@^RK:3K"'72X@"97!1U2TJI`$9S0C==*/:XVCFI$Z\,<2G-B, MU+D_EN"49J2._[$$IS,C=0J0)3BD&:G#@"$)6B(.V;($!Z61GY`$QZ&1A9!D M`S^;H!^M0[%`"?G4>N0!`?H4>N0!.?H4;>0!,?ET79"$IR: M1]L)27!X'BTD),$1>;20D`175.`G%`/<5(&?D`075N`G),&U%/@)27`[!>TM M),$E%;2WD`37]##;#/7^VSGF![AHQ#G%W:Q(W;QB">Y01>J&%$MPURE2-YE8 MLD'=-L&ZX:(1VD&HUKA.A'80DN!6$=I!2(++16@'(0DN6$;J^A[7#9EC":Y61NIJ'TMPG1+1"4FVLM&?#;S2\C#]@ M.O[/ZWB<^^S3X16_1XK%.'X3$3\TN\?O',S4#R%].1Q>Y7]0W,;*.JH(V6O$*D633ETII0]<-Y'U(AI2=M+O+ ME;P4S&BK2Q>!'`F!7N<\(1,"2O-9(2`#7W9D>)GC13)=CC"9S[KZ_!)\;\_> MD:WU_K,1Q5>A.!0;VN0;L-9ZXZDOA8?`F%Q9K[H&?#.HX"7=-NZ[WG_AHJH= M=#OS)DPWX`F>2`H_`I`Y/73G7A2NSG$ZB=+'+,E&:8;1FENW$MX8([:U3LO? M@94E2!\Z@R&$79.!XD_Q9_+ M`)SKI;?U!C?U/)IC>/;A9$G<"P07@3,\Y_2,BY"!CK-2_XC`<9;5X%U=P@Z$ MR9'<5/P3;QJ+F-XJL/*#TZ/]ZBU2W]SW^'"ZZ%:2]!]@4UI:\5=J*J$L:G@) MDK$/&IFP5.'B=`N1P[IH!RO2O=;P[^,P/'$$Y%)K=[J`8]+_3>=_````__\# M`%!+`P04``8`"````"$`3^;T\],"``!K!P``&0```'AL+W=O[D%0H-"JH2JNROM2JO57IX=,&`5 M8V0[3?OW.^;6`%'5O@0\.7/F86(Z5)G9%*U#3&+U3AN]WG3]NSD(^JI%0C8*A5C$NMF\BV55I23I0E&EK# M/[F0G&@XRL)6C:0D:YUX97N.L[8Y837N&"+Y'@Z1YRRE]R(]<5KKCD32BFC( M7Y6L40,;3]]#QXE\/#4WJ>`-4!Q9Q?1+2XH13Z-O12TD.590][/KDW3@;@\+ M>LY2*93(M05T=I?HLN:-O;&!:;?-&%1@VHXDS6.\=Z,DQ/9NV_;G+Z-G=?&. M5"G.7R3+OK.:0K-!)B/`48A'`_V6&1,XVPOOAU:`GQ)E-">G2O\2YZ^4%:4& MM0/CDHH*(L$OXLR,`%1.GMOGF66ZC+&WMH+06;E>@-&1*OW`C"]&Z4EIP?]U M(+>GZDB\G@2>/8D;6*[OK`W'&WZKW@^>O=_*L7PO"&_;Z$M/N\N^K?J>:++; M2G%&,$F0GVJ(F4LW`K:^W#[VV`"0(37HO8''.,0(2E-@?=KYF]NM_00=37O, M88EQIXAD0!@A((\Q&6C#1Y(Q<).,$<=D=Q@,K]EYL\@#8AX92O](9`./,?Q> MM&$S#77H,"[4.H*"*209(?-T_(^E8^`@(!0WAEK*TH/>RF>$S/.!:;QHSS`, MQMJ&'07H+:^2))>6B=;KJY3&.J7L+4YW!XW,R6""Y]5Z)W%@5B]2;P?<=S86 M^':W9#GCQF.:0V?Q8<6/\0+'F8DY@L;F=4NFNVZUBV-N]Z+D*GX5P6PM>?9^M&^UF?/X4>)?P1_"?M?:HP.L MP(84]`>1!:L5JF@.I3A6"#K+;EMV!RT:Z"$L0J%A^;6O)7S4*.CG6`#.A=## MP31L_$SN_@,``/__`P!02P,$%``&``@````A`->!*Z)5`@``404``!D```!X M;"]W;W)K&ULC%39CILP%'VOU'^P_#X8R-:)@%'2 M4=J16JFJNCP[QH`5;"/;6>;O>XT3)IFD4EX`'Q^?3/1UDBW;<6*%5CI,H MQH@KIDNAZAS__K5Z^(21=525M-6*Y_B56_Q4?/R0[;79V(9SAT!!V1PWSG5S M0BQKN*0VTAU7L%-I(ZF#I:F)[0RG97](MB2-XRF15"@<%.;F'@U=58+Q9\VV MDBL71`QOJ8/X;2,Z>U*3[!XY2%"/)YB^UTH:N6\C[ MD(PI.VGWBRMY*9C15EO_%B/*;4!R*#6WR#5AKO?'4E])#<)A"(I_`A`YO20XQ0<1.F:'(^FT606CY)T@M&:6[<2 M_BQ&;&N=EG\#*>G=@U8?PS-UM,B,WB/H*[!M1_V4)/,47'@TQS.,0,\" MNBLF<9*1':3!CIQEX,!SX+PQ"*@/%A#O#0N/>@N?I_=H[_!X?SQ?]C2+#!@QZ1VO^G9I:*(M:7H%D',T@:Q/N1%@X MW4'D,.[:P8CWGPW\NCA,4!P!N=+:G19@3(:?8?$/``#__P,`4$L#!!0`!@`( M````(0!WW1.[P@,``-(-```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``! M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````)Q746_3,!!^1^(_5'EG MZ39`:$J#1C?8I(Y5M(Q'RW6NK37'#K93.GX]YZ3K4KA8*D]Q;-_==W??G>WL MX[94@PU8)XT>):ZX(KHV&4/(%+/N:O7V53 M:RJP7H(;H`KM1LG:^^HB39U80\G="2YK7%D:6W*/OW:5FN52"K@RHBY!^_1L M.'R?PM:#+J!X4^T5)JW&BXW_7Z6%$0&?>Y@_50@XSRZK2DG!/7J9WTEAC3-+ M/[C>"E!9VEW,$-T,1&VE?\J'6=K]S6:"*QBCXGS)E8,L?9G(;H"'H$VYM"[/ M-OYB`\(;.W#R-X;M+!DLN(,`9Y1LN)5<>X05MK4_S5A5SMO\A[&/;@W@79;B MAG:R&7;W=L?R;?[N0[,#1X<[@X86"2X<8IQ+K\#=+Z?<>@+R.\S\"^8&18NX M!?2<18;<8-?:8[S8K6ZS+4T7^=Z'L<%$:P<%PY$S2A;&Z7XPEC4N0%V:2W7*TR%/J3>/ANH!G,L3`EL M8IQC4[!LMN861;VWI(7/6`_L@:L:V!UP5]N(^CMN'\'SA0*V*T'L+J16]+PN M:]70Y]ZO$<;8E)6%-=)+;DB16XVQP(+L4WF+D=4K&8Q?.H?%UX3XBS'%+ZFP M2>R#<$!.[)R^D9F!E@:C46,TL0\@,E)D8O3*@RW9_4+)59-*VL.9-^(QE%\H MEA);J6OS?KT-8U+W#)M3X,G-[0-RQ7@,-V"ZUG(AT6]29)?,.=_V!/H;8$=" M*F$_U"LVD7PA%58ZJ6P"*ZZ"90$06B&-$BO:XR(>,GV9^%)SY*&''D@88@<_ M:TPFNPXI17:CK[2Q>.W0=4T5#YL'5M(V^FLH2)&1BM<1#:NGD&+(R'J*"<3+ MBL;5J:N8:HKX;(97A:)&UI)1BI<`C::'KS%D<8[0?9SDR!7V+JF.)@F*D>[' M24+CZB-)"XTT0Y,DYDM4@DYEG%BT+UUB=<X@H7O]GX6I$A?XNRG0Q:7.:?M1$\-VO_NL=%XT$?[OG*,\#$N0N,Y.%/" MY?+EA$%XM-O_G")$_@XNSW]=ER=2/[KOU=Q) M[`:?`E8%)>-UN'45SWO^70BOEX?VB9:?OCT9G@_Q8=*9RU+L1[O'6/X'``#_ M_P,`4$L#!!0`!@`(````(0"]Q>@P,0$``$`"```1``@!9&]C4')O<',O8V]R M92YX;6P@H@0!**```0`````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````````"< MD4%+PS`8AN^"_Z'DWJ9I04=H,U#9R8'@1/$6DV];L$E#$NWZ[TV[KD[TY#&\ M;YX\WY=J>=!-\@G.J];4B&0Y2L"(5BJSJ]'39I4N4.(#-Y(WK8$:]>#1DEU> M5,)2T3IX<*T%%Q3X))*,I\+6:!^"I1A[L0?-?18;)H;;UFD>XM'ML.7BG>\` M%WE^A34$+GG@>`"F=B:B"2G%C+0?KAD!4F!H0(,)'I.,X.]N`*?]GQ?&Y*RI M5>AMG&G2/6=+<0SG]L&KN=AU7=:5HT;T)_AE??\XCIHJ,^Q*`&+#?AKNPSJN M`"9Q/?HT>Z4/)>W=YL58D5.RI20-+_> M%(26"YH7KQ4^M:;[;`;J2>#?Q!.`C=X__YQ]`0``__\#`%!+`0(M`!0`!@`( M````(0"=$[JX*@(```DC```3``````````````````````!;0V]N=&5N=%]4 M>7!E&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L````````` M````````8P0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`*A6C%ML`@`` MA"(``!H`````````````````B0<``'AL+U]R96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,`,QL:8!```*!```!D````````````` M````12,``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`%%H3'"&!P``C",``!D`````````````````M34``'AL+W=O MC=[.D%```& M'@``&0````````````````!R/0``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`((4 MK,2;%@``;F<``!D`````````````````-D<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`);FP=``"@X0``&0````````````````"W=0``>&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*M*0.T4`P``+@@``!D````````````````` M/ID``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`!5-O516#@``Y(\```T`````````````````EJD``'AL+W-T>6QE&PO+P$`>&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`$40K>RH!@``>!D``!@`````````````````)C,! M`'AL+W=O&UL4$L!`BT`%``&``@````A`':B9XHB`@``I00``!D````````````` M````(CT!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`,#N)[!L`@``_`4``!D`````````````````7DL!`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&L1 M]PUH`P``<0H``!@`````````````````%F0!`'AL+W=O&UL4$L!`BT`%``&``@` M```A`/^`$>VV"```O",``!D`````````````````]VX!`'AL+W=O&UL4$L!`BT`%``&``@````A`!Y>H@P.!P`` M&AL``!D`````````````````+IX!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)>GA$%@#@``"D4``!D````````` M````````>*L!`'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`-Z"$)K0`@``40@``!@`````````````````#N8!`'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&1E M)[L=`P``Q@@``!@`````````````````(OT!`'AL+W=OJ\-0T``&`]```8```````````` M`````'4``@!X;"]W;W)K&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`&.4CB5@`@``=04``!D`````````````````A1T"`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#=X M0$JG!P``]A\``!D`````````````````B$D"`'AL+W=O&PO=V]R:W-H965T#```9`````````````````#%>`@!X;"]W;W)K&UL4$L!`BT`%``&``@````A`$#F*1YG%@``[&8``!D` M````````````````27H"`'AL+W=O4T\#``!E"0``&0````````````````#GD`(`>&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#$ISXN-`P``'PL``!D````````````````` M.Y<"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`$_F]//3`@``:P<``!D`````````````````UJ\"`'AL+W=O&UL4$L!`BT`%``&``@````A`+W%Z#`Q`0``0`(``!$` M````````````````9+H"`&1O8U!R;W!S+V-O&UL4$L%!@````!#`$,` *1Q(``,R\`@`````` ` end XML 14 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 583,181 [1] $ 489,407 [1]
Marketable securities, available for sale 839,469 [1] 831,808 [1]
Restricted cash and cash equivalents (Alios) 51,059 [1] 69,983 [1]
Accounts receivable, net 120,281 [1] 143,250 [1]
Inventories 13,537 [1] 30,464 [1]
Prepaid expenses and other current assets 41,104 [1] 24,673 [1]
Total current assets 1,648,631 [1] 1,589,585 [1]
Restricted cash 127 [1] 31,934 [1]
Property and equipment, net 648,924 [1] 433,609 [1]
Intangible assets 250,600 [1] 663,500 [1]
Goodwill 30,992 [1] 30,992 [1]
Other assets 3,474 [1] 9,668 [1]
Total assets 2,582,748 [1] 2,759,288 [1]
Current liabilities:    
Accounts payable 51,533 [1] 101,292 [1]
Accrued expenses 280,848 [1] 264,884 [1]
Deferred revenues, current portion 31,007 [1] 27,566 [1]
Accrued restructuring expense, current portion 9,858 [1] 4,758 [1]
Capital lease obligations, current portion 14,429 [1] 13,707 [1]
Other liabilities, current portion 21,824 [1] 20,417 [1]
Total current liabilities 409,499 [1] 432,624 [1]
Deferred revenues, excluding current portion 77,354 [1] 96,242 [1]
Accrued restructuring expense, excluding current portion 16,280 [1] 18,570 [1]
Capital lease obligations, excluding current portion 39,381 [1] 15,170 [1]
Convertible senior subordinated notes (due 2015) 0 [1] 400,000 [1]
Deferred tax liability 150,203 [1] 280,367 [1]
Construction financing lease obligation 392,569 [1] 268,031 [1]
Other liabilities, excluding current portion 10,782 [1] 13,902 [1]
Total liabilities 1,096,068 [1] 1,524,906 [1]
Commitments and contingencies    [1]    [1]
Redeemable noncontrolling interest (Alios) 39,624 [1] 38,530 [1]
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at September 30, 2013 and December 31, 2012 0 [1] 0 [1]
Common stock, $0.01 par value; 300,000,000 shares authorized at September 30, 2013 and December 31, 2012; 233,592,201 and 217,286,868 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively 2,311 [1] 2,149 [1]
Additional paid-in capital 5,274,307 [1] 4,519,448 [1]
Accumulated other comprehensive loss (550) [1] (550) [1]
Accumulated deficit (4,011,180) [1] (3,521,867) [1]
Total Vertex shareholders’ equity 1,264,888 [1] 999,180 [1]
Noncontrolling interest (Alios) 182,168 [1] 196,672 [1]
Total shareholders’ equity 1,447,056 [1] 1,195,852 [1]
Total liabilities and shareholders’ equity $ 2,582,748 [1] $ 2,759,288 [1]
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.

XML 15 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Arrangements
 3 Months Ended
Sep. 30, 2013
Collaborative Arrangements  
Collaborative Arrangements
Collaborative Arrangements
Janssen Pharmaceutica, N.V.
In 2006, the Company entered into a collaboration agreement with Janssen Pharmaceutica, N.V. ("Janssen") for the development, manufacture and commercialization of telaprevir, which Janssen began marketing under the brand name INCIVO in certain of its territories in September 2011. Under the collaboration agreement, Janssen agreed to be responsible for 50% of the drug development costs incurred under the development program for the parties’ territories (North America for the Company, and the rest of the world, other than specified countries in Asia, for Janssen) and has exclusive rights to commercialize telaprevir in its territories including Europe, South America, the Middle East, Africa and Australia.
Janssen pays the Company a tiered royalty averaging in the mid-20% range as a percentage of net sales of INCIVO in Janssen’s territories. Janssen is required under the agreement to use diligent efforts to maximize net sales of INCIVO in its territories through its commercial marketing, pricing and contracting strategies. Janssen is responsible for certain third-party royalties on net sales of INCIVO in its territories.
Janssen made a $165.0 million up-front license payment to the Company in 2006. The up-front license payment is being amortized over the Company’s estimated period of performance under the collaboration agreement. As of September 30, 2013, there were $34.2 million in deferred revenues related to this up-front license payment that the Company expects to recognize over the remaining estimated period of performance. The Company's estimates regarding the period of performance under the Janssen agreement have changed in the past, and due to the evolving nature of the landscape for treatments for HCV infection, the estimated period of performance may change in the future.
Under the collaboration agreement, Janssen agreed to make contingent milestone payments for successful development, approval and launch of telaprevir as a product in its territories. At the inception of the agreement, the Company determined that all of these contingent milestones were substantive and would result in revenues in the period in which the milestone was achieved. The Company has earned $350.0 million of these contingent milestone payments and does not expect to receive any further milestone payments under this agreement.
Under the Janssen collaboration agreement, each party incurs internal and external reimbursable expenses related to the telaprevir development program and is reimbursed by the other party for 50% of these expenses. The Company recognizes the full amount of the reimbursable costs it incurs as research and development expenses on its condensed consolidated statements of operations. The Company recognizes the amounts that Janssen is obligated to pay the Company with respect to reimbursable expenses, net of reimbursable expenses incurred by Janssen, as collaborative revenues. In the three and nine months ended September 30, 2013, the Company incurred more reimbursable costs than Janssen, and the net amounts payable by Janssen to reimburse the Company were recorded as collaborative revenues.
Each of the parties is responsible for drug supply in its territories. During the nine months ended September 30, 2013 and 2012, the Company provided Janssen certain services through the Company’s third-party manufacturing network for telaprevir. Reimbursements from Janssen for these manufacturing services were recorded as collaborative revenues.
Janssen may terminate the collaboration agreement upon the later of (i) one year’s advance notice and (ii) such period as may be required to assign and transfer to the Company specified filings and approvals. The agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the agreement will continue in effect until the expiration of Janssen’s royalty obligations, which expire on a country-by-country basis on the later of (a) the last-to-expire patent covering INCIVO or (b) ten years after the first commercial sale in the country. In the European Union, the Company has a patent covering the composition-of-matter of INCIVO that expires in 2026.
During the three and nine months ended September 30, 2013 and 2012, the Company recognized the following revenues attributable to the Janssen collaboration:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Royalty revenues (INCIVO)
$
20,994

 
$
19,957

 
$
104,108

 
$
80,811

Collaborative revenues:
 
 
 
 
 
 
 
Amortized portion of up-front payment
$
3,107

 
$
3,107

 
$
9,321

 
$
9,321

Net reimbursement (payment) for telaprevir development costs
1,413

 
(503
)
 
1,422

 
(2,569
)
Reimbursement for manufacturing services
—

 
—

 
10,299

 
4,449

        Total collaborative revenues attributable to the Janssen collaboration
$
4,520

 
$
2,604

 
$
21,042

 
$
11,201

Total revenues attributable to the Janssen collaboration
$
25,514

 
$
22,561

 
$
125,150

 
$
92,012


Mitsubishi Tanabe Pharma Corporation
The Company has a collaboration agreement (the “MTPC Agreement”) with Mitsubishi Tanabe Pharma Corporation ("Mitsubishi Tanabe") pursuant to which Mitsubishi Tanabe has a fully-paid license to manufacture and commercialize TELAVIC (the brand name under which Mitsubishi Tanabe is marketing telaprevir) in Japan and other specified countries in Asia.
The parties entered into the MTPC Agreement in 2004 and amended it in 2009. Pursuant to the MTPC Agreement, Mitsubishi Tanabe provided financial and other support for the development and commercialization of telaprevir, made a $105.0 million payment in connection with the 2009 amendment of the collaboration agreement and made a $65.0 million commercial milestone payment recognized as collaborative revenues in 2011. There are no further payments under this collaboration agreement. Mitsubishi Tanabe is responsible for its own development and manufacturing costs in its territory.
Mitsubishi Tanabe may terminate the MTPC Agreement at any time without cause upon 60 days’ prior written notice to the Company. The MTPC Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the MTPC Agreement will continue in effect until the expiration of the last-to-expire patent covering telaprevir in Mitsubishi Tanabe's territories. In Japan, the Company has a patent covering the composition-of-matter of telaprevir that expires in 2021.
The $105.0 million payment that the Company received in 2009 in connection with the amendment to the MTPC Agreement was a nonrefundable, up-front license fee, and revenues related to the 2009 payment were recognized on a straight-line basis over the period of performance of the Company’s obligations under the amended agreement. The final deferred revenues related to the 2009 up-front license payment were recognized in April 2012. In connection with the amendment to the MTPC Agreement, the Company supplied manufacturing services to Mitsubishi Tanabe, until April 2012, through the Company’s third-party manufacturing network for telaprevir.
The Company recognized no collaborative revenues attributable to the Mitsubishi Tanabe collaboration in 2013 or the three months ended September 30, 2012, and $18.9 million in collaborative revenues attributable to the Mitsubishi Tanabe collaboration in the nine months ended September 30, 2012.
Cystic Fibrosis Foundation Therapeutics Incorporated
In April 2011, the Company entered into an amendment (the “April 2011 Amendment”) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) pursuant to which CFFT agreed to provide financial support for (i) development activities for VX-661, a corrector compound discovered under the collaboration, and (ii) additional research and development activities directed at discovering new corrector compounds.
The Company entered into the original collaboration agreement with CFFT in 2004 and amended it several times prior to 2011 to, among other things, provide partial funding for its cystic fibrosis drug discovery and development efforts. In 2006, the Company received a $1.5 million milestone payment from CFFT. There are no additional milestones payable by CFFT to the Company pursuant to the collaboration agreement, as amended. Under the April 2011 Amendment, CFFT agreed to provide the Company with up to $75.0 million in funding over approximately five years for corrector-compound research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), lumacaftor (VX-809), VX-661 and any other compounds discovered during the course of the research collaboration with CFFT.
During the three and nine months ended September 30, 2013 and 2012, the Company recognized the following revenues attributable to the CFFT collaboration:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Collaborative revenues attributable to the CFFT collaboration
$
3,515

 
$
4,315

 
$
11,318

 
$
12,772


In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs discovered during the research term that ended in 2008, including KALYDECO, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of corrector compounds discovered during the research term that began in 2011. In each of the third quarter of 2012 and first quarter of 2013, CFFT earned a commercial milestone payment of $9.3 million from the Company upon achievement of certain sales levels for KALYDECO. These milestones were reflected in the Company's cost of product revenues. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO. The Company also is obligated to make up to two one-time commercial milestone payments to CFFT upon achievement of certain sales levels for corrector compounds such as lumacaftor or VX-661.
The Company began marketing KALYDECO in the United States in the first quarter of 2012 and began marketing KALYDECO in certain countries in the European Union in the third quarter of 2012. The Company has royalty obligations to CFFT for each compound commercialized pursuant to this collaboration until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent life extensions. CFFT may terminate its funding obligations under the collaboration, as amended, in certain circumstances, in which case there will be a proportional adjustment to the royalty rates and commercial milestone payments for certain corrector compounds. The collaboration also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.
Alios BioPharma, Inc.
License and Collaboration Agreement
In June 2011, the Company entered into a license and collaboration agreement (the “Alios Agreement”) with Alios, a privately-held biotechnology company. The Company and Alios are collaborating on the research, development and commercialization of an HCV nucleotide analogue discovered by Alios, ALS-2200 (now formulated as VX-135), which is designed to act on the HCV polymerase.
Under the terms of the Alios Agreement, the Company received exclusive worldwide rights to ALS-2200 (VX-135) and ALS-2158, a second HCV nucleotide analogue discovered by Alios that was only developed pursuant to the Alios Agreement through the third quarter of 2012. Upon entering into the Alios Agreement, the Company paid Alios a $60.0 million up-front payment. As of September 30, 2013, Alios had earned an aggregate of $60.0 million in development milestone payments pursuant to the Alios Agreement. The Alios Agreement provides for development milestone payments to Alios of up to an additional $312.5 million if VX-135 is approved and commercialized. In addition, Alios is eligible to receive commercial milestone payments of up to $750.0 million, as well as tiered royalties on net sales of approved drugs.
Alios and the Company began clinical development of ALS-2200 (VX-135) in December 2011. The Company is responsible for all costs related to development, commercialization and manufacturing of compounds licensed to the Company pursuant to the Alios Agreement, provided funding to Alios to conduct the Phase 1 clinical trials associated with the Alios Agreement and provided funding for a research program that was directed to the discovery of additional HCV nucleotide analogues that act on the HCV polymerase.
The Company may terminate the Alios Agreement (i) upon 30 days’ notice to Alios if the Company ceases development after VX-135 has experienced a technical failure and/or (ii) upon 60 days’ notice to Alios at any time after the Company completes specified Phase 2a clinical trials. The Alios Agreement also may be terminated by either party for a material breach by the other, and by Alios for the Company’s inactivity or if the Company challenges certain Alios patents, in each case subject to notice and cure provisions. Unless earlier terminated, the Alios Agreement will continue in effect until the expiration of the Company’s royalty obligations, which expire on a country-by-country basis on the later of (a) the date the last-to-expire patent covering a licensed product expires or (b) ten years after the first commercial sale in the country.
Alios is continuing to operate as a separate entity, is engaged in other programs directed at developing novel drugs that are not covered by the Alios Agreement and maintains ownership of the underlying patent rights that are licensed to the Company pursuant to the Alios Agreement. Under applicable accounting guidance, the Company has determined that Alios is a VIE, that Alios is a business and that the Company is Alios’ primary beneficiary. The Company based these determinations on, among other factors, the significance to Alios of the licensed compounds and on the Company’s power, through the joint steering committee for the licensed compounds established under the Alios Agreement, to direct the activities that most significantly affect the economic performance of Alios.
Accordingly, the Company consolidated Alios’ statements of operations and balance sheet with the Company’s consolidated financial statements beginning on June 13, 2011. However, the Company’s interests in Alios are limited to those accorded to the Company in the Alios Agreement. In particular, the Company did not acquire any equity interest in Alios, any interest in Alios’ cash and cash equivalents or any control over Alios’ activities that do not relate to the Alios Agreement. Alios does not have any rights to the Company’s assets except as provided in the Alios Agreement.
Noncontrolling Interest (Alios)
The Company records noncontrolling interest (Alios) on two lines on its condensed consolidated balance sheets. The noncontrolling interest (Alios) is reflected on two separate lines because Alios has both common shareholders and preferred shareholders that are entitled to redemption rights in certain circumstances. The Company records net loss (income) attributable to noncontrolling interest (Alios) on its condensed consolidated statements of operations, reflecting Alios' net loss (income) for the reporting period, adjusted for changes in the fair value of contingent milestone and royalty payments, which is evaluated each reporting period. A summary of net loss (income) attributable to noncontrolling interest (Alios) for the three and nine months ended September 30, 2013 and 2012 is as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Loss before provision for (benefit from) income taxes
$
9,056

 
$
5,090

 
$
21,177

 
$
14,581

Decrease (increase) in fair value of contingent milestone and royalty payments
(1,220
)
 
(57,560
)
 
1,600

 
(112,760
)
Provision for (benefit from) income taxes
(3,306
)
 
21,394

 
(9,089
)
 
40,354

Net loss (income) attributable to noncontrolling interest (Alios)
$
4,530

 
$
(31,076
)
 
$
13,688

 
$
(57,825
)

The Company uses present-value models to determine the estimated fair value of the contingent milestone and royalty payments, based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the time to develop drug candidates, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liability. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments.
In the three and nine months ended September 30, 2013, the fair value of the contingent milestone payments and royalties payable by the Company to Alios related to the HCV nucleotide analogue program increased by $1.2 million and decreased by $1.6 million, respectively. An increase in the fair value of the contingent milestone payments and royalties payable by the Company increases net loss attributable to Vertex by a corresponding amount.
In the three and nine months ended September 30, 2012, the fair value of contingent milestone and royalty payments increased by $57.6 million and $112.8 million, respectively, primarily because the Company received positive clinical data from a Phase 1 clinical trial evaluating ALS-2200 (VX-135), which increased the probability that Alios would earn future payments from the Company under the Alios Agreement.
If VX-135 continues to advance in clinical development, the Company expects it will record increases in the fair value of the contingent milestone and royalty payments in future periods. Changes in the fair value of these contingent milestone and royalty payments, and the effects of these changes on net loss attributable to Vertex, may be material in future periods.
Alios Balance Sheet Information
The following table summarizes items related to Alios included in the Company’s condensed consolidated balance sheets:
 
As of
September 30, 2013
 
As of
December 31, 2012
 
(in thousands)
Restricted cash and cash equivalents (Alios)
$
51,059

 
$
69,983

Prepaid expenses and other current assets
8,821

 
672

Property and equipment, net
1,374

 
1,728

Intangible assets
250,600

 
250,600

Goodwill
4,890

 
4,890

Other assets
153

 
861

Accounts payable
1,251

 
1,054

Accrued expenses
6,689

 
6,099

Deferred tax liability
150,203

 
152,781

Other liabilities, excluding current portion
873

 
1,625

Redeemable noncontrolling interest (Alios)
39,624

 
38,530

Noncontrolling interest (Alios)
182,168

 
196,672


The Company has recorded Alios’ cash and cash equivalents as restricted cash and cash equivalents (Alios) because (i) the Company does not have any interest in or control over Alios’ cash and cash equivalents and (ii) the Alios Agreement does not provide for these assets to be used for the development of the assets that the Company licensed from Alios pursuant to the Alios Agreement. Assets recorded as a result of consolidating Alios’ financial condition into the Company’s condensed consolidated balance sheets do not represent additional assets that could be used to satisfy claims against the Company’s general assets.
XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 17 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Contingencies
 3 Months Ended
Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]  
Contingencies
Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of September 30, 2013 or December 31, 2012.
XML 18 R56.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Liability (Details 2) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Restructuring activities        
Restructuring expense $ 12,048 $ 696 $ 12,863 $ 1,650
Kendall Restructuring [Member]
        
Restructuring activities        
Liability, beginning of the period 22,051 24,830 23,328 26,313
Cash payments (3,901) (3,726) (11,323) (11,137)
Cash received from subleases 2,670 2,355 8,000 7,329
Restructuring expense 524 696 1,339 1,650
Liability, end of the period $ 21,344 $ 24,155 $ 21,344 $ 24,155
XML 19 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Long-term Obligations
 3 Months Ended
Sep. 30, 2013
Long-term Debt and Capital Lease Obligations [Abstract]  
Long-term Obligations
Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two leases, pursuant to which the Company agreed to lease approximately 1.1 million square feet of office and laboratory space in two buildings (the "Buildings") that the landlord is building at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company plans to transition its Massachusetts operations from Cambridge, Massachusetts to Fan Pier upon the completion of the Buildings. The Company expects to commence lease payments in December 2013 and to make payments for the period ending 15 years from the commencement date. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company is involved in the construction project, including having responsibility to pay for a portion of the costs of finish work and structural elements of the Buildings, the Company is deemed for accounting purposes to be the owner of the Buildings during the construction period. Accordingly, the Company has recorded project construction costs incurred by the landlord as an asset and a related financing obligation in “Property and equipment, net” and “Construction financing lease obligation,” respectively, on the Company’s condensed consolidated balance sheets. The Company bifurcates its future lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings are being constructed, which is recorded as rental expense. Although the Company will not begin making lease payments pursuant to the Fan Pier Leases until the commencement date, the portion of the lease obligations allocated to the land is treated for accounting purposes as an operating lease that commenced in 2011.
Property and equipment, net, included $467.6 million and $290.7 million as of September 30, 2013 and December 31, 2012, respectively, related to construction costs for the Buildings at Fan Pier in Boston, Massachusetts. The construction financing lease obligation related to the Buildings at Fan Pier was $392.6 million and $268.0 million as of September 30, 2013 and December 31, 2012, respectively. As of September 30, 2013 and December 31, 2012, the primary difference between the amounts recorded in property and equipment, net and the construction financing lease obligation represented the cost of finish work and structural elements of the Buildings that the Company was responsible for paying to date.
Once the landlord completes the construction of the Buildings, the Company will evaluate the Fan Pier Leases in order to determine whether or not the Fan Pier Leases meet the criteria for “sale-leaseback” treatment. If the Fan Pier Leases meet the “sale-leaseback” criteria, the Company will remove the asset and the related liability from its consolidated balance sheet and treat the Fan Pier Leases as either operating or capital leases based on the Company’s assessment of the accounting guidance. The Company expects that upon completion of construction of the Buildings the Fan Pier Leases will not meet the “sale-leaseback” criteria. If the Fan Pier Leases do not meet “sale-leaseback” criteria, the Company will treat the Fan Pier Leases as a financing obligation and will depreciate the asset over its estimated useful life.
The Company expects to incur restructuring liabilities related to lease obligations that extend beyond the cease use date for certain Cambridge, Massachusetts facilities for several years after it relocates to Fan Pier. Please refer to "Note O: Restructuring Liabilities" for further information.
Capital Leases
The Company has outstanding capital leases for equipment, leasehold improvements and software licenses with terms through 2019. The capital leases bear interest at rates ranging from 3% to 7% per year. The following table sets forth the Company’s future minimum payments due under capital leases as of September 30, 2013:
Year
 
(in thousands)
2013
 
$
1,883

2014
 
18,077

2015
 
15,608

2016
 
8,924

2017
 
8,481

2018
 
7,877

    2019
 
409

Total payments
 
61,259

Less: amount representing interest
 
(7,449
)
Present value of payments
 
$
53,810


Financing Arrangements
In the second quarter of 2013, the Company began supporting $31.9 million in irrevocable stand-by letters of credit issued in support of property leases and other similar agreements with an unsecured credit facility with a one-year term. The Company previously had cash-collateralized these stand-by letters of credit. As a result of this credit facility, the restricted cash reflected on the Company's condensed consolidated balance sheets decreased by $31.8 million net of other activity recorded during the nine months ended September 30, 2013 and the Company's cash and cash equivalents increased by a corresponding amount during the nine months ended September 30, 2013.
XML 20 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Convertible Senior Subordinated Notes (Details) (USD $)
 1 Months Ended 3 Months Ended
Sep. 30, 2013
Dec. 31, 2012
Sep. 30, 2010
Convertible Senior Subordinated Notes 3.35 Percent Due 2015
Jun. 30, 2013
Convertible Senior Subordinated Notes 3.35 Percent Due 2015
Convertible Senior Subordinated Notes        
Convertible senior subordinated notes $ 0 [1] $ 400,000,000 [1] $ 400,000,000  
Net proceeds from convertible debt offering     391,600,000  
Underwriting discount     8,400,000  
Conversion price (in dollars per share)     $ 48.83  
Convertible senior subordinated notes (due 2015) conversion       (8,188,448)
Stock Redeemed or Called During Period, Value       200,000
Redemption Premium       16.75
Original conversion rate, number of shares to be issued per $1000 of principal (in shares)     20.4794  
Convertible debt principal amount, basis for exchange     1,000 1,000
Interest rate (as a percent)     3.35%  
Percent closing price needs to exceed the conversion price for at least 20 trading days within 30 consecutive trading days for provisional redemption (as a percent)     130.00%  
Minimum number of days within 30 consecutive trading days the closing price needs to exceed the conversion price for provisional redemption (in days)     20 days  
Total consecutive trading days during which the closing price must exceed the conversion price for at least 20 trading days for provisional redemption (in days)     30 days  
Debt Conversion, Converted Instrument, Amount       399,800,000
Debt Conversion, Converted Instrument, Shares Issued       87,109
Interest Expense, Debt       6,700,000
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature       $ 4,200,000
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 21 R57.htm IDEA: XBRL DOCUMENT v2.4.0.8
Contingencies Contingencies (Details) (USD $)
Sep. 30, 2013
Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]    
Material contingent liabilities accrued $ 0 $ 0
XML 22 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation and Accounting Policies (Details)
 3 Months Ended
Sep. 30, 2013
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 23 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation and Accounting Policies (Policies)
 3 Months Ended
Sep. 30, 2013
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) Alios BioPharma, Inc. (“Alios”), a collaborator that is a variable interest entity (a “VIE”) for which the Company is deemed under applicable accounting guidance to be the primary beneficiary. All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2013 and 2012.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2012, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 that was filed with the Securities and Exchange Commission (the "SEC") on March 1, 2013 (the "2012 Annual Report on Form 10-K")
Use of Estimates
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, noncontrolling interest (Alios) and the income tax provision. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2012 Annual Report on Form 10-K.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements please refer to Note A, "Nature of Business and Accounting Policies—Recent Accounting Pronouncements," in the 2012 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2013 that had a material effect on the Company's condensed consolidated financial statements.
XML 24 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events (Notes)
 3 Months Ended
Sep. 30, 2013
Subsequent Events [Abstract]  
Subsequent Events [Text Block]
Subsequent Events
On October 29, 2013, the Company adopted a strategic restructuring plan. As a result of the actions to be taken under this restructuring plan, including those taken in the third quarter of 2013, the Company estimates that it will incur aggregate restructuring charges of approximately $35.0 million to $45.0 million, $11.4 million of which was recorded in the third quarter of 2013. Please refer to Note O, "Restructuring Liabilities," for further information.
XML 25 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories Inventories- Schedule of Inventories (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Inventory Disclosure [Abstract]          
Raw materials $ 232   $ 232   $ 3,754
Work-in-process 7,980   7,980   11,317
Finished goods 5,325   5,325   15,393
Total 13,537 [1]   13,537 [1]   30,464 [1]
Write-down of inventories to net realizable value $ 5,300 $ 0 $ 10,358 $ 78,000  
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 26 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Tables)
 3 Months Ended
Sep. 30, 2013
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
The following table sets forth the Company’s inventories by type:
 
As of
September 30, 2013
 
As of
December 31, 2012
 
(in thousands)
Raw materials
$
232

 
$
3,754

Work-in-process
7,980

 
11,317

Finished goods
5,325

 
15,393

Total
$
13,537

 
$
30,464
XML 27 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Arrangements (Details) (USD $)
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 28 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Sep. 30, 2013
Janssen Pharmaceutica, N.V.
Jun. 30, 2012
Janssen Pharmaceutica, N.V.
Sep. 30, 2013
Janssen Pharmaceutica, N.V.
Sep. 30, 2012
Janssen Pharmaceutica, N.V.
Dec. 31, 2006
Janssen Pharmaceutica, N.V.
Sep. 30, 2013
Mitsubishi Tanabe Pharma Corporation
Sep. 30, 2012
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2011
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2009
Mitsubishi Tanabe Pharma Corporation
Apr. 30, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Sep. 30, 2013
Cystic Fibrosis Foundation Therapeutics Incorporated
payment
Sep. 30, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Sep. 30, 2013
Cystic Fibrosis Foundation Therapeutics Incorporated
Sep. 30, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Dec. 31, 2006
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2013
Alios Bio Pharma Inc
Sep. 30, 2013
Alios Bio Pharma Inc
lines
Jun. 30, 2012
Alios Bio Pharma Inc
Sep. 30, 2013
Alios Bio Pharma Inc
lines
Sep. 30, 2012
Alios Bio Pharma Inc
Sep. 30, 2013
Alios Bio Pharma Inc
lines
Dec. 31, 2012
Alios Bio Pharma Inc
Schedule of Collaborative Arrangements                                                        
Drug development costs to be paid by collaborator (as a percent)           50.00%       50.00%                                    
Up-front license payment                   $ 165,000,000                                    
Deferred revenue related to up-front license payment           34,200,000   34,200,000                                        
Total contingent milestone payments earned           350,000,000                                            
Notice period required to terminate without cause (in years)           1 year                                            
Notice period required for termination after first commercial sale ( in years)           10 years                                            
Collaborative revenues recognized                                                        
Royalty revenues 27,012,000 25,586,000 119,705,000 98,047,000   20,994,000 19,957,000 104,108,000 80,811,000                                      
Amortized portion of up-front payment           3,107,000 3,107,000 9,321,000 9,321,000                                      
Net reimbursement (payment) for telaprevir development costs           1,413,000 (503,000) 1,422,000 (2,569,000)                                      
Reimbursement for manufacturing services           0 0 10,299,000 4,449,000                                      
Collaborative revenues 8,035,000 6,919,000 32,290,000 42,852,000   4,520,000 2,604,000 21,042,000 11,201,000   0 18,900,000       3,515,000   4,315,000 11,318,000 12,772,000                
Total revenues 221,700,000 336,006,000 860,818,000 1,193,048,000   25,514,000 22,561,000 125,150,000 92,012,000                                      
License fee paid upon amendment of agreement                           105,000,000                            
Milestone payment received                         65,000,000     9,300,000 9,300,000       1,500,000              
Notice period required to terminate without cause (in days)                     60 days                                  
Collaborative funding                             75,000,000                          
Number of years over which funding will be made (in years)                             5 years                          
Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661 (in payments)                               2                        
Up-front payment                                           60,000,000            
Milestone payments                                                     60,000,000  
Development milestone payments, maximum                                                     312,500,000  
Commercial milestone payments, maximum                                             750,000,000          
Notice period for termination of contract due to technical failure (in days)                                             30 days          
Notice period for termination of contract after completion of clinical trials (in days)                                             60 days          
Latest expiration period for royalty obligation after first commercial sale in country unless contract is terminated earlier (in years)                                             10 years          
Noncontrolling Interest (Alios)                                                        
Number of lines on balance sheet where noncontrolling interest is reported                                             2   2   2  
Loss (income) before provision for (benefit from) income taxes                                             9,056,000 5,090,000 21,177,000 14,581,000    
Decrease (increase) in fair value of contingent milestone and royalty payments                                             (1,220,000) (57,560,000) 1,600,000 (112,760,000)    
Provision for (benefit from) income taxes (751,000) 21,355,000 (132,863,000) 41,450,000                                     (3,306,000) 21,394,000 (9,089,000) 40,354,000    
Net loss (income) attributable to noncontrolling interest (Alios) (4,530,000) 31,076,000 (13,688,000) 57,825,000                                     4,530,000 (31,076,000) 13,688,000 (57,825,000)    
Restricted cash and cash equivalents (Alios) 51,059,000 [1]   51,059,000 [1]   69,983,000 [1]                                   51,059,000   51,059,000   51,059,000 69,983,000
Prepaid expenses and other current assets 41,104,000 [1]   41,104,000 [1]   24,673,000 [1]                                   8,821,000   8,821,000   8,821,000 672,000
Property and equipment, net 648,924,000 [1]   648,924,000 [1]   433,609,000 [1]                                   1,374,000   1,374,000   1,374,000 1,728,000
Intangible assets                                             250,600,000   250,600,000   250,600,000 250,600,000
Goodwill 30,992,000 [1]   30,992,000 [1]   30,992,000 [1]                                   4,890,000   4,890,000   4,890,000 4,890,000
Other assets 3,474,000 [1]   3,474,000 [1]   9,668,000 [1]                                   153,000   153,000   153,000 861,000
Accounts payable 51,533,000 [1]   51,533,000 [1]   101,292,000 [1]                                   1,251,000   1,251,000   1,251,000 1,054,000
Accrued expenses 280,848,000 [1]   280,848,000 [1]   264,884,000 [1]                                   6,689,000   6,689,000   6,689,000 6,099,000
Deferred tax liability 150,203,000 [1]   150,203,000 [1]   280,367,000 [1]                                   150,203,000   150,203,000   150,203,000 152,781,000
Other liabilities, excluding current portion 10,782,000 [1]   10,782,000 [1]   13,902,000 [1]                                   873,000   873,000   873,000 1,625,000
Redeemable noncontrolling interest (Alios) 39,624,000 [1]   39,624,000 [1]   38,530,000 [1]                                   39,624,000   39,624,000   39,624,000 38,530,000
Noncontrolling interest (Alios) $ 182,168,000 [1]   $ 182,168,000 [1]   $ 196,672,000 [1]                                   $ 182,168,000   $ 182,168,000   $ 182,168,000 $ 196,672,000
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 28 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Long-term Obligations (Details) (USD $)
 3 Months Ended 9 Months Ended
Jun. 30, 2011
leases
squarefeet
building
Sep. 30, 2013
Jun. 30, 2013
Dec. 31, 2012
Long-term Debt and Capital Lease Obligations [Abstract]        
Line of Credit Facility, Current Borrowing Capacity     $ 31,900,000  
Debt Instrument, Interest Rate, Low of Range   3.00%    
Debt Instrument, Interest Rate, High of Range   7.00%    
Number of leases (leases) 2      
Area of leased property (in square feet) 1,100,000      
Number of buildings under lease agreement (buildings) 2      
Initial term of lease agreement (in years) 15 years      
Optional term of lease agreement (in years) 10 years      
Construction in progress   467,600,000   290,700,000
Construction financing lease obligation   392,569,000 [1]   268,031,000 [1]
Change in Restricted Cash Balance as Result of Transactions   $ 31,800,000    
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 29 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements (Tables)
 3 Months Ended
Sep. 30, 2013
Fair Value Disclosures [Abstract]  
Financial assets subject to fair value measurements (excluding restricted cash and cash equivalents (Alios))
The following table sets forth the Company’s financial assets (excluding Alios’ cash equivalents) subject to fair value measurements:
 
Fair Value Measurements
as of September 30, 2013
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
308,981

 
$
308,981

 
$
—

 
$
—

Government-sponsored enterprise securities
2,895

 
2,895

 
—

 
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
555,527

 
555,527

 
—

 
—

Commercial paper
125,264

 
—

 
125,264

 
—

Corporate debt securities
158,678

 
—

 
158,678

 
—

Total
$
1,151,345

 
$
867,403

 
$
283,942

 
$
—
XML 30 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Marketable Securities (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Summary of cash, cash equivalents and marketable securities    
Amortized Cost $ 1,422,447 $ 1,321,019
Gross Unrealized Gains 252 217
Gross Unrealized Losses (49) (21)
Fair Value 1,422,650 1,321,215
Total cash and cash equivalents
    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 583,181 489,407
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 583,181 489,407
Cash and money market funds
    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 580,286 489,407
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 580,286 489,407
Government-sponsored enterprise securities
    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 2,895 0
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 2,895 0
Available-for-sale Securities [Member]
    
Summary of cash, cash equivalents and marketable securities    
Gross Unrealized Gains 252 217
Gross Unrealized Losses (49) (21)
Available-for-sale Securities, Amortized Cost Basis 839,266 831,612
Available-for-sale Securities, Fair Value Disclosure 839,469 831,808
U.S. Treasury securities
    
Summary of cash, cash equivalents and marketable securities    
Gross Unrealized Gains 0 2
Gross Unrealized Losses 0 (2)
Available-for-sale Securities, Amortized Cost Basis 0 111,350
Available-for-sale Securities, Fair Value Disclosure 0 111,350
Government-sponsored enterprise securities (due within 1 year)
    
Summary of cash, cash equivalents and marketable securities    
Gross Unrealized Gains 35 49
Gross Unrealized Losses (10) (5)
Available-for-sale Securities, Amortized Cost Basis 555,502 440,181
Available-for-sale Securities, Fair Value Disclosure 555,527 440,225
Commercial paper
    
Summary of cash, cash equivalents and marketable securities    
Gross Unrealized Gains 191 155
Gross Unrealized Losses 0 0
Available-for-sale Securities, Amortized Cost Basis 125,073 225,294
Available-for-sale Securities, Fair Value Disclosure 125,264 225,449
Corporate debt securities (due within 1 year)
    
Summary of cash, cash equivalents and marketable securities    
Gross Unrealized Gains 21 1
Gross Unrealized Losses (38) (1)
Available-for-sale Securities, Amortized Cost Basis 148,672 15,429
Available-for-sale Securities, Fair Value Disclosure 148,655 15,429
Corporate debt securities (due after 1 year through 5 years)
    
Summary of cash, cash equivalents and marketable securities    
Gross Unrealized Gains 5 10
Gross Unrealized Losses (1) (13)
Available-for-sale Securities, Amortized Cost Basis 10,019 39,358
Available-for-sale Securities, Fair Value Disclosure $ 10,023 $ 39,355
XML 31 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Guarantees
 3 Months Ended
Sep. 30, 2013
Guarantees [Abstract]  
Guarantees
Guarantees
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company entered into an underwriting agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated dated September 23, 2010 (the “Underwriting Agreement”), relating to the public offering and sale of the 2015 Notes. The Underwriting Agreement requires the Company to indemnify the underwriter against any loss it may suffer by reason of the Company’s breach of any representation or warranty relating to the public offering, the Company’s failure to perform certain covenants in the Underwriting Agreement, the inclusion of any untrue statement of material fact in the prospectus used in connection with the offering, the omission of any material fact needed to make those materials not misleading, and any actions taken by the Company or its representatives in connection with the offering. The representations, warranties, covenants and indemnification provisions in the Underwriting Agreement are of a type customary in agreements of this sort. The Company believes the estimated fair value of this indemnification arrangement is minimal.
XML 32 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (USD $)
In Thousands, except Share data, unless otherwise specified
Total
Total Vertex Shareholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Noncontrolling Interest (Alios)
Redeemable Noncontrolling Interest (Alios)
Balance at Dec. 31, 2011 $ 928,476 $ 786,843 $ 2,072 $ 4,200,659 $ (1,053) $ (3,414,835) $ 141,633 $ 37,036
Balance (shares) at Dec. 31, 2011     209,304,000          
Increase (Decrease) in Stockholders' Equity                
Unrealized holding gains (losses) on marketable securities, net of tax 324 324     324      
Foreign currency translation adjustment 313 313     313      
Net income (loss) attributable to Vertex common shareholders (30,884)         (30,884)    
Net income (loss) 26,941 (30,884)         57,825  
Issuances of common stock:                
Benefit plans (shares)     7,038,000          
Benefit plans 183,022 182,872 69 182,803     150  
Stock-based compensation expense 87,537 87,168   87,168     369  
Tax benefit from equity compensation 1,097 1,097   1,097         
Change in liquidation value of noncontrolling interest (1,263)           (1,263) 1,263
Balance at Sep. 30, 2012 1,226,447 1,027,733 2,141 4,471,727 (416) (3,445,719) 198,714 38,299
Balance (shares) at Sep. 30, 2012     216,342,000          
Balance at Dec. 31, 2012 1,195,852 [1] 999,180 2,149 4,519,448 (550) (3,521,867) 196,672 38,530
Balance (shares) at Dec. 31, 2012     217,287,000          
Increase (Decrease) in Stockholders' Equity                
Unrealized holding gains (losses) on marketable securities, net of tax 7 7     7      
Foreign currency translation adjustment (7) (7)     (7)      
Net income (loss) attributable to Vertex common shareholders (489,313)         (489,313)    
Net income (loss) (503,001) (489,313)         (13,688)  
Issuances of common stock:                
Benefit plans (shares)     8,029,000          
Benefit plans 248,216 248,286 79 248,207     (70)  
Convertible senior subordinated notes (due 2015) conversion     8,276,000          
Stock Issued During Period, Value, Conversion of Convertible Securities 402,265 402,265 83 402,182         
Stock-based compensation expense 104,818 104,470   104,470     348  
Change in liquidation value of noncontrolling interest (1,094)           (1,094) 1,094
Balance at Sep. 30, 2013 $ 1,447,056 [1] $ 1,264,888 $ 2,311 $ 5,274,307 $ (550) $ (4,011,180) $ 182,168 $ 39,624
Balance (shares) at Sep. 30, 2013     233,592,000          
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 33 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation and Accounting Policies
 3 Months Ended
Sep. 30, 2013
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies
Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) Alios BioPharma, Inc. (“Alios”), a collaborator that is a variable interest entity (a “VIE”) for which the Company is deemed under applicable accounting guidance to be the primary beneficiary. All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2013 and 2012.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2012, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 that was filed with the Securities and Exchange Commission (the "SEC") on March 1, 2013 (the "2012 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, noncontrolling interest (Alios) and the income tax provision. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2012 Annual Report on Form 10-K.
Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements please refer to Note A, "Nature of Business and Accounting Policies—Recent Accounting Pronouncements," in the 2012 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2013 that had a material effect on the Company's condensed consolidated financial statements.
XML 34 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net Income (Loss) Per Share Attributable to Vertex Common Shareholders
 3 Months Ended
Sep. 30, 2013
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Vertex Common Stockholders
Net Loss Per Share Attributable to Vertex Common Shareholders
Basic net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The Company did not include the securities described in the following table in the computation of the diluted net loss attributable to Vertex per common share calculations because the effect would have been anti-dilutive during each such period:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Stock options
16,807

 
20,226

 
16,807

 
20,226

Convertible senior subordinated notes
—

 
8,192

 
—

 
8,192

Unvested restricted stock and restricted stock units
2,838

 
2,222

 
2,838

 
2,222
XML 35 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Product Revenues, Net
 3 Months Ended
Sep. 30, 2013
Product Revenues [Abstract]  
Product Revenues, Net
Product Revenues, Net
The Company sells its products principally to a limited number of major and selected regional wholesalers and specialty pharmacy providers in North America as well as government-owned and supported customers in Europe (collectively, its “Customers”). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery as long as (i) there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.
In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customer's locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated costs of incentives offered to certain indirect customers, including patients. These estimates, and in particular estimates regarding INCIVEK net product revenues while they decline, require the Company to make significant estimates and judgments that materially affect the Company's recognition of net product revenues.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2013:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2012
$
5,416

 
$
63,560

 
$
2,852

 
$
3,565

 
$
75,393

Provision related to current period sales
26,584

 
155,269

 
3,687

 
8,161

 
193,701

Adjustments related to prior period sales
348

 
4,433

 
11,125

 
(228
)
 
15,678

Credits/payments made
(29,960
)
 
(153,035
)
 
(3,649
)
 
(9,641
)
 
(196,285
)
Balance at September 30, 2013
$
2,388

 
$
70,227

 
$
14,015

 
$
1,857

 
$
88,487
XML 36 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net Income (Loss) Per Share Attributable to Vertex Common Shareholders (Details)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Stock options
        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 16,807 20,226 16,807 20,226
Convertible senior subordinated notes
        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 0 8,192 0 8,192
Unvested restricted stock and restricted stock units
        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 2,838 2,222 2,838 2,222
XML 37 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Product Revenues, Net (Tables)
 3 Months Ended
Sep. 30, 2013
Product Revenues [Abstract]  
Schedule of product revenues and allowances and reserve categories
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2013:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2012
$
5,416

 
$
63,560

 
$
2,852

 
$
3,565

 
$
75,393

Provision related to current period sales
26,584

 
155,269

 
3,687

 
8,161

 
193,701

Adjustments related to prior period sales
348

 
4,433

 
11,125

 
(228
)
 
15,678

Credits/payments made
(29,960
)
 
(153,035
)
 
(3,649
)
 
(9,641
)
 
(196,285
)
Balance at September 30, 2013
$
2,388

 
$
70,227

 
$
14,015

 
$
1,857

 
$
88,487
XML 38 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Marketable Securities (Tables)
 3 Months Ended
Sep. 30, 2013
Cash and Cash Equivalents [Abstract]  
Summary of cash, cash equivalents and marketable securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of September 30, 2013
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
580,286

 
$
—

 
$
—

 
$
580,286

Government-sponsored enterprise securities
2,895

 
—

 
—

 
2,895

Total cash and cash equivalents
$
583,181

 
$
—

 
$
—

 
$
583,181

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
—

 
$
—

 
$
—

 
$
—

Government-sponsored enterprise securities (due within 1 year)
555,502

 
35

 
(10
)
 
555,527

Commercial paper (due within 1 year)
125,073

 
191

 
—

 
125,264

Corporate debt securities (due within 1 year)
148,672

 
21

 
(38
)
 
148,655

Corporate debt securities (due after 1 year through 5 years)
10,019

 
5

 
(1
)
 
10,023

Total marketable securities
$
839,266

 
$
252

 
$
(49
)
 
$
839,469

Total cash, cash equivalents and marketable securities
$
1,422,447

 
$
252

 
$
(49
)
 
$
1,422,650

 
 
 
 
 
 
 
 
As of December 31, 2012
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
489,407

 
$
—

 
$
—

 
$
489,407

    Government-sponsored enterprise securities
—

 
—

 
—

 
—

Total cash and cash equivalents
$
489,407

 
$
—

 
$
—

 
$
489,407

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
111,350

 
$
2

 
$
(2
)
 
$
111,350

Government-sponsored enterprise securities (due within 1 year)
440,181

 
49

 
(5
)
 
440,225

Commercial paper (due within 1 year)
225,294

 
155

 
—

 
225,449

Corporate debt securities (due within 1 year)
15,429

 
1

 
(1
)
 
15,429

Corporate debt securities (due after 1 year through 5 years)
39,358

 
10

 
(13
)
 
39,355

Total marketable securities
$
831,612

 
$
217

 
$
(21
)
 
$
831,808

Total cash, cash equivalents and marketable securities
$
1,321,019

 
$
217

 
$
(21
)
 
$
1,321,215
XML 39 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Liability (Tables)
 9 Months Ended
Sep. 30, 2013
Restructuring and Related Activities [Abstract]  
Activity related to the restructuring liability
The activities related to the restructuring liability for the three and nine months ended September 30, 2013 and 2012 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
Liability, beginning of the period
$
22,051

 
$
24,830

 
$
23,328

 
$
26,313

Cash payments
(3,901
)
 
(3,726
)
 
(11,323
)
 
(11,137
)
Cash received from subleases
2,670

 
2,355

 
8,000

 
7,329

Restructuring expense
524

 
696

 
1,339

 
1,650

Liability, end of the period
$
21,344

 
$
24,155

 
$
21,344

 
$
24,155
Restructuring charges and related liability
The restructuring charges recorded during the three months ended September 30, 2013 and the related liability balance as of September 30, 2013 for each major type of cost associated with this restructuring plan are as follows:
 
Restructuring Expense
 
Cash
Payments
 
Non-cash Expense
 
Restructuring Liability at September 30, 2013
 
(in thousands)
Employee severance, benefits and related costs
$
409

 
$
—

 
$
—

 
$
409

Asset impairments
6,650

 
—

 
(6,650
)
 
—

Contract termination and other associated costs
4,385

 
—

 
—

 
4,385

Liability, end of the period
$
11,444

 
$
—

 
$
(6,650
)
 
$
4,794
XML 40 R55.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Liability (Details) (USD $)
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2010
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Jun. 30, 2013
Dec. 31, 2012
Jun. 30, 2012
Dec. 31, 2011
Dec. 31, 2003
Restructuring Cost and Reserve [Line Items]                    
Restructuring expense   $ 12,048,000 $ 696,000 $ 12,863,000 $ 1,650,000          
Non-cash Expense       5,856,000 8,070,000          
Kendall Restructuring [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Lease term (in years) 15 years                  
Discount rate, lease restructuring liability (as a percent)                   10.00%
Restructuring expense   524,000 696,000 1,339,000 1,650,000          
Cash payments   (3,901,000) (3,726,000) (11,323,000) (11,137,000)          
Restructuring Reserve   21,344,000 24,155,000 21,344,000 24,155,000 22,051,000 23,328,000 24,830,000 26,313,000  
Strategic Restructuring [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Strategic Restructuring   11,444,000                
Cash payments   0                
Non-cash Expense   (6,650,000)                
Restructuring Reserve   4,794,000   4,794,000            
Strategic Restructuring [Member] | Employee Severance [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Restructuring expense   409,000                
Cash payments   0                
Non-cash Expense   0                
Restructuring Reserve   409,000   409,000            
Strategic Restructuring [Member] | Contract Termination [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Restructuring expense   4,385,000                
Cash payments   0                
Non-cash Expense   0                
Restructuring Reserve   4,385,000   4,385,000            
Strategic Restructuring [Member] | Asset Impairments [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Restructuring expense   6,650,000                
Cash payments   0                
Non-cash Expense   (6,650,000)                
Restructuring Reserve   0   0            
Strategic Restructuring [Member] | Subsequent Event [Member] | Minimum [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Expected restructuring charges       35,000,000            
Strategic Restructuring [Member] | Subsequent Event [Member] | Minimum [Member] | Employee Severance [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Expected restructuring charges       20,000,000            
Strategic Restructuring [Member] | Subsequent Event [Member] | Minimum [Member] | Other Restructuring [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Expected restructuring charges       9,000,000            
Strategic Restructuring [Member] | Subsequent Event [Member] | Minimum [Member] | Asset Impairments [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Expected restructuring charges       6,000,000            
Strategic Restructuring [Member] | Subsequent Event [Member] | Maximum [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Expected restructuring charges       45,000,000            
Strategic Restructuring [Member] | Subsequent Event [Member] | Maximum [Member] | Employee Severance [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Expected restructuring charges       25,000,000            
Strategic Restructuring [Member] | Subsequent Event [Member] | Maximum [Member] | Other Restructuring [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Expected restructuring charges       12,000,000            
Strategic Restructuring [Member] | Subsequent Event [Member] | Maximum [Member] | Asset Impairments [Member]
                    
Restructuring Cost and Reserve [Line Items]                    
Expected restructuring charges       $ 8,000,000            
EXCEL 41 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R,6-D.#@X95\S8S!D7S1F-35?.#5A95\R,SAA M,30U9C@Y,#,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?0F%L86YC M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D)A#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E!R;V1U8W1?4F5V96YU97-?3F5T M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DUA#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D%C8W5M=6QA=&5D7T]T:&5R7T-O M;7!R96AE;G-I=CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DEN=F5N=&]R:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K'!E;G,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/DQE9V%L7U!R;V-E961I;F=S/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D=U87)A;G1E97,\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D)A#I7;W)K#I7;W)K#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C8W5M=6QA=&5D7T]T:&5R7T-O;7!R96AE;G-I=C$\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K'!E;G,Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!R;V1U8W1?4F5V96YU97-?3F5T7T1E=&%I;',\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D-O M;G9E#I7;W)K#I%>&-E;%=O M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-T;V-K8F%S961?0V]M<&5N#I7;W)K#I%>&-E;%=O&5S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E;%=O#I% M>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O6QE#I!8W1I M=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0 M&UL/CPA M6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G M92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S(Q8V0X.#AE7S-C,&1?-&8U-5\X-6%E7S(S.&$Q-#5F.#DP,PT* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R,6-D.#@X95\S8S!D7S1F M-35?.#5A95\R,SAA,30U9C@Y,#,O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#`X-S4S,C`\ M2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)TQA'0^)SQS<&%N/CPO'0^)S$P+5$\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N M;&5S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO2!R979E;G5E'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO&5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-3$I/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"P@26YC;'5D:6YG(%!O'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO#PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S#PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N M/CPO6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA&-L=61I;F<@8W5R"!L:6%B:6QI='D\+W1D/@T*("`@("`@ M("`\=&0@8VQA&-L=61I;F<@8W5R'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S"!I;B!I=',@86=R965M96YT('=I=&@@06QI;W,N(%-E92!.;W1E($,L M(")#;VQL86)O'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XS,#`L,#`P+#`P,#QS<&%N/CPO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X95\S8S!D7S1F-35?.#5A95\R M,SAA,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C%C M9#@X.&5?,V,P9%\T9C4U7S@U865?,C,X83$T-68X.3`S+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO"!B96YE9FET M(&9R;VT@97%U:71Y(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(&AO;&1I M;F<@9V%I;G,@*&QO'0^)SQS<&%N/CPO2!T'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO"!C;VUM;VX@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO.*` MF7,@=F%R:6%B;&4@:6YT97)E.*`F7,@ M:6YT97)E*`F7,@87-S971S(&%N9"!L:6%B:6QI=&EE'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2`H=7-E9"!I;BD@ M;W!E'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO&-E'0^)SQS<&%N/CPO2`H=7-E9"!I;BD@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO6UE M;G0@87)R86YG96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G1S(&]N(&-A<&ET86P@;&5A6UE;G1S M(&]N(&-O;G-T'0^)SQS M<&%N/CPOF5D(&1E8G0@:7-S=6%N8V4@ M8V]S=',@;V8@8V]N=F5R=&5D(&-O;G9E*`F7,@87-S971S(&%N9"!L M:6%B:6QI=&EE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X95\S M8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T9C4U7S@U865?,C,X83$T-68X M.3`S+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD M.SY"87-I#MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^0F%S:7,@;V8@4')E#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE"!0:&%R;6%C975T M:6-A;',@26YC;W)P;W)A=&5D("@B5F5R=&5X(B!O2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E6QE/3-$;&EN92UH M96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HQ,G!X.W1E>'0M:6YD96YT.C(T M<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE(&-O;F1E;G-E9"!C;VYS;VQI M9&%T960@9FEN86YC:6%L('-T871E;65N=',@2P@*&EI*28C,38P.VET2`H82`F(S@R,C`[5DE%)B,X,C(Q.RD@9F]R('=H:6-H('1H92!#;VUP M86YY(&ES(&1E96UE9"!U;F1E2!O<&5R871E3II;FAE'0M:6YD96YT M.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^0V5R=&%I;B!I;F9O2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!O9B!T:&4@ M9FEN86YC:6%L('!O6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V M,#LS,"P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@,C`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`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`[8V%L8W5L871E(&ET2!E2!T;R!I=',@0W5S=&]M97(G M2!C86QC=6QA=&5S(&=R;W-S('!R M;V1U8W0@2!D961U8W1I;F<@ M9G)O;2!I=',@9W)O2!T;R!M M86ME('-I9VYI9FEC86YT(&5S=&EM871E2!A9F9E8W0@=&AE($-O;7!A;GDG'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[ M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S(&%C=&EV:71Y M(&EN(&5A8V@@;V8@=&AE('!R;V1U8W0@'0M:6YD96YT.C!P M>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE M(&-E;&QP861D:6YG/3-$,"!C96QL#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HQ<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@ M3II;FAE#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\9&EV('-T>6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HQ<'@[<&%D9&EN9RUR:6=H=#HR M<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT M97([9F]N="US:7IE.CEP=#L^/&9O;G0@3II M;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HQ<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@3II;FAE6QE/3-$)W9E#MP M861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O M=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY/=&AE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E M:6=H=#IB;VQD.SY4;W1A;#PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT M9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0Q.2!S='EL93TS M1'9E#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD M:78@F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#MF;VYT+7=E:6=H=#IB;VQD.SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+V1I M=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SY"86QA;F-E M(&%T($1E8V5M8F5R(#,Q+"`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@#MP861D:6YG+6)O='1O;3HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXV,RPU-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXH,C(X M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`S-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S M='EL93TS1'9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^*#,L M-C0Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXH.2PV-#$\+V9O;G0^/"]D:78^/"]T M9#X\=&0@#L@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^*3PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ3II;FAE6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^0F%L86YC92!A="!397!T96UB97(@,S`L(#(P,3,\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@3II;FAE6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.CEP=#L^,BPS.#@\+V9O;G0^/"]D:78^/"]T9#X\ M=&0@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@3II;FAE6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^-S`L,C(W/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R M9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X M.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N M9"UC;VQO6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C M8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O M<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M.7!T.SXQ+#@U-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P M,#`P,#`[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@ M9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXX M."PT.#<\+V9O;G0^/"]D:78^/"]T9#X\=&0@"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R,6-D.#@X95\S8S!D7S1F-35?.#5A95\R,SAA,30U M9C@Y,#,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X.&5? M,V,P9%\T9C4U7S@U865?,C,X83$T-68X.3`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`R,#`V+B`@5&AE('5P+69R;VYT(&QI8V5N28C.#(Q-SMS(&5S=&EM M871E9"!P97)I;V0@;V8@<&5R9F]R;6%N8V4@=6YD97(@=&AE(&-O;&QA8F]R M871I;VX@86=R965M96YT+B`@07,@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V,#LS,"P@ M,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.C$P<'0[/BP@=&AE3II;FAE3II;FAE#MT97AT+6%L:6=N M.FQE9G0[=&5X="UI;F1E;G0Z,C1P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE2!D971E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD M,S4P+C`@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!O9B!T:&5S92!C;VYT:6YG96YT M(&UI;&5S=&]N92!P87EM96YT6UE;G1S('5N9&5R('1H M:7,@86=R965M96YT+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH M96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HQ,G!X.W1E>'0M86QI9VXZ;&5F M=#MT97AT+6EN9&5N=#HR-'!X.V9O;G0M2!T:&4@;W1H97(@<&%R M='D@9F]R(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I M;VXZ;F]N93L^-3`E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&]F('1H97-E(&5X<&5N'!E;G-E'!E;G-E M2!*86YS3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@0V]M<&%N M>2!I;F-U2!W97)E(')E8V]R9&5D(&%S(&-O;&QA M8F]R871I=F4@'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M16%C:"!O9B!T:&4@<&%R=&EE3II M;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^(&%N9"`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R M.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE#MP861D M:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXQ M,#0L,3`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`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ3II;FAE#L@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`C,#`P,#`P.V)A8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MP861D:6YG+6QE9G0Z,C9P>#MT97AT+6EN M9&5N=#HM,31P>#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[)B,Q-C`[)B,Q M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&]T86P@8V]L;&%B M;W)A=&EV92!R979E;G5E#MP861D M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@ M'0M86QI M9VXZ3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP M861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,C4L-3$T/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[ M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXQ,C4L,34P/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`F(S@R,C`[35100R!!9W)E96UE;G0F M(S@R,C$[*2!W:71H($UI='-U8FES:&D@5&%N86)E(%!H87)M82!#;W)P;W)A M=&EO;B`H(DUI='-U8FES:&D@5&%N86)E(BD@<'5R#MT97AT M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,C1P>#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAEF%T:6]N(&]F('1E;&%P3II;FAE M6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('!A>6UE;G0@ M:6X@8V]N;F5C=&EO;B!W:71H('1H92`R,#`Y(&%M96YD;65N="!O9B!T:&4@ M8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@86YD(&UA9&4@82`\+V9O;G0^/&9O M;G0@3II;FAE3II;FAE3II;FAE M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[9&%Y2!E:71H97(@<&%R M='D@9F]R(&$@;6%T97)I86P@8G)E86-H(&)Y('1H92!O=&AE2!H87,@82!P871E;G0@8V]V97)I;F<@=&AE(&-O;7!O6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP M861D:6YG+6)O='1O;3HQ,G!X.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N M=#HR-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^('!A>6UE;G0@=&AA="!T:&4@0V]M<&%N>2!R96-E M:79E9"!I;B`R,#`Y(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@86UE;F1M96YT M('1O('1H92!-5%!#($%G28C.#(Q-SMS(&]B;&EG871I;VYS('5N9&5R('1H92!A M;65N9&5D(&%G28C.#(Q-SMS('1H:7)D+7!A2!R96-O9VYI>F5D(#PO9F]N=#X\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L M;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^;F\\+V9O;G0^/&9O M;G0@3II;FAE6QE/3-$;&EN M92UH96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HQ,G!X.W1E>'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE7-T:6,@1FEB'0M M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^26X@07!R:6P@,C`Q M,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N(&%M96YD;65N="`H=&AE M("8C.#(R,#M!<')I;"`R,#$Q($%M96YD;65N="8C.#(R,3LI('1O(&ET&ES=&EN9R!C;VQL86)O6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^5&AE($-O;7!A;GD@96YT97)E9"!I;G1O('1H92!O2!R96-E:79E M9"!A(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ M;F]N93L^)#$N-2!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&UI;&5S=&]N92!P87EM M96YT(&9R;VT@0T9&5"X@(%1H97)E(&%R92!N;R!A9&1I=&EO;F%L(&UI;&5S M=&]N97,@<&%Y86)L92!B>2!#1D94('1O('1H92!#;VUP86YY('!U2!W:71H('5P('1O(#PO9F]N=#X\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[ M8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#3II;FAE M65AF4@2T%,641%0T\@*&EV86-A9G1O#MT97AT+6%L M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,C1P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`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`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`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`@0T9&5"!M87D@=&5R;6EN871E(&ET2!E:71H97(@<&%R M='D@9F]R(&$@;6%T97)I86P@8G)E86-H(&)Y('1H92!O=&AE#MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT M+7-T>6QE.FET86QI8SL^06QI;W,@0FEO4&AA#MT97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,C1P M>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE'0M9&5C;W)A=&EO;CIU;F1E'0M:6YD96YT.C(T<'@[ M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^26X@2G5N92`R,#$Q+"!T:&4@0V]M<&%N M>2!E;G1E2UH96QD(&)I;W1E8VAN;VQO9WD@8V]M M<&%N>2X@(%1H92!#;VUP86YY(&%N9"!!;&EO6UE6QE/3-$;&EN92UH96EG M:'0Z,3(P)3MP861D:6YG+6)O='1O;3HQ,G!X.W1E>'0M86QI9VXZ;&5F=#MT M97AT+6EN9&5N=#HR-'!X.V9O;G0M2!R M96-E:79E9"!E>&-L=7-I=F4@=V]R;&1W:61E(')I9VAT2!D979E;&]P960@<'5R6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.C$P<'0[/BP@06QI;W,@:&%D(&5A6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN(&1E=F5L;W!M96YT(&UI M;&5S=&]N92!P87EM96YTF5D+B`@26X@861D M:71I;VXL($%L:6]S(&ES(&5L:6=I8FQE('1O(')E8V5I=F4@8V]M;65R8VEA M;"!M:6QE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SXD-S4P+C`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`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`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`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`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`V/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`P,#`P,#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$ M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^-"PU,S`\+V9O M;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O M;3HR<'@[8F]R9&5R+71O<#HQ<'@@#MP861D:6YG+6)O='1O M;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXH,S$L,#6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`P,#`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`P,#`[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@3II;FAE3II;FAE2!U6UE;G1S+"!B M87-E9"!O;B!A2!B M87-E2!D871A M(&9O'!E2X@(%-I9VYI9FEC86YT(&IU9&=M96YT(&ES('5S960@:6X@9&5T97)M:6YI M;F<@=&AE(&%P<')O<')I871E;F5S6UE;G1S+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN M92UH96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HQ,G!X.W1E>'0M86QI9VXZ M;&5F=#MT97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC M;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F M(S$V,#LS,"P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@=&AE(&9A:7(@=F%L=64@;V8@ M=&AE(&-O;G1I;F=E;G0@;6EL97-T;VYE('!A>6UE;G1S(&%N9"!R;WEA;'1I M97,@<&%Y86)L92!B>2!T:&4@0V]M<&%N>2!T;R!!;&EO2`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DN M($%N(&EN8W)E87-E(&EN('1H92!F86ER('9A;'5E(&]F('1H92!C;VYT:6YG M96YT(&UI;&5S=&]N92!P87EM96YT6%B;&4@ M8GD@=&AE($-O;7!A;GD@:6YC2!P87EM96YT M6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO3II;FAE3I4:6UE2!R96-E:79E9"!P M;W-I=&EV92!C;&EN:6-A;"!D871A(&9R;VT@82!0:&%S92`Q(&-L:6YI8V%L M('1R:6%L(&5V86QU871I;F<@04Q3+3(R,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O M=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY!#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXS."PU,S`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`@("`\=&%B;&4@8VQA"!#;VUM;VX@4W1O8VMH M;VQD97)S/"]T9#X-"B`@("`@("`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`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`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`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`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`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`@("`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`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`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`Z,3!P M>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,7!X.R<@'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/D9A:7(@5F%L=64@365A#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[,CPO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ M=&]P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MP861D:6YG M+6QE9G0Z,C9P>#MT97AT+6EN9&5N=#HM,31P>#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^0V%S:"!E<75I=F%L96YT#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$ M;W9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`X+#DX,3PO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1'9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`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`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#L@'0M M86QI9VXZ3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.CEP=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$ M=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ M'0M86QI M9VXZ;&5F=#MP861D:6YG+6QE9G0Z-#!P>#MT97AT+6EN9&5N=#HM,31P>#MF M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#L^0V]R<&]R871E(&1E8G0@#MP861D:6YG M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,34X+#8W.#PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[ M8F]R9&5R+6)O='1O;3HQ<'@@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ3II;FAE6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E#LG M(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.SXQ-3@L-C6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`P,#`P,#MP861D:6YG+6QE9G0Z M,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R M;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO#MP861D M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^ M,2PQ-3$L,S0U/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z M,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R M;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO#MP861D M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^ M,C@S+#DT,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P M,#`[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O M=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\ M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T M.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I M;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF M(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&-O M;G-I2!M87)K970@9G5N9',L('=H:6-H('=E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78@#MT97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,C1P>#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H M=#IN;W)M86P[<&%D9&EN9RUT;W`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S M('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG M(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY'F5D(#QB#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A M9&1I;F#LG(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`C,#`P,#`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z M,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R M;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO#MP861D M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^ M)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P M,#`[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O M=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\ M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T M.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I M;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF M(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$ M;W9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+6)O M='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S@R,3([ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E#L@'0M86QI9VXZ6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HQ<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,7!X.R!R;W=S<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^-34U+#4P,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E M'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E#MP861D:6YG+6)O='1O;3HQ<'@[(')O=W-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXS M-3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXH,3`\+V9O;G0^/"]D M:78^/"]T9#X\=&0@#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^*3PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`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`W,SPO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HQ<'@[(')O=W-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.SXQ,C4L,C8T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,7!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG M;CIL969T.W!A9&1I;F'0M:6YD96YT.BTQ-'!X.V9O M;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.SY#;W)P;W)A=&4@9&5B="!S96-U65A#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,7!X.R!R M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^,30X+#8W,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S M='EL93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HQ<'@[(')O=W-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.SXR,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+6)O='1O;3HQ<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXH,S@\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^*3PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O M;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ3II;FAE6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X M.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.R<@'0M86QI9VXZ3II;FAE#LG M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.SXX,SDL-#8Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG3II;FAE'0M86QI M9VXZ3II;FAE'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R M.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR-3(\+V9O;G0^/"]D:78^ M/"]T9#X\=&0@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L M96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP M861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^*#0Y/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z M,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.SXQ+#0R,BPV-3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F M;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.W!A M9&1I;F'0M:6YD96YT.BTQ-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/D%S(&]F($1E8V5M8F5R(#,Q+"`R M,#$R/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T M.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[ M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T M6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.SXT.#DL-#`W/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M6QE M/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.V)A8VMG3II;FAE'0M86QI9VXZ3II;FAEF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE M(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.CEP=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U M8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z M,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.SXT.#DL-#`W/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`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`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`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`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@#MP861D:6YG M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR,3<\+V9O;G0^/"]D:78^/"]T M9#X\=&0@6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^.#,Q+#@P.#PO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`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`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C M8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR,3<\+V9O;G0^/"]D:78^/"]T M9#X\=&0@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R M/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D M:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.CEP=#L^*#(Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[ M<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`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`P,#`P,#MT97AT+61E8V]R871I;VXZ M;F]N93L^)#4Q+C$@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD-S`N,"!M M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DL(&]F(&-A6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE3II;FAE3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X95\S8S!D7S1F-35?.#5A95\R M,SAA,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C%C M9#@X.&5?,V,P9%\T9C4U7S@U865?,C,X83$T-68X.3`S+U=O'0O:'1M;#L@8VAA3I4:6UE6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H M=#IB;VQD.SY!8V-U;75L871E9"!/=&AE'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HR M-'!X.V9O;G0M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D M:6YG+6)O='1O;3HQ-G!X.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$<&%D9&EN9RUL969T.C!P>#MT97AT+6EN9&5N M=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MM M87)G:6XM;&5F=#IA=71O.VUA6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/D9O M#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.V)A8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`S/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R M.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`@/&AE860^#0H@ M("`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY!6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`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`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ M3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`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`\+V9O;G0^ M/&9O;G0@'0M9&5C;W)A=&EO;CIN;VYE.R<^)#&-E'0O:F%V87-C3X-"B`@("`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`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`[,R!C;&EN:6-A;"!T7!E)B,Q-C`[ M,2!(0U8@:6YF96-T:6]N+B`@/"]F;VYT/CPO9&EV/CQD:78@'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M26X@2G5L>2`R,#$S+"!5+E,N($9O;V0@86YD($1R=6<@061M:6YI2!F6UE2!A;'-O(&ES(&5V86QU871I M;F<@5E@M,3,U(&EN(&-O;6)I;F%T:6]N('=I=&@@9&%C;&%T87-V:7(L(&%N M($Y3-4$@"!I;FAI8FET;W(@8F5I;F<@9&5V M96QO<&5D(&)Y($)R:7-T;VPM37EE'0M:6YD96YT.C(T<'@[ M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^268@=&AE(&9A:7(@=F%L=64@;V8@=&AE M($A#5B!N=6-L96]T:61E(&%N86QO9W5E('!R;V=R86T@8F5C;VUE2!O2!D871A(&9R;VT@86YY(&]N9V]I;F<@;W(@9G5T=7)E(&-L:6YI M8V%L('1R:6%L(&]R(&)E8V%U2!D979E M;&]P:6YG(&]R(&-O;6UEFEN9R!66"TQ,S4L('1H92!#;VUP86YY M('=O=6QD(&EN8W5R('-I9VYI9FEC86YT(&-H87)G97,@:6X@=&AE('!E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^07,@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C M;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[/B!A;F0@1&5C96UB97(@,S$L(#PO9F]N=#X\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P M,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`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`Q M,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.C$P<'0[/B!O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3I4:6UE6QE M/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY#;VYV97)T:6)L92!396YI M;W(@4W5B;W)D:6YA=&5D($YO=&5S/"]F;VYT/CPO9&EV/CQD:78@'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^26X@,C`Q,"P@=&AE($-O;7!A;GD@8V]M<&QE=&5D(&%N(&]F9F5R:6YG M(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ M;F]N93L^)#0P,"XP(&UI;&QI;VX\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXS+C,U)3PO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!C;VYV M97)T:6)L92!S96YI;W(@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE M.SXD,SDQ+C8@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!O9B!N970@<')O8V5E9',@ M=&\@=&AE($-O;7!A;GDN("!4:&4@=6YD97)W'!E;G-E3II;FAE#MT97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z M,C1P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2!T:6UE+"!A="!T:&4@;W!T:6]N(&]F('1H M92!H;VQD97(L(&EN=&\@8V]M;6]N('-T;V-K(&%T(&$@<')I8V4@97%U86P@ M=&\@87!P2`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE M.SXQ,S`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`E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^(&]F('1H92!C;VYV97)S:6]N('!R:6-E(&]F('1H M92`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`@/&AE860^#0H@("`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`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M('-Q=6%R92!F965T(&]F(&]F9FEC92!A;F0@;&%B;W)A=&]R>2!S<&%C92!I M;B`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXQ M-2!Y96%R6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE M.SYT96X@>65A3II M;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^0F5C875S92!T:&4@0V]M<&%N>2!I2P@ M=&AE($-O;7!A;GD@:&%S(')E8V]R9&5D('!R;VIE8W0@8V]N2!A;F0@97%U:7!M96YT+"!N970F(S@R,C$[(&%N9"`F(S@R,C`[ M0V]N28C.#(Q-SMS(&-O;F1E M;G-E9"!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E=',N("!4:&4@0V]M<&%N M>2!B:69U6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HQ M,G!X.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O M;G0^/&9O;G0@'0M9&5C;W)A=&EO;CIN;VYE.R<^ M)#(Y,"XW(&UI;&QI;VX\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z,3!P=#MC;VQO6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"!$96-E;6)E6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N M9"`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`C,#`P,#`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`Q-3PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^,34L-C`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`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`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`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`C,#`P,#`P.R<@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I M;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`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`Q,SPO9F]N=#X\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A M;F0@,C`Q,B!W87,@87,@9F]L;&]W#MT97AT M+6%L:6=N.F-E;G1EF4Z,3!P=#L^/&1I=B!S='EL93TS1'!A M9&1I;F'0M86QI9VXZ;&5F=#LG/CQT#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O M;G0M=V5I9VAT.F)O;&0[/E1H#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E#LG M(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.W1E>'0M M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O M;&0[/DYI;F4@36]N=&AS($5N9&5D(#PO9F]N=#X\+V1I=CX\9&EV('-T>6QE M/3-$9F]N="US:7IE.CEP=#MT97AT+6%L:6=N.F-E;G1EF4Z M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY397!T96UB97(@,S`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ3II;FAE6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ3II;FAE6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`T M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,7!X.R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I M;F#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@ M3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR M-RPU.#(\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@3II;FAE#MP861D M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXQ,#,L.3,S/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^.#8L-C0Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I M;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`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`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`L,3,X/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#L@'0M86QI M9VXZ3II;FAE'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR M<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXS,BPR,C0\+V9O;G0^/"]D:78^/"]T9#X\ M=&0@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO M9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ M=&]P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@'!E;G-E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO#MP861D M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXS,2PS,#@\+V9O;G0^/"]D M:78^/"]T9#X\=&0@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@ M3II;FAE6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,C6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C M8V5E9F8[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@3II;FAE6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^.#8L-C0Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0U('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E M:6=H=#IB;VQD.SY!#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.R<@ M'0M86QI9VXZ8V5N=&5R.V9O M;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/BAI;B!T:&]U6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D M:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`Q,SPO9F]N=#X\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[ M/CH\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[ M<&%D9&EN9RUB;W1T;VTZ,39P>#MT97AT+6%L:6=N.F-E;G1EF4Z,3!P=#L^/&1I=B!S='EL93TS1'!A9&1I;F3I4:6UE#MB;W)D97(M8V]L;&%P"!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$ M,3X\+W1D/CQT9"!W:61T:#TS1#@R<'@@"!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9EF4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`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`N,#$F(S@R,3$[)#,P+C`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`Q/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.SXD,CDN,3D\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R M.W!A9&1I;F'0M:6YD96YT.BTQ-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.SXD,S`N,#$F(S@R,3$[)#0P+C`P/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ M'0M86QI M9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXU-S`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^,38L.#`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`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2!3=')E86T\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L2!3=')E86T\+W-T'0^)SQD M:78@'0M M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^26X@,C`P."P@=&AE M($-O;7!A;GD@6UE;G1S(&9R;VT@1VQA>&]3;6ET:$ML:6YE M)B,Q-C`[<&QC+"!N970@;V8@2!A;6]U;G1S('1O(&)E(&5A2!A;F0@9'5E('1O(&$@=&AI6%L='D@<&%Y;65N=',@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V,#LS,"P@ M,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.C$P<'0[/BP@=&AE($-O;7!A;GD@:&%D(#PO9F]N=#X\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[ M/B0W,2XU(&UI;&QI;VX\+V9O;G0^/&9O;G0@3II;FAE6%L='D@86YD(&%N(&]F9G-E='1I;F<@2!E>'!E;G-E(&9O2!P M87EM96YT+CPO9F]N=#X\+V1I=CX\+V1I=CX\'0O:F%V87-C M3X-"B`@("`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`P M,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#,N,R!M:6QL:6]N/"]F;VYT M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^(&%T=')I8G5T86)L92!T;R!N;VYC;VYT2!A('!R;W9I&5S(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I M;VXZ;F]N93L^)#(N-B!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%T=')I8G5T86)L M92!T;R!697)T97@N($9O3II;FAE3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.C$P<'0[/BX@($EN(&-O;FYE8W1I;VX@=VET:"!T:&ES(&EM<&%I2!W2!O9B`\+V9O;G0^/&9O;G0@3II;FAE'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HR-'!X M.V9O;G0M3II;FAE&5S(&%T=')I8G5T86)L92!T M;R!697)T97@@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#`N,"!M:6QL:6]N/"]F;VYT/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^(&%N9"`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`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`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`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`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQT86)L92!C96QL<&%D M9&EN9STS1#`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`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`Q,SPO9F]N=#X\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@,C`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`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`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E M"!S;VQI9"`C M,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q M/CQD:78@F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SXR,#$R/"]F;VYT/CPO9&EV/CPO=&0^ M/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/BAI;B!T:&]U6QE/3-$=F5R=&EC M86PM86QI9VXZ=&]P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@3II;FAE2P@8F5G:6YN:6YG(&]F('1H92!P97)I;V0\+V9O;G0^/"]D:78^/"]T9#X\ M=&0@#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG M'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#L@'0M86QI9VXZ3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+6)O M='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR-"PX,S`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`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HQ<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,2PV M-3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F'0M:6YD96YT.BTQ-'!X.V9O;G0M6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SY,:6%B:6QI M='DL(&5N9"!O9B!T:&4@<&5R:6]D/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN M9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ3II;FAE6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE M(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR-"PQ-34\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R M+71O<#HQ<'@@3II;FAE6QE/3-$=&5X M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,C$L,S0T/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD M+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N M92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O M='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T M.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I M;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@ M'0M86QI M9VXZ3II;FAE6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M'0M:6YD96YT.C(T<'@[9F]N="US M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^5&AE($-O;7!A;GD@97-T:6UA=&5S('1H870@:70@ M=VEL;"!I;F-U&EM871E;'D@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#,U+C`@;6EL;&EO;CPO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/B!T;R`\+V9O;G0^/&9O;G0@3II M;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^+"!I;F-L=61I;F<@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#(P+C`@;6EL;&EO;CPO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/B!T;R`\+V9O;G0^/&9O;G0@3II M;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^(&9O3II;FAE3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#DN,"!M:6QL:6]N/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^('1O(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0Q,BXP(&UI;&QI;VX\+V9O;G0^ M/&9O;G0@3II;FAE2!R96-O3II;FAE3II;FAE2!E>'!E8W1S('1H92!V87-T(&UA:F]R:71Y(&]F('1H:7,@ M#MT97AT+6%L M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,C1P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE'0M M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`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`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`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`\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6QE9G0Z,3-P>#MT97AT+6EN M9&5N=#HM,31P>#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,X,C$R.SPO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[(')O=W-P86X],T0Q/CQD:78@'0M:6YD96YT.BTQ-'!X.V9O;G0M M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z.7!T.SXH-BPV-3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@#L@'0M86QI9VXZ;&5F=#MP M861D:6YG+6QE9G0Z,3-P>#MT97AT+6EN9&5N=#HM,31P>#MF;VYT+7-I>F4Z M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.CEP=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P M,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ3II;FAEF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@#MP861D:6YG M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXH-BPV-3`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M3I4:6UE6QE/3-$=VED=&@Z,3AP>#L@3II;FAE"!0:&%R;6%C975T:6-A;',@26YC;W)P;W)A=&5D+"!E="!A;"X\+V9O;G0^ M/&9O;G0@3II;FAE2!A;F0@8V5R=&%I;B!O9B!T:&4@0V]M<&%N>2=S M(&-U&-H86YG92!!8W0@ M;V8@,3DS-"P@87,@86UE;F1E9"P@86YD(%)U;&4@,3!B+34@<')O;75L9V%T M960@=&AE2!O9B!"2=S(&-O;6UO;B!S=&]C:RX@(%1H92!#;VUP86YY(&)E;&EE M=F5S('1H870@=&AI2X@($%S(&]F(#PO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^4V5P=&5M M8F5R)B,Q-C`[,S`L(#(P,3,\+V9O;G0^/&9O;G0@3II;FAE7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA3I4:6UE6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY# M;VYT:6YG96YC:65S/"]F;VYT/CPO9&EV/CQD:78@'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE($-O M;7!A;GD@:&%S(&-E2!C;W5R2!A8V-R=65S(&$@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C M;W)A=&EO;CIN;VYE.SYN;SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!M871E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V M,#LS,"P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.C$P<'0[/B!O3II;FAE6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+CPO9F]N=#X\+V1I=CX\+V1I M=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQD:78@&EM=6T@<&]T96YT:6%L(&%M;W5N M="!O9B!F=71U2!C;W5L9"!B M92!R97%U:7)E9"!T;R!M86ME('5N9&5R('1H97-E(&EN9&5M;FEF:6-A=&EO M;B!P2!I;G-U2!A M2!B96QI979E6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HQ,G!X.W1E M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HR-'!X.V9O;G0M7!I8V%L M;'D@87!P;'D@=&\@86YY(&-L86EM(&%S28C.#(Q-SMS(&-O;G1R86-T=6%L(&]B;&EG871I M;VYS(&%R:7-I;F<@;W5T(&]F('1H92!R97-E87)C:"!O2!T:&4@0V]M<&%N>2P@=&\@=FEO;&%T:6]N28C.#(Q-SMS(&-O;G1R86-T=6%L(&]B;&EG871I;VYS+B`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT M+69A;6EL>3I4:6UE6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HQ,G!X M.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HV<'@[=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C(T M<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3VX@3V-T;V)E3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)#0U+C`@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@/"]F;VYT/CQF;VYT('-T M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#$Q M+C0@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.C$P<'0[/B!O9B!W:&EC:"!W87,@7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`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`[06QI;W,@0FEO4&AA2!B96YE9FEC:6%R>2X@($%L;"!M871E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-E M9VUE;G0L('!H87)M86-E=71I8V%L#MT97AT M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,C1P>#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE2!I;F-L=61E9"!I;B!T:&4@0V]M<&%N>2=S(&%N;G5A M;"!F:6YA;F-I86P@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&%N9"`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`S+U=O'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO3I4:6UE'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE(&9O;&QO M=VEN9R!T86)L92!S=6UM87)I>F5S(&%C=&EV:71Y(&EN(&5A8V@@;V8@=&AE M('!R;V1U8W0@3II M;FAE'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN M;W)M86P[<&%D9&EN9RUT;W`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`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@ MF4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF M;VYT+7=E:6=H=#IB;VQD.SY/=&AE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY4;W1A M;#PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0Q.2!S='EL93TS1'9EF4Z.7!T.SX\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB M;VQD.SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R M/CQT9"!S='EL93TS1'9E#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SY"86QA;F-E(&%T($1E8V5M8F5R(#,Q M+"`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`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.SXV,RPU-C`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`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`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`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`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG M+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE#MP M861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^ M0F%L86YC92!A="!397!T96UB97(@,S`L(#(P,3,\+V9O;G0^/"]D:78^/"]T M9#X\=&0@#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^,BPS.#@\+V9O;G0^/"]D:78^/"]T9#X\=&0@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C M8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^ M-S`L,C(W/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ3II;FAE6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P M,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXQ+#@U-SPO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N M9"UC;VQO6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO#MP861D M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXX."PT.#<\+V9O;G0^/"]D M:78^/"]T9#X\=&0@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R M,6-D.#@X95\S8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T9C4U7S@U865? M,C,X83$T-68X.3`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P M86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY4:')E92!-;VYT:',@16YD M960@4V5P=&5M8F5R(#,P+#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXQ,BPW-S(\+V9O;G0^/"]D:78^/"]T M9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@#MT97AT M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,C1P>#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE3II;FAE6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`R,#$R M+"!T:&4@0V]M<&%N>2!R96-O9VYI>F5D('1H92!F;VQL;W=I;F<@'0M:6YD M96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^ M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD M:78@F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#MF;VYT+7=E:6=H=#IB;VQD.SY4:')E92!-;VYT:',@16YD960@4V5P=&5M M8F5R(#,P+#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SXR,#$S M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,7!X.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[ M/C(P,3(\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP M861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H M=#IB;VQD.SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S M='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`T M+#$P.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9EF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I M;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`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`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`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`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`C,#`P,#`P.W!A9&1I;F#MP861D:6YG M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXT+#4R,#PO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R M+6)O='1O;3HQ<'@@"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R M+71O<#HQ<'@@3II;FAE#MB;W)D97(M M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ3II;FAE6QE/3-$)W9E M"!S;VQI9"`C M,#`P,#`P.V)O6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@3II;FAE#LG(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXR,2PP-#(\+V9O;G0^/"]D:78^/"]T9#X\ M=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[ M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXR,BPU-C$\+V9O;G0^/"]D:78^/"]T9#X\ M=&0@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG M+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F M=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$ M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#L^,3(U+#$U,#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D M9&EN9RUT;W`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`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@#MP861D:6YG+6)O='1O;3HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXQ-"PU.#$\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F'0M:6YD96YT.BTQ-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SY$96-R M96%S92`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`V/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXI/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@3II;FAE#MP861D M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXH,S$L,#6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`P,#`[<&%D9&EN9RUR:6=H=#HR<'@[ M<&%D9&EN9RUT;W`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`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`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`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`L-C`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`\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^-"PX.3`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXQ+#`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#L@'0M86QI9VXZF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"!#;VUM;VX@4VAA6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@ M'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M86QI9VXZ;&5F=#MT97AT+6EN M9&5N=#HR-'!X.V9O;G0M65T('9E M'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HR M-'!X.V9O;G0M"!P97(@8V]M;6]N('-H M87)E(&-A;&-U;&%T:6]N'0M:6YD M96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SXR,#$S/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,7!X.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/C(P M,3(\+V9O;G0^/"]D:78^/"]T9#X\=&0@#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HQ<'@[<&%D9&EN M9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`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`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR+#(R,CPO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1'9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`C M,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB M;VQD.SY&86ER(%9A;'5E($UE87-U#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`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`[,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`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`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`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A M9&1I;F#LG(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.V)A8VMG'0M86QI9VXZ'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXX-C6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D M:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.CEP=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\R,6-D.#@X95\S8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T M9C4U7S@U865?,C,X83$T-68X.3`S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO2!O9B!C87-H+"!C87-H(&5Q=6EV86QE M;G1S(&%N9"!M87)K971A8FQE('-E8W5R:71I97,\+W1D/@T*("`@("`@("`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT M+7=E:6=H=#IB;VQD.SY'F5D(#QB#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MB86-K M9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1'9E#L@'0M86QI9VXZ3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@3II;FAE#MP861D M:6YG+6)O='1O;3HQ<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,BPX.34\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T M.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`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`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP M861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T M6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E'0M86QI9VXZ3II;FAE6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M6QE/3-$;W9E#MP M861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG6QE/3-$=&5X M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,X,C$R.SPO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`\+V9O;G0^/"]D:78^/"]T9#X\=&0@#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.CEP=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$ M=F5R=&EC86PM86QI9VXZ=&]P.V)A8VMG#MP861D:6YG+6)O='1O M;3HQ<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@3II;FAE6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I M>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.CEP=#L^,3(U+#`W,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1'9E6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R M/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`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`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`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`P,#`[ M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I M;F#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.R<@'0M M86QI9VXZ3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`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`P,#`[<&%D9&EN9RUT;W`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`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z M,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.SXR-3(\+V9O;G0^/"]D:78^/"]T9#X\=&0@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE M9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C M:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P M,#`[8F%C:V=R;W5N9"UC;VQO#MP M861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\ M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^*#0Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUR:6=H=#HR<'@[ M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C M8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXQ+#0R,BPV-3`\+V9O M;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ M#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I M;F6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F'0M M:6YD96YT.BTQ-'!X.V9O;G0M6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O M;&0[/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S@R,3([/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`P,#`P,#MB86-K9W)O=6YD M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXT.#DL-#`W/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG3II;FAE'0M86QI9VXZ3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[ M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC M;VQO#MP861D:6YG+6)O='1O;3HR M<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,X,C$R.SPO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N M9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C M8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXT.#DL-#`W/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD M+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`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`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@ M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X M.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O M<#HQ<'@@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O M<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M.7!T.SXR,3<\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`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`P,#`P,#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^.#,Q+#@P.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P M,#`P,#`[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI M9VXZ=&]P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A M8VMG3II;FAE'0M86QI9VXZ3II;FAE'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X M.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M.7!T.SXR,3<\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z M,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R M;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO#MP861D M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^ M*#(Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D M9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R M.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXQ+#,R,2PR,34\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO3I4:6UE'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE(&9O M;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!C:&%N9V5S(&EN(&%C8W5M M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@;&]S2!C;VUP;VYE;G0L M(&YE="!O9B!T87@Z/"]F;VYT/CPO9&EV/CQD:78@#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@3II;FAE2!46QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I9VAT M.F)O;&0[/E5N#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP M=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N M="US:7IE.CEP=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY"86QA;F-E(&%T($1E8V5M8F5R(#,Q M+"`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`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`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`C,#`P M,#`P.V)A8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`C M,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[ M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC M;VQO#MP861D:6YG+6)O='1O;3HR M<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.SXH-S4S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D M9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1'9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@ M9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR M,#,\+V9O;G0^/"]D:78^/"]T9#X\=&0@"!S;VQI9"`C M,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R M9&5R+71O<#HQ<'@@3II;FAE6QE/3-$ M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^*#4U,#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N M9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@3II;FAE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X M95\S8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T9C4U7S@U865?,C,X83$T M-68X.3`S+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQD:78@'0M86QI9VXZ;&5F=#MT97AT+6EN M9&5N=#HR-'!X.V9O;G0M28C.#(Q-SMS(&EN=F5N=&]R M:65S(&)Y('1Y<&4Z/"]F;VYT/CPO9&EV/CQD:78@#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT M+7=E:6=H=#IB;VQD.SY!#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HQ M<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E M:6=H=#IB;VQD.SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+V1I=CX\+W1D/CPO M='(^/'1R/CQT9"!S='EL93TS1'9E#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG M;CIL969T.W!A9&1I;F'0M:6YD96YT.BTQ-'!X.V9O M;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.SY287<@;6%T97)I86QS/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z.7!T.SXR,S(\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M6QE M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,RPW-30\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[(')O M=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z.7!T.SXW+#DX,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M.7!T.SXQ,2PS,3<\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.V)A8VMG#MP861D:6YG+6)O='1O;3HQ<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`P,#`[<&%D9&EN9RUL M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`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`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXS,"PT-C0\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X M95\S8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T9C4U7S@U865?,C,X83$T M-68X.3`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`C,#`P,#`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`Q-3PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^,34L-C`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`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`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`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`C,#`P,#`P.R<@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I M;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@ M'0M86QI M9VXZ3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'!E;G-E(&)Y(&QI;F4@:71E;3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQD:78@'0M86QI9VXZ M;&5F=#MT97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T M96UB97(F(S$V,#LS,"P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@,C`Q,B!W87,@ M87,@9F]L;&]W#MT97AT+6%L:6=N.F-E;G1E MF4Z,3!P=#L^/&1I=B!S='EL93TS1'!A9&1I;F'0M86QI9VXZ;&5F=#LG/CQT#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E#LG M(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.W1E>'0M M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O M;&0[/E1H3II;FAE#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q M/CQD:78@F4Z.7!T.W1E>'0M86QI9VXZ8V5N=&5R M.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/DYI;F4@36]N M=&AS($5N9&5D(#PO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$9F]N="US:7IE M.CEP=#MT97AT+6%L:6=N.F-E;G1EF4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT M+7=E:6=H=#IB;VQD.SY397!T96UB97(@,S`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE M/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@'0M M86QI9VXZ;&5F=#MP861D:6YG+6QE9G0Z,C9P>#MT97AT+6EN9&5N=#HM,31P M>#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.CEP=#L^4W1O8VL@;W!T:6]N#MP861D:6YG+6)O='1O;3HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@3II;FAE#L@'0M86QI9VXZ3II;FAE'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@3II;FAE#L@'0M M86QI9VXZ3II;FAE'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@#L@'0M86QI9VXZ3II;FAE'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E3II;FAE#L@'0M86QI9VXZ'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG M+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MP861D:6YG+6QE9G0Z,C9P>#MT97AT+6EN M9&5N=#HM,31P>#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^4F5S=')I8W1E9"!S=&]C M:R!A;F0@#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^,3`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`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`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ3II;FAE6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`T/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,7!X.R!R;W=S<&%N/3-$,2!C;VQS M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HQ<'@[(')O=W-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T M.SXH.#@U/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,7!X M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXI/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A M9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ M<'@@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ M<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T M.SXS,2PS,#@\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@3II;FAE#MP M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR-RPU.#(\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR M<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.SXQ,#,L.3,S/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T M.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^.#8L-C0Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`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`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`L,3,X/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`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`C M,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[ M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC M;VQO#MP861D:6YG+6)O='1O;3HR M<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.SXS,2PS,#@\+V9O;G0^/"]D:78^/"]T9#X\=&0@ M"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O M=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@3II;FAE6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I M>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.CEP=#L^,C6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R M+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A M9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC M;VQO6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ3II;FAE"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MB86-K9W)O=6YD+6-O;&]R M.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T.SX\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP M=#L^.#8L-C0Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY7 M96EG:'1E9"UA=F5R86=E(#QB#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S M('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SXH:6X@=&AO=7-A;F1S M*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9EF4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`C,#`P,#`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`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`Q)B,X,C$Q.R0S,"XP,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.7!T.SXQ+#`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`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`N,#$F(S@R M,3$[)#4P+C`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

6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N M=&5R.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD-#8N-S,\+V9O;G0^/"]D:78^/"]T M9#X\+W1R/CQT#MP861D:6YG+7)I9VAT.C)P M>#L@'0M M86QI9VXZ8V5N=&5R.W!A9&1I;F'0M:6YD96YT.BTQ M-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD-3`N,#$F(S@R,3$[)#8P+C`P/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,2PX M-#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^.#`U/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^)#4T+C0Y/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@'0M86QI9VXZ8V5N=&5R.W!A9&1I;F'0M:6YD96YT M.BTQ-'!X.V9O;G0M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD-C`N,#$F(S@R,3$[)#6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z.7!T.SXX+C8T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD-C,N,C,\+V9O M;G0^/"]D:78^/"]T9#X\=&0@#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,3$\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE M.CEP=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([ M<&%D9&EN9RUL969T.C$S<'@[=&5X="UI;F1E;G0Z+3$T<'@[9F]N="US:7IE M.CEP=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N M=&5R.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXX-3PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1'9E#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT M97([9F]N="US:7IE.CEP=#L^/&9O;G0@3II M;FAE#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N M=&5R.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXD-S#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@ M'0M86QI M9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXT/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M#MT M97AT+6EN9&5N=#HM,31P>#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#@P+C`Q+20X M."XQ.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^,2PT.34\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXY M+C@Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@#MT97AT+6%L:6=N.FQE9G0[=&5X M="UI;F1E;G0Z,C1P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2!F M;W(@=&AE('1H3II;FAE6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`R,#$R('=E#MT97AT+6%L:6=N.F-E;G1EF4Z,3!P=#L^/&1I=B!S='EL93TS1'!A9&1I;F'0M86QI9VXZ;&5F=#LG/CQT#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O M=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY4:')E92!-;VYT:',@ M16YD960@4V5P=&5M8F5R(#,P+#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`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`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`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`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`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`C,#`P M,#`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`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E M"!S;VQI9"`C M,#`P,#`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`P,#`P,#MB86-K9W)O=6YD M+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N M92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O M='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T M.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I M;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@ M'0M86QI M9VXZ3II;FAE6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M6QE M/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.V)A8VMG"!S M;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)#PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R M;W5N9"UC;VQO#MP861D:6YG+6)O M='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXR,2PS-#0\+V9O;G0^/"]D:78^/"]T M9#X\=&0@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@3II;FAE6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#L^,C0L,34U/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[ M8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/"]T3PO=&0^#0H@ M("`@("`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`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`\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6QE9G0Z,3-P>#MT M97AT+6EN9&5N=#HM,31P>#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,X,C$R.SPO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E'0M:6YD96YT.BTQ-'!X M.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z.7!T.SXH-BPV-3`\+V9O;G0^/"]D:78^/"]T9#X\ M=&0@#L@'0M86QI9VXZ M;&5F=#MP861D:6YG+6QE9G0Z,3-P>#MT97AT+6EN9&5N=#HM,31P>#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U M8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II M;FAE#MB;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^ M)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D M9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@3II;FAE#MP M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXH-BPV-3`\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@#MP861D:6YG+6)O='1O;3HR<'@[8F]R M9&5R+71O<#HQ<'@@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M.7!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^-"PW.30\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R M,6-D.#@X95\S8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T9C4U7S@U865? M,C,X83$T-68X.3`S+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6UE;G1S(&UA9&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S(&UA9&4\+W1D/@T*("`@("`@("`\=&0@8VQA'1087)T7S(Q8V0X.#AE7S-C,&1?-&8U-5\X-6%E7S(S.&$Q-#5F.#DP,PT* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R,6-D.#@X95\S8S!D7S1F M-35?.#5A95\R,SAA,30U9C@Y,#,O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`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`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0I(&9O'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S*3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%L='D@;V)L:6=A=&EO;B!A9G1E2!U;FQE'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M65A M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%L='D@<&%Y;65N=',\+W1D M/@T*("`@("`@("`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`@("`\=&%B;&4@8VQA"!#;VUM;VX@4VAA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO&-L=61E9"!F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&-L M=61E9"!F'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO&-L=61E9"!F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!M87)K970@9G5N9',\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPOF5D($-O'0^)SQS<&%N/CPO2!O9B!C87-H+"!C87-H(&5Q M=6EV86QE;G1S(&%N9"!M87)K971A8FQE('-E8W5R:71I97,\+W-TF5D($QO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPOF5D($-O'0^)SQS<&%N/CPOF5D($QOF5D($-O'0^ M)SQS<&%N/CPO2!O9B!C87-H+"!C87-H(&5Q=6EV86QE;G1S M(&%N9"!M87)K971A8FQE('-E8W5R:71I97,\+W-TF5D($=A M:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2!O9B!C M87-H+"!C87-H(&5Q=6EV86QE;G1S(&%N9"!M87)K971A8FQE('-E8W5R:71I M97,\+W-TF5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XS-3QS<&%N/CPOF5D($QO'0^)SQS<&%N/CPO2!O9B!C87-H+"!C87-H M(&5Q=6EV86QE;G1S(&%N9"!M87)K971A8FQE('-E8W5R:71I97,\+W-TF5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ.3$\65A'0^)SQS<&%N/CPOF5D($QO M'0^)SQS<&%N/CPO2!O9B!C87-H M+"!C87-H(&5Q=6EV86QE;G1S(&%N9"!M87)K971A8FQE('-E8W5R:71I97,\ M+W-TF5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R M,6-D.#@X95\S8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T9C4U7S@U865? M,C,X83$T-68X.3`S+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2`HXH"<5DE%XH"=*2P@06QI;W,@0FEO4&AA7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2`HXH"<5DE%XH"=*2P@06QI M;W,@0FEO4&AA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M"!I;B!I=',@86=R965M96YT('=I=&@@ M06QI;W,N(%-E92!.;W1E($,L(")#;VQL86)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO*`G2DL($%L:6]S($)I;U!H87)M82S"H$EN8RX@*.*`G$%L:6]SXH"= M*2X@5F5R=&5XXH"9"!I;B!I M=',@86=R965M96YT('=I=&@@06QI;W,N(%-E92!.;W1E($,L(")#;VQL86)O M'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M&-E960@=&AE(&-O;G9E'0^)SQS<&%N/CPO7,@=&AE(&-L;W-I;F<@<')I8V4@ M;F5E9',@=&\@97AC965D('1H92!C;VYV97)S:6]N('!R:6-E(&9O'0^)SQS<&%N/CPO'0^)S,P(&1A>7,\'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO.*`F7,@=F%R:6%B;&4@:6YT97)E.*`F7,@:6YT97)E*`F7,@87-S971S(&%N9"!L:6%B:6QI=&EE3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X95\S8S!D7S1F-35?.#5A M95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,C%C9#@X.&5?,V,P9%\T9C4U7S@U865?,C,X83$T-68X.3`S+U=O'0O:'1M;#L@8VAA M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2`H:6X@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S$P('EE87)S/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO*`F7,@ M87-S971S(&%N9"!L:6%B:6QI=&EE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\R,6-D.#@X95\S8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T9C4U7S@U M865?,C,X83$T-68X.3`S+U=O'0O:'1M;#L@8VAA3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X95\S8S!D7S1F-35?.#5A M95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,C%C9#@X.&5?,V,P9%\T9C4U7S@U865?,C,X83$T-68X.3`S+U=O'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'!E;G-E M.CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)S(@ M>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E M;G-E(&)Y('1Y<&4@;V8@87=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(@>65A'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO2!T>7!E M(&]F(&%W87)D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P M-#QS<&%N/CPO7!E(&]F(&%W87)D.CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPOF5D($5X<&5N65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E.CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E(&EN8VQU9&5D(&EN(&-O'!E;G-E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G0@07=A&5R8VES92!P&5R8VES92!P&5R8VES92!P&5R8VES86)L92`H:6X@6UE;G0@07=A&5R8VES92!P&5R8VES92!P&5R8VES92!P65A&5R8VES92!P&5R8VES92!P&5R8VES92!P M&5R8VES86)L92`H:6X@&5R8VES92!P M&5R8VES86)L92P@=V5I9VAT960M879E M&5R8VES92!P&5R8VES M92!0'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P&5R8VES92!P&5R8VES92!P&5R8VES92!P&5R8VES92!P&5R8VES M86)L92`H:6X@&5R8VES92!P&5R8VES M86)L92P@=V5I9VAT960M879E&5R8VES92!P&5R8VES92!0'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO&5R8VES92!P&5R8VES92!P&5R8VES92!P&5R8VES86)L92P@=V5I9VAT960M879E&5R M8VES92!P&5R8VES92!0'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO&5R8VES92!P&5R8VES92!P&5R8VES M92!P&5R8VES92!P&5R M8VES92!P&5R8VES86)L92`H:6X@&5R M8VES92!P&5R8VES86)L92P@=V5I9VAT M960M879E&5R8VES92!P&5R8VES92!0'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P M&5R8VES92!P7,\'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO&5R8VES92!P&5R M8VES92!P7,\2!3:&%R92UB87-E M9"!087EM96YT($%W87)D/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P'0^)SD@>65A&5R8VES92!P&5R8VES86)L92P@=V5I9VAT960M879E&5R8VES92!P&5R8VES92!06UE;G0@07=A&5R8VES92!P&5R8VES M92!P&5R8VES92!P&5R M8VES92!P&5R8VES86)L92`H:6X@&5R M8VES92!P&5R8VES86)L92P@=V5I9VAT M960M879E&5R8VES92!P3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X M95\S8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T9C4U7S@U865?,C,X83$T M-68X.3`S+U=O'0O:'1M;#L@8VAA6%L='D@4W1R96%M("A$971A:6QS*2`H55-$("0I/&)R M/DEN($UI;&QI;VYS+"!U;FQE6%L='D@4W1R96%M/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M6%L='D@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"!3:&%R96AO;&1E3QB M"!3:&%R96AO;&1E3QB"!#87)R>69O'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO"!%>'!E;G-E("A"96YE9FET*3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M69O=V%R9',\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2`HXH"<5DE% MXH"=*2P@06QI;W,@0FEO4&AA7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!R97-T'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!R97-T'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E(%-E=F5R86YC92!;365M8F5R73PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!R97-T'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO&EM=6T@6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H1&5T86EL'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO2P@ M8F5G:6YN:6YG(&]F('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA M2P@96YD(&]F('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X95\S M8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,C%C9#@X.&5?,V,P9%\T9C4U7S@U865?,C,X83$T-68X M.3`S+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\R,6-D.#@X95\S8S!D7S1F-35?.#5A95\R,SAA M,30U9C@Y,#,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C%C9#@X M.&5?,V,P9%\T9C4U7S@U865?,C,X83$T-68X.3`S+U=O&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U&UL/@T*+2TM+2TM/5].97AT4&%R=%\R,6-D D.#@X95\S8S!D7S1F-35?.#5A95\R,SAA,30U9C@Y,#,M+0T* ` end XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 225 279 1 true 65 0 false 10 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.vrtx.com/role/DocumentAndEntityInformation Document and Entity Information false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss Condensed Consolidated Statements of Comprehensive Income (Loss) true false R4.htm 1003000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets false false R5.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest false false R7.htm 1006000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows false false R8.htm 2101100 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies Basis of Presentation and Accounting Policies false false R9.htm 2102100 - Disclosure - Product Revenues, Net Sheet http://www.vrtx.com/role/ProductRevenuesNet Product Revenues, Net false false R10.htm 2104100 - Disclosure - Collaborative Arrangements Sheet http://www.vrtx.com/role/CollaborativeArrangements Collaborative Arrangements false false R11.htm 2105100 - Disclosure - Net Income (Loss) Per Share Attributable to Vertex Common Shareholders Sheet http://www.vrtx.com/role/NetIncomeLossPerShareAttributableToVertexCommonShareholders Net Income (Loss) Per Share Attributable to Vertex Common Shareholders false false R12.htm 2106100 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements false false R13.htm 2107100 - Disclosure - Marketable Securities Sheet http://www.vrtx.com/role/MarketableSecurities Marketable Securities false false R14.htm 2108100 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Notes) Notes http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossNotes Accumulated Other Comprehensive Income (Loss) (Notes) false false R15.htm 2110100 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories false false R16.htm 2112100 - Disclosure - Intangible Assets and Goodwill Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill false false R17.htm 2113100 - Disclosure - Convertible Senior Subordinated Notes Notes http://www.vrtx.com/role/ConvertibleSeniorSubordinatedNotes Convertible Senior Subordinated Notes false false R18.htm 2114100 - Disclosure - Long-term Obligations Sheet http://www.vrtx.com/role/LongTermObligations Long-term Obligations false false R19.htm 2115100 - Disclosure - Stock-based Compensation Expense Sheet http://www.vrtx.com/role/StockBasedCompensationExpense Stock-based Compensation Expense false false R20.htm 2116100 - Disclosure - Sale of HIV Protease Inhibitor Royalty Stream Sheet http://www.vrtx.com/role/SaleOfHivProteaseInhibitorRoyaltyStream Sale of HIV Protease Inhibitor Royalty Stream false false R21.htm 2118100 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes false false R22.htm 2119100 - Disclosure - Restructuring Liability Sheet http://www.vrtx.com/role/RestructuringLiability Restructuring Liability false false R23.htm 2120100 - Disclosure - Legal Proceedings Sheet http://www.vrtx.com/role/LegalProceedings Legal Proceedings false false R24.htm 2121100 - Disclosure - Contingencies Sheet http://www.vrtx.com/role/Contingencies Contingencies false false R25.htm 2122100 - Disclosure - Guarantees Sheet http://www.vrtx.com/role/Guarantees Guarantees false false R26.htm 2123100 - Disclosure - Subsequent Events (Notes) Notes http://www.vrtx.com/role/SubsequentEventsNotes Subsequent Events (Notes) false false R27.htm 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) false false R28.htm 2302301 - Disclosure - Product Revenues, Net (Tables) Sheet http://www.vrtx.com/role/ProductRevenuesNetTables Product Revenues, Net (Tables) false false R29.htm 2304301 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.vrtx.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) false false R30.htm 2305301 - Disclosure - Net Income (Loss) Per Share Attributable to Vertex Common Shareholders (Tables) Sheet http://www.vrtx.com/role/NetIncomeLossPerShareAttributableToVertexCommonShareholdersTables Net Income (Loss) Per Share Attributable to Vertex Common Shareholders (Tables) false false R31.htm 2306301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) false false R32.htm 2307301 - Disclosure - Marketable Securities (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesTables Marketable Securities (Tables) false false R33.htm 2308301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) false false R34.htm 2310301 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) false false R35.htm 2314301 - Disclosure - Long-term Obligations Schedule of Capital Lease Obligations (Tables) Sheet http://www.vrtx.com/role/LongTermObligationsScheduleOfCapitalLeaseObligationsTables Long-term Obligations Schedule of Capital Lease Obligations (Tables) false false R36.htm 2315301 - Disclosure - Stock-based Compensation Expense (Tables) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseTables Stock-based Compensation Expense (Tables) false false R37.htm 2319301 - Disclosure - Restructuring Liability (Tables) Sheet http://www.vrtx.com/role/RestructuringLiabilityTables Restructuring Liability (Tables) false false R38.htm 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) false false R39.htm 2402402 - Disclosure - Product Revenues, Net (Details) Sheet http://www.vrtx.com/role/ProductRevenuesNetDetails Product Revenues, Net (Details) false false R40.htm 2404402 - Disclosure - Collaborative Arrangements (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsDetails Collaborative Arrangements (Details) false false R41.htm 2405402 - Disclosure - Net Income (Loss) Per Share Attributable to Vertex Common Shareholders (Details) Sheet http://www.vrtx.com/role/NetIncomeLossPerShareAttributableToVertexCommonShareholdersDetails Net Income (Loss) Per Share Attributable to Vertex Common Shareholders (Details) false false R42.htm 2406402 - Disclosure - Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) false false R43.htm 2407402 - Disclosure - Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesDetails Marketable Securities (Details) false false R44.htm 2407403 - Disclosure - Marketable Securities (Details 2) Sheet http://www.vrtx.com/role/MarketableSecuritiesDetails2 Marketable Securities (Details 2) false false R45.htm 2408402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) false false R46.htm 2410402 - Disclosure - Inventories Inventories- Schedule of Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesInventoriesScheduleOfInventoriesDetails Inventories Inventories- Schedule of Inventories (Details) false false R47.htm 2412401 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Details) false false R48.htm 2413401 - Disclosure - Convertible Senior Subordinated Notes (Details) Notes http://www.vrtx.com/role/ConvertibleSeniorSubordinatedNotesDetails Convertible Senior Subordinated Notes (Details) false false R49.htm 2414402 - Disclosure - Long-term Obligations (Details) Sheet http://www.vrtx.com/role/LongTermObligationsDetails Long-term Obligations (Details) false false R50.htm 2414403 - Disclosure - Long-term Debt Obligations (Details) Sheet http://www.vrtx.com/role/LongTermDebtObligationsDetails Long-term Debt Obligations (Details) false false R51.htm 2415402 - Disclosure - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseDetails Stock-based Compensation Expense (Details) false false R52.htm 2415403 - Disclosure - Stock-based Compensation Expense (Details 2) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseDetails2 Stock-based Compensation Expense (Details 2) false false R53.htm 2416401 - Disclosure - Sale of HIV Protease Inhibitor Royalty Stream (Details) Sheet http://www.vrtx.com/role/SaleOfHivProteaseInhibitorRoyaltyStreamDetails Sale of HIV Protease Inhibitor Royalty Stream (Details) false false R54.htm 2418401 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) false false R55.htm 2419402 - Disclosure - Restructuring Liability (Details) Sheet http://www.vrtx.com/role/RestructuringLiabilityDetails Restructuring Liability (Details) false false R56.htm 2419403 - Disclosure - Restructuring Liability (Details 2) Sheet http://www.vrtx.com/role/RestructuringLiabilityDetails2 Restructuring Liability (Details 2) false false R57.htm 2421401 - Disclosure - Contingencies Contingencies (Details) Sheet http://www.vrtx.com/role/ContingenciesContingenciesDetails Contingencies Contingencies (Details) false false R58.htm 2423401 - Disclosure - Subsequent Events (Details) Sheet http://www.vrtx.com/role/SubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Element us-gaap_ConvertibleSubordinatedDebtNoncurrent had a mix of decimals attribute values: -5 -3. Element us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill had a mix of decimals attribute values: -5 -3. Element us-gaap_OtherIndefiniteLivedIntangibleAssets had a mix of decimals attribute values: -5 -3. Element us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities had a mix of decimals attribute values: -3 0. 'Shares' elements on report '1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest' had a mix of different decimal attribute values. 'Monetary' elements on report '2404402 - Disclosure - Collaborative Arrangements (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2406402 - Disclosure - Fair Value Measurements (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2412401 - Disclosure - Intangible Assets and Goodwill (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2413401 - Disclosure - Convertible Senior Subordinated Notes (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2414402 - Disclosure - Long-term Obligations (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2418401 - Disclosure - Income Taxes (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2419402 - Disclosure - Restructuring Liability (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2423401 - Disclosure - Subsequent Events (Details)' had a mix of different decimal attribute values. Process Flow-Through: 1001000 - Statement - Condensed Consolidated Statements of Operations Process Flow-Through: 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Process Flow-Through: 1003000 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 1006000 - Statement - Condensed Consolidated Statements of Cash Flows vrtx-20130930.xml vrtx-20130930.xsd vrtx-20130930_cal.xml vrtx-20130930_def.xml vrtx-20130930_lab.xml vrtx-20130930_pre.xml true true XML 43 R50.htm IDEA: XBRL DOCUMENT v2.4.0.8
Long-term Debt Obligations (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Debt Disclosure [Abstract]  
2013 $ 1,883
2014 18,077
2015 15,608
2016 8,924
2017 8,481
Capital Leases, Future Minimum payments due in Six years 7,877
2018 409
Total payments 61,259
Less: amount representing interest (7,449)
Present value of payments $ 53,810

XML 44 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accumulated Other Comprehensive Income (Loss) (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Balance at balance sheet date     $ (550) [1]  
Other comprehensive income (loss) before reclassifications     0  
Amounts reclassified from accumulated other comprehensive loss     0  
Net current period other comprehensive income (loss) 680 257 0 637
Balance at balance sheet date (550) [1]   (550) [1]  
Foreign Currency Translation Adjustment
        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Balance at balance sheet date     (746)  
Other comprehensive income (loss) before reclassifications     (7)  
Amounts reclassified from accumulated other comprehensive loss     0  
Net current period other comprehensive income (loss)     (7)  
Balance at balance sheet date (753)   (753)  
Unrealized Holding Gains on Marketable Securities, Net of Tax
        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Balance at balance sheet date     196  
Other comprehensive income (loss) before reclassifications     7  
Amounts reclassified from accumulated other comprehensive loss     0  
Net current period other comprehensive income (loss)     7  
Balance at balance sheet date $ 203   $ 203  
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 45 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Comprehensive Income (Loss) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]        
Net income (loss) $ (128,662) $ (26,467) $ (503,001) $ 26,941
Changes in other comprehensive income (loss):        
Unrealized holding gains (losses) on marketable securities, net of tax 166 69 7 324
Foreign currency translation adjustment 514 188 (7) 313
Total changes in other comprehensive income (loss) 680 257 0 637
Comprehensive income (loss) (127,982) (26,210) (503,001) 27,578
Comprehensive loss (income) attributable to noncontrolling interest (Alios) 4,530 (31,076) 13,688 (57,825)
Comprehensive income (loss) attributable to Vertex $ (123,452) $ (57,286) $ (489,313) $ (30,247)
XML 46 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accumulated Other Comprehensive Income (Loss) (Notes)
 9 Months Ended
Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Abstract]  
Comprehensive Income (Loss) Note
Accumulated Other Comprehensive Loss
The following table summarizes the changes in accumulated other comprehensive loss by component, net of tax:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities, Net of Tax
 
Total
 
(in thousands)
Balance at December 31, 2012
$
(746
)
 
$
196

 
$
(550
)
Other comprehensive income (loss) before reclassifications
(7
)
 
7

 
—

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
—

Net current period other comprehensive income (loss)
(7
)
 
7

 
—

Balance at September 30, 2013
$
(753
)
 
$
203

 
$
(550
)

For the nine months ended September 30, 2013, there were no amounts reclassified from accumulated other comprehensive income (loss). Amounts reclassified for unrealized gains (losses) on available-for-sale securities are recorded as part of other income (expense), net on the Company's condensed consolidated statements of operations.
XML 47 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (Parenthetical) (USD $)
Sep. 30, 2013
Dec. 31, 2012
Statement of Financial Position [Abstract]    
Preferred stock, par value (usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (usd per share) $ 0.01 $ 0.01
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 233,592,201 217,286,868
Common stock, shares outstanding 233,592,201 217,286,868
XML 48 R58.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events (Details) (Strategic Restructuring [Member], USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2013
Minimum [Member]
Subsequent Event [Member]
Sep. 30, 2013
Maximum [Member]
Subsequent Event [Member]
Subsequent Event [Line Items]      
Expected restructuring charges   $ 35,000,000 $ 45,000,000
Strategic Restructuring $ 11,444,000    
XML 49 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Revenues:        
Product revenues, net $ 186,653 $ 303,501 $ 708,823 $ 1,052,149
Royalty revenues 27,012 25,586 119,705 98,047
Collaborative revenues 8,035 6,919 32,290 42,852
Total revenues 221,700 336,006 860,818 1,193,048
Costs and expenses:        
Cost of product revenues 20,048 30,680 75,698 161,147
Royalty expenses 7,291 7,856 32,315 31,023
Research and development expenses 228,624 200,161 669,174 593,076
Sales, general and administrative expenses 87,754 97,684 287,154 326,344
Restructuring expense 12,048 696 12,863 1,650
Intangible asset impairment charge 0 0 412,900 0
Total costs and expenses 355,765 337,077 1,490,104 1,113,240
Income (loss) from operations (134,065) (1,071) (629,286) 79,808
Other income (expense), net 4,652 (4,041) (6,578) (11,417)
Income (loss) before provision for (benefit from) income taxes (129,413) (5,112) (635,864) 68,391
Provision for (benefit from) income taxes (751) 21,355 (132,863) 41,450
Net income (loss) (128,662) (26,467) (503,001) 26,941
Net loss (income) attributable to noncontrolling Interest (Alios) 4,530 (31,076) 13,688 (57,825)
Net income (loss) attributable to Vertex $ (124,132) $ (57,543) $ (489,313) $ (30,884)
Net income (loss) per share attributable to Vertex common shareholders:        
Basic (usd per share) $ (0.54) $ (0.27) $ (2.20) $ (0.15)
Diluted (usd per share) $ (0.54) $ (0.27) $ (2.20) $ (0.15)
Shares used in per share calculations:        
Basic (shares) 230,505 213,767 222,764 211,053
Diluted (shares) 230,505 213,767 222,764 211,053
XML 50 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-based Compensation Expense (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Stock-based compensation expense:        
Less stock-based compensation expense capitalized to inventories $ (204) $ (339) $ (885) $ (888)
Total stock-based compensation expense included in costs and expenses 31,308 27,582 103,933 86,649
Stock options
        
Stock-based compensation expense:        
Stock-based compensation expense by type of award 19,010 18,869 68,633 59,774
Type of award:        
Unrecognized Expense, Net of Estimated Forfeitures 184,969   184,969  
Weighted-average Recognition Period (in years) 2 years 8 months 27 days      
Restricted stock and restricted stock units
        
Stock-based compensation expense:        
Stock-based compensation expense by type of award 10,998 7,104 30,108 21,643
Type of award:        
Unrecognized Expense, Net of Estimated Forfeitures 103,454   103,454  
Weighted-average Recognition Period (in years) 2 years 7 months 10 days      
ESPP share issuances
        
Stock-based compensation expense:        
Stock-based compensation expense by type of award 1,504 1,948 6,077 6,120
Type of award:        
Unrecognized Expense, Net of Estimated Forfeitures 830   830  
Weighted-average Recognition Period (in years) 3 months 22 days      
Research and development expenses
        
Stock-based compensation expense:        
Total stock-based compensation expense included in costs and expenses 19,223 17,444 64,312 54,425
Sales, general and administrative expenses
        
Stock-based compensation expense:        
Total stock-based compensation expense included in costs and expenses $ 12,085 $ 10,138 $ 39,621 $ 32,224
ZIP 51 0000875320-13-000045-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-13-000045-xbrl.zip M4$L#!!0````(`-B"9T/Y0!:[\FX!`'=\%@`1`!P`=G)T>"TR,#$S,#DS,"YX M;6Q55`D``Z@$?%*H!'Q2=7@+``$$)0X```0Y`0``[)U;=^(XML??9ZWS'7+R M/$E\`TRMJIX%-NZ3GJ1R(=4]_51+V`+496Q:LJED/OV1#.9J''"X^+)GK9Y. M@RRDOWY[6Y*WMS[_ZW7D7DPP9<3WOES*U]+E!?9LWR'>X,OEM^Y5JVO["].UPA+W@PJ`8!=BY^$F"X<4?N&<1EU_&KJYFI<>? M&C6MU[?K=DVK2YJD]GJ2U)/[O:8BX3INZLU_OGYRM*:M][2ZK*NVIDJ:WF]* M$I)Z-H[J3&M[[5&7?!+_?\$;[+%/#B9?+H=!,/YTJ5)%^I\N6L.&&^ILB-^24_?_Z\CB[SZ8`7E]2;68GX`MZ3'RFEQ=<] MQ'!CY%`9G@%J7( M&V"!*6N_M0841W^W7@F;E7YC`;$MTJ,^(\SR0\_A%_K>RQ!3-,8A_Y+=O5,CP0#9E_//O"X5[W_+NU MB[#G+"Z1%6Z6BQ]VEBZ(/UWZZ?BC&8O'P?,WY#&&O=6+JH?@#C(`9I(>878& M'CZHHKZ_BOKQ5&QF-M9[$K"P1]B0O"`/]7#5K78?/#3Q9>I*Y MG_L^FRE^?\8LH*$=A)1/IA]=Y"U`^S?_6>2Z*R6*B=6LLY\2.SO#:'MOSP&- M+.T-S?228T&C=O$XF%-SYWN#`-.1B7O!"Y]`+\UT?8^O[P+2\2GW9#; M(E_@B3G;5S_`3%5KCYC:7!)N'`-6.!BC,AJLQ&Q84[3NQ MD8\W&U:>E"S4M5SBLS;Q'X>(CA"W[>H`MJ7K9V%)V=^)*<>[RV9D"6ZPI;S! MEH)-V!C.\\9P[AA3B[=0XWHT]I?P6*M>+F$1]]:%)/M.ZHZNXGRSJL7[Y!`W M%%;;Q79(24`PZ[S:;NA@QZ+^R/!'XS"(;BD/_0ZBG@@L>,2TR^.*-WE+_&/O*/=N3QKM8'NC,:N_X9Q-_#M'P]C M41.@_"[*6U4#B,\!9+5T%7-9Q$7N? M(RX7KU[T^,ZWHTG`^EP((RYEBS<#3[#KCT71SNN8CP@N-D,IW5^9V;S7?P!K M'[`BK]3%KG@+XU?L88IVC`D"V#AF$(.8S!#'7 MT,S-L?-WR#LGEKZ^)Y[@K-ST6K8=CD)7/!-\"(:8BF(4#\6@3/#4KHN-4ZH, MBYO?SCH`:!E!YJX!+-ER> M<8"(AYWXZ5,EP$GN-""T'T+1@O\9.QB/4,_%R$(4?]ZC^$N!&;R*B8OU*F;NP(.0_8\O,:H4,`C-SVUH?DZ)@2#%`@8IYHPE>`+_'G,5>@*?(S;5)T5D MHX:`H\(&'*E7T6$J^_"D'B]A'N<),NJ7.*.^NG]ZQJ/25L#TC.K^-P#UF#<` ME=\`1$;JP._BL?@$;@:%O1E$!R[(2G[8*F3J3W7_(**CJ_C=P>3['1X@MQ-U MJC1O-/%^?5KK5X[>7\HE"A!2]N$)665#RBH/=/GB)*H7559YB"&PK+B!9?F& M%V++P,OM#PJ$E^4GO*RHV$"$&>"RC@L$F14WR*RP8$&<67'BS'(.F8/[7*X` MWW&QG%LO0-Y`[`:U&,/B<<(]^LNGAHO84KJ8WU\518D*%!VNO3H_`VZ]]P#5 M.E3;DITFWAN7DJ1^Q<$WCV+DDO^*T9CP6:M0[%=$O#N?%7P[=Q=1$E/'[J0* M0/@A""V?8C+PC)!2[-EO520N50+`:QVO9_'(?86A>_1*1N%HJDQR++?ALX#/ M4,1TF$ZV[%_Q^3%%GHW3ZEF-">^*J0X>$#LA3GH1(1SV&/X[%-/N"?^_C?VS MM>^+3?Y\SCO]5OI`YRP<[0CP,$7W,-N&&%P,N)ACNIAI>*58$=^.QHC0*!(1O$M)O,LT@C1Q M=,&Q@&,YF&,!IY!3IP#&6#9C)![L5.37J)='!W8JP,%4S<'`3D7I/0SL5("+ M.8>+@9V*,GL7V*D`QW(*QP).(:=.`8RQV,8(>>]RF?R?-I%+F;ZD750W`'&0`S@1FDU__X?*_*Z?7S=;@/ MY-;//<>YRSI=88(AL7ZA$^OGE5S(J@_^;4]*(*5^KE+J%X\9R*E:D@._P?\%<&>!>U-`X#H'7#>FPZ(OAL7T1XAX0/=>=&^3$1C/`>/Z;'#T M:UD'NC/0O2D@<)T#KIM28SY=5G8WM9!&![U6^(1]D\?)!%IHE2`99958@ MGT>!\WD4GR5(YE'69![%9Q,R>>0]DT?Q&;LG`0M[A`W)"_)0#U<=MGWTJ#AU MMWP-K3YI$)V9O^A,XG$N^/5BA*YDY4J=\Q)_+E&^Q\]0/,5+7VB*G-^VB&F%=>*S8?25+, M4XIFU.+T],C2JNLX)#WRDW:&P?V0&O+Q;$D&1YIO1WJJP8P8`CX2H.`#S*.^NCO+QB`4_E*CGL<-3:R8]:RQL*<&1:+H],.PTF MRI/R6^CAI4T]V(W(XVZ$N>S@L^Y=A$E<6=W)U4`IJBPY5-,!IX1 M4KZFM=^J2$ZJ!.7%!)X:YO.IX4D&'YX:EN>I89Z`@:>&.7IJF",PX*EAQ0&` MIX;Y>6J8(RS@J6$EAQV>&I[WJ6$.4("GAOE_:G@23'Y';CC=E7%=_ZYF'&S"JE7<%)V$V%IL9&J`L"2`,L+10Y^QC8F$V%M M%08F68G*0S-[GCA&;_=\(3^(KGC&/>["*\+*[%'==@$`D>FD)9+$&"(ZX'_: M/T11DS#;#[VBSUCV0F47(^A]_N$?V!`ROT'(`P$<+I`CQ-,8`P M$X3Q(3&K-Q/A/C.C+D/KA8&B12?2?P&@*HQ\0%!`^+,)_D&!( MO)GDP&P&9A,4!$BS0/KMNGN]S^P>Z-V9WL-(6RZLU2<9WL8^QE-">!O[@`:@ M7DGJT0Q`*5IR!O5X"42Y&O#R6ZY??COJX!ZQZO*PMRZ=AMWXBZFQ$SG5& M8]=_PWCIH/MB&\%*-Q?WA:W]/`_^IQ_PR.?%*D1N@-@!=LHZ[I'3VZ&[E1S^ M2(7'D$^3$,/B1E'>H=_2U?(.NX4(%=%]N/TV__/_N.!B4OQV)Z;$J_Z?!62$ M`KY>G9>>_R%"_%R?A12O+9>6?N,^>D@2S:PMBO\.16:%U<03<=FEDNQ9K$^+ M/^':3>NEF]`>8A]R-;7#>"VER=AAP,!\\F0^2]L8<0Z*:)FP.X.NL6R M#DO^PH;`Z#]H](F/.L#XP?A3C3^%&G`"17,"Y0BY`>L_D?7G)MX(S/Y#9E^% M6&5P"B=R"@4)ULZGRYB7N?7&8<"B`C+LJ!W$DE.T+;3A@G&EFL"C:NJFW2L'$%I@T;5R4V<=BX`MN&C:N2 M&35L7(')P\;5(1S"0S#$5)P'3O%0J#CAV-C^"-_Y-IKG)HX+MVP['(4NGPHY M7W'PS:,8N>2_(OMM+/>OB'AW/BNXR>TBRM*)?GNJ`C!-[P7<[LC`,[@/$`ZC MBN2D2E!>3%9R_!H^"Q8G^ZZMSKV`(CMXP71$/+3(B;E+]N1N()9L`V*7-7_R MIG#+2]8MRAWR)IN6S3E-?0![GON3S\VH.-L:L-X)ZRVZ`=3GA'IZL+@X]>!V M-.;S_&AN#T"G`CT]D3Q1,X#Y9###<0OY.6[AS(-?>B\$UL\!Z`X1Q6W$L".6 M:%RO:&8[S+\2(F-G\5I/0M\-K^S MJ#\R?==%E"F2)+_XL_]0^>`7&ZLCB!BGQ,^@(L!Z6%C599DU@#4;K%M4!%@/ M"ZNV+',-8,T&ZQ85`=;#PEI;EKD.L&:#=8N*`.MA8:U+UY(<^`W^+^`T"Z>; M`@*BAT6T,5587RAL^B-$/`!U+U"WR0BX'A97?::S?BWK`&H&4#<%!$0/BVA3 M:LRG5@I,4+-AFBQBB5$-4!#%\W7^#GDCA=:^)QYG;8L MJ(3R6RSQ!K,[`I#$5:B^U&:`(#(=-(226(,$1WP/^T? MHJ@XW]4/O:+/6/9"91L@[;?6@.+H[Z7W M;%SBLS;Q'[E2(W3KV<6$9.8?=NMY_+I,*$S^?%&M%S6A-$7#%%F\WR%PDNA"=F#WV+>-Q' M$^3>>N*%D-'F`YFXAKY/V4H-!>;K:+(M39??T0V`S`BDJ)-7M%8UP)@&8YIF M`&)6$,N0%_9D!%8C3^J)T*M"'K13D0EYP4X*[@N-4L&]`9Z[XKE-,8!P3PBG M"^SI5*@%T,9ZF&$"8"<+DU-)FB%M]?N-Y\/"?&-&7(?7#P=`BD^@_ M@=$41C\@*"!\6(3_(,&0>#/)@=D,S"8H")!F@?3;=?=ZG]D]T+LSO8>1MFQ8 M:[-_/1@OJGP&;CZHC"Q=J?(AE`D],I7ECJ]=,%M38C3-!CX%R8U*Q'7%7RW7 M+RI+KIQX[]0M"F2JNOMWB"BV,`[2ZF=1J3XOE>E'>B'A['N#M)^(RV3Z`2], M\%]Q#;/QY']FJGN,WH1)IK5]5B13]3.+3U5_6B1;]='[@*G*3(MDJCUDSI:J M"?,U16[P9;V9M>9'3*.W&==^P2$3[@[6S5M<^)4[;S[/\#>22>[Q.N_N%EI_.U2OS?56WK_+@HI>41OXIXWS;P=7,P\US/N M3QVX\J1=7CC8)B/DLB^75^IE)+J%[."JJ1L-59,-3=6M=KLNUUNR4>LTY*99 ME]J2:5U>B)^-JHJ&7^;5-<6;H)]OTEN1J:5\!K6UI:8BF:U.1S4;EB+7VS5% M-NK3EM;X_<,TUUM:DVNJ>JR&
5FIRYRXM@SZ\X MR`)E2U<;BBPIAJ1;FF5T)*-A+:!LMS=;*REZL2-)LU9FFRVS99DF2VSJ9IM M+J+:EI2XR;66HJTW6:EKNKYA"\D-R=K>-#`,L\5IU9OMCM$VC4:CV6ZT8C#J M1D/>:"^WGM/8<%6PS0,N:8;JM7AYFO)M;H>=UW5M>9ZU^MUO7G:BK[1<:F9M>/OO78O#M[@!OG0?T&O>]F9 MVC1;FM3HZ(IJR@U#,36I'=N98>C2>A^N:IN.89_&';9GJ1:IMZ0V-\1ZO:[( M]8K7:M:1CJ?#;2WIQ#735J92#K8(8I\36<:3;;*O?4 MS;K65OD$RSE>=C+25MUE<_\ZY:A6`I?D\H=N36? M_1M:>V/:5%,:FBHU5OOS;I,^W(6T.ZBB:I)JR(V:P6\OG9;2L=3.O`N=VL;D M6JO)36U]ZK=W%_X*9R<$^ENNG0XD'[].OX_M0.1X2LXIQ<=YI;]FU%_USQ?S MH$EOMMZFC:91E^NZ;LGU>K-5TW2K'=/,^=Y8YLM2*H[>X+;= M:=?D3JTMZU:=+X.4F"W+JF^L@LHHSB$3K/P_>\_:G,B1Y%_IT,;Z[(@9N]X/ M*>8BZNF;.'L]Y['W.Q*M4=\AT/&P1O?K+ZN!;D2!$`A)H!U]F*&ANSHKWUF5 ME;F`6<<\]>@LZ;<]-OTK; MB+'LC"?#,D,H_2_2X.F70?\+<,EU>GKY$&PS].>R7PV&GR<03';3`BX8\<&X M'%'*/Y7#"P#03TH8EZ]`-U](B9`JO7<]PF(9P+-TM+K:G0_ M#2/;X[GV%;958)8A(WWTP%C4Z*@]A&1S]O*`@>7Y;CG3&J9]385NF`IH8H.( MDA#H**(<45K-#16C/K/S0NY`NATG5(O3^;(X_5Z">AA58V#>X5_51?FIWO3\ MO;P8?.G7H]1-C5]0V9B`A&%@N@BAF&LKO&E<)>I(AD(EP3'8&H=/0<8KHY[N MW^*M75\-CB`M(A.,"8]CY,WZ*B).+)."9A[KFR;$!K6FP1>3VF+L)`OPF6O9 M^&64N6QM).4[K#.;;QA_+Q)`"$H@PH70"R6.%D$HW9H8G7LPWY3*\]%".LZD MPQIK(].F+1C&V>ZR1!ZK3"XP8DQN;R6/GACK%0O5B%#.-&$!-@!U/M5E$F]=4?;:@AL'2/6BD`8 MQ59YRD68:PAJ\XUQ1N@./+H&V&><]@:/2R@C(_&8!T,U0PX+UN0MQ2C<$P/) M1TZXUTLK^V5W]?)%^)H^KA2;UJ[>=H;=^ZL,\[[@=3/3ZB(-WU;TWR`G2K!@ MH]'66:NE5R3.Y40@R50F)Q*4UGUN>-24]H(&NA8-\V^;#NF/GK\7/AJB0^2& MPZQ!39!F/859)/.]$(31X2'@R7P@/.'*1Z9EC)%(*@UKV,<%;'E)%D5(Q-]I0*>98G?SVUL%X[[JX6*)!<<;"2H!8L$PXIW.1^ M1*RSS!RLU+(#<0@(>!(/((L-52F3CTM%/(H^AB8GP>/,8F*]O,3SHBAX1HU` M@\,!W$9+*0&U*+2RC3089C)N@,B5T<-7CMLRA(TB."V!)5R0)%@=3",4,OK, M5X!OY4$RQ.YZP=)H#'B/U`FI"4&&Q";$"Y1GMH%K*5]3,3X3)X"/8*R3&AGE M@@C!1=2H&$-L$H892DA/I&.X(BS!Q'H<3RZ8)= M<-`?5]VJ-TGIJ.VAPO#UHC?IEMVT,9J&F(SK$7Z[G%?(GY^5,=6%Z;"D:`3ɯ@LT3*B9(8-\L;C+(WI:A>FA3;BX8)C*7S;U$' MZA3B5-!FM:(QJD M%(RP)@1!`K\1&7D%K;6#(?&1.A]Q9)([(8``PLYI0:Q>18OC]K$.GR1@0+1E MQ/&(D.0H:(9X&Q-2^^9L^R&[O80'$GCP42-)P8HXU:09(N56F?,7B0A'HW+\ M\?JF4PW3KOJT[\W6B0SI(!<6GFA.*$B_TY@1%!5S@5(E6;9'E=3#_9FM!&,G M4#2VL9]\&BM!X:%1AQK+B4V0;"+D#>!VKCH3/N*0X22/O<:`\=(2/$X(#L"=XG=$Y+(&NK<_I3;:83+@BH/1\O&7Y1._S?WVKOGX M'U4Y[`POKNY^*?\J>_?/_,[O^=@'K3&J;\!3/;9JR%^GU9`2[\=A^;^3=$YX M]7@+=Z8J(S!!T$.;TAXXM5@I;H"]-<7@9J,P/Y.!@,NRW%\AV?(Q]75(.Q#< MDM?"+>52NY0*Z2.C\!\3@LUQ2S'+*[`HJADY*MS2U\(M9X!/&YS6TGM0WX&1 M=A_2L`>SV0X(IV$TAMF-R]\NF[M7O/&UD.PLD3@%X&"/$,$Z\/;`EC;(9-H6 MV,T:;:SVLURUF[QQP0Q^#@@D1CA@2X([3)6=5!9GO,X`PPII\;78?4 M=6TMYDPTZ5!5E$%02:*$8+2M_H4R/DNF9SF!ZR@QM\]ZS^L/3(GHO-$<3!`7 MX",3W[!E6%&P@L,?D6\`N7.V?*!]R]I(',(#:D#72"L]F&T5`Y[C3&"<>>YO M1N/M+,+,$Q,L&&`G+$WG)3EILLT1RDE5Z$Y)S9?0$%)Q MIH@G@2L3`C$TMCT./"6K[!=>+B?_DF@_6"\K590-UG(FC97*T^#:.F.<\OP< M,'@!\K$KDT?,O\\2`%!#D"2@<[V)7GL;0FB0'1G)7-H4`#PVLC].7._&M`IK M0RBCV*4\#^I2[E^#1RPR3PQ<5Z(?&QH<-R)W7G8B&"R7Q2IXJM->/]*TXGFY[NQKU^12!U9P$PL%CH%$88P3#UA%EA%58R;BBZ@#"K^B"'(Z\`?BH2%-M`L.-@O[@C;7X5S2,OIH1\5AV[2S*6=,X';%0, M`D6!+-6L65P7`66\L=4>X^K\K*WAW]"YA0!`W!.J,)4(%$5#!0E1Q9,V6%;" M;SNC"ECLT[`_N](_JNAP5_RAOB]\'UYW^6?W;"'CH%*.;\=G)=U_&9TN/IY::[Z_*ZLO5 M^!3,_]_/;CK=U)_R_?E@/!YKX*KZ5R6@ M<_FYZ66Z_325GJHNIB/5V"T&E\4B?M/P/Z4'YN_Z"2;QI/E4_=1M]90P^&)/ M$ZJ?^^.J+#I`_^N;3O\.WIP(WDTGX+OITPCXH9L.RQ>75GVBYMA>0._=XOSN^*?Y1`F44P;-%V4DS&P76]4 MI`+C,\76+;X_F=YU4@R&Q1B@.G%3H$Y^**I^#>.PFPI\%;>@\^KK*<_"FRJ` M[*8'S/2E[)?#3J]WEWXO;]*X\&P:[<]^#6-=^ZXFEP&/'\"`]_YLS*>3'WX\ M+IIM0Z9A>=DK+\8U'@8WJ7#0"Q[P>W?7C/:'(^JKI59Y@6TA/AX?[%!^J>7$73E.M=^PL0_F!0?4'5:C[`HZU[#Q?>=8F'( M?WX,BP,6X,T!^-7%5;$PQS1B-_42ZP(/=\MAT;E)7:#KX1>XZ\NDFK+=>`", M70\`#'?=&=[!9;\$#0I8N/NQ*$RO5Z2LNF'"?@W?3*J*\TXOC3!%U'C8Z8]` M=]8D:,6E[%77TP+U,-0?"U!."08/`R-G++HE]P!6!\/3O]4%SM&41\%*#:8, M<=H?],LI@\&'I[ZJ'J>8-9I% MIZW`6/1+8.!1XOHD3)WBLE,-DXYO3%X:.;VHA>)F,*H:],"=D]ZX5CH+*NAR MINOG4YCV]QZ!5"=E!>U59N]XG+22Y(R`A52W$'`,U65 M&T2@&%T-)KUN&A#BT%H"09K^>]*O=?#4FTB#S]V8E6/,(4AOG7&GAWDM,0VN MF8:\FQF;SBQM&]3%*LDW4\G_O007:%P`*.#.7[>C8?3^/[=[[]10WG8`W*H' M=S936]CT3JP8OEY#$=E\Y^K%_Q M"*!/?GB0S>>?VWCF*0'*_5!G5A;VE[(S*G\[!]&8\M,N<9J2ADO-4]VUE*N@ M.>9M66F<=UI(L=S];,N'@7D2X`\%R$0IHU.=4*N0$*D_S7PIE6'O0PXX6]Y@ MW0/@X.6EN[M;=VC@R`HEF-7&XI`.>]LFRP%'EJ^M2\[)8X"?`_0TZ#>5@<<\ MG5S`B$DL??!4^2:V)S[O+T$57ZK0M@_H4^7N7196D+5&>@GX9T0JSP1N#MA' M*_/:W9HN[6ENA.>IX#\DKP&`!U:VS@CB,%;&1-(VI%MU>A#+1^'^,>"/XB1U M9_H5?*SKR?6GSEUM-?QDY;&=]12@+"KF!2$J!"DL5Z*A``EY^5.!"5\ON6MA MVF$:.RW42>EDVB>CSE,J+::LZ1JDHLEW&92BVT]FHU):^^3'?K-?LMV\A#%: M,*.TY89$[B5J&NR&*+/T(,4>$)/'0+?;W`:3X?9SXUZX$"B)3E$'3$>4:.9& MC,OZ>BI-V$YSFT.WT]S^N!J6.Q`NIB;G.%5J2_F$R'%+?4LXE%?6Y6)IX75K M^':;WNU@^\DQ0:-DA/.(G;$F:LF;X]Q@W_/%?;5<)G9+Z':8&OCJX(&G?TJ;<43"Z8?.IX;#7U30`O(V!T!2'(\D;>V'6&P[1*GO=9 MV33')(_:IR;#!L312P>A15LE,N^AQ].^S[+=>`10^YC'0VY6=)(2:5*>B]42 M_!,F=.N@T\S-8DJS+"YZH7G@!^9AF>$"4^2=3JT-+<:DL71:L\R*,Z!?YJN_ M&#T>B/:(9-H3PK0!=\MX1G4S#VOSD(-1H91XGGF\P3(+SLBO6?G[=) M-=V46IH",`/Q%K6I$PJ-)B!'4E<$I$!U9*FE&^FX\1#\P=#RN'_E.,XZ7HJ?+BBC2M=D8%`2RG&&)TCS%7 M29%&!;CC(C/P1TK+HQ')O1(W!&.L5L(ZYI4,1`B:DMFXMX$BHK)U"I*JAKXE M<3T$OV=+)1N$"`9;%!SG#H?H!$;-O@0+V5F/-T2M0_!L]BI_G#G&C#!($VJ" MPM:)F)0KQ%$L:)4/XEEA+#=:J8X!?5)\,*A:\H>JH;Y!&KE MN=!3B%.:U4(6]"/S385*O0"#H$1HA[4"5=)68A2"/WN^Z7/FEMY.WW,^Z'6G M`[686MC!WU<*B7KI#!)3C";7==[<+/5CE@DQS]3#\FQ47`"[O*O_+L6&Z,VGZ&J\SMN^\5YV1OJ/P6R,QD/ MYE\,:[#J;VZK[O@*[@;DG`^&W7+XOD[*O!F5I_,/&0.U<`^;3VD7/4';_W"2 M"BX-![>SB^;FG\;=]N-PY1`U,!]../W[O1$6AEXU6OL@WO$Y_<+O>^GGOLWO M,.`\[/FMD\J9WJG[.5QT>C--,%6A9_<48I-_>YFLP%75!76[5^O5IK@]G-QV#]D-N/3D85S-%.S<^-Q\+>J4_F*>N[HM M+O%F7*[`WT/V3N^&0+W6N6D.C!7IQ-@62/W&=-^8;E>F^WDX&(WJO/+S87'1 M*SO##RJ_L,N^#=F_<:L!\*LO\#S&P+& M;]SZC5OWPZUI-:BHEX,>B]!O7N43N1#S#6RX"[(.BJG^G[TO;7+<1M+^OA'[ M'Q@5ZYCJ"%:9AZBC/7:$2H>G9^VVQ]UVO/MI@B5!5;0E4DN07:W]]6\F`%ZB MKE*1.M,38TLJ'D#BR0>9"2#S5AR:"6+N^F.^Y5C)OL`"67SWZ([^>@J#V!_? MJ4-CHQ%CD\D1X+8<4BFTP+27`DIW9C%,5[V9+HYFI2?DM+4'XZI@S0..PCDH M^LD(ZVP9DA!'B"/$G;+@3D98A+AK0-SK3<,KL@!E?@M<>\7UUN5%V,UKJWN" M\QHQ2"XNX8?P0_@A_)RL?`@_5QE>L])=7W4;5S/%0&F%LG#:AFZUF[5+I)J1KX">IJO7-BG$<(96`O', MV?!,NBO;JE_5B&N(:XAKB&N(:XAKB&N(:\A_.AV>.?L%L]IC.MFQZCN>G*O6 M6'JP.G=8<9\`I'6$G::OV`)8M7I:>KOC5*:<6V1S*3I*`7W2IP.:UJ15I%6D M5:15I%6D563[G9U_=D*1H>/N=/P<1.Y4;G-M@N;,0D_A!_"#^&'\'."\KG:ZI?SEMASHJ)QWUV?VL<55Q MH)T/HYS981/'<73'L*K2S4M108KH7ZU&V)6=O2)E(&4XA&[$M#%[C-8N/M7GL9V;!C;:>K-%:TX4/*3@H;S- MJLR9(F4@93AS9;BUVU6CA-:<2%,N4%.$(>70?H4W>RPG%"`X:5?&G40L5)Z, M%CV#Q)Z>-4=\Y?6L16U)7WPQ00E#-\Q.93&)?:5V*0Q``<%#!`2O1#92N(K"U$0S1#.[KP@[E>V/((HABB&* M(8HI!5`:-2TX;)#*SI&2TX$.+<03_1#]U.-(-9J'HZ!+L7(N=W?#`2O=ZJ4R MMZ+V[?D%BJXF%=H5U"4R]89EZ8U&94D$J#(1K5Z=D[%&9'8Y9';(`!;1&-$8 MT1C1V)D'R:K;9W0ZD0_:9T041Q1WTA0GWC.YGU@6/,V*@2[U'EP_AA_!#^"'\$'Y.4#Z7 M&UVK/ZEB8ES-`I\MU"$#;0*"J>QL`>WA>(,K=/I;-!KMCMXPJCL7<.G[+RC$ M<$)6`O',V?`,%9\BKB&N(:XAKB&N(:XAKKD4KB'_B1*+5AO3R5'0QD\_(@_Z M,X8/F`<^#T(VUN`;"^>AQ_=,,U%97N%]1NW":N-ND="E:#2%_TFK2*M(JTBK M2*M(JTBK2*NN3:LN=P'_@'D#5^Z1K`>)E*FA6N%1&(OR-%`\_4#Q=*(RHK+C M&G)$9T1G1&=$9T1G1&=$9T1G1&?D:)Y3\.W:8FP_KRJ]0:>/3WC_VX7-F(0? MP@_AA_!#^#E!^5SNXF7MIX]_O_]TKWT.F7HTC>?Y^HFF:NEUAXOA+=P,IHG5"]@/QS-GP3'6EQ(AAB&&(88AA MEF^[K9]BRMI2GWBHBA?1#]'/^=`/.5*GMIYFGGG89_>#QU4%@G8^D[+/4!SQ MS$FC8>AFVZQ*-R]%!2FD?[T:45E-7%(&4H8S5X9;IVJ0[.P@EGI^_@XB*L%LQL*1YTZUN3MG8=&3T6IS8"J-8AU1(T$; M=:O3H*@#13=/9U:[%.4RG)YIS/=78INF;2OG/2*]*H&1\P^&*ZNV44CI3M`(9!+44IA2%:W M\V)?J5W*A$B)"WF<$-U5@`>65]7DU[9- MO6E6=Y1]:][6^C%T?`JD"#*Q%['7(?8=F0?,.$W,1`;43"G^?0J0-J^_JI1J\HC#O M&0;AKB5%VQ4433)UVS)UPZSNX,S5ETVBE<&SL@&)S"Z&S`X:BR,:(QHC&B,: M.^_`'.WA(HHCBB.*.XK;:9DU[7F[1GLM%Z/[5H235EU_L(;EA#;U?';WS`3M MF9;QS3(L32L)P>4DFP_)6<6(W-M%W9UZ`4\S\K2^TTI=>>53%:(4U$3;QVR$ M1ZZ\P'^/(E,*(((1ZL^2WCWJBT^;H6,CYGH\C[PJ8+ M70LF,D@J`J/PWH4*CVH34%RNN1RO.%1W/[%YQ&:/+,PF2-O0-N MST;+?3%%7\H;[_8=R!%R\%@+?"UZ9EHOF`&1+G)JQH%=4:,YPRW@OE@J<2/X M\NA.77_$-/[,6,0US]>2NRSCN]\8CT)OA->ET"@%TF^%2K_3T_M,D&[(-#^( MX'&C:8P-\V3#W$;R55]_ONW,;][#"=@N`05E]8-PQ=_XEAG8:^ MQT?3@,>MTV>5 M?1*7O_/Q(/NF?KL\Y\[5?G]UPYHY8C`:9GC'+Q_L_-FO625L''WR@1:.I MYUE,%B$1'!(%FHMF8C*L0'?N4\C$H(JD4-IJ\6@H%>WV1OWUYITV"4+QCC&# MR2^8XP-TF._\>`)Z`AHEJ2Y-%^S]GWP;S(`1F[KSD'WQ0EU[>?9&V3L?V9/K MJTD3I`@<`&:Q>,MCB(_SW1G3/GSL??CC%^3#$1C3KB>>Z0&-0A]!*D&(1\/A MUW0"Q'G"O->TW].GK1&`GC9$_#360%J/3$SR0/@>&N38ZT-->H[Q334S-HP!]`J%'2L)<@G([!?(+/>#5``*TJ;^*)J3;VHV1(N]P#*.(S MU4"]$\][!LN*?85YDB--"6^/X]CET<=RL,-'E0&#\RR";A"'P9SIVJ<@SCHB M]>EG;SP&$`Q<#ECI3D0/L0'=&&9Y>(M[QL210'_N+GB!/%P-QAOQ$08+=QK! M#^#$ND\H*F63S+SQ'?1!$],#FKFN-@>Y0S-=^`Z#[(,-S&&>%@9PIK_JE04C M*S.+Y#?5HHV>+[ M@9!V:^D%8&WFCF$4#^2WRY+P,R/@, MOZZ]"^#RR`2X9@!@>!=X)%]8N-8G`18%\QK="]`X+Q@C8N`3P&PFG))XVYP' M#>I>E%\JF!K,CQ?\U\&093?NK6J!!8`9LPD3,S/,6LR/&5+)5`RV`!=@93WZ MGMVH:`)^Q4"%8$3T=9]\I,046B&;`2,A[K8`2N%7/?5O&0"Q;4]N*&90829L M@6/!TA)-?H9Y11L]XQR2>KMS,=,BT6*J'Z52[$LP_8+O\5UA:"HK`KSP,1^Y MG_`,R<8JPE\.9EO4YV9NU#-25HSB?%]9\R[>UG`,_0.@Z.Z,&=P^`^F/I1ZXTZFZ@Z_N"9=LP>-' M'KF^<':QM2]!/$7EX_%4-"Q5PP2=$C?P3;HQTA9*I/."_1H]>W#3N*@VTF!U M0VS@X1C*J3K\N5FF&3J$^@8@-HQG21Y2-,2DI!>@6:$P_E?X0_BUVX*%^8"):FBH+WL\J[ MPP<*4U4^"L.:"W&?=,ID*\[8^>699)9T,9T-N>)X(`LPOL#K3%BF(%_E,T?) MD+C"O@=E'LG@;EZXZ5@$OG(G5@:0@7,B&57#-X+O*86QI:&RC5PR7,[;"!X! MR-2BA=3!%=#1A0,"35D-K#1>``A1[]51#*-"L##A2NC$!\F6 MX%@QR:M@:#!<((F>@0;]\0%9\"#&9\[F5Y("6WXEC$2L(Y.A"HV@])/1A0$4 MUV>RS@\;*PXN$V]1"QGK1^1\R7/@*N,ABT.MZ,=A8J=> M+A8%GG")K`A*M,8\[&7*!/C=!Y-8N`M3 M#SN0OE5?BH&^@&FO+/%8N*QL@OXN&-"1-Y4>[]>Y%Z;+,*NBKTF(5QD1V(1D MC4;\KFRR;12R,Q%KS+EL;"KMH MC:6#K/@]_VH?HW+3PAY1$Z])'RR[/&+3J;KF^QOC1GSG4?'_]IHR9&SYY MOFRD&T=!\H/<""U^>?'&T?/[3NN^:7:,1DO]V_HFV=8I!#_G['WRH:0[62_R MYY.SW9S-E=D==SCB+)KV_4W3_&;K1M'B=E5UX[[WM0[\/NH?]>_T^K=7W0WJMV..V.^-0+2/`,0MLCPV-%=Z6,1Y!+5:H%995F>"&D&-6(V@ M=A)0VYG5R("KV9/81U8GA:9;L:81Q!RW7E(V68+0H2!$*3WW&0%QVV]JB3== M,[J5*X9'5=^KR8YR_LE/+$/O=!JU"^12$IM0EJ;]9T&BF>NE&;.C=YSJ$F(2 MS1#-$,T0S91HQFCH9H4%%XAGB&>(9XAGEF]K&WK;K"XQ[J73#-5`W@:HWLHS M,._+6Z`K6">I0;97R=<7-I\1?@@_A!_"#^'G!.53VPJ9/'+\=9&'KID%A;`HOG:&Y0"Q#+$,L0RQ#+$,L(V[K8-TC8AEB M&6(98AEBF9-@F;>NE%U!.._>JK M'3:J.YYV*6I'X?FKU8=;QZC\M.8UURDF5;E858&IPZKL$#U-':0/9ZX/MY;N M-#LT>>P^>1QS&7N'X_PG[?<4DFX+3V=U@NTZ%+/2X-81-3;-CFS5'_>[E@F. M`I^D8*1@I&`GKF!;D@-5)N17YG^L_@2<;G4JLTGWEAKI)NDFZ>;2;0V]T2#5 M/)6ELJ.OE%G-FCW&G-96\NES$+G3->6:=J]5<2@%V&M?@7RFJ$=1>N!IQ%JJ MVUNPH_P.+*[J2=>QC(.1;OWX.3[Q4L2;B(N(JW;BLO2F45UB-B(N(JY3)"[B MIA/=MVF9NM&H;+5_FUR(8HABB&*NC&),4[>,ZO:&7PG%4++LO0$G`UBG$K*" MWFKC(,:7O\GUNY:S,-N$=P&'92Q'=\R:G+[72.Q2N)*6[PYBIQ&3$9,M,QGN MC:W)MB,F(R8C)B,F.Y"7"D:9Z=2TA$A41E1&5$94=J!<#)9>81E<8K)<*.Y; M$45:=?W!&I83VM3SV=VS+,YG6L8WI8V05A)IJUZR\BM>_MZ+X/$C^:2?O8C' MCQY_]K3/KN\^,NW79S>[Q-G>VKU\8-$JQA7?CJ3/SPPZ,@,8+[1G MEVMN,8"HN4\A4\DJ,,J8').PC.]^_OQK3^LF?T[_8'[W3GOQHF=M%[EIMS>E MRV[>:?,XY+$+[XP"[>79&ZUZF&SL))Y.%W=SUQMK,&#,YR(>FITO8YKKXX;> MV8R%(P^$^G],^SSXJ?O'AY[LT&.(%_CNC&F@[BQ<^SZ/PV/#OUB$1]:R5!WO M-,_7_NF"_,2;`GAFJ/$Y&WD3C^&;8S\*/<;QLB[WW/O-F?%/'BMS%Q@5NB,* M/(]3+`,9+)F>[!`K&D"8@'^R"?P M?S\`X@D%[M2SN&*/Z-GCZT0*CUA)*R'C\\#G'EH@"%^X1@M>_!*$BZ=F15H@ M;!U>#KH((@C"Q?WYLDM9-C-W@3V;@;I';!7)N"@8N,8#]D:8!W&DC=P8)H$8 M)'HPW#;+/O;;_*JQN^#I@<06*';H`2Y>X,:(^8`^L&G3=3\U>4M\E@0TY8$0 M(T@SE>18>UQHS%/P#:.%0)T+U\$EJ"F/(7-A#H2K\`6"7W4@V,<_@5'PM:H! M@E9QBA7$S$$F'%KQNP]J!O.#&TX]5(CTK?JJ$7P!94>R@EDU9HAFL++Q+3!K M>E-Q`_LZ]\*,L>&7J+IOF;;`/`8-_J#F M;STO3F5>E)XM"',V#[B'+;H+)G<@-7A><3:!ZP":LGV*02SSC%43D74)$Z,8 MEOPHPPS`@.W'B5VR;NK,9LW5ULZ+0`MT(F03F`C0H]*S3/V)93IA\"MJ33JY MA``95$CU5-&$I+$O.-ODIBB<2J#GH8O`N$.0:(\NA_D#P2ENGX,$@C%"$3Z! M3L.$`6JJM$9U.4B*L=DC:)5MZ`I2J/V'8]+V?:=:(O7\BD6(E_E(95LD M5Z_JU!M`ZBTXV$O:T'L,`^3K(086I030I7#G+(:_Y8S]O)L'T]X73P18\+H__M]=LPE" MQ*`%W8IO#";NPMRD'1SZ^7?AO#`OXGMA!RL=&@[7K6F M%6,/7XO&0)2^4$YP+RO:Q"]DABL%M\!7>!+6SV:<(0;6!+XXR#>$!Z"ORI5# M!P\7$(\"&"D@P"<5RP*[PG_B>@HB$7.#>]&T1.$G08*1Q/4DP?4XC)_245J4 MAA5<*P"@A?'V\04!LZO M&,ZBEUU0_`W1,QT#2FKTA4^5:9"D:NYW,Q\&() M%8=;W;EB(>._NS_]3W_0^P4H_HL[Z-HUGZHMV"Q-(V^C`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`G%O"4#!ZV6;=Q/MTJC]D/5#(`>1!('+QIZ_!A M-(W%.8AD$W]AXSYNT)9;]M4)@57"2X<>V9/KY[*CP(B+K!'JM(`X&ZW];^R&*CL"+@*)?DV\D$=+?['5&1AX MB2].(&W,VP+WE#3CE2#=^0Q,Y]ZN]@B,`%\>U2)5"4C.8U]8TKT1$*P+LI5# M-<43('*4$[1(6'"6/[JDCM9/IO+$GAI_]9J_<9$Q1B0'"(-Q/(K2,.R&@U&; MAJ%P5BK?(=`E,9BYO`!;^I%I..8K\=+$!/+FF?L7._#1I^BEH@/G\,0[D9YF MLR03D;T*"ZO4E\=XWHCGN20]1WKNJ<<2D$CFR9*QI<>@%.)_]SU$SJ<(`,23 M'U>QCN2C38]+9%](XX:/&\1A,&=P'[PL.\F^DO26((Z)91**SN??2""`(RN( M-#U'5CCT-5XZ@EA*-[4NK)\[XSYA'^10F"0K"5**;24+H?`K(\MEK.81+)U(/G0"J5HJIB%'DUU*> MABY,\EQ[\`*9IU+/W.D/_N@\3[8OSW`"[MA"^<2?5'(>',A>`3=97L]S[';B M@OPS]MG6/!1IBB*I@;LE/Y58V9#]5%R@"Q(`RL/CS2"=*6B>!_PU>O;!$'E: M".7-DK>E5A`T1+X`+;)S.@(G!4\Q MRQO\H.^JV=V?/MU!-PWMU@]>D!UFF4\%QH1I.^]TQ7R8=X!Q&%)IK+G`$*J- M^,9Y,`7V"H$=H8_GBZ7L`#^2*$^L4`RKD5DY(%_G210*1D.Y0Z4,AXM,:GJ*I=VLX(DT9@EM2D$8K:\`55>W`ZBE$XM M"CASN0\F7ANTN>+L*]Y$S0XX*Z21LE+BBK$,%R6=3C`']S#@D!/N"TCX$ZO!-\$LXRTC9R5 MR@2-2C598+2)?<7LMN-U5E'+X5F?..)L7:LWPO2S&?W5S*JR!4^.^48>0HJS:Q1!*6 MN\P2:^R7"J-$(J*:N"%),895R7/A'3(-U@(CU,N(>0:29OX3+NBIB)=\H@I* MBLB;C))BX*VBW.3+8MDG.?FJKJX(]R;>LXI_BMS.,LB\N'M=L28WN9A-5L@B4)"E'W7K,/?9@*RVL(MM3IF++]$0&_'/& M(QI023!;R?>,YY[49%;X5+8#>/D83I9KWYR!WN(W#)A'"UU8V/Z3^R17!V42 M.#7?+Z7ZE%2-#_4!/%.UVBUGB(C MD0M\@T)I$A))WK&G396F6W0Q"?A(+%"Z(S'@^+*GV!MC\+Z<[7_,)!^(]&?0 MAE3"KO;'AX%>^O$QYG`Q3RS8I]S`%*22"S.Q543?'7TM8\^`% MN3P?#?HS\`1(&5/51V8SK$;!4HY?\1;PU4#\'G\NI*@M!XH"A3V9Z3U+/BN$ M.L-5ZZQ_T70!2CY)KL;06##S1LL9[\5+SEF]`;$A-@%7OXK3OB_."XL)NH0P MCJMSJ6,LR4"@1TS+[E2(!\:#19F3L`H`A;?DV9D<]+6Z)I\R]+/>9F#!2)3?(H/^*`O,-.( M(0@U-611&$QEQM/2[V7LNZUW/DDB_+BUGU<7=,B]ROCQU1M MREAU-AFK.KKA-&N7QZ4DK**\>/M/D,0RU\LRCFYTRJ<]B&6(98AEB&6JDH5E MZF:K131#-$,T0S137Y+?ANZT3:*9V@(_1?TQ+C_`TV>C$(]TB_W1XI-(P[#G M/NU]@I;6<8.65:OHK:E;5F4.1QE:]9%5Q;Q-$?X:(OR7IBQ.2W=6)&,@;2%M M(6TI67]ZTZA,5R[%QB-]N%I]N#6QZ`E-'Z^9/FI;"[\"7^G7&A;`=];-2D-B MQU1:6[>-^I=]KT&7*8IZ@#GQ4O3.,G6[TZ#0(>G6">G6EBW5EZ)[MQW=:'TN!<(-W7:JFS/WE=JES*EO78Z[?`_SXUNS%=6#5>BV-@YB M;,*^IYW$1@/Y4)&.IX3^TYAGJMMLL*L`#RRORBE2=U:D)*]+:`=`T/%IDB+: MQ%W$70<)19JZT:HN%KFKV%[E?YT!\&CM^IR9[30P=%+D=2+\9-IZL]T^F&#( M?B*6(9:Y.I;!/7AMRSEM*^@TX+//+HMO1>AFU?4'X\:<;$XJK[^X+Y_Y/,;2 M8G,L7P?7R=WGLV#,IEQ6]5,U762Q$!YY,UG2HK!5758$VCFMN"S2@B6;.(]E MMG9,&O_DBH(=XFGS,'AT'[VIJ&XUT=S1L\>^)'\,V91]2.FU_1+9Y/UQS+&8%338%;M@N`=7N&%2B0+;AR\+7OQ<&3C5 MIF)#<;33.A4RJ3MNK1$#CFG=)0RP2!ES.4H"#R*$;.QA>2'^ERI*%/[%DN]+ M11.A/=$TZ<_44UV%IGSRT@(TVI_Q^$F4./*R]B1`2^[-R5K4")+RPT(F.L6LY\Z0[X$#+YJ&"@F/1?F,50J],V?OJ7M;2E,4@2O_B`])BF6( M7UX*]3,VH-MI50QO(8G3[*MI6O?M&G595\4$X:ZT'E%4K`>$Q=/'VCS@7B3* MJ*<5M849%@8ST#Q1,%9;+B:=U,M!;2P5W$[+ZJ2`6S8,(0:K@K2RE)/ M.8Y]'9.O88]T?(0%RDLF:/GQ_%5.4^*$2"LU9Q`GQ9Y4F?L-DX6>E"A.3=YR ML\\2*EMJU4EU>%#5S#Z)ZHT??%'M,EK%+N=4JTX6BQ)>DQAL684+KD.\LUG! M!)5R`-Q/XURUPC7E*[<7A*N[0-7.LLN]JA`E/?^*56WCWLG_4V'%JO9;"U:U M#EP0"(!S'I6+]KZO326/3GCYAG*6KT\1W!7VR+HX>*\SZ(Z=.U2$F"8NMVBG%'D=Y[0-'8YJM6RJCO; M=^FJ1;[6-CQ]\"/7?_)PEPCY5$G.0\>@E-GD59%711I!GE5-\\Z/03#&OO!EZ)#Y#U=K3:T MF[1"2YY356CJCD0VE/3D/9EYFZ+EED-UC\F#.J&YZW)4RZBPQL&EJQ9Y4#M, M:V',LDU_9#=^U]2;U97_N11-(C_JBO7!Z)`^D"=5%9[Z;,+"$#.+N%^S5(]D M]&V*ZQFZ9=!9#_*H3F@6NQSELO16F\(5Y%-5NRJ5S&R>R!7]%7-G01/2HU0B M\?"6'&+785^V6[1J1=X6>5M)@*]977F'2]$'\K;VQM-O;,S83.0CK*X:Z=49 MB78'U)+B[N2`G=#$=C&ZU:ZT*NVEZQ;Y7UOK"FJ M16[7]6I$IZE3$HM-DPV5QMN]--ZSRU6U"#:6V?-S6?(W))H4M^V>D#(M0'+K MOB-9;4#4-)%O MG\TWKRJ>E`P12=U'N\312I7]4Y0*T'DHRF7B^ZX^P"`86 M._!$&3P0:O"VF@@@*B&H7"F]L7PXO"C??5F"+I$9O)9#._ED`:KD>C/HR9/K M^3Q:VYHGYK,P?>;FLAW)Y[]_&_.[)]>=O^]AT8!'42[C"^N&(5800:GV/3Z: M!ECX[S/HV,,T&/WUPW_^AZ;]/;MQ-O,B49*DZX][@2I?,L):5HA!N.LW-OG^ MY@-F^?Z7?:-YX^]OANXHNNLV[8=FJ^LT^WVC.S0[O=Z#Y0Q:9J??,OKVH'VC MQ;XG;X[Y^$;[RKWWOC<%7@UC=J-]NW\[K'\U?F5A9^>W9"M;L^8C;R9.^7P MT\=AKGGM=JO;,2RST1]8W;YC]?L](VE>JSDTB\U+WG'S@W%OF/GQW=JLM_=# MC.^Z?O1:]M!Q;+O9Z0^;_4'?-.V&[$?#M*S&0_W]$'_EW3AZ#K`>ROAUXV#V MC8'5[_4;3K_1-P=6H]^UDW$8]%N-7/NY>-'-#[:A_EG9_N7F[-_NC7*WC&&K MW;.M5J?WT#9[#X[3ZR=JY@S,=MWM_L!Y_%I9#ZU&!U`^;`];#UW#=GK=]C#! M2L-N#U>T&4C0:C?A?QO:+)NR7WLWRG@(M-'J=/N]AU[;:-OFH/'02V3.S208;"8R*#_XHF+&/+/IE\MG]6FAF M7XAP?3/-0?^AUV^WA@#31@,XK&6V4Q&V&IWE9MXY.-C+#5W7E#>U^7\^]][#P!HF,!U8#^5FVX8%@U%[L^W-S;9!NQJ#AM5Q6IU6 M'ZTAPTK(MV[.^@-':-K)B!J=#MV M>30Q;,J_V!T^G;5J_=3,:T`9;8=5MMRCM+[#[[:`O:KW/E5AS1Z!KA,EM'M=SLPCW3: M5F.83M0#QRQ/U"V0QZ[2V*<#AY7.%E4QFWT@\[YE=Q]:1M_H-X`Q4]>RTVN4 M[0,#.+)DR9RU?-8*Y\$T3',X!#?DP6D/.H-.W[12'@'"7#$SM@!@ER.<35., M!;-KL]/J#-I&9PBF<,>^:3TWEBYMW'HRKVF*F#1^T@%=8\LQJP.\AR\TZ)T@31WD^`[;4VPC`(X2=?ZXD#.Z.%]CET?0X3 M)2[X=L=_QEPL(]+>(D+C`=#XNQ\R>!#,$H8/0!&/P>1NW-F:9JRWPA`TZ1BV)4!ZX0.I-12/76U M@!_4%C0WTO:N:4]5:/>7S054H;UM-9H'$T>F4/4)J&*L5%8T_H08ZN3F1"*@ MZR4@LU,__US*:0[B&.(8XI@]C!S'J?]\\C48.14X_<;QSR^G*[KI^>5V#?FC MBLNPGEC4UVYQ.1;/?4V"D.$)IJG+N3WY<3FNX(M9U5<7V$FJP9EIEIR6GV7 MC7=UJ.:VA=BFB>.CSZFWBC'#)3SGZ,%2\1V>;9-^RB:<. M059O.CN'@VFU6X#.`*>T"?K8&Q2).HDZ:Z+.*@O3[BW+`R#N^/8HL2.Q(['C M>;%CI5O'R;"L8.,YU3'9W*.A*L/A0\NT&5SPS#7F8YV,4I]>^7B%284@T8DQ MUN`0>]??H^QD"]((0L;T:T,)^_10Q_Z%3'O!?_F!YNZ]1ZNP`H65158^"00: M9^D[1'T.>0OC[S!_A_O%]:8(RCNX](Z[F*\MS>.AN7*C?UJJ9.Z&(J^';$_2 M`O9UCC5&WJGL;'Z^_L??UM8@X5@6013#$$^<,SD6>Y0%V9Q_<#E;H<^C,![A MJS[XOX;!4\@X_S'$3'/;4J8[^93IK7[#:?3ZIO/0MH?.PV#8[B3Y/`W+'I:R MG7:,EK&:@V4_+0SQ8_5*^VD93 MY"K>M\UB(@%D?8J1S3T?1[W/'B-,*JD66%^3I-ZPS?[0Z/:=?JMO=5H#H]5* M\\MV'BRCU'I#_5-H_?9&5=&/C=FRVU;/[C5:=J-C-CO=86O8>4CR>5KP[^5^ M'*/]QK]L($+;^+=ZS+]_"ORGB(4SO._S8LZZ7SW^[R]A]/7?^1M4[W:^GWX?]2-GI,F^Q\0*NFMI?_R(R`8/!-\9'97]HE6V.B,BX,S)"DK1N M*;>MN[OC#73#,UU=TUW'5H;E7`QO.&@TME;0X]V9&*V6.Z9#E^0RYP)HLL:8=`R/0@G4\% M%WV-(>K[&?R97^R2.9F$K;VJ2[/P1^'#^?]9AMF;5_3I3:E]**YJ[R*]PPKX MKN/(NFV;FFR9LJ(-#,?SE*&ER[8\<(T&!RFRMFX$]D&O(XIL]KDD37,4D`/% M<@8#=:CI0P?0T`:>[UIRT^>Z$/S`B'TLJC4$G].Q3=.50!T,=6?H#W!1#5-2 MI8'2\'TTZ9*+NBZ=-?]_:(`CZJO`I(9C>;9G#1$3`Y;:UBVYL:YT*-&)B*#[ MPCR;%-SOW,JDFE?G`^D5'5XV47I)54G:#BR:^%0*-VRAK(E@X?AKVR26;5)Q89E M$Q:`T2A5'H]O5AO7$O/`BB4>$C%.A/JZ:HDU` MGXY)\HII9\!\#(J0L@).^F:Y9E)$47VROO6H=4L*FO6O)M3'H/:%,,6AX2.< MBYGFX\WIA2&=S<,8@%$A'\9=3[$?/O![>XK]JI4D\LI*:AB=JJ(79'32?`:V M313RB>WQ@O;-S^>Y3\&>D$1D<]-'=#@H`(&V%N]%=01T(O]9@D*""X(%\.V? MX"-D)'KK4>E:CU8W&TYXB$F@[J(H@$[J"P-%>M1,6^L&!>;MX@+6U@LQZVU% M9!$NZ&A%6BQ>5N-K4(I?V'?H$*)*9&R97]@N^!7*D#]1U?:X;2JK4D=V-$=Q M5+K..>JXDPD"&I$@S7KDXFZ0RI)@3`U;\`8Z*\RFZ`&5QPM[]'IUT(C.,8I: M(#1K80?*2!!%&QAII7_$?$XA>.S4@<;%R95/_!(B1[:`*ZYCTV/X9C]:/0?K M%=J1B(PPW*">-77*D1)A4KV&^MU;M%7NM+>)_!TYXUBPE5)+AT%^SD)I%>TU M8QK2G&UO2%NB;%FBIEGG].#SV#\ALR""L6?!F&!R$X''90*J+8(WW*SH57/*QJ.I=R?D]Q"7 MBK@0=+0;)0,6"!7:8]%&Q127D5I?*1,-F!!/T=6MY<3#>N=>PT78S M]0)*->>GM)92Q5O+S!L:EQH+]J9G35&6[*Z5[&;SRIRB/0,)FJI\GM/2X:"J MX/H43)#+SE5U6`QBS]/*@"@KM,ZYMI:)^=\YB$.242JTY6LG>=%ZU17M44+U>4]/A&&P)R.(BS(+HT,+M#5N>S7W1U?9U90=PM;?Z'=W# M^A;O)6I8E6KYFR\YNC.0=4DS7!>K+0VYJ`XWS/5J4'@RW9=_^(UZFG4*[87\ M-IH5I3D_`!E_,@$'':*R')G@F>RJ7?[R^[""F#MT34F7+=-1+'NH.=9@8)=% MV(YC5A";+RF%?I,>I8TH[8!M7[1H$! M_802*WQ[@E?N,6;B5.^X2W3HY9]1,8:C_'03*-+O(=C:KR1(;[]20:[["G0D M)W6MP$KT9?VRU[@;HQ?1)0&/MQ+"O$[#T;2&8P`.$/,2Z/472DC(CW*W%C]% M)Y`($\*F-H.QQX0+INJBX`G?'R=O0KH(1J3/6H3.UO9I&=*IU6E>=>$6GQ]^ M85$(?AL!N@`7\&]:WH"YJ%)H`7,7_#U,"?XS2--@-%V"2Y3E#RTB(45JB'GQ MB_SW7_*$1\%."W@IJX?`\>[4K:);(?7GKX[&L8.!7C![2L+Q,UD'!!Y4OGNY MR(L$\@*BR@9XB?X:-.@+C]AC,&(@Z.$R-B_C)Z!!.:P5C1-+Y\80P_^[Q3N4XCD=*4EH8@*+*M:H-\T=9;9K!30!`$F> M[*8V+*?^&G>P?8N+A)X`7H>4NN&:$I>,@B7N$-32K<#L+W'TLDH6C"IG'S'] M_W\@+6)>I(,,/@U>\K(MW'`(G\(HS-Z0$T`PV#(+"XPC5Y+(XD?X,`GG83H5 M7N/DWU2DV'N6"7`#B5:'9&O2NYX>%O+D"7W3B-9/T<*!9;*(TW(KE-;#O,Y9 MP%][GC!>TK*S)JI4C#%A3;=!X)KH;7VC-UT%C#EEZL]@F(;LZ-U8>'JKZUPF M.[2ZB>(?E`$Y4`9";5KS6/J`U`BM].WW!#4DD!KO)/]9A@LD&#V,7-&]]-?* M7=63K)6W,(6W>I=8?00N+8M1D`(G5V'5%I620WR*

P?'!74-X[#/P`5B>U;+M M32:4C:A=K3/.7A/4=:[81`7`*$L(8]P-8EB8"6K32\CS9"B#A6H<=+!O6*=N M$4IQ5=BXM^79$;O635XE_)K'"83\M?@R_VI;1LTPNZZ!I+>_ M"SR6$.<.5=D;,KPMIJ+3)%2C+P?976PM8)TPUCLL(ZM@`:I7[*7U+ZH7FX5O$ M:H[!IZ1149P'_;?KDGW#Q:J%7<7ALK2Y!MNC3>J$DY<@6N)N<'L@(M`6;I1P M!!,@V-+K=4KH.1:@*[KP;3?.,`E)P0$\`)>`KD(E<,,>59\H8V#+N6IX1EUO M7.M5^?S&I^_UP`*$%N03,HM?&.JKL)46.^>&-0J#/`-`4T@8TFV.!=G="'XK MU,"6)&2$*^,&($J^[YKGKN&)*:LGVA25(J!I6E364-!7`HY(:A85H,/[` MKJ24"TB:T0V#L0".VV0)RQ=.;EJO;,@ATV0/JM-<%5-]G@L%]I:K>*#-\)JR M6YY!?2)O<6$FZ(68JT,AHIIA!*8E`&VS,2L^"4;%*_'ZE,!"@-#0S&=>6!1F M"$W,DB^5+#KPVG<&6T(F3)<]8#F`\.VS\*.&V-<58@_T-9-EDO?(FZ`YI^5( M-[QUZ>6JIMN=2^N2K(I)RWB9I5G`]B?6M"DN8L59H=]B,9L0SK#T._)1[[IZ>;UE6?.](11EZ\1W:+?7\(JKZHUH9;61O#AYRHL M>0!3;?,KXS7E@QE-1R2*\FMH'Q3\C)O,Q>?#HRR(3$!H&)#!,HN++UCK8?K- M:SC.II\US5PU&096BX)%2CX7?S1TT@KPZBB>LO&PWCI":8]A/A287Q]4%13Z MSJ;&]6;-^:W6L3<:Q]YHZ\?>J1UVXW$3D';,^+SH(*1<_E9,V_DHI'^!!MM> MA@Y:59[2/=%8^7*;A`^T]`O;>Q9E4S2-WR3BB>GRWM M<'K9]5#PZH2\(E-9,N&E*S=437K/6N5=:] M:R:#>T#<`]K!)I9H*YUYRN]:FUR1^>Y7S73F/U\1!6]7_]R+`V2)FB5S_X?[ M/\XS: MOI(T_5ST?"Z/*F(5>5'@S[VJ*U)/]^(U?31%3>O/85^QR:%DN9@K<-[ZU,OK MM.XH]9WI+`'/]M(^S]Q_ZK?BM!ZWJ!"WC.,E'I[DO`&Z]`U571 MDIN=_\]%M?=6BOHW>DBM[?K>`+ON(\'#\@R\D^!I5;+;3%SU,?8#QB(\D>=@ M+J3+!6T3U^?<&E5^M+N?AI`DY"4>L8.N>!SZT].;$)$LRP=WC!(R#K-B`E%8 M8D[=@Z*Y2W&HM9S8FX;P\B!A/9/945AZ+AHHMZ33P;`19/[H_(S^6WZ%``A_ MPM.X]!#U>M-<`#:,EVG$!@R.@G3*CG!F>*X__"_K#)-N0Z5M^%*8K@,CYOT\ MTBP)Z50K?!5V`LB'7-4[;?QUSZZ/V(8^(;15QU./,ZR`<3J>"S;/FT73Q0ZP M<1(N8-GXI])-=(ZM7V;PC&F*S8#AQ^:AY_7!<'0^6SJE7],_\"P^.*5Y&^(* M"0.@=L*Z]J`"*<+O`]]_S/"*M=[]Z\W])P1[G0[)&/GRRWP4S\C/X$^?M;=T MR9Q,PJRMW_^_?@ZJPPH^Z=7Y"P/9]#U#]6U-TC3)5`:^R@8`F))IFW9]L,3# M;[)B&I0WJI#O`U@[,C_("YDO6^/A"JG;!?7,*/;":N_&/8)Y" MM%&_J;BL.6&C1@G#L'S-LBQ'\:6!H4F6I^64,"3+'"KKE%`U90,AL0*J9N&-L@S($X M"M"U"1@U0+V!8@,S.4/;4_2A:WF2;Q:`#F6YP52J#/"?"NCO,6L&?"!1A[KG MR*9DNY9K2*;C^+*AE0-(0`K68;4-A2[\1EA7K:*>""(#MT2/RWHE/4USA-O2!)WB9Q\AHDXW0`\IY" M"+"3[E8-$5/U/@"W]XU$>I/6$G=C4# MX@]D63('UE"Q/-4:*`!^@9VFN`U9A]7=A5L[5!M1J;1*.E*H)-G1/-70##"$ MJF<;NJ8X!0X@/6K+"BD4C58D6N$Y$?IM&LQ2',/R9-_W)!L6P/-4VRBA]]T& M?RF6I!KMZO9,T!]IS1WP+5,WC+]/@V06@%_18L%KJAR<%U-3+,=737"O1P+=-1'4/SRZ%:LN3J34(HIB6?1(B\01T$ M`_`WZ^8'.LAA<^Z"O!EQW3-5FIYIS=M1+$-1I:$F^1:H3DG2)+=D:T=J&&9% MMV1K#8?=4'6`1XN'7<7#=H<@;9YN`CX:F`#3]$JO33>:#H8JF>JZQ3X8CQ!N MR$H;X<5I]B-^"Z+L+7?*#T5"-FS-!R?8=QS9]WQ#=TR_0,*PU:9SK*C4C%60 MV`72J1@H6Q0\>'BJJMB^[]J2-AR:KBU;!2_9AM_PG$U+-_J%?IMYTBS'GM()B2X&_=_S':E]A^99!JA1E=H4=Z`J MRF"H.T7,[-N*>5]#\_[`*:^?6"_8*BV%G/*WFZ"M)@%I+C(5V,1X-G,I%:NY MNGR6_'S<_!*9-\]%IB1Y">D@USD;OY06LTFPG^,SF6.&)&+#:EXP(,%)'G0< M3ME..J#>[EJ.$F0JI@TF6S1T-&6[D&:]_-,S]U:/$ MOIJ:_>&X3I7RL?=)?;^0(\@1O$8$;Z2.[NI*PTIPS0MT'-U5PEHO0NJUV^A/ MZK3\D_DJ?KNOLL&47Q#JVC8S+Z#D4G)F?OL='?IW(23ZX`1SD*:WAZ7XQ8$ M_FJ(=;.:DG,X]\!QA_N(5^8**F4!TSE=P:):\)+1VYVU M-SD?QIT/@;%%J;L&)??28H0G*+@*>#\JP!(M@W?4Y"J`JX#WJ@(,2S34SG8@ MN0K@*H"K@!M3`;HMFB8?TW9R"N&*TEB7S2W\V/^0Y#&9L/?2-UJ61-OF4UK/ M3@!NS-^?;)FB+'5F\KAH<='BHE7G7MX+]+$DZ+O6!YLK3.7CLL#EX<; MEP=#E/A@;RX/7!Y*>9`57DIV)X3I='$N.8Y4Z2'SW62^0XER_<-(>>;NEC)WEY8Z5;W"$ZGJ7N_/N_[T'J;G[_ZNP=+7[&$`#NCA3#^2A:CMETW!&. M*Z$EB?FOG1U_Y+/A^R+@C<^&5V51[;!$AL^&Y]EGKKRX\NJI!LD4=:NS]JA< M>7'EQ9475UZ]G:E11;N[\ZY<>W'MQ;47UUX]:2_+$`VMNVTDKKP.SK%=?[J[ MF(IH++J=:/FNNM==%1&OAG"<$SDG7@?A."=R3KP.PG%.?,^_>/,]$B2C*:UP M&Y,7$L6+&;RH\VJWHS8ESMMQY'HV)'9QX_5W!95M45%XJYEWD).XN"GD:N8= MJQE3U#3>B9&K&:YFN)HY8X,*353WGW[-U0Q7,US-<#5S^"@%3=24\Y\XOA?][ M$3*>BW^_`B&)LLK[=G*!X`*1'[RV14.1N4!P@>`"P01"$16%=SH_.2ZYHH0( M;\ARYH-UFY::G[BKGAT[(9ES"T?Q^F[A07$'>C(+LO14-UY!<0W(-R37DS6C(OMO=O&L%6#KX4W'D6Y$^K'.S560T*X2M9CB5>H+S=$K_G!)A$D>@H0$*@=)*2$F6 MPI=)-A4R^-F+9\`%;W]-A>4\(:/X>1[BD*)=:5%1F)-,B"<"2;-P%F1P&3QS M0L)LF6`9R-.;D+TM"%X1O`;)F"9-\7VOE#QD_"D`W@^>B;``Z..Q@*9$>)V& M(P0KR%;IUY3^.Q\DLB&HZ3\9KR@>S%1J1*,JO^?5!>J"?051'Q><6)O@9SD@J_$Y>A1_Q M+&@8XEF0/(=S!F2PS.+B"V;UZ3>OX3B;?C;-1[/ZS_Y0J!10%U&P2,GGXH\& M)Z^PJ&Y$E&K&:-T[VF,K@T+VZX-F?-BIP.HZ-K]1/O(^1>O[A=QAECFHC MQGW+%;CZKAXD-?/=M,-GWGAM**\3G!OZB:ELP"X:L^E?4XBBSK]R.= M_X!*/;H]DLL#R=XSW1(&?$Y+T\MTU\R]YVE$X705=S!X6&KY]R^N\@(V MMN.ENVRS1'[Y161$D$2DS*Y_I^.,CFYI,D53%CL"$:6-(T6D8M/E<&JFX@;= M&H]-SM]GW1BW]%;6>7:?"R=FW<_NQ+GI3YV;NKQ\Y''KN+MY4-0\C_]WT5%> M1])O!=VY=[[NF*_(E`G<6P.';CQL5#Q7B M,?/"CQHAGMF3Q>9&7/LF"4/IF%IMSP#/Y6$=.O&GAD^3.RV[^L9O\)RO/WZ( MPHI9$O!'IOPY+G_XFBQ^F4=!ULB[^+7.PU'?298[BHH5O]"]QKCD((N#MO'[ MSAB0O(:F^_WK5R&]]Q*VA2;-OM\5D98[,J[&&'< MA[G]/LQ\-/(2."X5@FC(=@;R)[C>;9QGI8=>II,$^";-P(=G)Q/:8L//+BCA=LZZMW.JDCI]@K?W M#DYCSQVQF^E&[` MEZD;@,RKGWFOIC4OEWGNU.%L)D.#6S[9=;YYT1W?2%/B386O2;!=W@:U?9\\ MZV73[W/.@KNU>X@;6'XN'/`MMGB/O"!BX?^Z(VRX0>+Y6>Z%PJ_!<&,SC3-4 MSPS-6VPTV&BPCV^P=_#:$/!CF@-,KF!RY0+PP5>/3@&T[=Z>N73`QK`.\]T6 M)XP8VJTV,0KMUD'4\%RV&9?@SLG0^(M_;P2S*^J%;AM$DGY^0\2N6-L.JQ8A M?5JVL47`-:3__#1%:[Y/ZGDA1KI:\_O9SPNR-Y+:)?H9@H8FK85L0Y/6K'Z> MV(L#Q_'JF!,GS7IU'5JZMN'3I'I*'5'7$)I5IZE=L[:V3.>%S!MB=N7: M?"XT.&W#ITGN&&)M75//"QBF5-+&]2DP+[8/U/*B!Z5@7JP%EJY%P#6IZ7J' MJ/5UZ[D,S-2N6E__CLN`[(VL==7Z&HNV!S0T:BUDF])1B8J8;:FA$&,V5(W_ M0G-CRJ)GIV)N#$/5G4V:6ENZ_[R@@5#UA)6J49NN:-WZ>G&BP6D;/HT&.3HJ MU5JETAMTE%KM;Q[8@U(7/2@-7LWUXL[`T3-* M1\_H2B?\]M>)6;\3H&&=CS@5LS[/[J*@,[M&?4\Z+PJY-X;<7=$'"`T:&K3] M#9I6VQODEP7<&T/J;M[`=K>6#9?A*-_$F1>>87!Q8F:O/<`U:^\ZAHB)IFTW MJ8GX`N>VNYZ5KG*./$.KUD*VZ1VYOFT=%X+9&UGO&KL4-UO?D'?5W[_\E*?7 M=YXW?N<$J1_&:9[0+T,['HUIE/(VL-]HZ&5T8,=IEGYG!79[7DH'7[WG$0PY MO0$(>F'L__7AG_\0A%^JB[E>PIK6I%]I4IT3^(!FQ"#[1H?OKQS6//8W^3\W MSI4PH'XP\L*4=V(+!N^O^IZ?76MRS[9#JH[77VX)ETB3L>U4I1=I"4O2FOKID9$D=B:UI?ZKD0)7^:MYEJ:3B1#-V6)$-TEHJY46B:KVGJ)7^;M7A*_ MP%W%U6W#U2S;M1Q9[TFNIND5P'U=6F\47N;NO@"O$Q[`KV M2K_J5:OF4@_OQ6;4-?EL_.-RYR2:";_&:2H`3`+'2;"R+`EN\Z)G=Q8+?X#? M09\$6`1'<50<$*7B;),>(8A M/L#)=-`5*GUMS;"%<9B#%$`%YEAYX?)ERXO1O_/@P0LIF^A-KOMX3PLYP0^F M?L8&,&"##QYH5SA9TM[`@)@GZD7/,)P!G]\@8KRA?+`I]0&)+`!X!C3U86IA MRH("B&$<0A3(8>*S77X-^(YA_AG\;.[85X-=60*1B9^'7M$G]Y;Z7I[2V4EX MC/-P,,-6+\J"ZVI:JDFDGG\OI#G\4TSEN[IF2]+FIVLI0%EKG^?B*''AH3C[ M/'OK*$Y@U9L+M21VS.3"!8P^#?F49>GD6 M5U\4D1S_AC>Z?V?H7\NH1>LJWJH/\ MS7U"J?`)?KM/!1=6CX'PG8XSROTF6>S4E0]$TB'IIM$=N"8U<`ZMWYY$)$<@ MXBM8'IN:+.^"-@^I=ABJG7!Q0:3::5$-K1I2K6U6#1VXAB.)7;!J%9O.I\OXJBB-Z]=-DG&VCR)F9^XO3+2)V"*GOK234+=2MXP/7$MW"=0MU M"W4+UZT6Z-:)%?X]0C1FQQ%'@>WO2FD4Q(F0YBPO&40>WU`79[2V*.V$%6]2 M&)G49I_.12&[7LEUKJ[XL%(?A-0F^#-TG_]Z+[N@W+Z-?(MM+[ZUHP/YS)R4G4AL$ M#Z(I?84(DGZ9/C$U1>'3U13:G+X MHW$8/U/ZG28/@4^G9=QF"[U9(="&__5E^(WZ\5T$9&^,@`TV" M;ZT1:&6V+2EDI6=HNB4:CJ+W^WU=-FRGJH9D&8Z]B(IA&/.@-#.,XV#U"H-T MV[1ZDBH2HO:-GJ(21S8GE:-425S&2CU?K!8J;,T!9>M]Q9#ZHBWV2!\.5A5] M4G+-5$5W$2A9-L\7*/D%H`Q9D61BJGI/1ED19 M47<`>Q<<6@XW!_EKGL"JE]*OH?<:U+"V&H9F.$Y/-67-44P5O(O*3!J*NF0F M9?%2<:Z^G8-Z(S[W%%W7-1&<&=V4;4G1E)D*@;(B+_'94(#\9X5S8<'Z<5)^ MQ8Z35IG?O4@^11R6,?7AJ_R)$.<``*\<^8F@ MO@'EIWZ$+-F**^NFVB.B)A%KXISJP&2+`.3D/\8GHB/H6U#]Q>5S2G?3L!2Q MY[BP3(H]$>CN2)-2SZ)<8*]_DL2V8/_DTS2]\9YZ-*+#(.LG\6BU`/T@\B)6 MYL[RL^"A*%:X9=1DN+;L*H[2Z[M*7W)=%XQK14Q'E98<7$DT]7G;NX^T30[\ ME1"(*,267`@->Q8LZK(CP\@FQ9\=>6G9.?:0R^A[GR'K3E^W# M_-Y@Y%GB%5N8D^>/&1TMIM<^CL8@-"LBO,',2K-5EFU1EBS=D.%_VS8EQ314 M6Y9AH9%-4]+T=96@)6+,#753^>;'U?>"Y`\OS.FTRO^T=/\K]:%M19%5J6=I MBMJ#Y=$RQ)^#%S.ZVY1E)>,C5-$=LD$] M\$&556_+NKJ378?ZSZDP+$RA%PI>FM(LY7MBPL"[#<)"LQ,Z#*G/ZS"OO@(L MM<#]C-_%X]%]6;,YF"N'FU"?!@]%L5[@7@379`5Y'X/LOBCLZX4304M1XD08 M>\':,T`KHG18%&1FGV>E#ECI78'72PF?BR.]XO1;FCVRRKPC+_D+-'KLL8<0 M`8R*C3WC%QI-.2`,8&1=0?BX+$)Q5%`699Y'F]6M7HUG9Q9'(:7TKY35&QYY M3\$(YI#_RFH*PT7BVQ3;9QGPGW\N!+2@@%C M<`?I&D1^!'AOYJHWSV!Y'X#QAICIF96WSEEY;A#?#^%*P?!Y'66+.MYE%>_E M4;'#5XV67SXH6A,+/@SI@WL,O6PGG\-%A8^?&SAW/[[%5'P>T>[P/_ M?G;A+6XY,:;S)\>^GR?%LIKFPR&L'L7Z1?_.:>0_<\/[$(?YB!?G'R?Q`\C. M!\?6BR`:,LM6%/@O%O[H+F:_P$H0I-WF]E@?GS-'UCV"NK=\WIW4WCS4DXPVF]/I)A MT1(H0;7TK%[/=M&#S?:"M3[KL`KP@.?C.>`I>`09O>/NPC#V\W*J_&*#`,!* M^72RJ2C#PBI4+B["+5`0P65RGJ(IIXO2(G+W$SH(,K!K'G/;`-B5]@[MD.Q+*57 ME<6?L2IB1UA9SG>7^>]L`"WH$4VX"HU`KN>)7YE'@[0CI/=QDEU#[#L2?N]^ M[PHW"4^R/,^T?9H[Z(YM_HW8=:_3,6AO#!,A\.`9%#2E5F%6ZV&YT8J+PRWRF!RD\!9EN:W_\^Z:;(&K?'V6#(1(A/F?,'(5FG".OISLFY. M^[UE%\A*D;=3IDX9#I:7*,S@U"*`,;@'_0F?KQ->1&;ZV_5=X@WHY&YL@881 M.=.T:\8;SK![1JP+""#)NH!0W@7D7#2`#X\]4YO/'5?=\1(FTX!'O2S*N&91 M!EC'$4,,J!/`T4'"5S7_WDON6":>-W=F6L&6LD4>O$`9&#-[;)3$85C$W<`X MF"GAK14&J'B*P M"&V8)SR8G$EZU+96':7;XV+7QK2,7\NG/!N9KK?3UJ*N7W%/,]^?F??L!`'>.H#Q)X=>S9< MD"Z^_=^:S3O<_UOUGJ;'P^.Y%H&K?75L,],,9>4&>H2\@M4IX(/\V=3D24

C^:/MPV/-1N>4".RYA5QZ;NLD.XJ0.'ZGEX1O_=MZ_%/;6J,Z^9]6N MYG^R<9YR\:6!U.OC_&-[7$1@^IX7#U_%?\V^Y94HM]??RB[Y+YWO7XOM5_[' M2M[YCN.NNFT7/J)*GY"5;0_^;JC%FN^FU]V;T%7>6+8LU_ULN/.]C*'ETB-; M.XA^&T?[NS4Z\OY=";1_$\7#VM"ON^%^RT=TG3[1/_-J6]3Y;<674.W3`*-S MZ32`":$Q(RF&#"8Q06Q`CA&5*AQH$=PEPFJG;-'68ZEKU2CO@(M82CND7L_1 MJK'U#^%C_87-Y9BZ,]$YV]@7[>LZ1V>FT]KY4:19!E.=UM;N:0Z;(FY3?I0* MO5?O1-;%X.LS"]V[4_PL M7/K'X-+BY-*J=VG=&C@]%-4F\F(@:MXU5H2A"YA9+MOCE:L#Y?=Y5>7=.]6W M6?6IZEZU:N]!W/*97DS_&Q>2!+HL27P_B#R8^B#LSL@%#'BQ1]1*`AX.,6$AB7P/D!2G M)PE%$"E=PIJC/<-ZUD&<.TDV"]%RNK8TQVK:UM-K86Y,@KO3UJ0]E4PA2`M+4AU'BA M$FQ1JG2/5+>--71)*]&E3:*F'AG@;[H6?5PGP76!'!414J335@%2->,]\=&B M15]XQ@&HES)*^%+,2T!,0.(Q$IX68UX(E<[=3VIH#0G2SV5-XU13C$S1.8.Q-GO8]-?MZ99=1"/W`]!YOD\6N3#,$UA[++8C]*(1A2X($`!!QDQ&,9Z M%XL6@VJEKM038K']X3& MYCAG>YS!H.[AN9%);06/WJAS>C*++!B=[!D[EB3@8LW?%9RAOP\ M)=*:CZ?Z>7X8,\C_ER+@`18A%S*O;24D+`J`6CT[M4\;GA].:'0+9"H2)2GB MYCA2%&!Y>LQHY3,BKNF<'F.V:)0F^I?Z,H4$:6WXU'S-*R%/5?XU/]1"Q$M(B]%Y!M+IZ_T/ M,)W?!5!5@9F';3G969QH-3&:@V,C*B7#VQ7MFI5V2Q1M7IM*@_UT9O4CY6-6 M'#8N96&(6>J1,*()B"%(3]H;HH#-J7^23=J@@!W4N350EO-Y5-``W09T\%VF M5U'"#M4$+50D_P=10U6K%/50BS1I161EE1)=7 MFQC$)$$>BU/:7JY`&(1=H]2%%"B=*)[6DF']Z\$Y`SKG2Y4=ZGTW'-'N'\>Z M$4MS1>F;2*Z3BV1,]F,J8T MT0T5U0MMM\?'8ULWXM>\$27ILKTX)7/3%E04(_8%C@`E+(DB%T2)3X,D0HC0 M`0>(Y`K)&FOBHC$J_R1,Q-8.2B!`<01O'04@*HVLL3ZI]?;LOA9_T78P7*FPU%3;AO5GO&JXDDH:5@P"N=-#5RIN9\(K MUR7,!H?HK^!^-%\H%!AX'#.#W"L%P[+$"@7#<_J"DN6HL;,NQP+&Z!1;A%[K>$T MOR^K_+=\N\_JNK@ONFV=>I-$`28@"-S0#R(,DS0\YT0#'&'I5:R)QA?9;]X^ MFY*+?DK>MU/R70ML1$Y?%,SN'W>ZX#FFU:])%-BQWC=I7+M37 ME5([;>^MSXUUI^,E)^P-H8!Y"4:,8N12'_.?3Y!(ZD+Y-(]9'*93/AWZT3`> M[LMDHR#W+7T0NJ"4:##L+YD$D#VN4DP&:7OIF8K;Y"Z5')$];ILRT4YV'__5 M\'[%:?-#3-Y\0NYT]O4L/7D&GL;]Q=33,AZU85Y>RM1R^0$SV_GH4?P<\[:3 MF!+&F\2!'[MIA(:V64"5[BS/TJ#A^5<O3=)'H[4),Y:IQRS"?HS](`64!H`BD%*Q M81`%C$&*6)^IIX>=F3S]>^VKY^D'J/^?I3?B"$L&L#'S)F;IU6B4'M8DOVO> M>AC,ARS!0!R0\V+?Y:LJB+I2QQ"@Q$^DDO%3VS"\CL'BF?FJ*;I#OH="E,`] MWO$.5ARZ0ZAEHUQ*19M.N;7*$DRJ+4\$(O7'(XU(W`5RKDC95#HMD:S)9I3S M]C+UBG&DX5__K#S8%K M0%XWZ*YNJFS;;&(O(HP!SX\``W[D"=C=VX8A]1"4'7-KP3,W9B6#B8_.R3ZG M-]`96RA>)GUNHS,8Z?P^F+FT"!CRUA416;M_6")"J]/PNB">!6Y1>,NFO"^: M-I<5,[[(BUE$G0`@P\I=OV"I]=(&LDF1(R]'C*P,25L:Q!ER7# M3P?YJ]=/-(V?-9UZV\;:_/=X8J)W)@=: M(L=+6JR1))Z5[,GR?[ZNV=_#'NYJ?CJ<+U^CJJCY?R+M=G&'_Y0;\]V(,D29 M1Q+HQR",_=@=\+H(*MUB7PVDX:EB=)WZ:W_;_:&][=[.#GG]D[CV_GB^]EZ/ MKKT?.H%JE*^]K^?Q:3.+5?;ZY4/A@N/PCRL6?*Q+W5CJ=F4YGIX5[CE-= MIC%]+=9++)_4EN-!<VD[U%YJ1N6L,MUR5FNYBB0>AA%" M@#`WP&G"/'QNF\+(W31ED^UG/!7Y7H-*4\P)F[0Z?1%_Q=DJ).0L4IJY#NO) M^N`'4`%UFW0.ZZD1MM:6^@:%A/H$4YA21F@:0/X@CFE^47CLU"DE*M9).M5ZAUU0P,R%1A^<250Q'LSZ@?5'..3G-X]+)D]%R;IQA\OEPTWM-S#[/)Y\?;JHQ-[7, MZE+[IY)YS96?.@S0/,=4L:$D!KRYE#$0$(8HCX].LU/JL72FJ./==M:+(%Z) M^M_SJLE5=V$G<3Q9EV>EU]""_Z7FWF;5U>V`I2563SZEF;=?&N5-D9<]17KD M2KR<7T7]>[8_9GV:]K^.V;ZX?^)ZBK;;]J)[^ZCAZ.53$,8X9C#R&?`B`#S7 MHQT4DD80>]*E70RU;WA_;OPT\A]5N3MN&Z?*O^6'8UZW^S;9?E]^%S]0D=.R9$^36!V?0SH!:Z3GJY?RB4+?% M`O_HU6OA@([[K')VYZMX;XZEM\=1-CCP0_,U+RKG+G\H#N*1YO9/Y8;A2E8[W_/]7OR[RH6X%_NBZQAW3XZ`*MH6>U3?BN;I=867GR:7>-%STQNS MZ!).MZ&DBVD3R^7&D&*`\9=C5F4\B,GKT_%6/\70CP#VH8L0)!$EOM^U%!.6 MQJ[DFE?CR^9T^@QFO3/DKPFYLFZ=P)XER]4I%I2S=27MX7`>>0'Q*<8P)A%A M(<,P`L&I*1*%2G?]=;YO>'%YAJ08-VMQI:H=9FC2%X_U[N^_P8F4?J@S:)V` M:)AP44%TZ9"+;V^[%>5O_8+RK3(!BH3.`+'-*JF$/'/0*1%V+LRDFOJ\)%&]G(@97A7"QH7YU0L1I_,L%YR] M3\:E0&Q&&FT(NN8TIS33VU2DG_2]C@=S]-#PR/[F<%]6CUV`-RQ;$XIB'KQ1 MUZ4T2=TX]C`\G2@(D_<.K\_7D#F]&N"UN9$.H#-"*!5_F6)70;,69UE/M>9@ M6TZW9`BYI%RSDFF#=LUK4&FJWTGJURXO-EUCO^4/A6CCT/R:/>8;#V&$A50" MY+D0(^JCTT6O-&#OU9#5_JXY=>J'R!F/(P!IA7)UOOVWA_+;OW,KNRB.__`R M>+O$P!L#93)9*X^+Z?C+F7J-2@*, MD!L_J^^22'=[U0\;[_<](*=%Y'!("_3\%R1<[?JZA%G3][4->-7YIU$AU?N[ M2U,-XROD;/_?>5;1PXYD3;X!08QB0&@_6V#YUWZ MJNP=)D>`XDNFG4-TZPW+CH-+7%P8"I.ILV`T3+>AG+$O*<\(K-CG%>Z.3SQM M8B_TX@0!U\,,8N)[C)T*O@0T?.^JB.YGC<\&+1QGP+/`5/#,_JL3@1Y3%G3\ M2?!?30)3:)#J[D.X\87_E0WT<1I[B.`$)#@)(0[YIX?BC3%^+Y>J_+T%DA`" MA]&./3;X0H_6XL2"KJR'NYS8&30Z[^WP`$$[*7C4][S():X7!"Z%V/>3Z#1* MTE1F]:[WX06Z&<4Z-)FT3C0-N&- MD3"-#HVQT`V]KK$H`2X*W"0&+(X30@("3Q=SJ/?NS;II'U]N//03P](C8D2& MU)C0(<^Z4:%EQ,5QH4^)U,A`O*5=V]H^>]@0/_'B(`HB#_$IB+BABT]#SXMB MF16^V@?-C8`3#D<`,=KGGYE\H9_KT6)!W]8$7D[M$>I9^O+QL3Q\;LKM/S]_ MS7C/^'1LZB9K3]]O/,0\Z"8X@A$?.0AY`?2'5I.(R"QZ9FC%?/Z^1>>T\#XZ M'4!GA'")=/X5@J[G]N=@UH(!,Z@YS>JB_G1_*ZZ[].I'"0(A)!TFQM$&2B\.&`6B M,C8USCJVV,7%GC%ZQ1/59AUQ70&M\X&:/KY)?WLH9@3=.6-W!O!K'NF>PO4; M4KNH"RTY)+Z,K>4*8T11Q/]6YY_N:=T4CUF3UYL8>J)8$?23-'4#X-$(@*$5 M$+I(1985/VU8:#D:,!0U5I4G.=4T2)&:#KYDYV,G=$_.[_V_UU.[YQQ= MT2]-,BU1)%WTY2P]2E$U?LV_C[2J*@_\QVTN8KFZZR_=_Y_5"P1)&(`(Q31. MPS2&&$(\X*`$*;V^-GOCAI7GMWR;OUA$/`.MJ$3S]8(H_F["L7ZN:*$GN^[R_YIOF+B_\!<0.?,N)&8EP*1\E12F5QC,CW1-*O MJ/E2[K1$W!9TMU?QJI)@5[#QV;:&>'Z/MZ4HWQ.HEA/F M95A6W!3J,8T(7C&;>9&A*_HXG55+E&\&0\JY.YSJ0K7AJBG6QY_NQP.1_L^Q M:)Y.5P\#1%F("75=F(8)=6.4N"#T,4Z#-")(=IMAGL8,KF8&?&(Y,T;X+TZ' M<;TZ4E+475N3S$J])>-O9J->KB\,4*92`WK8$OXE?[S+JPUR`6,T2@A*0]]U M7>+3:&B()C1663VH?]WPJF&\%E"OY*S*E)Q:F25)39G&_#B_=W"6EJ!7?%R1 M&WWN+)&6"0:\KK8\B0IIR4"[72%V);/];5;L;@XX^Z-HLGW?J(LQPQ[$0>J[ MQ$U)Z-/DU.C_L7>E/7+C2/:O"%A@X0;*`UW4L?N)I"B,@9XNPZZ>+_,AD96I M=&LF2ZI-95;;\^N7U)5957GPE.C%`HUN7VV^>"&^")+!($*QB'RHC61ZOV@$ MYS!T'\O*Z?$)"HLBGWPB,QV58H)SF<6YY.D2`_#ELB2)F-J$Q^AJ%S= MWK3I`="E3A1Y&/H0NS`+LIAJY`#`Q8%0YJ-OU)FWO=D>BZB@Z6.<4]QF(5M0 MZ,1VK6?2/EXBK^F@=F?8HHGZ#7NKCX:HX];*+\5^65;%>M@>&A+)`"4)B*,4 M!\"%`6#7"X?18)X+U65(#C&A"F;%IER5H@_2RU+'IW`3L"8F9P,@9]PFGDFR MSC-S19\4J;1$C%2MJ+5^7R*M++\4ZZ)X8F,4V^[$8U<\=Y7MC;/_8[EWGOM7GNL-_:W1.Q<>4&6/Y!1/]']9[GXX M1;M!KOZ@#2>19T**$3_8T(%4NTVUP0]7]B3R5QKP/M$?-@N0>;GON3CW0!QF M;I[@&`XCA<#S%R_%[K'FKH,3'T!D#IYB$3]QG.LX<>2"Y^Q0G#A+LC(5"RZ= M"LJ2P3TAZ,)R5RR;(BNZ_WZJWA]#?J%3-*]W?RYWZP6)_`2!(`K3$$<9R$B* ML@%&[J%,9#6H>VS#.=H`U_DP`/Z%QJ:S1_B"RT?M3N!;5\[)OUCJ)D"]\P\& MV>DQ3[T@%:3TBAZ:;[(8ER+\0N\E+B^:.> MYW&VZ)YLI)%@M^=,/83'$)FP;^%PSUW4O5[I?&A:?,+5\^+,\:F?6;K$]*W# MV M^MT2;@;2N>7DV@T6F@H5Y;>J:XV^^O&P6U8->U.Z;471_FS;-:98__/0[-DJ M];=B?[]Y6'Y?9!@#X.,01D&>0P]#+X[&*HX,`;&]E)E`&M^/Z;$[JQZ\LS_B M=98CX(EER`S;5V1I9O=:(E-SLU!;->>$FTSLC_`6.&);9!%P78(]XN<0)F,- M&?`R+*8^8G^W<=%@5][*ODQHVY8)+<_?>%MU5=SM:NOFC3=#/0M.F+LB`'(, M6S)O)<&_:R4@3P'?B?NGICFPI+:YWYP4B8\W2Z(8N$F0)U'F@<3#.,M<,BY7 MPI#_S6#%<4SOW0[HV%'C,$,8P/\2.>E5Y9+C&'U"&@6W8$\9?'U31.K9354N M!0[+)^14[HS\XT=6D5#\A?[;>?4W.,7WDAU\;^J=LS\Y2/^+\_&CZLGW=58N M'7AKXM*&9_FHCO2NMG7'.3>LY MR1;'XAR,A,1Y',+`(\3U4T(BX(5CR2P!0BVK=8\]I:SJ45-YFI7$ M=!*&]6EI"]=J*;U$J+B2*KO&;B%5-X]/1S71J"<_Q77U0N6&KG98SLQ^O"\? MM\778D7_Z+XLFD6.<1(A!,*80#<#;AZ=U&20F&C+5M6A&!;9$U!.4U0E718V MAT?ZN995>WNIJO=T@?YA?2@<.D7!+\YJM$AG@JO!91K2W6F]I3_Y/>+OME2. MKCV:8(>`<_(MFQGKH;D]1N/! M49PB'=JO"8EAZ>=(`=4$90[GJ>?IT_I->];^\\0`/K8E4WI]7K0[`N@V5B#= MUTVQ0,>HH1J@>:@O-(%I0]3CLBG6K/2@J)KV].,+N^37E'L*QYD;H)@@%/A!#O+CS9A$Z$K*[&"GB"(?6_#L&'1$[Q3? MV8^OE#Y:ZEN^"#([3G-!YL0T5@3RIJ66N>?VGCGC%8ZO9G#J[\G MAD[>B`%A%&`_ M3M,8800]!'-_+%K-,I`LJN(;.YS@"S^3P>*2K[23KU,+^,]J_J`_*YA<;4L: M<];=.NN%Y15LK^="DQO!6#2=%_F"D%WNDWL9\'QOJ#MGL*6+,:^L87'J4M^N MO\Y2@Z_+$5?BS>2^MB303&]W/?,D4VYV$(:1'WE)@CRU_)0;9,\(FM-G-[7XQTF??4\++Y(]_6 M?S;C'9,DS3TW2T$8ARG)`]XNCJK-=!KS5S58]&/\7C7/Q:K-%OI)\%"GV'>KQ<$$Y_&'\X%9X935+\YHB'.T MI"W.[FUQCL;,M]+4XX0K8CVQERU1]JFM?M\!:GK298JWV187!=J^1O!0LU*Y M:E5NBU<=K!YJ3EM&W*RT`6<4+@P(H%$NC5(RX"8D"R2+M^/FW_1^&;*T<#5B]<4YKW1W["$8# M6>7;FV=&Z6\+AL3Y8I]I#_)5@\_[\5@2+^WAXW(UN`V.XHZQ&7L4;56V`9W^ M>%OT'57A$SMI^G?7X"Y!!&80IX$?N`F,_#`%PXXW"N-$:-6E94##L>X4H[.L MUL[R!)SD;24]1/.%G,DY%@L;I_!895L/L&7Z%.+$,L_#VA6IUDJZ)7*KUZ;: MX%P-`#)(,Q#C(WPXG;CX8Q\,5::,D-87I;7/H.IKFZL7DV?5DGFE:L6Y,C)54L2>;^B3'-)]-8N+DA3.^A,U1..<)R5ATNT9UO2?XX]ZO-4R>XR]RR=D3DX%NLF=D%/LO+M;U; M-2(M42-5*][ND^H@16JITFV^#HD>BE',&LRF09I&(28^"+QQ;12DKMC%8?EQ MN*:-RDW@-TN7LCN=J:ZU(M!-)9_N&.902GHZ\L:3K?X$J\-.++?0YWO[)V? M1K&5HJHO+)%%$Y;=7BWJ(4]!..%J51^J??.E6!7E"[L%N4B3)/4)R!`B;H)R M`'`XC)W%>2S8"4;+D,9SNP$3J\;J0(@6) M^KPKGI?E>CA$Z-?2L%JWZ^QVVZ]9((P1C-,<)Q'TDSP.XM0?T&0>$MQU,P3" MN*CU*(>:@6YQ6[=;3:OV>?M]O^I5ECP]3I'5PNF\H5,D!^_T<%OG=/N`\(93 M)E).'EJ%)%6KGZS56KU6WA1A`Z1J6#!_7OYH,U MJ06R*-O6"J"T0=Q+8SFJU&1M=SA6K+#[,KW`CGN4)[^W`*$/$``Y3D.:!LC).8L.<=3J(07MG,LYNJ2U==<)R)/,]'A@ M\RN/[Z937P'.1<79A#MMUFXC]O)(NSFBN96??%\53?.P_-Z_%WWYT8(S5R@7 M29@@/TT0:TQ`D@S&7C:""HCKB>TZF,5B?/.A@\^*K%\_3=.6G9UME%ID.7&1E\0$QFF0$Y*F MQZB#0BA4.:YQV(DR^-TI8LG;Z3K)YM/FF7@6$^)7()T>Y=WP/N695'UBS>4G M\8K`&O"$)6IJPK+:^&>LO"LR[#E_*5Z*ZE`LPI0*L@])E+H)CE&(80+Z@0D. M8Z%G[-5',ZR*X\VV78='?0M#F$[9/0J33&K9A!BY[1'.OL/PAC&A+019MBW1 M-HT&W=P$4*/*0(_811J'OA?@/'$4D#OK!$+4U8)MU+59`\ M5?UDY6"-0#?7&";(32@8Z+D^C'T(QTYS=#6/A'I03`3)<$[YML=V.<#7WV-; MN[.45'A./VE5Z-&0G[#'MJ`3Q/7=E)?MUGYC5O/%!;.D<\>,S]U13_-0P]7_ M',I=`5^6Y995<>3U[NMR6WPM5H==%[:0!WT:IU*$0P#<%()DO-Y%<`H$;Q[H M'-E\R2[]]3^6K$RBWCA/R]V_BO;M/:<9,0K*OU;>^31^C'3;W[V%"HSE<.XHV(M`"+5Y38A"\LD5LCIM7F/V51X=S5JZ)8-^U9&1T1 M5NN_+=DV\/['_>8*G#P,THB@(`R\&.#$PQ$<.IV0.`R$KO:;PF`XG69HNNJE MIPYMJ5%73;F%4V,M\(B@WO:(^PH#IJW,,P-JYA>KY%>.X&M2;-AEMLBR:3/? M2O0DM,KGN10?3;+W/S[3V;"GX-A#R\_LCRSBP"7`BT#BNMA/,,ZC8,RT0R_Q M%=-<^8$GJ`U[+JIU2;U$!9G.=;;/W&)M):$8@*JFN@K42V:ZACG7EN@...^< M%NE=RSNYS?LTF>Y%%D427757V"*H!BR[E>;J(D^AN*`M>"A75%O8KL8"89I/ MIU2G41XE5+FCU!VS:Q1DJ9:+9()C2NBDQ#VR`1X[&-^-`+OS.39MVQ\PS7RA M`4Z\@%:=>=DR!!-LZZQ"..)K=WQG+T)XS9=0#8(DU98HH#Y[;E8@*!&E3>VH MXG;;MJTJ+Y"/*H?Q_*ZF1V\DBA\P%N MR[JY4BTYB7OT"*0)OQB4R]8A)X`MD\_7;"J(J:1;?A)IE;5.4&B52%1]'8/U M9NW:H?3=$L(LIFKO>6'@)5$`0A?C:]4UIO%JUK,BV]W3U=0D1I)L M6?4TS[,6V3RV?NY;\EC2_>4L?4(ZJ>8`:P52T2R^-S(4:9NHE&L1P!B##",, M7>B[L8^S%`VHDL2'&LIC=4&9MV3V7"77I(54E,?O45;OU4U5K& MJK2X76F)D$]EK=:J+$&2564_+ZMEM>*O%4OAP@* MO<8X$:2)*W@W`WS]%;S:G:44`.;TD]9`,!KR$U;P"CI!/#:8\K+=,<*8U7RQ MPBSI!GKCG`&\\"/?]7,W82\WX"Q,0S<>RBUR!%.A?VJ:`QVWN-^T ML)K?*^J'3_07:!AZ825WY]&R\I&&_K'M84TA?]W7JW_=/W<+FR3&,4)9$F89 M1#0^15DZ7.W.@R#'LN7)TR,U'"\&@]K*Y57]]%173L/P=9)4/#UOZQ]%,0:3 M9V:)0C'S#*[F++;[:;PL6)_WJC!ZL(QYN[/-.3#CG-&Z]F#U4B1JZ_GH>F4T MTFFM='HS9RRBUNXRSE+K^3X52T*:)61<*=N>VT4"K>+ZS+RYW]`EV$NQVY>/ MVR(K'O>+.'5]UH4.NFZ<^I".[`VE0GF>HD"B0%%EN&EJ$T]KBW?%NBB>NALU M5)6J>D^UZ\/Z4#A4'8!H#8X2U7P!Q3B]DJW@!E0L!)S@>AWCC*GB#14Y5U.4+"U52FVE75%,O?5([(H-`Y/6N+=@Y MMS%#V=2[7_JJ0PMVK07YY%STZ_2,)1IKS+PK"W/] M-$Y4H;((/!+@B*0Q#GP?0"_#03*@\E%`-!0FZH(R;V'BN0*52>M3;KMJBKH4 MK5Z:JQ[EIRI",59\PNU*2X1]*FNU%IL(DLQ?9++9%*O]_89\7_W!2A^^T/7[ M?=5?$6+_(UR\TQNXBPPL)5R?WB74U1-$JQ>4TG?C#M":J]N@S@)$BJ?@2NZP1'.-F,:7 M7&N@CUM)SVLYI+AVNQ\4P=^7VT.Q2'`<>AX,/"]*0>S&+DGZW9O(BY#K+I[; M-Z:^[I>[/9^2ZAE79`J_A2AV6>><7/[G?R2^Y__W8_&MK"HVFVF6UHTR\63F M(O/*--;K#$LFL&:C:I/?KY%)&Q",JKR.N&GFJK<1DE-53'*N*?JU\/S\[:]FK/<,@3Y MMO[S4[6I=T]M7!]O8X51%$<`90DAOH?"+"8H'H;W$B!T\4G7F(;WG4YA.NNR M66WKYK!K2YI7P_U8FB^/N$4OQ&JCGF]I,@?K8LN25X2W(LDP.B<@Y[NJRLG> M%674S;\EVJC=K-KL9RO<;(LJ1]'L/R_+]<+S(P*P%\$4N0#Z&'O#%26JP5XL MM"LO]!<;5KIVKCU3(&T7Z[)')MPI2X0I/LTR1I*8,`TP'(9C\I961PJNJ(L4 M4Y9(B!SV=QVHI`G@%@-6V]R5.C=4>NYW)5U8+[?L5^%3?:CVWL)#>1BP!548 MYAYQZ;_)N*!")(T7]/]]K'DU0GT\D3EQ"HU?.D9XW<6^8YU_4U0E59/F\$@_ M((I[?^8V1:LWI[JGG^3Y(`@!B#,(!`$`P%TF:](UJ.*,:,X:N<)B)(NOP+"J/]6;3%'MV+6TY M&MLF:A_+\4*'H&1J=!R?=,[C,S$)/<'8OB]R))O!9&>2/="[KN1X8C'EIO"* MJ.IW@R7B:L"PVO07;$!LVXO#[`IRL1XN(N.ZV3>+&'D!BD(/TF5Q$%%X*`D& M3-C-A-ZG-@K$L"3_7BV?:BJ^_Z9"^[_<75MOXSBR_BMZ.`>8!9*&1%WY*%+B MG@9ZMAN3'BP.YL%0VTJB,[:4E>1,9W_](:F+'7?LD!0IJ_=EIG-S57TE?55% M%HL;EC(5PXR"-5/O*'T]9>HE4K2ZN_6Q]BR>-D;DW42)3OV;P\`*;L$"^?T< MV!,I?[(/?Z(H,-U6A<"@"6#QUC.*5]8\?JZ_9'7;?\&OPVJ*;O+2]WS3#>/N M+\G:."O;B:,PC8'G`R>([,2U"1E4"6$220U`-2#?^/(G]U3Q[VZ/H0L$A[-^ M17G[Q$X3-8U5YUL>!2BUF#D.:,1[8HQ_;F33PY[-;]"DE8G@RM&H7/B*D>7 M9V=06(-RL_<9783J8H>1'I`70G?:S/FAJT@G3,(T1K*BY@U+/6V6FT]%]JW8 M\B-XOU)EV%2MS^5O;+Q6S<[GE1O*N_7P).4D*'>S8:90D*/4B M#]HA!KZ?VF&(4`IE"&\^K0Q3(S/$XI;<#'D-:R0\LL8:S&%+SZ-!_+>.3;*X M3=8?W*H+S337=K(8\2[3OW(4?7#MX,)==UCN@A/?=9\1[M:&]@66G]^C"XD' M5S"\NO;+I!ICT,O1FT+J_%_[O%R_Q-^+9L6N]8Y1C$&\V>(".\IUI*4UJFG]P115IOHI6$N2^$PPR]&S&J9F^?<\4"+,J@'FI7&F M#I/.L:$VN.1Y[BW!2;7+BG)%\_48)(1@V_=@R`8&8SB(METHM;NG0]Z,^>^9 M-[)35)GGIF`MR7,SP:R:AJHC;);USL,FPGH:0%\:Z^DPZ1SK:8-K$NLU8[+Y M:[[[EMZVUB+0,.\=:L!O++W60&[RD*JS MFU$TM=#;JS+[CT[+)1#<*7*2#*<,_((I3MTF`8Z;")A*"3O^\W^*O*8?\/CR M*7^F^/+$TD8P2D`*H.,1F(0I!LD@'>!4ZM2E)I$S)GBC=I-+UTD82U>O<\&K MSGSBR)HN8"]@)5;#Z@![:6RGR:KSE:P^T*:E=3_JT>>6F*`0Q`A'(++CT(E2 MS_$')7P`G,GYG;+DZQ2X-#\Y6N([>GWU5;L3G#$A,YS%#\H;,3)`SY<3GL-, M-CF%.O<2+IHB8(Q0?+-FVQ8T,.[T?)XS^2<41%G[L&MNTY00J&@)FN,?7N3^EH5LPR` M%\C1B!\6PHUF;#L=PVH.0/G\\F/YM&\;GL\ZO<@8V5Z:1@Z(4S>.,8X1 M`4!JJX4*<@SS'M?%[C8BZ>2D:B<6)Z+[$&R`Q.IU@D-XF9FF=8I":!NTC2FF;111+3`)8PJ?U:E?G+KUG]9]Z2?;EI>FD8.%'L`P_' M7NQ&-G*A#P9I:4BDAK,HBC!,7EPK:\?5LNZ97I(\I8J<&#?-`)H<'W5X=1I9 M7*5K565O0W.!BB9BN1#ZF6I%I?4!DZ29W^^^UGSK]N6.];KVISJYQ#!-G-3V MB1,0"`.?RG;&FH\DOA353!!CF&Y^_W#WP1J4LYI1.TG2F8*C&/',!*$<^?Q^ M=\#NH-:U".@\1!=(2`.N"R$B'994VA\Z:4+Z>_6Z>JK*IZGR3L@'* M3W71Y`V;9OV#+E'JN!Z$Q'6@Y]AA!.,H&'1)4"+5VV1$`<,D=M#XMAE4MO)1 MYRFT9L(;HH1W94=(4^&;;CC2F(_@7P1/RB-[D4$-.FHQW&K2QA]8USB@XI/H MJMTNK]<%&V3ZE-=#-NI@',$HB=,@#""*;,<;A7DXD1JHH2;!,*,>E+*>F%:R M(^;44!,C1O.`R3'?$5928UT$ZB(IZ0!X,>2DQ9@?2$H?1+..LOQ4E/G'-M\UJ]0+PY3`P(5N M0D"88&R/!\F)!]6.@2D8:T65V_D-AP)>,-C+=4=8'XC4]ZO1HO<-#O>O>MOPO9!9+5!_="B%.C0:ORD(+H1^IMEPVN\W M'9#IA>0JL'WJ7YBX<>RGT(-N$(]',T([AJN6C=&96$"^*T6*7D:%A%\7E5%` M$R";6`YJ14MC&;B4VD^EYA/&="%,H\$0T1I/$AJIVNXHA8I;G-7U2U$^:,0TP;2NZ3U7+??5W?KQWRS MW^:?[YGP4P7*3?R<%5N6L)&JOLN.\[;NHJLH37"$(X0BF/K$MB-:$SH>QG&2 M@I3^3X329E'$,.$-ZK.=7*;\S0]++7S]9;3B]KZJ;YOL53$C>2?A//Z[3*&+ MFU3K?>LHY8?WOQYO/=*;24OMH^YM1Y6.]>G60C[9O:C,XNC8\Z/ M^7;#;I)C'T2_4;0O'X1C+,.31TX;NC:/FSH0?B.JSNJX*\?<>6VMKO!FS!2O MJ93F\_VXH?RQ;-J:OVT-'U@!B9MX($Y<+PG<*$D@(MZ@;8ABH5&A5U;Q9XCQ MW$8^4'C;&/&YT$M#_GZ6#16ONT& M@]?Y$_W5[F&PRCUKUV7>[H-=8_WU6*P?:8;RU+)NDRYMZ29N=(_%H1VT.'HL MUMNL:8I[W@#43$ITKIG57/:D@7Q'TZ/SDV="NE#0E"-I=8I8]G1!9G][!7!3 MQP\C)X&LGQ[X*<'N(!6EH=!(/DVB#&5YPU>+LE[IZ+C84YX>\S&L*L4CD+,KU=K\YQ,V;JP3-=^$]%_ST^64)04RC M-961AU=+3^&;OF M.SCT,/`3/W62U+=1"M-!HAV)':S1(&:.U@3V=NU4AR_J@%(@SYT/145Z4IK& MJ!U)B>1V/D35$EN.;)^HTBQU7]=YN7YA)T@?>6[:6'_E6W82S-KD._:=3?Y4 M-05;32K:1^M;5OY),^#Z)`,NVCW3HOE@?6RM;-M4!Q%5^YC7UI\%VU*UVDX49#E?O]![(\:T^ MA,42[%G!E8MB4W$UT__[#EZ7VH!U0;V0A%N?/:=-P7J!$DN\V>1=F3EWR3[_ M)PWI1?FYS/\WSX;A5';D8CN"T/9<'_A^D/HN'%5S(R2<\2Z(9BF.]4!-$>Y%G]9]`6;!`U\DQ+Y]"?;#`NA,9'WIC43NLSA"+6F(Q M4Y3*C;E<*5&7+-"E:@7,K*X5JPGT8'NN>)C9BR*UM/;VH+8S M&H1N%+M^0,(8!`#%*4[#,<<@?B2^S:Q7K.FEMW/3'Z>&9\W@BRS.70UWR<6Z M<[,B]054S>#+K.==S0F*ZWNZG2&X+"8#T]EE,B-8+R&@&;*L,OZ@Z@E/\3UE M\EZ!KX]UM7]X),4S_W*\C\>'(<%Q9*=IXMHQ(`&Q!X6`#X5&<9C7XKK!*V,& M]+'+:CL++)]_*7SL=09/30IM,SM):Z3CNA^XM5??8OKS[RCN71EUEI90.+/3 MC$1&'I/XG,PKZ2"VWUSM:].G")/+9O;*$D#RKO7H.!JD"+=X">:K-657B756WQ;_S#:Z:=A5" MARKA0>3!%`11`@@A@SHQ",7CLD$=3'>C#,I83!O9+C]3N(L4MD^@UY[/E3NWQQB?V#_:`]OJ7Y MIC\SG-6'L\+,R65>\#;.K!M>0C/UNLZ9W;>6%D':-9]Q5M$;]O'K+RE-K%BBV;CQ>XI*^I=]S0R M92G7/W`9Q3UKY]32R:GV!%QJ\S3\3"TAWL]AYFF#Z"RP&HCN?Z^KIOF]K/-L MRY3Z.SL@AE-$(A!#8J,DC1P'>OZX)A!XKM!%\/-H8KJWBJED'72RF%+2)R3, M^D)WW#?MAEFB_YN.6Y;?3*4"IOVG.2%XX)[:'SSUP%XQ'HXOK'4=;3Q-R@>. M/NB#=;>G'W1&GZR?3Y)_7^=-,PQ9.UP^9+&&G'Z"23^:M/M^-OXR-9PQ/_W) MABHZ;W;PQD.A)4>8\K#]=)G")&.5\X7I$!O(&@[Z?*+:<157B*8R7D10B)&# M$Y+:"(?C0H4?^JLR?Z`/_D9WWJ"BBQ#AP8[PCM56SQR8;G++\>8=HCMU,.:) M.5.'$Y_UN<2R'&3C*%,8,XRBJ6D3V\\5AH MR1ZF/&X_7?8PR5CE[&$ZQ.K9PZ7]C?$^BA6)79K*`-?U$/)"!Z3`1^,*"`I\ MD8MH#*L@M<'\8.M("-[?C3^^%F'(51,A!R/8=X-@V"$(WQGB0Z$"<2%U]J2[& M<%4AG-(*W?2H'>.I#*@57HVDMQAZ4V(T85073V+BE@CSEB0X8@LG[,Q&^GW] M2!^PG&:6[$M0VR M#*=P_.#3H"*OV_AW#EJJ7#2F`V*!)9&9T97CK,4"*[&2,3/`:DL6L=4<'0#A MRP_K4_;'H8P8#/:>EF.'TJ5^$H"#`<#IM,M4XISU0V_+4KN3JAI M\(FEJ,:1DR-Z)=",I*9O`7,A*9V$XT+2T6DV5!H?K(G\,MP4X?L)A&Z,0MM- M:-*+HF"4EJ;`G\(P@B*NPC%R-]1,!5&-9PS@IX-IWH5N%JXY>X^,)C07RC>R M5KS#.$J@B([B87E36WQC!799T%)[_XW"592LU>X?59LWKNM_R>F35[;)/F?D MU@\L`(X#4B_U'3L!L9U$-DSAF&$A^CK1S_U6"4[B,:6$S%MWK*_X7O9!=:O3 MW3I6WN+:6^X'U[=Z`_@,$6:"W&@78VX2J*B7X1\Y5IS@&,7A.\8\)#5Y9PF> M4JW8*=NV[%*'?;:ULKIFY1V?W-I6%K6BKO[B97N=/V4O]%_L;."^I`&/5N]% MT^PS2M6LUM^.\7!]]`PTW3/0'#\#)0.$_GV>U:RAKV"3._.FM?H[(_@((/J! M["'Y;^N)]2*4Y7YW8W5]"/PO^`,SO0=!U6UG>Q",/P=+6%^8PANL. MH3"A-PY,5*/:7]I#=ZS^>TGFL\S#37U`*K% M%S]'%-5CJEPHU0BO^,VI1UH=Z]T"]D*4JS4:>7A!J`3/CU_%)7ZSS? M-(0:_;$O^#[?L\6RK_UBV2I)D./&R$O<@,0I"1S_L.UGXSB6>SL7)5<1M'UPOO, MY/<^9A>83R/@"Z$]G195QIY.6<++7OA8J\_W3,H@FW7K-JO()L0&;I!@E"8@ MC6,;C$L*P"9"8_!UR#%T@?G+];WQT[<%@V_$U:6R*;`*,A@,R$H25V] M5HRL>)O9R%Y.C! M^E(7Z]Q913@)_"!%!&(`G(!`W[,'!9(TD6J,TB=UEA5%WLKYQ!2R?BE*:\-* MV;KAFPC-8U;GHK=P&`!=C-&N@[<7/<4\LUG9GNA`&\0'[Z MG;`0*C1@6&7Z^96DR;NV6O_)")F6QWRW\`LMPJK-'7O[FX,2G^]?K86-9QQP M'`3`#6%HHY`@X&`G'9>X`M=+ARE.7\4IU+!&0N_YZUE.7Z=MV)Q=B.IN06(; M<'\[ZOJ>F0"FP7V!%6;RXT*H8BYKJZN\+"JD\EN^R?-=OOE,ME79J@-L>Y[X+W'K?J0W])'*K1JK>X4C=HPIS(!.^>6I[0Y;MB MOUM!A",((AO#*`&4@NTT'AMEH8U2&?J3_W3#3'=0R.HUDJ0S!;S$F,LL5'(D M)8.2$2;Z`8P+I*,.W$+X98(!E:YG2/:P]SO%X6^\<:5+]U81"6#DI=`A`-L> M!&[J!X,."+M8ZN2W3L&&N>9S73S0NFI[5$3QKM@;J]RSQD:VL,R7LQK>HYOS M/ER:";!EKO]R;-MFO_!$X\"Z>**?PE;"NE^7NH16N[RW_A*5 M3N.K.D#RL/FU'*'6!:?=(>*GSB6`.M?X9@KO)72Z&;/M]'"Z.0#EAYE08?F7 M@8)C?F3B]R;??"QIFK[>;[M7,$IQ:)/$(X#*#T,78CL=E4@\\6YP[9)G[/_F MS3*':#4>+V'3TGCKZC`P0G4VAQY7"$:OJWE!(7R-`U%^X\G%J*[5Z6LQA=EA MFR.5K^L#Q6DIL_M"==QK;NW+@E_0MLLS-I&,G\,ZVLCL9K;F#;OGN&@>\V:8 MJ][Y<3@ZQ;[)7ZMB9$1VS*JB">5N5PW9H-:)*R(87PI^1GRUE.AGQKASLUD, M0"B^4GZT*83XX<&B?/C8G_!CBJUL+V1CUT$`PB@,W#@F?CP(CE*QHDZ?-,-Q M;M"E>S-_R1HK8U4:.ZHFVXJ@`5G!E?!9095\@_ MEBF_X638G1R['>@?8QYY^9+]USK;Y!OZO;C=TC#?`CO)7II_%NUC4;HV_5,V MI;TMGO.OW:QU]M.5C]W8CG$*`A_Z-HD!PF.[A(="'.AIIE_<6MMER;_=U@ M]^M?87__=(#^_[N[DMVV82#Z*[H4O?@@:M?1C*A3Z_:0NZ'4#J+"C@0O0//W MY:*%LF6'E$E)3!`$@9!0G.'SXR,Y,[0.[:[YH"G"K'$5S*4UPQA]4UWC`@H7 MS@D6=\B2OUJM'\A"`357+%W&X=%FF#LL=I;,'$*?5RXA8$ZZ(.;\8E6.H7_R M-:$IES9LAE%C+%S;W.+K&\]Y&/>S'KTRO.1P?"10;F\+ZR7@>BE+H7QZPWR, M_^W40IHG:$%B5E%09!:8N+70GDO_A#$[AP6\>4XK3*8II>K\9_Z>[\_[%3TV M_?7Z>3>?F!JD1J^(%GPN$%6"%PY9Q]!-\5?@QBCP08J2*'9:&<8?:H@*:3BS#=/LMW4TV67'3:B7WA/!3(;+-0)YZ6;VP:FBN&F@*RN*% M5?F@$MVK&I?,#Q+9,6;!3:5P-@-VP\]X6K[KVSB@J_^\V-`2>%(<6!W\X(FZ MS-X_OA^[$GE_QEJ88\>L+'?Y'U*U_9HH7SXL+&V_$15.M5550:AI&P-Z001V M3I)0;]5:F7^_M,+.+[?6^9T-OLVO%\+_50$"(8V`EP4Y"&;32I6$KRO"W0K)6? MR0UHMR>##$!US/#)??+[6B/+ILG0Z$*T6P"`'5(YEN*F.H:)AXZRKBS M66_EZ^VT7:@"EDD471U1R2+KP-I=^DL[C&W/=R,7@@"!**K?[Z>!T/V4 MRE^J68Y>W)[8)%M@_N13,%AO!]3<4>-XL7BW27P^(%K[<7=K*[@CXKX[47#* M1V`FP7#J[>JIMJ/!<>HXDB7;L'H>8!TY`(2>#6"<)BB`^-MINSQ3JMFC8EQT(1>>H;!BT4*C@"TS!IQY>/\.FP03&%50=:)\NMCSA1 MF&'K`&?TK]QB^4S+W@9N:(>N#4,GB>$R!"F*FUCR=:N?:Y M6&[8>CW;_,*69S`+CVUU,_`&[FF]X,/_`O^&']2/\ MXR4[;O&3_U!+`P04````"`#8@F=#G[*_/9-P``!A:@4`%0`<`'9R='@M,C`Q M,S`Y,S!?<')E+GAM;%54"0`#J`1\4J@$?%)U>`L``00E#@``!#D!``#L75MS MVSB6?M^J_0_>S+/;Q(6X='5V"@"!WFPEL2MVNF>?6+0$6ZRF2#=).?;\^@4E M2[Y$%XHB*<5.34\LR\#AN7P`SCDX`'_[Y]TX.;JU>1%GZ?MWX!?OW9%-!]DP M3J_?O_MZ?BS.U8J=Q&I1T>?8O+ MT=&?]M+$B>M6'!\_M#Z:?7)?_G49%?;HKHA_+08C.XX^9H.HG#YQ5)8WOYZ< M?/OV[9>[RSSY)[8OCNR,F5%C7H M/[3\]:[ZXEG[;VC:&G#.3Z9_730MXF4-'5EP\J]/'\^G(A[':5%&Z<"^25*H]+41QYE2+^T8Q:>7]C MW[\KXO%-XC1TTI$(G[/2MB7`,UK]L'\172:M\?^94D\B#?SOBV=GMBN"?V&Y'H2HFT;M&P+E25)=)GE[H&W M5N1YE%[;:M;?R._&CETQ5A,5=?MWQ6:]6:-F]YV93(=N(K)#]Z%P^!E6LY2, MDFK=.A]96\?:=2ETSNI9E#L%C6P9#Z)D=[Z7DNM"B',WJ&>V/;U243$R2?:M MF=[74NJ<]>7KVNZ"K*?;M5BG-S:?3KJ[2_(]J:Z9/Q\Y$(^R9.@>'U*73.:GW=;D=H1\;G8;%#O7:& M+.\_I%=9/IX.^$V\UNF[(WLFBO,_HF1B/]FHF.3U?+FUG;I@J*9MZ_3M@KUZ MOEN-KCLR]_LD8TE?$G3]A[^Y&.5 MP!M.$GMZ]>3+VGIK2K$]4>K-4BL[[,C(1WL=)6=Y-K"VRB)OY&-5^UW9R-+K M"YN/`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`S"4W[-8P_(W3^K?/KI6#VTKFJW7TLX8L'>E38=V."O@=2PDV6##M%Q]$]9\ MIKAT7G$T6,2I2:6"]^_<0\(F9$+B^QH'`?<142A`"D.L`1;8]P-#$'RQX"=5 M!7:6S]6[1+H'G4XM>!45EU,S3HKCZRBZ.:FD/K%)6KAV`,/]=?_>/@Z M7%2(3!?R);(N;Q@BGQGB_B<%@,!0X1$#Y])0#.0F:9["1>2#HRP?VOS]._#N MR/WERN;YPVJTID)\"J#RNW$>Y8/O0/>\XT.+DYMI!=GQ8!0GPWGOJSP;]V'D MK$7M.GDZQ\EJZ6=:/00L!=DXBM,=T#0C$'K:^+XR$@8^U1PP`N1"K;[`YO7@J5T@;(FR1MKN M`V&V';D@JQX(93 MZ@'*D<:<"A'HN38`U4W=+?CF0->QYOO`X<)Y<&&6_>`^KG.\OF\<4DG]@!J/ M$^H)KC`AE,TEXD#CUX.EEMRLG76X'A6[A:E?LB1Q,^FW*!\N@4%#2J'RJ"0! M11A*YG,OP)Y``"L/<>7D\U[1(K>+<;,^E=SS$K?V+*\M3Z\NHKMZ*UP=2J$1 M%'@$^X0%)#"!#P+/F^O<>0"T+\#=K,AV[B.KT`@KJ]>[#NS0:&);QX>T5\XK M_&('2504\54\>%Y#^7)F:T`JY!2K`&#L^0A31;CT'QU+K*CZ\9>_OC#6DPF: MK9[CZOAU\?AL.S1.036ULG(EW8EJZ#Q'`[D21BOA::3_(\*PVZM\`21OYV\W.OM80=X20'- M#[;_2X61"&J(M9+(190!X\C7%`*?!1+AC1-O-[/`$JXK55\XY4KWQ+_6#/M- M7<,*5YA4F3JC*#=,0>+-)0XD?:M[Q+6!D'6J[WV/Z&65@S_8D`:*8RP-%40" M[BO"?*?K2N'$$QRIC0#O*#^\."&WC27JC/@=*87Z?3[9ZT;.87[$(V-)`BC'W#D):(<@%\$LPU92!NNLOR M8PW^VG#)]J;Y/I+<7PL7'>FBC,?1D_SA$L0];Q@R`J7"/D%<2@\#J"D`R)VGJ7NXV!V#>!4"?>S?^O,5-N2"@'F/@94 M,,VD+QE1;G6>:T,'C3<_#F@/N$-D=:SMSCR6FG>N-TU_;B3_,M&YLD.H?.5C M*$5`$4>`*@KIPQ3.JZ_VY&:LXC>(BT&257=XUMNPJ$TE%,;S/:0"Y]]R3C4! MU`=S/03&WYBG.7PGHBT@?+=+T962^Q^=K1X[;7&0W:I_2+B$5%:U#)[D'N5,>\%<%ACPC0>L M?Q#,=&CDK'NUMPJA!2,K3XQNTSVD/C1*0X`";A235;VSFDNB7#S[2@#4OF7K MX&8W93>"S?]&:>$,\IRC.1LKS^C5[1IJ#Q@7PAB#A7%NBW+Z,7,)/#?47CE< M&ALTZU3/C9#R*2Z+R65$"G:&E'MXU0L$UP M\''-\?'FQ$(@/`:Q-,PCFA&N"<=P,=,"^5K.U_44AO5A@U9CLL#>VB2[J3ZJ MK"BKEZ9-;R=WUCRS^+\2 M-[P?'+6CY%:GGL7;0:M/13Q\>)6LCO+4#G_/UQPJ;TXQ!$0JA3W`@8LL@H`* MG^.YO!C3IBGO0_/6#V!R:MT8K8+O<^8B4#N[J?F+_7L2.\.9+*]>G56]3[6R M[I6ST>Q%1DX,<7.39[=1\G\VRK?&Y4X/"XU'D&=\CGQA%/(]'S]JR[U`J'"@MA%"00^!5 MEQ$N\H>0D*;.(WV[8.M$\7U$(`\O"]H<@#QO&!*M/`BIE-(`K1CW`LD70P&K MWBY8N[7Y9=8EB-JV;-:B6IM>9967E3QGU<\L/;UZB)3/HOOQFGS:IGXA]3SE M@X`2Y3ZX.%MIM1@X&(JF2]BAI38Z`D07.F[5C7KR!L$O-AY?3IR67Z3PSO+L M.H_&+U[I5==[VOH!H9-9^7Y`(6:L.C&FH5C$YQ*1IM>*'EH2I$O$[]P:6A8GOQM%<#Y&63,&!5?61U49N6AJ+*"5S,I50$KR4;T+5OW4R= MK2Y-C]M/9U$\/$V%^W*XSLW>FE"H/2D)\K4$OL\HHI)ALICI$&X:S;,#`\L! MI([:LD&K"/L4)[8HL]0^Q`AN4%G78N7U_=O2"4'`276&RM-`^3#PI$"+NFV% M&[_@@?_$5T<1(S@/-L81$"23PPE4P`C>^Y.MG M[5=W5FB$LOFU1-/MR=-;F_\YB@>CU3S]&2>)M)^BXK/&3NA[W&!\N?87;O(53I>.T>I7U]3F912G MU49D\;%BOVJA,F?:09E-K^BLSA%L`F?K#PQ9@*&D&#)!N3/&U$X+WR3P&]_" M>FA9V#U@=]_&ZB,M,A?H(A.#J=`24@%8Y1ISA;* M-Y@W?NW8H65C^ZV2;%GM#4]8/HR'36G7[QJ&`=7.@04&><(3U'FOA#YFDV#C M`VQ@ZYQKYUO7/)@LCBYP'S:MIP6'EL<]@&"B0[NT7->]\^3.Z=7C6=6)O<@N[&"4QH,H,5&<3/*=2F&W M>U*((`"8`&@TJM['#'SGK2Y*A0EJ?%G3SPV-_5FI?Q1/BWBKN">QL[\H]\!* M@(O<#U@E^;J4<@KW:W3>N[KHM M]=U-/#L9-)/D:^K6E&(NC!WJ*$_B-7=]M$$\A-!WT9PA6!'D`CJJV&,R5@C2 M%+7PYR9,KX;I(YGS*4ZS/"[O/Z3.5DZ2#^EG6SZ^,*C2[/S5'TX,YZ27]2ZR MWXENR*&D7`I*C'8_N*88/A;-,M4T#03?YI[./FS2+,>>.6;2TFG/M;V>LSG/ MK58**$Y3&251.K#G(VM7EN1L32CT"(+*8((\Q353$"JQJ#Z#/GH%=T?VC(*L M1W,T`ELE[$QL4:S]A?1W5F>W<;%[-T(:E0-U@^I\[/S M/Z)D,AW-\\/"BYC2-7PX.3*/+E>!=^^,A8#Z"&EF)$<(,^()\%B\P@!Y12\_ MV,-@^-',VVAPS3<8IOL-13Q]A]@Z=I^=J5\U,'8B&DJ!#/,%#B#0DFO)$%KX M7EH$30NW#VC3Q>L2>U(: M$XA%G2GQ<=,WD1W0AN9^8->NWOO`U#-MU)G[UZ!M:UHAE5@2"(UP8\U'Q"!& M'R_1):2I@[O]N96LC))7B,.N+=+/@1>GA'C@U**B8E2Y&.Z'=C/Z;914GH,H M593G]TZ(Z82^]ES,5I2<2\*@4HH;"03R3(!Q\'CX1S2^QP@>D,NYAX"_6ROT M4FN4VYLH'C[,[4Z"Z=NM15'8LE"3O-+WNG*CS;W=.B&Q'R"EF/-A/:B="A:C M$*J@<:[T@/S"?50EJ:8ZW4(#&&6, M04T"R('O4QDLI#2@<44;/"`'<"_X:DWE_803I=-"[+R!V1!P7.J[03*IRIA_ MS[+AMSA)UL86F[N'P@,4:^B):H^!0\$T7DS>4K+&]Y0>VLGD?H'6@>K[`%P- M4"VX9X$)C(>(H#@0`?*PT\><>R!$TR-;\&W6O.VHWC[`\60MKD*3C6[4TO8A MA!A10IVGR'U&()6$+P)L#5'30\SP;9:HM:GK/C#T\!;6XBRZKX+7<3)-Q-1"TO(^ M(:/:JUX/10S7'H3"UVR11_:D:1S+O>YO>!7T1W3_BMM_.@M@78ZDXA=-+XY/_) MN]+=-G)L_2[S`#/<%V#^<,4$Z&D;'3?N3T*QRHGNV%*N)'N=G-I.ZFD^KZ=_ZZC!^ M:)C]*@AK'&56:J&\50Y#2[?X:X,YWIMXU_&-G\BQNZ)>C=)5Q$7'![];"#7O M:4%%1L3_J3@[([%DQ#?MG;6)C,G.JQ[90NQ!V&\WY!L0[*R@NPX[SG7\(.X2 MOU?KKF$*AS)PL)\.#$,:(41,0TD]8$Q!UB"8RAC_^E&IP])U+)(9B-N?[^_N M)LL?%S?U0?I'=9O">ZX6=2_69V,6\[X8G?F#01).B6$RM21)I;*L-Z1!2S*8 MK0!]=!Z7D<>`FE)4?>:K=)@\A:<]3XHX5%GJ1]7_'.>QK5CD9_/X,K/)[>5B M$^+;(0^LR_!`!4=&"(,]@)Y#0;R7&&GKH&8$D+U^VX%\T_4M3(1S-UILF+[P>@$#:> M6JN8UYIP)!%OY@4T6LDF%Q1(RR%PJO2F) M\*Y=70A:=V[TR9;[8GATBVPZ#Y/9;=)?_&*92@=^KJ[OEUTO3O>-367W-8VZ MNT0:8I@J6*MV36J973A\1";6,&SJ&]GS#O;71@FO#'$.4*H,0\30!@MCS!EE MXO7+LF%Q+ADUM"F37U^%5.ONL4-O#0LF=?5,?;^1H<0)Z*UM]VC/>&Z`]8CB MJP?:L_H#M4P(]4-\L<7RQ^Y8_.=?"]@!0;B'UL97%A9*J6`S"PQ9KL=P1!'1 MPU#C"!#/(RF($N^(E4`PSM*%'#?8;>9LF/$\-[9U1!'1PQ"G?VR+&_)=#?A@ ME$U]#JS`%B+GA&3,-_.0".1V`#@\_'GPA-J>SYTC4!R#7MPIUJO[0X(7&F$( M&':<6^R]]A(V"""GL^/HQ[K7'.T`&@S;7S7%$%MLDGYOB>+&*LB(Y,TLH]Z6 MRZ#1VE-',ZA'-(M%FWZ:3ZN;V7RVKGY+#<9>YJ7MBSO=,SP`)QE*49!6(*FY M-$2J9M9,^=S3;+16U-$<&@#5L24&:$A;_8S"@H%6H!,ZM9C5:HZ>GV\H#<2LA\6=Y$5$#^KQ>7/_GV^(V2F.U MB4/O<*'=]1%!&!S1`AQXA*B-\WYF\C.#.FC_9XNV677X8IK]>=GE4T@Q0R`)`'''&`DYU.S]+,"UV M7W!_O;Y?SN9?4[?BY4,'RNP8%23"&CKKG;<&,<6E5[;U0!*96\9BA+ZX`7C3 M'[!E@D2_SY(E6TU6U<67V]G76F@=CJG=`P.WBGBD&0:`*0_C]DI,JPRB;/UX MA*Z[`2C4*[:G*$>QGS[OC`@6QB/82``\\0YAQR4P3]NKSM5Q1NC@&X`W_8!Z M&G/\(#,\1`,31F5-^3B?N*%BK6&[D<;/0`<^J(+2JS&! M<,>-T1!RR"DW1&'3.KR!Y.=I.@WCKND+Y%.IQMW#9]X=&+2Q3@DFN&2.:V6T MYNV&FAI%G:5A-0R=>D7ZA!IS)UKM'1N@<5[%902L`X`;JK!XVHBUS:WQ-F[3 M:QAF]0UV$7(MY@_5"=1D?D!*`1)LA%0-1PL?- M.6J%#:(ZN]?@N(VS@4@V`.`EU:LAZE1J:8CE`#HIF';4"LE(&UT`<6[UMH-M MN"'+5!97MWI".ZOV22H(41_242#;6^7YUZD.YL).IFW%3' M@;"6T;/O[F;KNAI4RM]HVH)>[Z;*CE%!*((YI0I)"AQSVM6E4;=Y1'%!Y`9T M'%R<^PQVF?YP+N-D&D_A9`HTU7$;QH0(Q:QG6K2WTY)DEW:#!\<5G87N74@, M)4CZ&IU/\VT7JJM]?E#`4A(H+3IFI-ZCQBW3Z)#*C_.\B-Z M[D\JFD)Y^1N)UC/=M\F^\>W`C*<,8>:=(MPA)*1[R@:&*O=><93;YZGH\#IE M_T@QE%(8%_-.O'KYU;JD.H8IT<8R9Q!5%+=W&,3;W$/YX"WL`Y'J2!D4B0V> M3NNLC,GMY60V_33?7E<\>_-=0<)[!P>#!2".$F",3#Y"'!61-JQ5\-RM;(1W ME"/A7.\R*12A?G]W7U+]5\]7LH7KJ)_][M;ZXN9H\[HY;/^1) M<44*(X2'0GLC(MQ$@]9O'?7G8C>='VA7'%9$96SM]60VKZ9NLIQ'9%;/9F2K MF]GU;'=0Q[[!`4'*B>%1JU86><^-:C+CXC&!16XUTQ'>C(Z$DKW+Y#3&]$$& M<7"2.HTYK-L5..RA?"FS MNAON`^QGU"K=$>>R!O1;M9Y=3VY_?JLS:H\#*)6$&6<4XP(SI"7=M-?O">WRMTKU6Z[4_?I;U/_^JJ:=^?5R8$@%>(SWEI-X5OLX M;2=4,U/N:*X5.,*;S8*\.A+E4_'ITVIU?S"7-H,"4=`1(AE"$!B.G$#(-C-T M@N1J)J-T]!?F41;"I^+0Q?UZM9[,DQI_()&>C0RI.[/C@A&.`8*<2,Q`,U>" MR!EULRC.IGR8"]]P9^A2'48'#A`RU%@?K46,H-5&M\M(,94;ASU*Y_J`U.H? MZL+T.D"%VC$J"&E3EQC(2"K>9*`7VT[U<8Z69]>M'V&IB%)T.A+BD]!HK^;T MSHB@&=06:HT9EXA"I(C6K6+(]5FYS$O2)PO>DU"GF\*T:UA`VCL;=UDD8>I, MA+RE[3Z+*,LM1SS"U**R),K'N*PSL$5E=7&3NH#XV\5_3]XFNWV1P_Q_KX;% M[=]#8"4E43]UGCKK==1.%8E"55K;O2?LP#.MVZAWF5O]Q2!0W'DT$2;=SU%' MF(:\F0U!^1DZHUZK1PCUU:W1$6B6N>_\'[:RS MW%*"C/$:R92NTG_/5]^IZ=C.KIG9Q-YG- M=U'DO3'!(*"I@$("&G5CCJ5V;#L_K30[H_K?1\KW)5MZ0K3HAA*5A.I3_&NG MW:3]NOA>+2+J?2J\L/D_H^+8027KYP<"]5`2 MQ:%+G3XL3X5!;8,>4O0?"E@C2DQ+K6- MPE`8P2QI`-36\3-2B$J+_'53P#S,RV0K_>_]:I.2G\+!(DSU_GRU^*.ZCO^> MURP'P[]T\$ZJHR-M=3D4LG.1LU9/:J7F76J;OX^/;`X*%D!H%HW:EN,$66"/` M=F;&4)3;EG&$.^AH&=B+9(I5=]MBYQ[3F^[RX;[Q[>"=--0[XXRT2$;E7JL& M(D,LC`A)Q?0NLI=7"1*5%:=_X]@QS_(QJ1X^7O,0Q;`UW+#,;5G>/;),;E@WK[ZF0*>/R;N^ MQ',B);!!9%N)JH.OO?M#@C/`(ZX@EIA&(+20W#0(4$US"3I"*_S$7O/!9'(: M5C;-N^/:KF8/>T+XN@P/4@B)'+5:.R"TI]209M8VM>H=W/]=<*L<@@Q[^78T MYJ=A6J,U["[JOG->HHW\Z323.\9_OAL7TD%LZ_+`H(W1J5VT$4PAX3GF$C7(6*B'/VS/G88#2.&T MQ^OEY$?VV;H=&Q!%`"DO.7:IMA`45+3S!;I`'_B?673 M1@GNNL?K:K6ZFCSJ:E[=S-8^XOKV7?D;]MP.XA[UW""(T$@*G:Q`)VRT"FV+ M$W8@-S2\N__ZO,[SDL(H0=JWFB)?5LO98OH2S!T,[?Z08+T#&@KNHG:#O7-2 M/BU;352N!3U"%W7);?:ZNHXZQ9[,\X"E!0X4BYE(; M0BF0BHKV)')&TEQG]R@O4DK3YF6RUV!B*91#>%U5TU5M9\675?/IOR=)X5W_ MN+C)HVG>$X,G6#*G,<&04R-2?>@FW,AQ@G,=XR/,/#@U88L(Z"3[:IQ:Q&G] MX_)V,E_'>:4BY-_35P[95M]]2.`8.`H9%0`8)(SQ#+>($RARS_=1WMV4TIG?M29A=1Z$E4`^RO'\>&K2)AX:,RT][)N*"C!9A>X1HO+^2TR]WDW-B M(O8LD#'0+ZZ>#7KU"CN"C#\_*&ADO-(&4>F`8@Y9]&PA,I&K=':_P/DXV^.@ MDCEAHDN*T+Q?)@%DQ%^\^81`+(_K$L)4?X'ANF-G4WEOO M=3B/Z8$_$`00J48<9D!+K`A,0=5;Y#S1*I?A(XSY*.DQ'58*XXKU>&.NO<1Z MO/'<@!@"R`.1KOF,)9(`WGA`O%;9F3PC+,]2FEC942#'BZFTES5554]MYRYN M-@6R_YQ'$D3=*4IE]I"<<6]/-/D]5FUWQ[K`]L7W??K'H+\;!#<\[DZ"6*MT M%"R+.UB#,\;>G+W'MM1R&),8RP1-?=^Z_^)AN8A*V'*=JCK8ZLONIO#OC@I< M`I0"P!0`7"(5IPH;)XWW4N<:@;F>VY-YS4HQMC]9E.;;;XOYURB>NVULSV_) MDKWXU"N[]Y9A63W`'4) MNKV]5E2Y'>,_8NUQ?Q21EPUJ"',D?OG&/KU)&^W+V-1K+M^E3=9.A#_Z]H374=#N]3]7(D"Y4,3J6^T2[#K63'.JX6:3NL.SY/; MM!:BF;'Q?M<.QATLZ_R,P)A!"DH($:("4\H-)&[B&6#,"590"9A$P+7"#D@'VG-)R1\#,GL10Q&6V MJ0=\L;R,=OWV'W6ZT6JVB2UZK*:;H.5M$M)TUX&<\;0`H$HU0Q"A"#(!+`;> M-YAP:7/+M8SP?FUH:@Z/?AF7QYMWTI\V(?2[#(@](X,$+%K/?[]>W&V` MCMKJ-%6^G,:_K!:WLVD*]&B-\SHNYRX^^5O\SNRA>JK)_O/K58_K*CYG^K>! M>?_Z77ZOUAS+_?KE*1\M4@K?3%?QQG'=_K:F'L= M/#<#_6(0B-NXBR#,H8>8Q_DB01U'D%*'%-MKNP\607)0JV#A,='"!U,PM&4*XR/T(/Q,EY\'[OX,.$4.)XJJV.=_:-!K6W"Z1U6)''/SP((J53 MGGDFHOD#F,#.-(AI7*#&]X>E;7'AG9+N?\[CF]_._JJF__I_]JZUR6T;V?ZC MNW@_/N*YZ]K$=GE]=^M^0LDS]%AU-6*NI'$R__X"U)":AT11$$EQE*1 M.8^L9%BDFV,"U-H%BEU1\?OZYFRW54 MZ[:0FJN^V4M>>%1,=PHZ*0K9)2C:0Z9D!K MY'-#Q],/J?Z:FK.M+&RUUG2H6^74?2T"]Y18*CR6"`'C!*)> M(R4%U$!8#8]RU0R5NUQ5".C"V?/ZT<"$E$P(K+AV`J<+X!+7$FEA5`^SA:;Q^.E8%X^&)22$CM*F,8QW(46**IJ M21SGN6':!+?+>D/$61ILQT):BBL+`XE!9=_TF^@V+*(ER[3L_BQJ.?;8^/## MP0'K#/-"&>LQ2_FX5#>]='QXPI3W8^?>M#@.U_"1K\I1E-"6LW2L;8CK MH@)(0"`4E0APH2!J]!9_<3TS2^_0Z5NYX[@CZR)^)V4/V[AT+LJJI,=Q(+6V M"Q9P$F=G8RPGCM@X;$"C06E@[O)TLO,Z1N);[S#J4[6C[',4U9[KWXME!/XB M]EK=WL^7\Z2%Y(L?QU*W%P1!&<:.>&X,ESK.QT+;6G(M<6Y$-,$LHMXA-8B& M1YJ>=@6`S8_9ZNY(Y/3V\8"YQ4IBJ+U"0GL+M62U5`S+7'Z)":;X##$5G:O/ M45+\[W^;S5=;RH,/T5++N\1UNDTV^K"\+;Y'K&^*141Z5,W3*5+R\'Z?+Q8M M:#KGM0%;:#E@GG$!7:)R$T8U6F+9.[<33/?I'74CZOT2!SM?F:-=9/Y;+\F5OC_O4[0V#LUA8*8C$6D"+!%.^ M]O2\-RHW[7F"OG3ON.E3L>/P'S47O:-R]I$;ZN)[N7JZW?)U]D>Q_G6^+%,U MVN8:32IF]_PMB61L\_AKL?E1=J]D.%8OXC`6&B#K$=1":HX$XO4NB[<>YAZ; M3/"Z5-_@GJZ5QALI4:JGP?Q4^^8HJM^T"$9B9Z4Q1B.+-?,"XMH)]81EAYP3 M=/Z'0>"Y&AT#+:=F=&MK%1<,,2T05@(B3IJ504B32P8V05>^;TQD*W$4"IMB MLYOOSKS,?O*[`A-`80@\0-I!S24SB9!JJP\%:6[YON[TO&-?7^\;6T.K?'0( M=H578-9Y*)GVV,4IE9`XJD0M!Q,J=SXZF7;W_&ZU^RGRYO8-DYYT>@G$Z-EZ?G," M7*KG`U8&XNC)$\PMEY9"8$BS.$.:.Z-,\-;)^:8]@I4-BTTJ(= M:!$P@@XKKUPZR;;6&:(:V;Q%N:>Y$[QG,CA8\E0Z!ES^4\SO?L2NJ9_%:G97 M?'RX_U:LZL*9GQXVZ\ULF4YO.JQ0I[XJ8,Z-91YQC85F$$,J>*-=XW.WQN$$ MIZ.^5ZZ!=3TEY!U;Z4YZ3V`Q)A`H.8!8>`T-P`S4>G!(Y(9C$X3<J^SJ4!-<82\-QIY,<+D4 MX:KG/\I%-/!ZNU^OEK?MVU>CYA`_*VE2L5N_[&J'*C%=V@>BG*?&.@"8IM(! MH22`%!NCB>;V>*W5@67_FK:EN@A9/1B$$-&W)%I903W0(HK@:VF\$;E'O!-< MBWJV[NN[D^>H=93[MW4'MP(GRH)RF<:U^F/>MAW8VBY8[RSW`@@.`""<()AV M-[=R.G>5\#G1P(=PTH,Z1PGE7W;3EO>S^;(MD-_W?)#1TZ(QQ.!*82\PA(*A M6BX&S15YO#W9]W4LWX-61SGMK'3T:Y$/!62]9M8PQI-7A3`G&-=2 M`"-RRWY,$!MG6O'U>6>^$D?B-[HOE]5*>Q0/;YX-"D#O'9=6:8KC6+'8\6:@ M2'=%ZTJ>&=\2$)VEP#$`<:`.S5%PM+8+(`9B!C%#-`86:$NQDXV<6H]6/.V= M`*5/98X"FIN;A_N'18I$#U%]'@=0UW<$*D0J')X\3FD>3`2]9DQHS31AJ>R5:B9)2K*GD@FN/OW` M8T#ECKHA]TN<$#_$'SOMPC4/!VJA1Q`8#RDG%GAA>+.70"C,C9NG63:XY\VW M7"V.E%_P@B/_P_+M=O67"')?KGZ?K=J+E9_TIN`8$C%:9'$F-I,38^SA+V6O.?J%?U\(#@/C),,`HZ1C.$GH;;Q M$3G/3K0Z>:F\.HQ>PCRC)51?244Y(F-`#9DP2`HJA)&$-CO!DL,K"BO&@OU$ M3'7)@?#>RL=98RA%ABB&O5N`"=OTXT1+%UZ&(QJJNEFSAF6 M`@I&`7`&.N25$LUA"H4VE]KI9'Z!:X+<.1J>8K8WE#Z5F<$4&,6<)UZXW987 M\=?%`#`*0K*5F[4S_&&]?I@M;V*<]OW9$7S+5=,.K0+C%`CL!8L""VB,M<`U M<1XAN76<3J<`>/>@Z%_;HT75J=?%[7,O<;LAX.Y_6Y2/1AY&L=1]$8)-4SL-.RNH-10KYC8%P\/I^X+@N_?L\5#T0OV#KTI",<] M)PI#YP"2SC$*27,&[.@5%"NX`/1ZTO;%ISU3+J,?NXZF36I+/V\2V^P,`C`L= M5Q4H5`R/B#2Z":03<7KZ)\JU^SF^*K2*^%#?EW;)Z2Z63UEN]PWXZ(".\YQ9@S9W6 M&&%/FSL"A(KL<\EI4M*,`O^)V6S<$7)0XAT7X??OQV+/G M+P5CE'54"4,M(88XA1%LSA(HSMU%F"BQQN@L]Q];G;?@O*]/!*48-HA+R;71"FKE4;/[:RW-3A'J'C"^9#6\"HA? MR#K3O^9$"$,LE;J!1A+"`:6F69J0D-FL92#M7$7_=])Z2)Q''$#3'.2B^943+]`C*@J*5'"U9V M/!!\T8VO4:,Z-OS?0P>!^Y\.DBN#I-6`ND3E**&%H.XKAC*7]/!DSWVHWTL4G48D]=8D4!GCC[KTP^@B72;8 M]?Q1W=RL'F8+M3&SU>HQ_O+85E>G]L''Y<%Q#1C$PDO`+):REEV;["KN$PS7 M!\)$.;S6AYP$=AO&RWFY^M?#MVC`^3(%EA_+S866:EM\VYPTW/21S^HUK(C1T\BQI"N;;$^TB)@YJ6!G`.(!`;.**9`+9_$\HH*J9]K MX->UL'M1Z`6'Y277Z+Y&I[=>QSD6F!@0`12#;.]C8$2@I!$@!IZ\ZAYPC=/7 MW1\W/V9Q0JZ*5G_;[,[,#K$6=FP9`>@-4APQ@QS$GDDG&ADD<:O+R`Q@?"5Q7;+B*,RE4RZ"_E+'F>!YD^>GAK8,;':-D[BHA% M!#!DO*_EQE'G5W*%=H!E;7SMC\/!N1/HF2A)8>F4HDK.:]^]Z]`^.&^4T48A MS8DGG$E@2.-Z>CS:SM60\]NH^'A#[MF_%49*AKLIBMNJO&]]Z_W3][1"?'U: M(5J@=[QQL%;#N*00BYE7SC-(Q;.01^622D^*`.F2N.O=!*.`;O;X5*TB=;#N MMBG7K77'6UH%`;P'"#-KM+/(*050XTP@X'./U2?$GW!1D/6F^3'05?5QN=ZL M'E*GGZELYW]\7LUO"MB"M<[O",)81IG37AJ$(/.2$E#+;YW-W:68$+?H)9$W ME!W^S+E21C&&,)<<:.XU@@:ZQA8,'S_H.9OS8*Q"TY<$[J@V&@W-6R+/XO;3 MRLP6BST)-L=0>_0%`2&E/32;[XG[^<-^"M#?/!JF-D$@`(X5%<5`!IYJM+0FRL^PFQ-9P25"=J^^L MO;T.GL&7RE[;*;?MV/*$UP3AF13$2>B1`40B["BK)=,&Y]XBF%"B\260-((I MLD%6;V+&;Q?1UUS>S'^;+=1]^;#<_/>ZJ+**%C$L\ MBF)QCJ5)#`-/LEF2NTD\H;3@B\)L0%N,XHL]TY(N5ZOR]V>7V)-,;6[8L;8! M$`Z-]8@A+CC#2GFJ:GF%RY[BII24>U$7K&<#Y)Z,;5,C?;GZO"I_SM=5FN1N M)?_P_>G0;G97?%C&\5*LUW6PTD3=L?$S>I2OJ]EM<1M_IS:+8K;>Q+A[]KC^ MSWSS8[[$(-6KC?'-9OZS2`\F=LWX?UO.V";1OT`-5D`9AQB5%'B%M&FV%8C& MN1/QE#)T+S83OU,C#S/@?ITOY_TTV#) MF;:\V?H6RUNWW%2T+-_+U?V+PY*.^9B'CFA:OG",X[]+VR"CNCB$#@#GI`9" M(,.J-%=*8Y@KS\J+CE'$?]V5/_]V6\RWTT7\X?4L$7\5MKW[4MPE=J_9HW'/TTW_ MUMW65MKX^?IFMOB?8K9RRUN[_X"N[?$`B4Y5=*2PW%FG+1=&U'(XC\ZH#_>> M;-R3>H8:Q'Z^*%8F]N>N7+4/X1=/QL"&(B$5!-%+8,9BY+VI>T\,*\7LR M[OF:Z=^NM;`I2_*`09\_$F,+HP52UD@HC:3,T-C5I_XB87(W#.C[LN09*AG. MA)]KOL.6Z7?OLP$YC!`'%B!"@&,&8\D;$&J=N[ZR]VG4^+XN>HY/!(MK=G9PNI-[=&L9HW2,&I.&,1X0JA0C#M6R2 MVVR&;_"^#-Z[I@;;`/2S^:K**?FUF"4NK&IK\\2=OWYVV9N>[(BYUAWXV-J: M!<2HP-(B!@&12G(OT=/FD;`,'C\@'$_2+LR)K>T"4PAZ9H5U0B)+L*%>U;)& M=&7O_$]GX[]?DY?#*7?LU8X((@'?ZI!SK:^)RK$?*!V:#$8VQ!BGV8UL^O'9+.)7Q?\] M5!S/[4R0'5H'8)!06AFD+!/>24-5([/7/G"^/A^E ME^S0.A`:EVSKO0&42"ZXX4;6,H,8@%TA!OM`P"%T]:;I2Z%KW8S!@PR5IS0/ MDA)G+$':&:9!=`2=4+740O#1RHN,B*\^,-`!7V>J>N0EM/GQ'_-B%;_]X_&7 MXF>QZ+Z*MKP@`*!3@KY#$A(O+7<&V5IR9-S1>CO3IZ*@GUMOEC\6F^+353/H5TRRHX=NEVX"`X!`YE*5*0<`E523!@7)4/8M M\XS)UR\[RM'`'U4"OEO=W&[6VST)VZMYO[8*2@/BG(`HN1LJ8P0TIIXC0SI7 MNYOSP3LHP?K#>BH^H2P^/;0*.KW9(JLX"CUYO$`R"0E%$C"(*"Z"QI*B>F>.G!$3-FS&G+7,Y`+9CL.9?7_ZJ MML+X_C'%\E'F[&\4N+/0`>I3FG'):)PK;(YL;VDN>V9HO@W(GM[P'8=!?Y1W M1;7:9B6X*5?K,JZ12]'E-]5RG4J,?MUTXE;W[H)P$!,I/8:20,"%5(+5J%B= M[?LX0[5J4-8-COP8?$RNGT5UL4RAX3=%=91PKWX^&&A,M&"M4(6<4"O4'\:@73B>8O>\/E%D/J<&L,:-[Y?;2WST?: M37\M,>7*C;$#=M-ZY1&KA7/RT;:!$*6C[FL`A%QH"3T!C04EF#B#RM<3\^1E MUIV>5V24XWRQ_IY2$,4?[N_;Y=WB^MG-]>,<#AWM;?L(G`FLK;4"IK3D%$KA MFS,H'DYGY([1(Q=>GO(#H3W*O=OVEF?1MD+9:Q\/T6KR6!N@)4!::)ORVC<7 ME4;D9`C?>>5&X6UV^4 M.'VA.];1]D1"JHU95-5]/.Z/E9@[W#!0@15BWEL)&2/*^RA*ZYD:RW*O.V8H M@.:A5O6Z'./&/&ZMG_,)>71*&.0M$JEV9-SNRAF_#2\E%D'%CE8Q&6:F7RZ^ M%Y>WUT_=`EOR]=%";1/7W.OW!`"]4EIQ;RR'%EI"I:VQ])#EUA* MEC^:<#$&DR%_W"Y20LEB(I'Q^/4M!,6O'PY1>6280X,94(JE''H8U]'G7HNC M-V-#SZK-)G_ETX%8[(R)6A&WGGK#."3-O"RGV75FYK=53UG4LF\@!]MF[U;Q MU^*OQ3\3[;/F^SO=]QUH%;2VPL!HX#OH&'/:125\!ZPRE!U724>;9YLM>*A9 ML`YR"`VPEF$*@=+$@'JF3&=7'9_A7NQEO7]QUNH-VC%VYY0I0_K?I(Y#A75< M(&/*$(IU5RIH^X^+^>Y)Y/YIYNBBI"OOKTOUTD;BH,QD=7+G=ET M558_%]7EWAP?7;L(0``M"9:(:.!X9`S@H)X5=8C\'ANR]=J6H\!\^'IE;U&T MN@S!\JY0594JVVZM6'VOOE7%]O<]7MR=V@<'4H5$[S"GG%-L)=YYGJ:Y&`?. M0)\:;GG+X0'OE3S-0/8&]G9I'JR6TD@.`6>$8X,-LK:>B9?H#/)E#+2R;7AS M&MA9M%'7RW*ME^7G[XOJQR)*V+U^1(<^'I#@B#K/H0`$*;(BN[SN M&Z%%]L*5O6,[QL7^E[A0V^FF6^%M_LJ;GWXL*&6@IXYX2QC"BAG/U<,L#*/\ MC*XM3ES%LC<0QZ#"QS+:A*M-A"=V_:TN$WB4&H>:!2ZMDUPHC[CSB@&J5'UX M&Z-AKBXSHW-H&*KT"&J6*IL.TJ='Z/L#GLF'&P3D/8K*/+>2.$H<\MHV1#=4 MYP:&S2A$9QP#N2^$QPEN?KA=>B@RJHM5<;5L==?XO$40PFJG<+IYBH(2(Z!I M,S<@^;D80STL[K[;\9,`'<6U:5?!;*N'I0?ON(;77:C3JGU(5;.@A`P*SE.N MI;J@Z[\ZM(M1"O MEJOEIKA>WA67[I^+Z]M4(>*/LKS\N;R^/B2H3N@V&(#2'0:"E",?Q;YBKE8' MC+(T-]RF\UEX5U1?R[=%PQ%Q'X.=]F&Y?!%7,!7G['I@MNL@.$B]918H[@2( ML[="-W`[G.WN,:,`KX'X-@B^8S(KCO6)[U@R*':"O`6G]C4-BABHB#``&"L1 MP#+.N9FM];E>YYTC6]^@_.H9VY&9M).SSVR<9_A$-9:VD2H[OHK_!@+K=#A'HLBOURSJ1WE[C"K[6H54LH$8;Z'E1$`- M+=6-)4,]S7WY$&?:4&PGQ2?CX^@5R%_J]WD,@#":`O6&:>X<)E:HVAJU&*+N,"OC]Z-8+ MP@,Z'S^_)HGL?WG!-6Y(SL.7QW&\'%HGO^1._02%,(AZK,9":!G_QV,/MY[@ M#$D-_42E#5O-H56,3Z>.`C&,0.?.J(;20"QY&1DT)/Q3 M2(8IPQ2F$1#",6B19%@9PCVOT?#&G5$AR8%8LC>V=P#XVRNF;0O5OR^^+:[=MI3Z M'@?45SX5K'=)8'(6K3D%C=$8P7K40.HS\&0?>CG+OL#MGQ*[H>SU(WWYD4`% M"X\X4E`A&VUJVP""S!EE%1KX/!@2]CF' MQBF"0)2;UN*XHPR"7$%7S\1IE/O0/*,S9*"5S0F-ZP;VE*%QCE`HE.;1/-=1 M5LIXLJIZI)+*,S!.AEFX-J%QW;`=QXOXH$35]Q\6_RDK<[U8'PN6Z]A3,,I: MK9B1!!/FXP;30M98X'@XOWV?]9'.KW$68`9D?!S_Q\6/XFC0749O05JII+:& M.AWW(T7"/]Y`8&W.*`/V8&SIQLH>5F$,9OX9ES5^3\JC;%,1Q?)F>U8\'AM' M+;B6/03`,6"00H@9D5$.>"!$L_OC*?3;,/`T9I1CH)^EIOW['X30=HJ'];.7 MGPN`497\7ZT$R,?C@6E"FMM1Q')ETPP-OC&8T0?&8T@>?;M>KHHHA"_^OEVN ME]O%.ZR([6D1.'/$&(^<,=I:!*V@C00'--L#9D9NZB,K7/T`/16)TJ_1U#FJ M1AUM&TTD!HRD7%FO-+*:&^OK^2+#S\!B[&W%6S#H%&R?<^EMXYJ)PQL3[QW4 M\/V/C?7Q`QKJI;[U-[9[!KRM742CHZX*N<4;:PPM,Y'70@0:I%/#I4/.DS49R3) MC=>;X;WYJ&P.?^V52+N(C+U:*Z3QBX1;6*6V7]N:B^?(]`IWUVL?E8 M'.)>^TZ"]L0S(!VP'C"H$00*U@@8BG)CMV9XC3`J_P9;@3$XV.(,;B0WL'$E M%$@UXPQVAB-%13UZ!\T961NC\B<3WS'9$9F\+",,%U6Q6!>VV/ULP9G7&P8) M!.4``&:9$)A0#5@S4^!TKNTPH\CU29G4"^H#AE?K]#!>W1TLJGR\<;!<:D*`$HHS M3D0!OT_9?7?=ZO/57E1K+MS:G_K MH(657C%*.4RJ+%4,^V;.T0`Z)W^'`4G5&\*CLLI';7<=3XNDC'9GU?[6@1D` MO77,*J4`]I)QT.PDY'QNLMM97I\-R*K>$!Z558/'W07G2'8 M.*\;6*(AG"M$9GF'->31E`GH&&;+A)78^[=*&/7($8RM4YP#8X#G;E>ITRM+ MS43Y67XU!^\?DN!EE%@_W$6P0G@7CR$&L.408.$$JQ'`QIU1K9U>>'`@P4*/ M,`^VC[>!XUN5MTBOQEVW\1[/[9>]'MB4!S\?/!`8K2E*N4Y*U872S;54)OU3Y8+#&S1#KIM!`21UD/ZKEK M!\\@OJ&GM2^'1W>X_5>NOOU55#]L\77SZ>OU\MNV_:17?6DHG<[3UQL$0(2! M/AK+4D61*:U6%#A#$"&I+-#Q4CO#S,XL;I;)3D@O-&M_NXDC_A`MM!^W/SXO M[K?1SO:V17K?+MT$Z1SRDD#L@3=1O<<:NAH)XO$97?J=2H67U3Z&0WD,XZG5 M\-^M_OI9_F^QJ`[=UW3L*4`(@"8NA5U[@I@S++UP[["(ZL89U)>9DG'90,^) M=/$[B[YHU_052%2;I740\G2*`L^(934>F&3G1)CAI>%$Q,N%>D;4\^5MU1/S MFJX"3`DSN<&:)33 M31`(&&,)<41R*@VUF.@X,Z:0Y1JH7$?/&;KG]<2A$5">C=SZZWM1%8NKS<&< M&1U["I(BACDB)HIN*;U!V,AZ+WGDQ;7^W@5$! MH\PWE"LE%4=08=1HJISF%ON>426;R4C8&^KSX.;GW4K_>W%]6WRZ^EAL7OS] M)(8>ZSQ@*ZE0@&('/`%<1(W$UX@98+-SJLH1)/.*>`E9!9;@X`#QN[>XTC4FOS1B\/AWL(^E]?+ MB_LV[[JO?#I0ZH0%T;QP3GG)'$/:U/.29^7P/=2"_Q)^?"K(8^[A*1]RI]K* MPGNG&%,:>F11JN*J_&XUA.6&'+W.&`B-Y2H>`+L":7YQD4H>UZXYNJRJ\N=R M]2W.+/YEI8*X9-,/'X)%8."3\T])P6Y?T\D0.ONPD(*"+V6:\FV^DUU0`^WJ8$@I^N=C;9?H_/_6V"-"IJ@)0Y0(&( M.'`'>3UF14ANPOL9ON4.S)>^H_;R,6OBP3'Q^^^/)S5=X4U:N:UO%& MP8HX/";C@6Z=P@Q&VYTUHX[*__D\NHY!D#ZQ[D&`K&N*ZML(S5.G],-"Y-=V M@1FCE/;&Q9_:2"0E;\;NM,]U"IGAP^KX@N1DN+.H\FZUW"P7UULK^^KY@/:Q MY$"38`A07EEKH-=J^SY'<3UB&/]V/N^@8Q"D/Z2SN/'I)LVA&SD.M0F**ROB M\%C4G[1Q@`/1@&"IS0U>G.$CYACLZ!'J41Z-RJV"?9$&OZ7O]1E>N# MKT'[6P5@H=7Q&*4."\&`-=8TJK@FQVN_OYWGR)',H/[`SO,6>_+U?KE:K"[B M*?@XOX_EZF)O'$FW#H)P7$%,,4,449(>J6BCIA-[/);F#;T0CB&*A@)^#+GT M$"JW]A&Y/XO:U6V;56)3+2^B]6\6Z^_-K%2ZCHK'\L%T(-E]!H(T-CB*:"ZH MA9!RR%"C\B&<*]/@[WO%/=9:C/D*]A@5O0>UK!P"^YUX-QT?NEJU"\PZP2`E M$D(EI"=<.5F'C#JCCF;1'$8>/&+[S/]A.XO:R<&7U3-/B8RL`;F=!RX9E0H! MRISQB!&M$:M1PY;E*M$S$A`]LV=O1H&1EF`PP?!A4?VWV*2A?2GB^?KL4!KU M83P)T*T$7W]W?]\N[Q;7"<06#^&'&P:CM!;`80>,!EY1;W_>8\D23>HT3ZBXBF]". M1\*7Q3-FI'_=^]QR6K?13+)&&!'9+1WUD7E0BGKVZ3;XM]GAK6E03H9^WB-> M_A#CET;SY<%@2?5"ZG?K?772A_W"('T4B$A93"S#PEJI4Y*]'5I)0&$@L.HE7N#6[$@N-G4+QM+LM?#K@N MX\2JO':^'"V:?JA9T)0!:634`%/.*\Z13*GN=[-D%)Z+"=[C$;F9< M^O;[/Y2KXGZG4/O;U>5^5AQO%"@TG!A$+770.@JTDZX>-1`B.^9H/ISH=_'* M@9`=0Z;\Z\L?Y5U1K=)6^')3KM9E7!V7O`9OJN4ZV6-?-X^B^*BLR>DN&(RC M[;D-T$CI0X"1MMEZAO`SRDCU_^1=ZW/;.)+_C[;P?GQ$X[$WM=E)+IZ]_C4[P-R/,AD%@; M`+]OMO<_&`"-J&L:6@BBHG'`@6$0P($''O`+M=0ZE&O73PAA/>]R'7-X&,WV M6[IKZV'[=)+^.C2HL"Q(;[BQ*8TM$`0!5>X[-0C-*%+9G;!_TE0=<3?+4OK' M7R[^[F^7Z\WK?9NBX2=7-[`52U*8;K1"CG'`N/*>Z9BU5N>G+ M$])4O:%L/#$,DW-V>UMNDU;_LK@K#X/QZ/,%E18H4I)3&_E*-!A4V1C4:9\; M;)A@N4UO2JP+QF;FE&WO-MO%KCQ'39TT22&I,I2+(`T1!(RW7M8\"ESEPF6" MU3;]:*,^N=TQADSJ2?6RGM]NMIN'ZYNZOUXNI)KG+"S7,EBCD/>.(D.""*BB MF7"=Z_M-L%QG:(1USOR!#X<^57?P=G\,5$]=&+``.'@.$#UO4%9X4G$@_E=N M^>F$S*V/>."3*Y_L`.K;Q1U.80\=][">@B* M&!T0.*\PUHS7&X5@=`9M(CX0+,\74/_@?%W>I\WARJA.YBT@?IA,!8@>&+8N M>`16UASG,K>-5GN?5C^#IP8+?W9XGB^BSN!YC"5AL=SN._^=@LM6$Q;! MT/@M$DH9`).8>,*AWBE`Y`)R0K>>3@^.?4AFT%.ODTW-$V8UJR6AN:>ZD_(TQX-E?V*8EP89B&O$`HP`.*88(2(D-34N:X4:YL+MM.[ M:\Q/!7;._3'R^]]X2Q\\P3\HSIEQX!612@@9F%;[>@I!M*:X\:*7?JC]L2KT MG>7O[&*[?5JNKP_909DS%=98[PSBFD+TFD%8(5W%#^\A]]KWDZ,8C^7VVV;< MI/_6T-@,R?)!/_D1+P'OZX,GRG,:9##($1HTET28ZH;F*-?&[:WO2%`(\]"9)D(5&B)O*HOSJ::9'>JF(X%VC5\ M#M;[#B2#WO3$KV6Z'F)S6Z88P9=R>W$3^6IV4>5]>]BKC]\V_U-N=^4?Z;1] ML][_]\UF%>4]CB+QB^TZ]3&KE]JL0@X-*53*+0G&"PX=PPSP[C`FC@V MDK7P=KEM=,+!,85FT9]6FEH(#BE$N5*HHA%4R$UCFN"G?KZ8-_TP=8K?[IC5 MO5U^PL(80G700B$5W7CFM!,ODL`2C[__F_5N>;5U#XF MRN;NX5GRGW__"7('ZH'[>5&!G'$6F)288ZEM_&HH5-STE.7F@'PD9=$:4`K39/97FQB_;K<+*:A5Q#-KK;0:O+`85W1IC7*/-J980-,7 M=+I@[`=P/3X=R5_O^A6%%>"H4#B@^*&9P&CD8,4]+-D,"ISGY53D2NX#X-[< M;A[>[6O>Z?P%4=(Z#H)%JP4(U4[;2E_$WV)&34J&AUJW6,\2V!2CUR,>9'<9 MO$86B$MES<8(X"E;O+;TI34?/WA]TF%V5R\K)!4<0"@4%)71=XH\K;QZ&<3; MJ^T_LCXZ'UB]!;$SI=&;LOFRW5P]7.Z^EH_E^B$:S^7N1.UQ(-G]S;Q-[>L/ M/%YH(S0BQ(;X"U$ID)-UWW$D72-F\U;KEO>7J\W]P_%/M>7(U,L84:4%XLQ+ M`$*,JFE0`$7*_WU&ZP",Z$=I01!CR3'#)]\QBCJ2D MVW%VU)08^`SK]=5_/RQ6R]^?]I>"7"9S['NA-YSVGC1/80E1WB+J(%T!J2T1 M2E:\H('/I:'DV5#8#,?D(9S&U_6O5IM_+]:794I(^QIEN7U\;N':<.3:;H+" M-;99GAD*@4(0*R0PA.C M.:*LHCI=TS!'L'4#@Y-0EL7M02)AU6K#9OO;=G%5?BTOR^7C/@S0W)2R<7`A MC,;(6^>%QJD:(#I,KF:GUS-J*=@M`-[&I[KF=%8!\M?RVV)7WMOHB%['OU[^ M;Z(PJ>F]OC[>0JG-V((9*R&0Z%IC`4FM@ZT_/HOPC$XM>T%+7XP>6A&E6K_[ MK^7N8;L^30G]/+#@CCOC%$$!2ZTXC936UFJ*G,SG-',P!70VES/[NMTMGOZ^ MW+U<+?<"\Z:^;8?'1(6);,#1>[$.#.("0@BUPK0D-ZPRP!E?B+0I6!L$DMH38"`!:KH)8D/A[Z[<+C=7%[O%=MB4A=(!&^9` M,1D].!V<>@WE&"IS8V83=&,GHNRZ%,?X"K`K,TY*8KU2*'ILS'FC=.H'\$*W M@FPS[N3>>\]FG%_WTZ1T>LHOC_\#9K-DI93VF\P2E%3&<$NX=28:O)2!JS)_ MJ!"-+^XY]G8H.B,V0J)N8J8$Y(&3"3&!!%?T2J%G4N[];-%_7Y; M_QY9W=LGN"\^BKQXV,:E?EHNOBU7R]W3*#G=/RQEK[16R2\RE[OEXW.U<'.2 M=^LY"N,HLI3IJ%T5%H$S8FS5^"G0YHM^1^)!NV31`>6QA\D%9\1 M7G/&FQEDK/6(EO=J^_H5P,"J8=UW(`4I21^7[]AV+&F*Q`S".>>H)KOB@3)B!4=`C-@Z6=G3- M]\%*QJLU?XFN1$,.Z[O/%X@S(T5*/*($@J0J!%K119F84=N*7J1];(?)Y/$H MV&E,23TPH@!$HLEL+=)!>(U,NC*CHDW"=Y=O?7C\G"G;)J1D\3,K"OJW:!TL M5JL?5G`\&>?PB'1YBD.$&3`4/,07&2VK]0(VC?U"/[#\3Y78I@^.9B'@8I7IZ`@6-C"B$`@R4N4`@".QV!CZHU>VQG<`57+RCHD*=#[!H7#]_NR_][ MB%SRC_%'B[J9`R,**3PE+$@4L`X$L`99TP82)E"*NC&RZ/A*!&R^/@ MF"+Y_D$##RY^<2P@I+&OZ+->SZBJ_6P)-R,FBZKI>W#[>-TO_AN4+%E7/)I,+"$<*-(+SZ"IS":$Y1UASIOPAD M)0/[#4<:?=J#8PKB@L8<4L-9PJR5!M=\5Z MT>J6BX-C4H\=H2&H:,4AZ8QV2)O:/-39':XFI'C1=<37KR,_[7V[O M%LOMONCA^&'?^T\7PD"TZ'`TX`617F"*4:T0C64SZKO0G?2[X^?(;M*G%IT5 MV@PO'-92,Q5W4V*HX(%87>M(YE%NRM')]2:S=YAR69ZE8#Z5B_LRJ;9#.J5^ MH*"!XB"Y\,QK&VUYK[2-JU%&>"V0#?.Q5;L5SJ8#;N;+]OT,9'-YN7U8K*HN M55\CJH\"H/4LA?%2,HH"<<"8HTG/LCU=DB`NLD_L)FB?]HR2OE@^^'[TH][T M?]R5ER]_/SW%_.T,A5%(Q5V8^-06%QFF.$GA!F5=`$IE;KAW@I9M+W#KE]W# MFS[['GSM39WGQPM"#676`Y(8/"CF@]OK8A&M.2]T;BGM!`WDX4"4Q]L.\R)/ MRX@L@"(5206C&1-,:.P1?UYGD"!Q;EQE@N9M?_M6)ZP=0FE4/03"9MN$F:8A M!1?"FWW>EF)*"!'A+IZI<]B"R/6NQ9\$.!WS=[!P[J^;]>7B_B;MCNO[8V5B M[SQ=`*+.HX"4Q#9UN[9(R!>:7/R9F\0D3\7,8[G]MOG(J#F?N8/;*"^TM[51 M7AXO$$I%O:<8^.M4M';)M62U\&C_'KQ9VX+B+ MM!.#:0C<&*T3_5*EGDZ2SKE:_%2)M:P6/HVCH+$31?E;KD^C+6"10X97="K-9Y2@VS6$ MAN/ZA\EFD`Y3`@KB;RDMX8'3BBKL7*ZW-O5LAK[VL#RV?A2SAQA0'&O0@KO` M-7CG0T55\-E)G1/M(C^HT7,::P<^5"QF29]>F177&;$4Z&=>$4B21U5*ZE(=<\049,M>* MU6ZPTNZ,J4/^#]*QJ5W,*A^/AV8JI(2`F9&&D*"4%]+%K1419:G%`=G<;I13 M=Z"&Q&)'O.]METIW_'S^_;^6CU^VFUTRSG]9WRR_+:.%JO=T\5N6RYN M3]RP#B6,GO:RGS)(VPV/G[@R:A_498H"U@:IEZLPXN<>;8)3MY[SJ&EWZ\&9 M,Q;"`Q?"",2QDIYPP`Y5-`N+9Y"ZT`\$-F.P?^RO.>\>A'$_:HT(M@R0E-$; M)-Y';F/DM3:<>%#-_85:4A-7<5F65_?[>,5^:2_+^+J\OGGWZL0VPPH?D(,@ M-%&`N148:4ZKU2N>7>GP43_/UL+<],;CK)BE>^'UR^U++^__\K"]O(G$FNMM MN;\L[1!*6@XO+%8>4.`4>P'"@)/:14H,\P@IF=TE?$)V6?]HZ8?7_6GN7=Q& M(*XLVHFW*9]Z/_Y-EON@X8+7;2ZY4*]K^MZ&`M9F3`&-HX'&O#EKJHI(2@N*N)`:P!KGXQ_N^2)2#A:,:CP[ M[#N:](JY[XDSVVWJ7[DG!9Y^PJ5)\?CV.?5GOJ/0VD87+3IH&EGK@D/*LXJ' M%.:4<3\4V`Z&I885U1"!TU_647F5%U'Z^_5_2NA()!U/U3\RJK#I8C1G!`4? MM`&O!><5C9C.Z?K($7"QZ4L.(V*M,;7_Z+@BNC((&VDTYR'^P1E6JJ)3Q.]] M/GCK1-KM$)3%VX'R!LKXGANSOG+1*UUM[M*R7RRLYH;[S:,+1)@'9Q7QA!*J MM&6"5#1+G]V5Y>/@Z539_YQ/T#&/\QIKE*OXT/5?RW6Y7:SB8LS5[7*]3*;` M;OE8-B'FY#D*BP--;8N"(91*PT1T2&I^*9);J#:A@%,_N.F;TT-HI>>MO/ER MLA^>*P!320F2UCCLO10!V5IG.Y+=?6."B!G?4CJ'\X,D,&3SY96R]56J^OIU M<=OBAK,>7E=X114A`,P*[X`KI;FIN&JXS;V68(([9R::WOJ5XPMA"&C7O>`J1ZDLM9R-J_ MO#K:3/2U0]6!885FGA%L""@.<>E6IGKK:D^P-!=1$RR*F1ZBNI'))*R^0ZS[ MU**L_?S)"Q2XCQ:-Y0A;0$(KZ:#FV*SN7AC?0QE<7'EAE?=7N5I5P\KS(:#*\2T-S8\MV$Q0> ML&=.">N5)1*"8:*F7)!LNW!"(.P)"6^C+WVP>U#?M=P^+B_+)D:EPH7+S?5Z M^9_XI>ZK`O=GTG9QM]PM5NE?S6UJ?=_&\^WVC07E)$3;F0JO)<6"*1O516U1 MT=S@3'L71S]#>5U>)R#\]L$1/0TQC6>CGFQW%H+]?WM7UMS&C83_48+[J-H7 M-!IXRCI;*;NV]@FER(R653:94*(W/W\!2AS)DJ@1,<.YRD^6I1D,NOMK=`/H MPPK/(X#BC!/I@A;Q2!E!K#7H9_N2ESRX&09[O3!X.JOGS\)_"L M\]A)<@_E;($JBUX>%*TYMHT*%M1M>00/]WW0HLW3X57F.CJ$RKTXD20M(HG!$..DEII#I*-F%8Q38G^J:0719%=86^.]0!2`G'--HB>&H])"MY:1^I%6L$I" MR1@%"B$U(=0HP3T_\M"9^".MX&RP72RMX#Q1C7=H[*ZONI[Q$ M[9[<^I:[NDQJ^'NUNU[?KOZURVO\;X4'+6%U%_A:RNM[<$P[PBF+#@`=)XU4 MLS58#OQ'P.&[#C2&E-_$=>(EC941?IV^EK"D$GB916Q%%G0(SC<\-4HNJ1?' MF(CL3SMZDF1=8,V+;Y>B$[C]\N5J=VN)_KA]^#F+A[0$VYP_5.+49)Y&]%$K M;2G)5AF/%()84EK0J/C8#BJF_H&8IT*;>?%N2#PQ5L(`$H&Q`"08)T3>]39F MD=BX^.C"J4&Q'SGUCT7^=%ZB&Q9/C)4X2D>8U5&%3&/6.J_4H[[Q6K=VBA%= ML\!B/W+J'XOBZ;QD-RR>&"NA(%9IHKE#QIEBDEM[I+%T::_$X@2+?<\#B_W( MJ7\LRJ?S4MVP>&*L)"BW&O*FU0>#7H7,T,8/<:AJ;?0$6ZC/`XO]R*E_+"KR M$Z%W6YW_Z0+#E\,D`IESF8N`2ME@I?``1\JL9;6QUA/LQ3X/!'864?_@T_=3 M,H]3.GD,5#]8H@J]`T=55"6"7:@2Q'Y<[AFIW3F?W>#]!Q![%53_<#0/$S,_ M4=,!B"^'26C!:%0B,".(%DX$T>S$6!2UF?$3;!@_#PAV%M&/9*K;Y+G-GC-0 M;4`HXVT$TZBKCM7KZA2/@29ZHW1!<Q.I]\BL9C(7K238*STY,/^[(S^?6/7_=WMW=7F\_KS\].>WH0YF"+]WA/E+RG^]ZHT MYUA]=M]6NZN;U6^KL@$[-$_?'"(0]U=?/JYV7UF;HHT_PR2L!&*Y)@RM#>"X MY8T_SPW6[H%F<^4SG"+.3MC+4]3O7H'5S7I3V`17>;CKU5N9*U.:9F+4H41B M'7`3'09TV-Q$>Z5K$\=G*S]50?_E+.F4;R5%_.(`FG46BF;2!0 M8D1Y#/[(>^2T-DM^-K>`\_54.PMS=@;P)<5OK3.#&;PSIY7W$Z5ML4&JG6;` MP3+?[">,U;5MY&=SWSD_`W=9"8^3QSEB4_O)9G%Z$"2Z[(UH[4R6F^0/=66C M,WEK,7869S\U@,YK2M[S-U.0,3I+'!&2@@)AHY!''E-'%W3_,A083V9YCBNZ MNFJ/S>0_;7;-;%Z?^7$=:VW0W6',%*F36E/T8`^584N#Z"/-,H8%M4P8&*Y# MBV809[^\)?M2'T\L"&4QF(C@5536H(M'CGL7:D]F)GBK,?K:/1$9 M7LXUW?]^N_IKGU\,WPKKQNQ5^GPN[W`T3[V2M"S-'@GS0EHGG-7<"N94I!)T M$**U*,\@%+;6]'CE\62%]YX`L3';?QF)+U=A#Y1)K$XJG*#CUEVXS]6Z.S^' M,%^'Q@C[Z[O];KVY*4M)2Q6,5Y]/F*FQG-F\6Z>2:\XMXT>Z4-!:CVGZ.#E3 MK"^[V'5FYB@@:2T,<>*-1%%1H3D$BYHRH27W#6W.@(A>>6D1DQSEKJQ94-*&SU+:7X>D@:\8[ M2BH]EBU!%R*QEE+I,OQ`>*[Q?OY>Y;\MJ*YAOP:DDH&#`:"]6>[C4PF,RML4 MR8!P4$R0$%1#0T9W;7+B%!>&\^7VFN2K^#:$[/^YWJR_[K^V2O^[YU))=;3& MR,P&"0HQ;UG)D0Y`NJ#=1I7TMOWQ;A`,7/W]/@P\?2XAV!`T!D:-0A,A6F*. M=-A`]'(,02\8Z,"[00Y'GQF[]N;%)]Y(P8&'&(WS1-((A(D8CK0YRY<47-VG M@]`/.T>"2GOYP5/O)&<"C<1)P;F3)#H$J9OED-D%[3$Z2[@=,54\'0$SK:;F MU>>3!J?1*\*RQ?1(P7!!&[K4<,U^1\'*N;)]&RU5'!T!*;^\)QG[Q"M)<*4( MA$P26`\297"N<=DCU!YV3C&]X(*FJ):?@Y]WNLWG)S>`Y4;Z^N'G]YY_GAXA M"1O0<>LHBT)[Q46@C:;D/:%?[-I3(?ZWCD1[8W&/1Z3G'8XF;8+B5@*CT1/. M+?>RV0,P5IVD/L&=3V]0Z(^=@]UY?]C>C12`V>>-=SFY!B:LR&P-(#E18$A` M*0+CV8L8*VCRV73?%4%SZIT$,AJO:5DNO/-```1`!P` M=G)T>"TR,#$S,#DS,"YX+^^DV@;A)50)%4J]3D0[Z>AZG/ M`D)'7_:^/W9.'\^OKO;^]NN__]LO_]'I_//LX=J[8'XTP51ZYQPCB0/OF7)(0R$2GDY3VXD\O(O@L_#&>(`])R]L933SP<'S\_/^S,N7_9]-CGH=WN' MW9-#D`6DH^(SL/6C5/)EP,-]QD=0LGMXH'X>(('3XI11&DW,!('D!W(^Q0=0 MJ`.E,"=^1F#W7I MWLG)R8'^-2LJ`E-!@.T=_//F^E$;>0]L[GG:ZF0R95QZ=,E:0R0&FC02G1%" M4RUOI]OK'/;VO+BM7#,?2=THBS(;"0]P*$7Z32>'V@<>]KR#AOQP%F*Q(88T MUMH0OF:@R@>3Q2/O0_K\*BA*1ZIL.W.4Y%J MLXPT4$Q*L3X#YA#NPD>1\C8FW"0[J[&R!A_F;L31BU("5?-QPSH%]O=';';@ MLXA*/G>.;2:Z](^5@EH9->(%(N+KKKC7A).<*O[8R0%6Y$,0OS$7 M*8WZL`$.Y)0W9R$ETI_JF$"4,JF1]'?IM],IH4.6?`5?JC[\<]J1/^"AI_/5 MSTDO6I_5'DPYFV(N"217A2&`!AAS//RRI]+Q3IJ*_\M'X3[DP6F1I0K**8;N MKX#$CT(MQG7.9(J@XO>7/0'Z#G$J_!\N58"'3:4"$D))FX4*T:"I4$""P[;* M,^6XJ3Q`(F`$J MOF9"7&")2"CV/$7\_>'*/+#5O#5$S)A+VA!D]7X97J\.)*O+^H:O[J_26IZ:^_'"SB+U8=">"9_JH_+ZHXH4Z*U%$N MQ`5WPK+KF>F2;U,;;L"TMTSB31HVQJLU:Z_[J=?MKFE67<_.J&8C/*%!N%&K M)H"U9CWL?CKL]M8T:US1UMGU#`DB[H;W!4%.:0"Z4^,?0D?W+"0^<3.I,Y;% M27L&)]78'AMZ170/T<#+\;VT@IT1S8IOT)LVA;1TISU#=]K(I-O;G;I:XC4\ MUC'NSEZ+FKY''$0<8TF`Y\T8KPQIL^2Q=KS&EH1LHUC-SA.5CC(M0F)XCL3X M,F3/JWND&#I&G:67-2]>5IE,W:MP+98N;^JE:NG;W9F M7S#-W11SS>9F+%V`LQBWMZ)Q\QIVMEQ0_N,8.JLQ"P/,Q=>?$9%S&*O?,FC_ M5`(2((ZNJ,2@"+D18S>IS](:CE9L#446_M.+F=!3!V4VO)2/+6PS:OH$4]<) MGS)!_=Q`WS3_6@+8:G67_F@T'V`#J9\0Z/>.3,/,`L["7UL\(T!G:AT<1MF/ MF!+&'R,8B0>$JDCCO.SH@%+O1[U#LQ^EJ%X,ZQ5Q/0V\,]BBJIOYF2-8O;_U M#LW^9C??]GI>>HH#$H:O$(KD_(H.&9]HQEQL5TM?9ZYNEGEF!TD*'U7F$.-Y M!05H7:&:+:R4$MO657X M8%A5J##+]H8QHX+=EQ/JR"U+"1\,2PF5YMG2=81O$>((!GYNQBB4M@Q[^H:( ME5-OFY;C^;4G].*FYF)Q2UILVH.7S.9I^BW6=(-.P$!ER6<_&?+9HMZW-]Y? M`?=TI)+Z4R&P%)!^?F,L>":ATZI6';G%%TPQ)X?S8CR=OZ:(.]MDRFWD+584 MB_?TC=Y39ZEM]J<9","XX^1DL;C%7[I&?\G(MUC1A8_JR'P0A?AN6/BRD;,T M1K4X3]D50+W[1I.;=(`6AG@E7<9"47 M6>K7C0;9>4=!&7DF=8ZF1*+P&B.!"P7<>_DUT"WI@&E3L]FTQ7PMJ=+3=98; MP):F#S>(_X"FKUPFGN`7[\2 M2S]P;.@'-M4RMK3CN.81EC<8J>C`P8J2Y@WK6\F*%X*\U_*F#L# M-`C&U<26&-LWQ%BC.;8W9"[KUCT25M):`ES?$.`JS+*E\>H!"\E!'9#PT]$U M00,2$CEWL4D%I66F^<00MTI(7@:U,X720H/H50]@F7$^,42P"L-L;PRKU;#3 MG(H%P6ZDI5D5FY&V<%[%K&3W[J:6WC*]?V+HAG#]*CM'$Q52N4)9NR72H0D&KI9>_7_WFI>A>!N\E^%Y< MP3NY1,O_'&>@F4!=#8"HT2U]?U$?L9,E: M`(LGFN8O-6!'W8D<>$5(+\'<6:B@X"8NYX)C<333[*+-7CO?JM.X4Q[I!F2W MW5(ZZ6R[+LID_S+\9;YTX1^3S]0XWS;?8&,J.L^U0,:,0," M#">)C!2[WSB+IE_V]!.*GXG$,&",'\J(OP$(=:,2?*^4L.?%WTXQ)RQXTN6" MB";G7#3!B% MR,_GB^(,XLLTO^SY'`=$KB5E!$'M`?LA$D(_Q@K,3QS;7T$'ZZ&T3T/5;5H= M,[R:3!'A^A*`A29=]6L+6O19)`C%$#/]GQ$1NFT=(!'JSC"L6]VN(RDM#_WT`'.HG`FMJ311!A0A_)RQPC MGK7]YF1OTMCCQUEEL[8.LDG3_O7%SMJA7/LZ)W5E[2D-;D"G\WA/XV5$@P5_ MMA5J@5LK%M5_ZH[&&0I5BU,O25BJ5Q&2[J2 MCLPX[ZBOJ'C!X73$L?YPH>-=IAOGXFT(L17,JOV,F/L$A3,XT17L]E"MS?,PG_7\-Y&F*]/S>ZAJ&SD%]?IB1&N=?( MWRF(*-29T_C*4_")D!12U@V!K:ZN5.C7:T77Q%<+%9<8S$R".WH*7P83!^>I M(WR'T62QM3]@'T.)P*:&&KIWJ(5;)L&L<7N&O"IMS'HR+LLG3H0C#=!^%3QS"AK4_VE`=;78J)Q$O(OS$GK`_UG+!4#",.-Z(\JJ0WXO*'C"D M^=#"RP+J)G%)N"BD>BKQ;Z*RQLA_`I7%DRV0`9Y.IYS!Z.E_2Y-NKP3^OA5W M@>8;T%""TF95/&`!!O/'A0103G,3`X&C^-"0_N$9?S&T2C(4IV8(,2GAG_X:HS5[!WJ*]D M33-/GVTZ,1&T3^[&LUG6^+I>Z'RUM8XJ;L_F>?+Z0NS2+9=W$S:0GP,R42N_ M<;^P4;'-8J9>:92I\&/[6F5!'NB:5#'HH2'JSHA2'PH?<(`G4[WTRL"Y_$A) M],21ZL94[_T[D>/SD`GUC#@'![RB7U]\&.7K==D9Y@I%_U`%FZOLS>IO1_IA M$?]JF,RXH5&MD,FQ>[7M4JE)9URG,L1(R'XWU1BAAUVS/IW-\8'M MI:[#P^,DIEQ$N-_M'2_LCU@#X.T6]M;0QRD-\D2"\6N&U/9:K%@1[DJQH+0Q M@9RB^0W$N]A7'_!`K28LMH7:,JTT-Y\J"V!UE7#AZKH(ZVFB.XK5Q%`RK+N$ M:*WGB1:E7@OC76DE[K\2D5S58"9JH]QS8,&_)`,._;"X9!$--,K3&',TQ<"; M+]2NU430(!L)+6AB;9@6ZD99%9(1O=,3@I?Z,\]*]&FA5'RGDLZ#QO%<98S1 M`+_>H+'(\`,8!'(LZ+VG*(QW-7\7.+BBY_DI#).@CG0M'FHJ::YT?I;LODA[ ML-QX#QI&7]XEBDIH1K9&WZ8A-F'P(88\,TCF`)+3W/<1!UL*G+EC+J)K\=8E MK=7N7//*Y^+F7L>R[AWN[TGEOQQV.UV%P1> MC?:]:>&P*,E1,RU4T[XW+1P5)3ENIH5JVO>FA>.B)!^:::&:]KUIX4-WO]N3 M["/\TT0!1K+W)OO'6(A/N1#E/=>K$K\W/7Q*1/FTW_O40`-&LO7^0-9\PK#7DE1*32>[U&DZW(+.;? MUE+MR[S_@:@0F)97D@ABKZH'VC"'-G2&AXSC[''S;&U;K5G5G?3/SA1`P722+#F#DVFI!8RT]Q10 MQO?BSB73#^V;2J[TG1LB@3TBQN0)433`+FE!0YH6]*;F-ISUF.K2C#MZ%NOX M<8QQ%CI6(7S5GLHI@J?\U1Q@59N*_#&!-JO^A**82U"U.J,@KM5V8J&W(G&. M?:GW)$W56EFFEE>LH`4=?2J>7@V^FV'^^YCXX^KMZ;\#SV?X!@5X44$K(;2Q MC[V;ZD.^D+RHB[UH`#'_7(>B<\3Y?!C?I[C_SB^%\C5>UJNM1MJ^?B_319+^"36E$M]1G60?#V0TSI,@>['6I2B5 M+KOPW,IB5ES]\]LGQ0N\Y9<^+NWI""QN9 M',NV<"H&X@0;T?CVG>4]_HN-TKET^^;5U.9B/%%,F9/&)8NZ%F]!_ER:OE!9 M#)_A1RQEB`-]G@")L3ZE/I4Z<$8#M5T=YZ*N2-V^_J32^LZ/8<0J<2_^]L'8 M]4F'ZB"]%D([@W?Q&?EF-[0M[4C>#%3[`N+JO#M&!H\1I*@EK%W3`Y MK('"?*>?*)X6?,T*VG2\L"!GU>UE/GQ!Y/P62STB=9CEU"UH.9S](56U/N[9 M+HFKC72-B%L=VZR25$4S9\(6Q*\&@C]&DPED7G=#;;T'K*^8?F+Z/O$"3;+? M?`7G6KV"-W4I@PKK1SLV_32D;IOPZD[-5`"]`;WR+95J%:R$T39%J#6R>,,V M#?XG0B$9SM7M-WX\MK>U@H;4+>U5L.X+OV&*.0I55A),""6JM&K2B1'+`^B& M-"V<&C&WV-,0=&S<[-^@?`M&C3\CX/:2,77>/9D@#V#\!TCJ9>)$(DNA%JP% M/:KVA$?$+\UB9`)4_?I^IHG-(BSX6GV9%OJ66FPJ+C,MY:)U!=J7;]:,Q949WA31@7C6)UIPGS*B<"BR7G7C:&U8.HU[]\ASC_K MO:9JZTP\BRJR?3>IZ.[%6Q>A'$76.PCBA61QQ]/M!N?EZRS6@WA'\\Z_O?3[ M??VP3=D%#-__@8TY?I),0)(Z0?#G_P-02P$"'@,4````"`#8@F=#^4`6N_)N M`0!W?!8`$0`8```````!````I($`````=G)T>"TR,#$S,#DS,"YX;6Q55`4` M`Z@$?%)U>`L``00E#@``!#D!``!02P$"'@,4````"`#8@F=#V[/>5Q<6```# M.@$`%0`8```````!````I($];P$`=G)T>"TR,#$S,#DS,%]C86PN>&UL550% M``.H!'Q2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`V()G0VBIAW9W0@`` M;@X#`!4`&````````0```*2!HX4!`'9R='@M,C`Q,S`Y,S!?9&5F+GAM;%54 M!0`#J`1\4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`-B"9T.F40)5,`L``00E#@``!#D!``!02P$"'@,4````"`#8@F=#G[*_/9-P M``!A:@4`%0`8```````!````I('IDP(`=G)T>"TR,#$S,#DS,%]P&UL M550%``.H!'Q2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`V()G0]G]>`'' M$P``\MX``!$`&````````0```*2!RP0#`'9R='@M,C`Q,S`Y,S`N>'-D550% K``.H!'Q2=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``-T8`P`````` ` end XML 52 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Arrangements (Tables)
 3 Months Ended
Sep. 30, 2013
Collaborative Arrangements  
Collaborator revenues
During the three and nine months ended September 30, 2013 and 2012, the Company recognized the following revenues attributable to the CFFT collaboration:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Collaborative revenues attributable to the CFFT collaboration
$
3,515

 
$
4,315

 
$
11,318

 
$
12,772

During the three and nine months ended September 30, 2013 and 2012, the Company recognized the following revenues attributable to the Janssen collaboration:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Royalty revenues (INCIVO)
$
20,994

 
$
19,957

 
$
104,108

 
$
80,811

Collaborative revenues:
 
 
 
 
 
 
 
Amortized portion of up-front payment
$
3,107

 
$
3,107

 
$
9,321

 
$
9,321

Net reimbursement (payment) for telaprevir development costs
1,413

 
(503
)
 
1,422

 
(2,569
)
Reimbursement for manufacturing services
—

 
—

 
10,299

 
4,449

        Total collaborative revenues attributable to the Janssen collaboration
$
4,520

 
$
2,604

 
$
21,042

 
$
11,201

Total revenues attributable to the Janssen collaboration
$
25,514

 
$
22,561

 
$
125,150

 
$
92,012
Summary of activity related to net loss (income) attributable to noncontrolling interest (Alios)
A summary of net loss (income) attributable to noncontrolling interest (Alios) for the three and nine months ended September 30, 2013 and 2012 is as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Loss before provision for (benefit from) income taxes
$
9,056

 
$
5,090

 
$
21,177

 
$
14,581

Decrease (increase) in fair value of contingent milestone and royalty payments
(1,220
)
 
(57,560
)
 
1,600

 
(112,760
)
Provision for (benefit from) income taxes
(3,306
)
 
21,394

 
(9,089
)
 
40,354

Net loss (income) attributable to noncontrolling interest (Alios)
$
4,530

 
$
(31,076
)
 
$
13,688

 
$
(57,825
)
Summary of Alios' items included in the Company's consolidated balance sheets
The following table summarizes items related to Alios included in the Company’s condensed consolidated balance sheets:
 
As of
September 30, 2013
 
As of
December 31, 2012
 
(in thousands)
Restricted cash and cash equivalents (Alios)
$
51,059

 
$
69,983

Prepaid expenses and other current assets
8,821

 
672

Property and equipment, net
1,374

 
1,728

Intangible assets
250,600

 
250,600

Goodwill
4,890

 
4,890

Other assets
153

 
861

Accounts payable
1,251

 
1,054

Accrued expenses
6,689

 
6,099

Deferred tax liability
150,203

 
152,781

Other liabilities, excluding current portion
873

 
1,625

Redeemable noncontrolling interest (Alios)
39,624

 
38,530

Noncontrolling interest (Alios)
182,168

 
196,672

XML 53 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Legal Proceedings
 3 Months Ended
Sep. 30, 2013
Legal Proceedings [Abstract]  
Legal Proceedings
Legal Proceedings
On September 6, 2012, a purported shareholder class action, City of Bristol Pension Fund v. Vertex Pharmaceuticals Incorporated, et al., was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleges that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through June 28, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. By order dated December 12, 2012, the court appointed the City of Bristol lead plaintiff and appointed the City of Bristol's attorneys lead counsel. The plaintiffs filed an amended complaint on February 11, 2013. The Company filed a motion to dismiss the complaint on April 12, 2013. On May 28, 2013, the plaintiffs filed an opposition to the Company's motion to dismiss the complaint. On June 27, 2013, the Company filed a reply in further support of the Company's motion to dismiss the plaintiffs' complaint. The court has scheduled a hearing on the Company's motion to dismiss for November 25, 2013. The plaintiffs seek unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney's fees, as well as disgorgement of the proceeds from certain individual defendants' sales of the Company's common stock. The Company believes that this action is without merit and intends to defend it vigorously. As of September 30, 2013, the Company has not recorded any reserves for this purported class action.
XML 54 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
Marketable Securities (Details 2) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Cash and Cash Equivalents [Abstract]    
Cash equivalents (Alios) $ 51,059 [1] $ 69,983 [1]
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 55 R54.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes (Details) (USD $)
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Sep. 30, 2013
Total Vertex Shareholders' Equity
Sep. 30, 2013
Total Vertex Shareholders' Equity
Sep. 30, 2013
Noncontrolling Interest (Alios)
Sep. 30, 2012
Noncontrolling Interest (Alios)
Sep. 30, 2013
Noncontrolling Interest (Alios)
Sep. 30, 2012
Noncontrolling Interest (Alios)
Sep. 30, 2013
Alios Bio Pharma Inc
Jun. 30, 2012
Alios Bio Pharma Inc
Sep. 30, 2013
Alios Bio Pharma Inc
Sep. 30, 2012
Alios Bio Pharma Inc
Dec. 31, 2012
Alios Bio Pharma Inc
Tax Carryforwards                                
Provision for (benefit from) income taxes $ (751,000) $ 21,355,000 $ (132,863,000) $ 41,450,000   $ 2,600,000 $ (123,800,000) $ (3,300,000)   $ (9,100,000)   $ (3,306,000) $ 21,394,000 $ (9,089,000) $ 40,354,000  
Current State and Local Tax Expense (Benefit)   0   1,100,000         21,400,000   40,400,000          
Intangible asset impairment charge 0 0 412,900,000 0                        
Deferred federal income tax expense (benefit)     127,600,000                          
Deferred tax liability 150,203,000 [1]   150,203,000 [1]   280,367,000 [1]             150,203,000   150,203,000   152,781,000
Federal income tax net operating loss carryfowards         2,600,000,000                      
Income taxes payable                       0   0    
Federal income tax credit carryforwards         98,000,000                      
State income tax net operating loss carryforwards         1,500,000,000                      
State income tax credit credit carryforwards         $ 60,300,000                      
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 56 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Product Revenues, Net (Details) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Sep. 30, 2013
Product Revenue Allowance and Reserve [Roll Forward]  
Product revenue allowance and reserve, beginning balance $ 75,393
Provision related to current period sales 193,701
Adjustments related to prior period sales 15,678
Credits/payments made (196,285)
Product revenue allowance and reserve, ending balance 88,487
Trade Allowances [Member]
  
Product Revenue Allowance and Reserve [Roll Forward]  
Product revenue allowance and reserve, beginning balance 5,416
Provision related to current period sales 26,584
Adjustments related to prior period sales 348
Credits/payments made (29,960)
Product revenue allowance and reserve, ending balance 2,388
Rebates Chargebacks and Discounts [Member]
  
Product Revenue Allowance and Reserve [Roll Forward]  
Product revenue allowance and reserve, beginning balance 63,560
Provision related to current period sales 155,269
Adjustments related to prior period sales 4,433
Credits/payments made (153,035)
Product revenue allowance and reserve, ending balance 70,227
Product Returns [Member]
  
Product Revenue Allowance and Reserve [Roll Forward]  
Product revenue allowance and reserve, beginning balance 2,852
Provision related to current period sales 3,687
Adjustments related to prior period sales 11,125
Credits/payments made (3,649)
Product revenue allowance and reserve, ending balance 14,015
Other Incentives [Member]
  
Product Revenue Allowance and Reserve [Roll Forward]  
Product revenue allowance and reserve, beginning balance 3,565
Provision related to current period sales 8,161
Adjustments related to prior period sales (228)
Credits/payments made (9,641)
Product revenue allowance and reserve, ending balance $ 1,857
XML 57 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
Long-term Obligations Schedule of Capital Lease Obligations (Tables)
 3 Months Ended
Sep. 30, 2013
Captital Lease Obligations [Abstract]  
Schedule of Future Minimum Lease Payments for Capital Lease
Year
 
(in thousands)
2013
 
$
1,883

2014
 
18,077

2015
 
15,608

2016
 
8,924

2017
 
8,481

2018
 
7,877

    2019
 
409

Total payments
 
61,259

Less: amount representing interest
 
(7,449
)
Present value of payments
 
$
53,810
XML 58 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-based Compensation Expense (Tables)
 3 Months Ended
Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based compensation expense by line item
The effect of stock-based compensation expense during the three and nine months ended September 30, 2013 and 2012 was as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
19,010

 
$
18,869

 
$
68,633

 
$
59,774

Restricted stock and restricted stock units
10,998

 
7,104

 
30,108

 
21,643

ESPP share issuances
1,504

 
1,948

 
6,077

 
6,120

Less stock-based compensation expense capitalized to inventories
(204
)
 
(339
)
 
(885
)
 
(888
)
Total stock-based compensation expense included in costs and expenses
$
31,308

 
$
27,582

 
$
103,933

 
$
86,649

 
 
 
 
 
 
 
 
Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
19,223

 
$
17,444

 
$
64,312

 
$
54,425

Sales, general and administrative expenses
12,085

 
10,138

 
39,621

 
32,224

Total stock-based compensation expense included in costs and expenses
$
31,308

 
$
27,582

 
$
103,933

 
$
86,649
Unrecognized stock-based compensation expense, net of estimated forfeitures
The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of September 30, 2013
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
184,969

 
2.74
Restricted stock and restricted stock units
103,454

 
2.61
ESPP share issuances
830

 
0.31
Stock options outstanding and exercisable
The following table summarizes information about stock options outstanding and exercisable at September 30, 2013:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
Weighted-average
Remaining
Contractual Life
Weighted-average
Exercise Price
 
Number
Exercisable
Weighted-average
Exercise Price
 
 
(in thousands)
(in years)
(per share)
 
(in thousands)
(per share)
$ 9.07–$20.00
 
462
2.64
$15.27
 
462
$15.27
$20.01–$30.00
 
1,076
5.98
$29.37
 
801
$29.19
$30.01–$40.00
 
7,253
5.59
$36.58
 
4,525
$35.93
$40.01–$50.00
 
4,552
9.10
$46.33
 
570
$46.73
$50.01–$60.00
 
1,840
7.61
$53.72
 
805
$54.49
$60.01–$70.00
 
44
8.64
$63.23
 
11
$63.19
$70.01-$80.00
 
85
9.67
$77.73
 
4
$77.73
$80.01-$88.18
 
1,495
9.81
$83.13
 
166
$81.54
Total
 
16,807
7.09
$44.47
 
7,344
$37.87
XML 59 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Marketable Securities
 3 Months Ended
Sep. 30, 2013
Cash and Cash Equivalents [Abstract]  
Marketable Securities
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of September 30, 2013
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
580,286

 
$
—

 
$
—

 
$
580,286

Government-sponsored enterprise securities
2,895

 
—

 
—

 
2,895

Total cash and cash equivalents
$
583,181

 
$
—

 
$
—

 
$
583,181

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
—

 
$
—

 
$
—

 
$
—

Government-sponsored enterprise securities (due within 1 year)
555,502

 
35

 
(10
)
 
555,527

Commercial paper (due within 1 year)
125,073

 
191

 
—

 
125,264

Corporate debt securities (due within 1 year)
148,672

 
21

 
(38
)
 
148,655

Corporate debt securities (due after 1 year through 5 years)
10,019

 
5

 
(1
)
 
10,023

Total marketable securities
$
839,266

 
$
252

 
$
(49
)
 
$
839,469

Total cash, cash equivalents and marketable securities
$
1,422,447

 
$
252

 
$
(49
)
 
$
1,422,650

 
 
 
 
 
 
 
 
As of December 31, 2012
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
489,407

 
$
—

 
$
—

 
$
489,407

    Government-sponsored enterprise securities
—

 
—

 
—

 
—

Total cash and cash equivalents
$
489,407

 
$
—

 
$
—

 
$
489,407

Marketable securities:
 
 
 
 
 
 
 
U.S. Treasury securities (due within 1 year)
$
111,350

 
$
2

 
$
(2
)
 
$
111,350

Government-sponsored enterprise securities (due within 1 year)
440,181

 
49

 
(5
)
 
440,225

Commercial paper (due within 1 year)
225,294

 
155

 
—

 
225,449

Corporate debt securities (due within 1 year)
15,429

 
1

 
(1
)
 
15,429

Corporate debt securities (due after 1 year through 5 years)
39,358

 
10

 
(13
)
 
39,355

Total marketable securities
$
831,612

 
$
217

 
$
(21
)
 
$
831,808

Total cash, cash equivalents and marketable securities
$
1,321,019

 
$
217

 
$
(21
)
 
$
1,321,215


Alios’ $51.1 million and $70.0 million, respectively, of cash and money market funds as of September 30, 2013 and December 31, 2012, recorded on the Company’s condensed consolidated balance sheets in “Restricted cash and cash equivalents (Alios),” are not included in the above table.
XML 60 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net Income (Loss) Per Share Attributable to Vertex Common Shareholders (Tables)
 3 Months Ended
Sep. 30, 2013
Earnings Per Share [Abstract]  
Potential gross common equivalent shares
Net Loss Per Share Attributable to Vertex Common Shareholders
Basic net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss attributable to Vertex per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The Company did not include the securities described in the following table in the computation of the diluted net loss attributable to Vertex per common share calculations because the effect would have been anti-dilutive during each such period:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Stock options
16,807

 
20,226

 
16,807

 
20,226

Convertible senior subordinated notes
—

 
8,192

 
—

 
8,192

Unvested restricted stock and restricted stock units
2,838

 
2,222

 
2,838

 
2,222
XML 61 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements (Details) (USD $)
Sep. 30, 2013
Financial assets carried at fair value:  
Cash equivalents (Alios) $ 48,700,000
Recurring basis | Total
  
Financial assets carried at fair value:  
Total 1,151,345,000
Recurring basis | Total | Money market funds
  
Financial assets carried at fair value:  
Cash equivalents: 308,981,000
Recurring basis | Total | Government-sponsored enterprise securities
  
Financial assets carried at fair value:  
Cash equivalents: 2,895,000
Marketable securities: 555,527,000
Recurring basis | Total | Commercial paper
  
Financial assets carried at fair value:  
Marketable securities: 125,264,000
Recurring basis | Total | Corporate debt securities
  
Financial assets carried at fair value:  
Marketable securities: 158,678,000
Recurring basis | Level 1
  
Financial assets carried at fair value:  
Total 867,403,000
Recurring basis | Level 1 | Money market funds
  
Financial assets carried at fair value:  
Cash equivalents: 308,981,000
Recurring basis | Level 1 | Government-sponsored enterprise securities
  
Financial assets carried at fair value:  
Cash equivalents: 2,895,000
Marketable securities: 555,527,000
Recurring basis | Level 1 | Commercial paper
  
Financial assets carried at fair value:  
Marketable securities: 0
Recurring basis | Level 1 | Corporate debt securities
  
Financial assets carried at fair value:  
Marketable securities: 0
Recurring basis | Level 2
  
Financial assets carried at fair value:  
Total 283,942,000
Recurring basis | Level 2 | Money market funds
  
Financial assets carried at fair value:  
Cash equivalents: 0
Recurring basis | Level 2 | Government-sponsored enterprise securities
  
Financial assets carried at fair value:  
Cash equivalents: 0
Marketable securities: 0
Recurring basis | Level 2 | Commercial paper
  
Financial assets carried at fair value:  
Marketable securities: 125,264,000
Recurring basis | Level 2 | Corporate debt securities
  
Financial assets carried at fair value:  
Marketable securities: 158,678,000
Recurring basis | Level 3
  
Financial assets carried at fair value:  
Total 0
Recurring basis | Level 3 | Money market funds
  
Financial assets carried at fair value:  
Cash equivalents: 0
Recurring basis | Level 3 | Government-sponsored enterprise securities
  
Financial assets carried at fair value:  
Cash equivalents: 0
Marketable securities: 0
Recurring basis | Level 3 | Commercial paper
  
Financial assets carried at fair value:  
Marketable securities: 0
Recurring basis | Level 3 | Corporate debt securities
  
Financial assets carried at fair value:  
Marketable securities: $ 0
XML 62 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Intangible Assets and Goodwill
 3 Months Ended
Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
Intangible Assets and Goodwill
Intangible Assets
As of December 31, 2012, the Company's intangible assets consisted of indefinite-lived in-process research and development assets of (i) $250.6 million related to its HCV nucleotide analogue program, which includes the HCV nucleotide analogue VX-135, and (ii) $412.9 million related to VX-222, which also was being developed for the treatment of HCV infection. The Company acquired VX-222 when it acquired ViroChem Pharma Inc. ("ViroChem") in 2009.
The Company tests intangible assets for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstance suggest that impairment may exist. In connection with each annual impairment assessment and any interim impairment assessment in which indicators of impairment have been identified, the Company compares the fair value of the asset as of the date of the assessment with the carrying value of the asset on the Company's condensed consolidated balance sheet.
In connection with its preparation of its financial statements for the three months ended March 31, 2013, the Company determined that there were indicators that the value of the VX-222 intangible asset had become impaired.  This determination was based on (a) preliminary safety, tolerability and efficacy data from a Phase 2 clinical trial of VX-222, telaprevir and ribavirin, which was received in March 2013 and analyzed through April 2013 and (b) a review of the existing and emerging data regarding all-oral regimens for HCV infection being developed by the Company's competitors that appear to be generally well tolerated with high sustained viral response ("SVR") rates for treatment-naïve patients with genotype 1 HCV infection. After evaluating the data from this Phase 2 clinical trial, the Company determined that regimens containing VX-222 were unlikely to be competitive with the treatment regimens being developed by the Company's competitors. The Company evaluated the fair value of VX-222 from the perspective of a market participant and based on this analysis determined that the fair value of VX-222 was zero as of March 31, 2013. Accordingly, the Company recorded a $412.9 million impairment charge in the nine months ended September 30, 2013.  In connection with this impairment charge, the Company recorded a credit of $127.6 million in its provision for income taxes. In the nine months ended September 30, 2013, the increase to the Company's net loss attributable to Vertex related to this impairment charge, net of the tax credit, was $285.3 million, and the net increase to the Company's net loss per share attributable to Vertex common shareholders was $1.28 per share.
The field of HCV infection treatment is highly competitive and characterized by rapid technological advances and the development of drug candidates for the treatment of HCV infection is subject to numerous risks. Two of the Company's competitors have filed applications seeking approval for potentially competitive treatment regimens that include pegylated-interferon and ribavirin, and several of the Company's competitors are conducting Phase 3 clinical trials evaluating all-oral combinations of their drug candidates for the treatment of genotype 1 HCV infection.
In July 2013, U.S. Food and Drug Administration ("FDA") placed a partial clinical hold on VX-135, which is being evaluated in a Phase 2 clinical trial in combination with ribavirin. The partial clinical hold prevents the Company from evaluating a 200 mg dose of VX-135 in the United States following observation of reversible elevated liver enzymes in patients who received 400 mg of VX-135 in combination with ribavirin in a Phase 2 clinical trial in Europe. The Company has completed dosing of 100 mg of VX-135 in combination with ribavirin as part of the 12-week Phase 2 clinical trial in the United States. The 100 mg dose was well tolerated, no serious adverse events were reported and no liver or cardiac safety issues were identified. The Company recently completed dosing of 100 mg and 200 mg of VX-135 in combination with ribavirin as part of the 12-week Phase 2 clinical trial in Europe. Both the 100 mg and 200 mg doses were well tolerated, no serious adverse events were reported and no liver or cardiac safety issues were identified. The Company also is evaluating VX-135 in combination with daclatasvir, an NS5A replication complex inhibitor being developed by Bristol-Myers Squibb, in a Phase 2 clinical trial in New Zealand. The Company evaluated this data and the related partial clinical hold and has concluded that it does not represent an indicator of impairment.  The Company will continue to evaluate VX-135 for impairment each reporting period.
If the fair value of the HCV nucleotide analogue program becomes impaired as the result of unfavorable safety or efficacy data from any ongoing or future clinical trial or because of any other information regarding the prospects of successfully developing or commercializing VX-135, the Company would incur significant charges in the period in which the impairment occurs.
Goodwill
As of September 30, 2013 and December 31, 2012, goodwill of $31.0 million was recorded on the Company's condensed consolidated balance sheets. There was no change to goodwill recorded during the three and nine months ended September 30, 2013 or 2012.
XML 63 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements
 3 Months Ended
Sep. 30, 2013
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of September 30, 2013, the Company’s investments were in money market funds, short-term U.S. Treasury securities, short-term government-sponsored enterprise securities, corporate debt securities and commercial paper.
As of September 30, 2013, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, U.S. Treasury securities and government-sponsored enterprise securities. The Company’s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade corporations. During the three and nine months ended September 30, 2013 and 2012, the Company did not record an other-than-temporary impairment charge related to its financial assets. The Company’s noncontrolling interest (Alios) includes the fair value of the contingent milestone and royalty payments, which is valued based on Level 3 inputs. Please refer to Note C, "Collaborative Arrangements," for further information.
The following table sets forth the Company’s financial assets (excluding Alios’ cash equivalents) subject to fair value measurements:
 
Fair Value Measurements
as of September 30, 2013
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
308,981

 
$
308,981

 
$
—

 
$
—

Government-sponsored enterprise securities
2,895

 
2,895

 
—

 
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
555,527

 
555,527

 
—

 
—

Commercial paper
125,264

 
—

 
125,264

 
—

Corporate debt securities
158,678

 
—

 
158,678

 
—

Total
$
1,151,345

 
$
867,403

 
$
283,942

 
$
—


Alios’ cash equivalents of $48.7 million as of September 30, 2013 consisted of money market funds, which were valued based on Level 1 inputs.
XML 64 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Cash flows from operating activities:    
Net income (loss) $ (503,001) $ 26,941
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization expense 30,734 25,818
Stock-based compensation expense 103,933 86,649
Other non-cash based compensation expense 5,856 8,070
Intangible asset impairment charge 412,900 0
Deferred income taxes (130,164) 35,759
Asset impairment charges 6,650 0
Write-down of inventories to net realizable value 10,358 78,000
Other non-cash items, net (1,393) (304)
Changes in operating assets and liabilities:    
Accounts receivable, net 20,737 43,538
Inventories (5,212) 32,419
Prepaid expenses and other current assets (16,477) (22,698)
Accounts payable (46,005) 1,359
Accrued expenses and other liabilities 32,872 12,027
Excess tax benefit from share-based payment arrangements 0 1,097
Accrued restructuring expense 2,810 (2,158)
Deferred revenues (15,447) (32,203)
Net cash provided by (used in) operating activities (80,425) 227,282
Cash flows from investing activities:    
Purchases of marketable securities (1,850,015) (1,309,044)
Sales and maturities of marketable securities 1,842,361 941,314
Expenditures for property and equipment (36,922) (43,094)
Decrease in restricted cash and cash equivalents 31,807 1,923
Decrease (increase) in restricted cash and cash equivalents (Alios) 18,924 (23,075)
Decrease (increase) in other assets (1,094) 997
Net cash provided by (used in) investing activities 7,249 (432,973)
Cash flows from financing activities:    
Excess tax benefit from share-based payment arrangements 0 1,097
Issuances of common stock from employee benefit plans 242,360 174,950
Payments to redeem secured notes (due 2015) (158) 0
Payments on capital lease obligations (14,601) (2,408)
Payments on construction financing lease obligation (63,242) (6,272)
Net cash provided by (used in) financing activities 164,359 167,367
Effect of changes in exchange rates on cash 2,591 (110)
Net increase (decrease) in cash and cash equivalents 93,774 (38,434)
Cash and cash equivalents—beginning of period 489,407 [1] 475,320
Cash and cash equivalents—end of period 583,181 [1] 436,886
Supplemental disclosure of cash flow information:    
Cash paid for interest 6,700 6,700
Conversion of convertible senior subordinated notes (due 2015) for common stock 399,842 0
Interest on converted convertible senior subordinated notes (due 2015) offset to additional paid-in capital 6,700 0
Unamortized debt issuance costs of converted convertible subordinated notes (due 2015) offset to additional paid-in capital 4,230 0
Capitalization of construction in-process related to construction financing lease obligation 176,484 167,996
Assets acquired under capital lease $ 38,520 $ 27,552
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 65 R52.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-based Compensation Expense (Details 2) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended
Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price range, options outstanding (in shares) 16,807
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 1 month 2 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 44.47
Exercise price range, options exercisable (in shares) 7,344
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 37.87
Exercise Price Range from Dollars 9.07 to Dollars 20.00 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) $ 9.07
Exercise price, high end of range (usd per share) $ 20.00
Exercise price range, options outstanding (in shares) 462
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 2 years 7 months 21 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 15.27
Exercise price range, options exercisable (in shares) 462
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 15.27
Exercise Price Range from Dollars 20.01 to Dollars 30.00 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) $ 20.01
Exercise price, high end of range (usd per share) $ 30.00
Exercise price range, options outstanding (in shares) 1,076
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 5 years 11 months 23 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 29.37
Exercise price range, options exercisable (in shares) 801
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 29.19
Exercise Price Range from Dollars 30.01 to Dollars 40.00 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) $ 30.01
Exercise price, high end of range (usd per share) $ 40.00
Exercise price range, options outstanding (in shares) 7,253
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 5 years 7 months 2 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 36.58
Exercise price range, options exercisable (in shares) 4,525
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 35.93
Exercise Price Range from Dollars 40.01 to Dollars 50.00 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) $ 40.01
Exercise price, high end of range (usd per share) $ 50.00
Exercise price range, options outstanding (in shares) 4,552
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 9 years 1 month 6 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 46.33
Exercise price range, options exercisable (in shares) 570
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 46.73
Exercise Price Range from Dollars 50.01 to Dollars 60.00 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) $ 50.01
Exercise price, high end of range (usd per share) $ 60.00
Exercise price range, options outstanding (in shares) 1,840
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 7 months 10 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 53.72
Exercise price range, options exercisable (in shares) 805
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 54.49
Exercise Price Range From Dollars 60.01 to 64.30 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) $ 60.01
Exercise price, high end of range (usd per share) $ 70.00
Exercise price range, options outstanding (in shares) 44
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 7 months 21 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 63.23
Exercise price range, options exercisable (in shares) 11
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 63.19
Exercise Price Range From Dollars 70.01 to 80.00 [Member] [Domain]
  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) $ 70.01
Exercise price, high end of range (usd per share) $ 80.00
Exercise price range, options outstanding (in shares) 85
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 9 years 8 months 1 day
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 77.73
Exercise price range, options exercisable (in shares) 4
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 77.73
Exercise Price Range From Dollars 80.01 to 88.18 [Domain]
  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) $ 80.01
Exercise price, high end of range (usd per share) $ 88.18
Exercise price range, options outstanding (in shares) 1,495
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 9 years 9 months 22 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 83.13
Exercise price range, options exercisable (in shares) 166
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 81.54
XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8
Intangible Assets and Goodwill (Details) (USD $)
 3 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Mar. 31, 2013
Research and Development Arrangement
VX-222Asset [Member]
Dec. 31, 2012
Research and Development Arrangement
VX-222Asset [Member]
Sep. 30, 2013
VX-222Asset [Member]
Sep. 30, 2013
Alios Bio Pharma Inc
Dec. 31, 2012
Alios Bio Pharma Inc
Dec. 31, 2012
Alios Bio Pharma Inc
Research and Development Arrangement
Sep. 30, 2013
Vertex
Indefinite-Lived Intangible Assets [Line Items]                        
Intangible assets $ 250,600,000 [1]   $ 250,600,000 [1]   $ 663,500,000 [1] $ 0 $ 412,900,000       $ 250,600,000  
Intangible asset impairment charge 0 0 412,900,000 0       412,900,000       285,300,000
Deferred federal income tax expense (benefit)     127,600,000                  
Extraordinary Item, Earnings Per Share Impact, Net     $ 1,280                  
Goodwill 30,992,000 [1]   30,992,000 [1]   30,992,000 [1]       4,890,000 4,890,000    
Goodwill, period increase (decrease) $ 0 $ 0 $ 0 $ 0                
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.
XML 68 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Abstract]  
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive loss by component, net of tax:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities, Net of Tax
 
Total
 
(in thousands)
Balance at December 31, 2012
$
(746
)
 
$
196

 
$
(550
)
Other comprehensive income (loss) before reclassifications
(7
)
 
7

 
—

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
—

Net current period other comprehensive income (loss)
(7
)
 
7

 
—

Balance at September 30, 2013
$
(753
)
 
$
203

 
$
(550
)
XML 69 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-based Compensation Expense
 3 Months Ended
Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based Compensation Expense
Stock-based Compensation Expense
The Company issues stock options, restricted stock and restricted stock units with service conditions, which are generally the vesting periods of the awards. The Company also has issued, to certain members of senior management, restricted stock and restricted stock units that vest upon the earlier of the satisfaction of (i) a performance condition or (ii) a service condition, and stock options that vest upon the earlier of the satisfaction of (a) performance conditions or (b) a service condition. In addition, the Company issues shares pursuant to an employee stock purchase plan ("ESPP").
The effect of stock-based compensation expense during the three and nine months ended September 30, 2013 and 2012 was as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
19,010

 
$
18,869

 
$
68,633

 
$
59,774

Restricted stock and restricted stock units
10,998

 
7,104

 
30,108

 
21,643

ESPP share issuances
1,504

 
1,948

 
6,077

 
6,120

Less stock-based compensation expense capitalized to inventories
(204
)
 
(339
)
 
(885
)
 
(888
)
Total stock-based compensation expense included in costs and expenses
$
31,308

 
$
27,582

 
$
103,933

 
$
86,649

 
 
 
 
 
 
 
 
Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
19,223

 
$
17,444

 
$
64,312

 
$
54,425

Sales, general and administrative expenses
12,085

 
10,138

 
39,621

 
32,224

Total stock-based compensation expense included in costs and expenses
$
31,308

 
$
27,582

 
$
103,933

 
$
86,649


The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of September 30, 2013
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
184,969

 
2.74
Restricted stock and restricted stock units
103,454

 
2.61
ESPP share issuances
830

 
0.31

The following table summarizes information about stock options outstanding and exercisable at September 30, 2013:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
Weighted-average
Remaining
Contractual Life
Weighted-average
Exercise Price
 
Number
Exercisable
Weighted-average
Exercise Price
 
 
(in thousands)
(in years)
(per share)
 
(in thousands)
(per share)
$ 9.07–$20.00
 
462
2.64
$15.27
 
462
$15.27
$20.01–$30.00
 
1,076
5.98
$29.37
 
801
$29.19
$30.01–$40.00
 
7,253
5.59
$36.58
 
4,525
$35.93
$40.01–$50.00
 
4,552
9.10
$46.33
 
570
$46.73
$50.01–$60.00
 
1,840
7.61
$53.72
 
805
$54.49
$60.01–$70.00
 
44
8.64
$63.23
 
11
$63.19
$70.01-$80.00
 
85
9.67
$77.73
 
4
$77.73
$80.01-$88.18
 
1,495
9.81
$83.13
 
166
$81.54
Total
 
16,807
7.09
$44.47
 
7,344
$37.87
XML 70 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories
 9 Months Ended
Sep. 30, 2013
Inventory Disclosure [Abstract]  
Inventories
Inventories
The following table sets forth the Company’s inventories by type:
 
As of
September 30, 2013
 
As of
December 31, 2012
 
(in thousands)
Raw materials
$
232

 
$
3,754

Work-in-process
7,980

 
11,317

Finished goods
5,325

 
15,393

Total
$
13,537

 
$
30,464


In the three and nine months ended September 30, 2013, the Company recorded within cost of product revenues $5.3 million and $10.4 million, respectively, of write-offs for excess and obsolete inventories. In the three and nine months ended September 30, 2012, the Company recorded within cost of product revenues $0.0 million and $78.0 million, respectively, of write-offs for excess and obsolete inventories.
XML 71 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Liability
 9 Months Ended
Sep. 30, 2013
Restructuring and Related Activities [Abstract]  
Restructuring Liability
Restructuring Liabilities
Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in 2018, and that the Company has not used since it adopted the plan to restructure its operations in 2003. This laboratory and office space currently is subleased to third parties.
In estimating the expense and liability under its lease obligations, the Company estimated (i) the costs to be incurred to satisfy rental and build-out commitments under the lease (including operating costs), (ii) the lead-time necessary to sublease the space, (iii) the projected sublease rental rates and (iv) the anticipated durations of subleases. The Company uses a credit-adjusted risk-free rate of approximately 10% to discount the estimated cash flows. The Company reviews its estimates and assumptions on at least a quarterly basis, intends to continue such reviews until the termination of the applicable lease, and will make whatever modifications the Company believes necessary, based on the Company’s best judgment, to reflect any changed circumstances.
The activities related to the restructuring liability for the three and nine months ended September 30, 2013 and 2012 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
Liability, beginning of the period
$
22,051

 
$
24,830

 
$
23,328

 
$
26,313

Cash payments
(3,901
)
 
(3,726
)
 
(11,323
)
 
(11,137
)
Cash received from subleases
2,670

 
2,355

 
8,000

 
7,329

Restructuring expense
524

 
696

 
1,339

 
1,650

Liability, end of the period
$
21,344

 
$
24,155

 
$
21,344

 
$
24,155


Strategic Restructuring
In October 2013, the Company adopted a restructuring plan. The restructuring plan included (i) a workforce reduction primarily related to the support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection near approval, and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in cystic fibrosis and other research and development programs.
The Company estimates that it will incur aggregate restructuring charges of approximately $35.0 million to $45.0 million, including $20.0 million to $25.0 million for employee severance and benefit costs, $6.0 million to $8.0 million in assets associated with this restructuring that have become impaired and $9.0 million to $12.0 million for other costs. The Company recorded $11.4 million of these restructuring charges in the third quarter of 2013. The Company expects the vast majority of this restructuring to be completed during the fourth quarter of 2013.
The restructuring charges recorded during the three months ended September 30, 2013 and the related liability balance as of September 30, 2013 for each major type of cost associated with this restructuring plan are as follows:
 
Restructuring Expense
 
Cash
Payments
 
Non-cash Expense
 
Restructuring Liability at September 30, 2013
 
(in thousands)
Employee severance, benefits and related costs
$
409

 
$
—

 
$
—

 
$
409

Asset impairments
6,650

 
—

 
(6,650
)
 
—

Contract termination and other associated costs
4,385

 
—

 
—

 
4,385

Liability, end of the period
$
11,444

 
$
—

 
$
(6,650
)
 
$
4,794


Fan Pier Move Restructuring
In connection with transitioning its Massachusetts operations to Fan Pier in Boston, Massachusetts, the Company expects to incur restructuring charges related to its remaining lease obligations at its current facilities in Cambridge, Massachusetts starting in the fourth quarter of 2013 and continuing through April 30, 2018. Most of these restructuring charges will relate to cease use charges that will be incurred during the fourth quarter of 2013 and the first half of 2014. In addition, the Company will continue to incur restructuring charges related to several buildings in Cambridge through December 31, 2015 and the Kendall Square building through April 30, 2018. The continuing charges will relate to the difference between the Company’s estimated future cash flows related to its lease obligations and the actual cash flows that it incurs.
XML 72 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Sale of HIV Protease Inhibitor Royalty Stream
 3 Months Ended
Sep. 30, 2013
Sale of HIV Protease Inhibitor Royalty Stream  
Sale of HIV Protease Inhibitor Royalty Stream
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of September 30, 2013, the Company had $71.5 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
XML 73 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
 3 Months Ended
Sep. 30, 2013
Oct. 31, 2013
Document and Entity Information [Abstract]    
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2013  
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   233,756,871
XML 74 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes
 3 Months Ended
Sep. 30, 2013
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
For the three and nine months ended September 30, 2013, the Company recorded a net benefit from income taxes of $0.8 million and $132.9 million, respectively. For the three months ended September 30, 2013, the benefit from income taxes was due to a benefit from income taxes of $3.3 million attributable to noncontrolling interest (Alios) offset by a provision for income taxes of $2.6 million attributable to Vertex. For the nine months ended September 30, 2013, the benefit from income taxes was due to a benefit from income taxes of $9.1 million attributable to noncontrolling interest (Alios) and a benefit from income taxes of $123.8 million attributable to Vertex. In the first quarter of 2013, the Company determined that the fair value of VX-222 was zero, which resulted in an impairment charge of $412.9 million in the nine months ended September 30, 2013. In connection with this impairment charge, the Company wrote-off the associated deferred tax liability of $127.6 million resulting in a benefit from income in its condensed consolidated statements of operations for the nine months ended September 30, 2013. Please refer to Note I, "Intangible Assets and Goodwill," for further information regarding the impairment charge.
For the three and nine months ended September 30, 2012, the Company recorded a benefit from and a provision for income taxes attributable to Vertex of $0.0 million and $1.1 million, respectively. These were due to state income taxes. For the three and nine months ended September 30, 2012, the Company recorded a provision for income taxes attributable to noncontrolling interest (Alios) of $21.4 million and $40.4 million, respectively.
The Company has no liability for taxes payable by Alios. As such, the portion of the income tax provision (benefit) related to Alios has been allocated to noncontrolling interest (Alios). As of September 30, 2013 and December 31, 2012, Alios had a deferred tax liability of $150.2 million and $152.8 million reflected on the Company's condensed consolidated balance sheets, respectively.
As of September 30, 2013 and December 31, 2012, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of September 30, 2013 and December 31, 2012.
The Company maintains a valuation allowance on its net operating losses and other deferred tax assets because of its extended history of annual losses. As of December 31, 2012, the Company had U.S. federal net operating loss carryforwards of approximately $2.6 billion and tax credits of $98.0 million, which may be used to offset future federal income tax liability. For state income tax purposes, the Company had net operating loss carryforwards of approximately $1.5 billion and tax credits of $60.3 million at December 31, 2012, which may be used to offset future state income tax liability. On a quarterly basis, the Company reassesses the valuation allowance for deferred income tax assets. In future periods, if management determines that it is more likely than not that the deferred tax asset will be realized, (i) the valuation allowance would be decreased, (ii) a portion or all of the deferred tax asset would be reflected on the Company’s consolidated balance sheet and (iii) the Company would record non-cash benefits in its consolidated statements of operations related to the reflection of the deferred tax asset on its consolidated balance sheet.
The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2007 and any other major taxing jurisdiction for years before 2005, except where the Company has net operating losses or tax credit carryforwards that originated before 2005. The Company is currently under examination by Revenue Quebec for the year ended March 11, 2009 and the year ended December 31, 2007. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year.
The Company currently intends to reinvest the total amount of its unremitted earnings, which have not been significant to date, in the local international jurisdiction or to repatriate the earnings only when tax-effective. As a result, the Company has not provided for U.S. federal income taxes on the unremitted earnings of its international subsidiaries. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to U.S. federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries. At September 30, 2013, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability.

>4UN6>]=,&VVL-_5[NGT+:UQ+9=8`LW_OX%VD'DV@&XMIAN1]HA[0Y/.^S# MB[0[`NTP@FU-TF7O8E['IA:VN3QPD>+^XB,MWTN2@`[8.TG3AU3;[`' M<`Y.0L-P>+'MO? MT$(6C8YIU/;T^.Q;6F!"H47.`=H9M#-H9]#.H)U!.S-'F%K[C*.M05N#M@9M M#=J:&FQ-#3F>BTON_&OC&BB[9"+)<3?X-=#\UE3K4L=ST3K,S*,^H#Z@/J`^ M-.&TH5:@5J!6G*M6G.]3Z<9W^GWBSZ/+4F=5C((O=AP[+=4B?K8..&0<,@X9 M=Q+`M08L9-PE,.[D7^S`/'6;(BY553LJT3':PAP$YB!0(U`C4",P*X=:@5J! M6H&YZB,$+_9"(Y\F%*U6L(^H@1)1.T13&L_5G(M:8K+J`*O8N2@7[BI%!4,% MP]4+E0N5Z_24"U>O0T1MEQ>G!VH@JUEQ>^]C+G6IT--VH31M?0>=)]E' M)2^FQ,9KX)U!#0ZI(ZE21U9J>\5Y=]#.Q?9AOG=W5P.-&1JSW<$R-+VCB!LW MMT-3AJ8,31F:LC::,F+('5.IK3TLFC(T96C*T)2=91KM$LW93(+M)UXA9-7Q M!Q-L!K0PB.CU?=$D6"+B#XO$E$B5/YM!=C:?1N;3:?M#;85!G$Y(J/\L^`L- MU(1X*"P-;\L[E2PKZF_(J"=]`! M?*?CC(YN:3)=262Q(Q!16HZ[=AJ.'T=ID&9TP$8U6NK+TA$>[P/_7GBD"2TZ M'0^$6R]EAT?"0IMS20BB<9ZEW9>UJOS[EY_R]/K.\\;O^EZ0_,$N[02I'\9I MGM#T!A#IA;'_UX=__D,0?JD._5<<#QYA-IG8#+1O=/C^ZB-#XS?Y2@`$@Y$7 MIN^OKN%3,'A_U??\[%HSI;ZHZ+;EF*[K&/V^INFJJTNFHXFR:3E70AX%Q:7R M='#U019-D\"T3"6L;KNA,.0W9:TP?5MTB6&HFM,37554%$.T*V%T2]1J%P:0 M^?,AR9[^M.,P]&XYQ1ZHE21>=$?9V^]I[]FZ2RC_VWH*TN)HKL:](/YZ[R4C M[V/D?^(T7#LNVS$LUU)$HLDP-L/5=$+]Q:=*,-&!N<$[%=NG_%9% MC1"UIX@Z41V%.+;M3"CE$.?JP\*B,6L<;H(1387/]%'X%H^\]=[O2VM.0RLW M__A8W.AZ#;`_CB>IS$ M/DU3`98(\)A@86*3/V#K4#QFFEY="$Y_&_QX.#^#J&)7J]?12&CH,22R6`A@ M1/^V_Q"B'!S%.`L&`%CDA?%=3@5`Y"[Q1M5"'41^F`]`I1G4Z\[YX_^N)5GM M!H?$29%(UVP,)Q@7(:2"`JQY+#R"OW9+01LJEL"1PSCA\&0)]3+.&J`+ MPRJ(AM1G(G<%X69*5<'SP7UEY6&*&_R7O6?M;1M)\J\0P7U(`-O@^W&#^\`G M+H?)9&XRLX>[+PM*:MFQB8TED5U57U[NJ MX?VL@$T9?)Y597C#=@K7*PHHEBOE[1OY\9MW\&HX`JH'+YX3^]6R@]* M1NOEW8>]1M`)G`",[=7`6@TW*'NY<0-V)3I+S4VM,(!UHWP@ M9204G3'>T@T#IMD!,3:<,>$[8&?RJ`:,(K\:[Y00.--C!HP$^P(2=L<$>['- M5>^)@?""V]OT'6*=9_AU=5#J=,N:`X!=YJQ*5UF>-0=B>K;= M`H#K`S):"N>SW"DI"KF:]:OIRAJV&L-&(%&19`"[E,0-"&=8Z!;X&%]79:L4 M_IT5G5^9HBY?,Z'?!1V1AN+,I?GA"Q&N*MOK&\7?5UG>?_]V]0[@P?>#`2M( M1@<=69[@W['JFJ0_PE^QZ[3:T'=Y?@GJ*<>/P`(N^.:.=,!,;:P.L_.RV[,F MZ[_!*D%-M&+*-2N`ECG(LCL&#@PG+9XGXKL;.!8@KX"[B#&`*`0,32)C MH#H^_>,WT!KX@.`[J:LNBY237C>\GT":[&%[B3OIM;!HV1SV3-%F"LW?`CLH M#-DK)?H(^2&VM4&6H9U5IAMZFIT["J*7`MC@JZ6>1!YOBSS[BP$9.%DDT6#' M>S'5:^+N;8^A_D1="QP)P*D0%9`)E(%\K*KW2*-;^CJ5T0\0"$VVSN!]7/IW M1X?H1'Q9#\[8X&PO+XB,_F![YQZG;&QM#=R)H@3C(Q\Y3N*CXR;9%U:5YXR, MC24A\MT:5L5#EQ_&C%0A."@\TY=)F:V`!@QU36J`"(*')N)2GF1-'GJ M>.10B2UH:SI\,QH>9:LUJ,6L>52\]ED93-.=L1UK'D)M4,S@<:#C=X3NP-+` MO/PW-V6^`47^.(I^:RQ#N]+G_3]?=6@[7*]>L7.%%ACXL_EF%DT9F'=P/M#R MS0\C.Q!9`\]*ND;W^@NW]JITGP''L/5-`3MR3>9HNKE%5[3NF&D8^H-E-U5[ M#3XO>%6;WG(^&>E!B.IV]2?\A;Q5M.`PE"TX)5G]%]F5=Z4\NLN&/[GTVRQ' MA;/?Y^C.P6OAI8S]19[&'F4QP(ZP[,L&W7[R"H8$6+!_>0R#1_.`0:X/)&4N M*0*Q!1B+J4.%?]9`CHI[8,PI`M_Y7"[O+PP!_7'VZ4I*RW-#N1$@>?P/N`GBH M(M[P]DT2^>#I[?-T338+.1Y(8;D+*-O0\9!!6Q%BDAY2[^R`ZD^/>'`4*>NW MC!M3'>\(]VEY9?3>R;\:_'EL.,!O][?O2G[T(')EQ^M M?!SA^T@5MQ7XG!.O$GY-QRAG"!<@2AAL%>UQ2\-;D-#RB&HZ:&7VUPE@9@2\ M(K"T`<%1[8V##&!SE"`-J@QE&4A-H"L0E6\D>>45VY<5OA,9$W[+Z8RQ58R0 MI&L1$@(^JULFGNECEA/2X#90U/8$?7`=_8E)U>U;4(K`PGQQ))C`Y^\D&24G MLI%P/4&33;H&\9_60!<4],HOGRP?X9'J1A#^,SQ\DZU0S"_%3P)0:H#NY8<# MVDJ?_M5FJ]7%?6G11\F'8?3P5KJ=,@0L*Y@("M:LA@EI)+$DQP%Q?_Y[B+- M]L@#F]=LBKW?'DD?W)-$%"'ENHLIXQ'DVUFW.1W$MMBFMV`"T"U9G-^!F$MA M8MB(LK@N20I4RK9M6K0[)I%BY--UVG*E08]@=!QM`?11B+7[H"W%ZZJ2XG5D M==3M&K/!VQ;M*<'J8KUU-R`U^](?KG&DX*YL]%V`QD`P^?+18&]J6,[W]) M!G6"GJH:=FBJ21Q[@9;$GNEZLI;1]%UC6LNX4,6X#,:W@OR_OT?'H3:B1`OB MQ+(-*W(,UW=T)]0L7PL"PS4->U:!^3Q0Z_=`[;BA9WA)J`5A&/N>JH5JHEF> MHX8.T-Q*_C:HCX,=7FV![3X@TJPQ86J90/ M:5V#FP66?@.V>Y[>C4SQ0;](K?B8><\9KQ*KKM,B^\(]`50OP>$2'A8)K@WK ML^XCYP\1VX$]?U#6K,*B!%G74Z*C@MXOU8V"B[.FD"@ZA/*7X&EGNYKJ;+BW M?PV?4E$9VW'G?)J3Q-`G!K+@S>@PI85'G8BX37!;D\.R0G],%!Z"7MZE?S%!9/AMS3KD96R@RP76&'#`.AH-6WJ0>)*2P\_S3-8.`<7:BFR@/5A% MZXP);#@&`'D+7^&&8,M)@R5([/.>%"$OVRG(P]0.YTT(.`!,=P+\C;IW40GZWL<]W6`$1:94A%[*_HW&0J\L"=A#VN MN$./&[QJ:T"HKJF.^01G%OQUN[Z6:1:+NL6-N!85H9CMR!J^/*Y#N8=A.DC$ M-.H+I;_>L2\;GZR5KE,`+5N+V!Z0I:RPV'R;81(&EFU:RG52+D2#$6`9^)&1$GQ<11.7LATB`OLR1W3!6E:/NG)8V4=AP M80^`N%)^G29R3RHP/?%8P>JC^GE,Q0UB)S*\V#79E,.-`NC^AV*VC((RDW3N M2*I/LTJT@:7&*WQZ;=FO34.'>W ML+/$D-,->N3VG%"N"H:8P=/;/)+6"L4/IP6"6,NZL`GC'Q$'E.?8%G%,3Q"# MUX8B5EEQXNW+YXP45@UZ.^?EI)U^TB-<"+LB2*Q`OJKU'\2026.*TG_Z#6%DR(VTPJ[F']LRQ] MEU0B]`A_4)T\4,$#O2"-J"3T#0YD^=D5#AV6M.= M*J/]8:H>,57I+F]B2[(+.*/?X4T,6+'0R0&R_SZPJD+'\>=#L;ZY4'[-P/X! ML9,P\/4&\43Z%_Y/^;3#Q]X7:WG7PT;AL=^%**1N4!125=[B%DF!KZL__3&$ MJ.M6[GZ@_?3N8J0,*1O5@NQ9H_O%#Q;946G>I?A@(0M\H*8S'9<7D7)@7-8&X[H.G=>_9P\(N4F^FBK&*)-%U!:-[6`\$`Y[J"P]3U M`]'`!'GNMRC59;Y0I"C!26BY6%R*&4Q0*7=9/5QM_.:"L-: MH25'!(2!99V([7X+C$^([:F!'[X!2-INI`>FZ6B.9>J.S;$U-5_33D6R7RBV M\W3#"&'7#PW?T"^+_%._^9__\S_C\]/7!X4/Z9UF%.3C4_9"3?WS6 M=9U^L##=Q!J2T7`]+3)]PTL,1X\3.XH[OK$BUWSU9-RP[)\_L^LTCT$U-0OA0=)\5TO,;K:*K>M3"NFN93P=A:B-YV,2@#A@8/(S_[G?L]OF0%24HUL-[LH7KAG+0P[?$8`4VAP\, M3`KX!@-A7*T^4@+%L>>AD`W41$^\R'<<-99TBDS=G=+)=N'LCLGT?,B]'*J> MTF*!!I2+(M\&BMJA:NB)J4D9YT;6;%+4)1Q.4S-^$/4>W1$'-O"D;5NZY_FQ M[B2V:4BZQI8Y*X.XM`W+M.]2BR.J+:KC,S,"\M M3=-?$DGAA8^?O&5IMF\&GF5KGA6:7FPY?C]9SM34LU0F\+ZW-BJ"_?(W&6;YN;?-?>:\I1VGW<<'S&/%FWN^"=]GGM1&7<=T5!^*^M%!JR\ZZIB, M!L-\WU601YOML7-WQ0J&*7/J`!AVG3]K%;!ZY9YYYFOQ[?LG>H:-E2;ZN<=(+/?<7W7,-9=O+YFW.)&\ M*^WO91P*RS\'IIING%T$'F$(,4MDFU6`Z+_:M,),$2#RH#%HQTK, MF\]$@W.Q,$+GR>:[//-LH&\>R_+"38?EZ8L/F>ES5Y4-NP3!RVLXZKI<9SSG MRK:LHFJ&]/.@;.#OX(@G&.;#.5_4#"U+#E'2=Z01:3"\$$A2=JYT5SKT73/; MK[QBK4(>09F%67'E_87RYO0,Z8LW1)YM6]W3BSICVC/W#`\O';%_^#1+O'*N M;L4C/LWHQ''U?<+B.S*HZ&QJ73UW<^,9_9HSVU8SK^9W*F"BF0K"9N15TI/1 M9C^X]G$L>K^O&;8)]WX?Y70WK[![N;<(R>"A([!/#\3] MX+\3DV-M)5ZNY7?W MG#,.P_5LW)G4;@^M\?!O_R&&:.6>J6_/,G[<+?*TL\= MRP"'`+L0OGJ@P]0X>;WR_9%"YTRN\@_A\[5&'HJ@HNR+@]L"S;[K@F9FHD`2 M>JF6,\K2S9^MS.=C"Y>05]B:@0UP?4!`3#CCO2&3.MIN*!?[S'O!^+"N^L3R M5)0EP<3K/.3`5PSYR$`7T%1I[EA^*PWTZ;K91LP"$XN,*Z,[)8H]8:Q()=F="<"\)PB!OV5W#*\(WU2\N@= MS8?F9Q&,0^RM$"-N>6??R.00U^P,QJ;QOBC1PW:#(_ZJ`V\CH!MM^.LZ"_/T MK5PD86AJZ99MJ!=K#AN_5`8,ZKNTVM`[:<;M9RJOA[/^K%FOU;D-FWY`]_.F M\#SWS-$=F3[!%IT5XZTH32FSEZ+-3>[RP,OI;%H13IG&6;#A;X]#-!=4T\OE M%>W*^GYXQ5;/GP-?$@P/8*`9=PS9YR-F+412$#:;KO^:1JWXK56B26=)1J+G MWDG`P4)<$%(&4G:_4@,MK)!A9U:1B@:>+O$HAVKSGAZ\<$S>3'.3%F1I=(G) MNT7ENCAV MV>D:$KD]L\.>%7P):HDAA'36#RRMAD];%[#6&HQGO':Q8K-918O&$W^_O`!F MK(3HD)=5=HW@(V/U2\TIU,\,XGWR0[17!^4W'(30,N6_6P8669=611R&-\,- M9MV3<%6];N+0X*?'C&K5X6.-ALYB`'\?HXO&T4MN22;;<\Z,2- M^534!\S'=R%H8L0''S%Q1,+@02E$G_<,64F',?`@)^ILDX'<(9_BCSUEQ07T MG5#']N2>:((6U(N-EW1D")@8.T-L>)?5TX(/J>@&'O\RQ=,F67;M@\ MFTF2O&,5N7GM7C#U!J_9P&RGX$O,\0Q0Y$.WQ//\-,/2V#._EDS0F8Z\[JB3 M#]R0X7;-*`BV9*CV%O%)<3KO'S_5F7*DAR7^O,?P=2#J%A[3;V;;NI?8IJ9: M3N*&@19JCBI;>*PX\F8M/(ZUU,$W`^*K(3W9`!QJL1/;>F(G21R;:F+9<=<< M9WBS%N]+S=!=>ZDY[DSPWM,?Z=BAK3ENXMJ>I3FZJP66-F@Z6^BT-2WU2:$] MS@,@!F`CKJIVIYJ]Z`Z,]+JFF%93\T(O+$Y[,=CW3)_,+PF.'1C(_HV M:,K:!5G)[^2&]19Z?8W1?&0GUC1-M[S`T2)5"_PPD'-F;<^=-97#`Z[WI(@_ M!];`EH81V&KH^HYI:$$2JJK$VM>2^;$W#-5^2L[4GP/KP`VBP'0"SS;\Q(GU M)(XZK$-G/E4:F-Q;:@$]J_1X#L15-PD=-4A,4PO5.$XT-;(EXH:NS;;;5`WK M"1%')I<-^9]D!(&W;:(I""80(/[XMGT[,G7#=CS+2#37C]0XZ.>=!(DQZ_'5 M[6G3_M^+Y"^C M$''=]#PM!&VEF7'B64&H1V&H^[9JZFZ=:>N"$ MIILDNFE$B&@0(3I:O#`2P'"_$M71"/?W!8Z?P\EVOPHC^Y'V3Z1Z'I@\GJN# MF>G:=@SB1X[DT4)]9O_@93TSW7H:I&_%X!Z+4[?\P+4MPXA,8*D8\/'M[G09 M^DRDF"!29F;1>3#XC6Z]^YIM,%1/-4W'2V(S,OP@=LW(DK:=9T7SF1(@08B# M'H)%#]89$+EO-VPO`K)KIFW9=N1ZAAZ&%EA[%JJ#KZ.9]FZ8TE=[0;F3%=K.OSP?AP?`?$3 MXW_/)MMZJ&N^:KF1Z?N1[QJJTQVYP)Y/+0,7SYD-E7A2_"/A[LLP\&./8Z)[ MNA,Y26@#8B#'3:_S"L%?G!]'0]?5F1-[&J9O1>&>/7*=,`C`VO)@4YPXMI,H M";O!'^`\S@4[>+OW,>DC4<#1'D535E_!8A%*0\/SU=A,?`W`]KT._&0!?$N? MCRTY#LVW`'X/ZVB^D20^G`_7M/3_9^]JF]O&D?1?4:5V:Y,J>Q;O+[.U'P`0 MV,W>3))+9O<^TQ)MJT:6?)*5C._77X,424G0JR4K2N*IRI0L46)WH]'H;@+/ MPYWP,H3&=6"A6N$Z#&];4?<0O9PR]3C]TFR#W=/\AE&0/X`+>8T,98IZ5*<% MPNH4-@93A%,LGIUD.Y)&6\;%2*4T(Y@1PWRF"`'5&B`L29.%B7*Y-=$Y0)^8 M3U=//V8'W?8<()C=&5'((X\EJ."\,(TZ`H)M.D`HK9-W$>PXVFR;--([ZC(L MG200;SWQ`C5X/<$G'1ZMMT6J)^GR(3XPZ??J$9TEXO4Z]+2!HLIJ1R&SQCP8 MCS,H\W6MF@)/3'(%P>0VY7:1\UETW3*,V@DN#3$$Z1B,O=.VU=51G%3WD"UN M2V*/H>O'(CYOB+LR7-PNL6^VXQ4D`$XI)@/+D(7ULXGHL"ZEQ1W%"FT;PD61 M#E1@&PHIA1S-"L>MS+@E1NO0M):L]&G_`6NR+9DY1/X2#NS),'$25AIC#"%8 M(F:YQR[@=CAT"A.'E2;;0M\F`8^JW):A8IYJEA%"E-/.64,59O50X16M;A@G MN:V8W4>W113,=\7#9D3/MZ5&[!3]T:!1X+#&&<8UDPZ2)ML\_3#6)HT*PE': M.]RNWA$,\@%#-/4,EI3FP2AD;#M+%V^^AUC;%C<>2&8)A@I7*,\H%"V-6!1&X""Q MJJ+E<4?\QE+,-E\WD=Z22(,H-Y:HH`VNU27V-GU_4H M[J^M]NV43/0QB[P>C1]NUVZ&[<_5VI$)`:+$ST?;WK:$SM$MJ4=V<8<$<7+> M=/'O^5O/#GO.PX+@!93*O:!"]W#DNWQ\TQ]60N;3AU']1DG=5+U388,J]!.? M_T_\^6\QVA;CRY)$ZGY2_%R_2)QF-?1H`W"I%H`OFP';CAQ:2O;W5TS_>4_0 MTMD7\1._1^B);WCJ[YU(P?T08:L9N8CDNHRE,__W;`;/OU5Y-=D%Y79N)D=2 MJ6L(2C_?]GLP>X\:\N8(B#;N(%LP=B,N?;795K,96L>R^S\ZY:;[3KTQ<5]; MXNVV7&&_3>%3/\V`>NTZV)Y[OHJ4B44^_ONKN-_RU5\7]EMVUFZSW!>Y]\4M M7]SR4+=,#FCM:O67"'J@J\HMKOH46YV5X[TNM^B/II-\V)N\>1Z_BN#E5WGW M]YMQY)R]G&U^[W:+XOKZ*WC;H+%[T>9FACFIC[:8ZD??FY^ M\X4<$<^\JOX6$9*>Q]\@(>CT1M.X=>6IS_8.M>4Y-I-VM='Y-Y4PO>#T:"G^ M5L-\+T'II2A^B3(O46;WUC6Z8.)XO>L?)O_YD@GU3%'DS[M/SYAI[ M5M;O&9M#=S0I8?'NQZ/>M!L)&\ISVZ?CB_H3/SH@]DDY;IZ7@.PBCLT7N+:D M4*WP%R.D[F1&,G`%U5Y1HG@W6^0KJM;S]^YG9=([&^_^NL2/)Z6KDL>G03AT M*FQ>25>@=JX_C[3FY%+=LHZ'X>+IN/?7'XM),?Z\!`OQ=@N")[9.4I8IQYGC ME#';('@*%(Q-CJQR2I8/=6X5Z'`-R'^SM1IP;Y4B$BE-J`P9-X8T$&8*D>2P M(>94+Q\A?JH*<,U>LCI,)%,$"Z--,$XYXD@MJ_$^L39%+$&N:&^]AU";7$`; M17PFK$-9YJP**I[%KE&JD$X-2'D"B[15J(_YEU_KO8M/]U;ALY!)SD/0EA@) M_U0#X:HSGR"8$+J,O+)-G(/%WS3\AL,RE!EAD0G*!6Z-:@X."LV28Z!4)CB* M3Y0_[JF(@`7ECHH#["]X<"I(%X\_"H+!A6F-O:*02HYDRA)#894"ZP4Z7(.- M0^`IY\0R*3)!'`>Y4:.!<#0YZXHQQ6N6%,AA!G9T M41RKMQ"JK+QW/,"L!S8 M2T+PHI(2XC7560.@$K2T1SGTO-=AU%6U_::;=M;>=<7CF^IL*E:[]*H66T3/ M=4KQ872_3_\H:84L:9^<(GYJ6V,^5V]/AQS<4XL/S`[2]Z2'Y,L9UBG7@B*: M=><])&M;:6?-E/)^V&D//(J:^BNO:-[&);73;3XN(E%&$=MY>:R52O*2BX,K MX+EJL?\`"GIV4?'A1YKW,_B(2@ M_>OKBA%KTQ?`@+#(C\;#XG%2?3F"TTZ*P6Q(FY^J'3,2WU3JE50KY<>1WB<4 M5^-I)&"IJ*9^RMR/^X-:=UH1_,4AG(T6 MK:RQ2K+1?4V_6W/KM'ZRY<;5;2JOD//W658`7+:D>.IOE=_E-1=AT5=SF@^M:K?OI0XG\5(?F8>4* MD>LL7A*[E]6[184W5!(RS="7&A<#F:^+^%$>J:!ARN7E_+T9C6NE M)M*9Q7;L:/K0N8MQ>D:*U]!Y5?>-?#Z?^R#U:#J)S.R=/0G.OZFG,#735].O MKIK7LT*Z6H/`;.TZ/K]V[]O5W*GL6*I4UB`_;V],4*>Q8"%CU",F;9;9%M[1 M)-4GAIH4B<4:>2V&\R:A-O4:")-268V\XX@X@HBP3;>/A"QI]V!.F%XB2ME% M*+#MIS@QJG1K4G$&[->7%"IXEV6$4D9\!B5R334D$5<^D91(KHE::[Z5`ATH M_J;1I\0RE!D66Q`8W$!1W[2`+;/)Z!.N8A_V..*[69:UC\"<&TF5)\931&4F M8_>U[D(YE"7L$PQIIO4Z>6<2["WA)H\`&QJ!@V'.$9UYC9'(FDZKT4F?C%$B MEJ`LMTLX+-Y?NY)=#^Y9`A3/+K2C\;C$ZG)YK/M7N@-9V^GQ!D6J!8)L\`CF M'LVRIDN,&$G:9;0$N5X4?7?1EI0:329MH'LLH>/S@7EPD4X4WOQ//E@"3%_A M*V_?A7F,U*"UTTI3[2"^N8QEM('TAR%*&E?S>NPBS3$46'*E1068CTZ>21L" MQT1[P7%#O!!4.AZ'*?!K/OZ]*$OIN>Q^%1!F#009\OZX_!W[V+S\9[\81Q+6 MQU\@M1@LL*[XR4/)1/[^NKFZ>=$^OJL`(5?=X]'`DJ*#-*8YII(:7$HHY8AJ1(PQ');8E88M7`G';HFFO>#B$#GI07 MX#,8*5>W(/8:$N248!B6#L:%X:2$&VZ!\/&FAO'+4*P?BCNH%;K]?/`AOR_& MVX8`,R,1]9(P8@Q%C)IF5GB1`CZ?U1!\,X%LOS&)?&:!(8680PBR[X!0,R9! MA?1Q-N%DZ2'[UQ^;5=.#G,%0''5-"=1H90,R0B#IO/6ZY17,7,K!=O8C1+^W M$3+<<4C[#?<"17X\J%FR>BY1XI*Z\.Q'Z!SFT'[AC&:>$<$CU9`EV&?6,-44 M,XBDG8UO)9R=PV39,54YH% M&K",W`-">XQ"PU&A?98P,7PS5)%4&!.INU6\:H2^+7 MV0_%>2PA3QD*XXSU1F*C'$8:<9NAAIXF$)X0-47\X@OQ]W8ZLC2G8)C M)[.2&VFH0!I[SX7%VC9<4X&D&UF/KNB)V)4X\2YS@1EF78#5@P6?M0FP2UGJ M#O6WFIXJC$=WU6Z6WT6JJ\7]6SXG6[)C=D=2[M,W'H@?FBE-W]9VV M1GBF8(E%ADE!/+*<$=5P-2MADWKM$A-!-YKJJ<8XD8F?ES!^X6&NMAE&X'X< M,^JT18(W!V4R2I,&>$)J^4U:=JTYK"3."PS+CW9>9QYCU#S3X9HFM=#W88Y3 MSF4MI*/!9(YP*BA5F##9LG/J'6A4OS$3;SE@8&UFA0PN4$*",/XEEWQ4/D17RPWCTN=\K M>O;QWY.B]W98/0Z>PK=G[.MQ9^F^7):,.\D$]22>N]/6<-&PQ'N"DC[!)56, M+DZN/:0[GEI;@C(A4#ID5%HEM`Z<&=(2^D+MG;"I:BKE\VH5^L-\&`]NF'B8 MMMH+<@1%@]>29I@&[>.6*8P@$ZX5!:72&D0PND29?9C`SZK\%N@FUAX&FR;3K)Z9S` M$O(+IH+51`U@SA#!'"R3RDF>>1[:IXD02=/$ M!RF5I`B'B+9G0ONQB*<%BI[/Q\-XKFY+*@N!`#N)C!8>%D4HGCAN6]PL;7$? M4[\G]2+VU,]:[RD&Q\>*4B^ME,*VX[ZPZ8GY>ZFW$(:#8P?`YS'@6".BG31/8L+7)PXE+J,N73@E\=16W!$CDD1+#TX*DFD(5<)"4$"9(B00)K&3B:(/`K*R*'0"L=$ MDDB!##X6D;NUTUJULVC6HV*AGA0U(HS&G;P\XC\M`0'B,=MQI6W>:GN_H&WG M?A`[R7#==3&.AW;?C1Z*]JBLN>B\>I<_3,=%>0Q^.@&E9P>:YPT8?1"JXNI[ MBF"RUZ/[ MA_*8[1`<<[V>9S#R-49[=N\Q`ZHD2"*Z^NB^Y`>B(=(T8N'SR,V MP;`DERCQ%*ZK)B5\<5)76'OC+>X;M99B'L3%?'+[?OPA'S_,_C!=J/(JM(+0 M_Z/HFGC?-)1K:3FC&:"YFRY7#]8S6ET^/?731?M4W%33\HYOLF'_?\K5Q/7Q&KXP^:3_N3]]8G.ZUP][H)HUGG]JKKJ56<&+_9JEE^]>A/S MVRCCN`P&?S'_4AU_Y<@O5 M]>/EZ,LP@N9-KR;]7C^/$.+EP,/U\U\HVP.=IC]PT7X"@_Y3YW5=WY#9I7/SWG7S;1?N1U4=%?%#"8*UJ]QQ',: M%M<0O^!U!&,:#-I*H92O6^,^Y8/X"Y6A'L;Y<%*A%$WFIDLQZ-_!V,$8+E5G MU8#!E\&13U5`:5+`(5-BN:M>CT0-4T<4" M,&#%"%#BMD5,LC89F$CMC3]YID1IS(I$"%\_H_OI;U8?GD&)S$2F1L@T_V9+(%G(@/"AWY3V7G6F`><0-L1BG:-I M(.GU![\MFI81X&2(LZ-1ZZ]+;>2Z/YKVUH[.-D<3/`!TYQT&3!/!G_ MMA@WH_=*-($/;\.8K<]H*<"W+K6SG9:YIC2T'9O9.!N4`*8$Y=B\WOF/J-0= M]][&4:Z&N7:LK?6WH2IV`T2QJ;B9>-K[OH1<[U*`<&N"K-VOS#9FYPZXN7[#3CN>8[O].\!=EL#=01,F@&[Q9; MLJ*NPU-:'U*Z7D/O6%H:3C!JZSJVDDUC0&;'Q?ZK$*(,06Z,WWBX8?O`H%XM M5A.(6YI?K2,%%:BA8;$+1;38[SJY*^NYFKU:QIZ^_M"?+>?TPJ^;IRX_4AXR MGRZNYHT`NE\7\XXQQ:%-.`;M1F?BZG'9`$? M*L-WUW1T?>`LBG>ITU>CZ=7B%E:B1/[7BW+R`]3\ULA^]JK1[;5=L1H/.UDZ MJ]ED7-*1)C\I"[7^5$PZ0)`E9FN\Z%7Q=(/1-1Y!E2&V\X\3T)B.1_A**+:_ MJ-/:OIL.VUBP<56=5K:/7KJOY7QK^*E+J#`1*O+^[QB2PR\LCUZYX]G:IENO M+BP->Q'1H)0"/S0B>LKYW@F'=E^P3_UV4/SMH/C;0?%Y#XK/>K*Q<8B"+K`Y MJ<1CS!.F"C/)J,F*6I]LTCE+E5='D$Y7E\RXV.C^VDK"*53NFQ^1HO&6=,")E)F.(RNCVA(HG7YUF&D7/ MP^^%+O`EHBW/*N1@0.VR9:(=DR4)\:KN3Y/\)'[1`$R''Q'GY=-P=30)!A=\ MV;@9UWQU_WY5&8;=6'YJ0G+7U>$*=MM["&N//%M53CK%C%+"&T.-U,FX;@"K M454/_&M=\_GL3+R4H':?E%L;N81]GK.V(IC$6#>:G_I0G91+NL4H?1UB.G3M MP3GE33+&.N\H=9:[[M*/#F[+W/(M&^>KD=3N=O5,0^1@2JUW'O:@RJZ[(TJ, MJ-P<-5O\Q]1 M?;6&[Z2>MJ)1*N;:4$50 MYEAE@-0&#O3E6-@7<$&XKAVU(B78SX8JKWEHVV>8)OO&6U^(@0,18Q0IQJHZ8RM1\<9+:L'>/%$M(GD`$36,"<=!` MF,]=*,%%JCL3SR67U=+B-*C1^->6@3?CU4F[FXYF\*=8:J!ORZG)J7N'$^,C MB=*'[`P8,'!%I-W\D(-5+1:F*0M90;24V<#3X$ZT9J9 M&%,].%BIKUE4^WP[$40&*1PX=&-BEHFU;2""ZDPKEZ+LURRI`_Y7,D:)2TDE M[PV+/%K>C3-2BE91Q.-,SQ!`Z:9^[7--D7962O^V$D])-IQ)U8&ITS-GF8`R5EA2S1"NMX5-EV4:5+J@JN7DR??QP/AM;X#$H\[K"]AOQ?D!FIZ!BWWGL]PH[R'2HY`= M*TXIMEZV>T384!W?80?IBW&Q!L2P][O^_I_]WR;3@&C6&_.WFMMW;CR(J[MW M:V>B2\"',YV;KL/6"@$)O!7*@*XDS$B"6YT3ZUP)_D75IQ-@>^MAK>=Z)8+_ M_,$8*P^I<#/.NEP[9X<0/2RBG8$99O8P!>2,?\W_4)E MG+4,$82K&!@2P;3F:[$,JP?X/%VV3\2Z-M)EFV@DWFF/,&M,=?=F9+!5"801 MR.5JG3B$=_U84O&Y.B-`%>KHNY@D1FIMI$T\BH/*%+^1"<,UV?PJLR9>5S4*9T>WDC.+ M"H0#Z@/F@1,A,P\Z)0^B8AF+JRI6-^TN)J-GX(V8:!'G/F9B5:8AP"(7-8C2 MLRV@!T]4@Z;><*+Y M"%E+^36$HELN`NZDYTFT'[KIF2(U*61-79+.2\93=T4Z.+8%VXEN33G.1OQN M]$_ M$(VK8CRAY);(_I%TO^W?%]^8)],'1NZ+="L$(CFO81TQ2/92.@O**`58-VJ] M-?MNR>R2PP6E=?F(3H#+#=Z!HV+"JQ")MQ+D!?K'/`\U+L4+R.L9N(04Q)&4 MF&.(P`.!JX-T&;E,C@'?GZE6O$0$BV*2 M00!&RP+L9\(A_!`K#QCKF=L<`GS<@M1EN,!8I(74@E.4[<(& MINNK_A#K;EPR?/Z5/1^[FECP:%%'&8EV*G`INMX2);H1G^3?'/MM.Y9_FHQ_G8,[PV]VL./+,MD88H+YJ&!_CT>3Z;O% MA\ETT(Q`PX;H&>?R[7"*+J/;G!2`TCR77\GGOQCBF9!&BY=R!9\%D3>8'I7 M.!4ZU65=3BP18BL?CR#O^?@ZE&B*2*1@,5@GN/3"*-FE$)98.[ M`[)X.\4T87Z/!@EC$+Q1T4QU.;;'5$>5-:\ZX'@[^AK@G1&ZS!A5CCDJ917>!3D:[<:3< MO@/"O#^1M?G?CZ/L6;C9.\8"ZQG!FEW>AM#3]>BIOR@9E;S#]. MIGCAYS@NE"1:09)//(_`C7)&=_N?2O=@&'MY$1[E;5J`O?0\B?:]^N03Y<8A M$C-5V40F_>J.FE(/].ELM*.;/E;F8&(A2J3*)N.3TY$(V<7%E%&_A>X#%#=4 MG$SM7BF#VU21:\Y<-I9`_HK8`VWU4#P8,?_,U+Y9S''2U&`SMCTH8&.9B\;+ M:(@G8!.3BK;=FJ#DYGB2UTAY&MU[11UMT)1ZJ:C!@T'KF.W:VK/RYZ.[&)NC M+BS(P"+G)+*H\3*ND%)W[8C:N7U75[:\^GC:]A4PC7"@L,J#W^>"6$A&4I>) MB5S7C(^D[:X_&BQKF>`_UV9PG'2C)OGD(VXJ'H2`!8^\RQJHWO2)W_V-";5Q MI/X(BI[.PCYQ4PN[BG#C8P8K+$5*='45!%Q+?5.,;IR*7(J%2]R0\#1S)J/V M+`5%!=[KZ8!:HJU/](UA]/+"N-!-&:N2L29$EHUSEB9A0I=V*5NC<"O-GBJ+ MR=5P.)CEZ>2VS:#?7&,9X/VR#/!9U0PT,4&#"86=+QBHC`ZDN_[A&:MOV5NZ M>9'U,,>/D5#C+7[!.8^PJD`_:L-X4'[M<9IF6!NFB:G#[,=VZ&2QE&_N3D)I M=Y")L^BS-5'@9(8@?->5&U4-7\X$X^HQ_#\3/R\IND/XU#EQQAT$"*`[(8,! M9J$+(DVL;PQJ/,G['$2W5O8KVSDWT^?V(L8?T"/P*#%&HH*.$$\KD`?ICBRU MT36.N.*@2CN%\0@*GY>]`VL-(:R1RA!P'R0:Z7.W3301RM6U5L4J0_I,W/T, M!KDM4Y:B[0@GMH;^[..)R[AN#KTR@5D(<:21)@6N()SH.NQRJF]74+/'&AY% MZFZ.L;('^O]/'(DYFM^_N7Z^JB1PIQB-&F^1X'TDB!Q8NZ[>T4IMJ4'[MQDN MG$3J>?@]5%W6"L(=GV(6/,/^TTR9;GU-KB)%""PYW0P5GX?=Z]'\%+PUAD>3 MAOH<@Q>P7%:XT#HLB'"J.C)35E3KM7SWHVDZI$402:F40[)4IP0Z%4E'DV:^ M.GAX#7D1V3QH.YZJO7=?=/2)4:`D&V4S54YVUX1SJJY&<5QA941/6[HC^P:WHPD?NI1NL#5<,Z8%9=)F MSML+^9+X;2ZPAAB_%'^/ZHODTJ4(T4VPEABA#%>L\P7,;IF<)HS=G'ETFE9? M:,$@46;<&R=AQ2#RE5QIVET$(/70K!J0^E+L/6J](DZFRHDY(D/F5G,=NGB4 M:U9;(8AI3&7;=_&S_5B`25@0&I-!G.B09K[U9=8KQNNA*X]>V%J+[(6&"7#1$I><)2$#$R M")6Z/EO)ZS&6FE6&[1SL7ZBB1"23F6%DS*7"*2A"J^[L.M>3WRC7I^KLST-$ MI,,(:KM):\Q$5R3-_='T^/*L9,G(3&C*I?RB71*ABP*]K"[?X!!DR!7``$>IE=#4 M=>&,4J&Z)OCZD#"Q-`@XQRCEEE9$S6YU6A.!I>Y1E4J(WBP!.X MVC8?X91F&N<#AZPO9.N)SHGB(,^."?A=/7B`4+7)Q1YBGD+WWK(#Y=8[*;!U M-8*EU7QUHN\>A_YT MBN#FQ\?*D0820?@>BSH^"R6H:RO$!+9##0E!I-UDY!CJGI>UO6EMR%K&&+W! MR1Q@G8(07<&*ARI2@?4T_/-A[5(0,1ES/.V#5CX0J9)?0>)X[BLI?7X*<)%[ M!LPA0@K)5.'$"8<9+F=?#BBZL2R?.6,&Q%>`/=)#*2>L%@:AO=:/9U8D_ MTT?QM&OXQA/8V3OC)C,OO+542>&,CG0M\E;)53Z<4\LK?W(Z0VUW2>ES*Q,H M5Z=_L<-I[2#'=KK+M0HUT<"-9)F:3*W1H('=-;.D['=_VX`/7(=T>S^Z'VMOY MUFGWOT'[\-]'@_G'OU`#S_RN-YW\#N\?__4[4,*KR4W[_PX>;CY8>\#C/_SG MM1=O(:$D!5?]FR6\XGQR=Y"2?>B-&]RWTD/4QK\09/,I*)2_-R_Z,+D9K!ZT M&T_O@R"+P-K=-E*UWO`_Y<+ M,/KCN`>Y%'^U#B39`'`B"';O[J8_1@C1%:KRL(`:+UO_"X3V!/1T-+X:#9:P MW*."YGN%^,*C%D5YC*"5MW8+KXM7>%5Y@'!2EX_G$Z M6?SZL7<%LBHXR>M`T.5=M[?#*8)9+L$HER"B#W&?6]#M>_C]3?/<26]V-VR^ M!ZPM@Y7)]+X@GTZNKT=7PQ[:W&&#N`ET%AC5`7YS73AWBRE>I2K$]"\&,TKE MLZ")OKZ'K*=AK&%SOAP&T``V@QLT+^N/T5K]#[?O3#"HYV7E#FL9VV`?X>-4%4 MD27>\IM=XRX9@XTK+_ZP&-T,7D\6\[+51@589+8&$=X0\?T*E+P;`]*\Y8=7 M\,?-]\.7!J^!NF%O/+P:SF9]6')\_7)=RX/+NIMOVTB2_W[`_0^$L8/+`DZ&WM@]P#B6S$=5==6OJOI1];#O`&.-\H/JLU^YICHOK9)3" M)>6C$EY*VH#QQ4[*LZ;7_(<2;@)N_CT=W$A#N*P`3C6R5QVJ8]7M'B27%O%T M+,_BQ$JONH(E<6A4DJ,>/>[PK-SGS`FN\[+#O`('\-Y)A5\ON".W9$^U.']( MP,6!7QSF(VDS[SOS16QQU.7B5U*L'>:Y)[=RG'E=D9_G7YWE!:3QLY=#_B$? M_'7'Y'2+['<<%3=I5A$932=Y\T6AR%+?5-FH8.]LN1T"U3_1=S_(U<&D>!O+ M^::[,GG?_-*RDM7)[F-*Q19RK2V2547:APN+?K=EGES?B':];^<;S^6^LR%4 M,WA4!K>;1JI`=7'Z1P;[\[@W_[D&X?FO*F#"SYD:FP/C'`B1P=3[VW0``-RI MFW[T;5O,.\W(Y1=/RZH&V<8=W7TURGR4#HS&^>XBRY5P.R>MI_R=O9NX[+6S M5U!"D]F88,!T<+>DWE:Z;32+2O=9QD2[Z]S&OWV5$1R!$7<(,MC MJ^;*Y$ACGE:U7E0-:U73JJ913:O:BU*U9Z.:#N#VU#^YK[9S89V4.KU)Y8)$ M/BVC;%#^M1_%DOM-KJ/XCYLBGV:#M_7T>APGR7!X!'5;GK]=H`"1I;GLMVAQ MX6./$5"W-1M8Y(I0[E3KU&,ZDK7#M(^`NQ/>7[J2S49U?*[] M/E\42ED[E`7&ER9%O0NDFX'O`,CAONO"B$=)5'RXD(MP%]_/^#R$1KQB?ZAA MYA7#C'4IB*EA1L.,AAD-,_W!#+DD6&B8T3"C84;#3'\PPRY)=U.U+QYFMI_G M>6W3.?+@H-%4-=AEBA$?=X:Q:P-[0RYML[-9B;9F]`U-XO"RJ2.$GODX$Q M+/+QX]G7/HRQ4\$?T4KQ)>-Z;45/>IZ0GWLYID5HNY2%-BUM6MJT]C0M<6F: MVFMIT]*FU;EI\4N";6U:O65LVZH#.O/$;+%X7EWVJ1<#[/@D!CJN'5)L=6:% M&R3S4HQ13S9J:UIC3B2D.YB1&U/VIY>NSTQVMUTQBNQ M)[U8MK.^S9T`350QXA[.?BZJ(7!D#'*Y(+?7R?BU(UB_3=5U[$GC3V<3]";) M[K-+N@]!=KZP`O&'U5-VO(TX#Z!TQX=9/7F\>SRC`5(#Y)%.S*(.EYXU0&J` MU`"I`?(%`:2.(#5`:H#4`*D!4D>01P?(M>T!YZ\_&&%S0CO!GH1?)K(SU4T: MOZ"NA#_%DUP61I:'#K0U[\,<1=-4M53[3I1]Q>)>I?JG=@\7C;;2QZ,<3)( M8WA(^=A@25ZM>B'"D_[A_0:/'R85^9EL[:=:D]U'H\NZ*1HP*V][`$DG;_/A M4-X6`QY%0%94ELFD;)KQ1=530'33T:0Y+C(G]_\J5>/?4EX$SW> M@[@KFC)C.%6-_W(E,=GP-ZU:"\;?2@!!8YA>%[EL`JD:_L'C"_E&U8I=?37? M[1$XN2FB\3GW^+M:T9ZOK!M,3JKF9:H=GQ'=W!3)C>POMZB[\6U4W"1E]UWG MJMB`T'>F`9>-8%0[>:)4C6Y(L[HF[=)X[%G8#8G8/%GIXB= MU2V#U4IVNM]YN_K5$IXIT1S_5:/,A?Z8"\V`E#CJ M3LS)+!Y];+AY'8TJ^%6AP8I;%5Q'$%6I,3(FW^Y4ZUJIX\]!&14S1SVUMUP: MFU?;WM+&[Q@5G)BH^LE/J;TE?IF]`X]XGWDNA&H&U]S'='O+$UX7F)&[MC_- M&"@=):^Q/\WBB;-@ZQ-G6O>T[NVJ>[(,S;I9]Y^WK]&I55&KXJZJ^#G/WL:R M*I)&0*UVQ_*^LY,&1C19D;H_5^8Z3-1MY#;HW2':R)W>AJ7CGB,*6FLDE\T" M2;7JV4SFJ>GF8SJ@7@J1'%;8Y]]$X;#RLDQ=QN9@*O.*?:S&*HU5^\JK4CR! M$>[?9#5F:EGG<# MOL/*C759\>JE6-SI&=?)!0&OV69Z"+BUY6C+>066\Z93=]-6C/Z"Y".$-+JW MGS8Z[:Y.+[4ZH;FA([?Z@Z^**)X8DZ08IYDZ5C9WQGKNQ,^VVP[.I-G+@>=, M+HG0;Z>T#&M@TL)T2L%F7W-9I95^3:[IC0W-?]5%>OM"Q(8PRX^H6\"DJRRB^G9;)!#[E=TE5`KF4 MQ8)G4DDSP\W+29Y=+EZ_V`AB5HXXKXOHKRN_.VOF(`DHDG&4*G)`G\K$R*]! M/#4-JBQ_:<"S"MF`8!C%/K(AW<)$M$@9@B0`7)7_9$;6.U&Z=N M%)&J*L!%/KVY-9R[(ATUQ7_$.P-4HIQL*MJL.@=4C$F^8L4)D#.[0%4)5U== M)Y5TBN<48)Y5'!ZF12G+C(^&]9\LH`P&6.J8E-7B2*@7-4TPMAB/JD0*T#A- M1U)W%^4\$Y&?Q'6))*2D1&=D_BO)!A&\^XOD(YD]9[UPKQZ[=3PA3_GH03H< M)J`&L2RT/GE(DFR>Y5EJSW\H9YT=!DWW"U5B3$9-+>U;H7,U*Q'("40Q=VO3 M)D()1-'=^P50<;+!KQ4A#ECGO=)I/RWC45X"O5>`"NXH MC__X\3__PS#^MN$)'NAGH$RO^EW)$Y[P:S+\<.%++?J%_.^5_WO]F-]_C;*; MQ/F:EK-O/D5?T_%T_$D-ZN-U\Z^3#U:O+)/B?O'NG^2.MH6+GWK0SZ,H4[?? M%Y.OO\\ZY3QU_Y?I=9G\.04$".[AQ]6WNT4"EOY>W7VANJ.,HU'YX>(MO3#2 MP8>+$,;T;6CZMDL(=VS;,3%%%+L@)&(Z+A6N:8H+0W9)4<*;EH.+'P'+U7\; M1W)Y'$YZ\)3TU<&PCX_GPDYZW(3#0N2$U`S`R@GS+8L*.6YVZ""$N;L\;N(E M#EMS75/4ZDM3T^JDAPYQY%#F62$F`75\QW(144-G$8_QD"P/':8G/G80K[P& MD[.HPXA//!?^#P0*D>\@.6[,;8V3TW/ M]>B*#,(2Z^FN2=B!2/P$D<0D(C1=AW//1"PPP3>[#9&^Y_DMWVVS/DBL%'4M ME8$0/G="RV4F<9!M"U>PALJ`>BN2,0'FV8\HGZ*3N>!+N'9<[BLIT*WX3%TA.N% MA%`9`7+B<0\QCV#"X'_N(MQ"&4)Z81+WR22,FX"@BB/J"T$8(#K!#932$+>4 MOB\HQ>N4?F\./20$^(N0VN"L0M^SI%TK#BT4L``=SO7VQ*!+(>)Q`^X*ESK4 M*PYZ)+'$W%A-@`6]X4CP'21Z1//#P(E)^:;-O-;@=%Q M)70LY\4)#<$?.3ZV+$``9OFFCR@-/`*N/Q!L*^=U6%$=/GH$PPM#1I%-7KS(]3CWBN.U4_,GH<7=IX5_P/Z=90LR^'"'C&"%FAX'OVXYP?,)IXP@] MG[7XQ)8@3WC"?1CMRU'0D`,WPK<\%UBU!;S+`4=!A>M3*MH!+K;`*@ZJ^7NS MB*D54L:0BP7W/#NPP"M*%L/`LAF,<(M%1*Q>/`7^Q>J)10>2%,ZYQ2`2M9'P MA.>8'G9LG_@X<-HK;Y@0_,1\Q^XLHMY8))X)6DD]2U#.?3<(7(\"BXX30C+F MTM8\!&8$/3$/L8^BXKZB4A/9*`QL!CCJ"T@$PU+0B4+O6XH6@FQ6N)F1WBL'"UMN([7!;8&&9 MU(?LE/B.RV<31&;84B"+=TGQYSR+=Q"SY3L0CB!F8B^TF(TAZW2:V3?DHI:8 M$5-VO8'J1V+V(OPI:5LA1Q98J<:#$!@UMT2_K,Z?OLQ MBPNY@GB@+8=HD";A^9Y+$VB-$L&053([82E$\?3\50M M"/C),(W3+3$H]`0.P1Y,SX)DWC;]!H/@7TCV6F,#"2)"+?O81-/>/#QE)\PD MR!0A@\C9H:'#*6=!,Q8N9!XM'@B%5)?Q/7FX3[+IMLL5)"0`\CXRF4,P1/D$ MS2@EV&M12@@SS>5ID^J]SZ?F*36FID/LD#$+4":P0\%-AF=J;+KM:2IDD_8R MSU84/:6-`7%Q()>/AI%U[GYCV.)6FX(R6V3>RD7/@J?MA=B'PL*[@F;@OHFL6?N M-J!V*VRP):7[L8D/KK)$8`=2TL`T(5OC/N;VS"Z%*UIN"V/*EL/\E3SFWZ+1 MY%O]QVW15`!BV4X`824U*8?@ES&_05/;-,-V0&]:2UYHX?U;T;8!R:@@'@D0 MMKD0V+)!1#`:5)JNX(B$CHX\.1BAF@8YI`#M'?=V_)P\&+_FXVC],?\M#J"*0Y\_O5+'&D>C_"&51P"E^(QR.AY'!5Q7JD-V M\:U$-W7,,'HCP_#L8(AL"X_J:^S3,@^-+(DNI@9O3U?6>G=-FBE&)X M45(\1_P+E0S,I9J`\O/\J[.\`+U?.+R/Y#6S!U?2BI/1J+[FPP6$[O)S>1?% MS>?M%0>$?Y-F%9'1=)(W7U3%*-0W#^E@IN\8L2`#:GY^UYR:CZ6KN2N3 M]\TO+:UZY&*^J./C27J\LHCG,^I"*M(^7%C\NXV']!?+!=0WHEWOHX=^H6;P M+!D\DX*F)U=$9D8NV51+>*&T1[MX1P^R?+KL1\M!B-T$*)KB%`^5A[C.1X.Z M-D5>P%>94:T&QM^,*UG$852U%'$&_YZ6$QGKZY)&6AL/H(W_DQ4)O.O_($K[ M1UX5=_A[E&:E`/VC6OITQZUR%;KTQM52"B?EE$V*)]=._"E-5#K48,G3$T*HD_.) M&H!>+P`ANW_\>2FE237&:(S1&+-#D$,[+/[^FH.<#I)^\_B=QV8KNK/.8Z+3 MSF,_K5B&3=5ZN/%&+L?^U;A.AGDAB^+&HZ@LTR$(3551W64>X23:SW>9D'0- MZB_9(/6$VZLUE,[LY+5$Q]H67JPM]-"A[*5819_3Z<>/Y=3FNX58#G?;1=89 M@Q14NX4F5)/E\8M\_*R-=WV8YJ:%R>.VC3YIF]Y9="\%#/0$T@%\IS90;:#: M0+6!:@-]@09Z)MN>CALTJX-+=7V:.U6"9&6$O#`GJK-8/?6IIS[U=(^>^M13 MG]H6]-3GB4]]OMR=Q%^2NTF]E;CJ-TKZ21ZZZFJ^;KQTN_/YSMU[;.(YAS[H M;S@]G)IVNP7H#/14;X(^]@9%#9T:.GN"3FR>`'(>0...'X]J=-3HJ-'QO-"Q MTZWC.K#L8./Y]ZI2PLKK5_P^5]ILO\)E:ZN@99-TD(ZFLH#@8_6&X&L\F@Z2 M05CD8_GXZ41M\/YIV%0#_SDIOMQ&Q=.%T>8KP7(:FJ;K^+)L:.C[Q+=FE6!] MRPU[KXK6DV-=/1TA%Y#D$!@@)D/)R7`FDR*]GE9E,B:Y\1N86/+5`.&.\ZRZ MYA;N3XJG-UV=R>!M)/MTW21&-E43.OEPX<[2R*>34%9H"Z:&+?P:N,Z23(@KYS"%<"((:G-\HGQ#5B\ MAYN3P3O#E[8#?S\9MHV[T12H`%60%AN-VH^M'Y;\.4WOHY%\NEH,*>M$<#YVV98 MFD%,HOC6**?PHQI*73:QZ[*)@K]CMK`0KG[R$ZJ:2,FN)?#,MO8TBV_;[2/,?2I%: MRI%(-P4&XTRGI<1)^H[4/=V39.;J?*R8(: M6U8-39GE#H`:H/8VU"IMT@>HM0EJ4#5`3355@P-7<"11<"FSJAV$`2%`J-0F MU,(6*A7OO-W]S%Q=_$?E+OZ[SJ<"H_&V# M*ZIZKH'<,G3-,-!86$F(@%OUYA;&+7`+W,*XI0"WM@_3VA:-]:,PMT*^B3`/ MO2@FR23+2WIAWKDPC%(N+4JK,?&PC![IM(+&J1JSPM%H3]HD)?@`/M2<#Q@E MP`JP`J,$9I"*C%G^"J>+P[99=8:DPAM)!045$1(FT:X9E++,*0-?:`6 MJ*6`X92A%D8M4`O4PJBE3B0GH?>,I'8QK[6CZ;-DE/UW\=B<(CD-W>M1%*X.'=.+T^G[6=L_:QWV2^\_MXM`??-IF8:$C MAI>09!3=A^269X+X)B+15F+[MA)4UR5VDK`KZR2QXW&]NK1+P/WA_M`E0S&W M^/%R32QS6UU59;5R=AWYY;W1&<;<0@0ES@!_@!?H`?9>T#_+0RO68\5GT5[5P% M4<@?9B5M9"@,4^DT3<$%J.KLQ;G'5IN*%!Y;CJX9#OK;(,500R\!.E,;G2F@ M3P.T!EH#K8'60&N@-=`::`WBIQKH3.TGS`K/Z7S.]"W,%H0>)>,H3**8NR2O MC!O'7K*X6'&7!&05&R1M40)80,N"GB6-G&MLTQ2.(J$//I7H6H-58!58!5:! M56`5?+_:Q6<*98:JK72\B5+F3\L<7ZIW+`:)XJ:(&TVRKBZ[TK15&:=UQFM$ M2LK4J$.K-UE3-!&Y\8)RXY`R2%FU@1'D#'(&.8.<0^G("PE]>B0/PL7=N($B:N0+3%^H'R=B/0ZR6K7V(:`UT!IH M#;0&6@.M@=9`:Z`UT!IHC?):4_QTV@;[J"B=]=E\K;&L/-#&BU%JMMC$LBS- MTJ5MX=P4"B*CWUI&F-+67H$,($/-R7!(==DH>7KBV]YZ90Y]I1-&8$HMF)([ M4D878\>^L8RT3$K=@YQ^%`0\'GC,)V,VYO%R*$,*BV"D/H`*&4D-2].[V^S0 MU^ZT`U*<)8QJC2%73U[]/(@%8H%82)B#8"!8.6ZA87=`KL(BN/8%:O$XBEG* MBG(1@GFG,"4 M!C(E=Z0LU"OL';$HE"!0.I1APY3'LTB&I"-AL;L1L?*W23%S46O:%S)L%+W1>+0:&D=K-J#!+E=94MSB2R)YIAR]LX=YUEFJ)5 M2%-#9B`SF\\(6]+J(R`QD!A(#"3F60*E4]"$PQM6V3A3H@YT,!$/^8'\%!-( M=>SR)*@I7DYSJQM*W.E6>[;-;;[W;?T21:UIA=:"?8FHUC$,K=.1UD0`.Q-A M]JI.SAK$K#EB5F8""S(&&8.,0<9JGB235V>D3N8#=4:0.$BRKI573RIYHZ!2MD*N`*N@"O@JBZV`JZ`*^RBJ\3$ M:/[N?OH0;R/?G9[G-"'1D)SS`0]N>4Q,JA%#I]MD=#>&;9D/H?[!O#J(5\7@<>\F.;2:D]17>Y:DU;&_<-19J"J.1_@>K MP"JP"JP"J\`JL`JL:ANKFCN!7V+?P!=K)(M!(CHUR#4>TECHTX!\>DGY=$@9 MI*Q:1PYR!CF#G$'.(&>0,\@9Y`QRAD"S3LFWMN78OKZT]096'RM<_]:P$1/X M`7Z`'^`'^%'0/LV=O"Q\]?%?[Z_?DYN8LV02/RSX5N30G7!R[Z4C+R3TZ9$\ M"!>WTCTO6Q-(UC].I)1JIL3&\4T/`Y'14LA_@,[41F?D;24&A8'"0&&@,*N' M'18O,<_94IQYL(L7Y`?R4Q_Y02"EVGP:K7G:9_.%Q[(201NO2=GE452XYJ33 MT37J4%G<;`H%D=)O+R.D[8D+,H`,-2?#H24;)!L'B,_NO/X!(HC26*)D?I1A M2&-+4X:."J>VZQ[C]*,@X/'`8SX9LS&/ER,94E@`(S6+52$C!1LUH]=!U@'9 M375&M::0BUK2ACH0"\0"L8I<:P>"@6`@V();V)&7XVL\N3`9M3Y0B\=1S%). M7'Z;OCKW5%S$5C,&4D%``TEVY`Z5R1U630AP`5P`%Z833M+(@(I$$*7!1($7 MM7^THEY^0.E(A@U3'L\"&9*.A,7N1L3*WR:8BGK#KF9/,RT'*0?D\]09[IK" M+8JZH>)&U.?F.3;941J@'H,*,/58.JJ:1J633I MZ/(F9>&3[9104RC]K4*F+=M]5WNV!V^^,6\-DW!M:='6@DV3J&8:5-.IO(4S MK=\V"3.#M?(!(6:-$;-26NC MO[:0H_N0IY->_/X+KS]^F"1'=XR-CZ\'(^Y.?/YMV&?)*/OOXBE9=1JZUZ,H M3F]X'/P>_N1)FO7I3FZRG[H1=CGSH\&/3[_^0LC'Y^>[",9^],#Y-8]_>@-^ M/6(Q/V,)=_M1,.9APE(O"D]]<8K\U;?A%1]$=Z&PD/M=6"P2WTO$;\U_1CRF M,'L65WQX`%/R!_\GEQ%`7M=:1<.][V0'XUX+NS4T-^M$L^9YQ@7 MH+.8DHYCS/2X;BID@@3CY*"!?7Z9)G2-SRTF:\FQ$R-X`K'G.<7\QQAOCIU5_S M<]["?GY\]L39S/(/4N(^/\P$LB[7[-Q\Q;/F]K+#WR0 MM[#?!$E+XZ*^DIK.WB_^=!C%`?.75)]FWWD\\32K/."^/_O.R8%^D+\7&C>8 MO]^>`P&+[[QP>I%LDD;S#Z:N3?[)O>>FH^.>^=ZV]&[/G/W;>3<7:H$%GXT3 M?CQ_\8P@3W>Q../PI,_VB_7:&TQ:Y)=VMD_B!O$ M#:IX@SNMYD;,]72YW3W7S12Q/&;9RW]K]-LC>,C?W4^'O]O(=^?N3N:T?)WZ M*AAM\3' M40?"*V.LVBHE$`?$`7$J&TX98P%Q;4!<[?O/%=Z1/'<%233.W#]IBUWWCDCJ M7SM)"@@`>V1`$=S;&QU`@F`!+15`FQ'LTUI,Y"0`$@` M)*!F$F#UM&ZW`PG8-X6@4!JKVMS"%4_2V!ND/+-6EF;(EGO%JQ].0B_=)O/0 MNHUBJ*[U>MCZ&M6E#7F@%J@%:LT/,W7!+0Q;X!:X54!_/*:_P_\84T(E[X4UQ+%&^W>TOY.01:+5:\G;X`>O`.K!N$]8YCKP&YV`=6`?6;<:ZXN=_V\"ZVL]?E;2YY]I(T0L' M_B1KN.F%X@O);.//V5\5W^L36R0W;HMDDVHF=DA&]KED1P3B!?&24(/4U2Q' M6GM4B!?$"^(%\2IM38VI]>2M=X5Z0;V@7E"ODM3+L36[(V\:">*U=8Y-_73W M?%=$>RQW1\M6=:]3RHC*&`Y(!!+5,!R0""2J83@@L86;RW]R/QH' MXH>D5[OM-"E1;,<1=28DUJ%1_:Z@M*<9!EK-M"`G4?E0")EIL0&<@,9`8RL_U6"AVM8Q2_XK@I,E/[Z;/BMVED/D\T MYIM4!`"A``AIH0P-,-`I_.]XQ*%$B)HR%+PPKK7'C56W"VN'=LC MF5.'I7AEMW"I$'35ZS'2T06EHR&0$,B&M(F!0$(@(9`0R-H(9.FM:*"04$@H M)!2R-@I9=KN;5@OD0L[S0\J$75[\_@NO/WZ8)$=WC(V/KPA^\=BMYWNIQY.OG"63F+O? M0G'R21P+`HA+\)*;[.8>3RV>6)@]EBL^/#DX-W1J_FD>$,\].;AD@_3H[-SJ MVA?G/=.V;$NG?;NKGUH77=H[M_6>95T>?%IYQ(N/Z\8+>$+^X/?D*@K8ZT*^ M<'BV%/IHOK[=T-^M4M>9IV\74+28SC66L[G[P^IFQ,DP$D_J7EP%R8%!,EN+ M#^-T1%+QY^R9LO!A.K0X!NW^)O[JA2P<>%G)2OYHR"'_)\OX9B:K69*WEXJOH5% MJ;ULTH$X.X\W>59+`YN^DE?/WB_^=!C%`?.7E)EFWWD\\=2T`^[[L^^<'.@' M^7LA*(/Y^^U1%K#XS@NG%\DF:33_8.J;Y)_<>VXZ.N[1]X[`>#?#>O9O]]U< M^(2H^6R<\./YBV<0?+J+Q>F2)S&T7YSBVF#&);^TDX-.[]U:G5T>"F8'TEV/ MT\O^0=P@;E#%&]RI/QZ"IH7+M=9UUUER3)][F-L:<\O=7YX->'NX[?F[^^F( M=QOY[O0\F9M&_H_'XZQ;PP.T31%M*P*:VVM?J7C,:[:@@\!: M"5C[DG6D>;*JM%ILP`ZPVQQVTNI2`#O`;G/8(8)5)NE2\#J-XJ%UZ(4D'463 MA(5N4N".L@H51E2[LN%R=4IKP.+8XRYAZ<(D52$MC!7KOUTYS94Q5FWU$8@# MXH`XE0VGC+&`N#8@#JUXUOE__94J)6Q6@9DUY30-^`%^@!_@!_A1V752R'U_ MTZ?JK%8UR_:IOD8A?R`!BW_PE`R%/;`[!1JM;M1^0W>TGB-M]KCQG5:14%#( M.8#.0&>@,]`9Z`QT9@DPCD&-XJD&K8'60&N@-=":S;5&0HZG=Z?M3J;QRA8V%%U6DHA?"IG."`. MB`/B:F$X98P%Q+4!<;5?V($\M4H1EV59FF5T$6TA!X$2)+=7KOJX,MX,P7> MW&B2K2?9AY*M:;&QSG@-Z,%!-6I1S>Q(6^*\N]&:HGW(]^[N:D#,(&:[&\NQ MNUI'WWAS.T@9I`Q2!BE34YIO*'L:NE\\=NOY>8G` M5\Z22.5\XM&$F?VO^/#DX-S0J?FG>4`\]^3@ MD@W2(_WLLM\SZ<69^<=:O`%/R!_\ MGEQ%`7M=7Q<.][V0'XVF6Q]30W^W2C?ZV`IFBI?9MLN+>4)C.4WXZD\MR>5J MLC%[OW@M810'S%\2`YI]Y_'$T^XQ`^[[L^^<'.@'^7L!_,'\_?9&"EA\YX73 MBV23-)I_,!WQ\D_N/3<='7_K7+LZ<(7T\://+5> MG`[8(/&<7\S)@6D*85RK`]<#>]:N1W:V.W"G7=Z+F.R1EKX$XLN(X4FJ8.%.)W!\J:))=G1ARCQ"Q"#O)GZ)TG.+I60)BE(H: M-Q\3FB[]TE8R0>$;VS.!.IK>16L=N)A[Z(R\$AMU+%A?`6K*@D%J:;8NK^J[ M17ES>$!S9;+A`<$#6E=;I?4,:9YRJ]5$H>&[7)F1YC\K9,'ZZD]3'"!'ZV!? M;/@_^PB3-/<9^M-8_Z>K.4@`-=W_D0>7!>Z\^4JH3P]ND4*RM*Z^H"EN4T>7 MA[M=3=9J&6R2VN5KELEX5MD);PK>U!K`V%0S+&D"U&H=46C4+S%J^\*3Y)BP M0-QW2F(^CGDB?D5<.O&RI/"J%)*GIGA-AUVMTRG/87^"27'+?22[`L76 MIU:O:?(L]7VJ6>1GMO*&1$/X3XU8N=BFRM--#5CS"E3+U!RJEV:UMI6B2EC` MN.,JP]=6+?X>_A0'1_%#?Q+'XM56:Q//[,[YN=7OF-8YO;1[EF.?=Z=K$VW= MZCJ]LMZ[-[/3>[;;:D>YXG&&6_(-E'U?2#=;$DU?..:ULS2-=;\NWO8GBUSR> M)EE$])J3<4Q,72,RE^\!EH#ESK`\YX,9*FF.RHW;-T%!]X1JM]KI MD6:L`:]3&V9JCHMMPWS%[DG`Q%/UF%]I1JXUK;#JW^G*,.4U[&MZS02FW0K* M:D-C&JTQIM:UL/=F<0Y0V_R<_XWB'^+<1^,X&O"DD`T!:S;'W]5ZCK3)GJ80 M"<%H:_E`J6;*6[O7%$)4&%IOD"=3>LBY]$(O&7&7W$616\D6M%(?1874M#33 M*&CGGA:6\2,D+:,2M"74I(*;O8*VHFDA-VL?R!EVP:.J^OL&-BV9)*'Z49&D M$C4URY37GF.=89HB2@B*H3)0F7EKMNB,E(KI=^N;'ZM'OJ*)VD\ M&:23;/>7T]"]XCY+N=N/DC1YLRSZWS?G"Y71Q@7MG9TZY[1+>T[7/CTSSZFA M&T[?[)_9]*Q?^JXM1A6ET?&B,!W++?!8..&%YU=(+APZCF'`V&)&`_4>\ MS$JNLV\.Q',5!R71P,O/>._E9=M>LG+M8W%ZPN+\!Z8%WXF\BNV59]/:BNV> M\=ZVG*ZIT^F_77D5V]3>MV3;*+L2NBZEUSL?I]?E0G&#KQQGH^A>X8!D?75S M(*[4YVW<:&C)S2,7_XQYF'`$P\!>"=CKLV3T6J3T'0OC`<7RH/A'%!X-!!RA M@(!=9:/OE\I656P)U$8S]Z(%G?1&$I;(D MG49N>Q-O&>1IX"6Q@D!B=0A M*:_][T\W)0ZO(PVE&7)(%F($ML3+='U57U=55U=ATK[)`FE@#-)-),;T8W-WW!^-=#_>Z==-VOW(35X+#[?0] M;'(GY@274LR9'9,7'NUN>D_G!,0L8(1@A&"$8(1CA>1LA.**MQYCG%DJ6UU.NX37.5\#R`O(JYL1 M$C`8,!@P&##8?ABLV2*!VE+;J8K@"/0.R@>`V(#8ND1L[$IJ""O;2JZ]O9EM MK;:TM7K:IG\4XZ^%_?[I^WWZ7?Z$'?K:8N:\PCJ2J`WGB%!E$0\2:R^1B8[M MNZ^MNC]`6]LDB,'7P70PZV7[V+QB.GIJ3+O/C/:6HGZQH)H2;W&EW5OOR]ZR_CRLH.^PLMIO*5CNOD=!L>7DD^,5_ MBI8:YHI[:)B;&^8JT=.(28&?_H^[U#"70\-<6"`L\``+/))CO* MH#\7?PZ&PWR^T4HI]*M.I-LMU._.:?2A.K`U)PM"KA#'K0OD5`Z1X8)42Y4Q M0#.G33/L2M'F"O6`9H!F@&:`9C9HAEY1HH!F@&:`9H!FVJ,9<46;2]6>/,WL MGN-6UG6ZP+MS,:2$??WK&(HD` M8P%C`6-YV5@P3B%BX\?L8"U@+2=J+9A*L);ZU@*'VF^+@L;%=3'X6MQ MK6_'.P:G"D'H8[S'$?@_? MBO'U8%)\'`^NBU_[PS^+9P<2+4TC4M8$Y3'S3&"/N,<&N<=I1`P[ZO593"-Z MG*Z3"V4>Y]%,'N[N^EG>DXO!\$N>89-E?='_/'K(GY^E.IJ)?W*1?C*9]H=Y M";.I/<4C$K./Z4]/9B(1#!YJ>O`0QWRQ*5V_==:0>N.H(95VR-?-55&O?N/K MO_(0[SS`5[+=W@E-?SO2%NC$Y%,^[KZ;HP7W>Y6R_B_*')S?@P\(-`,UK M7O,.49AR))H7%@[G*P*?^AO%`41P]L9R M&6>G?K\\S&9X5:4\6MA^SES@_Y[]H+CYH9_$TT^F7R7Z7XN[_F#6R[_J%2Y] MP;A_/7WHWU[\//BRRRT<0*@!A%89&P@;"/OPA/T*KPT$?D@Z@.0*)%?.0#Y' M,((*A';Q/5$:"*RNP.[3/CS)YZA'+#'@K2YI%/#67LSP5*Z:/0EWOY?-+B]T M#\E'VU8$X_^^)*BWA^Y-P(U'([B6['_V-B8:&\%])A(C/=%<:?1YB.P2\QYI MK-5QAX0&E-9!;0-*:]<^CVSFT&&\NNS$X66OCC;IU0'3=4T^;9HGOD*R\2$T MIR$:WM.-S:0\+':K=T@+_864=-U M#XI!7JP#3-8BD/D%H'M4TAR(SM:I^LQUH\#.V" MM/;LUXEUOTY"9@P"U5=FQAJK4C\MN:@&Z_=/2S*7@O8(I,6`;5X3$T+%6*5- M0<78?KRG["SA'RX5Y,(Z0&\=$ERKW@1$C;N>2HI3O`G8ZAXBY0XG*T$UW"_N!!P]]>3HJ1X^XMM?1\9^1Z"&31YQ,MW2?*=3%YWN MJ>9..L]**]K;,`0)"`T)[.Z&)QFZ0GY?@+A7N\=H^\>M&-IR'H_QI-.W? MGF!P<62TUQW!M@:LUD%MDXW.93\/F5U2 MV5.O:6[V]F'#;)M'_3S$LQOU;,[PQ-W>#X6`RS=-GOQ;A6_[F M8OM\X9OB>G#7OYW\X]T/R].&M<-!6:V4]!Y19'G(_^5IPQQ)2\.[BX?AX/&C M'B8W[WY44G*6?/\E(=1ZJ$860OY)?__D*]="@PU<"H&Q"TP([I&CCVL1"&DK MUM="B4A&=L#%5*Y$<4XI"<++H+QR/!`BYC.@D5=J?25:"G6PA=#G48DT M0C"]^NQ;G^-5S_J"H(5W4CBFD]X8@X06GKM2T-AMJ#]&5%/:UL,^"O:/IW?] M\=/P>G17_#;M3XN[Q/L_CZYG;S/?!I,_OHZGW_ZHA_'[V4CM2A%PBA5BP2&3 M+`\$0\+,L1+(LPVCD%R1=O5J MSU#I8`V-"'GJ`Z=<$,;Q'"I%A-F`2@N"6Y3`GI?/*%%))S&Q"JG`;5""S9?O M^::F8H+RZUM;?N6#)O?`NZ")8XGQ6/(1F"]Q0A+'#9PP1:I%DZJ%T_PUOQ:3 MHC^^_BN!Y(NOQ>WH/K^T'D(AVZ=()LIXTCWKA15JOG##,-]`2+)U9^(@;-K$ MVK$RPFCFC8Q>&I+6'-&=F1 M2#=`UX2TMH7NP,M-K-U'I;B(D0='1<":4U):.E9J8^V"4=S:GE37TIMC9&>= M09'D;=D(X9/64SZ'/OTAF^X3IDT17:U`<3-,_'GTGV+\^+?!W6#ZK.4T'*$N MA+_YNS@>W?G1[6U_/)D5ZDY'LT+=1_G[49[.NHP"60(A[3!,)[>`&AE,4,XB M*QQ-BH9UH$:M^44?T[/F!;S[%/HZ=_9,;?-*IE.!.4 M1"7/1@C$A.4ILC-/L9]$#KE*.!G`N1[W%DN.(9`FG4*8*3@IP[@5.C62) M)JEAG):'&+!-KAMRP0OC2]>5*5MIG'DH&8#9.IADV3;IBV@2BT1$3FC$<`J_ MN=2T1#/%U[X*30*VN1.;162/.#@`_4!&403EHY*7/I`W%7:I0`D M]X*D>@I1T7:2.>)$7[.PLD'CEL05JA.2A,0/@@OKV9M M&15.6TKR>1XWV;LJ4_66!K4%7"P$@-OI/-(JPEYY1#T1P4F.,-(AA+GY6HFV M(T6_5D2#)3YX@S@7")4^2ARG,J M@ZS=YJOR6J>S`/'A2S*<`0YIKII-I?YB+RKL+\*XL'302B`6M!%66 M2.P)U2DL:E#1"_+B8A*;04UBA/K/62:QT#G7M:FC&V=2/F M>\@:`<1-98U4D%0+I!A60B+*DGM56K%RU&]SIF>%^`#QT>S$`HLH=2"YOH^' M@#0SY4[,'=N6^ZU5B7NZ"%?'GOEZ1PPJ,2-&1G+,-7*424R3(6''M^;A%))G M+M"\6T-5%RCG`^#9L?@T4DMUDNTZ?FR_SK_K[C%2<[%E$3A[S@5BBON&;A"(H] M"=I)YLKX1B%!GZO6!#@[$`LQ/' M*BO6*9D*PA"O?299K!*\I2N4_*+G[I,!G(<.1)>1%%$FGL66,V&PPX216-YO M,#I4(BD!R0Z$G2NWR#BWVB4GB"JA-#=&B)ST%0(SP8F)E0Y0_NB#(?FYH6_: M/#'_=Y$;HQ4WYFLQ[I'P+/KH$PXK-LD""BLPEVTTN$G5TD?NUV%4&HK.^ MNFM('TC^H`F-!;(V7XSP^;0S*(D(YVK>&DLBP60E@V/>(^L7#D$;NJ<-.P9. MU#@FG1:668^-I%HS5)*#7^^4MI2ERJ.%01U>5H!NE1)2O/FF6"X#MOA[LFI#`RF`6&'%?1:^J-P+YL+1=YI3[,AAN!/G1> M'W;,@!@A$QD\MG8--.8:\;*6F(9J>B"ZAX&7NZ\..V90\C5T&I4*Q-#<*U0J M+N>G^U3RRN,'RGL:V*'[ZE`_`\-H"MJ9U-CF&[%6,:-5J0G:5OKOLS''H`F= MUX0=3YES+]:@$36<1T6B07J1D-,XXLK4JC@'MV&S@N&Y)['%GX/A,+W6]M/' M=5,]=@SO$/;!:"&0#41Y%)B?=Q>2*#F:E;TO..U)TI)ZO!$44)?VO$Y/B)2" M)R5CGA-!A53EC7PBJ]4E>9VTK:`4U*6+2649J9"3/0H.`G'KRZ[GI8)PEB(,3JCM?"&:;VX,Q-B M]?%(FZ=E1ZPOOQ99V.G7+FG&.`GXH7_[J1C?D>TSAQ;91X^II,P++@D5F"!* M378AD=.,68/?_?A1_H[?$W\HD57YQ4FFB#ES(PPP)R7GL9R@$L M-F8=T$D'!.C`L>I`5:"PB"0EQLS$%$8Z@X@(!B]4@!'CD@J0W^5[@D$'CE4' MMF4&%[NQ)3A*X37'(H%,*!7EW?.HJ)Q1@'Y/8!\X6ORWY?L6WKN)3DOBJ(@D MBN0)Y,Z%3\E@DSR#A+\"^S]J_"L/DA:;0!3)[_.,:1D"BHHS7A:P4:=-4@+^ M.T[.(`4M.%8MJ#Q]7FIS:FB(QDB-8C#$&\_*JU[JT160B0HP`B4X5B6HS`0N M6A^8?+N(26Z<(AX[YTU9O!BH(3,JD!`6'J\.5.=KEGJ_DQ"9,0)'*ZG!/L:R M4$T:J69.H7I_'#[!9.G3-M)GY)]L`<=\W&GXOX?!]'M>QVB8_CE9F?>:?GR7 M%I;7\%('?>9GO2:4MBH@A5W4)9]BP_"6YC`$2Z*V-&=;7L.N2US1N(:7J"CC M%E-K'"9(*B(H*@?8,H.W->1,$0;76]J3O66)N$44=52"8TD==M0C&7RD97I; M)F2W+1%IBK:T<'K+$DF+*`;NC*5.<(7S07\(6I6SIRFEVSHC$RPHVPW%_"`_ M328/Q8U_&*=??RS&@]'-X[N2&2?#GB1+__#E\>_3P>?;XK?B.KUT.B@FVWAT M>5)STR*)QCJ*$0F2DX"],F%QI2/YR-M:OBNRWI+M32MN67JD%,K/H^&?T\2= MOO@\_?3]?FD;6?FLX6`T_NWA\VBA*,U=8NZU@IQM0!I!KN[F]'WXO"%L/BRV":MZJ7 MAL0WK86);1#55B#CD0F463=OC2(085M'*$FT/B)[QS4V+*&6[=0@2I!)NZ:A M.#(=?=J"R@V(A6T;D$)$MR^A_^W?/A1[HK6/Z4&'TY=('F.,-"+>>1R#]BF\ M6SIV(VO'M+F!!R&"UQ%4O:5V3FJ_C(;Y<\:CV23[G](G)KBG&P$1E4++J`./ M@B7G+"J%2ALT28AK[Z?BA>'?Q7YU;M[FY&62?NG_[L3^X M^6GH^O>#:?_V!?7A,J2=D!%&M/(^<*U5&1=&O^(&S=4'*W+"ZE.?HP2)7!LI M>&"4)ZF$W+1C?L\C:=>ZZ!0])K%5+IO18(27QNE`)78Z&5#9"(HR2KM#./7W ML6J,4Z!LE2.[)MVH=:VZ5K[CHF8:605 M=\R87'](:1D%>T_7^7,F&77LDJE/#DDBA(4@DUB4D]X8&UW9Q`&M-S-,_ETM MWV4_HB'/VX3TC`2BN4(V=YLBPBP*?:0(=GUI.!$?J;]E[&EY;=@$BT)0F^00 M\GCC%!"IQ8X@I3";DB%*=D@R>_0[F'0X\6K\?_:N_;F-&TG_*ZS<76ZWRO+B M_;#KM@K/5.Z2V&<[=74_CLF1-1N*9&9(V]J_?AM#2 M:#"6FE.*`XF@M;M8H'9!;*-TMGWGZ\E)T%$P.JM#O/7*1D.QI\PR6`V=@5949KI":XW5 MCEYO].#@'MYT\8]E6#%)$9><,(VU#LM:$N"/*QPS`22"*;4C-'A0%W\>]8>S M%-M_/:Z3@3+3:5V]GTU3O8!WX]TKZ2#@O9?<2D.$=XDCQ53UL(L0(YES1@R4 M8/N&MWOI]J-`<=,,!TP0+!BE)7).*)2.5G0RN'FUTQP*QB3B.SRGTX#B\#T\ MT^_/+F?#I)=>32_*.CU6EQ?EJ*D^EM"G\66YCS&E#5EM!8Z<:P]K"<4N1&&% MS#33&4;;%T:>#L"';W6_*:=%-2H'H:C37GNS_P).K4F4,F(+?HT`E[8C6$RP MG#JTT3"Q@ZQ_;8"VAG5NP=(W[&Y_'[S<:.Z]$DY1(/.4$>5&*\P!8^$838*[NCL6?N38$KW#/?C:L+T31;8&2THM%QP6 MN24!<=TI5TQER.P7N/B8?3N@'JA=O5,<4(P<$VFLTBIXV]5W(=M%)I-V98S# MGT\5T,/3EHZ+FA@7+/P7X1\.QB@;T(IQ[@@P<2(9W15A.@U8CZ!91\$*_@D! MG6J98<1&Z@(1JYH#V+!L]P+K]'T&FMS8Y8TZWBG4\6Q-MSH'MQ+AD&HDY1C`%K;FW*K:9+ M<`G?OJ3#%>NA6W34(.12()Y[KPDB<14_L3H_!'+&0"6?,-,_7!G,M89E+'%P+"X+3S%-\[B= M!B$^V42OAZQ08`V5(@B>=D92L0FC0D?P>23YV2-TTCC>L'F1-BZ,P>#E>.41 MC%ZLR(W*MAQUNHSK$7CX6OZL'=?U^-/:HV_@W2Q1%_TO?5M.IH^5K,LV3YQ+ MZ@`5([5$,F+'NSMEN=1H##DI!DDNSMZ/I]/Q);PW^?PR]?>L&%8?1B^&Y?GTVG;3 M^[OZ58W`_ZRRS[4O/\V_^SU(Y[RA%7*].72IY;^E9Y=?\S?H_Q%#$3"2Y5O3 M\:1]O3VR]G4U&L#WOB`,'KBGH;:?>S7JO>I/QR!>/:*?]=+\E\:IG_6F;&-Z;#(O1\U[/-/`,_&4VG/;&YVT; M(#RIHE!O.NZ]+WO3XH]R!$(-*Q[^6C4[FGG6JY9*`!X9-\L/5:.V/?A4/>C] M.2MJ$/'T)7EWH4E8:[`:X=UBVJNFO4_5<)B:G=6]XL.'NOR0],#F5_ORY;6)XU_6L]\.; M#0'ZI2K>5\/V+/2S'WKGX[IW/JM3@`O:AU>7;86NYS7O&]I]M[K>U.KO MBL^N+@?5U!5U?07?]JFH!^9R/!OM/P^P?G8D1J44]4BI`(1:.LMLM[L;K,R2 M7G4;JU@WZ3?T).MRV;PNKI)E=[,ZA0%V^A@+PSL<%F#G`,./I:GK5+4L4;K& M7AE8SNWO*S-M0&`:6XU?PY*^+(!2Y$;XY]_B>IX`%YI);;QR:2=!NHBZ(S-1 MRRQ.LSG>[6%LCO/WIGQU'CJ-=+.5Q8(QP6S:7A/68JLQ764=6L2^.BO;/OXB MA=6K_KPEP"NMO15BQ6C0>SN[O"SJJ_2'M]"/ZKSJ%_!EIM]/@I56W^LQM`!+ M[[Z,\LZ1/Z@5?@N?`]D;]JAC" M5RQ\FR8IL:*?%%JZ(@$,WO2B]Y,QKT%M`;$&4]<#D2CFJR8IL4NPJ;T^D-D" M/EAN@%TTS>QRLK#:R8`6Y^=E?]KJ2.@?$/-$!=HE/3>735-.YQ\=KG1@^WI0 M-?WAN)G5Y6(X::Y2#Z[[S/Q;TC"7_.$`#)ZU[;6D8]6[N@3%.5OTI_R<:B7" MB\%<9V\,:=*>;FM`XZ_+V`J;N9EH#NI2[Z+X6`+Q`?YR60S*U`9\9E2VI&@^ M2^T@BV$_;8DLYGW9YT2%DMH?U\FH),)2%C58KQ9:>&8XGK3SN1S6,_AFL`UG M;6%(^*)595'5O8_M84;H1#6:@II-OLYBMI[U1AO^5WIB M[C;^I=6X?^W@K]I='.!MGT&BQQ^K5#8$8'VWQM%2%P%20&@%,'03*&$:+>#1 M=@W&G:0YM?NQ@-F9P4.M25V3T76^F.!=R'2_JONSRU03A/YM>L[;HBI5BGRP4>PO1H&SZ=?5^#E'B83\6 MEY.7_X8%>FF`D/U63!>JQLX:&%XS7_4[S`0PM`6@B1'US&B4IO%-"WJ2PPB$ M;=4V1F?_?6EDRHP'0R;(&^3.#?\R:Z5Q][#F9 M?G-#V\&+27'U*^C9#^TGWI3O4\?V)0F($&@0,5CCI8\$:]]6"46_.X;_^A$D.H2$Y9/P>)_ M6PS+YDT)ZF2T#R9J3"`&>86UAO%+@FUW--Q;F5>7P9CPKP6G=S6PFC=EOZP^ M)DNY%ZL8C`J>@4!IQV*0GG588>(SD:+L$=;>XEJQ&W>X'@\BK9SFRA$/WE^J M?BP=,MTY="^RW#9"U2$8+0;[A/`Y8*E%*I`C`$A,9WNT0L'PE?BP?*DQA`]9 M:O<+SO5;Q2BJP"()!E-L0;/&L+K_`VF\/0REV%:5\D<;QDW%(Z3#,FK+@])8 MB\"L)-UL4%BY618FI_H0`W&_PWAD4<4R[0T2'YRP#G-,(^L*>`HCLCDFVV4U MGC(V=^<61$A@E5;AX*@P7DDONN13ZTAF"`1M2VV$ M3*=?NRP2EI\(PXI_(RJB$2LW M5F6P@+:Y,V_8ND/EMW;__M6YKX8S>/?F*RANX8()11XAF3$JL(Y`B1;@*C0CLG$*N#S18=W$\GE@3-PC;V!`<5@ M4YY9IXF<=CMGCZ8DH@$AX0R8/-"?ZY=.[+I&Y_8JY::A M)W]^=#(<=L[_]W,6J:5C M^[*THU:1F:`)5\GPLY3)N?19K<].9U&\J#USJQ'>!8Q%3.Z1\5!*8*R,,S9Z M@Z16@$47O#0FB^]K2O"CX?'88#BJK4-4$^]EM!)XU5+IIX7*#^1O-4GO[53T4U2M^QKY"+L,Q1!$0<;"/0.4HY7V;7 M*Q$SM;*&T1T&_M`(7L_,E41,@NY,"@6/8;D;<4H9DC!Y[CH7RGC*.F56KV`8*Z,%!7>Z9F_Z?LZII MCS[/J?`_FON6+ITJ[MEBB,J\K#( M&6XO#'GRV!UI*P^%+Q7OPMIZ1I7A&!&GEI4\!!)"YN=2!7KRZ!W/-`Y&SSLJ M*/5!@7ZS$CF+.BKNJ,FVC\XPGE_Y>=\`+NHZ_)*RO)O8)HK]6HVJR]GE9,Y4 MFL&LK$9OJ\]795$W!VWU&6J`$!@GK57M"5&]"O*`XLHHI51RC5(>V+.-,347 MZ5\Z5?6Q&+;'W4;@T175,(61%WM9J]N[.L"NS\%^V[\H![-A@O3`QE,`MWEU M'I?YD3^/4@KB978&[_>W/XW!YQREO[R=I-3*NAR$E&0XJ2M`(!W(6K6Z+^1+ MK#!$6`-,U7!)F$P4#:>CHEA2E9?949JO(W\D?@\R!S?MPJJV8`-EBD:M8T"> M.--%256>H86!I!/\E(?ZT.(VUVW0(+3RZWA47OU:U'^4TS@;#?9NKW`:6(A$ M(L.IH4IYV6W/I5/*64J4T@S);QCK[GCM'.ZMIOPN^(P=/DDMI&.DR0K2WF4.%V>+RQB<[U",N+T*M*%;XJ:+]B,OX7BVT3`7<-(XN8!0,8>D*&F0I3(=" M"N"^SN%]6N@_@JS?P6`1JZ-!"N,0A++(\[5;+!S/;U8"Z)?7@3XHUM1!KE^+Y'6M[OQ7[ M1N3]*+RY40Q+E^ZO5#%(9#7J?'D2\]+7MZ&CWXA\WZM^L2&5G8G4:2:1&Z\#D6)+_P M_OL2V%4ZL:S3$Z^+2;D/<*:L$5H0K7$D5FDI5R7O&(D[[BD\$<2_O.8WYT"H M%V+_[J(>SSYQ%)-I(:H2044MM MV"J7FHGOF#^B"48B6.&3FR1PC!K,`34I=19I)#F-F8MT"G/QF(&`?[%WK0TJD M9$JV[,BRGA%J&F@/0UY9Q,[;9_E&K_)W2;POD1%(@YFCJ8J],[0/MMB MZ.GY[FXXQ;&K-`JD71`I%3)+(\N)8!'3EH"R%]#AS79/8.OWK6#Z8-/PLSR7 MD0;L2T$-GGH#JB;VKBO0YFT\+-!V7S?$#L`>$OO'WP]W,7!T*!Q,A+`^C)C1 M&KAPGV)NARET7#^/67C:9^!"N%#%6&;4L\#&0L2N\\&1'?G;]Q4%W][2OY^. MQX2SADEM(ZRF;9R/?:?C24X'/L_O8!_#H-1,!E;9T#D:LTB$IDL>HF%\',_: MM\=5OD*E%EC,DS(?F8@Q04,+:[U;Y5X-0BF^(WZR>7H>M-_/ZT-%8'P:M(A`>BFT[^(+:6P'M0WN[=?Y]OCNP]D[ M-,(3:J9I',)RU%H(0<'>`5O44@\_'"O>\!OE$@\R)UHY;G1$B3"!Y8R!/M(Y M0$,IAW/"G\>D/-?35^:(#ZQU02QTS`V(TBA`N4JMY=0/2]0]A[EXLJ>O2I+( MZD"H*';.&5#/95?GDBM_'-_GM[OP[WWZX@/E`ZZI#3W7`H0SZQV;H1K>?^XO%;=$XZ1BPVX_C;?GV$/^:&`:JK%61 M(BYV6)6,=#&?(/'H4*O[COC)C''@-Z%@)(P,(SZ6W$K:N>),K(=W?-PWUO[; MDWU?F;_-).6Q\D8K&PMJE.I"3+1^GDSHN49Y!AA>HFG(B0=1P&,P/)O:+TR! M+B[HH&SG0\S%GNJ&O0'Q2Y:G]0(DW:IBR&`N.(K%?A.0]?7L7SGB@V#;66Q M)!QK6`?,Z:[$=^1V^!L/AO"VT1\`H>NO=,8T96RSRLZ6V-`'F)_TT:JDOWWG M-P^30V6))TR#Y`I):`/%NWCAV&[=,50T=P?`]OTQN`7`V\?^(``2^:LX367U M;0QC:P`_YE0DG!?$"&=<%WX41.9)8/BA7,"_=V2$?U\6\($NRM_2.?YR"L;H M'#.:4Z4HB[T6@LB@.^L/&1F&2;;%WSY0 M\I];H+K3V`[!*AOCQ?0^!9RSR?O"P(^377._B7;%$OS[)ZFGU*BN0L MO9=$P2QQPDPD*`=A;`W5??:$H6*@R5`2'"11]@)P`'C7UVA[?UPZ.=::BJ[J M13;VV1D(MJSVY;*8-)/^:0IR;YX"QQG76&)^=48U.13+.%),@,5*0\.L#*+8 MD/Z8(`P&YU'-=:*W(KD/C2,"^15BY*&PC`*C(J*="2WS!-AC0+L`5Q&H89[] M01SQ!%A2^K@;&G`#F:&%I#X01E%C>^`(&09'R)M&7G:_B7*LR(; M)_FG"L3_T:R8`^2R@>9!F*@P9HQ@WG9?T%)Z3D$N@PUS"UK'&/*QD'7+]%/Y M*1U/F[8]F.W+*CT=G@H+HQ,32<[0BB8:E,3N_$?&&O#DQ\%SYT#OB.+']'_+ MK$JO==+,E,^J>L-HQT./DQJ&O;P.I5,A);'&^T?C@$JI^R0*&ARD.=Y_T,=# MM/5D@`%OYO.J_)SD_QG<]'`R4#T/8]##A:8BUH%3TO3!HHSZ$$$]$J:[AWT4 M6%UR=33\[B;6^^)F)`#!31GS3H>2<;`*.]^^`/WRSOQS_T@/@`SO"DZJ\73# MID3/V:YK5>FOS,RK+']*LAP,;&(ECV+GP=CQ%%3S+KC3^&%:OCI,*]J/RD&0 M?DZ+95J_2^%C-CM;5O7`;*_*BRJ9@5V*QM13N(&2&<5]"':BHG%DA(ATU"47 M1T;ON+"*\$-PO",4)X'W$>YP!$,G]M0;&9%`NTB!1.^$/*?#M!XJZ'.&]U%N MA0PUMR8*9[=!+N=J\B&L?=QH$%2"1?UP5%D ML(9?L4"&CPOQ*N;TTS2K)A^2:G'U2U(LSV$PRPIX.?1X65:_/P7^$%-!+"%8 M5@/^95B,J;MI14F^/RWD&``\.*"/(,^(B$"<1=P'QH+>JHGO(_FDC?=G?3P3 M0!^#`1C*(PF+D3,+=KX+B3%=S;`@H(-%*H2XP_Y_&L@^CO!R1'L1$:6DL@QL MU%A:M0[_XPQ#B/CH\A%7D^^9\W?^= MZ;LI5PK339JO-T+/INNO%9.[#R')/2$R8H M(]+W)22)#@?>!,Y8N&_>[TTCNYG&R$NE8BZ9U\`^26RI7ETH*BBEX4!M$DP' M^S33K\3QY&R-2HXJH(V"0(.P$`'M='*LIK\CJEDB/H'S$>!TCWD1!2*RY MB8C0W84)H.D-BSC@5=H/LBI/;X51RJQ@TAB.5]G%D>Z.$9P;^E;@:4(?8+&? M7#52BG--J"8A59$W7M,^KEF;X0V<`7L@/O1H#DKC`A&K6$42[R`U,HA\=P^1 ME,,[A:D.]\K@4T_]40"P1I-(V,`;'L2=X"%).N#"*L-!$=TE/O",$!4M!/QW!]U"P,*>-8%Q+C):U5"K&.LO4Z1T' M5913_43VR4-APH6(8RVM#Y4!M=-:+>)^J00#:YT'].BJYCWUA`?;/4S%GEH% M7$5@U6%)C5^KC<+L4!OYW2`I)AF2Z>TPE::/^QK=H`Z^97_ MELX773C_SV5QL4BK&8;M8PK`9FXA]K#(SC"6OLC*ZK]W7_C@8W66:WIZO1IQJC+XK=%.?X=26V=AYZ[<&VPI`L2;& M^#$C-0W!+HUHERNI8B=W!"G3'SDY=%9/!.E=9OF7K,!8WG?-:-Z?W][XYOI[ MEZ:3^E.)`\%[QK:&\%;9M.!5!UE)#=>GR>ML$!QK!EG8`0XZKHC8AGJ@0[,P^M.HGN-I$UR M&6/:&%!J<]B3NX^Z^FP1,,V!PLB#>D$#([DD7;8CT=:]^-N?\L6;2?9Y5"^N M\O2G%^?0W*OS9);E5Z\_93-0(-ZEEZ./Y2PIWC1_J[/_2U]3,E^\>?&GB\6; M:Z_G69&^FJ;9Q73Q&FS>/[Y!VEXE,+#B=9Z>+_:V@;_OHB$K0,'(!N\U7R_; M?L[*?-(VM`41MOI7?&[=Q5^!SD-(GB<3W#JOSLK%HIS!;_,O@V$TW[-B`E/T MF@EXX$CC:MX#G6J$\8!)<36:)B"5@`&MBZ^V:4ZC/$O.LKS)LQLMILEBE&`6 MX`@>6L#++8.JKN`-=#..RO,16'ZCLR7P`6#S(U@9V>?FY1]'H\W>DO&X0J4Q M&55IG5:?T]%Y6>WK]W*:%M#N**M'\ZH\PR3`EI;SY0)#"U/T8P(O@\_P<);G MH[-T-`,1,DJ*R:A>CJ?;CXR3`I_`7&O@>&?YU2@%G7.&C+8E$]J\Q'\&,WM' MD,=E7E:O_]">C;=3"?N\;%,G7A=ED;;S4)1?VU/3S`B'@*&<^X!L49^,8*IA MIDXU.A2`C:3Z4S*;O_D#E>0-)R]'R$*.,VQ8.4=IR*7CZW32ADYVE.9_O)%1 MK#_WC'L'$][@TJA!@'2=HC7U$>8=)"L\.T]R,P.;:?'/.IV\+:(D'R_S9*>E MP,$^.Y&VN9T4YTD4Z"",.4=3/0["P'87FFLF!\;IAF"^ZZ"/B==)5+E]F&GM MM"6*FX"S2!L7;MQ5@;K=PV'6YXEO#*M7Z#XV[_PV3:H=1P`GADQLA==J$L5: M!3Z.E:.>@F73>;(BNZDXU0WQ6/[V1Z%"L0';'<:^A=IY"CK59'5,\+&\2O+% MU8=E!7-0]Z>?M^J!6V>AU#BC).A8+@R9UIZY[BQ4AW8P_VH[S^=`DC8&\1:: M`TF"`;#OSW].]Q*^&NR7QDG'D.<@W6, M\PT=;I"U_8>U:=+\.EQ^U^C:M[<"[1T77E(GL#B29#SN3H:,\IOGJFU'L%16 M1-]$SEZJZ_5S=IGEJ`#>FW*KP')ASGIJN&,N-L3*KJP9V?(HGZWZVD?[D*CK M]'],6TNBB7'X>:557!E4*9+<9?48N0DRF.L+F_!?1<<"MEKYD"=%SP/^`1I: MDN=;3]QR M%%\[V'X#62.H5CH,9:"49L3WE2!B'VUOH(ZJ34K+NCDLG:5FT2:)H_+\J42[ M#]/&RQR,DHNW6-T#"+%8WRUMG_^4?.D.!;`$2R,^WA8^R:I_)?DR;4YP5CIF MEZH%#ZY9RRIK^HANE4.RQ;=F"TA2203W,*NZ=N2`,ME5:@]89(T;2R$H#AJXG M?<6B-&D\SP!:_PJ/M62DFJ-8_8VI%W?BP MP,H:+QIGUAQ=UT\P4&`;;Q+).`RYC2,3>6*%LZJ_%]ENW9,^;Y'80/RA4-LQ M,TW*ZGLPO/\]S<;3_?F$_\[RW*:_X.'OD\JW[`$/J0K!PHQ#)JT$W<;KSE'B MN,)TU4ZEO__@-Q!\WSCSOM*49[%4,HB,Y^C6"0(?1'IM(P>RH;I/`;^IQTW" M%M.V'$&53M.BAFEH63X*BU8$?$S'>5+7V7DV;M#>J\2L#:[]3;8-;%>U'H^7 M,SST2B?OTD5?1?!M\1D6,1*+%Z@A-;=%("D2.ZMM'(,1"C:X"?M`-4+E(+1D M0[>Y!P9/"$'8NVEV442-"W%\=2!<1AME`F$BYWG`6IG7Y;U).4R-?8)X[1U< MJ%PL0AD&VED*8S2ZSY.R@N[-D_JZ@8&*A'[VVE?E#'GK^_.5_O,1O8V#01#= MI)7LU41H#%*!*EBZSL3.,!G%76V"2)EAP?!KJL@MY&P3/EF.N\0:/'#)RWI9 MI8?ZG8T'&U&0D(6*6A\8'06],R$PXMOR.Z_@&JWQ>@G$+[X-_W.=YGG=>(_G M[2#QP\I3D5^-%N4H&>79+`-N/6H/\]"'.4O^6U:MFS?-08>`/U;I12-]1I?3 M$K0,6'Y5W3XQ3U%'65R-YHTV.K["KCYC%<\:'=KORFHQ'1E096"'H8_T$DC" M_R^Z@KBORLL"_:>-6WD.LAX['"]!Y9FM&HF753E/1S^,0;U(T?N=YEU>G_ED`10(,>="`4_?$==`#7 M'+A$8S$BM5.0;?#^.*G2?M#7?/*@@Y47!%A?X_P_97WKOZ:+QI*/7'CI;)LC41BEV#1KX*IB@&"6] MZC5*0;A@^$"ZN$S3-L*@"QB`033?5Z"\A*XV^UKCW9[?8J<;[GU@F\!2VGF# MUZ[1B.MLW-!YGGV!IV!!3=)%6_D#K-2;W;9/>G^]+3!"`W8*+`=@H^-\.5D! M?_NP7V[!/P/8,6:BC;THM^=YO'(>ILTZOVB*`*_7R_8J:E.3Z];_C`MS)2VO+?:.YKT$GX':"J@4&UAUT'6M`".Y M2.NM3J_WM!Y#O7\09U\LIVZ.NTG M[673-S0P3RHP\F#)5!LS"K(FJ9H6WKZ+WOXK_L?N^;V<9DW(4HKS/$8^\1+^ MV%09VEI.0.\L^3T=U<`>&CT/>6+7&1+RW^7DHCT';-;B.N`'>1R,>;RU.O]< MKUEZ$\\`$.TB#H9\+`:G'T-_."]Q\>,4-&>*L/YGLZ1JI-@J^NP*IR]-8%L` M!!M2<@U!OWT:B-Q'@GDRK0S3K=4.X;%Z3=2NKI8/?-[LN2E#@\J[S13G'AK_T#;>+80R* MT>J9GUZ0%\WW>IZ,U]_O;A/`VKK(BI;(9+DHUS]4#5G-+Y?99#&%IV&#G#7B M]Q4J)\F\3E^O/PRV24]WU7U"WH;4%C^]8$!K55ZV7VCW\%\7D_YCM;.)AIB? M7O#PCULM]$WO;*U_D=[SO5/W=_+WG@VAWR?P^_@>K+]];&?%6)N8.5"U5ZRN ME1%OMC@]&D6;;'SS^TJF;/[4\EG\Y58R-V0+*J_G(.1?3[,)R).C*B&]1+XY MOG<+[/]G[UJ;VT:.[?=4Y3],L>*ZVBK(QN`-[=I5%!^)DZSMI70WE4\NB!R* M2$B`BXTV>Z>WJZ9Y^KU]Z6U60%F:ZN MXT<2AT._1Z8FP[:RI.ME^8K\WEK0W=T$Z*X,$RS#0%L`+L,P)YN-JS" M;"`*3N&@3N(JQ2 MX>DB.Y$=IC&W)..?"@66L&3O(Y$"=SD)7W>[C/7[1T# M0J;'@LG*T\`[+B&[R&NE\,LAMK](6U[7@6Q3Q=Q<%!D$)6>K$-0T%OACAVSZ\L>3#:U)]^'KO/VE>]2N>]^+'W'F/"O?AI<[",2TWPT%8K6@! M8&4[/\4R%$-'Q!JJ!=62;TU2A6K8=(9N0;>DZ]:%IA5O$"Z#I+BM:,F[\AL? MU('60>NVV%%2+!N.6#%QDW/,;VA$K.R=NR MJO)+Q05/`!!;KJ1\R%K$OOJ]:_\_,N'ARAYO)IT1>I,VB>+IEW# M4+27O^6#OAZ&W?]^^O.?"/DEN[C#XB3B5Z<1AV4G;RQ\PY)DR'K_\I-!PXL' M'=9E_CAI1^'H1DR3%S/1JUV(L,/Z'VM-T7'@-_W?M\WO:7QY[WGC[PM/_3;T M@OJC'W\7+_S^#Q;TO.%PX8I?LRV9FF@][8^\8?RQ=JG7B-_[6&M[W>32L5K4 MHNU6JV%=ZZIA&([1-ELV=9L&K:NT72-IX.??DL:]VB=;UUP.B(DX=AMA(2(J M2#YFNVZK#F%#9-5.7@YS/E9G`WT\["HD8(D0[?16;Y0UPA1/O6.$ MK_0!ZY$[_O>@1WHI6_H2A?3Y#'B$6P.7"<<5Z7*EF'Z`>/#2=.PBF;_PSWVO M$G[=T`\#*8]\3\CM@*OTLM#R&A1BI$(V6>6)*?C&4_#Y4_#%"ODQ\+L#,O"X MG!@+.!,]L&$XYF(;IU&<>OS3,J%U10=Z;NAYB2A7Z=U'C&4RNF/)#W'?_*0+ M:;\U;?SCZ[$,Z4[,T(FEF:&;,^GD(Z^$C3?1P&E^R?-GK$PTV64V%C$O9"D' M-S9];TJ%#9]Y/L-]%D5\@J.)*3I?MD2,XU5EF`+%3X@O[NB&]X'_?YQPB'#' ML_N&?C_C.?'S*KC\X(!X$QODC@.TQ[\A>XQ8WN++L'\Y^58R8LD@['$`<;81 MA"<>ORA]L?+XV;!R:LF^\UE/9H-F?Z3><#KDG#>F'Y\1Q&5.57%Z-R,7#FLO MX!?U8[Z*BJ%/_X4]CEG`]4J0R1L/F(CR_=LNQZ+;L/L:/+^0=P>LEXH'-9[G MY8'5H\@+[K.)J7?Y'_SDZ0M+_AG&<3U)(O\NS?R/NK/HB4= M-RUNLW_<<,4W:,-LU0VWT6RW+%IWVZV&-EWQVU:=%K[BOU@>G4.OCG4.A-'( MBYX$R`0S\]F*R87/)3MB/Q%O3N`9=R^(G*MM+G-R4>=<$/\TAS2N61DR`SYB M,N+W##BV^2#VYZ"RL&LV/.&J">;QN%D0BE;N\94T4\E:!,-2T\65*%L(W:DO M#E.*W^=?'801-_$78D]47#-[<#[Y738<3J[Y6%-KV>_QV.M.?]]>/SCJ[OT@ M_T@O3<+I'_+H:_:7'WXO&5RY]+VU\-^[:6@GH_-QS*ZF/RPIS_,HYK-03$ M/D(+ZU(U&+[-+)1?<\.DE1DF"^G^LK8O`#J`;@:Z+\(8WA]S8+\]@:@?`8AK M9'EL:,H\W02H`6IO0^VH/>X:2;S'K=IO2(OP65M=%=DZUJZBF5;@\JI(4C5,C!9T: M`,,T.V:0)_K?BU,%_'DL3OA, M9*G"+X_$[!*TK%SE7D73T&\$9:Y1YGH#93%MQ41W'F@+M&6C(DV6*DU7JF+C M01_.5A\N*-44&\O'-LM'87OA9^`K?2M@`WQCW:Q*Y],+7='5XK=]ST&7$44] MP)I8%;W3J**[!D*'T*T2Z=::E.JJZ-Z%JZB.M#Z1>TL-:R+T%GJ[`>H,5=%- M>6OFKE*KRIJZ[W9<]3W,+_M6*RH&J[)*::-B]K(`3[PPMJ&8NKSTRK5UL<^A M_#4BVN`N<-=!0I%446UYL]2DS6SDP5"KR*@D_45VQ#MCW M&/836`8LC`U01WZIF^4U>4/MK_W/"1G$G+V)_ M&V8QI\9\_?FM*I7;IF;0AJ4Y[>N6H]NN:]GM::5RL]5L5[Y2^>V`34ILBUA> M'N/+:Y?SZV+B"V'/MPS(Y"TR38:I*+3H+_2"R!<"1Z/VS[$0?$_4R1=!_2#S M&;)GW'E#+^CREPP82PHOZ[VQ[.9>M;"VG'Z=;T=];\[_)['.M[-OF6_[P&64 M.7!.H][SSOU4-'W]6X3\,4`RT/#LLFZ$U32 M#)6H58A"Y"2'G?8! M42SA5`);)E544U[69=6SLY`Y65`\'313:9JQ7,5UI#E$E:<9)(&N/V;(QA[W MZR:M3N/,%@H3?CWIIE$DJK!X<4E54#)[LV>J#94MK0U,5 M;8!3OL=*%(Y9-.G'+1SQ<=Z?/&!)$;I6E6-#5-%MG+2%WUFB9:PZJF5K\C(B MJZY:\+76X>ESD'C!O2^R1.!332M%F"H*C<&K@E<%C8!G5="Z\]F\=+7;0N05N5)G6+:C6.:H6W*AU>/J:[4[!@YI&*4QI^\%5T2%X3V>K#8Z% M'5IX3K+05.]VN1226/2@6!0^J1&M7=51+E5@9LNJJ!0]J M@V4M2MESTA_LQI\MQ9)7-+DJF@0_ZHSU076A#_"D9.&IR?HLBD1E$>^1#'WO MSA_ZR1.,OK?B>JJBJ3CK`8^J1*M8=91+4VPTMX9/)7E7:KJR^2Q6N'LE:F?Q M3Y@=I1J'D2AH;P> M+F=G).HN5TO$W>&`E6AAJXQN.5)[^51=M^!_K>UF=OAU[L14CCJ:0BUI!QJK MHEIPN\Y7(UQ+01&+MQ:;@AH*[%CB_]4V`AW6#>\#+H'>PMLZ[($%*=NJ1T#; MNG;MNGU-W59#;S9US;+=:8^`>L.ZKGR/@&8:B<53%/I/!A%C62V.@'\E&?&K M!S%A@>@%L`2D+=\UL=$FI82S$?7X+.93?B4`FW_.K!3T,VNMK`F]RW"SX8E: MOLI\;P,2S1"5_?FY:4*48RI>:I2:W=UNWPJE?P8O6AX4WO+`HN;X45J7`VKM MV>9`M[AX=BO+;^UZH^'N?.>N-YH8)`99]D&B[GK!==>+:!%0JKKLMYD)]&MN M^;0RRV>A.04\3(!..NB^"&M[?\R!_=`@138TT8L'4#L+*`9 MT`QHID":T11;7AYXY6EFYP3Q%V.<_UZD3Y]W^O3?O2".67#8#.H-0%:QA&G7 M?F]15S7LR?^U=^7)GK;HN]TR0W>]SS[P^S`^C*]\X\-.,W)6D2@-T)T8Z)`H M70X@(L\+*86`VBFD%`)J@!I8#5`[":@A4;HLGL299KD"0H`0$J6/5L$V?/*& MR=/SGM'%YR^-S[]_/:KZ8D?_9';T-55Q7=3N/1@BSG@5!,V<+\U05W%-&S0# MF@'-@&:*HQG54*B*/&CP#'@&/%-@5RY5<2BZXA47WSFW,,[KY]VOEE.@)>R3 M%"#;L^3KBJUGP`_P`_P`/\!/">53V`Z96GW;JCX2W83%,:M)6V$2]DDZONQ' MXEEC[TET6H'C!\=OHYI!5$48&^&E$S07P#)@&;`,6`8L`Y;);G,574,,&RP# ME@'+@&7*P3+[[I2=03CG"TM(Q/S171K%69-<0=3ZN*VB$\?[;Z<&&JTD]K/D]Y<>NT9),% MQ[V@*ALL'9JT0_18.J`/)ZX/%YIB6BX6C\T7CV-N8V]PG+_4?D]GP><1GL[( M"]*^UTWR:JHQBQ[\+BO$QY$:W#JBQN;TY6A4*S[N=RX+'`*?4#`H&!2LY`JV MICB0-"%O6?]1_@DX17.EV:0[2PVZ"=V$;KZXS5`,`ZI9EJVRH^^4:5;!'N.< MUDKYZ39,O.%\XXEUK5E?[55Q*`78*:\@?V;6CV+I@>6(M(.X0%R%$Y>F6*J\PFP@+A!7&8D+W%32O$V-*JHAK]7C M&KF`8D`QH)@SHQA*%4V5EQM^)A2#8MD[`RX/8)4E9,5'2WIA*EZ^E^MW+F=A MU@FO`H=E-%,Q:4%.WS82JPI78OON('8:F`Q,]I+)1&YL0;8=F`Q,!B8#DQW( M2^5&&34+VD($E8'*0&6@L@/58M`4B6UPP61SH;@/613IU>M?^?F7#P]1\GAU MTQVP7CID7_L=U@WO`_YUO85*X)T\5'4KGGW+!7$]#+O__?3G/Q'RRXL'_&\0 MS1YQ,_`B=NW%XF&C,0OB+(C5>A0_/C^&RST0PNVP_L=:4S2M_4VO$;_WL=;V MNLEEFZINT]1:FMLRV]2DEM:LFRV;NDV#MJ];5NW3BXF:%_JM/V(Q^<)^D$XX M\E;SYMSM0S]@EX.\GR#5U'+WCZGYBD<^+G+^+BO;P3$\"%_#P#A.53H)"`):(( M*8L3?^0E_#+^S#[SDS1BL4+NGDCR-&;B"N^'%_6(%_2R]^7M%EGOTN,:Z=TS M,N9?'_:(6*;(CX'?%9_E)=/W$#_.?NR*-R0AN1/I>M.OO'H3Y%M,#+469V:I MR>3**5]8CM07L5_Q^_RK@S`:><,%LJ7BFMF#\QGJLN%PK>69?W(CW?$^S3CT"W>];SO)H(GR MGF#U&S9.V.B.1<_2U%6%;-,Z'E!$/WG9X)RW(LG$ M8%1665[`,>EP^[F?ESQ./[72T-Y%4@G?E=FG:^Z MYEMF9(.62T++<+SL;%\X0?^C@)O1+R:44J[*_""/^U.139$;E>WOCS/#JVN.%+T8=%B>1GVV9 M9ONXV>9K]/*/:>`7TTV@*H4`J:HKABGO*$/54TE@7E??+RET<=@\V1X.R3II MMFZ^?2.QR*(B?ARG7E!06>43XW1'EY8%?2ZT#78NFWP*U`_UO;X+">^9.KI] MYN>K":2_>\,TN[H>]'Y+N8#Z3US(]6Z7+YU)O)B!NB9UM-6LJ[INJ$U+TQO7 M]7;;T!IYZJBI4LT]T]31=#3R(GY=3+B,_`<_>2)^0)C7'8CPOTCO'$=A+^TF MTP/JQ!-/$(O/U`=AT0,C72]A]V'DLSAO=\9O#+@`R(A_R"`FC(^I1Y9@N.4P M)J;29*'(2NMLBCVD72>Z6I6H;R%)=E:5*555>7JJF[IF8 MJKL'SA,]]/L.?M_)?"@F$.,K['W(PD)RK.RTF-O(ZZW.)*Q/C35I.YA%I,(# MKF<#UPZ[XYY"K*Q$;(,[B_=,Q$?CE=<(QZ/IQ[D3"&`#V"4`]K>)F[P*LQV6 MI)&\1!*@%6C=`ZU?$W[M2JQ^#L07^`^P&@#74L`U*Y&YJ2SA9>T)0.H>=X>P MK*=7=@)6.7?Z)2>'7GO#?$<@(4W6S4+O1*=9Q%U:89==Y'4V98).OPJ0J1C4 M*EP>Y[+#7R+6*=TZ!Y8Y7Y:Q=,6TY%5-!,V`9D`SH)FEQ%?%,>55-`3+@&7` M,F"9E[<)6\8$RX!EP#)@F<)8QC85W=VX_M_9TPS.,:T#U+A\EK\01^@#R>N#]35%5M>0_.J:$35DKD6O\!8\N$UJ3Y\ MO?>?-$Y&_-'QO!<_YLY[5+@/7Y5J5+KA(*Q6M`"PLIV?8AF*H2-B#=6":LFW M)JE"-6PZ0[>@6])UZT+3BC<(ET%2W%:TY%UY:6UFH'70NKD=)<6RX8@5$S8!DY/48`I%\>7,55][A"RQD"-M765NHJ2NJ+LW5@KI` M7:JL+KIB&=+2@J`L4)8J*XO+E47:CC"4!K"Q.+Z7:FCY^)+TP%17>]RFWMG)ZBF@G7=KS7.LDN\^!KR($*?]D MN^[("Y;N+,T#8.[XH=83(LS262/@1_#C44[+JHJF23N.`8($08(@09`5(DAJ M*"J5ET`&@@1!@B!!D!4B2,4Q84""'\&/X$?PX_)MCJ,8\@H>@"`WW+=\Z?\DXDVTM^B<,QG\VFIXS/]3:N/(W]X^?>4CY3T M6-7YMNTYYV@K;J5*^1-/#SATY>SUA2 M^T1I-K?3D;WU8?,#2"+1&MGO=EB<1&DW22,^[M=Z57]/X\M[SQM_7[CRV]`+ MZH]^_%T\[?OK3_LUVT9:&.]\Y^N&I35;#?<$)^G=M9MD$]R)^\,'3^7^WIES/^^;6SJ]IA="..J4^ZLZV1CM96G;K1MHP6;5#=H->NH4ZEX^CF M]9)T=,NQ3ULZ67O1#NLR_T%0]#H)M4TN$\M4;-&XO^%<$%BET@ MCOE^)&T`/K'&IFG:M,7NIX5B*XE0V2HDI49QS)1F&7*;+[8UGC,\ ME[R\#PXO-4RQ2#F;](<(;.[T$!%E!9\OWE^4UO@;HY-_,LH@`O1.A6XT%$C"VX$QGWL-W"R MZ*X":%"4^W;;'W;"7ZHKZ[T4I&.@3DIQZ:U#G))H)@VT!/.$EZ*(\K]^5WY2 M8@E33,'DBD)X,+,0L00S2FRT((DY)XCZ`B3NZ+^%PY(8(R5U$BM-,9NZ$*$0 M[W2A%NS>1NO+Z@!SV-$E,_]:(V+N'GV;W#PWOTXN5B^O0,C%-V=W'GQL[X9` M!.LT7_T;TL4`I@HT+M,TEESQ2)EA,'>#$CR$*9;&6E'HG%-,3BD^-/ZI5HX\ M_/KB[=5TR_/]44(1KFTS1(RG6(+-0(9:;7640:`QJ3)`4B2F%NY2./"[WV!0)HF$UH6@Q$:N M0^1T).`-E@<"ITB?4G2;QJU6[I(8)E:F[>#9,.:"8HH%BV#'_>3XJ902^VW[_=;7?SZ\N/4_?S M/2-V\^M[]].0(AVMROFS^`%9A(SC2.&!C@W.V&CY.#PNP/`I/K3+`?E$O+$66<8$T8B>*8WDB8RT^'0&9F M+BX6\-3]H5_[YW]([E:#'[/Y_!)^_"G\:_;\'^;'[XP+/_]T[LS3%[/S9VYV-OO.?$CK=LL'7JOE M]:^/7JW7N^OU;O$4/LS>[R]MUL,2VYO=[K='9V?OWKU[^/[E9O5PO7E]1A"B M9\._SX8;3V[NWX$:?WL"@H!A78`[&!X^/GZUOKBYZ\UF$/.K@R9@PQPX#>$$ MI8/%8&1RTYPA.CYY-7^Y6(W:D\'\9_5R=9L1M#W?K<'-G=V'$H6,!QG/O?1$ MRX"D#%-O6X*2E#*86DK,*0R)!`'O,K2B"2CGJ(_,I2EE,)64L+#,(J*#(I10 M<+383^Y.:.53E'*86DJ:88TH^/X8E>>0JN)I42(RII.4,IA:2B[&`!;90@H- M?I@QPHI3#U%*"$$%9C0(X M!0*!"Q%V\I@D^IBDE,'44@*[KZ+`V@8=9(Q#VF##R))*8.II`0Q%Z'2 M2*\9YT;A&..D%_`!IRCE,+64B&40=3*K),4:"T4#G=8OF$T:@1RFEA*%`$)) M"5D\*$ MYIY0A2E(J<1Q"8\IDJ24P=13`G=4,A+(86HI!>,C%41$ M+ZA%$6-Q=*%4)HU`#E-)"5)P!W9&XZ`H15)H8287JJA.6N\9TBGT@I4A3RF!J*;DHN??>JF$F$RT<8Z/$ECJ;I)3!U%("30T"E(&X M"+,(II@1='Q$.<4CRD32!3>MBVO+DP.4PM93`I"CC.(G, M6@'N2FDV!1K&)I.F'*:6$D075`5B`H78$#)J8=VHJ@[YI%W*86HI@=<$K^") ME^`6'(2)<@K'I#$A22F#J:44G2+#"UCD&"0;&OEQ]L!OS=+JG<%44A*(8@09 M$.2)AD^&S(-Y,3Z>>I-,FG*8>DH1^MX9 MKT/P*D8AY+2*KDW2H>0PE90D@F0#;(L5BA&I/!-XBGVB30>Z.4PM)44$EQ!3 M..1@]C@+<>*8DP46DT8@AZFGY"B8%\I@#FD39=33["'P\Q.4_A!32\DY'[!1 M,4!V`2Z*:C8]7@24II3!U%(:WH1!>`BQF&;1,271I*I2Q>0J7`Y32RD2RZR& M$>#,*.FQ/2ZKBY".EW*82DJ*&*$@_#@TW:I1RFEA(S'A+4 MX=T090CR?'!7HPME,?UV((>II<1-U`%[B+VD-3`$Y)A,U["QU&E=RF!J*<7(03>P MJTRAZFE)"'?\,,K M!\-@!*0#'9D6^1!)FLH4-IGMYC"UE+21 M6A'%$/)#!&K<-'1^M,JA,#F'B''2[>8P MU93,,'VT#9"..1#=RN-[6B>3P4D.4TG)#^MFCAB8183;R`3#9M0+%%U2EW*8 M6DH$^6&6>$@[,(33!*+"H]GSR3PNAZFE9+U!T1NOJ;<0?U%[W.7/#4F^M!A-ZI36B(']@89'\,TH2$,2E'* M86HI26:&-R)80M(1*>&"3FO81HJD>N' MJ:5DADWQ&I)#1S"GF$H]91N2Q:2IS&%J*=EA#)AU1A"'L3(F3B^R+$_OA MP]12(H[;H9),*P9/)=*1HZK:F*:4P=12XLY@R'2LLH=W,EA,J[,:G%:24@93 M2PFL+S;B\RN MZ9L[SEX-I,9GC?!7F_75G]GFO`;0S:-.O3,T>J81`R/LD="&Z"FBMZD]K4#I M'D+*!C*6[)ON(>-QT>TS"EFR$[N'D/CSRUBTM;N'C$(T$+)DLW@/(3EI(&3) M]O,N0JK/+V31AO8NMK6!NA9MD>]B7%$#(4LVW7=15]Y"R()M_%VL:P/#4U08 MT$-(VB#@*2HUZ"$D:V!=BXH7NEA7VD#(DG*(+B/9P+H6%5ATL:X-XO.BDHTN MAJ>!=2TJ`NGB0EI8UY*RDBY"-DBUB@I5NAB>!A%/4>G+%YHS%]72=(G/&\A8 M4IS3Q;8V\))%Y3Y=XIT6VEI20-3%MGY^&8LJDKH,9(-UY:(:IRYFIX'_**J: MZN(_&AC7HCJL+D(V2":+*KNZ>)`&,I:4BG4)Z5H8UY+BLRX.I$$H4%3.UF4D M&]B=H@*Y+E.R@;H6E=Q]H1E(40W?EROC_8L"N\C80,BB,L,N0C98IRLJ7.P2 MN#8P.T6ED%V$;*&N)<657?*L!EZRJ%RSBY=LD&<5%8!V&1;!#P%-5,]Q"R@9:9A6=6M!E#:O!0!:=@]!E#:O!RD?1 MR0I=A&P@8\E1#5UF9(-0H.CPARX#V<"!%!TGT24#:1"=%QU0T<6XMA"RY,B+ M+G.R@7$M.D2C2[S38B1+CN7HDH,TV*14=-!'%\/3P+H6'1W294XV"%V+#B/I MXB<;+)X7'6_21<@6<[+DP)0N0C98%R@Z@J69D#?WC6?#_)DV,OUQZ(R/^N'` M:[/8KM]N+H:K5RO@G/+TZ>F*O]MZ'/EM<7J[>7B]GNS6(VWVX7 M<&E^?3E;+>D#O%M#( M;K;8?]WG[&_#+00]_N4\[/_"C__^8&96R_5V9I?KYV_FFZOY@Z^_P@(]/K^^ M>#C=O[]E1#S\N+FQE0.U]^0F) MYIL%?+Y:#E^END>MMR#]Q<6@C?LK!P+0\&PYP%]O%HOAFW,/[>W)/IR]6"QF MSX81=@]F)VZ]@B%>;X#7[XN9V6R@K_>0[8.3&V+;_3>O7BZNM]`&_+5=KY:7 M^V]S?;6\GE]?+.>KV78'%_:PV:OU9C8_#-+#;\YNZ=1>T3ZZ]A0^P/5OS@;E M6#X:?L+'_P%02P,$%`````@`V()G0]NSWE<7%@```SH!`!4`'`!V4YF4\BJH[,"<`7TZ'M2W1_] M#M&7)&75RLFD*7TT_XG]\8\(EW#T5"8_E.0>IO@R)[BJ>[ROJH"KI\1$;5U8*M-^4_.&) M_V&E_'>[+FV&87A2_^M+T3)I*\B:-4_^06R!K#2EA[QO^$HE2;_:F,#!_`)ETEY'=\44+(/M?[43C/*),EG M6<6^T9L\34C2+_NN[6@26Y#Z>S:G:1"R=2!9%V=YFN(H+UB'CW!:%#B[`S[K M]\K;6U&58(*L$*VO2DRQ64.P^F`A,\HF(J#LAY+QA_)9ZA-.^;IU>P\@HFW1 M%I2+>H,+!M`]5`G!Z7"Y6YM3,8A;]E'/=7L=G^'R_DN:?]\/]\Z6E(O>OJX- M'TAWNZJ'=?T`13WI#A_)9E.JA;^]9R2^SU/*#/S/?\Z2ZIDM';_D#,2L8BUP M<_TBJX`M+=7@T>W1U_#A\P60[5<$EM'6PC(%6/E%>"T2;&"XH&R/5R5LZ;B% M+,F+VQE;6]@FCRM1R`H7;T&YJ.+8[M;00,$7VV+&^L],D=7S11;GQ;3^X/MD M%:D[4+PO."E^P^D,K@"7LT+,ENNLI$(@0=V*U%4AGICM)E!UH'`_S3"S""OH MEV6SY,"NYROP-_S4WW=+47F="S)E>XW!HE3,)N>SRVE9,G.1?;H_Y3G]GJ2] MMJ=`577"">,FVL)@41_9YY$7`DMX2U%YG2_]R!UX=);"=;ST1V'<]FU1WE#$ M9JFM%08*<@EW.+TI<@+`O#^,-58R)TCH8.%!F#M`9 MJ;X",U%F4#*Q^B3?7D.Z*(*LZ:TH73`Q'??5&RC65RBK@K7/YK'L[C+!49(F MU7.?4-VUE(@DJ$:ARBH%[%W;Q&HK$5&,<2)U!XIWB[G%]G/RR-A=<8/M(KM/ MHH1M;[[FSSBMGF^K`O"T3](=F]$CM"!1]VMMZ!"JG/SQ"=?'`M,'R,K:1O[\ MQ'^$7HE%*JL44!39'=K0(&[OA+!3(RH%%IL>=FABJ+"SJ(0_9Y!5GQ]W\#;W M5),LE-!Q3&>E5H$(3@F/0F+07K)"35$N@?10M'G_\%1!1H%JD:!E_%K[;Z.I M'`'V"\'2V[="_0^+?I(C@V!$D^+.ND&N>V1]ICE9F3J:?NK8UQB741VI.BLG M=Q@_G/`IY032JES\I9YD)H;91-'^L_DS6MD7KNX'NT_XV5`@_7C,I$)[MX5\ M0HCA&V02>JXW,4VP)D$`_L2T;-.F)C8LWUF%)>7QQ7FQT$0++IM3*O\+XC+- MI1.1[!/$>0$O1TS,\'I,RCE#S^ZYXBZRE[-`'LC2G.]75PF;+*H\`U:P,QN"(<^,/#.TR(0`CB=@&'3BAS2>N.";$?O-II3T:6'IBS@MR%%> M4"@^'IO'1]\AN;NOZA_G+>"";'PHJP'<38F33/.XR*=:>95X\2L5"^?4;-_^`09Q$G7>K2E!ON$ M#()#!P]9==J)9+\C(LE'<8DE/YZLF5`J["IUIONNL=&:C+F%!XY9RVSEJ'?? M*V&;'=]*7U7D@0G4I(9,4TWZJ,4&R,;BAD`,2_X$H,?@D:NL7"90.E:")0G/ M9@6/Y1?3>U.8H^/'D?<>U+^;AK9K>G]H="B\<0J4S`CF4WJ_TMLK(,/U;".R MG7>@^+T4EBM"21,'BAG0G;[]K760X1D^MDT%)J">O81\)D@#2@<9SB$&)A]M MCKK[F=!>`5DX#,W8'&34C+D3D$P#:2CIX,#*V3/[!8I'`2)TU$+8,D(#3$\^ M&YQ#9(-UD/6RI@0+7 M,9S0">2SP3M$-LB#:03+@?O+=C4>7NNPE3&*#4_%Q*#=C!RTDY2)T%BV@Q`5 MNBLB;,:!'7D*I@;M]N0@/DB':43K08@7O779JDAB<'T%4X5VXW(0-50@I84= M2Y?.EZZ;\VMD8@P1J8\L*\1A3!6X)K5;FL-8H@@MG2;&-_RT!,=.EL:VJLB* M',\(5/BMM-N>4@P.B4#M%2;!S__JE8X-_0OC:$;8@O-Q&+H3V_BH M;(O&!WO(/X9R>_FU!ZHZN/(R[=82]RV0+:51$./()[$"M\Q8;-E-5;D*B/3X M8^H\!2)Z7R^*V!"P:QH'Z[:7K'0)^&B)`**TCF3'Z0U.Z$76>!*7I.\*!>JM MC`S/\XP0'VQ8N&16*$%,4Z28T,52J*[C;_BI.WYLEY88'E9,3:)@-Z['QR^; M0F\@M)?&6';QKZ24$0]+G_)I%&"F`Z> M7"597M36>N\>>;TH\K$3&P8,N@?[M@P2[7L6"9CJ,EN3JKZ>Q&^!MJ4NWV+! M;JG%C#73`B=2,']H/UB6[RF1"YP6ZZ5.RMMEE-0%D$'`M,%^@_>QY@(*1.&@B(GB"9\IY_2>Q__/-\Q&G];55GN"B>V;?5 MNQ<7J8_,P+8,RSG8&UH#-+D1+J,&+RU3V2-.4K[@?\D+GL/L-0>JP.305Y>A M&GO8(@?KQ)''$158:8O"3`BS[(?.*CNVA+!)L!&H",;3X^J1QQWUR.F\(/H5 M"##)^6$M5.+71-NJ(8/'KYLJ;@GKL:LESB]R8=*3+&3^!,+S4KK@U@PAK\60 M%[I6S'8$A^J(D:?P@;!H.OE[P`EM:OV,(IN/01JH]"(@S#$"GPR>D(M MY=%!#5IOP<(0O_,AU`A;':F!/16)173:I(,VL4K1TC.SY`]05,\W*9X_V\9D M?^`>I.ZEI*L:"AV>4,$Z<'MS$"\DXZ,M6//RU\NCP/:I9X8*"%>80%#@D6]]6:&Y`'7" M6M;;I^=?2SXGS\_/9OS*S<:#U^WYH$5;07Z$?3#QH'50*Q:-[-G=*:F2Q[[L M@^*-()]$+BBYC:$M&[,:K><:(=6TT8B3:OG%^_9M15,(A3:X`/9[(\9@A6UN M-/9'3,_]X(<"2%)#QGY.8?'TP92'RORU+8/V+M61;074,Z*#/1S3Q!5%6&JY M)L-?Z-MX6Z>#-^T5$([\(/;,@W5-:&**-/2T;62XY929O%D9>2`,/Z,$F6=$V@TA`3K=Y/+^&MIN1O%('!79@N::E M@!WA*SLFAT\/F0B.8Z-LQL'M9)]L5D>>14S'P@K.BDSC79%'$9KC\&@Q478? M&7368U:8YSJ!JX(Y[\H;+!O%<1C31.`MC/'62+R=J"32($,G,DUKV)-?6SAF MO?/921&^XZY[S3M!>RUZ35TV1\?$B$&!M63:[YQ3PZ$ M\!O:-$,,4]-7\O#;NW)KCP"T#FI^?B)0EM_P4_.$Z1>&;_NYSF[!'8/:18X- MU#15Y/\PWY4;7#?*VNXGK+V3<`-%DM/U3["#?N*-(&R9.,*>@CLMYKMRABN% M=)Q5>.V)EIV6V;6ZS'!U7$?),R?FN_*2JT!2!WNVP,-WSN4J/'(B0@4;9KH( M`TI!053"J%%-ND(CU<&L)5P2/\]?=<]/R9^SI(#M:0^ZXBG%6T$!)K'ANBI6 MRU&WJDIXL!Z%J11G3>&Y!("6M9W)!&8;GBO,+8+J^3K>CWO[M8A"VPR(`0K\ M<*-.>UIHJ`WR4:;`K9 M:0>Q6I69O82&L:TVO/2=$DL!N&^!3NR+F*-7?S4#R+7:4.TECTT5J9[WY!JLC`>T6'R\D*=;(>)8,-,(P'/ MJ:Q@YS#JY1Y=#A-U,+^MXZZ6<4HY[FIIMSZ(P49TL*E==5)E[Q,P.<#K]K)< ME.6,YV"XCNM1E;]FE">&(6SV3Q[YUKU]L'Q#5;[DFZ\3B%\_]$VL2OM%H>U@ MWS'>F\=&!\G?FF+T'`,_--Z"ZWCIY6O^VG7GN>_66@B;MA/A6,$)W;B>&QT, ME(NK;OY.;G[)QUGW MHKWP>VC3R(Z)AYWHO25-D+[;'@%HG9GD5M*XM3]YMRJ^=2^Z)8^HYI@HGLA[_B#2^;+[D-3+._\T) MIY4MZK5Z:(GCMCVB^FM6`$Z3OX#^G*=U]A><9'PCQD;XFX;TA)8WX&?&1L0\-TG\U?I2#/WPJP[E#^`2TJTC'!]`!O#IC5E"% M!B&NBM<,-%T8'\%Z503LV#/QP'GU]1,TL1W:AVOARA_DH:S^8YIGHZ$^YH*C MU;.UZ5+5_4+!ICNM/8#JM1SR";&([0YRKOQWXR_)U[RO7@YMV[XT,3`8VAS: MGR!F4\:\')L%H+Q*LIS?45FL_W6@[7(KW$->/5]!=9^+ATWKD@)YAAM00TE: M,RWDW)=2FS&M;QAR+0;BXD*UT%S=4AH%AA706$7XOAXJO5D.K-LS4K#7$^Q2 M7YWOCF29%T'8"4([=`^6/8.ULA%ZLC1F6W&$?=L* M+!4OG^A1^7XJ6G^M0@XR6C[G_!FGU7-_6I+5@@P>"D:@XIDL/3M4*7H>C$FW MAOF6L-:;$=I&K37^%W26ITP_.9^9'J%C.MY>&(66;T#LV!,K]KR)'SHP<5Q& M31=\$[N4A`[%;]GW/4A[4G'1XW`N*Y[PK4ECV;7TKA=%EAUZ?A`HB&?0Y!*6 MO09+0$B7SJ_C>O&XS5/:H_*EDLBRJ`NAB@=)P2/R M%DSG0C=+2W]F_-ZZR,8.,SQ`[11P*(10`9>>;5<)K!\>HGG.5JLTKW-7]-.C MLQ["IH]=$BLX,-1U!BZ1&K*ATK)E@_J@\B?(&*%3_G0BG2994E9SPZ:?'V(- M((P) X%+4$ULME2C*,-,TD;SFUNQ_IZFM./L6XA@B%:\TZ;D&(GO:D(&0 MEJ.0O]4KA'I2XDKETCM\:W"11R1?W<>)/_G47A$%KA6#H>**K1ZK]F!.)F2K M0=^9+P.M$;/)V-![/KM1`WFF07#HJ/5SJO2?2#U,E8&/IH1`KU_&P*#,G=OB MX13$\`T%M[/UO=LC*3I$!WACA6#5V2_N\Y1IIIS/O&Q"[J;76HS60NI]Y>/3 M,61DZ8ZWL@Y6?CF'"B>IJDX7&1]N(4ORXG86,?(G&4?_E[Q2-M2>7A4.^3PG M,TXI;D0RD/GZSA;^^8>JHK\OS,3\#:*2Y?Q#I/ M2I+F7+*.Z7]K'610RS%"XPU&,U[AX@^HIUFAQ-AMQ9$?1#0RS8,-(I.DMUP) M5%I.D%HO].]&?N$VD!G8)+!4.`CU;,?4T$4E?HK,GM9)^QMGO)(UXJ<9+C"S MDM2TOK1Y5MR\0OM@W1'$"+7NE-/4G=)!;CS*JZCYI1]OR3W060K].H.F.^KS$8>1*9M M'&RDP_YJW'#.*,!*CY^N$?SWO/B#/]N;\Q2K.U-D>VTV;@!JFP>;Z$`^1Z2" MI94D7_@A*YNQ%R&UNY%D>VW^<7A^%!QL&(1\DD@%2Y&ENK1FJ[-/+^$.ITWN MOB2[4]-'DX62ISA=RCZIT-I:]-B2F51Q-WH']6K@;U#2P/>=GZ>-?+!G)K2/J^#2(VP42F&[L3"!UWP@V:"6;[YGEX=A2$ M1DSB74W='4:]5<+3*<^S\A<_*F@]2AK8(C)]#\=1'$UB"X>3B-KVQ(F;<4[P[&+A#\5>5F^YI/@B22DD*RE713X!HD<3":4L/_8 MD>=//##H''/'=QP:&V_17CX(JLD!7#WA7D7DQ[:UU%((U](N,CW+`0KNQ++8 M^!W+"B=@V'YSY088-,[;3)5_$(R3@[B.7=Y>3[IV/"%J4&I:(7Z#;K'][8@= M6T`&&('K':Z#3)9ZQMKW:A/HHR.J/2Y7*8SIF,;:NG:]JK; MS*^$L=U`48=^K8:S_09%!4]G^72:9\N186],'(7^EP%2J=/<39'3&:D6-[R7 MSM74]J(0Y\W.U,&W%,+8V:&2.:N]1W7*X\O'=?QS\L@8 M4\U?=;U/HH39=\V5U]N*K2C3$;M6J-[ZW;F-M^G6KIUHZW"L@:JD"TR,#$S,#DS,%]D968N>&UL550)``.H!'Q2J`1\ M4G5X"P`!!"4.```$.0$``.1=;7/;.)+^?E7W'WS9SQZ#`$@`4Y/;`D!@UE=) M[(J=V;U/+%J"+=90I(>D'/M^_0&21=N)7BB*I"UO32969*#1+P^`[D83_.WO M]]/TZ,X499)G'S]XOX`/1R8;Y>,DN_GXX=O%,;^0IZ_GIQ\__[]E_NK(OTE+VY.(`#HI.ZUMH7[U_&R MV;'[ZMB#Q\C[Y;XIO%57M@![PPOBCB[,6Z#V,KOUHY] M,=80%4W[]\5FLU6C8?>]F3Z$.+"3NJ%;<^N95Q.=)I_;Z?WC91Z9WWUOK:_()OI M]BW6V:TIYHON_I+\3*IOYB\F%L23/!W;6$#]-4NJ![MU?,FM$K/*4G">_6E6 M&;NU5'M+UV*L_<5W&Z`-;1ILHRL;=\G`BW\TWHL:$MB?41L.5HG=.BY,EN3% MQ=$9LY(4WI]`[J\UUNQNA/1E?1M`6]>6>PZ]V($OX_OM8Z]HVMW@#9&ROL?>K%36)W>K"R]+ZR[:J?M[GH^_)^E6 MW[-!U_Z8:ZRWIA3V9O7.3H^\:+"%KVC:W>#//KH$WGB6FK/K9U\VUEM;BMV) MTFR56MMA3T8^F9LX/2_RD3$NX;R5CW7M]V4CSVXN33$-S55U=I4F-PO/NZ$9 MF_7NB,5G`S3E:T67[IG945=#ZNEI0LGX-JGB])/=:LVS!LWFP/Z4]Q3M%N_/=GZ:LJJL/3M M.I;=?$KBJR1-JH=M3&WNU0M+#+JK"Q--MG.Y(9ABF&P*U';5]1:CRT9\B MGA\+3&]-5LY]9'7O/IJM'#?IW">#336[`XT!V-VZ(.Q$I$^&FRT/.Y#8E]G9 M56G^FIFL4G<[9)NW=.N8J4;',1L[K60H+D9+GAX_/F>KKHQ+LNIDG$Q/'MN< MQ#^F,]?4WBW+Z5S)GC]G,=Z2S6S)D/WLCH+S['ALKN-96K5D;RV=GIC-IW&2 M[<_K"S*=LCJG?#PUTRM3M.5S%8TNF9Q86L5H=F6.:Y6T9'4#I94,6Y`D6>(6 MID^VS6-+QU/GA9R+XEIACWU>`>0J_%"IU%<)YL51J_U+-=X\F$LT;1LBG.K#_">Y! M3Q,.`@T7TH2:8$]LD^8))+P8'>6%C8L_?O"6O1Y!O-.:>UWDT^Z,D'1- MND+%4E0L0'`LJ&16P#<':T=MZ[?N90>F54A"\VUA:X M6!"(@-*^+[6`H4\4\VC@B5JM/LCA=\NE<_4^O_",5Z!D8[^(>C1D'&HJE`Y" MIKCT_.5&'R@O'`H10-?3/4M*TR<)O]GQJX.HZS< MQMP8);N2BC!GFA$"/,*0PHQP'JJE-CRBVCFV\$"!T[/V-F/IYU2.^R9J&"I^ MS=/4XOY[7(Q7P*,EI4@"(H*0(`P%]1D(,>#(PQ(@)FW\`-[8LM)!`#2,H@9> M5#8^'&FJL^O+^+[9FM*$4J0Y\4"`_8"&0:A#WPL!6.K2@#L`OJ& M,JZ=&R7O55>MK/TYJEM5OT'\HJ&>GDJLAMI*IM6#J>1ZF7$U/$MV9F?UFZ)$%Q MZW@TXX;8V)-LI#S@AQ[$2`8JD(0I#,F3;E$[N/23.>T5+L/JL5WF/4WR4B3Y M^20NIK%E9C,RUC2/,*>`$@OV0#."&+;X1O6B)WF[7'D_.+=Z-?CIU`$-S M9]+\UGV4>5FYJ[[FS]1:79_;Z&H>B.[F$VZG&`$?("L7\X(0$<6PPH#7_A3: MGF$9T&$8,!,QF$([!="W6UWDKN9AY)Z*TF9MFJHQ@0@A&7J:6P<),<:D+T+B M+Z7Q$7A+_L0;@,>^^AOB("TTUZ8HS/CQV>X-9V8_M(P\`C@*K)Y88*4(N5T8 MO:4LW$+T#3D+PV"A&T5UN@34]T.Z3V4R?KQ,5,5%9L:_%QO.X-M3C+Q`2(F! MQSSK_X0AX3[#2WDQ)NV2D/WX%&]@D>A+_A_W-WY55D5\6AM+-:L=R0D M#J7BG$O(H`TM/<+JC`$,@G;.%#ETP/2BO"&\ZL?K4[8[U2\;1H&2`$(BA-"> MDI2!4+`:SEB^I0KIKFV3=ZB8MK6L1>7D.7<_\^SL^C%^.X\?IANR+=OZ100` MZ7LA":3]8*,_J60-?0QYN\V@GZ"Y)Z/VH:=.G8IG-YM]-S.0ME3.([[C>R#\VB4+J:EY;7,>="44*"!$@7PG/]RE!1%`\5(1VH<.,<9Q@\]I-<=U4APXODVW))2HP!AR;"J2QZP+]K!QP/O%3^] M:+7CZ*,TEN#D66BD9YE[<`#7A$-0U$8*%+4N.#KZH9#"-[H6@I^.8'_?1TBZ"?#1)+*/NG[:I*2JK M8'=L4WYR[+L6,B\*,ZKR^?.QKLYR&\`Z'S"B(8:"8$@Y8=889\--_!Q:RTVBM+4ZXKDFG:-6(^D8QX5$#"*254,5HK M7V/6\J:D0RZ'Z4EU+9_(>,3TMM3:3PVCD"CKT'D:`0XXL=Y<0)XR%;!EL;QW M\`4G^RJJKQKJ\[RR?Z]:QC[']\ET-MW5&=Z%=D0$@RJ4OJ^E_:,UP$%=!LQ\ MV/+!W'=;$=*C;CNNKUR[.;9$U7:*D1Y`U:.BP'7RPR MF$9[2_6\3!N<73\]V3(SE_FE&4VR9!2G.D[26;%7.=MN(T4(>AX./*@5K[UW>IROP"UO)7BW::=!]/T\$B<%^(Y3SXUB]](.Z`3X+*P$VROE&3;,2/? M.H:AIP&'BB(J%2)!;3LA1%*V"^(1A+Z-3W2`98!LB$(D?4K5<1ZT0QY\MZGR/I4[1)K@ MRKNA0+@3NA&#@C#!2:"5 M_<$4P?"I;([*=@D&>,B9]]?0:[LL:IZY.Z:L^FS;FR6;R\R;4T!YEHDXC;.1 MN9@8L[:08&="$0@0E!H'"$BFJ(10\KKN!?IHJ)NB&E[@/9`E\P%5V@HP3MB% MV"_?L+R:V<7%P(OVE_']>9'?)>7B+D0Y<1/N-+-^9_%'G,[F,W+Y(%H=)]F& MCW78RXAI'0!?G;'((SY"BFK!$,(T`-Q[.JZG7M#N`+*W]Q6\`J`/S42M)L@R MA3S/*)=SETL M]:W58E MJMOU6F`_1%)2Z],!J*P*ZID$9=@REW;(93C]:6\8Q.2WIK#> MOXV0*\NT@_O\0/?+RC1&DVZ1]BBAE$(5A)!YOD]$6$NIO9:U-/!=U-)TI[9A M7.3*:B&Q.^L"QI9+=3]*9ZZ0\?<\'W]/GBZ@7^DO;^\><>`1K"#@+H_,(*<* MUXNH$+3E766'7)_3H_J&`$T#8-3\CQ^<,'7=O]R=8<(\0`A0E2`,<40AS[5]:4AA(IVE]O"0RY;Z51A M`T&AF)GQIR2^2M)YD-\(#:O[1)0HX"YV#S13`$+N*UKG"H'0+6.,0ZX4Z5IG M0V!B>;_F97S_C-]&.\:VKN[1&>+Y#',_]!FGQ).TKE7V`Z]=#@,==N!X#Y46G2EMF`SIV`KN]KW5 M25T7.]M(NG@$?'T&M3%5VHYD1#UF@W&%H-U=41!J!E']J!Y!L"6DWD?.=!"5 MOD;=V`ZE8)'US57`;?@-A0288`[!TZK*9+NR!O0>TJ)[JNJ9X;M[Z>S:]U;U M]IY7F5L26>ENU7DZ$'M>EO0Z@Y[';O&?F,K5#`_%P45E_YZKVR(P+B:"1K]Q+5,BC-!S;23I0K>'*EYIV882\0^GC[E]*VK'Q+T8F MBXLD7_/"THWM(Z%"%9+0QU!*+2!CV.-+9?@"M'QV;6+/10R MA+>R9.];5MZ:47*=F/':5U!N[1-)"(1//Y4/KTMS,1I[LX\U4B]AF=W=OM8^ODJ MHU],K&<[R5.+OG(1@O)LO+E\[Z`\3S_T-/2`M(X/P2'05!+N^4A*@07VMR=` MWYCG2:F=7%CPD/H:""I(J)?2:-FR!J!_S[.Q$;9XGCM)__8]S\5\F]\CE,W+ MYAIZH*OZ1:&VR[AV;W<$P&4+H*=K'2LUV\D2;VG<=3#I0S!!^R`]L;O5! M5K:/&'6)0*J)J]6ER/.HN]YS(5?@27X`GNA^]LK[T]+[0<';]4+?@/%?H8IT MGD=<^V[C5R1H(060](T]VKJG)7ZZ4ZVU(H8PI[N+ M)\\NJGSTYU:;_M36E21JK0@+N?"1Q7N(%*G!SM106W9#P[8S1=ZM$@:IT1F/ MYTJ-4W?+^FDFX]NDBM.M!M[8+P(VO)8PD%@@$`(1^DBQ6DXAVB6->WN>MQ-C M=ZF0@8JS9M-9ZD+D>0'`BB3!=A`TI1'YE`9NZ8-<`AZBD#!7B;34ZO^S=VW+ M;>-:]H^F<+\\XMJ=JG2H%-9" M4,YDK#.J,,62TVYFRH_TVO#<:U#2QYI5##$.N:>`2`+C M'!TWW2PMD2-]-%^']I80F%'9$X9\;I[_B,]I7IE`7,V8T)IIPDCX/E2_6%$R M\I/.MI*G$7%&@`KE-&CKV:JV]?;/-UN=]+N#\#_#9'S3_CUK#V5Q']E3Y1@2 M0=-E@?6&66J=U+8_Y()Z9/[L7&1)>)B;%Z@B]X?QKF1U=;]>K6?/U1MY]MF* M$F$1(HYY2`S04#K8?V'$\XD)/INTGI[=OA"G(G+_8>8!G6UXX6/MUQ=FOTCS M@LIY8)QD&[=0&91F0FV_HW(NQZ6US:9J%&/8)<`M%@YPP(3Z:QGP7,3*A+^' M6<<8V"".39:1Y8?Z^K[=YA9IYZOP3W93_W.;N/)=O;ZZ_3C[YPA1<[VR(C(8 M`)`)@Z0(MI^1A/:G0#%KYK14J%+4G0CJZ`X0\[Z4RVKQZW! MV0E&A3+"W,[7`X+>/51!Z3%'`%-@%'.>>.%V)C;QXY:&Y"D<2DMY-$"C3H3> MK%;W,:ICZP+8744=R6E]0JN*<0H$]H*%"0MHC+7`]18+(>.NKNOB^:A[G(QQJ1$0];<&5W%D%*%@A9F'$=!,R/4,+%# M>&2!XSQAN*GD>LA&RP?9!0FTB>%,PI_G>JJ$XYX3A:%S`$GG&(6DOT=Q=&1: MD)^`/HD0N_CR8YKEM[`T;^N6;'Y>QV17.U-O[&(TV''EC1%,:TJX4\!2X-G> MXN^X&\6MY!EG+G*D5`K42R]>&=AW6K\5`"QF.U8$"A54?B*-[LT[+O4X\B7/ M;C,1\F7!M(R[56?7Q\JIAUV&-E_6I]DFCN4NI@W=G`ALRM.OYNLPO_;;7M'Z MZ^;S5NQ#:2YRO[I"1GC/+<":.ZTQPI[V'NV$BI%W/LG3[Y2F\,1P+\OR9V>\ MR_Q^>UM?KWT0SP8$_12$XQEG$[^I,D991Y4PU!)BB%.QIE]W5DSQR!#G5W]Q M>5F8+Y'FI4,TSL/.5]L[LQBW^-R=V>];S(]P-=4K*J48-HA+R;71"FKE47\Z M:"T=Z4K]ZN\^+X1OKIC>;<&4ZWFNS#.[_K_[Q4;_Q46F=^YTM.6\:3_LR:=L-T<)'+C$@,G"@8N*J,F)VZ3#2-^VRP_AT7Z+D[Q8QCJ0/3PH<KA!A2BU4F*E M.<`601`^J'YFSB$ZW?#AEPEJ0.HO0N=GDG]YN0\$#D]![`ENH(JG(F@M@5B8& M>3>7O5E$F$Y*$'U2^\IYHXPV"FE./.%,`D.Z>0./IW1'75CMS(EC(3>FZ[J^ M6<4S@>Y^]NHV?FT?'[^VX^Y-`XTK:S4,GR>QF'GE/(-TIX\!HR92R/B2S$D. M8IE,%@^/*<3B`+MAFV9UL*CV":TJ`;P'"#-KM+/(*050O[0BX,=5A\V3&?I2 M1$F&7@F&;,:X7`5C^6Y;Y;B#;&>QO6_GUS4\PI>3^ZB$L8PRI[TT"$'F)26@ MF[]U=IPIFZ>4WH78DPO+7]D_QBC&$.:2`\V]1M!`U\N"83+.12%/3;X+L:XH MP,6HN(U\KF^N6C-;+`YX8@Q1;K"#"B&E/3?YTMU%TL8OC7JMZXD"RN[[>!;Z=< M$9[23R6/<+!GG*)ZG6N"EKPXSX%E$-]E#23=MV_R] MY\L1YW1,+1EJ6P'"H;$>,<0%9U@I3U4W7^%&+C7IO1DOJI(D!G'L%-R"F-ZU\6(KXBL55)Z/YH\@ZKO[NW?W44A7M\.C-HLF)F#8 M8/`NGN]^;")"FUH,^_B,_DRRC2BHR]B'_QB6,3;*.QN4YQW>(P/2T[M33O?# MF(IH\GP*AZ<0)[@_C6,+PL%N1W\(F<93(4*))XYQIQFP$'OH^FY-2*&[CI.Z:+"BBK`)2`4"ZPA5&R/U%_$I^\ZJ@2"D!,`M?36,1W^1_T1&;%Z9)S/3W67 MD171$MSJBTW_$V./Z@'GC@-/5PQSP#'0'%FI%0\*B.SGA"`>5^`;_E37$B^' M;2IAMWL`QEEL]NV>_KZ>K>_;EX;7GO**RE*JA2;"8^N=XU1JU$O"J;$54'ZJ M*X\+89TETLLVU]L]>GGCENM-^-IMT]Y]=QB>,![*S^;MYJ;PCWJV"A!L0"SU MGG&A5FF6@'Y`:K6JUY&7;^>S3_/%YN;]<9`W5\L_XVU\O%3=5H9LNU_U;#7? MU;T_L@XD?4_E".?.RV``!X8B;HT!RB!*'>#<$PF&%H/I8CE4##+9.RIHP_YC M('#"6NV("+#Q#D.M+QLZ=F'6--/`?+)A9ST@^F%O'?-M_9_[F+YS(`KMA-85 M,$@H':2C+!-!43)4]4!Y/;*<0N9*EA>@R7-$389L"2WTT)[8CWDPM.F$UA6A M3"'KO0&42"ZXX49V7A;?ZL7IRLT1SJH`-#1\]`A"8F7ECN#;#=S9-R@T9(H".KUZC3IP+W8 MVO/C%$9M5<_V4QFO.5+:""2`XE`X`FF'`T4(O@I5)XF@3UF<$L/XZ])JRKK0 M]-E4GD5NM9[?S=;UU6T_Z/X'.U_%TX8PJT$%Z9QN*@8`@.BBE(""3^M69\/P**+T9OEU_OU:O-=P=/5ZA];54H#XIR`2#FLE#$Q M!7@W1X;T.&TZ6PZ_,B1)A]>E.(%&<>*Q5:6!#!.TBC,'J9#"((Y[U1'PB02% M7YX3X_"Z%"?P*$X\MJJ$5E9KRXBA5@J,,+:^MU$-&9=1(EN-K9?Q0 MOM6/R7.',]?]^'!%C>0,$D6PDLI;YAC1NY5/CKN_.G]5>&7F](N!+$\-$_2C MSTT[_]_-Y?_@JC'4+\T2SKAS]F[;_KM;]?WJP&27"X0640%(HB8A116`"-)47=S!SW M(Y.(Y](K4HKJ:=KP%/B4D/Q?'SZVFYWS89JN+/0`>ICSAO):)@K M[#4E/S:-?,8L\MD8D`RC,BSXK?E6M\N-!_;79KEJ@B;EHA?NUW:^BNG,/ZW/ MXL?YW57"04RD]!A*`@$74@G6H6*U'7?`E;&`=4;F9$>O!*=BQ&K0[>?1A38H M^8.D.?A\9:`QP0BWRC'.I!8`DGY>Q-AQKDP9JT%G8T4*>,J(O?T:W;+K,]>, MH^TJ:PF$`2<8=#`L.!`.]#<-@NAQ&F7&^LX9:9`.IB)!$AM3_<"I_)&*P2>W MK0A1.NRB!D`8:[)!3T"O3PDVMCI8]G.LB_KCID:UR*(R6WV)01_ACUC:Y]ML M\=T1X&X.QQ:84_NH.!-86VL%C$E&*)3"]U]1^+R*7=>>QJJ$\GRZUF1"K(A% MN[&]9J!5T*(^U`5H"I(6V,=-,?P1@Q#@>9+-E\O$@`3@7W6K&;#$5 M`[$`@K18*>HDD9BI_OR'`U7J@/SBPD^%4*EM8F^E4FLS:]N'L'4.)10]WK"B M`BO$O+<2,D:4]V%)ZV9J+!MGA.2_5K^HFI$4TBQ!D@>O%3?W0SEB%W^[G[6S M8,1GZ;RODYF[]Z1U[4*/&U+<;FLT'HV$/-Z@0MXCBBVWDCA*'/)A0XJ']Y12 M8Z@>/'8\<<17P?*>Q;*&;YM5_+#B@,+'-%]_-ZRC9>G.Z*("(FRO!$L43#?' M#:"`@\=9:>I0J9(AS]>G2R"0I@@V&8(!GTW]U`6FS[_5JFUC+LS-RJ(?U.>V MWOS\S'7]6>TK!V(N-^\PIYP'J"7>WE=%`(P#(S.,Y;G!SR?=)C]TQS67,VG0 M#^19%^-SFE=62VDDAX`SPK'!!EG;S<1+-,'8O$R2.H4':IX/;IG'J^0X(@ZSZ$`!'+DL4"D&RFRPR5WBU80 M2PQ^DQR?$@;IA_5LO9GNMB!YK%C?+#?FT'&'O:/M*J$L`,PQ#KEV-,S20]S/ M$^E2]<"FL?/G@*Q(#,GWPQR,.#KX?.4$1@0A!2"U+'Q*%*%^7H0I-;W]/[&\ MGD:$)$3IYV'!9+;]*0J_O-#?SV(AR\$;\?W'*J4,]-01;PE#6#'C>6]/,\K' ME:S)=B?U0DG\4+1O-!`EQ!EKDS;+=J8%"\QYI57%HGN5`><><5`U0I MVQ^?:#A.U-,_7@Z^IBM4M?+`/[QK*`'6U1"6.T4#O#P0&Z, M@*8]M8'D4]+OTQW\I06ER"W3MA#Q9@^+ERM!#HMSQ']2^PI1)*"$#(I8%\[LWR423U M(MC$-^Z?Z\5]S.?^6]/<_#W?';$?6C!>T&UE`(JF-8(TF,3!G%+,=/%=+<9V5,)L!*D&CC\O%^]A`/9LW@&G+@Z4IIH[461!,E M%``XF&W=::Z1:J0+99ZT\^E)\')`"@GYQ\/X;7&7X\)^KE45$V02XRVTG`BH MH0WV?C='ZNFXX\@\!76S"#T1,!/;)KXSQM+L%=]U61%I!8`Q6R>I\<>2?U5GWW;)8N%[,X;WL;SAJ>CU`]_S/[5 MM&8Q6YU4$V1,=Y7&$C+G+==46&>LUBK8L0IJYV"@R.`U4B8WB>LO]UI]GBVU5I&>\<`X\5070//:0LZ"I M*6B,QK$2W7:J0.I2GG5GYF>GYS[P(]28I#-,7WV0<7RXBM=?AV6*)X)`I+P1#`A".'.MG M094=634UM0X_'OQCSBSGS3VIYWGR>!1AH?->>,21@@K98+G8'A!D2@5)3FF' MS`G@E,,0%$$@K&'6XO!M&`2Y@KWZZ322T]M5,TEJ3#S"./!>,QTFLTN_(A8D MD'ZBJ!1'*!1*<^QC]7.Q>/*1PF!B MZ;-ZJHRR5BMF),&$^?"1:"$[+'!0@`KY(DU)1R@#Y01HM1O_N]E=/1CI,**W M2EJII+:&.AV^+(J$U[K'1!L[/;TCN_3/8UE"5/^?<1&;R:@V/P/1RA/LSWI5 MA_?$+&@VUH-HOF[4A9WF,'C4<6(/%>`8,$@AQ(S(L(%X($2_;01%9!I:5!'I M-B40'*4Q__<_"*'-%(^KRD^?JP"C*CJ)6@F0#[H!TX1T8X.(C5LF,F;%SB_= M%#B56`'T_6J^K,-B>/V?^_EJ*X+C.O$S+2K.'#'&(V>,MA9!*VB_D@(ZTKWE M?)_J*>J^:2"[%!WBC\%^'-0O!ML&NY,!(RE7UBN-K.;&^FZ^R'`_7?WUQ1(\ M@1$IL/KY.3(YC7-ZU+BD)N")M=YZIY20&&NBH.F72"/].*_X;'I>0JR/[OOG MH5+B([Y:?ZG;@4WOR'=\2O/*<&XQY0@B&S9+SZ#SO<8*G"EV+IY$*TSKB)0! MOU\V_I,)C+Q!87%U1CA*K.J_4.K9.!^)2]D>:5E6$->?*3I486B=#ZL^(-0B MCR#1CU9:L-@D&;>'9:S44Y!161`LP1WWS[J=!5',E[/V(6+@9NTRT'WUOFX_ M?)FU=?Q6KM?OZF/\.;V32GOB&9`.6`\8U`@"!3L$#$43JT!;E$/94"S!HQ-V MLWX%!18`K$`L(&"P,QPI*KK1![UO7$ZCC$5]"G)@)$8E)1S8.&\"#->QS%UM MZ^V?)\C]<,-*`D$Y`(!9)@0F5`/6SQ0X/4X;3AXO?%$V)$$N4X#/MZ!%->T\ M4P+ZOO>]'_Q?KAUU] M6LP_;ZJ29<2M>^'>R\J\I>B4=F0TLZ_S]6SQ-GZ:>P]DX\RQ2D>97Y.T&L0^ M@JLO3\N'+&_4M_"N^'[?M!]F^\-X>R1:+E77V\!]Z!W5VDBBA6$NJ.W&*.MP M^*?!ZYOL*!RM.O'";BOAK!%&:"VDHQX``:5XG'T\P"V58?3Y2A1%1=Q<#-D, M,73IB1A&NKJZ]<%^6<9ZI6^6JS#$NR-IK_.^L)(>_Q][U];=-HZD_U$?W"^/ MN/;VV>XDFZ2GSSSA*#9C:T>6O)3D[LRO7T`*Z?@BD2)!BO+T2^(X!`A\]1&H M*A2J+$'*8F(9%M;*:#95$'.MQHJM:)\O>S1.92)R5OP[G<<<&<+Q&/;&A@'A MJ*-S`:U,%553@GF#J]%KQZ=ZF6$"XER-@/.EL64RQ[-ODR3CNT->+Y+:7.[Z M2+.@*0,RJB"&2')=O<*%!H.#&(6NJ@=11H)UTU:B"F5JXZCP!6`Z$SQK?]^Z>?5P]% MN4QT_G0?C?A565R[E)#\OIROD_U[4HG[+MT%@S%'T#FGTC$1!T;:^O,Q9"IY MH`?AS(BXC<&F>C/]NBK73S;31N8T-0T,B;C1IG1RFFFJJ:<>5J:KL:";B3-0 MMO#!=HS,*(VSPGPN=]5GOYVTCAQJ%`SQW"FJC-+>>`2T!Z::H0)@8F5"\@GL MQ8J1":%.FL/O/WWZZ905RVZ+/^:;V_GR_;+X9S$KCZL8>7H/0&`#A)2`8(HH M98YB64.+1;>T&X/M*]F9)\!EM,9\NJQ=]EHN3.@D<"X4I\UPAAK1R MQO$:(T]%-Y$/%I8SS*HP)&*9>:"^QI7J^W@^WY:K[._0.>O/4W:KV,8\.=M!XFCP#D^GG\O5>OW[ M,JK@BS3&GX_E$.K9;S!.>X&4]$!;)R"4A-:?$B-83$./O2!J]0=Y>((]#B]E M1]^-.`O!7NDWZ/AQ$>%UU/>@L=X!;7B-..43B7:_((+U!SD;P8Y!XF?S\A^S MQ?9@3$WG#H-7.'Y-"&.B->$0.41UO5YKUHU2PY37FA2EAD!W5,_OR8K7B3T$ MP`B(6H"WW!!'H%,0UU!SA;N=,`U3INL3BQT9RS](A:;N;7\\4VY;U\E-G^ M3FMQ[>-WEHIWQQDD--Y_?7[A[-<6Y4ARO2(8IBUF`GJ@)%.>8*GW!8U8_,(X M:3S*'`;!Q\6GYT3;ES#)\:(`K+(FJD$<4LBE,2!E(=VC"1TFW5QUF4N#$Z.2&ED$[12UW MF#LIXO>DHHK-JKG&+VIB.6P'(T->F,:@Q,=BO2GG5YOB>D?@-BFK7SX?.,-& MH)2RT7`3[2IF(*SF)24`G<0_7##84.+/`<[YE(O6^VEC_?4[)EZH0'& MBE(%&4V1WEK8N*QZK\>Z5MZ+5"/Z*"B6 MV[A6%)M17G).MW`Z+]UQ12VO_V<[6\R_?HM\45=7B2=K.U\G?]2VG?_WY+Z" M$3C%SG(,*,'4$4JTHHXC2"PBRC?&FIX7DR8_[DG]!(.0<`9@JZUB2!K$!*^P MP)Z.=>/SJ)MV0`FOQL-NLN[6QTDO%JL_9\NK(AUJINH7YP*:O1^E7YN9Q= M%Q^+JV+^L%/(FZ\P-S8.N^*8SEC'))021Q.:VQI.)R=V>36O$)];>KG1ZA0R M^['X,ML4:Q/-KYOXX]6_T@S3;KO;=H]?,&K3-A!EN/:(:9I*/<7=69OZ`S(` M3LRG.(C$AP)K[`4A1<6M/Q:;;;D\;3%XV3!02ZVR`@$/N104QYG2:J9>8#XM M7^-H"T%OI#K>/KR???LMHKE/9/J=JDVW"P^WB0L7,!XRRHW5"E"FO??UPF50 MMYOG@]TQ'>ZCSPC2&!_[;ZN'G47\R_(X)!]7BT4DZY^S\OK("M"AMT",BSPW MPA/@%$+48UXO@$A/5S\8VETR/);G-T3T;)%^U=D2^=X^L/09&>,9X-(A3337 MNIXWZEB!?#`.#2K9DXR2;OAUVG".#^1#N7J8_^@M>E%RK5WSH(E@7FCK(,&" M.0\,J+=.:=5$+HZ.R80!X3O_`J*N_W>[WNS23'5>1'[H(RBE`8!$0*-W1<@D MQ;#>\@GL%ALSF(XZG86D.X8#+"8[C=J4Q?5\LWY??IA]VXW+;,NR>/7TNV^7 M04@/%;%:$!Y51NFM>+3A%.;=#-[!=-^)+#HY(1WD./OEJ>Y@I]2[^)/XKFT9 ME*M#F@;M,\6"BY),*AQ!U&/3*2(J5X M5'@L<^?/1D$KL)+*+1N+NL>K``1(=>@@=4`88<3#6*XLRQ0_`[#D8H M/U;"EJ/GT7D%>O!*4&ZP)GL`_62B'Z*ZWW#>_.KS(=JNBK/DD\9(>XZ%][@" M`Q,VJ6(+@PK[M<#!GFB-%BWZXS@;CP`/M`@:(`^1,4!ZYB10*9-'-3>NC9KN MB7%/635)OA<^;XL#DSOYG8;H,Q@^_QU5LKA]/AG!<:?]X18I/8\%B"BML'8Z MODA)7HU70]6MAO1@7K/>J*^&0*63%#]M4HK!F_G5"7(\UB8PIJ$VR'JL/8-6 M1O*":LPNFFW3\GIEE61&7,98A#]MOZR+_]M&S<^EPI,M`@`/M`B<.8R(Y]$N MEQYI*#6OYZ:Y[A9<>KK,)Z>2Y<'K3%QHW)(/M@F0>>JEIM[&;X=X`"1TU?R, MDV*ZBEEOB34SH!=&;X\+DU/0ID.!LXN^,<#U))3KZSE'BF@-,*D5EN0 M!]VB:P93YC+(Y[C$.Z$RBA4V6]XT;?GU,P%20KE+]Y$Y8%HJ04"%AI5JM#2E MD]ODNR(TFH2;[^,^/A4B!!3'%0Y"Z+7$ED:^5G.(*]^$M^X.49XATBW#>;>\:A?CDN2#BR"DG7$!F$:**(5HM4%9`,)$<][TD\#SN MK,?\1Y'C[*]V"C*%%?6/AO:TQ8!4\"XDBE?)B<&0X>LK.<&],2\)AED="@)6B]9S4=[-E[-6J0\/MDE7NYG47D25%W"KI`52U;JT[)@E8[#P[OR"SX5,IU-O MM5X7FU_N[F?S\JYHO&G\^M.!*1T57PA374;N&,00U`N3,F1BUPSS23`?)IUD M]VLQ6Q>)-8?$53\0L,?0<\H<<=)$E<,):>)HA&).,F#\M+;40<)->R'273ZO M!W>KJZMR.UM4]\X_1F/RJ!!;]Q*4XYQ@X)'5A%B<*$QV\^((4-;QR&F^YVV2W:N^OVCP>$%2;&:<"A=EH0Y^UN361QPW),=KNQ.]@^ M/AX1NN&3,0KQM/C#D*JEQZEJ)0EAA$GH`-V/TW/-83=3:K"BT/C MK2[:^579)/>F)D%I::V,6@U$7G*J(DEUG)T!V&%H.X:=9B\S-\I'G`FCT3PI M[U;+JU1K+^XTR_6Q^V6O/!TTP-8!#P2')N5&,X#Q/:NMC7]VBTKA%RGW_O", MOF-_GWO;'?O[XP%0X'6<%+.:^X@*3JEQ]D2&BG=,%2\N4N@9\!GDQO+1V[V' M:D9>_O5>9J(MQ:"#%CC'+1-1EDA)K;$@V-!&77*@L,[1K_="0)0%`!LBN%4V M10V`B`,C0$%)=6/J[T\#ZXU?[W640N6,$%$II5P[H_P.#$5T MU%M'2^4Z6,1$:V&WNMY[&EJ7=;73$V0A\0@!I317!$>==3:[6E-LX=*8B]ITI)F>;/!;4:,0H(^,VICKIT%S:9Y9Z$34;;61 MPF!+**;(U+.3TD_Y:#:CX#/!TVDK?VU.GXK-9E%<_S'?W)K9^G:7_?]^DRJ\ M?=I&,V7VJB.V1V^!&ZZ$0HP[R#V.4R2*UO.DN%LD_#C'K1EH,!YREW+JRIC0 M!'EM`0+,1=U8LGI65.%N"L$XIZY#[0?=H!G1?3M8TLF4@//]U_^:/WPH5YM$ M^E^6M_,O\RCQCZMOL\7FVZ=-6PT@57G5\<77J;1FM#)WH9#/ M#L/&>M\YLV_NRZP_'Y@JRW0!+>V=^MOC(]^W4Y4^OC;.^_Z=!^"IBWJ^H5%3 MTX!)P>T^,7F*4&X1L#NT:[]QBNM#[)'"OH;OI\ULLWOQKXD0"8?C!PM'6@4C&`96,:R=ERIN MV8S2"AB(U5AU4#L>+XQ&B]50B(ZAGAX8;:,3^FB[X!@#4'$E*?7Q+TJ@$-4\ MF19HNL<16:37CA&]L'J[W)C<,<7T*'$6*[:([[E-E?"*AV*QND_#_JX)-R=8 M:6X=`").6R.00QAA(0UAJ)HS=QU#S`?S>6:2WTL+-S-.W2*,BT5\Z.;G8EF4 MLT4$1]*O-(3U$YZ>?7RW8'3/-TT;<.'MDV#T(A19+&V#%LO&-+,53/P MWG8K%C28%CX)6@R$;2]V[%[^81O-R#CQ-+]VS#C0+$CB"((*:4%U'+KA*8:O M6ID-GEAIS>FQ(@^NW>SXU\%8+"H/UI?U+JW,01N^9?O@C26(>Z9VM7CB'QC6 MMHP'8*R#@EPW5.31?1VW707`:.F(%,TX8Q+57A-4S M9ZCC%I2=2`-)\[FA/P1DHRJK1?DPORJ:@$H7@:Y6-\OYO^/75I3SU?X&D)G= MSS>S1?JMNDM)6-JHNGG?&#!%/F[3F#G),61$F/C)UPM_QSB\[!K1.'2<;-`'1B0QV&O-,,*`*L>)KV8&K.VV*V;7G,9A3Q:(IK-XW=R4Q4U-#?5DJ/ENM7R( M=FBQMV?6GU=QM?WQ_],J_&ZU^6>Q>5R?^U*VRSM#7.BM8L1ZRAV``-`(ZJ/] MTWS[?UR;840^=6'R"!*X:(;O-9#=?9+=K])S\!RT?W4@@4IM@2<*$$4-A1!) M8VO?H>A8=&:P9?T-?@LYQ#+(W8(V$>CGR1`S]1!T@R7%4D,N-&'"2*]%%*8! M`EO&?7,%H+]#T(M`&/6>6$(H!P`*1K#!%89*^+<2@MZ:*H.%H)\&]&1#T%^' M8??;M=IN;E=E6FQ_CZM3^<,127**1WS<7T5Y-5\7'\JXM+"?5]]_1@"`A@")T[L*&(J(J;?&<\8E!!CC6J/49+P[+GW\M"/)>#4J MU/G)%(<"ZW'A?FPZT%>P3E.K$7(:.*$(@4S6>AF0_B(BLZ9&ISQ8Y^<3_G%< MI!^?#O05L*4*(,D]AFZ=Q8@LT9I!9EGZ;XF M8>G*9K7LHN;CI'%KIUP&F3*!G9]2XOO`Q$]0]"#3RVZ"E5IPRXA#@@!.%'&D MMBZ0[U@'=;!J+)=!H]XP7YP;]=?5GT6Y_VE^-S\6&S"1%AKA!-4,4H\$U[7HH>]X M#6[*D;>3X'H_*5P/!Z(ZE7\]W$?1"OH!L`AGM8_B2:>8O9_Q',;^Y38&=#T4YNRD^ M%HD)NZ(3RUU&6=5;8^C#&, M_W]WU[;C-`Q$/PG;XTM&XL7CL9^`!_B`")850F)9(2CB\XG1-LMVVZ:-$]?= MMU:U*\\YCF=BS_',$W16WEA^@8_=HJQ=;=3W\$O.Q+Q0U/=\!+WVCK53#J.@ MG#8$*88M]@QRGHBU\B;Z]49]Q81CN7-*?*P M`UUZ#=8*BEHJPD"&3?1>>9ND"98331ZO5+%P4K^UIWF/.H0@AE>0)+0Q283\ MQO_/,G*&9Z8`+BW%*J9E=W$H1Z)9K=0R%3JQ'K/\_!Y M67.@.4E+&]0OD#?R(5_)?_OEZ\T9Q;Z/]>E5TBGG09!-H(-$9E;;,3NTC4E% MBI&_7P>7*H_O"9KD1\$5^Y@$HI3&#U.(=`#'8\SC=\O.KW9@?$'//!.*:E1. MEZUY;-539RVR422`K-(B1CO:,,Q3;MCKGL_#/B:+<+A.3MOSHE6IK$_AVP'. MN\W=)(E/VO4YXQB[S@PP&++,R%%L[2"6C5P:6\3`_7+V5^'QXY_3>/R_7<^$ M,3J.2G:6NT0)1;>U`Z-PE3QF31X+[*^RL[\3#TQ7>#K0HX^>`J74^2",3"24 M3G%KFT>HE3QTN6AH&6`N1/KTM0V'^O2^BS();S2`-R)Y)N/&Q4EAPY5`BQF; MG@%%&+V\N=!9*#97S3-P^=3MRH/_T.O,;(']%(E[8(%'>5H^_`Z M$YJ>$>5'6NO`M.!6YGF;F+WKH@4TI&0*`@`AF#'T56JF!F@]7<12="X'R3I9 M!3OG^^_N?QW/(WC]*O^4\S"&+W\!4$L#!!0````(`-B"9T.F40)5,"TR,#$S,#DS,%]L86(N>&UL550)``.H!'Q2J`1\4G5X"P`! M!"4.```$.0$``-1=:V_C.);]OL#^!V[-AZT"DHK>C][I&8AZ]`13KZU4]PS0 M6!BRS21"RV)&DE.I?[\D];"=AT-*I*SY4N4X"N^YA^3AY25%_OFO#YLLO@7_0,LDR\F?5>?G[=.@^42^_.,G^L\RK1!XJ+*?JM4M MVJ0?\"JMF=G;NK[[Z>+B^_?O[Q^69?X>ES<7AJ:9%_U?O?@$_>F\>^RF_OZA6K\!Q+FB8K8YC'2//SQY_KO)GM9]W[]@O^T?K;+G'B3%ZA?__/CA MBOEYGA55G18K](:P`4##1XES]!5=`_K_KU\O7X3G7]`G+@IT0ZG^@LH,KZ_J MM*P_I$N4$QRLM-L273]?1%Z6!R50BGQ*D>Y0BO[T2L'UCSOT\YLJV]SEA)^+ M,0X,0%P_1:L,'J/ATQ"4QWA]7*!LP-](ST5R(3\M4C;HIK'%Q5I%&WY-)D2^#SNEC'\BG]DE:_!$99M9;<=TK&3W4J%BC=2.>!V6# M;/WS&_)IL:W.;]+T;G%9W)-Q"9<_HJQ:Y;C:EBA85G69KNI%8FJ>[T//#UW# MCPWRCQOH5F#9=A186J0M6)$+5)S_>M4A8%_),_%&A(BG')>HPMMRU8Q3!!L= MH1NX?^E1@1TL\'L'[/_^?+%SYY!&O'JN93`\UVFU9*!:UPDXW;Q`>5UUWYS3 M;\XUO1UN_\3!T6-F\4HJLPU1.0TL<-FUQH,V$Y0K@,LU*DFPT_U56JY>J9+V MB8L5)L/X77U^4#O7)=XH<`7+;W@-/<299ZGAZ4[?2'>$Q-4_%@XTDQ":GFUY M5A+ZT/?TJ+4)'2O2%W4_C@SI5/R&1'I5_<+8QM&U,E2]W(T4T#=8CM0P)T./ M*#+`H,U`D7J:Q"1)G-WY:M(`7UX7I:$$O:I*]V7]L`C3NSJC(0@B$[;/RSR[ M85/(JI=")XH]1["PXE5.`RDB MT$,Z94KJ66Z.SOW&L3F3CCC:C29KXA,,+=H+WSS?-_Q/#-P8>R9 M7NA:OMG9@5YHB01)PH4K#GDZ/#\)!C#B)/$)BE)^Q)2D@W(Z!7E,QA'I&,S; M3#1C.'XLJ0&)3K[2'%6ML5\P7E>?4+W0#<_RH*'KGN?ZO@4U6]-;6[[N&J'0 M=&J(`<5J\:7$Z^VJ!F5+\ADH4"TZ]1E$'.=D1C5G@M,3"@>T>,X`0W0&/AVC M3,U$XQE:CDT=QK`X$ST9Y\/C\'X\(?S1!_Z1YO6/UMHB"'S?C&V+)K:-4(^T MP`XZ*['K1D*QAUC1JB./!DVO):(!B"!/G.&'.HH$@X^6G1;)U(''`0W'PHYA M?,U$)(:B?QQRC"&!W;+0+IS4W) M=IMU[0Q0M0"K9YO@>W!9@ZQ8Y=LU">_JV]UO`$K+`JW!\@?[FD#)B(:SH@I< M$('>%FN:]CL#V[MS\G51@SQ;H:(B]A"J_H>&TZ2P;+/]R-)= MZ#F1[?FV&_FMO5B+7:$U_L%&E,>*!!<;X%"+3#2A/9P^/E&8A#G1H+$CK0-U MNE3W2_0<49+1C,Y$6<;[@24WM0'*\_F:)<:N<+Y>:'JH^T;DQ;KG0FCYD/S; MF?%B4R@++EKV!#I#(_*[1XGP`6(CQ!B_QJ@B2UQ:*$\,"Z!@3J`G>U2\(B-# M2)N1>@R"_XQH#*>!6RNBK$2K^O,=HI.>XH9:;=-GK5HMR"0GT`Q/U[S`]@W- M]0+=Z$6*?"&B'N.M390$[Z(601V1P":?LDQ+I)C6--A`#PY0=&>@H[8%.+'^ MO$K8$4621_9,-$JB0UA5NQ3.IC0I.1)F1;ML7&BB9L],O>0 MG4C&CM)T-,LC@]Z9R)7DMS>_H((H9DY,!^M-5F1T?DAS MT)UUSW9,,[82-PQ='Y(0T(-19QWZ)M?"HF23B@,QML7C#-PT*%GO2P]P#E4S M68SSR=H)R!;3MQ;@&?AEC^E#D">2.C[JCFV;DLO]3,1/ME>/MU:I($TDBJO+ M;;M2&MZFY0VJ%J8;F8%OZC`)#`\FD0Y]I[/EF+XMMMU[@`'5<\Y]3)VLB<=H M`XCC#LW4W1U>*9/@Q[0LGQZ&LX@S/1G7$^/(VUQA+"_\;5YB[-2AK+ M?;Z^+&K2E+)ECH*J0G5U6:S1-9&W&N5$W-;Q0[ME@Z;=OF=YOC`C/7(U)W%< M3X]-1X->&/28'+$-Y$J!*-:H'5Z04L`@ZYT!*U9_H@>C**T5/F&;386(">`. M-LWH[]5,@_P,[+"?,_#@;0\?=/C?3?WRW0BNCRCK)%4X$P6>QM?'[_I-1_#@ MG14+QXQ--_2@9R:&JUEQ[!MV9\XW8:/)$ITH==;YH1[TNAMR=RBVUSO,WI-!SL_ M[>T2%60"7K/8[EVGOC7U6OB8XOGP*G32U3P@*\SU[0>A30R_SZ<=<,(8^*,3)'K,B6BF15I^0-#K).5V3 MU.RQS.(,V]=,AL)94O/L&64SPSADD";0VF``-FJ_"'TSCOPP#*$1F=!)/-WL MLJJ)Y8BMAP^UH7@Z\47I.#>`4I$Q22V;@\8/`JE+BH*W+:K)5X">)^=5"1Y. MYZSD-,+T#Z:..5CS? MT<#;(,^PL(0IJ"P^I3M1!A9+H MO@,3,R9AHV61D<#KC#A>(!33B94\=5CW1$-_0V6-'L9(Y>OL#9!!J<3)EK@O M:8F*DRH:KUIQTSA')>('?TQE!"G@5I`X+0MZR_<75%[=IGN74#H1D2E#@T2Y MH..']!:`;ID]"2W7%TE-#3:B.#?U5%?N4`DJ"O$%A0'DX0V9++%G;G%.&I+P M<4C#*>=3H$G8%A.C#A(@F``#=;KCD%ZBYX@8C69T)KHTW@\LN:F-5"N85MEJ M80:A;D+7L$PW]NNV.D2H^"XIUBH$`;[?5>B=0HO/"@=0-DQSY MK(W5FS/`,)U8:Q@&`:$1XW&F*B/HQ"L2,X22P?H29?FV1NN%:>BQ&21!3`\- MB*(XM(+>7!(90B_M#[6A6&-:&))5AIO`83JC@KOQ2M.B.K'6M"@$U$:4S9GJ MC;`;KRC.,%JX->4']ZA,;]"G[6:)RL_7S'3U>5M7=5K0A9H^MC)= M-XR].U59JOMGFS'41T M0B:_!OC4[*3DB\E`4\WR1.E]HA**JNEF`VD:9CP-@S:++-]!*HAYKI:!V(V/`"%6K+9WF:22>35^%52,D:B(M53F',SU*.R8I0=![Z^1*=X@HZNF+FK:'C MW>-344DT\MTT2`_"_'S]M^S^2XEKE%;HLKC-EAGAOSU8^:HN4;I9^)JAAQ;4 M7%6M5'FK19QH$4P.KOFVV=GT;)\K))1B2''\]TM)=_O>M2"; M%SVKMM.5W<7,#"DHT0IE]VR'"7OLESQ]P%>;K+[].['%>PZ?'/8YQI0IB1<; M2[X4K`Z_Q7655K<@*ZYS_+TAF5["VC7KW86L_UTU M;9ONF&I:-VG:VWI;HK[M2[L<]17B7AI49/$]A\%$FB]808,4&3PB=(W*$JW; MFQQ;@U](@[PEHUAP4R)V9>\BU+V81."VJ<<.=`)(%_^)[<"*-LL`^('FE+(J6@6-/_Z"D3I`G3-M8O:AI>;)N)FP1:9)B);[N& M$]BQ:^AV$AB^S[MW8*05=6)*$;&36]F'/6PGO`#W*%='NBAAH26/Q8.]+78 MHCNWG,1T?)=>OMDA,TET*W03DWHXJG=6;3<;>GX4&6SI7.^LF?&AO?Y+.S5Y MY`_4O!-3H=6VS.I,_-JF":J.3T1G5FOB0GOV5&5I+>W!!;\SP(`B!@SRU.H[ MGN0C"CUA#UI7G9H6P8,(M?T M3=T-7<.-&FL^_>JUMUM&EJZPZ^]C`ON@1.:G(W@3F)%.P]^P.>@0'OGF?"]Z M_=(L;SQ-1/&\PRJI5CJMMN2=E0:+9FAE&IAW[OAL[NFOK M'80HL84N4Y=I5W&<.%I[E'#-.6D^$>7+:BBC[NU?[U=E6W.;;==-_2O""$EA^8FF&14,^Q79O9LB(C#**85DY>0-B[8&D6@$=Q-(=0:[0/6&*C M$0RS?DOS+6L[9-+XO]LTSZ[I:D^P6N$MB2/V)(Q.'A>A87AQJ)D1C`+'\$/# M\=P.A)G8CDB@)=>RXE"K!\N2.CNXH,-[&!!0R+QRI*@F^,*PTU6"F.K+Y5]) M+"9$Y9%H3$V5S"0>4^0'B./2RBEL#\[A93CU8O2*)$T29H8X4V:%42/30@3:(2.Z\1& MX),)L]79UD(HE,V38O#D>OA[`U2N&/*R+4,*%1`M6PA?Y_@$*MA@&JR!@K3_ M6RB@J$]"^C>(,&[UZTTFN/Q6IFOTM7_II/J(Z%N0"R?P=2T.H]CQ==\W=5UO M%U.H[L9^+*)]$LPI5CZ&:K]'_M[@$A4Z&<3RR=S$G(J)7`^.W>_4D+N'CX-= M)1+W.F='!$XBX3.1-YD>866M4V0!XBM:IC6JPMNTO"$?5W]02:6S;#;=;@U; M0>C"Q'"@K3N0SJQAV$>4H:9SS7/E65,L;"U&L`>211L]3%&ED\@SQZK/Y!2+ MZ=RR[UX]9+\M&_?.P.I1-:W[ M:LJ:%ST*7&[2')`O24>CNUZ7VRHK4$7?0$EK0,\4I'>?K^A)(\3.$H%ML<)Y M3K[)B+2-?BN$IR)>6K^26HES6,R2ZQ!6U=Y'A-[T1 M93_EBC/"'D'R#*/K,=XI05Q5KUF00');TYB485]^+I`0DT<@3+DS$H)E$,%MCA M`EW4/#V)0EO4)R)SVEAXQ2ICLZN,-CB>2P1\C/:7(E\I536'B%>.(UAV*U:T MD>L#:5>7-=I4B]`SS1!:KJG9EFG'EFW!H`-B!8G0M6+RK<]J0Q>%#1AN5;NZ M!*I%=$'N%#4R='5.6F6<=(M7SZF$;5[B]3.32%RA@P.W>PVEDEN#/^)[MO/_ MLCB^S/B5#-UD(O$]+=<+*XS)K"'T$DN+`\.P$]/M$QX&%%OQ4V%_LGQ$(00M95(*5U`J?")^Z0L1DN$-+HU*.#1.<=:)$B0<0>T2+55;3 M3-18J8MXNE8O=<,9;$Z86C@T`@_#Q-%^.&9BWN4)GA]56=EK5H M/#S&KDA7?PQ16(&[X[S2`P4N&\AG9,YYDQ7T,J[N7"ZIF]&X:T(T^)V*_J$! M[POJ2J\:>87E$VQ':S$-WH\F2OQ,M%.R4T([TH91QI=A/FZ9Z,)]5M&,';0\ M)_%@%.N6Z3EQHH5:G]WVH\!;%.@FK='Z&V?.699=KO[I-_WS"401?6SP$"W, MTS8#M]J6)8V4&M5EI^\*'?@AC7J.!/6D="O:G=NC/`G)`@GL4Y`]\-1/7*,FE3`<1CN]_J-OD.[<+:^$7J,QZ@#EU<=T MV&L/J&W57Z<[2U(_#3WL._VM<9.V]@5UGU/DS:.A+Q]2O.+MUS,S#:=F@=M+Y=E?M7'D:&G6Q8G`8Z2&..`D*!.N@&(W`R[ M,2`P"B+$N4(UK(6Y+&M4U55<.V/5G4YW![?[=HWZ;QO]ASQKOE=,U``_,_\G M\J0E@6$J:XM9IHOT*RJ-[)3)'FLW;N^Z;0RO([N#1G>IN^"R5'0&5OC7#X\%W6QTKQB)3.U9PR^S*#KB#+E,[VQ+>&8&PT\^US(M]/SL\ZQ:S5=+M*]NB]WZ MW_G5G]O:4U^J8O6OC_?L^Y_JB5CK2__.=ZMUF7_:K5?Y9V9(TT,NBCV*_`BY MP/,SE*8$`7<@RA"'0CPT@WZF&>E$K.J2W=(YV.7LF6%.8YG3FN8TMEVP6-:; MYS3V.8V!4X=`GT\I\D=?,4R3X5E-:Z$O2^U*Q,W^EIT M_ZX=XG;M!(`7UZR:$9Q%,$H\%P!`>CW2(/:YBV1,"#?,4,\&TG4Y5)WGG M1NS(O_^_[[YS7:D6*$9\PU$_,[=;-"QL7I-'!$IEYO:,EA*99M^);9WFO>?N MF3EEZ[0WO;?>M&ZZKYF^9&&SZ6K#?OY^O[LOVIXU5^VY"CM]+]LLX;ZH6!.< MY6;SX*S+U9?-KE#T03=.FU8ELZ/?+-A?Q?-C8+V.\YZ M>\W:Y+!_*Y?J2/CN5(F.R6%@0VF.4?N*B>:3-A:N97N#(N"@"*%I2%+?IZE+ M8Q0$'DR&?5DWR;AJ_,U)GYV'6?CPQF$?F`G[TNY19>(I/*.;BJUWBBXRGL(Y M4[#QX+`WX!>BXQ/>D^)CU9%@/2$K&\C-R'J@U$#)8*Q(,,H-2(AD*%EU)%A/RD*%EU)%A/R%`D\D$2IZ\68Q@1#F@5TV$%' M!&K:N):5/CLEAX^C/S03_:7=HTK)4WA&-R5;[Q1=E#R%Z!<]!Q-DXYL,^A,#@'3`0ZV6DAU2Y=A+GZ&;<5^`7700\ MB7_D:-BDGS0PX"GDI'A0V0W6LZ&ZA=R9C/36G^PE7&&*OT9]H-NXK/1!;J8SK`K M3'&'0XB?I^SWX^PCU58 MQD+WZN$?]0Y`%TYC9;?$:.RT@I[TN$R8N"8>*593VM18F&P3I.:@>6CPS_O[ M(YU!D!`/QS0.4^B%F1]'Z4#=7@:$'BZ<5=&):?!V?7-K+0\*.WD&'C3I7WMX ML+'R9^'!1RZ;B@=E1\K/R(/26)CD034'S<.#'_;LK.[C]<=#W5/[^7+AXS`. M7!*E+DHI3OP8H^'>!DZ3^5:&"CI/RHXM(5[T%61'M67L6?"V&FU6AE1Q_PQD M.9'G[>'-UF"67(U,[GYRZL>-)_+D5'2J82S]C,RJ`Q:3)*O-;6)\>ZE)_:=J M_Y772Z@JOT+?\]WR)O^'?+F3X_97 MX!81[G\%YKS.W."9C.#"Z3%Q.E"<`15G!(O#<)DC?9A_,+R47LRO(?=PM2G] M>$VP/9>>O";];4Y?CGXDS6_66V9K]S:QM_`]1$+B)B@%<88()8@,[9DPC#Q[ M'MM*?0(\./M) MB(3.LR8D^4%?VTY"9-P_XTF(8<_;DQH<3D)&)O],)R%//3GU28C"6+*)N6V" M98J3$&6WS;.5\%3M+CX70G3J)LMJT#W8;8PLRO M<:M`^Z":86M@SO%D#]\_P_(_]5:`H->G6OJ;&HPV)0S68V5R:6_6P=RIQ1_; M57&7?ZF657/7[CT;&+4RZ.]UN<`Q!"Y!$*0T2U!*$QB&(8U\+TS9R\1"RV\5 M.::O+Z]N\ZO]INE91^_N-\5#GCM?\MUW%A5/AUJTV71&L!_\G*^*FVT3<3_E MNW7!/EU6=>B\?*B_=U_L*N<]NRS[C5DL^BB]DI/XF'0J_X@17:N5,ZCE]'J] MB*,1XCD#TAE>T`&M)6%;BRF%_I&G)^AU;2'/="82:97)-J#W5&D$VNHH\DW2M'.@%NTQ3O17CA&(][)1CEZ`;8[ZHD:PQ?W MI"#BCGR?\S*O/WR+ME]U3U`YH2'/O4!SZ($QQ`OQ<= MU7^+Q#\=\@Q'P5Y%9[F]QN):1RHG8EL.C&W)+YI-:DP-T1%6E5^R3?UMV[^D6_KQ?2FEHZN[M;;=5GM MZBC[/3]6`'L9B.ME=89\`"(40!>`(=C&OLO=IU*K5-/+WN4FKU.VFU;79I(N MC[05#8`&<#\?!N>%7'#+ME73^<<([F--!<*B:=@%VE#.!K]<#\JOM[FS/*QE M?BMV3O^?W]MG#UH?5`4[9/G=*5OS>*:)\AL$(E`^0U#FW&%#@THSAA6F1[)@ M>M[T-?M:_TRS^Y%Z(`*^&V%$/$HCF+EXV/T@/N1JGRSWFR?<<3VUY\#=A?"B M:T;(C&NF)]MP=SXL[R0W6P5]P)>IFX-?C(9&4,VR@WJ$PYDL6PXO2_)I2>4+ M'4-&=R_<\E3WQ8-ZVRLVX]B$Z_79A34`J7.0XD0'S8B#: M(M>\0[@9I3]4&E5`=#ES1!/,-K4QB#*4193ZL3=L\P24+K[GN\N"EQCDY8C$ MBK%*_.GM^/TZP)X&-\$8.QQ$CLO49MH>/@G0F8BI#JHE84^#(87N M\2;T0E$G[7->K]O7JRJ_>BHW3GT8^@2D!`*2Q=!/(>WE9AD1>(Y>@S#SAUN= M:MVKFFR!O'O\Q?UV70GM\FJ!F6-S=VJ$)4_\U7%/O&]QH)MUK/)TCXYVT^9MAQZ MZ6R'6U'M%;K^ES5R'IQE+=4I[_/5^GI="^UZ]BY+YRJ_7F_KKW0?7][L\D9) M]0=L7W;CJ3UCG2/`AJUBK?84AJ:*#*DUTC[5,^2V3O-9-M_)3`(:^![RTSA, M:Z$X2N"0R1/,UT-;BR#3]6I?/GWJGIMN7H^NAX(4:TGC*,!84T"HE&3WNK7; MY2I,)0VG!$M-`:ODZW9J\(I%^1,PO!3A5=&S*;HKV_)<9-<#$&>%RO.;.L/A M-+HLFSY5BPR3P(\RB$"<9:#^`WC!0"FNRW4-0Z]$T\>#S`O=4=]J?"38G;3_ MIU!EA#:8>8I1YD!8L!#EY'GKH2SB6Z^G6`V*-J1%ZD_F0%R.(=Z^=3X4V_Q= M_:=S]!OJ<;TNJ]*YKMVZ=/)-NRAPWKY5+BKAQ.=D08EN?&W@$/U&%2:' MI&@122NI7IT\JTA7R+*@J4<#$D-,8^Q':88".$B'/M\VF&:1,_,**S-AOX0M MZY<2[Y+J`IZSI&1ZS`5K37H%3]?X=$I.783"A=RYZA2]T%NR]Z_;JL?U+"9` M$S^6;*^ZO12C/UX?[KBU5]R:&VYX>;^NEAOV5717[+?5`H1^1D,*($TBX,$@ MQA$^G*(";['-;YC17_F#Z5RJ+507NV(;O> M?J_SH6*W%KZ-,YO?!4]C;?2UXC:3KDNE(^NGXSM>#='I_0%SJ3X:G<8"[M[2UP1B9P[;G/F-V>05TYC]7A44N"\H0&2^6F M^J#6&^H_%%M6=)6W!>MED[R-O\\2YP]%];]Y=4BI%W6>3!`,2!9&U/5<-ZRU M/)S*AD(/YZB%QL,U&$I+QD2HY&1T7KXFT MS`(A0V83N&9^DFOWC>KHW'V)?GV`R7)V(O=@*YI-3 MW3`=_O6XM?I(N7[?6?H96L3=@U]N;?+M:Y^5A+7Q8"L,H\V.: MAIF7);Z7(C]ILP3H(8PSWLBJ5ZBYP#C2LSG^.-)TM$LUWR:5$))G(I(9CU@2 M4`P95TPQJ`6G\_NB+`^B']!JM=LO-ZC"R]WNH?[B_RPW^WR1$0QHE+K0`W&6 MN)"`).F%IS@1VB#2(]%P=OO?R_J'ULN-L^HUK9S->GFYWM31M9[*2Z;UN<6] M2;#Y8N;T.(O%2J;?*$`^.)V&$P=$+IC.!$*],%L2`#4;59@*-NZO=?E7M M=[6D.NY^SC=LWQ:MJO7W9FX/$3?!?N8G48(SC". M5:6I!OO*7H!:>/5RA]0PXB".""(AR#RW5@$&+O*2,$V$6N9IE&OZ1L:H$>CI MR=SHZWQK-!;NE*?3"9QU6C/A+UB\I1-Z,W5=_#B>*_8RX`U+8J@1TQZ7A1F# M3R[U89>RFX:H-`P]1'$<1VD41BG%*&N$H2`-`IAR]>Q7DV`X-AY/RK:-@$P_ M8TGX)+)$(\BI9(1/,\81PMB4>*1IS+WR0AD8\Q79/,+/")%V2^ M[R*41B@`210VXL(T3%,J=-`J*V.&."/7E5@:1,E88P`_]6@S3X?@$]B(1!Q! M-&V-.:)FO!1UI&#AZP#S7_GV:KG9'(GL&LZ0E(2D#G$^\D"6A0@E"0MS41R2 M%$0`PZ9[=*IN"]I'8A4?CP&6U M7S$&)`A!Z.-!7I)DD4B.)"W$<'*$E^6M<]\I)QA3Y('CBRN38"866WJ5NHM" M(Z4F#C"GL#D39)3AM"30J-M1:!YG(F<'ST6V+WG%WKCY:UW=LOGXF;US5?]I>;?%GFBPA'*$8^C*@79:#6(D#AH`IK6\A[KF!(_A1AJGO_Y\IA8X(] M^].H)O22B"GT.4XC+`!>QWJO4]GY4>OL-&[IM&Z]TNMM@U,$#CDL<([D^UI- M(T*V-%@=39'NG:IVK<`ZL5[O-YN'.CC79+^KULOF/]?797[TX-6%<[_+OZ^+ M?5E_N[MS,G36WAV-!]9S3_GQ*SG83QV^&':B#0T`@H9G3$Y*9C':/\.4@@DB=2CY,`6Y#UF',MF*"$2O>;^*QV`]%E7_- M_Z[2&I!_+3Q*@P"Z-`O93PBK&.R\AZGQC6CJ-FC/TZC@+VYDT3QOBEJ1\^NQYVH1#)U`"?3>V-U_S MW1W)+UD92O>4P7NV8OMXN5G?-%Q]"*XN3BARL\2#!!#LN]3MF_D$&?:SC+LG MA%:IYJ8E4_1M'2#O'*9JVTNG5=9IM'5&ZLYW,5T,SC/3U9!?+)F\IJQ[TE;" M((C<$YM)_U1LUJN'0PP)0QH3UT644I0ED$(_Q;VHA-!0)$61^?V&LY+#9!WA M+)B*2,'&%_1,(R86V9@V%TZKC_.M^WN^'.,9<,[$*14H+0E&2B84^D:6Z%ND MJQ4[6&!WJ9C`<=>-P*44(^SZ$&(40>37DEN)K%L8(KS/8,I+,+HMU"GE]%K- M1_>G$3HS933`:LG,T6')XZYR$P"$PHUXF^NA3#5-TJQ@XLBEXUI^QT$V1L!23Y`M(T((K% MHP-^@U;.EQ?Q,Q*-3L)S)ABI0VI)+-)@2*%[M(D;KXY[Q\^W6R2#+&\QDFY'69*IFK51M%6K.J#&G85H=YC)$OI=!$A,:)SYA#0LRU`M%?B#TF+.:),-9RFB*%==.MMXN MZY1RN7'^V+((*+.?]?_<75F3X[B1_BMX\SA"[>5]/!(\-F9C>KJBI\9>/RG8 M$E1%CXJ42:FFR[]^`?#049(*)\G>"+NGCFXA\TL@OP20R)0$5MQAZ<%4C<>: M+M2XBQ2GT^)'>,9>2T`9!KT M@K3OI;;E9+Z1F6%F03.$_C`<]"'709GH&+J]]B`6H'(!(IA8]7AA%-D"RS$` MY/360MCI:8!Q'9P[4:0LG#.)'Z75N&QBH006&<_359$VO*^GQ&"A#UC`4^B-J0R7_3/AH>I`NJSK?2.V<2&1[I\1>:IIG!T$Y<[%;Z(?"6BJ\Y%L?GCK/:!7M@ M\>##L>(U0".TYB=J;W6$X*-USPG4G%8^K^C7UKZ0^LRK_W-1%B^'EVZ0`'^L MZSM^8'J)9;F19[EF/TA@&ERW]GR?K-D#=,*(;ADX46+S`OH`XO,#[-AH\01G M,-SQ!6)PS<0;"`I?J9@QO!XA_WXRB.TD#K1\S_%)5K1O.$X6](-X9L3G$;@^ M6;=':(41]@A\*#%Z!&T`<7H$9FST>(13&.YY!"&XYN(1Q(2_]`@2$*AHF48W M)A8T?0OO2WSHQ=@3)7X6>H,C\CRN!ZNR8^G>27S0PTNZG;<(O(R;CA&1Y=R( MG($ZW>WL!PC=VZSR4^BF:?]=B5Z;[(JQ([#9'`DLU-C0,CGX,215"+E[H) MT!W_)`_J3#R3`D4JU?.-TQNE+[MM]8;0;^@5U3G6N@_>7,/SH]#(;.@[L6VF M5A(.PQF0Z_Y6=`S-GJ@7"PQRB6Z_A$%D.(Y#&=B2=2H,B[ZN=JH&'L@-,T:/_SRRXO:OI`NW^V M%$$K)575+,_R4\^T36,(O*+886K@(//YFOT/E0J+WL$/ZHW[NZ^A=:D9_1+N!%N=E6?S8D9^F_JAI4AWW[/?Z0O*Y) MX[E\WW80QE*2UX*O?6$S\L/[J[-&*^+N\>A-_P^^Y5MZ4]4\([P+6&.QU5`9 MLTWO\IWZF3$;4M2@VCOFU`6?;%%EDE>4?M_164^^7D:!$>#]C)6FCN<:D1.X M%LDJ"N(D@[;MN3)#,"S\P7ZI.$Y?E$-X^=1"+I4KRHL46*NN'B\Z]M MDE0GSL=@Z&&+D<, M$':^K9_RLO@/#=/BJFRJ;;&FW\"\*9HOFX?VC++]T:$I2M0T"6I6=;$C/\)[ ML/==78_5Y9/8#+#0<6I9T(HMQ_=MKZTN;V59ED9<6<^32JIYV5(=R(GNJ1;T MU.-*3V3>X&!:$S.&&3^,=3D#EA.]%N!,LP6X:G7\XTX_<*+@K;DP9=,.K3:[ M%U+-8J[,A'EF`L9EF#N2^81\!,[LA+#D?4>]KK:MV]< M)6&:P]F5O!*5RIG#&4_3\3[G>Q(#8B]VHP-N8H=^I M:?/$Q6I&U)[$>;%*.&-81;"RQ:+C(RKBNCL!:6"HH/^UFI"0";H[H9U:Z&<2 MHBE6JM(Y6[EN1%?/:'W8HB^;N-KBGU8UILY7%-4U*:E)J#1ZJA']HGG,OVW1 MTG4\&QJ.YZ5)&%B1F=A>VDIA&H$9,96YUC2T[GO43F"RVSL3&9S(#(Y"XT5, MQ.;K'BQWL).:@O-Z]L>T`L_5[J36$'R_!)K>+IB*MFA%3SB:XJDL-L4J MQQ99'74A1R%'^Q0E^/.Y6#W33$C\$Y(C6=`$YKS>XUWC#O]KZ71(;DQOWBQK M,\X<`G>-VE6CS'`>[KLU=@/?AN%IN34OA)8/T]0Q#1@:?ABD1M(/3FJ.,%.> MLA$U,]U-O]J`;V]'W\I7QE$QY@RT-@G1E(CW$ MOR"I$P46Q!Y%N2Y>BS5YYS$0F#0UL6)VBY&48SX'(E*O5*5SFJJ@G6'DKJR> M[UI9G%JFG819'$`#IEG-@TJ MST7HQ^T*5J2&F64Q_K\39::;QIC(LGY<`V^IF+E$Q6":>:03$3P\Y_5+OD*' M/5YL"_#KW_Y^9UEI@I6!,L9&E(\N>C`O:.-(%0)U?I0@RT$38R,L1A'Q=2X@ M)V*HID4N]A7XL]@_@ZL3?-O.<+"I:GJ0MD:O:%OMR$'C8YR49$]*YI M5;V\H'I5Y-LNOZ.ML+&KJ_5AM>]?);=G<=)SX7^^;PK6B>B\>\Q+^^*X`3!&DYQ54I9:U#FX:S+T=9,8R[JX1F;C M\Q>/"6X1F18SSH'1]"A6Z5X!7.=U;WCOOLJ*;W75%$U6'C;H8.#!WO8 M+,>1QU[B7'``S61,Q0)8KC[LQI)QU>H6Q8V!1,>`C(\&N;H@;`6R46E(ND*Z%?!^86'\CB.`<_+ZU#I7!BZ&E@1>F7NA8P_;/A+&6W'3VX>>0G\[Z:D>G%1@X8'H#\#$$?U8ZD1I0 ML;6EIG.81%-ZNA[3B+'/IT^DZ!#Z&_X3G'T"0-^+!INDW>G@#1':MIE]X-.G M,?/.![!4Y)[S(S\'OM*LH6@.NBB8<@F!R7''32IBTM9/Q;<#F;(/;6UW4E'& MQA0;FEYB^VGHI(X1#?F)-@?A:91!,^LE]>'I[()@59'%C"/);PCL\F)-$G>/ MB59XC8N7Q]=I*9;3Q7D8B?-@\28;GHA-*P"#4\$7H!-]+O91D)2/E\7>&7A;Q:DJGVS0ZMB4[2=6[6C>'DM3%Q^N5_*.*U@DD@[SUQ?OU)]U_;"+>G$F%1I\#0X^A)DMF MI7)8Y;CZ]UU68Q%^*5:D'&*&T-*VX\3,HB@S[3`,8QG9P`"SH1U@K(42_FXGUF MCCUB:/N8RSF^0>3%\PIA90;F:N^YP.Y0-P?ZO*S"\>;JS(XG3\NT<=D[1'FI M2]PDX_7B8-7&I4'_[?M(X)7UKL5R<IYF0[B'2,;IF64>$[TEW MQ+/0^LX!D[;0^F.4>6-MA7:;<_"M4DV6:%PYK'+$^FNUQU'J`ZJ+"A/[OP\% M)OBLJDESY:*DDD4;S$2?\_H/1.2.=KNZ>LVW_R3MK9>9X=E&YH:V&V6Q[1JN M9CEOAR;T.EA[O$%KQJ8?HY$39RH!7*B%Q@4`[UF"T!U^P',KB`DF(_YQ:,% M+&GQ/"Z2@Y@T9QK'KG*.)D1!@"33&-,8H M,4A6U.1:K7_7\5N^1)IXE$J%;@J!8@>LW=V..%(+J-+OUL M84SCCQ*)7$%<4Q@B8]O_!S&(E/H*`Q!Y,[!%'U_1JGHJB_^0;NXG`G>W&4,+ M%Q@[29Q&411;H64:ANF'PYL^R_/8"Y,I&D]SE'#N2KK;S(8D$'3"\W"!*H@9 MR'P"=/D(^BC@Q?.+3D3!SEBJ(.:@T`F@_H'>4["A$\JTFH>7PGST`) M8[=[/H/C3G*&(&XSRD]6W@/Y;U5^V71Y90_MC>C2 M-XS8-1/?B_$79A;%:3P\1'*LB/TH1GHDS2'3(!_8M0*2P]\AZ4L@Q5@>6H:` M:514^4*E(Z`/1T"'7.*'*0#EJ6XP)K"B]Q7'F`<[]%W;)[=I7[!R#S4U5.= MOZ3?=R1!=HEEB%TW\2TG"*`;IJD5#9F$T/82Z5-\]2+I/KQ'9*&>2`I^ZI;A M7[L3_&V.E_%K4;]_::KB]%:##25.Z*Z9(F%7FTV#]C25)"_?S@=%+6KOQST=9]'U.LQK='+J1Q[- MKJX>#6K+5.">#;S7`OJFVQP"BPFT9KD$T`VZFE#E\;FN#D_/>''7ZP?ROOOS M4$X2KRPL^Y]5_ M3J4$#:I?B]6]@Z/)[*0@%!G?1*K#$-"I`*@.@"H!SK0`G1HSM*#"Z&-\2ZJ- M/(8[.T((YR'$[45)"N&^%J2VQ;Z;!%F6^3`_$AJO"CA.ETFOM# M-3-P^]QOJ@N:;MA[5S.\.,WE4H9;[LOK&#'%Y6+9X_O^A[Q8?RDC_,,U/?Q+ M#0@]VTVAZ;J!;_LP<+QA;=F.?-]6\:$UKY"^#@FIB4$KKQUV)/FM%X_6A.]3 M\%5$.1(VD(A)QX%?5?QY4AL&$'D!ML@@\<1&4!!6CF,,5=5C&(K&7%DREZ5C MM+]BN0DJ;P0H;YTY1WL*M&.)[%2!*,=WG_LWV=T=U]=N^B[-)/3PB*&1FK%K M)0:,[*%%>NRDCC3="8^LF>T^7[Y2'Y:T"K-E)&N0YDY.\9,KJI55?.^ M3P!>V?O\!N%/>#[)+L@.Y;HHGY:QX64P#),T=*#EQ9$=.<-1;!8YD8++>^&Q M-1/LN??>M$*IN=05AUN"+D="6A5%]N*>)?EE\[""DGOT4:RA/EVO6PB`]'BH M;QUI`DQBYLGQ)PELZMZ@I-'L2?JMQDOQ6Q#SWX!+&VO.-*A"/;:[;44PLM'= MKS1X^[*AI7F^O*+Z'R1E\[80_RBV6X@^YVNTC,TPR3R8):EK>E;F1Y8QE/J& M8<)>H4^C#+KWEQ<5NBHL?)?TVKN`/[&PI-_+"Q97L`B?3ALQ<.5,S,/'F4?+ M_//2,O=()E1QK1+X/$L:#O6$'DAR:,:8O'X<`Z<2$WNZ-^R:0-")ILZ`8G4A^Q8THBU"4F^*C`&8ZV\\IOID0 MA6OAS]1&8<[`[Z5ZK*(5O2.`AZ8H4=.@INUV$+I^'/IF`"T_"@(_2,-@*$V0 M.2'3XW]E@VF.6'X7JQ*C#LO[]#\)C'Q$_G#BFSOAP%&Z#[OG:'D*\1%<=YY( M*$-Z)D\GU.E3:9J2/)N[P;4>'W3XJ6M%9F8;D1'YJ>UZ_K&RG&4';#7?!#^< M9U4)U7Q[ET#*E;(A@!;#;D0O3'S.YXA/+XQF?#@B=;TXJ3\K/"LU6Z^[G*$K M0;BR[,UW"-T*?,6AG$/`*B%]I60^J4CD."T/4>WQG]<"W<_Y=]*"9>G#T$J3 MV'6S&/\ORPS'&]JJAZXEW_E1J32:0\S3^Y+WJVF!=[-43!6)!VJ-))$0,IE] M5*6(G)5_ZC6XIYT_N\H8<+W4)T:A<@RY'Y=Y]6+'I?MV=6F/FS6E''U+,"7]_/"(G]9VT MI:KPV)`W>47+_)@#98^K,$N"BT:H91M!WSSWZL4QO10ZIAV[26RGL9>9T$F/ MXGCL%V<:9=">\7GG/DQI#*#"'A+,/[(I5/']W4LHI22OPCY*FD"/:B)9Z_T_BRB?HX,CF@ MQ^H1K9[+8I5OL[S8'FJTM"W3=#S3RE(;6HEKNE8P,'SDV:[2EXJ*9=.=A'+V M>O&RNV+71IYT)0'K`VK?674*@$VK@;[GC*JM+$'4,S&P*@(_?_9XV5T/6WW0 M"22MV0>U0*?7W(VM^(7DA$97$@V4[]![NAD3/M/$*>TLR(^FQ6] MAJ!5\<>9"V,%+V/.B0G"&`9/,6U$\P'^6F(;53;_X:,<94`HBW?4FD:R'F^^ M1\T^_;XKVKNZ5O3?RRUJFEYZM$[S>EN@>FE9;NB;F>?$GNU'@1\'QV?#4>3) MASAJQ=$PW_\?=U?:VC6OIO\)O,P.X`XEZ MH;3?*%):%.BT11O,8C%8&([-3(1QK*QEM\G]]9?4F^W$5DB*E)4+##IIFIC/ M>0[Y\/"0/*R>LS]*THJ#^8`',DN1P-T^@WUE[4'>\O)0]68%6&V[YOW?D;K! M@"#G>CW`5#33=(N#"6U@4QL!#E:`QHP)>M!$C>&K>=)(#+*V.KKK4Q!](]Q> MF6(5OZC&)G:YX7T)#^24_KG]^GY0VUJ%P]?UC#!KP+H;P#O^#+R M=K^K'BS<%>"2L_YJT?_?R)=[!E'=<_-G'!=.Y%K02,86UQ@E2M4B3GIWBZN] MT_E)7&CZLDD6?,PLV?=[QG9S)_0@R?S0<]-`)M3PH5#VXJCO,Y'E?C!Z^3FH61BOQ=H(D#5=XOK:'L.7`*ZR6+UA6CC`*5*5/,U/6+,B]V)Q]W&3+?+MGXOUGE7SOW@YFQT] M&\!_\%N=@6B/ZLU=%'A>&F5)['E^%#K8/;P<$+FA?.7@Z9MB.ZW+"1#I56'2 M;^"V,K!^B5085J5_?KUE&W:7[ZK73'\#]<^"W>))[:[M]*F6"0NF;X6],*/N M*Q^;OB*[3&SZ5+/&Y"R`CH;J%E1-A)@-!16@XJ*N"M6R<70@7_Q"0TAW./\_ MK!,J!$73MV;\1/:)GO%N=&DQHBIU]8V]KJ_>B;[ZH^VKRT-??3CIJVWJO+LZ MOZK?;*YN)U8)S,$1VM4[P:6([^K`I'OG%"+(=\16\2XE2"7";2O95(5MRNKF M<"\^D;7*>>^H-3O!7A8%V*?039,X32+/Z_8>4DP=Z>C4+@S+D25ERRU;U$]# MU5_]-D`X529YR]Z3B!*GXSBU"*_%#8Z`RP1H)_@GY"J%6&HZ+C-;V.=.(I,[.BK_5LAK`7BA"&< M[XK=8BVWF6^^=:7)O0.JM&M\NM1:O$@'7%IWO;G%;V7+6)G@GFUB>\Z:R-:P M10.+L?J]XO#_QC][FR]W;$46Y;U8CO#_I5R?^'PI)C>\(XOM]IDCJ>2)+SHB M2`B)L\3%GI-1WZ==6IUB)+4';*MMRW']`2Y8"W-&= M:SI`+3X_XIZTW%=?'*&=`;+?;EE?)6,K$JO(8H_`VO+'1.35FGG%.-U:M=HX M7U4L\E7Z]"AVN3F,+WPYL,5ER79ETU/GCIOX`?4(B7AX[\"4(^E4'1(J==7" M9'N6);2!*(Y;"XQU;KD0,,&R1@@6%5[58N0FJ);3S+%95M/)EN`&7L5O!1#4 M"*^ED1*L]>BB2[Y*^^5.]ZR4-VJ.>9 M&Z$HBF`:4AB[08`2VK69N8JO*PQIR+K*U=BJT<=:8#.PD3YW9H9.64$;B4E5 M):MAS4`%K.(R/7#YN8]+2Q)VF:=>[3)`[V1$RX0MK]3*&$'2,L57U;ROY7R] M7:LB;RI]6J[WXI&^_RZ*E7@`'$0A1$D8 MA]T.(?1BE6&NUX+E,5]G,K2"$TW&Y$3`/EEJBG":\3E`&EDASM+2(Q?#:)R( M=@PTHC#9LQ15!2^K\A7EU_H\2YLJ\G#H>0BEH>]'/O1I$&5QVQJ*DE!%5C2; ML*PK+:KV)(^BMNCR)B\R4DRI9TP_5;L"XT`UNU_ MJ0N-+GO26C,"<GG[1&4CI='1GJ"&OI<<(-=+J0]D=XPVL M;A9/1XT>!5;$C9$;Q#X.:!#C"+DDZIZ5#$(7RCVI:ZPYE4&E]YRHNMQ3W2:MUK$Q%>^W:^.JT^ M"K':E7[GOH?2$$,^6/-16/[2:)YL1:0K5\OM$3=M@BDD9/2P$^AY^#@K2(4@S_?XLCI(($: MT_7J2%]BIV>$#"9T(B-EN!V%X9XV<.3N2S#Q@B1Q M,M$@HHZ'D*MT-5>_%[9Q!5$YDQ`RUXM76C0%2I,<*63SF MHMZ,J`A79OL=;Y*'V_G#_J$MZ4?WW?F;.$UA%ONNESD9B2'U$C=M,?B9%ZA, MYD8;MCR_B_ZN.(N;Y55.F:Y&J9I>-3!!C7,&:J2@@=H5$@94E$;[+**`FY]L M_8/_!%^^W_<<3[(B:BJD]DB=%=],1`#MV%:,T+EMB.7'S/7YENWKZ"!)0558-BLAMHAUZZ*"LR3UM&.5`-*JNZ@=Z:E&@9JJJDNE:;U M-.,#H=%U![H^(E[BHXCKNI]UNDZ#,+42CLHW;E]-0SMJJL"O43&U0ZU5+160 MIRRE':7#E53=.^]+2#7LT]-172*-RVC^HY'S('$XABR#?NR0&"+"O]'B@!$F M-F14NG'[,HHLR:@\OV9EU`JU=F640YZTC+:4&I!19>^\,QE5MT]31C6)E'NA MZ3*(]CV2U9[EF^_YTW.%(8(.(=3W4S]&04P"ZOD)QQ!B2%'BX%3Z32;3#5N6 MSS<&^M&[=-5`Y[#!<_\X'\$7_7)[=3<8E=II>D#AX:1K>D+OJ23S'I%[JDB1 MJ3-SF57"I_`1S`T$/0)WP1$L<9@1Z)VVDT M@YE2W6C3;=M?!$0V%@$J[!I<`U@BUMX2X`!XBO'_`=W0\%_#,>\I^MC@*"$ARAP/96G8-NY`:O[TV)LM6M;)&_&2F^J;J88Y-:B3 M1NFTIHY3E,2A0BC-_'N2/WFC=$1/D3*#4M?>4ONX$64_V.KCIGL<.PPBEP>O M)$`8QQA!%WNPRV"C0*EXOU4@EH7Q$RO+_P*+!U'C[_`Z[O%=5^-B.<0KIC1T M)(=8D=99=V$6M/#%:OSKFY/;E53W,M>#Q-B`"]^-1INP55FZC1%L4-&_UOK4 M/(7\F>U>_/O^&]$W9[&R]!LFV]IK MTP23E'(8L9>@V$U"OKZ@5?6)$,9IFCAJ]5A-MZXB)%KE68GRZ]+_80\FGD#'SA6HU'A%3UQR;S8/G];_/QCP<.7?+$6#UQ]N>,`V?8'*^<4Q8GO M.SC"*$1^Q/N7AUT?^T%``TI3I42D@>8LAV,<&'AHD2F_GC><3+D0:V0>U4*H M#MP,"#8[?/4#>CQ2:C&._F[>6Z3UR)Y!QB>B="8M>O5BGF&RU/7L?XKM/WPU MO"V6K'S1=!+1.,-A$"`7)L0+<.AE7=-9Z&@)VH#V+"N:0/8AWWQXK+'I:MH0 M0A5%;20NM55-X*O2>37"R>C:9=YDA,T`ZU-3-A,F79(V8W2I:UO&5WKE/5N) M)PI?-!T2Q\UH&E*,L>-E<8B<3E9AFBD]]&6B/;>75\B&UT%(F;VJ2HF'!Q664)AER-^V^+WD`K9FXCX0\\-.'`8)FX<9$X8 M8C=L%CP@)9/!8O&EF--$6N#-3<,_)IS6Q[8;V#Q MXM4>,Z_,389NM0G_?70+_>C@-"0X,A"T%E;I6F&C['-.Q@***_81K>CC??05 MO5#EVVET4O:+BOB12AV.^U>Q,1B#6./Z[8#E^FZ>5G0S`3[.AT(3`&8T;FIF M\B]W'W?LH?Q6#[>;HAIH)^/L!=K81X%/PCB+$PQ#@FE&_!9M'+I2#S5>&>)X M,5(%]1>0"_P\UCG2+\,V9;'.5Y7BW2[XIRVY*MXS)GW' MXMI.-Q(&3<'?-H*?HPY160:^'2:W,Q.;]9#'6B\P&NA,H3<,#F]6;+?(UZ5( MF_`O-E46I6AE85&6?(2#Q68%UH<7TU_IQ%)&)T:(AC0=HA\#V>X![R/RL@QP2(T13 MG__5@0'U0L?!4*I:H+[=^L#@E;=38L MQ/I.&"3"H_"O)L"GU`O*VW59!7&RR4: MVLWBZ4@@1A+%O\:$@3-@_4"52`PYK$^\@] M)/6>LAM.[43&G1%37IV[,T6/7*;\RR,3Z]7-WU7V?K/B+9,M6^7U[?:[8OMS ML5V5U50P=R(GB7TOAG[BI(@X`8^;VO:#%/K2N6^3C5H.4#JH];:MF";%^*OA MSL`)X&;*5$I7&N5?(@U]+>K5E.Y=L:Z0]KT6^WJ)W&Z)SB>--5M6_A"9W'PC MTOKYAN-]J#YQ!LK]\AXL2K#C7EKL=_?%ED?LLZ8F8CFK/,B>'O,FQ2]2N/R[ M?&4OCLP4G;>KPS/+8RYF33ZXCE&KG'%95ML*_)=%VF:=_\/6^7U1K,1W]KM< MG,RO&A%M"CS+BN'3CQV<+U;PY*4,L(W.,(6\G(>8>HX(0]X792D@1?!S/7:1B%,I#:)S;1D>Z^W!3<#-3QP MP,<#4XY05I8-$2NY2!^-4[5I3YU#.POO/GKZEME&:)U(<&_(F)=+:(,428O5 MB[9H\;#(-_,T\J`/(7;<@(9Q3`((N\;\$"N)E%X+EL7IY6@"?]6X5"5)DSXY M*;+/W#`)DB#-B@:=Y:5'>X;Q.!'-&6A$8;)K*6K,U\66M_$'>[AEVSG&Q,V" MU,^H'T(/AR1#316"@(0!4MIA5OI@RXI2OX#Q)U\"L2?P_9XCNR_6O$^4OS3A MCZ*RJ)$F)RC6^%+3D1H&^*L&,K9Z')/0(QI:7$U$*_2P%P8ZBZ(RG#\$W+2) M8IK&*,(91&F&0R?`F+9MDL15*B0PJ"'+RG'I>H?:O1\SE,KIR&ALJNG*Q7LR MUQ&:/I9ZA,<(N1,1(C.V%!9ZG\H^B,@A'6>//N4;5AWQF\,L@X%'$8W]-/!3 MF"6TDT42)/*U!O2;L!W6B-3Z,3*55/H`XB2V*\;A3$V"7M$%_A*PZL/M2ML0 M`[A3V'08AT.]+88/'\3-1_8[_Q.^7L^)`WWD$>@& M"&9.X.`P;5.`!--`\<47JU!41K/6\R\'Q/5]-)!WYC3'D<<^53>`SKYC=V-X M:2+C?AQ;7Q[<&X]@:96@[(YQD5IEC#.^6'=G"U]H5.H&&0VI@U$:.1P!C9(N M7DN]0.G^@:$F+<=,+4IP5\,$=;V>ZK@0:Z?R6[V8R13IE35,/L3T4_35A56NZRF)O(&:W$^.4UVLJ*E'%>YRY?ST$FH M[T0A3;,`94'D^&WETX!`'"B]L&6C?G=)RS"&P\NOB61S6 M;5;4S.[)(81Z[:^E2GA1&6G:V4LE(\*"W`*8JF%G-R MHFB;,N7]%DY2`V<&&D`CZ]D92GKT:@B!$]&C0284YOJ3NIZ\O@N`JVLH\P03 MZ).,NA3YD9NX-$BZ7%R0!4HG7H>T,WZX=NX*C+K&FO-8G0_386(:>[##,_9A&CHL0))A"B)`79.TE M8!(Z(;2T%E4#85GAZATXJ>6HEM;9)^_@3KW0U<BIH.Y'^JXCG4K+>TT@AM&K7O\&:7 MK_+U7A10_^V:KC!,CKJ;MZ^.>7^[2Q5;4!RZ_LFUULZJYOD\Q M)8F/D!NX*";$R;RD0AFZ+@>M=)IO9&BVA?:H?N:Q/>!@$&@M`J(;@B.;Q"^U M5@%N5GV93;&2RK5<+B??$_:VFLI?Q=&6"_J9<$G/U'$EWT]DAKF6]1>K!5[! M"=+SU4!LR?/Y#ZC*.82$QE&2(.(XF$8A#IS`:2##!,O=')H"3LLSF2%1FXF" MT9<^2ZL6S57[AMPL]UZZA=J4I^M%*[.618I[IK`I.'8B\]DDJ"BF-^Z,S'2? M%P^LK0P",6\$>7&8>0Z%GN=6Y7NK=M-4[93;X,:N,^?,@("H6RAH.,-#1-\2 MN4:46YK7$17\P)>R#&M0/6DMU;%'2A"UB9*O;?;PN"Z>&?N^*Y;_?'D4D93\.)G,A` M,F#(RW)=AJB1OT]=;'Z(:K[_YN[JFB/%L>Q?(6(W=FHBW+,(\;G]A"2T6Q$U M717=M1T3L0^.=":N8B/(]UNSPB=AH)O4$VT9'D8]>%:9'K*\ ML,KC@WB)LD-=$>.05RETNVHRO6K.P)S,PGR!/JD2VHN5W#+I>FZ0-2! MB7QI:\[EI6BM-"E+65V/)-N*H5JK9YLGR,*S&L5I( MIJ[R,B!.TWAUZ,?(]BY)*0!2'G'%::9!Y$J MM'VI2FFK2D]"E<^ MR)1SEY!.9RJQC[GC<\2M"@X3?BXT_5:3,]X>OZ,]Z<:\)6Q_O!L M_7GSOWEAT?VFA%8<-=4Y:FJ[8+_`Y!;8)4L?85=A4^F(NM9N68GDFFK=FT?, M#9!X4W1W:7;_(?VRV2?"Q:N>Z[-[C"<<$_)S@!@3"CI\;\+^XE)[]T)HIUS;,](]6C37>,_H MUMU1G;*$%E]C=KP>3^JG?PY-GM9$F"YKH!-RER`:)JDJ'"]X"T&%O0'9U,W_2J12>[->WUTP0)M:'?3??SB.4\MP M:\3WY.&C@$6VPWV.?.*ZW4D%QU=R1,<]V;"\_?Z7GUI`"B-,!U/#HF6>))@T M_?X7`64S(SV`DN9&:1I7R;QYG::6)K]LV!5QG4;`&@J1CP>?ZW@'@!XB.9;9 M(2W+>/NW8U9F\J6H@P6!+^^1<2>AE##F(!9Z7;#`]F")^,?:,"R1+2RKAVM< M3',TB6J.WAS\P=1S%'5&W+@WN!EPVZ:RN1(W;7(SV@!;=62W&L;$_#22/5RAS_$[7*A"UL^G6 M"\:`"C:.[15KV<@&*:C:%*I,;#Q_Z.Y6$APA/^$L(%[($LH(B9/NN`?CB:'= M9W4`\^V+O'DP^H/*]>@9NT3[]K.9WM"_!ZW4$4OO1']0N)-NM&]6HK!FVSA^ M8WHLHUNL]UHKD-@ MT+1)>DA54\[9^80I90W/NJV7,TND"FL#DJB5])5(H-XVY0;?4FB2V!]5L6FR M.1;/4DPO;UF___:TV5:_I-4]X2[W[2BQ&;=]1!QDQZ>;`AQ1SP'EQ]!HUK#< MO4!:NRQWUS+O-'CO+($8J(T!-%1[4X0H;E_IG*KIH4ST@K3OS.C#33K?<JC*^+#[\Z;X M:UK)F^'GO#R?TQ\5$3S\54"QP\AC"%/,W"A*7.IC+Q&NJ5A\VXX/BC2:L&]8 MZ\[@>EFTH!G03="NIGA+,PZ308GTSI+_6CW`=_6AP*L=8?V/A&W5N&?/H0ZG M=D`U37;42J34:!,O\Z\;IU,]%Y&L!"[/47U\Y,)Y/6RSS?Y3?MIA:O,@>6'@ MT#"DF-N(!RAT.8^P0UB"B._:KG*2&QVVS(WO#I[,;=,!M%J$R^4/4^%M8/!J MI7TEHU5OFRX3UN@G3#U_;!UBZZQ0Z60Q#S'N.F*\4X*BL+62)(R`$L'"'FW8 M=;D53M;"CIHN&20&ID#=M=B%A.8E$0.2,I*QE8C'6/27.4.GD``4!'HL9)*! MSI@=.YARC['8YX2X@1,Y06O,3K`/UP6H!HOF^R MO0RS\+SX;=./MIQT]YZ%-O&0[T4.01A%PEC)/DL47];9/`.?VTVX1-N2S:2-[ M)4*GL4&7OIQFJM0%;KN5Y2C*7]-M*K15(/@EK5J;U,51B`+A4E+/34)Y!;T3 M5>X'H)1%DPR9CB^=L%E%!^[..H"/1$WC4E'`YJ(1J%TM@[_V&!3(%I.M`9J& M%$L'NVL1*RUMN=0I?00!KA5]%T_/BV=Y(@HG=N@&'#$F'A@R%$4Q:FU@Y`>P MZT*`!QN6H!;+X)Z\H9LE9Q8&AL8HLE8R%,9A?W7#8S0!XP*X,GFA3V/,0LR0 MDR1AY/N\,4+]R+'I?957F_V(P.W-)X->]@Z$\LO^6?Z)M7T1MIT2M;W-U(AH MK5:2)D5IEPS-JH9DE=E:B22,!#\4@@52`$EH=RI\?3T4\HMH\0D!#XF#D>WC M1%Z[X)SP"+4('.#)78UF#<^=O2+O,@P+SV"GC5XUF5F(69@&]4@=B,>>H09B$7A`0S_7%/Q3;GMT]/<0([B;= M?.0L_M$$O^@V)Q"'2"L=8SRA11R@FYZ/,BTKT00HZJN^#K#1RF/Y0[9YR/9U MQ%-(R6]5OOWKUWPO&"FEI%3/YSJ;%$8F>E,W_Z,$'JP;PJ' M8%$S2=]H&5O!.;^W*5*3K;&\KD^H1K?D;6F:1HZR&+'T,16&=K^FW]/#,6W# M78[OXH`'0OUDNDQA$`>D\P1=!MJ*&6G"L`BUJ*RB@24&5!NT?LH+><4#*$EC MF523HQE(A$E1Q]\)T5(1[>O$#`C01"97(CY36Y%K?;W&1+V/V^I89(,@XC%K33(W`J7)G6+'_+&4XEBK3P^BE?YX2@]E.E6* M)O$+B'//0.V(P';'Y@G64LHT0-&MN/5$8E>B45J:P/6(ITR&>67. MBX\/^^Q+76JBVQD,6.QRA_C8MOV8H]AA+NU6B0YLS3;1E.EU6X/.VMEU&N8:8&Q$L3Q2O1+UVM>77I02-)L,2Q MK]>7]PRY":61;7.7)PY.@LBF9Q>/4'"NV!$V#.M6D]-TWX^=3-.KT5RJ"=4< M-,(4JF'P6O1IB3RPKZD9D*2I9*Y$BR8WXUJ"U\FT3(AYWSL>0XF;Q%S8$5X; M)@1UWIKX&8=L[8]X_*S'('O:,SG0?9NXL0%NK9Q-#VPO'LT&1;&5R5N)H$QI MPOTQW9_W,EH MA];H-83940%L0Z1.C6$O=N;Q37K4(]DC*%V)%FEHR'`\>S0UDT+:/:N$LB0. M_3"(_"0@,24DZ-PJ&KO>U*@VP-2R@6U=>C65[_%1;D-4:PET+WMD^TVB@.'N M$0RO1,ATM48AZ#V:I*EQ[YYA1!,>"SFU66+;`?5B')Z]/,)`176G6ULN^JU+ MU#0P/BD4;HAL;='PQ>3M)E_PF/@(KE-.'-JN2[$7!^+;NGB'TT7F"8;)G1:+IB7O#-(JTT,F$P#U MP%J'O$I+Z]WNF%IBX'C04O-D)!\I>C^L^0$LB7%+Z5'@;DC^MO*]% M`O4VZE(!V4PJ_%]4/:;GQ-(7LGE)>'[Z[ M]A>ZOE)":LTFS8MA!]1Z;)&^<@<5-5`WW<,BN"#38!4\D]R!['F!:DIHE.I= MOCW*K/#U'ZZ1\A<``2&%)_%;>;O7JKZF8FX_7"QF9#F$S>E];S>TGF5:+2FW M.VM3BM^*)QSW=>&$;>/+9?^0_20Z4O5#/;':$[7I>@_7+E8G-4,T8N[[GN^+QG0GQLY';SS>?.\N^LY;]YML4@3>: MM;(S>H=YN8UEM1UE9996X@V/@O[V'C*P^8!%_K=O624G1GGO4XB1G'52(4+" M9!B[./"\V(D\._$3DB"[VQ6*N`VZ[S3%CG$?MH/69#;O@P.OWB?0J;IFGX=) MJ(_ZDD2J1J*AU?F;#`VNR:?SNA+MT=*45^MO7?0`MH]W:?JMSKDIVBTL"@[$ MQ[^\/XA1GI95)1WQ,L>N&L<^X3\+NAE;DHOC^>UH\ MY.I;RX9@0$9C'S%@]=(BKUZ:&>VDE8]M\ M.U_ML\Y"+*`HXV5NBO>'TT[CIV9-'E=5D3T MYXX?L',^"R>&W52:&9IAOZB?=.??_B5T4/!S7?"E>H8FIIB[R]0DS8YT9W6-L4ZML?K-L:K<>MD@JVW1DK4\=?;(P&2Q4->O9`I9JO6O*HDN MV`G*TTTWL=5PFYG-I]SS'>SS)':#Q''"*#GGO44QA_F78RP8=QT[4%8I4=U9 M_VK_R4;6TZ:PODN$/UOHSK9M^9]5RHE"+/N.U=>\R/Z1[GZ6[F9J964I#SW* MY6!^K,I*?"-U9E-9OXFW-/WVD!86MN_D-CFN/\72[>FGJ/ZI`YQG1O65VF1A MNI-@BG_NG=^:WJD!"K+#ST[*+9# MC'B(.?,3ZGBQA[LCDBYGP&4R^/'&-:Q!]*:`X4:^KDL81*5^MAR,[[S(N1/_ M5W]$^,IW3NC?A7[8/GJZ&-[)C<2G=%MEW],]-/TEO//5HY'&>AT>@A3=O0)% MO"3E1M1Q%'\KT<+Q^*_$%R<0H9Y#>[>K:]5O]I\VV>[]X72\LF?^GN+0=A// MM2F-2$1='/O=5HL7!J!L2QK,&5[FGQ$*<# M81,'Y@#JMF[V#]G:"[3PBHAZ>T!1$!>D'JB./:]+L1HD$;`GG2UR0[I+MD4 M![%^*WNP6/J8;;/JWD%>X-+`8SAF#N;,^T^]@;TKH$$ MOK4\G5(UF9R939@RMN"L%IWUKL_M">#\._6W*!O+7NVS:R9K MPH[Z?1)Y"<$!\@D2WV&.&/:[K*$Q=2`'@4<\?I;SP+^G197^:.)S5[>Y)^]R MWZ9Q[$ZU5@:G[S:_VEK^M%G@5MYKFD!;P,J^('26C;D?ABNXD34,?K%OAQ0I.1=]7&&9M% MW'L7V.H=8FUB/YUK-1F?E6:80%^OA;BR`H@#"JJ-VI5HH[[V``L=`HD"Z-DA M_?A(BW275;RYU/U\2@Q+\J+(_RXTE6Z>Q&\$AH#XB1^$/@MC+Q8K^UBL^+TD M$.O_D!''CV$E#S4:-AQ,E%AEO+]!:[5PSV7].L16"QDL=3J[057V%NH!J`1J M)-^0/JH3.:B5!OIC-;IIHFVO--08@8"LUP_5^SIU@KR3V'JCOVZJ-'E\;`[) M?4K%BWZH-E_2>S=PW8`$KA.Y$8L)"N($M2"B&(6P3-@Z+1M65`G6.J.].]_R MD(#OK`_YW^68_U7\30K.CJVU!]2T=#GR86)ZB_<.K76&.WMV;0"5`W)JIDM6 MHJ>&&O6G+(.BUO M_*5(4VG^EZ.\L?'QL?YI>1_1F#K<\Q/;L\.`ND&"@M9@[+I*=\NG6S&LB@T: MJ7M-'CKK7?-5-?&M!AJ'!6]>!H%K[CIQ8(?KSCJSV6";CT1`!L?9R-23M/'R M!4UKD=A9#\_U[XNTSN4H"W(<*K%BG9Q(<8B>*].`/DK7D"Y13T-RW6\;1--_ M^]MQ4Z0\S^6L<;*T^U3D3VE1/=^S4#S:CV*&61)C'^'$]CN+OJ.>Y'>:&=/' M.HMTTPV9G?5T@F6]RPY660.W'M-TZ#BB=EX55'X^2H';_PUC)V"=N@O']81M M1AH!.C\?G>.$_K-0[\VW_'BH+PEL3J]L^WJ>RJ#LK0//R.7I98)C7R4N#@^J[/#VS^BUBU!8%$PA= MPU2@KS%O+PXF4Z0V(;P_9%6VV7].BV^G":A#<$]=.^8Q8Q1Q$D<1IXZ'6WM( M_$YY+IABQ/`T<()FB3_]UBT2^N(O%@G/Z::`:?\D5A5D?RY"88K?$)G9@A[PUR#SF*VOY)"N&Q;S%IEG-IQ&K(.>S<0K3 M\XY.#8(^C4.`HL_&Y61)W_2R%9U4/;?2'U5Z,*?O0^R\)?!:&%V#PNMI2*[[ M98/7,NVJ++T_?"IR8;`L_[/(R_+>9H@1AIF7X##T;489[;:%BNE\FZ:[DHL&BFEN\UR',3X^UM7MLVV5[NBF_-H5AHOE6<"F M()3K$$RQ$,4@]!A"7H!\IPML.!@D6^90F!:UK_*LG1R.9ZB6Q&J1C?B@W/0I MY:].]1<_%YM#N:G[%ZI[!CM*3177T4YH.R98\^?4!^.CF/+H'``D2JDIM>3V2)>+<TMP[)$>O-.B_^BT^'O/#18XOPL;G-:(I=^5 MFRW'TO]GMTV-T<&CY6BKM]CNHZ;^HS MXC.*`$,($@A<0-T8L"!PO:!#X26,4E]%VV=NVOB&X0#1Z3"V9[$&&Q2%?&[6 MY71[1<+59'H`VE+\FOB1BJ^HR&IL7A%@0VZQ1&]-65J[Z1?VEK5)T`ND"AE"*(H9)!`@@ M09B0%F1`/`:@4A7>99$9UN(^&,JX0'2*4!_O_I%O&[&1_N1T?#'JU&3YS)HE2_-K/%V1REGHM43YYK&E--#_M)?4-X=O M?&565D.=IA>Z2.*8400"Z/I<&%T_IG%_2IHA'U.E@G.S-6HZOSQ:$`U(Q+RK><3*VZ/?AD8W28`Q=E,W86X0ALS%%"<>@@R$:102II2@U6K`M.*= M,#DMJ'X(7AEW,W(G*6NF:5.4,&7&S"C5&ZQ<4Z4I)-JB0)-L>*DVTPG159:? MBT-^T^2/]2;P(713&@`O37`:\K@3H:X]#`E+I0I'3&YD<841T)P6VT2942!2 M2VK,<#A5;J3H6T)S3O3(ZXXZHW9JCX8=U_5'EQB-N(\^_K$OG_+\9-\O(V.]BWE_"=QH+@TR@5/+FW'YV3R[N22"#'W8F`7O!-HQYF+NU8U,+79J_J1[&"5 MTYOU[+33V+*/SMFVMBSHR3JG,Z\[+F53'#RSQZ0"Y[5ZB2USS?I$7`S-UW6- M9+&V$]J_':I3\V]#[0^.G@$Q@,(H`@3SV1=2DHJ6@X M+RVYJ;2TIU3JT=GB,;UKS*/]O4S<@.D*SO$Q5#?.77==Z5_KKSD?7SO^FTY_ MYUD